#chr	pos(1-based)	ref	alt	aaref	aaalt	rs_dbSNP	hg19_chr	hg19_pos(1-based)	hg18_chr	hg18_pos(1-based)	aapos	genename	Ensembl_geneid	Ensembl_transcriptid	Ensembl_proteinid	Uniprot_acc	Uniprot_entry	HGVSc_ANNOVAR	HGVSp_ANNOVAR	HGVSc_snpEff	HGVSp_snpEff	HGVSc_VEP	HGVSp_VEP	APPRIS	GENCODE_basic	TSL	VEP_canonical	cds_strand	refcodon	codonpos	codon_degeneracy	Ancestral_allele	AltaiNeandertal	Denisova	VindijiaNeandertal	ChagyrskayaNeandertal	SIFT_score	SIFT_converted_rankscore	SIFT_pred	SIFT4G_score	SIFT4G_converted_rankscore	SIFT4G_pred	Polyphen2_HDIV_score	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_pred	Polyphen2_HVAR_score	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_pred	LRT_score	LRT_converted_rankscore	LRT_pred	LRT_Omega	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationTaster_model	MutationTaster_AAE	MutationAssessor_score	MutationAssessor_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	VEST4_score	VEST4_rankscore	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	Reliability_index	MetaRNN_score	MetaRNN_rankscore	MetaRNN_pred	M-CAP_score	M-CAP_rankscore	M-CAP_pred	REVEL_score	REVEL_rankscore	MutPred_score	MutPred_rankscore	MutPred_protID	MutPred_AAchange	MutPred_Top5features	MVP_score	MVP_rankscore	gMVP_score	gMVP_rankscore	MPC_score	MPC_rankscore	PrimateAI_score	PrimateAI_rankscore	PrimateAI_pred	DEOGEN2_score	DEOGEN2_rankscore	DEOGEN2_pred	BayesDel_addAF_score	BayesDel_addAF_rankscore	BayesDel_addAF_pred	BayesDel_noAF_score	BayesDel_noAF_rankscore	BayesDel_noAF_pred	ClinPred_score	ClinPred_rankscore	ClinPred_pred	LIST-S2_score	LIST-S2_rankscore	LIST-S2_pred	VARITY_R_score	VARITY_R_rankscore	VARITY_ER_score	VARITY_ER_rankscore	VARITY_R_LOO_score	VARITY_R_LOO_rankscore	VARITY_ER_LOO_score	VARITY_ER_LOO_rankscore	ESM1b_score	ESM1b_rankscore	ESM1b_pred	EVE_score	EVE_rankscore	EVE_Class10_pred	EVE_Class20_pred	EVE_Class25_pred	EVE_Class30_pred	EVE_Class40_pred	EVE_Class50_pred	EVE_Class60_pred	EVE_Class70_pred	EVE_Class75_pred	EVE_Class80_pred	EVE_Class90_pred	AlphaMissense_score	AlphaMissense_rankscore	AlphaMissense_pred	Aloft_Fraction_transcripts_affected	Aloft_prob_Tolerant	Aloft_prob_Recessive	Aloft_prob_Dominant	Aloft_pred	Aloft_Confidence	CADD_raw	CADD_raw_rankscore	CADD_phred	CADD_raw_hg19	CADD_raw_rankscore_hg19	CADD_phred_hg19	DANN_score	DANN_rankscore	fathmm-MKL_coding_score	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_pred	fathmm-MKL_coding_group	fathmm-XF_coding_score	fathmm-XF_coding_rankscore	fathmm-XF_coding_pred	Eigen-raw_coding	Eigen-raw_coding_rankscore	Eigen-phred_coding	Eigen-PC-raw_coding	Eigen-PC-raw_coding_rankscore	Eigen-PC-phred_coding	GenoCanyon_score	GenoCanyon_rankscore	integrated_fitCons_score	integrated_fitCons_rankscore	integrated_confidence_value	GM12878_fitCons_score	GM12878_fitCons_rankscore	GM12878_confidence_value	H1-hESC_fitCons_score	H1-hESC_fitCons_rankscore	H1-hESC_confidence_value	HUVEC_fitCons_score	HUVEC_fitCons_rankscore	HUVEC_confidence_value	LINSIGHT	LINSIGHT_rankscore	GERP++_NR	GERP++_RS	GERP++_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP470way_mammalian	phyloP470way_mammalian_rankscore	phyloP17way_primate	phyloP17way_primate_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons470way_mammalian	phastCons470way_mammalian_rankscore	phastCons17way_primate	phastCons17way_primate_rankscore	SiPhy_29way_pi	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	bStatistic	bStatistic_converted_rankscore	1000Gp3_AC	1000Gp3_AF	1000Gp3_AFR_AC	1000Gp3_AFR_AF	1000Gp3_EUR_AC	1000Gp3_EUR_AF	1000Gp3_AMR_AC	1000Gp3_AMR_AF	1000Gp3_EAS_AC	1000Gp3_EAS_AF	1000Gp3_SAS_AC	1000Gp3_SAS_AF	TWINSUK_AC	TWINSUK_AF	ALSPAC_AC	ALSPAC_AF	UK10K_AC	UK10K_AF	ESP6500_AA_AC	ESP6500_AA_AF	ESP6500_EA_AC	ESP6500_EA_AF	ExAC_AC	ExAC_AF	ExAC_Adj_AC	ExAC_Adj_AF	ExAC_AFR_AC	ExAC_AFR_AF	ExAC_AMR_AC	ExAC_AMR_AF	ExAC_EAS_AC	ExAC_EAS_AF	ExAC_FIN_AC	ExAC_FIN_AF	ExAC_NFE_AC	ExAC_NFE_AF	ExAC_SAS_AC	ExAC_SAS_AF	ExAC_nonTCGA_AC	ExAC_nonTCGA_AF	ExAC_nonTCGA_Adj_AC	ExAC_nonTCGA_Adj_AF	ExAC_nonTCGA_AFR_AC	ExAC_nonTCGA_AFR_AF	ExAC_nonTCGA_AMR_AC	ExAC_nonTCGA_AMR_AF	ExAC_nonTCGA_EAS_AC	ExAC_nonTCGA_EAS_AF	ExAC_nonTCGA_FIN_AC	ExAC_nonTCGA_FIN_AF	ExAC_nonTCGA_NFE_AC	ExAC_nonTCGA_NFE_AF	ExAC_nonTCGA_SAS_AC	ExAC_nonTCGA_SAS_AF	ExAC_nonpsych_AC	ExAC_nonpsych_AF	ExAC_nonpsych_Adj_AC	ExAC_nonpsych_Adj_AF	ExAC_nonpsych_AFR_AC	ExAC_nonpsych_AFR_AF	ExAC_nonpsych_AMR_AC	ExAC_nonpsych_AMR_AF	ExAC_nonpsych_EAS_AC	ExAC_nonpsych_EAS_AF	ExAC_nonpsych_FIN_AC	ExAC_nonpsych_FIN_AF	ExAC_nonpsych_NFE_AC	ExAC_nonpsych_NFE_AF	ExAC_nonpsych_SAS_AC	ExAC_nonpsych_SAS_AF	gnomAD_exomes_flag	gnomAD_exomes_AC	gnomAD_exomes_AN	gnomAD_exomes_AF	gnomAD_exomes_nhomalt	gnomAD_exomes_AFR_AC	gnomAD_exomes_AFR_AN	gnomAD_exomes_AFR_AF	gnomAD_exomes_AFR_nhomalt	gnomAD_exomes_AMR_AC	gnomAD_exomes_AMR_AN	gnomAD_exomes_AMR_AF	gnomAD_exomes_AMR_nhomalt	gnomAD_exomes_ASJ_AC	gnomAD_exomes_ASJ_AN	gnomAD_exomes_ASJ_AF	gnomAD_exomes_ASJ_nhomalt	gnomAD_exomes_EAS_AC	gnomAD_exomes_EAS_AN	gnomAD_exomes_EAS_AF	gnomAD_exomes_EAS_nhomalt	gnomAD_exomes_FIN_AC	gnomAD_exomes_FIN_AN	gnomAD_exomes_FIN_AF	gnomAD_exomes_FIN_nhomalt	gnomAD_exomes_NFE_AC	gnomAD_exomes_NFE_AN	gnomAD_exomes_NFE_AF	gnomAD_exomes_NFE_nhomalt	gnomAD_exomes_SAS_AC	gnomAD_exomes_SAS_AN	gnomAD_exomes_SAS_AF	gnomAD_exomes_SAS_nhomalt	gnomAD_exomes_POPMAX_AC	gnomAD_exomes_POPMAX_AN	gnomAD_exomes_POPMAX_AF	gnomAD_exomes_POPMAX_nhomalt	gnomAD_exomes_controls_AC	gnomAD_exomes_controls_AN	gnomAD_exomes_controls_AF	gnomAD_exomes_controls_nhomalt	gnomAD_exomes_non_neuro_AC	gnomAD_exomes_non_neuro_AN	gnomAD_exomes_non_neuro_AF	gnomAD_exomes_non_neuro_nhomalt	gnomAD_exomes_non_cancer_AC	gnomAD_exomes_non_cancer_AN	gnomAD_exomes_non_cancer_AF	gnomAD_exomes_non_cancer_nhomalt	gnomAD_exomes_non_topmed_AC	gnomAD_exomes_non_topmed_AN	gnomAD_exomes_non_topmed_AF	gnomAD_exomes_non_topmed_nhomalt	gnomAD_exomes_controls_AFR_AC	gnomAD_exomes_controls_AFR_AN	gnomAD_exomes_controls_AFR_AF	gnomAD_exomes_controls_AFR_nhomalt	gnomAD_exomes_controls_AMR_AC	gnomAD_exomes_controls_AMR_AN	gnomAD_exomes_controls_AMR_AF	gnomAD_exomes_controls_AMR_nhomalt	gnomAD_exomes_controls_ASJ_AC	gnomAD_exomes_controls_ASJ_AN	gnomAD_exomes_controls_ASJ_AF	gnomAD_exomes_controls_ASJ_nhomalt	gnomAD_exomes_controls_EAS_AC	gnomAD_exomes_controls_EAS_AN	gnomAD_exomes_controls_EAS_AF	gnomAD_exomes_controls_EAS_nhomalt	gnomAD_exomes_controls_FIN_AC	gnomAD_exomes_controls_FIN_AN	gnomAD_exomes_controls_FIN_AF	gnomAD_exomes_controls_FIN_nhomalt	gnomAD_exomes_controls_NFE_AC	gnomAD_exomes_controls_NFE_AN	gnomAD_exomes_controls_NFE_AF	gnomAD_exomes_controls_NFE_nhomalt	gnomAD_exomes_controls_SAS_AC	gnomAD_exomes_controls_SAS_AN	gnomAD_exomes_controls_SAS_AF	gnomAD_exomes_controls_SAS_nhomalt	gnomAD_exomes_controls_POPMAX_AC	gnomAD_exomes_controls_POPMAX_AN	gnomAD_exomes_controls_POPMAX_AF	gnomAD_exomes_controls_POPMAX_nhomalt	gnomAD_exomes_non_neuro_AFR_AC	gnomAD_exomes_non_neuro_AFR_AN	gnomAD_exomes_non_neuro_AFR_AF	gnomAD_exomes_non_neuro_AFR_nhomalt	gnomAD_exomes_non_neuro_AMR_AC	gnomAD_exomes_non_neuro_AMR_AN	gnomAD_exomes_non_neuro_AMR_AF	gnomAD_exomes_non_neuro_AMR_nhomalt	gnomAD_exomes_non_neuro_ASJ_AC	gnomAD_exomes_non_neuro_ASJ_AN	gnomAD_exomes_non_neuro_ASJ_AF	gnomAD_exomes_non_neuro_ASJ_nhomalt	gnomAD_exomes_non_neuro_EAS_AC	gnomAD_exomes_non_neuro_EAS_AN	gnomAD_exomes_non_neuro_EAS_AF	gnomAD_exomes_non_neuro_EAS_nhomalt	gnomAD_exomes_non_neuro_FIN_AC	gnomAD_exomes_non_neuro_FIN_AN	gnomAD_exomes_non_neuro_FIN_AF	gnomAD_exomes_non_neuro_FIN_nhomalt	gnomAD_exomes_non_neuro_NFE_AC	gnomAD_exomes_non_neuro_NFE_AN	gnomAD_exomes_non_neuro_NFE_AF	gnomAD_exomes_non_neuro_NFE_nhomalt	gnomAD_exomes_non_neuro_SAS_AC	gnomAD_exomes_non_neuro_SAS_AN	gnomAD_exomes_non_neuro_SAS_AF	gnomAD_exomes_non_neuro_SAS_nhomalt	gnomAD_exomes_non_neuro_POPMAX_AC	gnomAD_exomes_non_neuro_POPMAX_AN	gnomAD_exomes_non_neuro_POPMAX_AF	gnomAD_exomes_non_neuro_POPMAX_nhomalt	gnomAD_exomes_non_cancer_AFR_AC	gnomAD_exomes_non_cancer_AFR_AN	gnomAD_exomes_non_cancer_AFR_AF	gnomAD_exomes_non_cancer_AFR_nhomalt	gnomAD_exomes_non_cancer_AMR_AC	gnomAD_exomes_non_cancer_AMR_AN	gnomAD_exomes_non_cancer_AMR_AF	gnomAD_exomes_non_cancer_AMR_nhomalt	gnomAD_exomes_non_cancer_ASJ_AC	gnomAD_exomes_non_cancer_ASJ_AN	gnomAD_exomes_non_cancer_ASJ_AF	gnomAD_exomes_non_cancer_ASJ_nhomalt	gnomAD_exomes_non_cancer_EAS_AC	gnomAD_exomes_non_cancer_EAS_AN	gnomAD_exomes_non_cancer_EAS_AF	gnomAD_exomes_non_cancer_EAS_nhomalt	gnomAD_exomes_non_cancer_FIN_AC	gnomAD_exomes_non_cancer_FIN_AN	gnomAD_exomes_non_cancer_FIN_AF	gnomAD_exomes_non_cancer_FIN_nhomalt	gnomAD_exomes_non_cancer_NFE_AC	gnomAD_exomes_non_cancer_NFE_AN	gnomAD_exomes_non_cancer_NFE_AF	gnomAD_exomes_non_cancer_NFE_nhomalt	gnomAD_exomes_non_cancer_SAS_AC	gnomAD_exomes_non_cancer_SAS_AN	gnomAD_exomes_non_cancer_SAS_AF	gnomAD_exomes_non_cancer_SAS_nhomalt	gnomAD_exomes_non_cancer_POPMAX_AC	gnomAD_exomes_non_cancer_POPMAX_AN	gnomAD_exomes_non_cancer_POPMAX_AF	gnomAD_exomes_non_cancer_POPMAX_nhomalt	gnomAD_exomes_non_topmed_AFR_AC	gnomAD_exomes_non_topmed_AFR_AN	gnomAD_exomes_non_topmed_AFR_AF	gnomAD_exomes_non_topmed_AFR_nhomalt	gnomAD_exomes_non_topmed_AMR_AC	gnomAD_exomes_non_topmed_AMR_AN	gnomAD_exomes_non_topmed_AMR_AF	gnomAD_exomes_non_topmed_AMR_nhomalt	gnomAD_exomes_non_topmed_ASJ_AC	gnomAD_exomes_non_topmed_ASJ_AN	gnomAD_exomes_non_topmed_ASJ_AF	gnomAD_exomes_non_topmed_ASJ_nhomalt	gnomAD_exomes_non_topmed_EAS_AC	gnomAD_exomes_non_topmed_EAS_AN	gnomAD_exomes_non_topmed_EAS_AF	gnomAD_exomes_non_topmed_EAS_nhomalt	gnomAD_exomes_non_topmed_FIN_AC	gnomAD_exomes_non_topmed_FIN_AN	gnomAD_exomes_non_topmed_FIN_AF	gnomAD_exomes_non_topmed_FIN_nhomalt	gnomAD_exomes_non_topmed_NFE_AC	gnomAD_exomes_non_topmed_NFE_AN	gnomAD_exomes_non_topmed_NFE_AF	gnomAD_exomes_non_topmed_NFE_nhomalt	gnomAD_exomes_non_topmed_SAS_AC	gnomAD_exomes_non_topmed_SAS_AN	gnomAD_exomes_non_topmed_SAS_AF	gnomAD_exomes_non_topmed_SAS_nhomalt	gnomAD_exomes_non_topmed_POPMAX_AC	gnomAD_exomes_non_topmed_POPMAX_AN	gnomAD_exomes_non_topmed_POPMAX_AF	gnomAD_exomes_non_topmed_POPMAX_nhomalt	gnomAD_genomes_flag	gnomAD_genomes_AC	gnomAD_genomes_AN	gnomAD_genomes_AF	gnomAD_genomes_nhomalt	gnomAD_genomes_POPMAX_AC	gnomAD_genomes_POPMAX_AN	gnomAD_genomes_POPMAX_AF	gnomAD_genomes_POPMAX_nhomalt	gnomAD_genomes_AFR_AC	gnomAD_genomes_AFR_AN	gnomAD_genomes_AFR_AF	gnomAD_genomes_AFR_nhomalt	gnomAD_genomes_AMI_AC	gnomAD_genomes_AMI_AN	gnomAD_genomes_AMI_AF	gnomAD_genomes_AMI_nhomalt	gnomAD_genomes_AMR_AC	gnomAD_genomes_AMR_AN	gnomAD_genomes_AMR_AF	gnomAD_genomes_AMR_nhomalt	gnomAD_genomes_ASJ_AC	gnomAD_genomes_ASJ_AN	gnomAD_genomes_ASJ_AF	gnomAD_genomes_ASJ_nhomalt	gnomAD_genomes_EAS_AC	gnomAD_genomes_EAS_AN	gnomAD_genomes_EAS_AF	gnomAD_genomes_EAS_nhomalt	gnomAD_genomes_FIN_AC	gnomAD_genomes_FIN_AN	gnomAD_genomes_FIN_AF	gnomAD_genomes_FIN_nhomalt	gnomAD_genomes_MID_AC	gnomAD_genomes_MID_AN	gnomAD_genomes_MID_AF	gnomAD_genomes_MID_nhomalt	gnomAD_genomes_NFE_AC	gnomAD_genomes_NFE_AN	gnomAD_genomes_NFE_AF	gnomAD_genomes_NFE_nhomalt	gnomAD_genomes_SAS_AC	gnomAD_genomes_SAS_AN	gnomAD_genomes_SAS_AF	gnomAD_genomes_SAS_nhomalt	gnomAD_genomes_controls_and_biobanks_AC	gnomAD_genomes_controls_and_biobanks_AN	gnomAD_genomes_controls_and_biobanks_AF	gnomAD_genomes_controls_and_biobanks_nhomalt	gnomAD_genomes_non_neuro_AC	gnomAD_genomes_non_neuro_AN	gnomAD_genomes_non_neuro_AF	gnomAD_genomes_non_neuro_nhomalt	gnomAD_genomes_non_cancer_AC	gnomAD_genomes_non_cancer_AN	gnomAD_genomes_non_cancer_AF	gnomAD_genomes_non_cancer_nhomalt	gnomAD_genomes_non_topmed_AC	gnomAD_genomes_non_topmed_AN	gnomAD_genomes_non_topmed_AF	gnomAD_genomes_non_topmed_nhomalt	gnomAD_genomes_controls_and_biobanks_AFR_AC	gnomAD_genomes_controls_and_biobanks_AFR_AN	gnomAD_genomes_controls_and_biobanks_AFR_AF	gnomAD_genomes_controls_and_biobanks_AFR_nhomalt	gnomAD_genomes_controls_and_biobanks_AMI_AC	gnomAD_genomes_controls_and_biobanks_AMI_AN	gnomAD_genomes_controls_and_biobanks_AMI_AF	gnomAD_genomes_controls_and_biobanks_AMI_nhomalt	gnomAD_genomes_controls_and_biobanks_AMR_AC	gnomAD_genomes_controls_and_biobanks_AMR_AN	gnomAD_genomes_controls_and_biobanks_AMR_AF	gnomAD_genomes_controls_and_biobanks_AMR_nhomalt	gnomAD_genomes_controls_and_biobanks_ASJ_AC	gnomAD_genomes_controls_and_biobanks_ASJ_AN	gnomAD_genomes_controls_and_biobanks_ASJ_AF	gnomAD_genomes_controls_and_biobanks_ASJ_nhomalt	gnomAD_genomes_controls_and_biobanks_EAS_AC	gnomAD_genomes_controls_and_biobanks_EAS_AN	gnomAD_genomes_controls_and_biobanks_EAS_AF	gnomAD_genomes_controls_and_biobanks_EAS_nhomalt	gnomAD_genomes_controls_and_biobanks_FIN_AC	gnomAD_genomes_controls_and_biobanks_FIN_AN	gnomAD_genomes_controls_and_biobanks_FIN_AF	gnomAD_genomes_controls_and_biobanks_FIN_nhomalt	gnomAD_genomes_controls_and_biobanks_MID_AC	gnomAD_genomes_controls_and_biobanks_MID_AN	gnomAD_genomes_controls_and_biobanks_MID_AF	gnomAD_genomes_controls_and_biobanks_MID_nhomalt	gnomAD_genomes_controls_and_biobanks_NFE_AC	gnomAD_genomes_controls_and_biobanks_NFE_AN	gnomAD_genomes_controls_and_biobanks_NFE_AF	gnomAD_genomes_controls_and_biobanks_NFE_nhomalt	gnomAD_genomes_controls_and_biobanks_SAS_AC	gnomAD_genomes_controls_and_biobanks_SAS_AN	gnomAD_genomes_controls_and_biobanks_SAS_AF	gnomAD_genomes_controls_and_biobanks_SAS_nhomalt	gnomAD_genomes_non_neuro_AFR_AC	gnomAD_genomes_non_neuro_AFR_AN	gnomAD_genomes_non_neuro_AFR_AF	gnomAD_genomes_non_neuro_AFR_nhomalt	gnomAD_genomes_non_neuro_AMI_AC	gnomAD_genomes_non_neuro_AMI_AN	gnomAD_genomes_non_neuro_AMI_AF	gnomAD_genomes_non_neuro_AMI_nhomalt	gnomAD_genomes_non_neuro_AMR_AC	gnomAD_genomes_non_neuro_AMR_AN	gnomAD_genomes_non_neuro_AMR_AF	gnomAD_genomes_non_neuro_AMR_nhomalt	gnomAD_genomes_non_neuro_ASJ_AC	gnomAD_genomes_non_neuro_ASJ_AN	gnomAD_genomes_non_neuro_ASJ_AF	gnomAD_genomes_non_neuro_ASJ_nhomalt	gnomAD_genomes_non_neuro_EAS_AC	gnomAD_genomes_non_neuro_EAS_AN	gnomAD_genomes_non_neuro_EAS_AF	gnomAD_genomes_non_neuro_EAS_nhomalt	gnomAD_genomes_non_neuro_FIN_AC	gnomAD_genomes_non_neuro_FIN_AN	gnomAD_genomes_non_neuro_FIN_AF	gnomAD_genomes_non_neuro_FIN_nhomalt	gnomAD_genomes_non_neuro_MID_AC	gnomAD_genomes_non_neuro_MID_AN	gnomAD_genomes_non_neuro_MID_AF	gnomAD_genomes_non_neuro_MID_nhomalt	gnomAD_genomes_non_neuro_NFE_AC	gnomAD_genomes_non_neuro_NFE_AN	gnomAD_genomes_non_neuro_NFE_AF	gnomAD_genomes_non_neuro_NFE_nhomalt	gnomAD_genomes_non_neuro_SAS_AC	gnomAD_genomes_non_neuro_SAS_AN	gnomAD_genomes_non_neuro_SAS_AF	gnomAD_genomes_non_neuro_SAS_nhomalt	gnomAD_genomes_non_cancer_AFR_AC	gnomAD_genomes_non_cancer_AFR_AN	gnomAD_genomes_non_cancer_AFR_AF	gnomAD_genomes_non_cancer_AFR_nhomalt	gnomAD_genomes_non_cancer_AMI_AC	gnomAD_genomes_non_cancer_AMI_AN	gnomAD_genomes_non_cancer_AMI_AF	gnomAD_genomes_non_cancer_AMI_nhomalt	gnomAD_genomes_non_cancer_AMR_AC	gnomAD_genomes_non_cancer_AMR_AN	gnomAD_genomes_non_cancer_AMR_AF	gnomAD_genomes_non_cancer_AMR_nhomalt	gnomAD_genomes_non_cancer_ASJ_AC	gnomAD_genomes_non_cancer_ASJ_AN	gnomAD_genomes_non_cancer_ASJ_AF	gnomAD_genomes_non_cancer_ASJ_nhomalt	gnomAD_genomes_non_cancer_EAS_AC	gnomAD_genomes_non_cancer_EAS_AN	gnomAD_genomes_non_cancer_EAS_AF	gnomAD_genomes_non_cancer_EAS_nhomalt	gnomAD_genomes_non_cancer_FIN_AC	gnomAD_genomes_non_cancer_FIN_AN	gnomAD_genomes_non_cancer_FIN_AF	gnomAD_genomes_non_cancer_FIN_nhomalt	gnomAD_genomes_non_cancer_MID_AC	gnomAD_genomes_non_cancer_MID_AN	gnomAD_genomes_non_cancer_MID_AF	gnomAD_genomes_non_cancer_MID_nhomalt	gnomAD_genomes_non_cancer_NFE_AC	gnomAD_genomes_non_cancer_NFE_AN	gnomAD_genomes_non_cancer_NFE_AF	gnomAD_genomes_non_cancer_NFE_nhomalt	gnomAD_genomes_non_cancer_SAS_AC	gnomAD_genomes_non_cancer_SAS_AN	gnomAD_genomes_non_cancer_SAS_AF	gnomAD_genomes_non_cancer_SAS_nhomalt	gnomAD_genomes_non_topmed_AFR_AC	gnomAD_genomes_non_topmed_AFR_AN	gnomAD_genomes_non_topmed_AFR_AF	gnomAD_genomes_non_topmed_AFR_nhomalt	gnomAD_genomes_non_topmed_AMI_AC	gnomAD_genomes_non_topmed_AMI_AN	gnomAD_genomes_non_topmed_AMI_AF	gnomAD_genomes_non_topmed_AMI_nhomalt	gnomAD_genomes_non_topmed_AMR_AC	gnomAD_genomes_non_topmed_AMR_AN	gnomAD_genomes_non_topmed_AMR_AF	gnomAD_genomes_non_topmed_AMR_nhomalt	gnomAD_genomes_non_topmed_ASJ_AC	gnomAD_genomes_non_topmed_ASJ_AN	gnomAD_genomes_non_topmed_ASJ_AF	gnomAD_genomes_non_topmed_ASJ_nhomalt	gnomAD_genomes_non_topmed_EAS_AC	gnomAD_genomes_non_topmed_EAS_AN	gnomAD_genomes_non_topmed_EAS_AF	gnomAD_genomes_non_topmed_EAS_nhomalt	gnomAD_genomes_non_topmed_FIN_AC	gnomAD_genomes_non_topmed_FIN_AN	gnomAD_genomes_non_topmed_FIN_AF	gnomAD_genomes_non_topmed_FIN_nhomalt	gnomAD_genomes_non_topmed_MID_AC	gnomAD_genomes_non_topmed_MID_AN	gnomAD_genomes_non_topmed_MID_AF	gnomAD_genomes_non_topmed_MID_nhomalt	gnomAD_genomes_non_topmed_NFE_AC	gnomAD_genomes_non_topmed_NFE_AN	gnomAD_genomes_non_topmed_NFE_AF	gnomAD_genomes_non_topmed_NFE_nhomalt	gnomAD_genomes_non_topmed_SAS_AC	gnomAD_genomes_non_topmed_SAS_AN	gnomAD_genomes_non_topmed_SAS_AF	gnomAD_genomes_non_topmed_SAS_nhomalt	ALFA_European_AC	ALFA_European_AN	ALFA_European_AF	ALFA_African_Others_AC	ALFA_African_Others_AN	ALFA_African_Others_AF	ALFA_East_Asian_AC	ALFA_East_Asian_AN	ALFA_East_Asian_AF	ALFA_African_American_AC	ALFA_African_American_AN	ALFA_African_American_AF	ALFA_Latin_American_1_AC	ALFA_Latin_American_1_AN	ALFA_Latin_American_1_AF	ALFA_Latin_American_2_AC	ALFA_Latin_American_2_AN	ALFA_Latin_American_2_AF	ALFA_Other_Asian_AC	ALFA_Other_Asian_AN	ALFA_Other_Asian_AF	ALFA_South_Asian_AC	ALFA_South_Asian_AN	ALFA_South_Asian_AF	ALFA_Other_AC	ALFA_Other_AN	ALFA_Other_AF	ALFA_African_AC	ALFA_African_AN	ALFA_African_AF	ALFA_Asian_AC	ALFA_Asian_AN	ALFA_Asian_AF	ALFA_Total_AC	ALFA_Total_AN	ALFA_Total_AF	clinvar_id	clinvar_clnsig	clinvar_trait	clinvar_review	clinvar_hgvs	clinvar_var_source	clinvar_MedGen_id	clinvar_OMIM_id	clinvar_Orphanet_id	Interpro_domain	GTEx_V8_gene	GTEx_V8_tissue	Geuvadis_eQTL_target_gene	Gene_old_names	Gene_other_names	Uniprot_acc(HGNC/Uniprot)	Uniprot_id(HGNC/Uniprot)	Entrez_gene_id	CCDS_id	Refseq_id	ucsc_id	MIM_id	OMIM_id	Gene_full_name	Pathway(Uniprot)	Pathway(BioCarta)_short	Pathway(BioCarta)_full	Pathway(ConsensusPathDB)	Pathway(KEGG)_id	Pathway(KEGG)_full	Function_description	Disease_description	MIM_phenotype_id	MIM_disease	Orphanet_disorder_id	Orphanet_disorder	Orphanet_association_type	Trait_association(GWAS)	HPO_id	HPO_name	GO_biological_process	GO_cellular_component	GO_molecular_function	Tissue_specificity(Uniprot)	Expression(egenetics)	Expression(GNF/Atlas)	Interactions(IntAct)	Interactions(BioGRID)	Interactions(ConsensusPathDB)	P(HI)	HIPred_score	HIPred	GHIS	P(rec)	Known_rec_info	RVIS_EVS	RVIS_percentile_EVS	LoF-FDR_ExAC	RVIS_ExAC	RVIS_percentile_ExAC	ExAC_pLI	ExAC_pRec	ExAC_pNull	ExAC_nonTCGA_pLI	ExAC_nonTCGA_pRec	ExAC_nonTCGA_pNull	ExAC_nonpsych_pLI	ExAC_nonpsych_pRec	ExAC_nonpsych_pNull	gnomAD_pLI	gnomAD_pRec	gnomAD_pNull	ExAC_del.score	ExAC_dup.score	ExAC_cnv.score	ExAC_cnv_flag	GDI	GDI-Phred	Gene damage prediction (all disease-causing genes)	Gene damage prediction (all Mendelian disease-causing genes)	Gene damage prediction (Mendelian AD disease-causing genes)	Gene damage prediction (Mendelian AR disease-causing genes)	Gene damage prediction (all PID disease-causing genes)	Gene damage prediction (PID AD disease-causing genes)	Gene damage prediction (PID AR disease-causing genes)	Gene damage prediction (all cancer disease-causing genes)	Gene damage prediction (cancer recessive disease-causing genes)	Gene damage prediction (cancer dominant disease-causing genes)	LoFtool_score	SORVA_LOF_MAF0.005_HetOrHom	SORVA_LOF_MAF0.005_HomOrCompoundHet	SORVA_LOF_MAF0.001_HetOrHom	SORVA_LOF_MAF0.001_HomOrCompoundHet	SORVA_LOForMissense_MAF0.005_HetOrHom	SORVA_LOForMissense_MAF0.005_HomOrCompoundHet	SORVA_LOForMissense_MAF0.001_HetOrHom	SORVA_LOForMissense_MAF0.001_HomOrCompoundHet	Essential_gene	Essential_gene_CRISPR	Essential_gene_CRISPR2	Essential_gene_gene-trap	Gene_indispensability_score	Gene_indispensability_pred	MGI_mouse_gene	MGI_mouse_phenotype	ZFIN_zebrafish_gene	ZFIN_zebrafish_structure	ZFIN_zebrafish_phenotype_quality	ZFIN_zebrafish_phenotype_tag
16	31091138	T	A	H	L	.	16	31102459	16	31009960	163	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.488A>T	p.H163L	c.488A>T	p.His163Leu	c.488A>T	p.His163Leu	principal1	Y	1	YES	-	CAC	2	0	T	./.	./.	./.	./.	0.023	0.48186	D	0.045	0.49390	D	0.148	0.27908	B	0.038	0.23361	B	0.216932	0.16230	N	0.600548	1;1;1;1;0.993711	0.81001	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;H163L	2.635	0.77114	M	-4.78	0.98140	D	-2.12	0.48184	N	0.314	0.35408	0.7635	0.93960	D	0.8771	0.95918	D	10	0.27055126	0.44587	T	0.40734	0.93525	D	0.424	0.73226	0.284;	0.24121	Q9BQB6;	H163L;	Gain of stability (P = 0.0053);	0.845000919365	0.84351	0.6543734478150642	0.65373	0.599886947289	0.55091	0.408798217773	0.26291	T	0.114569	0.43249	T	0.165816	0.70739	D	0.000406364	0.70362	D	0.581297218799591	0.35668	D	0.429857	0.11651	T	0.098281495	0.23180	0.103327505	0.24789	0.098281495	0.23179	0.103327505	0.24788	-4.726	0.59903	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1257	0.26607	B	.;	.;	.;	.;	.;	.;	2.166174	0.33995	20.6	2.533739	0.44464	22.6	0.97385024492657768	0.33691	0.94672	0.61935	D	AEFBI	0.605070	0.59592	D	-0.230648454252305	0.31883	1.792237	-0.146114337516103	0.33558	1.920835	0.999894655250395	0.45129	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	3.96	0.45097	0.862000	0.27553	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.551000	0.30197	0.0:0.0:0.1641:0.8358	10.3731	0.43249	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091138	T	C	H	R	.	16	31102459	16	31009960	163	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.488A>G	p.H163R	c.488A>G	p.His163Arg	c.488A>G	p.His163Arg	principal1	Y	1	YES	-	CAC	2	0	T	./.	./.	./.	./.	0.042	0.41637	D	0.033	0.53072	D	0.08	0.24543	B	0.027	0.21085	B	0.216932	0.16230	N	0.600548	1;1;1;1;0.99858	0.81001	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;H163R	2.635	0.77114	M	-4.77	0.98126	D	-0.68	0.19509	N	0.241	0.27197	0.6979	0.93149	D	0.8731	0.95783	D	10	0.228248	0.39725	T	0.34993	0.92241	D	0.380	0.69780	0.289;	0.24921	Q9BQB6;	H163R;	Gain of MoRF binding (P = 0.0045);	0.845242517371	0.84376	0.6304051138130554	0.62974	0.591138451535	0.54561	0.430630117655	0.29295	T	0.0657	0.32755	T	0.132516	0.67606	D	-0.0474265	0.67199	D	0.347430020282874	0.26917	T	0.483152	0.14651	T	0.053768836	0.10224	0.07204399	0.15495	0.053768836	0.10223	0.07204399	0.15495	-3.776	0.38690	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0753	0.05623	B	.;	.;	.;	.;	.;	.;	1.970058	0.30010	19.03	2.233572	0.37863	21.6	0.99604976487298724	0.74456	0.89328	0.49726	D	AEFBI	0.572071	0.57580	D	-0.304294551255459	0.28984	1.60335	-0.205507622864356	0.31337	1.772561	0.999894655250395	0.45129	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	3.96	0.45097	0.862000	0.27553	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.551000	0.30197	0.0:0.0:0.1641:0.8358	10.3731	0.43249	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091139	G	A	H	Y	.	16	31102460	16	31009961	163	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.487C>T	p.H163Y	c.487C>T	p.His163Tyr	c.487C>T	p.His163Tyr	principal1	Y	1	YES	-	CAC	1	0	G	./.	./.	./.	./.	0.013	0.53900	D	0.362	0.16865	T	0.518	0.37483	P	0.094	0.30180	B	0.216932	0.16230	N	0.600548	1;1;1;1;0.996668	0.81001	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;H163Y	2.635	0.77114	M	-4.79	0.98155	D	-1.35	0.33598	N	0.297	0.33578	0.8498	0.95027	D	0.8705	0.95694	D	10	0.2894286	0.46524	T	0.346265	0.92149	D	0.364	0.68407	0.326;	0.30873	Q9BQB6;	H163Y;	Loss of methylation at K161 (P = 0.0767);	0.876251582345	0.87503	0.6378116168205253	0.63715	0.436763823359	0.43757	0.435338318348	0.29940	T	0.096404	0.39817	T	0.146659	0.68955	D	-0.0271115	0.68560	D	0.549739778854995	0.34468	D	0.550145	0.18957	T	0.0717017	0.15893	0.11255899	0.27159	0.0717017	0.15892	0.11255899	0.27158	-5.692	0.71313	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0698	0.03407	B	.;	.;	.;	.;	.;	.;	2.437883	0.39875	22.2	2.387972	0.41233	22.3	0.99660633141322641	0.77883	0.92333	0.55470	D	AEFBI	0.470255	0.51629	N	-0.035254548903399	0.40263	2.388153	0.00907979342447909	0.40136	2.390497	0.999664980481683	0.41534	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	4.09	0.47038	3.597000	0.53777	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.541000	0.29961	0.0:0.0:0.8302:0.1698	12.3037	0.54210	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091144	T	G	K	T	.	16	31102465	16	31009966	161	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.482A>C	p.K161T	c.482A>C	p.Lys161Thr	c.482A>C	p.Lys161Thr	principal1	Y	1	YES	-	AAG	2	0	T	./.	./.	./.	./.	0.004	0.65419	D	0.028	0.54934	D	0.997	0.70673	D	0.879	0.62418	P	0.001268	0.39594	N	0.164448	1;1;1;1;0.944299	0.81001	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;K161T	3.07	0.87108	M	-4.98	0.98487	D	-3.22	0.64939	D	0.401	0.44187	1.0774	0.98801	D	0.9475	0.98287	D	10	0.622204	0.68041	D	0.587146	0.96320	D	0.610	0.84719	0.266;	0.21261	Q9BQB6;	K161T;	Loss of methylation at K161 (P = 0.0085);	0.95801790563	0.95756	0.5973448261245778	0.59665	1.05516137449	0.76297	0.500309467316	0.38872	T	0.210223	0.57065	T	0.254476	0.79018	D	0.127761	0.78745	D	0.941841661930084	0.61547	D	0.533547	0.17787	T	0.1744508	0.38250	0.12846309	0.30906	0.1744508	0.38249	0.12846309	0.30905	-4.093	0.46692	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1198	0.24700	B	.;	.;	.;	.;	.;	.;	3.536664	0.65033	24.8	3.127894	0.57718	23.9	0.99558706475429593	0.71645	0.97902	0.77993	D	AEFBI	0.776070	0.70929	D	0.480869468394418	0.65974	4.890465	0.387568745006674	0.60798	4.271483	0.999968127087821	0.48965	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	5.07	0.68106	3.545000	0.53401	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.391000	0.26581	0.0:0.0:0.0:1.0	12.7806	0.56853	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091147	G	A	A	V	rs1028233658	16	31102468	16	31009969	160	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.479C>T	p.A160V	c.479C>T	p.Ala160Val	c.479C>T	p.Ala160Val	principal1	Y	1	YES	-	GCT	2	0	G	./.	./.	./.	./.	0.46	0.08736	T	0.577	0.08594	T	0.0	0.02946	B	0.001	0.04355	B	0.312132	0.04022	N	1.470090	1;0.997477;0.997477;0.997477;0.997477	0.22644	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	A160V;.;.;.;.	0.22	0.09567	N	-4.75	0.98096	D	-0.52	0.16187	N	0.023	0.00407	0.1734	0.85457	D	0.7332	0.90876	D	10	0.038259238	0.02232	T	0.026903	0.49766	D	0.411	0.72252	.;	.	.;	.;	.;	0.668480267452	0.66568	0.17339912344060593	0.17259	0.36559189452	0.38146	0.261636048555	0.05087	T	0.061075	0.31559	T	-0.248543	0.14279	T	-0.240757	0.50724	T	0.0246909763664007	0.01233	T	0.462854	0.13445	T	0.014793551	0.00108	0.028834553	0.01158	0.014793551	0.00108	0.028834553	0.01158	-4.523	0.56265	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0695	0.03301	B	.;	.;	.;	.;	.;	.;	0.855472	0.13259	9.958	0.221177	0.07439	6.150	0.57346436245873766	0.05749	0.02120	0.06265	N	AEFBI	0.189725	0.31697	N	-1.36942052684305	0.02929	0.1300636	-1.36636391237569	0.03616	0.1690681	0.999249749096951	0.38873	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	-4.82	0.02938	0.206000	0.17174	.	.	-0.259000	0.06933	0.576000	0.27554	0.361000	0.24521	0.272000	0.23818	0.6815:0.0:0.1932:0.1253	8.0421	0.29688	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	2	250600	7.980850e-06	0	2	16116	1.241000e-04	0	0	34530	0.000000e+00	0	0	10050	0.000000e+00	0	0	18366	0.000000e+00	0	0	21638	0.000000e+00	0	0	113212	0.000000e+00	0	0	30568	0.000000e+00	0	2	16116	1.241000e-04	0	0	109300	0.000000e+00	0	2	207576	9.635030e-06	0	2	236492	8.456950e-06	0	2	243988	8.197120e-06	0	0	7144	0.000000e+00	0	0	17086	0.000000e+00	0	0	2320	0.000000e+00	0	0	9044	0.000000e+00	0	0	13392	0.000000e+00	0	0	42760	0.000000e+00	0	0	15646	0.000000e+00	0	.	.	.	.	2	16078	1.243940e-04	0	0	30474	0.000000e+00	0	0	6198	0.000000e+00	0	0	13390	0.000000e+00	0	0	16732	0.000000e+00	0	0	89296	0.000000e+00	0	0	30560	0.000000e+00	0	2	16078	1.243940e-04	0	2	14878	1.344270e-04	0	0	34214	0.000000e+00	0	0	9556	0.000000e+00	0	0	17688	0.000000e+00	0	0	21622	0.000000e+00	0	0	102444	0.000000e+00	0	0	30478	0.000000e+00	0	2	14878	1.344270e-04	0	2	11892	1.681800e-04	0	0	34396	0.000000e+00	0	0	9968	0.000000e+00	0	0	18362	0.000000e+00	0	0	21636	0.000000e+00	0	0	111122	0.000000e+00	0	0	30568	0.000000e+00	0	2	11892	1.681800e-04	0	.	10	152194	6.570560e-05	0	10	41438	2.413240e-04	0	10	41438	2.413240e-04	0	0	912	0.000000e+00	0	0	15276	0.000000e+00	0	0	3472	0.000000e+00	0	0	5192	0.000000e+00	0	0	10628	0.000000e+00	0	0	316	0.000000e+00	0	0	68032	0.000000e+00	0	0	4834	0.000000e+00	0	2	32906	6.077920e-05	0	6	134780	4.451700e-05	0	10	147942	6.759410e-05	0	8	80756	9.906380e-05	0	2	9096	2.198770e-04	0	0	60	0.000000e+00	0	0	4688	0.000000e+00	0	0	136	0.000000e+00	0	0	2428	0.000000e+00	0	0	5496	0.000000e+00	0	0	246	0.000000e+00	0	0	6854	0.000000e+00	0	0	3112	0.000000e+00	0	6	32468	1.847970e-04	0	0	862	0.000000e+00	0	0	14830	0.000000e+00	0	0	3388	0.000000e+00	0	0	5192	0.000000e+00	0	0	6986	0.000000e+00	0	0	310	0.000000e+00	0	0	63908	0.000000e+00	0	0	4832	0.000000e+00	0	10	41116	2.432140e-04	0	0	912	0.000000e+00	0	0	15088	0.000000e+00	0	0	3302	0.000000e+00	0	0	4958	0.000000e+00	0	0	10628	0.000000e+00	0	0	304	0.000000e+00	0	0	64808	0.000000e+00	0	0	4802	0.000000e+00	0	8	24816	3.223730e-04	0	0	112	0.000000e+00	0	0	12902	0.000000e+00	0	0	998	0.000000e+00	0	0	3750	0.000000e+00	0	0	10536	0.000000e+00	0	0	272	0.000000e+00	0	0	21044	0.000000e+00	0	0	4806	0.000000e+00	0	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091147	G	C	A	G	.	16	31102468	16	31009969	160	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.479C>G	p.A160G	c.479C>G	p.Ala160Gly	c.479C>G	p.Ala160Gly	principal1	Y	1	YES	-	GCT	2	0	G	./.	./.	./.	./.	0.343	0.12592	T	0.303	0.20164	T	0.037	0.20876	B	0.035	0.22741	B	0.312132	0.04022	N	1.470090	1;0.99738;0.99738;0.99738;0.99738	0.22680	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	A160G;.;.;.;.	2.015	0.55033	M	-4.84	0.98229	D	-1.11	0.28703	N	0.073	0.04668	0.3537	0.88394	D	0.8512	0.95039	D	10	0.06557137	0.08867	T	0.109074	0.78589	D	0.313	0.63482	0.184;	0.09259	Q9BQB6;	A160G;	Gain of loop (P = 0.0435);	0.650812743361	0.64791	0.2084686050572802	0.20762	0.377654865507	0.39193	0.255743741989	0.04396	T	0.122003	0.44537	T	0.011618	0.53246	T	-0.221088	0.52633	T	0.101395919919014	0.12509	T	0.444656	0.12411	T	0.025210006	0.01434	0.036058955	0.02977	0.025210006	0.01433	0.036058955	0.02977	-3.773	0.38610	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.069	0.03128	B	.;	.;	.;	.;	.;	.;	0.923202	0.14086	10.69	0.248800	0.07780	6.537	0.80122125508198672	0.13055	0.05570	0.11469	N	AEFBI	0.292870	0.40363	N	-1.19375423403694	0.05094	0.2314144	-1.25141522603195	0.05110	0.2427184	0.999249749096951	0.38873	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	-4.82	0.02938	0.206000	0.17174	.	.	-0.259000	0.06933	0.576000	0.27554	0.361000	0.24521	0.272000	0.23818	0.6815:0.0:0.1932:0.1253	8.0421	0.29688	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091148	C	T	A	T	.	16	31102469	16	31009970	160	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.478G>A	p.A160T	c.478G>A	p.Ala160Thr	c.478G>A	p.Ala160Thr	principal1	Y	1	YES	-	GCT	1	0	C	./.	./.	./.	./.	0.633	0.05106	T	0.656	0.06598	T	0.0	0.02946	B	0.001	0.04355	B	0.312132	0.04022	N	1.470090	1;0.999495;0.999495;0.999495;0.999495	0.21100	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	A160T;.;.;.;.	0.77	0.19370	N	-4.79	0.98155	D	-0.14	0.09135	N	0.039	0.01274	0.2911	0.87416	D	0.8422	0.94729	D	10	0.041015565	0.02720	T	0.057116	0.66849	D	0.361	0.68141	0.173;	0.07894	Q9BQB6;	A160T;	Gain of glycosylation at A160 (P = 0.0158);	0.692246650911	0.68960	0.1509110930171959	0.15013	0.355965481617	0.37353	0.264332234859	0.05417	T	0.061554	0.31683	T	0.00120539	0.51819	T	-0.236045	0.51183	T	0.0189314410090446	0.00603	T	0.435056	0.11905	T	0.020026706	0.00548	0.032607324	0.02023	0.020026706	0.00547	0.032607324	0.02023	-4.093	0.46692	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0714	0.04002	B	.;	.;	.;	.;	.;	.;	1.100540	0.16327	12.78	0.419657	0.09817	8.607	0.54745552159582767	0.05199	0.03467	0.08621	N	AEFBI	0.173151	0.30022	N	-1.09260648309404	0.06778	0.3130183	-1.07864135591045	0.08122	0.3979522	0.982663346453699	0.30435	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	-0.244	0.12388	0.183000	0.16729	.	.	-0.213000	0.08312	0.523000	0.27135	0.266000	0.24016	0.246000	0.23158	0.0:0.4858:0.0:0.5142	7.7531	0.28074	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091150	T	C	K	R	.	16	31102471	16	31009972	159	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.476A>G	p.K159R	c.476A>G	p.Lys159Arg	c.476A>G	p.Lys159Arg	principal1	Y	1	YES	-	AAG	2	0	T	./.	./.	./.	./.	0.166	0.23183	T	0.534	0.09965	T	0.948	0.53620	P	0.533	0.48638	P	0.002482	0.36462	N	0.195623	1;1;1;1;0.997526	0.81001	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;K159R	2.535	0.73915	M	-4.92	0.98371	D	-0.86	0.23372	N	0.119	0.10911	0.8470	0.94991	D	0.8928	0.96441	D	10	0.435744	0.57781	T	0.419437	0.93762	D	0.419	0.72855	0.241;	0.17371	Q9BQB6;	K159R;	Loss of ubiquitination at K159 (P = 0.0309);	0.96693425096	0.96657	0.3571237960638693	0.35626	0.356548275652	0.37394	0.388959646225	0.23523	T	0.095974	0.39730	T	0.110266	0.65380	D	-0.0793873	0.64949	T	0.498723566532135	0.32583	T	0.534247	0.17838	T	0.05973881	0.12177	0.060374968	0.11487	0.05973881	0.12177	0.060374968	0.11486	-3.776	0.38690	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0715	0.04041	B	.;	.;	.;	.;	.;	.;	3.148537	0.55383	23.7	2.806068	0.50415	23.2	0.99714512708875258	0.81563	0.95610	0.65411	D	AEFBI	0.641873	0.61905	D	0.212700566237059	0.51816	3.359845	0.212908637421568	0.50562	3.247022	0.999941644429603	0.47345	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	5.07	0.68106	3.883000	0.55880	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.257000	0.23443	0.0:0.0:0.0:1.0	12.7806	0.56853	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091151	T	C	K	E	.	16	31102472	16	31009973	159	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.475A>G	p.K159E	c.475A>G	p.Lys159Glu	c.475A>G	p.Lys159Glu	principal1	Y	1	YES	-	AAG	1	0	T	./.	./.	./.	./.	0.017	0.51248	D	0.095	0.39492	T	0.259	0.31472	B	0.039	0.23607	B	0.002482	0.36462	N	0.195623	1;1;1;1;0.988113	0.81001	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;K159E	2.885	0.83555	M	-4.94	0.98409	D	-1.22	0.30964	N	0.34	0.38129	0.7098	0.93298	D	0.8413	0.94697	D	10	0.36519605	0.53044	T	0.362327	0.92543	D	0.494	0.77973	0.256;	0.19689	Q9BQB6;	K159E;	Loss of MoRF binding (P = 8e-04);	0.929337570862	0.92861	0.6112849000359232	0.61060	0.766311475387	0.64530	0.415308505297	0.27191	T	0.104827	0.41474	T	0.20641	0.74493	D	0.0587177	0.74160	D	0.829819858074188	0.48516	D	0.50435	0.15896	T	0.13844593	0.32018	0.13950899	0.33283	0.13844593	0.32018	0.13950899	0.33282	-2.298	0.10703	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0882	0.11749	B	.;	.;	.;	.;	.;	.;	2.562088	0.42604	22.6	2.270096	0.38658	21.9	0.99819264911211736	0.90238	0.93808	0.59250	D	AEFBI	0.536839	0.55489	D	-0.211032236039362	0.32681	1.845692	-0.0906561784001004	0.35774	2.073789	0.999956037053493	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	5.07	0.68106	2.581000	0.45742	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.267000	0.23694	0.0:0.0:0.0:1.0	12.7806	0.56853	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091151	T	G	K	Q	.	16	31102472	16	31009973	159	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.475A>C	p.K159Q	c.475A>C	p.Lys159Gln	c.475A>C	p.Lys159Gln	principal1	Y	1	YES	-	AAG	1	0	T	./.	./.	./.	./.	0.062	0.36912	T	0.155	0.31936	T	0.985	0.61118	D	0.655	0.52639	P	0.002482	0.36462	N	0.195623	1;1;1;1;0.992892	0.81001	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;K159Q	2.335	0.66956	M	-4.97	0.98468	D	-0.98	0.25986	N	0.171	0.18239	0.9376	0.96212	D	0.9210	0.97385	D	10	0.4805178	0.60403	T	0.501253	0.95156	D	0.418	0.72780	0.185;	0.09388	Q9BQB6;	K159Q;	Loss of methylation at K159 (P = 0.0162);	0.958144174057	0.95769	0.49109224767051246	0.49030	0.486635153239	0.47518	0.399471759796	0.24994	T	0.114229	0.43188	T	0.171222	0.71235	D	0.00817231	0.70864	D	0.673352301120758	0.39487	D	0.557644	0.19406	T	0.11167893	0.26389	0.06162687	0.11930	0.11167893	0.26389	0.06162687	0.11930	-3.169	0.23871	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1086	0.20663	B	.;	.;	.;	.;	.;	.;	3.057651	0.53311	23.5	2.791541	0.50111	23.1	0.99357213170580561	0.60862	0.88129	0.47922	D	AEFBI	0.500340	0.53364	D	0.312660016076061	0.56799	3.845174	0.278486734765632	0.54286	3.593989	0.999956037053493	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	5.07	0.68106	2.581000	0.45742	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.267000	0.23694	0.0:0.0:0.0:1.0	12.7806	0.56853	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091153	C	A	G	V	rs775243992	16	31102474	16	31009975	158	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.473G>T	p.G158V	c.473G>T	p.Gly158Val	c.473G>T	p.Gly158Val	principal1	Y	1	YES	-	GGC	2	0	C	./.	./.	./.	./.	0.261	0.16520	T	0.226	0.25438	T	0.001	0.07471	B	0.001	0.04355	B	0.728242	0.06354	N	1.140370	0.989388;0.999955;0.999955;0.999955;0.999955	0.52396	D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae	G158V;.;.;.;.	1.355	0.33814	L	-4.68	0.97989	D	-0.68	0.19509	N	0.083	0.05929	0.2326	0.86456	D	0.8247	0.94111	D	10	0.06945008	0.09967	T	0.08599	0.74645	D	0.403	0.71636	0.169;	0.07419	Q9BQB6;	G158V;	Gain of methylation at K159 (P = 0.0424);	0.856506259199	0.85512	0.2840526353174208	0.28318	0.464426208277	0.45914	0.275047600269	0.06811	T	0.088995	0.38279	T	0.0542528	0.58888	T	-0.159846	0.58366	T	0.0240427933526311	0.01150	T	0.533947	0.17813	T	0.02702924	0.01838	0.043715574	0.05501	0.02702924	0.01838	0.043715574	0.05501	-4.523	0.56265	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0797	0.07650	B	.;	.;	.;	.;	.;	.;	0.702912	0.11444	8.482	1.040043	0.17435	13.70	0.83401820081019407	0.14706	0.09135	0.14951	N	AEFBI	0.391650	0.47001	N	-0.886118235121621	0.11172	0.5377243	-0.855919695716278	0.13145	0.6803399	0.987738012910594	0.31331	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	1.79	0.23992	0.161000	0.16298	.	.	-0.328000	0.05798	0.022000	0.19841	0.013000	0.20296	0.263000	0.23594	0.1906:0.4407:0.1585:0.2101	1.1471	0.01669	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	8.236e-06	1	8.379e-06	0	0	0	0	0	0	0	0	1	1.522e-05	0	0	1	9.415e-06	1	9.498e-06	0	0	0	0	0	0	0	0	1	1.848e-05	0	0	1	1.102e-05	1	1.125e-05	0	0	0	0	0	0	0	0	1	2.425e-05	0	0	segdup	1	250728	3.988390e-06	0	0	16126	0.000000e+00	0	0	34542	0.000000e+00	0	0	10052	0.000000e+00	0	0	18370	0.000000e+00	0	0	21642	0.000000e+00	0	1	113314	8.825030e-06	0	0	30560	0.000000e+00	0	1	113314	8.825030e-06	0	0	109302	0.000000e+00	0	1	207624	4.816400e-06	0	1	236576	4.226970e-06	0	1	244112	4.096480e-06	0	0	7146	0.000000e+00	0	0	17094	0.000000e+00	0	0	2320	0.000000e+00	0	0	9044	0.000000e+00	0	0	13392	0.000000e+00	0	0	42760	0.000000e+00	0	0	15640	0.000000e+00	0	.	.	.	.	0	16088	0.000000e+00	0	0	30482	0.000000e+00	0	0	6198	0.000000e+00	0	0	13394	0.000000e+00	0	0	16732	0.000000e+00	0	1	89330	1.119440e-05	0	0	30552	0.000000e+00	0	1	89330	1.119440e-05	0	0	14880	0.000000e+00	0	0	34226	0.000000e+00	0	0	9558	0.000000e+00	0	0	17688	0.000000e+00	0	0	21626	0.000000e+00	0	1	102514	9.754770e-06	0	0	30472	0.000000e+00	0	1	102514	9.754770e-06	0	0	11898	0.000000e+00	0	0	34408	0.000000e+00	0	0	9970	0.000000e+00	0	0	18366	0.000000e+00	0	0	21640	0.000000e+00	0	1	111224	8.990870e-06	0	0	30560	0.000000e+00	0	1	111224	8.990870e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091153	C	G	G	A	.	16	31102474	16	31009975	158	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.473G>C	p.G158A	c.473G>C	p.Gly158Ala	c.473G>C	p.Gly158Ala	principal1	Y	1	YES	-	GGC	2	0	C	./.	./.	./.	./.	0.87	0.02606	T	0.934	0.02742	T	0.001	0.07471	B	0.001	0.04355	B	0.728242	0.06354	N	1.140370	0.999943;0.999943;0.999943;0.999943;0.998352	0.51968	D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;G158A	1.13	0.28900	L	-4.59	0.97830	D	0.27	0.04306	N	0.06	0.03175	0.0175	0.82605	D	0.7451	0.91302	D	10	0.03596908	0.01872	T	0.058342	0.67285	D	0.378	0.69612	0.123;	0.02942	Q9BQB6;	G158A;	Gain of helix (P = 0.0325);	0.686812231222	0.68413	0.2285663970288938	0.22771	0.395717466595	0.40705	0.274502456188	0.06737	T	0.054904	0.29856	T	0.00733586	0.52662	T	-0.227239	0.52038	T	0.0213830646121933	0.00841	T	0.548145	0.18826	T	0.01753733	0.00281	0.027007483	0.00824	0.01753733	0.00281	0.027007483	0.00824	-3.435	0.30034	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0782	0.06942	B	.;	.;	.;	.;	.;	.;	0.247026	0.06418	3.669	0.516418	0.10968	9.556	0.52520753078271798	0.04763	0.04273	0.09810	N	AEFBI	0.213786	0.33933	N	-1.07369744637561	0.07131	0.3303561	-0.993790491657338	0.09924	0.4966397	0.987738012910594	0.31331	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	1.79	0.23992	0.161000	0.16298	.	.	-0.328000	0.05798	0.022000	0.19841	0.013000	0.20296	0.263000	0.23594	0.1906:0.4407:0.1585:0.2101	1.1471	0.01669	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091154	C	T	G	S	.	16	31102475	16	31009976	158	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.472G>A	p.G158S	c.472G>A	p.Gly158Ser	c.472G>A	p.Gly158Ser	principal1	Y	1	YES	-	GGC	1	0	C	./.	./.	./.	./.	0.762	0.03461	T	0.557	0.09205	T	0.001	0.07471	B	0.001	0.04355	B	0.728242	0.06354	N	1.140370	1;0.999986;0.999986;0.999986;0.999986	0.18198	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	G158S;.;.;.;.	1.355	0.33814	L	-4.63	0.97902	D	0.41	0.03407	N	0.055	0.02658	0.0852	0.83903	D	0.7947	0.93043	D	10	0.04682526	0.03922	T	0.040365	0.59336	D	0.303	0.62400	0.178;	0.08503	Q9BQB6;	G158S;	Gain of glycosylation at G158 (P = 0.0338);	0.765767290641	0.76362	0.2428647932569744	0.24200	0.368983407752	0.38434	0.273155272007	0.06556	T	0.067321	0.33173	T	0.0261318	0.55206	T	-0.20024	0.54624	T	0.0249739951576413	0.01269	T	0.572043	0.20399	T	0.040542334	0.05807	0.046417132	0.06466	0.040542334	0.05807	0.046417132	0.06466	-2.754	0.16113	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0801	0.07841	B	.;	.;	.;	.;	.;	.;	1.074941	0.15992	12.52	0.947139	0.16255	13.06	0.7454957694477794	0.10737	0.13416	0.17844	N	AEFBI	0.274177	0.38942	N	-0.921494914154413	0.10340	0.4936539	-0.910093822805931	0.11855	0.6065366	0.984540847959136	0.30735	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	4.7	0.552	0.16419	0.706000	0.25365	.	.	0.590000	0.31872	0.011000	0.18532	0.000000	0.08366	0.269000	0.23743	0.0:0.6585:0.0:0.3415	7.7894	0.28276	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091156	T	C	Q	R	.	16	31102477	16	31009978	157	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.470A>G	p.Q157R	c.470A>G	p.Gln157Arg	c.470A>G	p.Gln157Arg	principal1	Y	1	YES	-	CAG	2	0	T	./.	./.	./.	./.	0.25	0.17126	T	0.524	0.10317	T	0.0	0.02946	B	0.0	0.01387	B	0.771911	0.09541	N	0.887852	1;1;1;1;1	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	Q157R;.;.;.;.	1.86	0.49225	L	-4.7	0.98020	D	-0.59	0.17624	N	0.066	0.03841	0.0317	0.82884	D	0.7795	0.92509	D	10	0.08844006	0.15229	T	0.050953	0.64459	D	0.215	0.50805	0.234;	0.16305	Q9BQB6;	Q157R;	Gain of MoRF binding (P = 0.013);	0.7698382883	0.76772	0.13669533676692963	0.13593	0.396760723216	0.40786	0.272690445185	0.06494	T	0.074984	0.35069	T	0.0183493	0.54157	T	-0.211419	0.53558	T	0.803862392902374	0.46618	D	0.483452	0.14697	T	0.04694596	0.07945	0.060217958	0.11430	0.04694596	0.07944	0.060217958	0.11430	-3.776	0.38690	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0601	0.00949	B	.;	.;	.;	.;	.;	.;	1.188748	0.17480	13.55	0.994411	0.16856	13.39	0.92175367366487637	0.21540	0.07107	0.13132	N	AEFBI	0.245554	0.36646	N	-0.895394289014105	0.10951	0.5259559	-0.865238379113382	0.12922	0.6674937	0.990543407238792	0.32188	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	4.7	2.35	0.28166	0.168000	0.16438	.	.	0.654000	0.53741	0.009000	0.18154	0.007000	0.19602	0.264000	0.23619	0.0:0.0959:0.4267:0.4774	5.6791	0.17038	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091156	T	G	Q	P	.	16	31102477	16	31009978	157	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.470A>C	p.Q157P	c.470A>C	p.Gln157Pro	c.470A>C	p.Gln157Pro	principal1	Y	1	YES	-	CAG	2	0	T	./.	./.	./.	./.	0.279	0.15561	T	0.201	0.27503	T	0.0	0.02946	B	0.0	0.01387	B	0.771911	0.09541	N	0.887852	1;1;1;1;1	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	Q157P;.;.;.;.	2.555	0.74557	M	-4.75	0.98096	D	-1.58	0.38151	N	0.226	0.25377	0.2028	0.85955	D	0.8343	0.94451	D	10	0.12887213	0.24516	T	0.069067	0.70625	D	0.278	0.59497	0.265;	0.21103	Q9BQB6;	Q157P;	Gain of glycosylation at Q157 (P = 0.0053);	0.847007184374	0.84554	0.2668816976975354	0.26601	0.709609435278	0.61644	0.271060347557	0.06280	T	0.133201	0.46373	T	0.114912	0.65859	D	-0.0727133	0.65432	T	0.0538056586953754	0.06156	T	0.454655	0.12977	T	0.20899877	0.43153	0.15426663	0.36213	0.20899877	0.43153	0.15426663	0.36213	-4.659	0.58755	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0548	0.00375	B	.;	.;	.;	.;	.;	.;	1.299813	0.18989	14.39	1.081981	0.17976	13.96	0.68085528064339995	0.08550	0.05803	0.11740	N	AEFBI	0.349663	0.44337	N	-0.758540060866594	0.14402	0.7171358	-0.766897784260085	0.15307	0.8044181	0.990543407238792	0.32188	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	4.7	2.35	0.28166	0.168000	0.16438	.	.	0.654000	0.53741	0.009000	0.18154	0.007000	0.19602	0.264000	0.23619	0.0:0.0959:0.4267:0.4774	5.6791	0.17038	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091157	G	T	Q	K	.	16	31102478	16	31009979	157	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.469C>A	p.Q157K	c.469C>A	p.Gln157Lys	c.469C>A	p.Gln157Lys	principal1	Y	1	YES	-	CAG	1	0	G	./.	./.	./.	./.	0.372	0.11478	T	0.355	0.17217	T	0.0	0.02946	B	0.0	0.01387	B	0.771911	0.09541	N	0.887852	1;1;1;1;1	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	Q157K;.;.;.;.	0.965	0.23975	L	-4.64	0.97920	D	-0.33	0.12472	N	0.123	0.11483	-0.1040	0.80007	T	0.7970	0.93125	D	10	0.092607886	0.16320	T	0.066509	0.69897	D	0.299	0.61955	0.215;	0.13498	Q9BQB6;	Q157K;	Gain of methylation at Q157 (P = 0.016);	0.762071947071	0.75990	0.2338736435427771	0.23302	0.470108560931	0.46299	0.277462393045	0.07141	T	0.077223	0.35603	T	0.0492216	0.58244	T	-0.167073	0.57710	T	0.0304845041523393	0.02064	T	0.483452	0.14697	T	0.07045584	0.15520	0.050454877	0.07922	0.07045584	0.15520	0.050454877	0.07921	-3.305	0.26997	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0674	0.02609	B	.;	.;	.;	.;	.;	.;	0.999310	0.15034	11.61	0.984475	0.16733	13.32	0.78837397309988677	0.12474	0.14650	0.18514	N	AEFBI	0.291402	0.40254	N	-0.912311531490767	0.10553	0.5048428	-0.871282792924491	0.12777	0.6591905	0.99330596378742	0.33163	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	4.7	2.6	0.30173	0.973000	0.29020	.	.	0.665000	0.62972	0.022000	0.19841	0.118000	0.22871	0.250000	0.23263	0.0:0.0:0.6547:0.3453	11.5776	0.50128	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091159	G	C	P	R	.	16	31102480	16	31009981	156	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.467C>G	p.P156R	c.467C>G	p.Pro156Arg	c.467C>G	p.Pro156Arg	principal1	Y	1	YES	-	CCC	2	0	G	./.	./.	./.	./.	0.352	0.12226	T	0.127	0.35082	T	0.004	0.12183	B	0.007	0.12992	B	0.027463	0.25751	N	0.372017	1;0.999999;0.999999;0.999999;0.999999	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	P156R;.;.;.;.	2.16	0.60381	M	-4.67	0.97973	D	-0.55	0.16799	N	0.21	0.23380	-0.0931	0.80257	T	0.8198	0.93937	D	10	0.10008407	0.18204	T	0.041381	0.59893	D	0.272	0.58758	0.365;	0.37199	Q9BQB6;	P156R;	Gain of MoRF binding (P = 0.0013);	0.901312021487	0.90033	0.2816000967057124	0.28073	0.996515861578	0.74251	0.294072449207	0.09520	T	0.083187	0.36996	T	0.102926	0.64607	D	-0.0899306	0.64167	T	0.340119898319244	0.26628	T	0.710329	0.32115	T	0.03274928	0.03360	0.0374688	0.03407	0.03274928	0.03359	0.0374688	0.03407	-3.776	0.38690	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0843	0.09868	B	.;	.;	.;	.;	.;	.;	1.625516	0.23845	16.54	1.072796	0.17864	13.90	0.9962121995771519	0.75413	0.06639	0.12656	N	AEFBI	0.227412	0.35122	N	-0.563090656346828	0.20076	1.05562	-0.544398015981837	0.20954	1.131335	0.997678732909213	0.35891	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	4.7	3.74	0.42108	1.181000	0.31626	.	.	0.665000	0.62972	0.041000	0.21027	1.000000	0.68203	0.209000	0.22154	0.1002:0.0:0.699:0.2008	5.4347	0.15772	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091159	G	T	P	H	rs2057286468	16	31102480	16	31009981	156	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.467C>A	p.P156H	c.467C>A	p.Pro156His	c.467C>A	p.Pro156His	principal1	Y	1	YES	-	CCC	2	0	G	./.	./.	./.	./.	0.545	0.06691	T	0.092	0.39954	T	0.001	0.07471	B	0.002	0.06944	B	0.027463	0.25751	N	0.372017	1;0.999999;0.999999;0.999999;0.999999	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	P156H;.;.;.;.	1.555	0.39373	L	-4.7	0.98020	D	-0.55	0.16799	N	0.153	0.15749	-0.1685	0.78464	T	0.7781	0.92460	D	10	0.08230412	0.13568	T	0.041056	0.59718	D	0.252	0.56159	0.273;	0.22369	Q9BQB6;	P156H;	Loss of loop (P = 0.0073);	0.890335178546	0.88925	0.2248557229375831	0.22400	0.540324238068	0.51227	0.29214912653	0.09236	T	0.077404	0.35647	T	0.0790093	0.61925	D	-0.124285	0.61448	T	0.167485639345869	0.18407	T	0.653935	0.26417	T	0.046654556	0.07844	0.041726552	0.04809	0.046654556	0.07844	0.041726552	0.04809	0.0	0.02703	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1021	0.18037	B	.;	.;	.;	.;	.;	.;	1.513542	0.22092	15.82	1.022596	0.17214	13.58	0.99214118535912099	0.55685	0.05606	0.11511	N	AEFBI	0.204648	0.33107	N	-0.635418687663774	0.17888	0.9243	-0.589790838831924	0.19758	1.061547	0.997678732909213	0.35891	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	4.7	3.74	0.42108	1.181000	0.31626	.	.	0.665000	0.62972	0.041000	0.21027	1.000000	0.68203	0.209000	0.22154	0.1002:0.0:0.699:0.2008	5.4347	0.15772	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091160	G	A	P	S	.	16	31102481	16	31009982	156	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.466C>T	p.P156S	c.466C>T	p.Pro156Ser	c.466C>T	p.Pro156Ser	principal1	Y	1	YES	-	CCC	1	0	G	./.	./.	./.	./.	0.399	0.10517	T	0.239	0.24477	T	0.001	0.07471	B	0.001	0.04355	B	0.027463	0.25751	N	0.372017	1;1;1;1;1	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	P156S;.;.;.;.	2.71	0.79292	M	-4.64	0.97920	D	-0.27	0.11366	N	0.131	0.12627	-0.0746	0.80673	T	0.7972	0.93132	D	10	0.08020052	0.12989	T	0.065573	0.69619	D	0.267	0.58126	0.312;	0.28612	Q9BQB6;	P156S;	Loss of loop (P = 0.0073);	0.69121795763	0.68856	0.27195774231381414	0.27108	0.663932451619	0.59042	0.278360337019	0.07265	T	0.066206	0.32886	T	0.054578	0.58930	T	-0.159379	0.58409	T	0.108750339343248	0.13294	T	0.751525	0.37371	T	0.0187009	0.00392	0.026793528	0.00789	0.0187009	0.00392	0.026793528	0.00788	-2.754	0.16113	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0879	0.11606	B	.;	.;	.;	.;	.;	.;	1.152604	0.17005	13.25	0.161882	0.06715	5.261	0.98843247810396373	0.47169	0.10380	0.15903	N	AEFBI	0.249048	0.36935	N	-1.06871314063017	0.07225	0.3350103	-1.1013183103582	0.07675	0.3742786	0.98298615432636	0.30486	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	-0.51	0.11376	1.079000	0.30378	.	.	-0.147000	0.12262	0.037000	0.20830	1.000000	0.68203	0.184000	0.21420	0.2393:0.2704:0.4904:0.0	5.6045	0.16652	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091168	A	C	V	G	.	16	31102489	16	31009990	153	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.458T>G	p.V153G	c.458T>G	p.Val153Gly	c.458T>G	p.Val153Gly	principal1	Y	1	YES	-	GTC	2	0	A	./.	./.	./.	./.	0.012	0.54683	D	0.013	0.63109	D	0.0	0.02946	B	0.001	0.04355	B	0.439062	0.12650	N	0.723471	1;1;1;1;1	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	V153G;.;.;.;.	1.245	0.31408	L	-4.82	0.98198	D	-2.45	0.53577	N	0.253	0.28616	0.2183	0.86218	D	0.8068	0.93471	D	10	0.17292145	0.32091	T	0.085508	0.74547	D	0.507	0.78786	0.575;	0.69957	Q9BQB6;	V153G;	Gain of relative solvent accessibility (P = 0.005);	0.919757709133	0.91894	0.5050707014549071	0.50429	0.658412193222	0.58747	0.314019948244	0.12514	T	0.397323	0.75572	T	0.145802	0.68874	D	-0.0283427	0.68479	D	0.0396647319750506	0.03630	T	0.454355	0.12956	T	0.45978498	0.64657	0.28439075	0.54437	0.45978498	0.64658	0.28439075	0.54436	-3.773	0.38610	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0817	0.08609	B	.;	.;	.;	.;	.;	.;	1.247758	0.18275	14.00	0.703775	0.13238	11.18	0.9628806177855449	0.29305	0.44974	0.27436	N	AEFBI	0.256609	0.37550	N	-0.780114138960156	0.13829	0.6841527	-0.761019709232963	0.15451	0.8127322	0.982914875030526	0.30475	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.07	0.444	0.15803	0.599000	0.23788	.	.	0.743000	0.86499	0.092000	0.22623	0.006000	0.19429	0.139000	0.19909	0.4068:0.1791:0.4141:0.0	5.0122	0.13662	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091169	C	G	V	L	.	16	31102490	16	31009991	153	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.457G>C	p.V153L	c.457G>C	p.Val153Leu	c.457G>C	p.Val153Leu	principal1	Y	1	YES	-	GTC	1	0	C	./.	./.	./.	./.	1.0	0.00964	T	1.0	0.01155	T	0.001	0.07471	B	0.005	0.11217	B	0.439062	0.12650	N	0.723471	1;0.999999;0.999999;0.999999;0.999999	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	V153L;.;.;.;.	-0.11	0.04642	N	-4.59	0.97830	D	0.96	0.01488	N	0.157	0.16308	-0.1822	0.78125	T	0.6257	0.86842	D	10	0.05126944	0.04983	T	0.051246	0.64581	D	0.357	0.67782	0.467;	0.53891	Q9BQB6;	V153L;	Loss of MoRF binding (P = 0.1004);	0.683511509103	0.68081	0.29390074273523537	0.29303	0.369890665842	0.38515	0.324094772339	0.14041	T	0.044042	0.26692	T	0.0415603	0.57250	T	-0.178078	0.56700	T	0.0168481599539518	0.00438	T	0.69663	0.30630	T	0.08652927	0.20117	0.05146655	0.08289	0.08652927	0.20117	0.05146655	0.08289	-4.726	0.59903	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0986	0.16538	B	.;	.;	.;	.;	.;	.;	-0.265236	0.02511	0.370	-0.148598	0.03346	1.014	0.51271815393960962	0.04533	0.11479	0.16661	N	AEFBI	0.301647	0.41011	N	-1.40148269334888	0.02626	0.1162254	-1.31886809355748	0.04186	0.196939	0.987948220196593	0.31379	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.37	1.13	0.19758	0.083000	0.14718	.	.	-0.198000	0.09030	0.001000	0.13787	0.000000	0.08366	0.113000	0.18872	0.2902:0.5537:0.0:0.1561	5.1171	0.14173	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091170	C	A	K	N	rs760409299	16	31102491	16	31009992	152	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.456G>T	p.K152N	c.456G>T	p.Lys152Asn	c.456G>T	p.Lys152Asn	principal1	Y	1	YES	-	AAG	3	2	C	./.	./.	./.	./.	0.008	0.58626	D	0.007	0.69154	D	0.0	0.02946	B	0.001	0.04355	B	0.928806	0.08435	N	0.967406	1;0.999997;0.999997;0.999997;0.999997	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	K152N;.;.;.;.	1.625	0.41611	L	-4.78	0.98140	D	-1.38	0.34198	N	0.085	0.06190	0.4824	0.90298	D	0.8844	0.96162	D	10	0.16138926	0.30274	T	0.202553	0.86827	D	0.281	0.59861	0.441;	0.49648	Q9BQB6;	K152N;	Loss of methylation at K152 (P = 0.0015);	0.944577172479	0.94399	0.478956372068343	0.47815	0.601327463896	0.55178	0.291544616222	0.09147	T	0.217379	0.57980	T	0.0330204	0.56126	T	-0.190345	0.55557	T	0.127059750354288	0.15108	T	0.492351	0.15167	T	0.13836181	0.32002	0.08217889	0.18734	0.13836181	0.32002	0.08217889	0.18734	-2.908	0.18623	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1384	0.30264	B	.;	.;	.;	.;	.;	.;	1.194786	0.17564	13.59	0.848841	0.15016	12.33	0.95998217243652539	0.28408	0.08101	0.14071	N	AEFBI	0.284606	0.39743	N	-0.883802721330504	0.11228	0.5406917	-0.888115491195249	0.12374	0.6361919	0.997312056713959	0.35488	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.37	3.38	0.37806	0.118000	0.15436	.	.	-0.237000	0.07570	0.001000	0.13787	0.000000	0.08366	0.103000	0.18424	0.1575:0.691:0.1514:0.0	9.922	0.40639	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	8.236e-06	1	8.341e-06	0	0	0	0	0	0	0	0	1	1.516e-05	0	0	1	9.415e-06	1	9.466e-06	0	0	0	0	0	0	0	0	1	1.844e-05	0	0	1	1.102e-05	1	1.119e-05	0	0	0	0	0	0	0	0	1	2.413e-05	0	0	segdup	1	251030	3.983590e-06	0	0	16178	0.000000e+00	0	0	34570	0.000000e+00	0	0	10064	0.000000e+00	0	0	18378	0.000000e+00	0	0	21646	0.000000e+00	0	1	113478	8.812280e-06	0	0	30586	0.000000e+00	0	1	113478	8.812280e-06	0	0	109350	0.000000e+00	0	1	207834	4.811530e-06	0	1	236726	4.224290e-06	0	1	244412	4.091450e-06	0	0	7150	0.000000e+00	0	0	17106	0.000000e+00	0	0	2320	0.000000e+00	0	0	9044	0.000000e+00	0	0	13392	0.000000e+00	0	0	42762	0.000000e+00	0	0	15662	0.000000e+00	0	.	.	.	.	0	16140	0.000000e+00	0	0	30506	0.000000e+00	0	0	6206	0.000000e+00	0	0	13402	0.000000e+00	0	0	16732	0.000000e+00	0	1	89414	1.118390e-05	0	0	30578	0.000000e+00	0	1	89414	1.118390e-05	0	0	14888	0.000000e+00	0	0	34246	0.000000e+00	0	0	9562	0.000000e+00	0	0	17688	0.000000e+00	0	0	21630	0.000000e+00	0	1	102596	9.746970e-06	0	0	30496	0.000000e+00	0	1	102596	9.746970e-06	0	0	11948	0.000000e+00	0	0	34436	0.000000e+00	0	0	9982	0.000000e+00	0	0	18374	0.000000e+00	0	0	21644	0.000000e+00	0	1	111388	8.977630e-06	0	0	30586	0.000000e+00	0	1	111388	8.977630e-06	0	.	1	152166	6.571770e-06	0	1	68030	1.469940e-05	0	0	41434	0.000000e+00	0	0	912	0.000000e+00	0	0	15274	0.000000e+00	0	0	3470	0.000000e+00	0	0	5190	0.000000e+00	0	0	10622	0.000000e+00	0	0	316	0.000000e+00	0	1	68030	1.469940e-05	0	0	4830	0.000000e+00	0	1	32892	3.040250e-05	0	1	134746	7.421370e-06	0	1	147918	6.760500e-06	0	0	80724	0.000000e+00	0	0	9094	0.000000e+00	0	0	60	0.000000e+00	0	0	4686	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5490	0.000000e+00	0	0	246	0.000000e+00	0	1	6850	1.459850e-04	0	0	3112	0.000000e+00	0	0	32458	0.000000e+00	0	0	862	0.000000e+00	0	0	14828	0.000000e+00	0	0	3386	0.000000e+00	0	0	5190	0.000000e+00	0	0	6980	0.000000e+00	0	0	310	0.000000e+00	0	1	63906	1.564800e-05	0	0	4828	0.000000e+00	0	0	41112	0.000000e+00	0	0	912	0.000000e+00	0	0	15086	0.000000e+00	0	0	3302	0.000000e+00	0	0	4956	0.000000e+00	0	0	10622	0.000000e+00	0	0	304	0.000000e+00	0	1	64806	1.543070e-05	0	0	4798	0.000000e+00	0	0	24812	0.000000e+00	0	0	112	0.000000e+00	0	0	12900	0.000000e+00	0	0	996	0.000000e+00	0	0	3748	0.000000e+00	0	0	10530	0.000000e+00	0	0	272	0.000000e+00	0	0	21038	0.000000e+00	0	0	4802	0.000000e+00	0	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091170	C	G	K	N	.	16	31102491	16	31009992	152	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.456G>C	p.K152N	c.456G>C	p.Lys152Asn	c.456G>C	p.Lys152Asn	principal1	Y	1	YES	-	AAG	3	2	C	./.	./.	./.	./.	0.008	0.58626	D	0.007	0.69154	D	0.0	0.02946	B	0.001	0.04355	B	0.928806	0.08435	N	0.967406	1;0.999997;0.999997;0.999997;0.999997	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	K152N;.;.;.;.	1.625	0.41611	L	-4.78	0.98140	D	-1.38	0.34198	N	0.085	0.06190	0.4824	0.90298	D	0.8844	0.96162	D	10	0.15980914	0.30017	T	0.202561	0.86827	D	0.281	0.59861	0.441;	0.49648	Q9BQB6;	K152N;	Loss of methylation at K152 (P = 0.0015);	0.944577172479	0.94399	0.47895635829730854	0.47815	0.601327463896	0.55178	0.291544616222	0.09147	T	0.217379	0.57980	T	0.0329967	0.56121	T	-0.190379	0.55555	T	0.130060712224433	0.15388	T	0.492351	0.15167	T	0.13836181	0.32002	0.08217889	0.18734	0.13836181	0.32002	0.08217889	0.18734	-2.908	0.18623	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1384	0.30264	B	.;	.;	.;	.;	.;	.;	1.212038	0.17791	13.73	0.838290	0.14895	12.25	0.95590681508701347	0.27312	0.04716	0.10409	N	AEFBI	0.188976	0.31624	N	-0.883802721330504	0.11228	0.5406917	-0.888115491195249	0.12374	0.6361919	0.997312056713959	0.35488	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.37	3.38	0.37806	0.118000	0.15436	.	.	-0.237000	0.07570	0.001000	0.13787	0.000000	0.08366	0.103000	0.18424	0.1575:0.691:0.1514:0.0	9.922	0.40639	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091171	T	A	K	M	.	16	31102492	16	31009993	152	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.455A>T	p.K152M	c.455A>T	p.Lys152Met	c.455A>T	p.Lys152Met	principal1	Y	1	YES	-	AAG	2	0	T	./.	./.	./.	./.	0.003	0.68238	D	0.002	0.79402	D	0.256	0.31372	B	0.277	0.40197	B	0.928806	0.08435	N	0.967406	1;1;1;1;1	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	K152M;.;.;.;.	1.625	0.41611	L	-4.84	0.98229	D	-2.15	0.48687	N	0.215	0.24010	0.6843	0.92979	D	0.8931	0.96452	D	10	0.26362407	0.43842	T	0.232217	0.88311	D	0.440	0.74377	0.55;	0.66576	Q9BQB6;	K152M;	Loss of methylation at K152 (P = 0.0015);	0.965361646043	0.96499	0.5411059181764242	0.54035	1.21715415396	0.81002	0.27522701025	0.06836	T	0.265356	0.63722	T	0.15045	0.69310	D	-0.0216649	0.68919	D	0.278941247165799	0.24127	T	0.652235	0.26282	T	0.14363152	0.33004	0.08630325	0.19986	0.14363152	0.33003	0.08630325	0.19986	-6.249	0.75275	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1559	0.34492	B	.;	.;	.;	.;	.;	.;	2.263574	0.36065	21.3	1.337286	0.21463	15.39	0.97959741970407022	0.37165	0.18111	0.20124	N	AEFBI	0.308961	0.41540	N	-0.721272297101652	0.15424	0.7772172	-0.79100782264061	0.14716	0.7703501	0.988032467055573	0.31402	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.37	1.85	0.24418	1.071000	0.30278	.	.	-0.144000	0.12334	0.002000	0.15269	0.059000	0.21998	0.101000	0.18331	0.0:0.2802:0.1726:0.5471	4.285	0.10296	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091172	T	C	K	E	.	16	31102493	16	31009994	152	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.454A>G	p.K152E	c.454A>G	p.Lys152Glu	c.454A>G	p.Lys152Glu	principal1	Y	1	YES	-	AAG	1	0	T	./.	./.	./.	./.	0.16	0.23721	T	0.093	0.39799	T	0.0	0.02946	B	0.001	0.04355	B	0.928806	0.08435	N	0.967406	1;1;1;1;1	0.08975	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	K152E;.;.;.;.	0.135	0.08676	N	-4.71	0.98035	D	-1.08	0.28084	N	0.024	0.00445	0.0356	0.82961	D	0.7461	0.91337	D	10	0.08971813	0.15567	T	0.029668	0.52133	D	0.328	0.65026	0.476;	0.55342	Q9BQB6;	K152E;	Loss of methylation at K152 (P = 0.0015);	0.870800041853	0.86954	0.4436416283278772	0.44282	0.5188062491	0.49721	0.282377123833	0.07826	T	0.180703	0.53213	T	0.0749528	0.61444	D	-0.130112	0.60963	T	0.0284942164957966	0.01760	T	0.49565	0.15376	T	0.11206906	0.26478	0.06672031	0.13707	0.11206906	0.26478	0.06672031	0.13707	-2.298	0.10703	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0661	0.02228	B	.;	.;	.;	.;	.;	.;	1.163255	0.17141	13.34	0.532261	0.11161	9.702	0.9114431730423701	0.20398	0.01234	0.04361	N	AEFBI	0.116408	0.22848	N	-1.10019745559572	0.06641	0.3062524	-1.12296235263015	0.07262	0.3526207	0.991960251910272	0.32671	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.37	-2.35	0.06302	0.430000	0.21147	.	.	0.654000	0.53741	0.001000	0.13787	0.000000	0.08366	0.105000	0.18517	0.0:0.1728:0.4033:0.4239	5.9703	0.18584	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091174	C	A	R	L	rs199952041	16	31102495	16	31009996	151	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.452G>T	p.R151L	c.452G>T	p.Arg151Leu	c.452G>T	p.Arg151Leu	principal1	Y	1	YES	-	CGG	2	0	C	./.	./.	./.	./.	0.188	0.21304	T	0.158	0.31629	T	0.13	0.27095	B	0.098	0.30479	B	0.057474	0.22478	N	0.415463	0.999999;0.977109;0.977109;0.977109;0.977109	0.25333	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	R151L;.;.;.;.	1.155	0.29575	L	-4.55	0.97753	D	-2.5	0.54382	D	0.237	0.26717	0.0229	0.82711	D	0.7891	0.92847	D	10	0.13849774	0.26339	T	0.223038	0.87883	D	0.451	0.75143	0.436;	0.48828	Q9BQB6;	R151L;	Loss of MoRF binding (P = 0.0259);	0.760201544561	0.75802	0.1856589658950141	0.18483	0.824600543176	0.67326	0.209350556135	0.00784	T	0.2393	0.60739	T	-0.0247132	0.48179	T	-0.0911283	0.64076	T	0.108941785991192	0.13313	T	0.740526	0.35940	T	0.31501484	0.54217	0.21635547	0.46260	0.31501484	0.54217	0.21635547	0.46259	-4.726	0.59903	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.1365	0.29751	B	.;	.;	.;	.;	.;	.;	0.691509	0.11308	8.377	0.476579	0.10494	9.180	0.88016202822961975	0.17653	0.09654	0.15361	N	AEFBI	0.345216	0.44045	N	-1.25883647313792	0.04184	0.188374	-1.27883227304382	0.04717	0.2231648	0.987107982168267	0.31185	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	-1.59	0.08003	-0.062000	0.11631	.	.	-2.791000	0.00187	0.007000	0.17678	0.000000	0.08366	0.098000	0.18187	0.0:0.4324:0.0:0.5676	10.9833	0.46722	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	251044	3.983370e-06	0	1	16190	6.176650e-05	0	0	34568	0.000000e+00	0	0	10062	0.000000e+00	0	0	18378	0.000000e+00	0	0	21648	0.000000e+00	0	0	113480	0.000000e+00	0	0	30590	0.000000e+00	0	1	16190	6.176650e-05	0	1	109350	9.144950e-06	0	1	207850	4.811160e-06	0	1	236724	4.224330e-06	0	1	244426	4.091220e-06	0	1	7150	1.398600e-04	0	0	17104	0.000000e+00	0	0	2320	0.000000e+00	0	0	9044	0.000000e+00	0	0	13394	0.000000e+00	0	0	42760	0.000000e+00	0	0	15666	0.000000e+00	0	1	7150	1.398600e-04	0	1	16152	6.191180e-05	0	0	30504	0.000000e+00	0	0	6206	0.000000e+00	0	0	13402	0.000000e+00	0	0	16734	0.000000e+00	0	0	89416	0.000000e+00	0	0	30582	0.000000e+00	0	1	16152	6.191180e-05	0	1	14888	6.716820e-05	0	0	34244	0.000000e+00	0	0	9560	0.000000e+00	0	0	17688	0.000000e+00	0	0	21632	0.000000e+00	0	0	102594	0.000000e+00	0	0	30500	0.000000e+00	0	1	14888	6.716820e-05	0	1	11960	8.361200e-05	0	0	34434	0.000000e+00	0	0	9980	0.000000e+00	0	0	18374	0.000000e+00	0	0	21646	0.000000e+00	0	0	111390	0.000000e+00	0	0	30590	0.000000e+00	0	1	11960	8.361200e-05	0	.	2	152176	1.314270e-05	0	2	41428	4.827650e-05	0	2	41428	4.827650e-05	0	0	912	0.000000e+00	0	0	15274	0.000000e+00	0	0	3472	0.000000e+00	0	0	5190	0.000000e+00	0	0	10624	0.000000e+00	0	0	316	0.000000e+00	0	0	68036	0.000000e+00	0	0	4834	0.000000e+00	0	1	32892	3.040250e-05	0	2	134756	1.484160e-05	0	2	147918	1.352100e-05	0	1	80734	1.238640e-05	0	1	9088	1.100350e-04	0	0	60	0.000000e+00	0	0	4686	0.000000e+00	0	0	136	0.000000e+00	0	0	2428	0.000000e+00	0	0	5496	0.000000e+00	0	0	246	0.000000e+00	0	0	6854	0.000000e+00	0	0	3112	0.000000e+00	0	2	32452	6.162950e-05	0	0	862	0.000000e+00	0	0	14828	0.000000e+00	0	0	3388	0.000000e+00	0	0	5190	0.000000e+00	0	0	6984	0.000000e+00	0	0	310	0.000000e+00	0	0	63910	0.000000e+00	0	0	4832	0.000000e+00	0	2	41106	4.865470e-05	0	0	912	0.000000e+00	0	0	15086	0.000000e+00	0	0	3302	0.000000e+00	0	0	4954	0.000000e+00	0	0	10624	0.000000e+00	0	0	304	0.000000e+00	0	0	64808	0.000000e+00	0	0	4802	0.000000e+00	0	1	24804	4.031610e-05	0	0	112	0.000000e+00	0	0	12900	0.000000e+00	0	0	998	0.000000e+00	0	0	3748	0.000000e+00	0	0	10532	0.000000e+00	0	0	272	0.000000e+00	0	0	21046	0.000000e+00	0	0	4806	0.000000e+00	0	0	32782	0	0	122	0	0	112	0	0	3438	0	0	498	0	0	628	0	0	56	0	0	98	0	0	7050	0	0	3560	0	0	168	0	0	44784	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091174	C	T	R	Q	rs199952041	16	31102495	16	31009996	151	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.452G>A	p.R151Q	c.452G>A	p.Arg151Gln	c.452G>A	p.Arg151Gln	principal1	Y	1	YES	-	CGG	2	0	C	./.	./.	./.	./.	0.344	0.12552	T	0.326	0.18789	T	0.0	0.02946	B	0.001	0.04355	B	0.057474	0.22478	N	0.415463	1;0.977109;0.977109;0.977109;0.977109	0.25333	N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae	R151Q;.;.;.;.	-0.295	0.03650	N	-4.62	0.97884	D	-0.64	0.18670	N	0.071	0.04426	-0.2526	0.76289	T	0.6974	0.89572	D	10	0.031776756	0.01317	T	0.050693	0.64350	D	0.380	0.69780	.;	.	.;	.;	.;	0.798984377137	0.79711	0.06350337650616902	0.06289	0.440126787605	0.44029	0.202910378575	0.00546	T	0.093351	0.39192	T	-0.1934	0.21762	T	-0.260536	0.48772	T	0.03825523984559	0.03377	T	0.60194	0.22516	T	0.05283004	0.09910	0.05534108	0.09690	0.05283004	0.09909	0.05534108	0.09689	-3.169	0.23871	T	.	.	.	.	.	.	.	.	.	.	.	.	.	0.0703	0.03588	B	.;	.;	.;	.;	.;	.;	0.700796	0.11418	8.462	0.492690	0.10685	9.334	0.80940025482544575	0.13442	0.02801	0.07522	N	AEFBI	0.156357	0.28170	N	-1.40502274861453	0.02594	0.1147697	-1.36025855749108	0.03686	0.1724712	0.987107982168267	0.31185	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	-1.59	0.08003	-0.062000	0.11631	.	.	-2.791000	0.00187	0.007000	0.17678	0.000000	0.08366	0.098000	0.18187	0.0:0.4324:0.0:0.5676	10.9833	0.46722	41	0.97903	1	1.9968051118210862E-4	0	0.0	1	9.940357852882703E-4	0	0.0	0	0.0	0	0.0	1	2.6968716289104636E-4	0	0.0	1	1.322401481089659E-4	0	0.0	1	1.1627906976744187E-4	13	1.071e-04	13	1.084e-04	0	0	1	8.741e-05	1	1.162e-04	0	0	10	1.515e-04	0	0	11	1.036e-04	11	1.041e-04	0	0	1	8.996e-05	1	1.273e-04	0	0	8	1.475e-04	0	0	12	1.322e-04	12	1.342e-04	0	0	1	8.750e-05	1	1.789e-04	0	0	9	2.171e-04	0	0	segdup	23	251044	9.161740e-05	0	0	16190	0.000000e+00	0	3	34568	8.678550e-05	0	0	10062	0.000000e+00	0	1	18378	5.441290e-05	0	0	21648	0.000000e+00	0	18	113480	1.586180e-04	0	0	30590	0.000000e+00	0	18	113480	1.586180e-04	0	7	109350	6.401460e-05	0	21	207850	1.010340e-04	0	19	236724	8.026220e-05	0	23	244426	9.409800e-05	0	0	7150	0.000000e+00	0	1	17104	5.846590e-05	0	0	2320	0.000000e+00	0	0	9044	0.000000e+00	0	0	13394	0.000000e+00	0	6	42760	1.403180e-04	0	0	15666	0.000000e+00	0	6	42760	1.403180e-04	0	0	16152	0.000000e+00	0	3	30504	9.834780e-05	0	0	6206	0.000000e+00	0	1	13402	7.461570e-05	0	0	16734	0.000000e+00	0	16	89416	1.789390e-04	0	0	30582	0.000000e+00	0	16	89416	1.789390e-04	0	0	14888	0.000000e+00	0	3	34244	8.760660e-05	0	0	9560	0.000000e+00	0	1	17688	5.653550e-05	0	0	21632	0.000000e+00	0	14	102594	1.364600e-04	0	0	30500	0.000000e+00	0	14	102594	1.364600e-04	0	0	11960	0.000000e+00	0	3	34434	8.712320e-05	0	0	9980	0.000000e+00	0	1	18374	5.442470e-05	0	0	21646	0.000000e+00	0	18	111390	1.615940e-04	0	0	30590	0.000000e+00	0	18	111390	1.615940e-04	0	.	16	152176	1.051410e-04	0	3	15274	1.964120e-04	0	1	41428	2.413830e-05	0	0	912	0.000000e+00	0	3	15274	1.964120e-04	0	0	3472	0.000000e+00	0	0	5190	0.000000e+00	0	0	10624	0.000000e+00	0	0	316	0.000000e+00	0	10	68036	1.469810e-04	0	0	4834	0.000000e+00	0	7	32892	2.128180e-04	0	15	134756	1.113120e-04	0	16	147918	1.081680e-04	0	11	80734	1.362500e-04	0	1	9088	1.100350e-04	0	0	60	0.000000e+00	0	2	4686	4.268030e-04	0	0	136	0.000000e+00	0	0	2428	0.000000e+00	0	0	5496	0.000000e+00	0	0	246	0.000000e+00	0	3	6854	4.377010e-04	0	0	3112	0.000000e+00	0	1	32452	3.081470e-05	0	0	862	0.000000e+00	0	3	14828	2.023200e-04	0	0	3388	0.000000e+00	0	0	5190	0.000000e+00	0	0	6984	0.000000e+00	0	0	310	0.000000e+00	0	9	63910	1.408230e-04	0	0	4832	0.000000e+00	0	1	41106	2.432730e-05	0	0	912	0.000000e+00	0	3	15086	1.988600e-04	0	0	3302	0.000000e+00	0	0	4954	0.000000e+00	0	0	10624	0.000000e+00	0	0	304	0.000000e+00	0	10	64808	1.543020e-04	0	0	4802	0.000000e+00	0	1	24804	4.031610e-05	0	0	112	0.000000e+00	0	3	12900	2.325580e-04	0	0	998	0.000000e+00	0	0	3748	0.000000e+00	0	0	10532	0.000000e+00	0	0	272	0.000000e+00	0	5	21046	2.375750e-04	0	0	4806	0.000000e+00	0	3	32782	9.151363553169422E-5	0	122	0	0	112	0	0	3438	0	0	498	0	0	628	0	0	56	0	0	98	0	0	7050	0	0	3560	0	0	168	0	3	44784	6.69882100750268E-5	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091176	G	C	F	L	.	16	31102497	16	31009998	150	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.450C>G	p.F150L	c.450C>G	p.Phe150Leu	c.450C>G	p.Phe150Leu	principal1	Y	1	YES	-	TTC	3	2	G	./.	./.	./.	./.	0.579	0.06011	T	0.563	0.09022	T	0.159	0.28304	B	0.056	0.26147	B	0.000883	0.41231	D	0.168520	1;1;1;1;1;0.974652	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;F150L	0.885	0.21608	L	-4.53	0.97713	D	-1.48	0.36189	N	0.106	0.09066	0.2786	0.87212	D	0.6911	0.89342	D	10	0.26194155	0.43658	T	0.083902	0.74213	D	0.482	0.77206	0.445;	0.50302	Q9BQB6;	F150L;	Gain of disorder (P = 0.1121);	0.977126969176	0.97687	0.3203071419917317	0.31943	0.95540662763	0.72788	0.46743953228	0.34329	T	0.541953	0.84333	D	0.125513	0.66922	D	-0.057486	0.66508	T	0.617646753787994	0.37109	D	0.762724	0.38847	T	0.19492608	0.41261	0.104565516	0.25116	0.19492608	0.41261	0.104565516	0.25115	-4.726	0.59903	T	0.06272665302798927	0.01878	B	B	B	B	B	B	B	B	B	B	B	0.613	0.69415	P	.;	.;	.;	.;	.;	.;	2.179852	0.34288	20.7	2.304561	0.39411	22.0	0.99490437852856384	0.67403	0.97288	0.73812	D	AEFBI	0.867239	0.78694	D	-0.220191764257679	0.32305	1.820513	0.042387372788496	0.41705	2.510092	0.999984798034344	0.51787	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.94	0.64645	2.775000	0.47387	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.412000	0.27050	0.0761:0.0:0.9239:0.0	13.4682	0.60721	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091176	G	T	F	L	.	16	31102497	16	31009998	150	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.450C>A	p.F150L	c.450C>A	p.Phe150Leu	c.450C>A	p.Phe150Leu	principal1	Y	1	YES	-	TTC	3	2	G	./.	./.	./.	./.	0.579	0.06011	T	0.563	0.09022	T	0.159	0.28304	B	0.056	0.26147	B	0.000883	0.41231	D	0.168520	1;1;1;1;1;0.971814	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;F150L	0.885	0.21608	L	-4.53	0.97713	D	-1.48	0.36189	N	0.106	0.09066	0.2786	0.87212	D	0.6911	0.89342	D	10	0.2673815	0.44249	T	0.105729	0.78098	D	0.482	0.77206	0.445;	0.50302	Q9BQB6;	F150L;	Gain of disorder (P = 0.1121);	0.977126969176	0.97687	0.32030712822069723	0.31943	0.95540662763	0.72788	0.46743953228	0.34329	T	0.541953	0.84333	D	0.125512	0.66922	D	-0.0574874	0.66508	T	0.692427039146423	0.40361	D	0.762724	0.38847	T	0.19492608	0.41261	0.104565516	0.25116	0.19492608	0.41261	0.104565516	0.25115	-4.726	0.59903	T	0.06272665302798927	0.01878	B	B	B	B	B	B	B	B	B	B	B	0.613	0.69415	P	.;	.;	.;	.;	.;	.;	2.206370	0.34847	20.9	2.358605	0.40593	22.2	0.99479589777967004	0.66795	0.97151	0.72989	D	AEFBI	0.867239	0.78694	D	-0.220191764257679	0.32305	1.820513	0.042387372788496	0.41705	2.510092	0.999984798034344	0.51787	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.94	0.64645	2.775000	0.47387	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.412000	0.27050	0.0761:0.0:0.9239:0.0	13.4682	0.60721	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091178	A	G	F	L	.	16	31102499	16	31010000	150	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.448T>C	p.F150L	c.448T>C	p.Phe150Leu	c.448T>C	p.Phe150Leu	principal1	Y	1	YES	-	TTC	1	0	A	./.	./.	./.	./.	0.579	0.06011	T	0.563	0.09022	T	0.159	0.28304	B	0.056	0.26147	B	0.000883	0.41231	D	0.168520	1;1;1;1;1;0.996349	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;F150L	0.885	0.21608	L	-4.53	0.97713	D	-1.48	0.36189	N	0.106	0.09066	0.2444	0.86651	D	0.6790	0.88896	D	10	0.23413137	0.40446	T	0.109827	0.78696	D	0.426	0.73372	0.445;	0.50302	Q9BQB6;	F150L;	Gain of disorder (P = 0.1121);	0.967988836193	0.96764	0.3203071557627662	0.31943	0.95540662763	0.72788	0.46743953228	0.34329	T	0.541953	0.84333	D	0.123743	0.66745	D	-0.0600279	0.66330	T	0.619997501373291	0.37206	D	0.762724	0.38847	T	0.12693848	0.29719	0.07536698	0.16586	0.12693848	0.29719	0.07536698	0.16585	-4.726	0.59903	T	0.06272665302798927	0.01878	B	B	B	B	B	B	B	B	B	B	B	0.613	0.69415	P	.;	.;	.;	.;	.;	.;	1.985015	0.30301	19.14	2.273329	0.38729	21.9	0.99406213221822792	0.63028	0.90627	0.51960	D	AEFBI	0.466574	0.51416	N	-0.366798605029431	0.26660	1.456657	-0.101246163548931	0.35341	2.043438	0.999949914087985	0.47345	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	2.191000	0.42272	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.517000	0.29406	0.9225:0.0:0.0775:0.0	9.7997	0.39925	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091178	A	T	F	I	.	16	31102499	16	31010000	150	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.448T>A	p.F150I	c.448T>A	p.Phe150Ile	c.448T>A	p.Phe150Ile	principal1	Y	1	YES	-	TTC	1	0	A	./.	./.	./.	./.	0.248	0.17239	T	0.322	0.19016	T	0.826	0.45919	P	0.294	0.40804	B	0.000883	0.41231	D	0.168520	1;1;1;1;1;0.996688	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;F150I	0.805	0.20218	L	-4.55	0.97753	D	-1.64	0.39314	N	0.368	0.40963	0.5649	0.91435	D	0.8002	0.93238	D	10	0.52869725	0.63058	D	0.267555	0.89752	D	0.466	0.76156	0.475;	0.55182	Q9BQB6;	F150I;	Gain of MoRF binding (P = 0.0851);	0.990378510434	0.99027	0.433584517920013	0.43275	1.11629051259	0.78181	0.445637613535	0.31348	T	0.549272	0.84708	D	0.156055	0.69834	D	-0.0136144	0.69448	D	0.708521962165833	0.41128	D	0.729427	0.34485	T	0.15089145	0.34329	0.08136195	0.18485	0.15089145	0.34329	0.08136195	0.18484	-5.673	0.71160	T	0.08223324159293262	0.04325	B	B	B	B	B	B	B	B	B	B	B	0.1795	0.39099	B	.;	.;	.;	.;	.;	.;	2.309065	0.37057	21.6	2.614952	0.46264	22.8	0.98557620845311278	0.42935	0.88439	0.48367	D	AEFBI	0.456648	0.50842	N	0.163351514579814	0.49447	3.144899	0.276696501090742	0.54182	3.583954	0.999949914087985	0.47345	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	2.191000	0.42272	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.517000	0.29406	0.9225:0.0:0.0775:0.0	9.7997	0.39925	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091179	A	C	S	R	.	16	31102500	16	31010001	149	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.447T>G	p.S149R	c.447T>G	p.Ser149Arg	c.447T>G	p.Ser149Arg	principal1	Y	1	YES	-	AGT	3	2	A	./.	./.	./.	./.	0.004	0.65419	D	0.014	0.62352	D	0.989	0.62824	D	0.856	0.61001	P	0.000016	0.62929	D	0.071118	1;1;1;1;1;0.970799	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;S149R	1.91	0.51138	L	-4.85	0.98245	D	-1.38	0.34198	N	0.611	0.62781	0.8263	0.94737	D	0.9132	0.97123	D	10	0.90337396	0.89701	D	0.53589	0.95656	D	0.702	0.89284	0.672;	0.81002	Q9BQB6;	S149R;	Gain of MoRF binding (P = 0.0162);	0.9949161453	0.99486	0.6833639954596349	0.68275	1.03574248498	0.75590	0.391884922981	0.23935	T	0.712222	0.91800	D	0.216374	0.75432	D	0.0730294	0.75112	D	0.804720520973206	0.46677	D	0.788921	0.42853	T	0.9663418	0.97910	0.73214597	0.84171	0.9663418	0.97911	0.73214597	0.84172	-3.776	0.38690	T	0.3949142857817379	0.48757	U	U	U	U	U	U	U	U	U	U	B	0.9511	0.87028	P	.;	.;	.;	.;	.;	.;	2.798907	0.47714	23.0	3.124289	0.57640	23.9	0.99720735868265742	0.82054	0.87159	0.46615	D	AEFBI	0.544006	0.55910	D	0.144001409246685	0.48528	3.064002	0.0866581327201949	0.43876	2.680373	0.983999566820733	0.30647	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	0.047	0.13594	0.897000	0.28022	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.536000	0.29845	0.5044:0.0:0.4956:0.0	10.0675	0.41486	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091179	A	T	S	R	.	16	31102500	16	31010001	149	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.447T>A	p.S149R	c.447T>A	p.Ser149Arg	c.447T>A	p.Ser149Arg	principal1	Y	1	YES	-	AGT	3	2	A	./.	./.	./.	./.	0.004	0.65419	D	0.014	0.62352	D	0.989	0.62824	D	0.856	0.61001	P	0.000016	0.62929	D	0.071118	1;1;1;1;1;0.97271	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;S149R	1.91	0.51138	L	-4.85	0.98245	D	-1.38	0.34198	N	0.611	0.62781	0.8263	0.94737	D	0.9132	0.97123	D	10	0.9033929	0.89703	D	0.537582	0.95679	D	0.702	0.89284	0.672;	0.81002	Q9BQB6;	S149R;	Gain of MoRF binding (P = 0.0162);	0.9949161453	0.99486	0.683363940375497	0.68275	1.03574248498	0.75590	0.391884922981	0.23935	T	0.712222	0.91800	D	0.216372	0.75432	D	0.0730274	0.75112	D	0.805959197207609	0.46763	D	0.788921	0.42853	T	0.9663418	0.97910	0.73214597	0.84171	0.9663418	0.97911	0.73214597	0.84172	-3.776	0.38690	T	0.3949142857817379	0.48757	U	U	U	U	U	U	U	U	U	U	B	0.9511	0.87028	P	.;	.;	.;	.;	.;	.;	2.785421	0.47427	23.0	3.131317	0.57823	23.9	0.99713989018618299	0.81563	0.86462	0.45747	D	AEFBI	0.531482	0.55174	D	0.144001409246685	0.48528	3.064002	0.0866581327201949	0.43876	2.680373	0.983999566820733	0.30647	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	0.047	0.13594	0.897000	0.28022	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.536000	0.29845	0.5044:0.0:0.4956:0.0	10.0675	0.41486	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091181	T	C	S	G	.	16	31102502	16	31010003	149	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.445A>G	p.S149G	c.445A>G	p.Ser149Gly	c.445A>G	p.Ser149Gly	principal1	Y	1	YES	-	AGT	1	0	T	./.	./.	./.	./.	0.017	0.51248	D	0.066	0.44501	T	0.91	0.50240	P	0.468	0.46719	P	0.000016	0.62929	D	0.071118	0.627494;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	S149G;.;.;.;.;.	2.255	0.64187	M	-4.85	0.98245	D	-1.66	0.39692	N	0.302	0.34120	0.9910	0.97038	D	0.9106	0.97036	D	10	0.7083769	0.72884	D	0.357254	0.92421	D	0.623	0.85406	0.601;	0.73226	Q9BQB6;	S149G;	Loss of helix (P = 0.1299);	0.997466362089	0.99744	0.32797350441952433	0.32710	0.36694288524	0.38257	0.354144454002	0.18530	T	0.702555	0.91448	D	0.202171	0.74096	D	0.0526278	0.73758	D	0.741306475231483	0.42807	D	0.751525	0.37371	T	0.5990275	0.72639	0.33430183	0.59257	0.5990275	0.72640	0.33430183	0.59256	-3.773	0.38610	T	0.2125683830110313	0.28525	U	U	U	U	U	B	B	B	B	B	B	0.1325	0.28636	B	.;	.;	.;	.;	.;	.;	3.658482	0.68231	25.2	3.676248	0.71774	25.7	0.99664373917391813	0.78138	0.90718	0.52130	D	AEFBI	0.765221	0.70178	D	0.467425659720947	0.65200	4.792514	0.5157147963114	0.69045	5.304846	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.504000	0.73615	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.545000	0.30055	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091181	T	G	S	R	.	16	31102502	16	31010003	149	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.445A>C	p.S149R	c.445A>C	p.Ser149Arg	c.445A>C	p.Ser149Arg	principal1	Y	1	YES	-	AGT	1	0	T	./.	./.	./.	./.	0.004	0.65419	D	0.014	0.62352	D	0.989	0.62824	D	0.856	0.61001	P	0.000016	0.62929	D	0.071118	0.896434;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	S149R;.;.;.;.;.	1.91	0.51138	L	-4.85	0.98245	D	-1.38	0.34198	N	0.611	0.62781	1.0506	0.98130	D	0.9338	0.97819	D	10	0.895339	0.88886	D	0.389806	0.93162	D	0.729	0.90501	0.672;	0.81002	Q9BQB6;	S149R;	Gain of MoRF binding (P = 0.0162);	0.998188707412	0.99817	0.6833640230017037	0.68275	1.03574248498	0.75590	0.391884922981	0.23935	T	0.712222	0.91800	D	0.253978	0.78971	D	0.127046	0.78698	D	0.855653295794756	0.50659	D	0.788921	0.42853	T	0.95294327	0.96565	0.7030307	0.82497	0.95294327	0.96565	0.7030307	0.82498	-3.776	0.38690	T	0.3949142857817379	0.48757	U	U	U	U	U	U	U	U	U	U	B	0.9511	0.87028	P	.;	.;	.;	.;	.;	.;	3.885853	0.74825	26.3	3.941288	0.80245	27.2	0.9980853174271177	0.89264	0.97618	0.75940	D	AEFBI	0.842720	0.75980	D	0.562299118155416	0.70835	5.56015	0.584074631936938	0.73799	6.029808	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.504000	0.73615	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.545000	0.30055	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091183	A	C	L	R	.	16	31102504	16	31010005	148;43	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.443T>G;.	p.L148R;.	c.443T>G;c.128T>G	p.Leu148Arg;p.Leu43Arg	c.443T>G;c.128T>G	p.Leu148Arg;p.Leu43Arg	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	2;2	0;0	A	./.	./.	./.	./.	0.013;.	0.53900	D;.	0.01;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.997;.	0.86255	D;.	0.000015	0.62929	D	0.000000	0.912066;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L148R;.;.;.;.;.	2.52;.	0.73523	M;.	-5.06;-5.06	0.98629	D;D	-3.82;.	0.71997	D;.	0.824;.	0.81957	1.1004	0.99678	D	0.9675	0.98969	D	10	0.8882742;0.89044464	0.88385	D;D	0.483571	0.94882	D	0.912;.	0.97662	0.677;.;	0.81496	Q9BQB6;.;	L148R;.;	Gain of MoRF binding (P = 0.0043);.;	0.968142040279;0.968142040279	0.96780	0.6876107208384643;.	0.68701	1.42526408802;.	0.85695	0.527685463428	0.42709	T	0.91014;.	0.98302	D;.	0.525994	0.95048	D	0.517777	0.94975	D	0.991941821623815	0.82317	D	0.780422;0.458554	0.41514	T;T	0.8536947;.	0.87610	0.8396138;.	0.90813	0.8536947;.	0.87611	0.8396138;.	0.90813	-3.776;.	0.38690	T;.	0.6538734779680815;.	0.72641	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	0.2718;.	0.50581	B;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.020677	0.79323	27.1	4.123885	0.86300	28.8	0.99750541750257549	0.84228	0.98678	0.85476	D	AEFBI	0.837491	0.75512	D	0.759812480943305	0.83542	8.044813	0.729258097267262	0.84598	8.337374	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.518000	0.80701	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.646000	0.32584	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091183	A	G	L	P	.	16	31102504	16	31010005	148;43	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.443T>C;.	p.L148P;.	c.443T>C;c.128T>C	p.Leu148Pro;p.Leu43Pro	c.443T>C;c.128T>C	p.Leu148Pro;p.Leu43Pro	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	2;2	0;0	A	./.	./.	./.	./.	0.033;.	0.44358	D;.	0.023;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000015	0.62929	D	0.000000	0.999998;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L148P;.;.;.;.;.	2.52;.	0.73523	M;.	-5.07;-5.07	0.98648	D;D	-4.32;.	0.76655	D;.	0.835;.	0.83066	1.1007	0.99690	D	0.9678	0.98979	D	10	0.91215897;0.91735774	0.91095	D;D	0.491622	0.95008	D	0.935;.	0.98526	0.719;.;	0.85408	Q9BQB6;.;	L148P;.;	Gain of disorder (P = 0.023);.;	0.967419715028;0.967419715028	0.96707	0.8034783181810182;.	0.80301	1.50425018939;.	0.87093	0.559634804726	0.47217	T	0.904402;.	0.98149	D;.	0.521106	0.94919	D	0.510756	0.94844	D	0.989590353311436	0.79822	D	0.728227;0.390761	0.34274	T;T	0.9575234;.	0.97029	0.93796194;.	0.97633	0.9575234;.	0.97029	0.93796194;.	0.97633	-4.659;.	0.58755	T;.	0.5373030317086975;.	0.60738	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	0.6387;.	0.70462	P;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.139602	0.83458	28.1	4.198948	0.88217	29.5	0.99901957342989345	0.97350	0.98675	0.85440	D	AEFBI	0.923954	0.90124	D	0.768928026691203	0.84132	8.203032	0.73700253483672	0.85184	8.505103	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.518000	0.80701	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.646000	0.32584	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091183	A	T	L	H	.	16	31102504	16	31010005	148;43	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.443T>A;.	p.L148H;.	c.443T>A;c.128T>A	p.Leu148His;p.Leu43His	c.443T>A;c.128T>A	p.Leu148His;p.Leu43His	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	2;2	0;0	A	./.	./.	./.	./.	0.006;.	0.61437	D;.	0.005;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000015	0.62929	D	0.000000	0.849528;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L148H;.;.;.;.;.	1.97;.	0.53315	M;.	-5.07;-5.07	0.98648	D;D	-4.41;.	0.77391	D;.	0.713;.	0.71587	1.0977	0.99565	D	0.9597	0.98701	D	10	0.85729545;0.8568709	0.84932	D;D	0.44118	0.94168	D	0.860;.	0.95728	0.626;.;	0.76141	Q9BQB6;.;	L148H;.;	Gain of disorder (P = 0.0174);.;	0.974291720129;0.974291720129	0.97400	0.499714953357644;.	0.49892	1.33326140951;.	0.83686	0.526642203331	0.42561	T	0.876049;.	0.97362	D;.	0.474862	0.93514	D	0.44433	0.93433	D	0.984075422361267	0.75510	D	0.708429;0.369163	0.31914	T;T	0.6453821;.	0.75118	0.6342548;.	0.78653	0.6453821;.	0.75119	0.6342548;.	0.78654	0.0;.	0.02703	T;.	0.4434507304771614;.	0.52855	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	0.3015;.	0.53103	B;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.057736	0.80619	27.4	4.163801	0.87403	29.2	0.98427309076280167	0.41354	0.97725	0.76683	D	AEFBI	0.793974	0.72182	D	0.690226297255525	0.78993	6.984573	0.682459855210731	0.81047	7.436409	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.518000	0.80701	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.646000	0.32584	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091184	G	A	L	F	.	16	31102505	16	31010006	148;43	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.442C>T;.	p.L148F;.	c.442C>T;c.127C>T	p.Leu148Phe;p.Leu43Phe	c.442C>T;c.127C>T	p.Leu148Phe;p.Leu43Phe	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	1;1	0;0	G	./.	./.	./.	./.	0.019;.	0.50132	D;.	0.02;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.994;.	0.82059	D;.	0.000015	0.62929	D	0.000000	0.544798;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L148F;.;.;.;.;.	1.97;.	0.53315	M;.	-5.02;-5.02	0.98562	D;D	-2.18;.	0.49187	N;.	0.364;.	0.40565	1.0661	0.98489	D	0.9527	0.98463	D	10	0.7616787;0.7880539	0.78418	D;D	0.202467	0.86822	D	0.671;.	0.87820	0.582;.;	0.70861	Q9BQB6;.;	L148F;.;	Gain of ubiquitination at K152 (P = 0.1162);.;	0.982176923483;0.982176923483	0.98198	0.31766208431822623;.	0.31679	1.21594706112;.	0.80967	0.463122725487	0.33739	T	0.800402;.	0.94904	D;.	0.250871	0.78682	D	0.122583	0.78405	D	0.848164999665588	0.50008	D	0.79872;0.483452	0.44372	T;T	0.28815556;.	0.51820	0.42940304;.	0.66623	0.28815556;.	0.51820	0.42940304;.	0.66623	-5.86;.	0.72623	T;.	0.2270330132579713;.	0.30690	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1556;.	0.34427	B;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.784991	0.71751	25.8	3.961291	0.80926	27.4	0.99897369978467287	0.96971	0.95283	0.64121	D	AEFBI	0.770750	0.70560	D	0.692003507013442	0.79108	7.008721	0.693899767266831	0.81917	7.639698	0.99999982988767	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	3.826000	0.55438	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.706000	0.34326	0.0:0.0:1.0:0.0	19.1019	0.93261	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091184	G	C	L	V	.	16	31102505	16	31010006	148;43	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.442C>G;.	p.L148V;.	c.442C>G;c.127C>G	p.Leu148Val;p.Leu43Val	c.442C>G;c.127C>G	p.Leu148Val;p.Leu43Val	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	1;1	0;0	G	./.	./.	./.	./.	0.691;.	0.04289	T;.	0.548;0.0	0.92824	T;D	0.905;.	0.49920	P;.	0.751;.	0.56062	P;.	0.000015	0.62929	D	0.000000	1;1;1;1;1;0.808913	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;L148V	1.365;.	0.34158	L;.	-4.88;-4.88	0.98296	D;D	-0.55;.	0.16799	N;.	0.252;.	0.28498	0.9396	0.96242	D	0.9243	0.97496	D	10	0.47346756;0.597277	0.66713	T;D	0.190791	0.86145	D	0.568;.	0.82403	0.541;.;	0.65304	Q9BQB6;.;	L148V;.;	Gain of MoRF binding (P = 0.1045);.;	0.973135473859;0.973135473859	0.97284	0.31623667208299816;.	0.31536	1.16937237842;.	0.79717	0.434761464596	0.29860	T	0.560157;.	0.85262	D;.	0.135131	0.67858	D	-0.04367	0.67454	D	0.632589995861053	0.37726	D	0.79532;0.478252	0.43818	T;T	0.20897701;.	0.43151	0.22040804;.	0.46815	0.20897701;.	0.43150	0.22040804;.	0.46814	-4.523;.	0.56265	T;.	0.13993941890408107;.	0.15617	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1251;.	0.26419	B;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	2.734097	0.46333	22.9	2.920938	0.52946	23.4	0.99666695191152921	0.78330	0.95091	0.63404	D	AEFBI	0.779530	0.71170	D	0.458235147562194	0.64672	4.727073	0.517114346287529	0.69141	5.31827	0.99999982988767	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	3.826000	0.55438	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.706000	0.34326	0.0:0.0:1.0:0.0	19.1019	0.93261	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091187	A	C	W	G	.	16	31102508	16	31010009	147;42	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.439T>G;.	p.W147G;.	c.439T>G;c.124T>G	p.Trp147Gly;p.Trp42Gly	c.439T>G;c.124T>G	p.Trp147Gly;p.Trp42Gly	principal1;.	Y;.	1;2	YES;.	-;-	TGG;TGG	1;1	0;0	A	./.	./.	./.	./.	0.056;.	0.38185	T;.	0.143;0.258	0.33219	T;T	0.009;.	0.15093	B;.	0.003;.	0.08700	B;.	0.277845	0.03814	N	1.493360	1;1;1;1;1;1	0.08975	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	W147G;.;.;.;.;.	1.245;.	0.31408	L;.	-4.67;-4.67	0.97973	D;D	-2.87;.	0.60348	D;.	0.28;.	0.31702	0.0627	0.83481	D	0.7406	0.91141	D	10	0.16285041;0.16285041	0.30510	T;T	0.05834	0.67285	D	0.392;.	0.70764	0.5;.;	0.59147	Q9BQB6;.;	W147G;.;	Gain of disorder (P = 0.0127);.;	0.707169387218;0.707169387218	0.70461	0.45911291733223225;.	0.45829	0.694318581252;.	0.60760	0.314022511244	0.12516	T	0.784963;.	0.94357	D;.	0.121237	0.66495	D	-0.0636275	0.66078	T	0.0699488371610641	0.08645	T	0.546045;0.248275	0.18695	T;T	0.30090523;.	0.52986	0.18714176;.	0.41929	0.30090523;.	0.52986	0.18714176;.	0.41928	-3.773;.	0.38610	T;.	0.0874994226670896;.	0.05148	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.077;0.0776	0.06663	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.680283	0.24745	16.90	1.535727	0.24454	16.47	0.9070316142772481	0.19954	0.02298	0.06609	N	AEFBI	0.123535	0.23919	N	-0.90478735447369	0.10730	0.5141556	-0.857395619701241	0.13110	0.6782802	0.988592379171305	0.31567	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	-1.7	0.07721	-0.440000	0.06959	.	.	0.743000	0.86499	0.000000	0.06391	0.000000	0.08366	0.811000	0.38219	0.3067:0.1526:0.1515:0.3891	0.5477	0.00614	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091188	C	A	M	I	.	16	31102509	16	31010010	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.438G>T;.	p.M146I;.	c.438G>T;c.123G>T	p.Met146Ile;p.Met41Ile	c.438G>T;c.123G>T	p.Met146Ile;p.Met41Ile	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	3;3	0;0	C	./.	./.	./.	./.	0.043;.	0.41364	D;.	0.025;0.159	0.56192	D;T	0.002;.	0.09854	B;.	0.01;.	0.14941	B;.	0.857430	0.08920	N	0.939484	1;1;1;1;1;1	0.08975	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	M146I;.;.;.;.;.	1.935;.	0.51832	L;.	-4.59;-4.59	0.97830	D;D	-0.68;.	0.19509	N;.	0.328;.	0.36884	0.1420	0.84918	D	0.8123	0.93668	D	10	0.20094457;0.20094457	0.36159	T;T	0.180298	0.85480	D	0.280;.	0.59740	0.56;.;	0.67958	Q9BQB6;.;	M146I;.;	Gain of MoRF binding (P = 0.1673);.;	0.809368434872;0.809368434872	0.80758	0.3767374948609942;.	0.37587	0.42200000603;.	0.42705	0.333470642567	0.15458	T	0.551014;.	0.84798	D;.	0.0886652	0.63037	D	-0.110415	0.62579	T	0.0820575022545976	0.10249	T	0.806219;0.445055	0.45479	T;T	0.13430785;.	0.31210	0.110837415;.	0.26729	0.13430785;.	0.31210	0.110837415;.	0.26729	-5.673;.	0.71160	T;.	0.1232171711202297;.	0.11910	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.4636;0.2875	0.62874	A;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.273966	0.18631	14.20	1.473008	0.23474	16.12	0.93982715008674689	0.24064	0.07894	0.13883	N	AEFBI	0.173546	0.30063	N	-0.780189216228289	0.13827	0.6840371	-0.810418795151024	0.14243	0.7432335	0.996875113802678	0.35080	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	-3.6	0.04277	-0.974000	0.03904	.	.	0.590000	0.31872	0.000000	0.06391	0.000000	0.08366	0.838000	0.39538	0.4571:0.2841:0.1005:0.1583	2.6461	0.04682	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091188	C	G	M	I	.	16	31102509	16	31010010	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.438G>C;.	p.M146I;.	c.438G>C;c.123G>C	p.Met146Ile;p.Met41Ile	c.438G>C;c.123G>C	p.Met146Ile;p.Met41Ile	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	3;3	0;0	C	./.	./.	./.	./.	0.043;.	0.41364	D;.	0.025;0.159	0.56192	D;T	0.002;.	0.09854	B;.	0.01;.	0.14941	B;.	0.857430	0.08920	N	0.939484	1;1;1;1;1;1	0.08975	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	M146I;.;.;.;.;.	1.935;.	0.51832	L;.	-4.59;-4.59	0.97830	D;D	-0.68;.	0.19509	N;.	0.328;.	0.36884	0.1420	0.84918	D	0.8123	0.93668	D	10	0.20881718;0.20881718	0.37224	T;T	0.195343	0.86416	D	0.280;.	0.59740	0.56;.;	0.67958	Q9BQB6;.;	M146I;.;	Gain of MoRF binding (P = 0.1673);.;	0.809368434872;0.809368434872	0.80758	0.37673752240306313;.	0.37587	0.42200000603;.	0.42705	0.333470642567	0.15458	T	0.551014;.	0.84798	D;.	0.0886673	0.63039	D	-0.110412	0.62579	T	0.0539654321817146	0.06183	T	0.806219;0.445055	0.45479	T;T	0.13430785;.	0.31210	0.110837415;.	0.26729	0.13430785;.	0.31210	0.110837415;.	0.26729	-5.673;.	0.71160	T;.	0.1232171711202297;.	0.11910	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.4636;0.2875	0.62874	A;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.253280	0.18349	14.04	1.420008	0.22674	15.82	0.94270413889092752	0.24557	0.08699	0.14590	N	AEFBI	0.246547	0.36728	N	-0.780189216228289	0.13827	0.6840371	-0.810418795151024	0.14243	0.7432335	0.996875113802678	0.35080	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	-3.6	0.04277	-0.974000	0.03904	.	.	0.590000	0.31872	0.000000	0.06391	0.000000	0.08366	0.838000	0.39538	0.4571:0.2841:0.1005:0.1583	2.6461	0.04682	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091188	C	T	M	I	.	16	31102509	16	31010010	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.438G>A;.	p.M146I;.	c.438G>A;c.123G>A	p.Met146Ile;p.Met41Ile	c.438G>A;c.123G>A	p.Met146Ile;p.Met41Ile	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	3;3	0;0	C	./.	./.	./.	./.	0.043;.	0.41364	D;.	0.025;0.159	0.56192	D;T	0.002;.	0.09854	B;.	0.01;.	0.14941	B;.	0.857430	0.08920	N	0.939484	1;1;1;1;1;1	0.08975	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	M146I;.;.;.;.;.	1.935;.	0.51832	L;.	-4.59;-4.59	0.97830	D;D	-0.68;.	0.19509	N;.	0.328;.	0.36884	0.1420	0.84918	D	0.8123	0.93668	D	10	0.2049368;0.2049368	0.36703	T;T	0.182497	0.85624	D	0.280;.	0.59740	0.56;.;	0.67958	Q9BQB6;.;	M146I;.;	Gain of MoRF binding (P = 0.1673);.;	0.809368434872;0.809368434872	0.80758	0.37673748108995975;.	0.37587	0.42200000603;.	0.42705	0.333470642567	0.15458	T	0.551014;.	0.84798	D;.	0.0886673	0.63039	D	-0.110412	0.62579	T	0.0776878043850516	0.09689	T	0.806219;0.445055	0.45479	T;T	0.13430785;.	0.31210	0.110837415;.	0.26729	0.13430785;.	0.31210	0.110837415;.	0.26729	-5.673;.	0.71160	T;.	0.1232171711202297;.	0.11910	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.4636;0.2875	0.62874	A;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.326746	0.19364	14.58	1.513632	0.24112	16.35	0.95005900389049991	0.25972	0.09038	0.14872	N	AEFBI	0.223940	0.34823	N	-0.780189216228289	0.13827	0.6840371	-0.810418795151024	0.14243	0.7432335	0.996875113802678	0.35080	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	-3.6	0.04277	-0.974000	0.03904	.	.	0.590000	0.31872	0.000000	0.06391	0.000000	0.08366	0.838000	0.39538	0.4571:0.2841:0.1005:0.1583	2.6461	0.04682	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091189	A	C	M	R	.	16	31102510	16	31010011	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.437T>G;.	p.M146R;.	c.437T>G;c.122T>G	p.Met146Arg;p.Met41Arg	c.437T>G;c.122T>G	p.Met146Arg;p.Met41Arg	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	2;2	0;0	A	./.	./.	./.	./.	0.003;.	0.68238	D;.	0.002;0.012	0.79402	D;D	0.111;.	0.26235	B;.	0.072;.	0.28043	B;.	0.857430	0.08920	N	0.939484	1;0.999999;0.999999;0.999999;0.999999;0.999999	0.08975	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	M146R;.;.;.;.;.	1.935;.	0.51832	L;.	-4.68;-4.68	0.97989	D;D	-3.09;.	0.63438	D;.	0.492;.	0.52563	0.4033	0.89146	D	0.8657	0.95533	D	10	0.48060358;0.48060358	0.60407	T;T	0.237486	0.88546	D	0.625;.	0.85511	0.695;.;	0.83219	Q9BQB6;.;	M146R;.;	Gain of catalytic residue at M146 (P = 0.0242);.;	0.812674756878;0.812674756878	0.81091	0.8635825076244021;.	0.86322	0.765334159685;.	0.64465	0.341790229082	0.16706	T	0.835229;.	0.96105	D;.	0.263058	0.79810	D	0.140088	0.79550	D	0.414822667837143	0.29498	T	0.742326;0.360464	0.36163	T;T	0.82300794;.	0.85423	0.6682222;.	0.80540	0.82300794;.	0.85425	0.6682222;.	0.80540	-3.776;.	0.38690	T;.	0.37457239261458003;.	0.46972	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	0.7522;0.3444	0.75149	P;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.916082	0.28962	18.61	1.963845	0.32219	19.45	0.96003965720594142	0.28425	0.21509	0.21427	N	AEFBI	0.340645	0.43739	N	-0.545058273536102	0.20639	1.089473	-0.535857166074629	0.21182	1.144695	0.985944324822143	0.30976	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	1.38	0.21262	1.237000	0.32298	.	.	0.743000	0.86499	0.009000	0.18154	0.000000	0.08366	0.854000	0.40426	0.5162:0.0:0.4838:0.0	9.6772	0.39212	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091189	A	G	M	T	.	16	31102510	16	31010011	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.437T>C;.	p.M146T;.	c.437T>C;c.122T>C	p.Met146Thr;p.Met41Thr	c.437T>C;c.122T>C	p.Met146Thr;p.Met41Thr	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	2;2	0;0	A	./.	./.	./.	./.	0.027;.	0.46513	D;.	0.025;0.02	0.58613	D;D	0.0;.	0.02946	B;.	0.001;.	0.04355	B;.	0.857430	0.08920	N	0.939484	1;0.999999;0.999999;0.999999;0.999999;0.999999	0.08975	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	M146T;.;.;.;.;.	0.895;.	0.22405	L;.	-4.65;-4.65	0.97938	D;D	-2.64;.	0.56630	D;.	0.211;.	0.23506	0.2332	0.86465	D	0.8270	0.94193	D	10	0.23857176;0.23857176	0.40980	T;T	0.102837	0.77653	D	0.409;.	0.72099	0.654;.;	0.79172	Q9BQB6;.;	M146T;.;	Loss of stability (P = 0.02);.;	0.762483548826;0.762483548826	0.76031	0.5896005058706884;.	0.58890	0.42472068864;.	0.42894	0.373661637306	0.21356	T	0.773412;.	0.93954	D;.	0.12465	0.66836	D	-0.0587255	0.66422	T	0.11887763034566	0.14321	T	0.555844;0.318368	0.19272	T;T	0.186705;.	0.40091	0.17988372;.	0.40752	0.186705;.	0.40091	0.17988372;.	0.40751	-4.093;.	0.46692	T;.	0.08363331177960168;.	0.04536	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0968;0.0998	0.17060	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.117017	0.16537	12.93	1.206648	0.19635	14.69	0.91870292103833662	0.21185	0.05957	0.11915	N	AEFBI	0.127558	0.24497	N	-0.681507444127836	0.16548	0.8441374	-0.628284424092314	0.18767	1.004038	0.985944324822143	0.30976	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	1.38	0.21262	1.237000	0.32298	.	.	0.743000	0.86499	0.009000	0.18154	0.000000	0.08366	0.854000	0.40426	0.5162:0.0:0.4838:0.0	9.6772	0.39212	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091190	T	A	M	L	.	16	31102511	16	31010012	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.436A>T;.	p.M146L;.	c.436A>T;c.121A>T	p.Met146Leu;p.Met41Leu	c.436A>T;c.121A>T	p.Met146Leu;p.Met41Leu	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	1;1	0;0	T	./.	./.	./.	./.	1.0;.	0.00964	T;.	1.0;1.0	0.01155	T;T	0.0;.	0.02946	B;.	0.001;.	0.04355	B;.	0.857430	0.08920	N	0.939484	0.837475;0.837475;0.837475;0.837475;0.837475;1	0.35013	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;M146L	-0.095;.	0.04716	N;.	-4.36;-4.36	0.97317	D;D	0.44;.	0.03243	N;.	0.232;.	0.26111	-0.1344	0.79299	T	0.5704	0.84453	D	10	0.07845658;0.07845658	0.12507	T;T	0.082855	0.73990	D	0.278;.	0.59497	0.557;.;	0.67547	Q9BQB6;.;	M146L;.;	Gain of catalytic residue at M146 (P = 0.0954);.;	0.736121406842;0.736121406842	0.73376	0.31337516128979837;.	0.31250	0.344170030353;.	0.36343	0.318026393652	0.13122	T	0.408127;.	0.76354	T;.	0.0573466	0.59280	T	-0.155402	0.58764	T	0.0326954943352558	0.02420	T	0.615438;0.336666	0.23533	T;T	0.07855071;.	0.17894	0.054351263;.	0.09333	0.07855071;.	0.17894	0.054351263;.	0.09333	-4.726;.	0.59903	T;.	0.038828993448247036;.	0.00299	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.103;0.0711	0.18414	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.897615	0.13772	10.41	1.278838	0.20626	15.08	0.78890005996605261	0.12497	0.33208	0.24773	N	AEFBI	0.316106	0.42049	N	-0.851662497841163	0.12009	0.5828106	-0.622648716877763	0.18912	1.012398	0.995837308389585	0.34354	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.56	0.39892	0.122000	0.15515	.	.	0.654000	0.53741	0.011000	0.18532	0.000000	0.08366	0.862000	0.40904	0.0:0.2369:0.3394:0.4237	3.9869	0.09010	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091190	T	C	M	V	rs1349022789	16	31102511	16	31010012	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.436A>G;.	p.M146V;.	c.436A>G;c.121A>G	p.Met146Val;p.Met41Val	c.436A>G;c.121A>G	p.Met146Val;p.Met41Val	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	1;1	0;0	T	./.	./.	./.	./.	0.064;.	0.36509	T;.	0.014;0.091	0.62352	D;T	0.0;.	0.02946	B;.	0.001;.	0.04355	B;.	0.857430	0.08920	N	0.939484	0.824464;0.824464;0.824464;0.824464;0.824464;1	0.34824	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;M146V	1.935;.	0.51832	L;.	-4.57;-4.57	0.97792	D;D	-1.24;.	0.31375	N;.	0.184;.	0.19995	0.4504	0.89840	D	0.8124	0.93672	D	10	0.20980835;0.20980835	0.37355	T;T	0.178386	0.85353	D	0.285;.	0.60338	0.584;.;	0.71118	Q9BQB6;.;	M146V;.;	Loss of MoRF binding (P = 0.1949);.;	0.860447315387;0.860447315387	0.85910	0.3912600146749652;.	0.39041	0.375150715054;.	0.38969	0.29718965292	0.09983	T	0.568161;.	0.85658	D;.	0.0827708	0.62364	D	-0.118882	0.61895	T	0.0854771667502575	0.10672	T	0.644436;0.359864	0.25592	T;T	0.107411556;.	0.25398	0.08934812;.	0.20888	0.107411556;.	0.25398	0.08934812;.	0.20888	-4.523;.	0.56265	T;.	0.08786256733448722;.	0.05207	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.108;0.1019	0.20430	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.777878	0.26425	17.57	2.073437	0.34460	20.4	0.93831953565113213	0.23819	0.21135	0.21294	N	AEFBI	0.262878	0.38053	N	-0.456169972187645	0.23532	1.264323	-0.333921168887144	0.27011	1.495892	0.995837308389585	0.34354	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.56	0.39892	0.122000	0.15515	.	.	0.654000	0.53741	0.011000	0.18532	0.000000	0.08366	0.862000	0.40904	0.0:0.2369:0.3394:0.4237	3.9869	0.09010	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091190	T	G	M	L	.	16	31102511	16	31010012	146;41	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.436A>C;.	p.M146L;.	c.436A>C;c.121A>C	p.Met146Leu;p.Met41Leu	c.436A>C;c.121A>C	p.Met146Leu;p.Met41Leu	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	1;1	0;0	T	./.	./.	./.	./.	1.0;.	0.00964	T;.	1.0;1.0	0.01155	T;T	0.0;.	0.02946	B;.	0.001;.	0.04355	B;.	0.857430	0.08920	N	0.939484	0.837475;0.837475;0.837475;0.837475;0.837475;1	0.35013	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;M146L	-0.095;.	0.04716	N;.	-4.36;-4.36	0.97317	D;D	0.44;.	0.03243	N;.	0.232;.	0.26111	-0.1344	0.79299	T	0.5704	0.84453	D	10	0.07210961;0.07210961	0.10720	T;T	0.084516	0.74343	D	0.278;.	0.59497	0.557;.;	0.67547	Q9BQB6;.;	M146L;.;	Gain of catalytic residue at M146 (P = 0.0954);.;	0.736121406842;0.736121406842	0.73376	0.3133751888318673;.	0.31250	0.344170030353;.	0.36343	0.318026393652	0.13122	T	0.408127;.	0.76354	T;.	0.0573264	0.59277	T	-0.155431	0.58760	T	0.0218281283256365	0.00890	T	0.615438;0.336666	0.23533	T;T	0.07855071;.	0.17894	0.054351263;.	0.09333	0.07855071;.	0.17894	0.054351263;.	0.09333	-4.726;.	0.59903	T;.	0.038828993448247036;.	0.00299	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.103;0.0711	0.18414	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.826946	0.12913	9.664	1.172612	0.19186	14.50	0.71571573346595851	0.09674	0.15309	0.18848	N	AEFBI	0.166435	0.29302	N	-0.851662497841163	0.12009	0.5828106	-0.622648716877763	0.18912	1.012398	0.995837308389585	0.34354	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.56	0.39892	0.122000	0.15515	.	.	0.654000	0.53741	0.011000	0.18532	0.000000	0.08366	0.862000	0.40904	0.0:0.2369:0.3394:0.4237	3.9869	0.09010	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091192	A	C	L	R	.	16	31102513	16	31010014	145;40	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.434T>G;.	p.L145R;.	c.434T>G;c.119T>G	p.Leu145Arg;p.Leu40Arg	c.434T>G;c.119T>G	p.Leu145Arg;p.Leu40Arg	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	2;2	0;0	A	./.	./.	./.	./.	0.001;.	0.78490	D;.	0.003;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000073	0.52346	D	0.000000	0.999988;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L145R;.;.;.;.;.	2.78;.	0.81115	M;.	-5.16;-5.16	0.98796	D;D	-4.92;.	0.81675	D;.	0.854;.	0.85027	1.0906	0.99263	D	0.9730	0.99155	D	10	0.9821129;0.9821129	0.98272	D;D	0.642422	0.96955	D	0.958;.	0.99315	0.861;.;	0.95829	Q9BQB6;.;	L145R;.;	Gain of MoRF binding (P = 0.0071);.;	0.977232403614;0.977232403614	0.97698	0.933831487652078;.	0.93362	1.42526408802;.	0.85695	0.554748535156	0.46526	T	0.941378;.	0.99083	D;.	0.548244	0.95678	D	0.549738	0.95614	D	0.99711537361145	0.90803	D	0.79532;0.481052	0.43818	T;T	0.9804613;.	0.99145	0.9612158;.	0.99037	0.9804613;.	0.99145	0.9612158;.	0.99037	-3.776;.	0.38690	T;.	0.7915303177744321;.	0.86988	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	0.8058;0.6516	0.77555	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.067817	0.80964	27.5	4.181863	0.87824	29.3	0.9975625582016292	0.84694	0.98302	0.81423	D	AEFBI	0.832348	0.75074	D	0.844479630719237	0.88791	9.713334	0.796616440505866	0.89558	10.02428	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.518000	0.80701	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.862000	0.40904	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091193	G	C	L	V	.	16	31102514	16	31010015	145;40	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.433C>G;.	p.L145V;.	c.433C>G;c.118C>G	p.Leu145Val;p.Leu40Val	c.433C>G;c.118C>G	p.Leu145Val;p.Leu40Val	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	1;1	2;2	G	./.	./.	./.	./.	0.037;.	0.43085	D;.	0.016;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000073	0.52346	D	0.000000	0.999671;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L145V;.;.;.;.;.	2.435;.	0.70606	M;.	-5.07;-5.07	0.98648	D;D	-2.13;.	0.48354	N;.	0.492;.	0.52563	1.0959	0.99486	D	0.9675	0.98969	D	10	0.94897974;0.94897974	0.94229	D;D	0.662004	0.97162	D	0.872;.	0.96170	0.766;.;	0.89373	Q9BQB6;.;	L145V;.;	Gain of MoRF binding (P = 0.1433);.;	0.976457933175;0.976457933175	0.97620	0.5798120958872723;.	0.57910	1.16937237842;.	0.79717	0.447436004877	0.31594	T	0.718247;.	0.92017	D;.	0.472029	0.93415	D	0.440261	0.93332	D	0.91642290353775	0.57385	D	0.680532;0.441356	0.28920	T;T	0.75010526;.	0.80874	0.5173355;.	0.72113	0.75010526;.	0.80876	0.5173355;.	0.72113	-4.523;.	0.56265	T;.	0.4139684918182165;.	0.50382	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	0.2269;0.1549	0.45906	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.152915	0.55488	23.7	3.569636	0.68905	25.2	0.99846172986729487	0.92576	0.97078	0.72561	D	AEFBI	0.684766	0.64700	D	0.672685677981347	0.77842	6.753429	0.619241355277274	0.76337	6.472625	0.999999840435449	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.95	0.64894	4.133000	0.57743	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.853000	0.40368	0.074:0.0:0.926:0.0	13.9038	0.63325	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091194	G	C	S	R	.	16	31102515	16	31010016	144;39	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.432C>G;.	p.S144R;.	c.432C>G;c.117C>G	p.Ser144Arg;p.Ser39Arg	c.432C>G;c.117C>G	p.Ser144Arg;p.Ser39Arg	principal1;.	Y;.	1;2	YES;.	-;-	AGC;AGC	3;3	2;2	G	./.	./.	./.	./.	0.109;.	0.29288	T;.	0.35;0.167	0.30729	T;T	0.003;.	0.11197	B;.	0.004;.	0.10090	B;.	0.004181	0.34034	N	0.254343	1;1;1;1;1;0.988943	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;S144R	0;.	0.06538	N;.	-4.77;-4.77	0.98126	D;D	-1.42;.	0.34992	N;.	0.326;.	0.36674	0.2946	0.87471	D	0.7835	0.92649	D	10	0.35085213;0.35085213	0.51948	T;T	0.123748	0.80497	D	0.492;.	0.77847	0.464;.;	0.53404	Q9BQB6;.;	S144R;.;	Gain of MoRF binding (P = 0.0124);.;	0.969100443935;0.969100443935	0.96876	0.569728407382894;.	0.56900	0.413911585866;.	0.42082	0.506655693054	0.39755	T	0.676708;.	0.90463	D;.	0.15273	0.69523	D	-0.0183902	0.69135	D	0.189527278129625	0.19817	T	0.70513;0.69513	0.31558	T;T	0.26926377;.	0.49999	0.2683841;.	0.52706	0.26926377;.	0.49999	0.2683841;.	0.52705	-3.776;.	0.38690	T;.	0.27561040427612976;.	0.37004	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.8919;0.823	0.82214	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.702725	0.25130	17.05	2.198972	0.37121	21.4	0.98673122776005684	0.44498	0.89688	0.50314	D	AEFBI	0.364063	0.45274	N	-0.393107468551397	0.25713	1.397932	-0.177408031718684	0.32370	1.840889	0.998721608150582	0.37539	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.91	0.44383	0.593000	0.23700	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.836000	0.39433	0.1446:0.0:0.8554:0.0	11.9562	0.52270	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091194	G	T	S	R	.	16	31102515	16	31010016	144;39	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.432C>A;.	p.S144R;.	c.432C>A;c.117C>A	p.Ser144Arg;p.Ser39Arg	c.432C>A;c.117C>A	p.Ser144Arg;p.Ser39Arg	principal1;.	Y;.	1;2	YES;.	-;-	AGC;AGC	3;3	2;2	G	./.	./.	./.	./.	0.109;.	0.29288	T;.	0.35;0.167	0.30729	T;T	0.003;.	0.11197	B;.	0.004;.	0.10090	B;.	0.004181	0.34034	N	0.254343	1;1;1;1;1;0.987195	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;S144R	0;.	0.06538	N;.	-4.77;-4.77	0.98126	D;D	-1.42;.	0.34992	N;.	0.326;.	0.36674	0.2946	0.87471	D	0.7835	0.92649	D	10	0.3544943;0.3544943	0.52232	T;T	0.118358	0.79837	D	0.492;.	0.77847	0.464;.;	0.53404	Q9BQB6;.;	S144R;.;	Gain of MoRF binding (P = 0.0124);.;	0.969100443935;0.969100443935	0.96876	0.5697284349249628;.	0.56900	0.413911585866;.	0.42082	0.506655693054	0.39755	T	0.676708;.	0.90463	D;.	0.152748	0.69525	D	-0.018365	0.69136	D	0.223114578204096	0.21618	T	0.70513;0.69513	0.31558	T;T	0.26926377;.	0.49999	0.2683841;.	0.52706	0.26926377;.	0.49999	0.2683841;.	0.52705	-3.776;.	0.38690	T;.	0.27561040427612976;.	0.37004	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.8919;0.823	0.82214	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.692253	0.24948	16.98	2.211058	0.37375	21.5	0.98503531231267039	0.42252	0.93941	0.59637	D	AEFBI	0.395548	0.47236	N	-0.393107468551397	0.25713	1.397932	-0.177408031718684	0.32370	1.840889	0.998721608150582	0.37539	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.91	0.44383	0.593000	0.23700	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.836000	0.39433	0.1446:0.0:0.8554:0.0	11.9562	0.52270	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091196	T	C	S	G	rs966141166	16	31102517	16	31010018	144;39	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.430A>G;.	p.S144G;.	c.430A>G;c.115A>G	p.Ser144Gly;p.Ser39Gly	c.430A>G;c.115A>G	p.Ser144Gly;p.Ser39Gly	principal1;.	Y;.	1;2	YES;.	-;-	AGC;AGC	1;1	0;0	T	./.	./.	./.	./.	0.53;.	0.07025	T;.	0.396;0.545	0.15206	T;T	0.0;.	0.02946	B;.	0.0;.	0.01387	B;.	0.004181	0.34034	N	0.254343	1;1;1;1;1;0.999303	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;S144G	-2.075;.	0.00166	N;.	-4.75;-4.75	0.98096	D;D	-0.67;.	0.19297	N;.	0.122;.	0.11340	-0.0395	0.81428	T	0.5966	0.85613	D	10	0.16879103;0.16879103	0.31451	T;T	0.025237	0.48216	D	0.434;.	0.73951	0.39;.;	0.41279	Q9BQB6;.;	S144G;.;	Loss of stability (P = 0.0974);.;	0.916725881963;0.916725881963	0.91588	0.191537393605332;.	0.19071	0.337341450307;.	0.35727	0.410057961941	0.26465	T	0.476179;.	0.80692	T;.	0.101416	0.64446	D	-0.0920989	0.64003	T	0.105813824744687	0.12984	T	0.438556;0.458554	0.13215	T;T	0.13163844;.	0.30677	0.06953601;.	0.14664	0.13163844;.	0.30677	0.06953601;.	0.14664	-3.773;.	0.38610	T;.	0.07017739614945405;.	0.02690	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0417;0.042	0.00023	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.641200	0.24101	16.64	1.804410	0.29122	18.23	0.9691294404021964	0.31585	0.13937	0.18134	N	AEFBI	0.080915	0.16366	N	-0.692030912287333	0.16247	0.8261074	-0.380236910835459	0.25587	1.408015	0.999498916674884	0.40007	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.95	0.64894	1.414000	0.34344	.	.	-0.199000	0.08999	1.000000	0.71638	1.000000	0.68203	0.759000	0.36109	0.1464:0.7784:0.0:0.0752	9.0429	0.35492	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091196	T	G	S	R	.	16	31102517	16	31010018	144;39	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.430A>C;.	p.S144R;.	c.430A>C;c.115A>C	p.Ser144Arg;p.Ser39Arg	c.430A>C;c.115A>C	p.Ser144Arg;p.Ser39Arg	principal1;.	Y;.	1;2	YES;.	-;-	AGC;AGC	1;1	0;0	T	./.	./.	./.	./.	0.109;.	0.29288	T;.	0.35;0.167	0.30729	T;T	0.003;.	0.11197	B;.	0.004;.	0.10090	B;.	0.004181	0.34034	N	0.254343	1;1;1;1;1;0.996445	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;S144R	0;.	0.06538	N;.	-4.77;-4.77	0.98126	D;D	-1.42;.	0.34992	N;.	0.326;.	0.36674	0.3443	0.88249	D	0.7742	0.92325	D	10	0.34261745;0.34261745	0.51290	T;T	0.190212	0.86110	D	0.494;.	0.77973	0.464;.;	0.53404	Q9BQB6;.;	S144R;.;	Gain of MoRF binding (P = 0.0124);.;	0.960121114925;0.960121114925	0.95969	0.5697284486959974;.	0.56900	0.413911585866;.	0.42082	0.506655693054	0.39755	T	0.676708;.	0.90463	D;.	0.160411	0.70239	D	-0.00735738	0.69858	D	0.150427560057615	0.17138	T	0.70513;0.69513	0.31558	T;T	0.24652703;.	0.47622	0.22620077;.	0.47590	0.24652703;.	0.47622	0.22620077;.	0.47588	-3.776;.	0.38690	T;.	0.27561040427612976;.	0.37004	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.8919;0.823	0.82214	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.997856	0.30558	19.24	2.185523	0.36821	21.3	0.98281951176223459	0.39861	0.75311	0.36868	D	AEFBI	0.236580	0.35901	N	-0.48023267980653	0.22729	1.215712	-0.241037279213411	0.30081	1.69069	0.999498916674884	0.40007	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.95	0.64894	1.414000	0.34344	.	.	-0.199000	0.08999	1.000000	0.71638	1.000000	0.68203	0.759000	0.36109	0.1464:0.7784:0.0:0.0752	9.0429	0.35492	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091199	C	A	V	L	.	16	31102520	16	31010021	143;38	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.427G>T;.	p.V143L;.	c.427G>T;c.112G>T	p.Val143Leu;p.Val38Leu	c.427G>T;c.112G>T	p.Val143Leu;p.Val38Leu	principal1;.	Y;.	1;2	YES;.	-;-	GTG;GTG	1;1	0;0	C	./.	./.	./.	./.	0.369;.	0.11586	T;.	0.649;0.755	0.06762	T;T	0.0;.	0.02946	B;.	0.005;.	0.11217	B;.	0.238480	0.15764	N	0.592925	1;1;1;1;1;0.996136	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;V143L	0.96;.	0.23930	L;.	-4.49;-4.49	0.97628	D;D	0.17;.	0.05125	N;.	0.058;.	0.02964	0.0933	0.84051	D	0.6955	0.89503	D	10	0.20681271;0.20681271	0.36956	T;T	0.190827	0.86147	D	0.349;.	0.67049	0.558;.;	0.67684	Q9BQB6;.;	V143L;.;	Gain of helix (P = 0.132);.;	0.821721304607;0.821721304607	0.82004	0.29902172223696794;.	0.29815	0.375361950805;.	0.38992	0.351661324501	0.18166	T	0.412042;.	0.76632	T;.	0.0834962	0.62448	D	-0.11784	0.61980	T	0.13158118724823	0.15528	T	0.757724;0.680532	0.38135	T;T	0.13922298;.	0.32169	0.07393657;.	0.16121	0.13922298;.	0.32169	0.07393657;.	0.16121	-4.726;.	0.59903	T;.	0.08274921705288538;.	0.04402	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1401;0.0923	0.30713	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.866941	0.13401	10.09	1.455275	0.23194	16.02	0.93746286620810493	0.23684	0.24265	0.22340	N	AEFBI	0.154807	0.27989	N	-0.763439126483513	0.14270	0.7095118	-0.533363017208987	0.21249	1.148628	0.99908889536901	0.38397	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.79	0.42757	0.853000	0.27431	.	.	-0.205000	0.08568	0.905000	0.31549	0.452000	0.24958	0.649000	0.32665	0.2249:0.6933:0.0:0.0819	8.8695	0.34465	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091199	C	G	V	L	.	16	31102520	16	31010021	143;38	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.427G>C;.	p.V143L;.	c.427G>C;c.112G>C	p.Val143Leu;p.Val38Leu	c.427G>C;c.112G>C	p.Val143Leu;p.Val38Leu	principal1;.	Y;.	1;2	YES;.	-;-	GTG;GTG	1;1	0;0	C	./.	./.	./.	./.	0.369;.	0.11586	T;.	0.649;0.755	0.06762	T;T	0.0;.	0.02946	B;.	0.005;.	0.11217	B;.	0.238480	0.15764	N	0.592925	1;1;1;1;1;0.996136	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;V143L	0.96;.	0.23930	L;.	-4.49;-4.49	0.97628	D;D	0.17;.	0.05125	N;.	0.058;.	0.02964	0.0933	0.84051	D	0.6955	0.89503	D	10	0.21059376;0.21059376	0.37459	T;T	0.168395	0.84651	D	0.349;.	0.67049	0.558;.;	0.67684	Q9BQB6;.;	V143L;.;	Gain of helix (P = 0.132);.;	0.821721304607;0.821721304607	0.82004	0.2990217635500713;.	0.29815	0.375361950805;.	0.38992	0.351661324501	0.18166	T	0.412042;.	0.76632	T;.	0.083501	0.62448	D	-0.117833	0.61980	T	0.0975895310337616	0.12090	T	0.757724;0.680532	0.38135	T;T	0.13922298;.	0.32169	0.07393657;.	0.16121	0.13922298;.	0.32169	0.07393657;.	0.16121	-4.726;.	0.59903	T;.	0.08274921705288538;.	0.04402	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1401;0.0923	0.30713	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.828552	0.12934	9.680	1.382465	0.22118	15.62	0.94673047690694534	0.25299	0.32729	0.24656	N	AEFBI	0.272389	0.38803	N	-0.763439126483513	0.14270	0.7095118	-0.533363017208987	0.21249	1.148628	0.99908889536901	0.38397	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.79	0.42757	0.853000	0.27431	.	.	-0.205000	0.08568	0.905000	0.31549	0.452000	0.24958	0.649000	0.32665	0.2249:0.6933:0.0:0.0819	8.8695	0.34465	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091199	C	T	V	M	rs372656557	16	31102520	16	31010021	143;38	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.427G>A;.	p.V143M;.	c.427G>A;c.112G>A	p.Val143Met;p.Val38Met	c.427G>A;c.112G>A	p.Val143Met;p.Val38Met	principal1;.	Y;.	1;2	YES;.	-;-	GTG;GTG	1;1	0;0	C	./.	./.	./.	./.	0.104;.	0.29959	T;.	0.129;0.168	0.34837	T;T	0.01;.	0.15535	B;.	0.012;.	0.16012	B;.	0.238480	0.15764	N	0.592925	1;1;1;1;1;0.995756	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;V143M	1.59;.	0.40313	L;.	-4.75;-4.75	0.98096	D;D	-0.07;.	0.08033	N;.	0.1;.	0.08227	0.5001	0.90548	D	0.8091	0.93554	D	10	0.0524469;0.0524469	0.05281	T;T	0.282283	0.90274	D	0.353;.	0.67418	.;.;	.	.;.;	.;.;	.;.;	0.876908796361;0.876908796361	0.87570	0.27115062198391965;.	0.27028	0.47277561626;.	0.46512	0.365493237972	0.20183	T	0.504525;.	0.82357	D;.	-0.187874	0.22570	T	-0.093085	0.63928	T	0.0269361392654476	0.01535	T	0.779622;0.726827	0.41374	T;T	0.12396892;.	0.29098	0.10638567;.	0.25594	0.12396892;.	0.29098	0.10638567;.	0.25593	-6.249;.	0.75275	T;.	0.1913190346495936;.	0.25096	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1193;0.0889	0.24532	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.436636	0.20937	15.33	1.978340	0.32522	19.56	0.99788805479999632	0.87484	0.29907	0.23945	N	AEFBI	0.259697	0.37799	N	-0.482060211444634	0.22669	1.212057	-0.323379076317054	0.27346	1.51672	0.99908889536901	0.38397	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.79	0.42757	0.853000	0.27431	.	.	-0.205000	0.08568	0.905000	0.31549	0.452000	0.24958	0.649000	0.32665	0.2249:0.6933:0.0:0.0819	8.8695	0.34465	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	1	1.1627906976744187E-4	13	1.071e-04	13	1.080e-04	0	0	11	9.582e-04	0	0	0	0	2	3.021e-05	0	0	12	1.130e-04	12	1.133e-04	0	0	10	8.969e-04	0	0	0	0	2	3.684e-05	0	0	13	1.432e-04	13	1.448e-04	0	0	11	9.592e-04	0	0	0	0	2	4.805e-05	0	0	segdup	42	251266	1.671540e-04	0	0	16228	0.000000e+00	0	40	34580	1.156740e-03	0	0	10078	0.000000e+00	0	0	18380	0.000000e+00	0	0	21646	0.000000e+00	0	1	113616	8.801580e-06	0	0	30608	0.000000e+00	0	40	34580	1.156740e-03	0	19	109384	1.737000e-04	0	31	207984	1.490500e-04	0	41	236850	1.731050e-04	0	42	244648	1.716750e-04	0	0	7162	0.000000e+00	0	17	17106	9.938030e-04	0	0	2320	0.000000e+00	0	0	9042	0.000000e+00	0	0	13392	0.000000e+00	0	1	42766	2.338310e-05	0	0	15682	0.000000e+00	0	17	17106	9.938030e-04	0	0	16190	0.000000e+00	0	29	30512	9.504460e-04	0	0	6212	0.000000e+00	0	0	13404	0.000000e+00	0	0	16732	0.000000e+00	0	1	89478	1.117590e-05	0	0	30600	0.000000e+00	0	29	30512	9.504460e-04	0	0	14900	0.000000e+00	0	39	34252	1.138620e-03	0	0	9570	0.000000e+00	0	0	17686	0.000000e+00	0	0	21630	0.000000e+00	0	1	102674	9.739560e-06	0	0	30518	0.000000e+00	0	39	34252	1.138620e-03	0	0	11998	0.000000e+00	0	40	34446	1.161240e-03	0	0	9996	0.000000e+00	0	0	18376	0.000000e+00	0	0	21644	0.000000e+00	0	1	111526	8.966520e-06	0	0	30608	0.000000e+00	0	40	34446	1.161240e-03	0	.	45	152184	2.956950e-04	0	41	15280	2.683250e-03	0	1	41438	2.413240e-05	0	0	912	0.000000e+00	0	41	15280	2.683250e-03	0	0	3472	0.000000e+00	0	0	5194	0.000000e+00	0	0	10608	0.000000e+00	0	0	316	0.000000e+00	0	2	68042	2.939360e-05	0	0	4830	0.000000e+00	0	3	32886	9.122420e-05	0	43	134772	3.190570e-04	0	45	147928	3.042020e-04	0	41	80740	5.078030e-04	0	0	9096	0.000000e+00	0	0	60	0.000000e+00	0	3	4686	6.402050e-04	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5480	0.000000e+00	0	0	246	0.000000e+00	0	0	6852	0.000000e+00	0	0	3110	0.000000e+00	0	0	32470	0.000000e+00	0	0	862	0.000000e+00	0	40	14834	2.696510e-03	0	0	3388	0.000000e+00	0	0	5194	0.000000e+00	0	0	6968	0.000000e+00	0	0	310	0.000000e+00	0	2	63916	3.129110e-05	0	0	4828	0.000000e+00	0	1	41118	2.432020e-05	0	0	912	0.000000e+00	0	41	15092	2.716670e-03	0	0	3302	0.000000e+00	0	0	4960	0.000000e+00	0	0	10608	0.000000e+00	0	0	304	0.000000e+00	0	2	64812	3.085850e-05	0	0	4798	0.000000e+00	0	1	24812	4.030310e-05	0	0	112	0.000000e+00	0	40	12906	3.099330e-03	0	0	998	0.000000e+00	0	0	3752	0.000000e+00	0	0	10516	0.000000e+00	0	0	272	0.000000e+00	0	0	21052	0.000000e+00	0	0	4802	0.000000e+00	0	1	26588	3.761095230931247E-5	0	114	0	0	86	0	0	2804	0	0	500	0	1	628	0.0015923566878980893	0	26	0	0	98	0	0	4588	0	0	2918	0	0	112	0	2	35432	5.644615037254459E-5	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091201	T	A	N	I	.	16	31102522	16	31010023	142;37	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.425A>T;.	p.N142I;.	c.425A>T;c.110A>T	p.Asn142Ile;p.Asn37Ile	c.425A>T;c.110A>T	p.Asn142Ile;p.Asn37Ile	principal1;.	Y;.	1;2	YES;.	-;-	AAC;AAC	2;2	0;0	T	./.	./.	./.	./.	0.0;.	0.91255	D;.	0.0;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000706	0.42254	D	0.157487	0.999953;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	N142I;.;.;.;.;.	2.91;.	0.84121	M;.	-4.62;-4.62	0.97884	D;D	-7.71;.	0.95665	D;.	0.763;.	0.76111	1.0971	0.99538	D	0.9574	0.98622	D	10	0.9465951;0.9465951	0.93986	D;D	0.548315	0.95825	D	0.831;.	0.94653	0.783;.;	0.90693	Q9BQB6;.;	N142I;.;	Gain of helix (P = 0.0696);.;	0.997771826911;0.997771826911	0.99775	0.9438525730337861;.	0.94367	1.31008914953;.	0.83189	0.581618309021	0.50314	T	0.881305;.	0.97514	D;.	0.396878	0.89733	D	0.332312	0.89604	D	0.994654893875122	0.86077	D	0.856914;0.856914	0.54589	D;D	0.9688243;.	0.98150	0.9498892;.	0.98393	0.9688243;.	0.98150	0.9498892;.	0.98393	-5.673;.	0.71160	T;.	0.5692435034584533;.	0.63652	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	0.8839;0.855	0.81709	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.002718	0.78705	27.0	4.013847	0.82770	27.8	0.99378110424585886	0.61759	0.99252	0.93473	D	AEFBI	0.903129	0.85185	D	0.823820443739617	0.87572	9.264548	0.783260430949187	0.88605	9.645642	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.504000	0.73615	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.767000	0.36405	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091202	T	A	N	Y	.	16	31102523	16	31010024	142;37	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.424A>T;.	p.N142Y;.	c.424A>T;c.109A>T	p.Asn142Tyr;p.Asn37Tyr	c.424A>T;c.109A>T	p.Asn142Tyr;p.Asn37Tyr	principal1;.	Y;.	1;2	YES;.	-;-	AAC;AAC	1;1	0;0	T	./.	./.	./.	./.	0.0;.	0.91255	D;.	0.001;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000706	0.42254	D	0.157487	0.999948;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	N142Y;.;.;.;.;.	2.91;.	0.84121	M;.	-4.73;-4.73	0.98066	D;D	-7.04;.	0.93833	D;.	0.757;.	0.75559	1.1015	0.99721	D	0.9627	0.98804	D	10	0.95019233;0.95019233	0.94353	D;D	0.489958	0.94982	D	0.910;.	0.97587	0.792;.;	0.91365	Q9BQB6;.;	N142Y;.;	Gain of catalytic residue at I141 (P = 0.0517);.;	0.998142824464;0.998142824464	0.99812	0.9508371040032314;.	0.95067	1.29351261363;.	0.82853	0.60907793045	0.54185	T	0.960668;.	0.99492	D;.	0.530004	0.95168	D	0.523537	0.95096	D	0.989684700965881	0.79907	D	0.805919;0.805919	0.45429	T;T	0.9670291;.	0.97977	0.95731986;.	0.98825	0.9670291;.	0.97977	0.95731986;.	0.98825	-5.692;.	0.71313	T;.	0.8104649898905116;.	0.88552	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	P;.	0.8901;0.8407	0.82098	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.036950	0.79882	27.2	4.055675	0.84195	28.2	0.99464931964791625	0.65996	0.99253	0.93488	D	AEFBI	0.894203	0.83294	D	0.880913649939174	0.90793	10.56883	0.828533411027794	0.91701	11.02296	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.504000	0.73615	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.850000	0.40195	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091204	A	C	I	S	.	16	31102525	16	31010026	141;36	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.422T>G;.	p.I141S;.	c.422T>G;c.107T>G	p.Ile141Ser;p.Ile36Ser	c.422T>G;c.107T>G	p.Ile141Ser;p.Ile36Ser	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	2;2	0;0	A	./.	./.	./.	./.	0.001;.	0.78490	D;.	0.002;0.003	0.79402	D;D	0.901;.	0.49677	P;.	0.583;.	0.50264	P;.	0.122225	0.18964	N	0.522388	0.999181;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	I141S;.;.;.;.;.	1.975;.	0.53506	M;.	-4.7;-4.7	0.98020	D;D	-4.34;.	0.76822	D;.	0.612;.	0.62866	1.0433	0.97978	D	0.9232	0.97459	D	10	0.8560046;0.8560046	0.84798	D;D	0.541465	0.95732	D	0.794;.	0.93227	0.534;.;	0.64293	Q9BQB6;.;	I141S;.;	Loss of stability (P = 0.0066);.;	0.993486708828;0.993486708828	0.99341	0.7803704397253802;.	0.77988	1.27704976579;.	0.82433	0.526205062866	0.42501	T	0.853595;.	0.96690	D;.	0.374532	0.88355	D	0.300213	0.88207	D	0.980382800102234	0.73331	D	0.90391;0.906409	0.67021	D;D	0.8411306;.	0.86689	0.8303659;.	0.90208	0.8411306;.	0.86691	0.8303659;.	0.90209	-2.754;.	0.16113	T;.	0.2933001507406781;.	0.39007	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	0.8015;0.8243	0.78447	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.120664	0.82810	27.9	4.072095	0.84723	28.3	0.99413278426210516	0.63405	0.99512	0.96919	D	AEFBI	0.950418	0.96403	D	0.684011911428752	0.78584	6.901318	0.710326876171691	0.83161	7.950089	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.518000	0.80701	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.925000	0.46118	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091207	G	T	A	D	.	16	31102528	16	31010029	140;35	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.419C>A;.	p.A140D;.	c.419C>A;c.104C>A	p.Ala140Asp;p.Ala35Asp	c.419C>A;c.104C>A	p.Ala140Asp;p.Ala35Asp	principal1;.	Y;.	1;2	YES;.	-;-	GCT;GCT	2;2	0;0	G	G/G	G/G	G/G	G/G	0.003;.	0.68238	D;.	0.005;0.016	0.72224	D;D	0.99;.	0.63424	D;.	0.93;.	0.66466	D;.	0.000110	0.50451	D	0.081609	1;1;1;1;1;0.872981	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;A140D	2.295;.	0.65404	M;.	-4.96;-4.96	0.98448	D;D	-3.12;.	0.63782	D;.	0.726;.	0.72746	1.0771	0.98792	D	0.9468	0.98263	D	10	0.8690718;0.8690718	0.86165	D;D	0.553772	0.95897	D	0.864;.	0.95876	0.693;.;	0.83032	Q9BQB6;.;	A140D;.;	Gain of sheet (P = 0.039);.;	0.998203058377;0.998203058377	0.99818	0.7901682415543003;.	0.78968	1.44363233563;.	0.86018	0.562423586845	0.47609	T	0.913097;.	0.98379	D;.	0.406814	0.90302	D	0.346583	0.90181	D	0.971615108167215	0.69384	D	0.892711;0.883612	0.62952	D;D	0.9313586;.	0.94374	0.838016;.	0.90707	0.9313586;.	0.94374	0.838016;.	0.90708	-0.64;.	0.05512	T;.	0.6106836865559085;.	0.67827	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	0.9247;0.9216	0.84574	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.688104	0.69028	25.4	3.711299	0.72787	25.8	0.99757338234809023	0.84772	0.95756	0.66020	D	AEFBI	0.597690	0.59137	D	0.585684588365167	0.72281	5.781024	0.556485658791516	0.71851	5.718071	0.99987311684484	0.44625	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.95	0.64894	2.066000	0.41078	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.968000	0.53726	0.1511:0.0:0.8489:0.0	10.8912	0.46205	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091208	C	G	A	P	.	16	31102529	16	31010030	140;35	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.418G>C;.	p.A140P;.	c.418G>C;c.103G>C	p.Ala140Pro;p.Ala35Pro	c.418G>C;c.103G>C	p.Ala140Pro;p.Ala35Pro	principal1;.	Y;.	1;2	YES;.	-;-	GCT;GCT	1;1	0;0	C	C/C	C/C	C/C	C/C	0.01;.	0.56456	D;.	0.004;0.061	0.74150	D;T	0.99;.	0.63424	D;.	0.93;.	0.66466	D;.	0.000110	0.50451	D	0.081609	1;1;1;1;1;0.870818	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;A140P	2.295;.	0.65404	M;.	-4.95;-4.95	0.98428	D;D	-2.35;.	0.51968	N;.	0.637;.	0.64989	1.0800	0.98881	D	0.9469	0.98266	D	10	0.87663805;0.87663805	0.86956	D;D	0.539595	0.95707	D	0.875;.	0.96280	0.718;.;	0.85319	Q9BQB6;.;	A140P;.;	Loss of catalytic residue at A140 (P = 0.0331);.;	0.995316507137;0.995316507137	0.99527	0.7521504916273074;.	0.75162	1.33711377298;.	0.83765	0.534222841263	0.43630	T	0.814474;.	0.95398	D;.	0.360665	0.87303	D	0.280294	0.87139	D	0.939076283321497	0.61022	D	0.909409;0.90121	0.67928	D;D	0.9695668;.	0.98219	0.8909151;.	0.94332	0.9695668;.	0.98220	0.8909151;.	0.94332	-4.659;.	0.58755	T;.	0.5254153580785235;.	0.59706	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	0.8433;0.8654	0.80614	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.765906	0.71205	25.7	3.755045	0.74093	26.0	0.99729378936662239	0.82619	0.92803	0.56584	D	AEFBI	0.759897	0.69809	D	0.593228426426755	0.72752	5.855304	0.56441933458633	0.72409	5.804888	0.999988367760751	0.51787	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.95	0.64894	2.143000	0.41811	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.979000	0.57723	0.0:0.8489:0.0:0.1511	10.8912	0.46205	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091208	C	T	A	T	.	16	31102529	16	31010030	140;35	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.418G>A;.	p.A140T;.	c.418G>A;c.103G>A	p.Ala140Thr;p.Ala35Thr	c.418G>A;c.103G>A	p.Ala140Thr;p.Ala35Thr	principal1;.	Y;.	1;2	YES;.	-;-	GCT;GCT	1;1	0;0	C	C/C	C/C	C/C	C/C	0.037;.	0.43085	D;.	0.13;0.204	0.34716	T;T	0.822;.	0.45767	P;.	0.657;.	0.52725	P;.	0.000110	0.50451	D	0.081609	1;1;1;1;1;0.963365	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;A140T	2.295;.	0.65404	M;.	-4.9;-4.9	0.98333	D;D	-0.9;.	0.24244	N;.	0.385;.	0.42639	1.0307	0.97731	D	0.9317	0.97747	D	10	0.5358565;0.5358565	0.63443	D;D	0.472016	0.94696	D	0.708;.	0.89559	0.496;.;	0.58520	Q9BQB6;.;	A140T;.;	Gain of glycosylation at A140 (P = 0.0757);.;	0.990183999653;0.990183999653	0.99007	0.22783497607544412;.	0.22698	1.14049851225;.	0.78910	0.48091506958	0.36183	T	0.602926;.	0.87300	D;.	0.210057	0.74835	D	0.0639564	0.74507	D	0.826118409633636	0.48231	D	0.79822;0.784022	0.44280	T;T	0.37342542;.	0.58837	0.23333238;.	0.48519	0.37342542;.	0.58838	0.23333238;.	0.48518	-4.093;.	0.46692	T;.	0.1903354362934785;.	0.24932	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1086;0.0982	0.20663	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.663665	0.68374	25.3	3.677297	0.71805	25.7	0.99923349433664421	0.98917	0.91822	0.54337	D	AEFBI	0.408726	0.48029	N	0.45891921531877	0.64710	4.731854	0.469241897762591	0.65962	4.890507	0.999988367760751	0.51787	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.95	0.64894	2.143000	0.41811	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.979000	0.57723	0.0:0.8489:0.0:0.1511	10.8912	0.46205	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091213	G	A	T	I	rs755295304	16	31102534	16	31010035	138;33	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.413C>T;.	p.T138I;.	c.413C>T;c.98C>T	p.Thr138Ile;p.Thr33Ile	c.413C>T;c.98C>T	p.Thr138Ile;p.Thr33Ile	principal1;.	Y;.	1;2	YES;.	-;-	ACC;ACC	2;2	0;0	G	G/G	G/G	G/G	G/G	0.06;.	0.37326	T;.	0.063;0.013	0.63109	T;D	0.997;.	0.70673	D;.	0.935;.	0.67021	D;.	0.004433	0.33751	N	0.247257	0.999887;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	T138I;.;.;.;.;.	1.845;.	0.48678	L;.	-4.77;-4.77	0.98126	D;D	-4.95;.	0.81910	D;.	0.562;.	0.58629	1.0488	0.98092	D	0.9493	0.98348	D	10	0.8657326;0.8657326	0.85816	D;D	0.1341	0.81652	D	0.788;.	0.92988	0.68;.;	0.81788	Q9BQB6;.;	T138I;.;	Loss of glycosylation at T138 (P = 0.029);.;	0.990929346663;0.990929346663	0.99083	0.7352182060346711;.	0.73466	1.14713465814;.	0.79097	0.699333310127	0.67047	T	0.833538;.	0.96049	D;.	0.34445	0.86132	D	0.339867	0.89909	D	0.926025748252869	0.58807	D	0.916408;0.889911	0.70110	D;D	0.5410407;.	0.69454	0.63529223;.	0.78709	0.5410407;.	0.69455	0.63529223;.	0.78710	-5.673;.	0.71160	T;.	0.2611700724747514;.	0.35261	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.562;0.9027	0.82932	A;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.054714	0.80509	27.4	4.037265	0.83582	28.0	0.99894579888185864	0.96819	0.98565	0.84156	D	AEFBI	0.944787	0.95231	D	0.802472636263582	0.86259	8.82863	0.824859830592464	0.91467	10.90104	0.999999999996755	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	8.054000	0.89239	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.992000	0.67800	0.0:0.0:1.0:0.0	19.1019	0.93261	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	8.236e-06	1	8.302e-06	0	0	1	8.705e-05	0	0	0	0	0	0	0	0	1	9.415e-06	1	9.441e-06	0	0	1	8.962e-05	0	0	0	0	0	0	0	0	1	1.102e-05	1	1.113e-05	0	0	1	8.714e-05	0	0	0	0	0	0	0	0	segdup	1	251296	3.979370e-06	0	0	16230	0.000000e+00	0	1	34576	2.892180e-05	0	0	10074	0.000000e+00	0	0	18388	0.000000e+00	0	0	21644	0.000000e+00	0	0	113642	0.000000e+00	0	0	30610	0.000000e+00	0	1	34576	2.892180e-05	0	0	109388	0.000000e+00	0	1	207998	4.807740e-06	0	1	236870	4.221720e-06	0	1	244678	4.087000e-06	0	0	7162	0.000000e+00	0	0	17106	0.000000e+00	0	0	2320	0.000000e+00	0	0	9046	0.000000e+00	0	0	13390	0.000000e+00	0	0	42766	0.000000e+00	0	0	15684	0.000000e+00	0	.	.	.	.	0	16192	0.000000e+00	0	1	30508	3.277830e-05	0	0	6210	0.000000e+00	0	0	13410	0.000000e+00	0	0	16730	0.000000e+00	0	0	89488	0.000000e+00	0	0	30602	0.000000e+00	0	1	30508	3.277830e-05	0	0	14900	0.000000e+00	0	1	34250	2.919710e-05	0	0	9568	0.000000e+00	0	0	17692	0.000000e+00	0	0	21628	0.000000e+00	0	0	102692	0.000000e+00	0	0	30520	0.000000e+00	0	1	34250	2.919710e-05	0	0	12000	0.000000e+00	0	1	34442	2.903430e-05	0	0	9992	0.000000e+00	0	0	18384	0.000000e+00	0	0	21642	0.000000e+00	0	0	111552	0.000000e+00	0	0	30610	0.000000e+00	0	1	34442	2.903430e-05	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091213	G	C	T	S	.	16	31102534	16	31010035	138;33	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.413C>G;.	p.T138S;.	c.413C>G;c.98C>G	p.Thr138Ser;p.Thr33Ser	c.413C>G;c.98C>G	p.Thr138Ser;p.Thr33Ser	principal1;.	Y;.	1;2	YES;.	-;-	ACC;ACC	2;2	0;0	G	G/G	G/G	G/G	G/G	0.006;.	0.61437	D;.	0.009;0.042	0.66756	D;D	0.568;.	0.38507	P;.	0.156;.	0.34472	B;.	0.004433	0.33751	N	0.247257	0.998853;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	T138S;.;.;.;.;.	2.54;.	0.74080	M;.	-4.59;-4.59	0.97830	D;D	-3.54;.	0.68651	D;.	0.368;.	0.40963	0.8402	0.94907	D	0.8782	0.95955	D	10	0.7641507;0.7641507	0.76573	D;D	0.069604	0.70774	D	0.523;.	0.79765	0.578;.;	0.70347	Q9BQB6;.;	T138S;.;	Loss of glycosylation at T138 (P = 0.0617);.;	0.956173475357;0.956173475357	0.95570	0.4817042855982549;.	0.48090	0.417197321614;.	0.42347	0.598761916161	0.52729	T	0.79525;.	0.94722	D;.	0.232528	0.76958	D	0.0962336	0.76658	D	0.919891328829656	0.57882	D	0.853415;0.809719	0.53896	D;T	0.5923466;.	0.72278	0.70038176;.	0.82347	0.5923466;.	0.72280	0.70038176;.	0.82348	-2.754;.	0.16113	T;.	0.27943329395803995;.	0.37449	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.4057;0.3405	0.59893	A;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.182645	0.56182	23.8	3.158388	0.58478	23.9	0.99740230830431631	0.83409	0.98843	0.87588	D	AEFBI	0.944558	0.95179	D	0.445865690791465	0.63969	4.641294	0.570083879726384	0.72806	5.868104	0.999999999996755	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	8.054000	0.89239	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.992000	0.67800	0.0:0.0:1.0:0.0	19.1019	0.93261	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091214	T	A	T	S	.	16	31102535	16	31010036	138;33	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.412A>T;.	p.T138S;.	c.412A>T;c.97A>T	p.Thr138Ser;p.Thr33Ser	c.412A>T;c.97A>T	p.Thr138Ser;p.Thr33Ser	principal1;.	Y;.	1;2	YES;.	-;-	ACC;ACC	1;1	0;0	T	T/T	T/T	T/T	T/T	0.006;.	0.61437	D;.	0.009;0.042	0.66756	D;D	0.568;.	0.38507	P;.	0.156;.	0.34472	B;.	0.004433	0.33751	N	0.247257	0.986358;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	T138S;.;.;.;.;.	2.54;.	0.74080	M;.	-4.59;-4.59	0.97830	D;D	-3.54;.	0.68651	D;.	0.368;.	0.40963	0.6561	0.92621	D	0.8540	0.95135	D	10	0.7477995;0.7477995	0.75415	D;D	0.181696	0.85572	D	0.589;.	0.83582	0.578;.;	0.70347	Q9BQB6;.;	T138S;.;	Loss of glycosylation at T138 (P = 0.0617);.;	0.939902952548;0.939902952548	0.93927	0.4817043269113583;.	0.48090	0.417197321614;.	0.42347	0.598761916161	0.52729	T	0.79525;.	0.94722	D;.	0.206786	0.74528	D	0.0592575	0.74196	D	0.939931213855743	0.61182	D	0.853415;0.809719	0.53896	D;T	0.64853054;.	0.75285	0.5446398;.	0.73679	0.64853054;.	0.75287	0.5446398;.	0.73680	-2.754;.	0.16113	T;.	0.27943329395803995;.	0.37449	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.4057;0.3405	0.59893	A;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	2.917457	0.50254	23.2	2.803850	0.50368	23.1	0.99608418402618171	0.74634	0.95978	0.66984	D	AEFBI	0.771202	0.70590	D	0.163182793944718	0.49437	3.144199	0.258352864867648	0.53127	3.483119	0.99999146892696	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.78	0.60666	4.812000	0.62303	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.991000	0.66497	0.1354:0.0:0.0:0.8646	11.4358	0.49312	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091214	T	G	T	P	.	16	31102535	16	31010036	138;33	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.412A>C;.	p.T138P;.	c.412A>C;c.97A>C	p.Thr138Pro;p.Thr33Pro	c.412A>C;c.97A>C	p.Thr138Pro;p.Thr33Pro	principal1;.	Y;.	1;2	YES;.	-;-	ACC;ACC	1;1	0;0	T	T/T	T/T	T/T	T/T	0.002;.	0.72154	D;.	0.003;0.009	0.76473	D;D	0.997;.	0.70673	D;.	0.935;.	0.67021	D;.	0.004433	0.33751	N	0.247257	0.999085;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	T138P;.;.;.;.;.	2.885;.	0.83555	M;.	-4.82;-4.82	0.98198	D;D	-5.07;.	0.82830	D;.	0.572;.	0.59478	1.0814	0.98927	D	0.9608	0.98738	D	10	0.9051193;0.9051193	0.89876	D;D	0.521626	0.95455	D	0.885;.	0.96651	0.69;.;	0.82748	Q9BQB6;.;	T138P;.;	Loss of glycosylation at T138 (P = 0.036);.;	0.988813974172;0.988813974172	0.98869	0.8944454890539142;.	0.89415	1.27339813745;.	0.82345	0.59043109417	0.51555	T	0.947379;.	0.99217	D;.	0.52255	0.94992	D	0.51283	0.94919	D	0.981181919574738	0.73768	D	0.846915;0.80282	0.52723	T;T	0.9791047;.	0.99040	0.9647217;.	0.99217	0.9791047;.	0.99040	0.9647217;.	0.99218	-4.659;.	0.58755	T;.	0.7978778036594266;.	0.87521	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	0.5937;0.6455	0.70739	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.049483	0.80320	27.3	3.802968	0.75561	26.3	0.99601704990526541	0.74219	0.96492	0.69408	D	AEFBI	0.883752	0.81292	D	0.696713069798078	0.79416	7.073179	0.636583001637578	0.77615	6.713633	0.99999146892696	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.78	0.60666	4.812000	0.62303	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.991000	0.66497	0.1354:0.0:0.0:0.8646	11.4358	0.49312	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091217	T	C	T	A	.	16	31102538	16	31010039	137;32	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.409A>G;.	p.T137A;.	c.409A>G;c.94A>G	p.Thr137Ala;p.Thr32Ala	c.409A>G;c.94A>G	p.Thr137Ala;p.Thr32Ala	principal1;.	Y;.	1;2	YES;.	-;-	ACC;ACC	1;1	0;0	T	T/T	T/T	T/T	T/T	0.092;.	0.31682	T;.	0.304;0.021	0.58089	T;D	0.948;.	0.53620	P;.	0.754;.	0.56161	P;.	0.001176	0.39978	N	0.166448	1;1;1;1;1;0.59327	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;T137A	1.67;.	0.42885	L;.	-4.65;-4.65	0.97938	D;D	-1.09;.	0.28290	N;.	0.275;.	0.31140	0.7988	0.94396	D	0.8925	0.96431	D	10	0.5127986;0.5127986	0.62194	D;D	0.215687	0.87521	D	0.638;.	0.86181	0.511;.;	0.60846	Q9BQB6;.;	T137A;.;	Loss of sheet (P = 0.0126);.;	0.990545463348;0.990545463348	0.99044	0.267316270232094;.	0.26644	0.951642404872;.	0.72659	0.58256071806	0.50445	T	0.559984;.	0.85253	D;.	0.182793	0.72299	D	0.0247936	0.71940	D	0.710367609724605	0.41218	D	0.888311;0.667933	0.61778	D;T	0.2084117;.	0.43077	0.11183017;.	0.26979	0.2084117;.	0.43077	0.11183017;.	0.26978	-3.435;.	0.30034	T;.	0.11730899822837602;.	0.10702	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1085;0.1245	0.26232	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.100839	0.54292	23.6	3.021061	0.55206	23.6	0.99611682016390501	0.74873	0.89635	0.50226	D	AEFBI	0.543361	0.55872	D	0.376490266478256	0.60149	4.200921	0.416896331890032	0.62617	4.48017	0.999809832611067	0.43304	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.77	0.60425	2.142000	0.41802	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.975000	0.56047	0.1327:0.0:0.0:0.8673	11.6481	0.50533	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091219	A	C	I	S	.	16	31102540	16	31010041	136;31	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.407T>G;.	p.I136S;.	c.407T>G;c.92T>G	p.Ile136Ser;p.Ile31Ser	c.407T>G;c.92T>G	p.Ile136Ser;p.Ile31Ser	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	2;2	0;0	A	A/A	A/A	A/A	A/A	0.001;.	0.78490	D;.	0.002;0.003	0.79402	D;D	0.97;.	0.56973	D;.	0.743;.	0.55802	P;.	0.009719	0.30236	N	0.284770	0.976144;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	I136S;.;.;.;.;.	2.54;.	0.74080	M;.	-4.86;-4.86	0.98263	D;D	-4.87;.	0.81269	D;.	0.568;.	0.59138	1.0732	0.98678	D	0.9370	0.97927	D	10	0.87362385;0.87362385	0.86640	D;D	0.383171	0.93019	D	0.811;.	0.93892	0.603;.;	0.73466	Q9BQB6;.;	I136S;.;	Loss of stability (P = 0.0428);.;	0.97137963822;0.97137963822	0.97106	0.755210993868502;.	0.75468	1.35464816004;.	0.84160	0.533653318882	0.43550	T	0.884445;.	0.97603	D;.	0.347319	0.86326	D	0.261123	0.86147	D	0.990300849535999	0.80523	D	0.942106;0.962504	0.85970	D;D	0.8004224;.	0.83932	0.8717521;.	0.92987	0.8004224;.	0.83934	0.8717521;.	0.92988	-2.754;.	0.16113	T;.	0.30373676033043184;.	0.40126	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	0.7234;0.811	0.77802	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.166649	0.84366	28.3	4.061654	0.84408	28.2	0.99468630516799439	0.66207	0.98626	0.84855	D	AEFBI	0.949763	0.96273	D	0.712019290524632	0.80422	7.290346	0.734843364908065	0.85021	8.457924	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.954000	0.50415	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091219	A	G	I	T	.	16	31102540	16	31010041	136;31	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.407T>C;.	p.I136T;.	c.407T>C;c.92T>C	p.Ile136Thr;p.Ile31Thr	c.407T>C;c.92T>C	p.Ile136Thr;p.Ile31Thr	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	2;2	0;0	A	A/A	A/A	A/A	A/A	0.002;.	0.72154	D;.	0.005;0.009	0.72224	D;D	0.822;.	0.45767	P;.	0.475;.	0.46927	P;.	0.009719	0.30236	N	0.284770	0.914625;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	I136T;.;.;.;.;.	2.54;.	0.74080	M;.	-4.76;-4.76	0.98111	D;D	-3.45;.	0.67589	D;.	0.4;.	0.44090	1.0368	0.97847	D	0.9187	0.97308	D	10	0.85631716;0.85631716	0.84830	D;D	0.31289	0.91240	D	0.752;.	0.91498	0.618;.;	0.75232	Q9BQB6;.;	I136T;.;	Loss of stability (P = 0.0143);.;	0.968059607529;0.968059607529	0.96771	0.46289354827861656;.	0.46208	1.22315291198;.	0.81134	0.615337491035	0.55069	T	0.81338;.	0.95360	D;.	0.252515	0.78837	D	0.124944	0.78562	D	0.958259879354385	0.65222	D	0.939506;0.960404	0.85096	D;D	0.70840317;.	0.78520	0.77688205;.	0.86838	0.70840317;.	0.78521	0.77688205;.	0.86839	-4.093;.	0.46692	T;.	0.21336141971290465;.	0.28648	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	0.6855;0.7186	0.73729	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.838714	0.73357	26.0	3.737319	0.73544	25.9	0.99791255818399593	0.87661	0.98536	0.83832	D	AEFBI	0.947592	0.95831	D	0.587188406219849	0.72373	5.795685	0.646647716331357	0.78362	6.860873	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.954000	0.50415	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091219	A	T	I	N	.	16	31102540	16	31010041	136;31	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.407T>A;.	p.I136N;.	c.407T>A;c.92T>A	p.Ile136Asn;p.Ile31Asn	c.407T>A;c.92T>A	p.Ile136Asn;p.Ile31Asn	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	2;2	0;0	A	A/A	A/A	A/A	A/A	0.001;.	0.78490	D;.	0.001;0.002	0.83351	D;D	0.99;.	0.63424	D;.	0.899;.	0.63802	P;.	0.009719	0.30236	N	0.284770	0.968851;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	I136N;.;.;.;.;.	2.54;.	0.74080	M;.	-4.9;-4.9	0.98333	D;D	-5.83;.	0.88361	D;.	0.678;.	0.68516	1.0962	0.99499	D	0.9476	0.98290	D	10	0.88862884;0.88862884	0.88199	D;D	0.514591	0.95353	D	0.812;.	0.93931	0.597;.;	0.72739	Q9BQB6;.;	I136N;.;	Loss of sheet (P = 0.0357);.;	0.970972472218;0.970972472218	0.97066	0.7740650961756653;.	0.77356	1.55586283606;.	0.87969	0.59407222271	0.52068	T	0.942795;.	0.99115	D;.	0.252266	0.78813	D	0.124586	0.78536	D	0.991181135177612	0.81448	D	0.955704;0.970703	0.89491	D;D	0.9460604;.	0.95864	0.9508803;.	0.98452	0.9460604;.	0.95865	0.9508803;.	0.98452	-2.908;.	0.18623	T;.	0.6118553947844878;.	0.67951	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	0.8656;0.9256	0.84648	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.190795	0.85158	28.6	4.130108	0.86484	28.9	0.99324526312863382	0.59507	0.98562	0.84121	D	AEFBI	0.949763	0.96273	D	0.764266091370676	0.83832	8.121525	0.77170064842114	0.87768	9.33707	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.954000	0.50415	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091220	T	A	I	F	.	16	31102541	16	31010042	136;31	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.406A>T;.	p.I136F;.	c.406A>T;c.91A>T	p.Ile136Phe;p.Ile31Phe	c.406A>T;c.91A>T	p.Ile136Phe;p.Ile31Phe	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	1;1	0;0	T	T/T	T/T	T/T	T/T	0.042;.	0.41637	D;.	0.15;0.009	0.66756	T;D	0.942;.	0.52977	P;.	0.743;.	0.55802	P;.	0.009719	0.30236	N	0.284770	0.893216;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	I136F;.;.;.;.;.	2.19;.	0.61577	M;.	-4.85;-4.85	0.98245	D;D	-3.59;.	0.69236	D;.	0.425;.	0.46462	0.8898	0.95533	D	0.9076	0.96936	D	10	0.7540096;0.7540096	0.75846	D;D	0.39683	0.93311	D	0.763;.	0.91962	0.54;.;	0.65161	Q9BQB6;.;	I136F;.;	Loss of glycosylation at T138 (P = 0.0884);.;	0.954277040396;0.954277040396	0.95379	0.6674609294407172;.	0.66684	1.364717818;.	0.84419	0.526180386543	0.42497	T	0.844188;.	0.96393	D;.	0.188396	0.72816	D	0.032842	0.72463	D	0.919154763221741	0.57773	D	0.940206;0.960604	0.85218	D;D	0.4300489;.	0.62755	0.43197113;.	0.66797	0.4300489;.	0.62756	0.43197113;.	0.66797	-5.86;.	0.72623	T;.	0.23869830849039325;.	0.32330	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	0.2711;0.2717	0.50572	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.384401	0.61141	24.4	3.373325	0.63890	24.6	0.97886576983495388	0.36642	0.85037	0.44139	D	AEFBI	0.534451	0.55349	D	0.299439226587865	0.56119	3.776341	0.29592358209923	0.55300	3.693282	0.997311229536222	0.35488	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	3.34	0.37357	0.740000	0.25856	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.941000	0.48210	0.0:0.3112:0.0:0.6888	6.6579	0.22189	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091222	C	G	C	S	.	16	31102543	16	31010044	135;30	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.404G>C;.	p.C135S;.	c.404G>C;c.89G>C	p.Cys135Ser;p.Cys30Ser	c.404G>C;c.89G>C	p.Cys135Ser;p.Cys30Ser	principal1;.	Y;.	1;2	YES;.	-;-	TGT;TGT	2;2	0;0	C	C/C	C/C	C/C	C/C	0.026;.	0.46910	D;.	0.106;0.0	0.92824	T;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C135S;.;.;.;.;.	2.63;.	0.76995	M;.	-7.2;-7.2	0.99853	D;D	-8.68;.	0.97599	D;.	0.92;.	0.92317	0.9846	0.96934	D	0.9941	0.99865	D	10	0.97988;0.97988	0.97933	D;D	0.396301	0.93300	D	0.882;.	0.96539	0.879;.;	0.96784	Q9BQB6;.;	C135S;.;	Loss of stability (P = 0.0587);.;	0.980837406348;0.980837406348	0.98062	0.879607419756251;.	0.87928	1.26176195627;.	0.82047	0.700263142586	0.67181	T	0.961027;.	0.99499	D;.	0.513458	0.94704	D	0.49977	0.94627	D	0.986131906509399	0.76932	D	0.915608;0.89481	0.69895	D;D	0.933646;.	0.94603	0.9194616;.	0.96360	0.933646;.	0.94603	0.9194616;.	0.96361	-2.754;.	0.16113	T;.	0.6017311926984502;.	0.66878	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	0.8989;0.8643	0.82674	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.826588	0.72990	26.0	3.964402	0.81039	27.4	0.99493984114137601	0.67630	0.98276	0.81177	D	AEFBI	0.937250	0.93476	D	0.907482895584726	0.92119	11.24487	0.871042184274943	0.94184	12.56592	0.999999999996755	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.416000	0.73240	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.922000	0.45779	0.0:1.0:0.0:0.0	19.1019	0.93261	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091223	A	C	C	G	.	16	31102544	16	31010045	135;30	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.403T>G;.	p.C135G;.	c.403T>G;c.88T>G	p.Cys135Gly;p.Cys30Gly	c.403T>G;c.88T>G	p.Cys135Gly;p.Cys30Gly	principal1;.	Y;.	1;2	YES;.	-;-	TGT;TGT	1;1	0;0	A	A/A	A/A	A/A	A/A	0.006;.	0.61437	D;.	0.011;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C135G;.;.;.;.;.	2.975;.	0.85398	M;.	-7.21;-7.21	0.99854	D;D	-10.32;.	0.98973	D;.	0.918;.	0.92084	0.9269	0.96057	D	0.9944	0.99872	D	10	0.9835522;0.9835522	0.98499	D;D	0.604226	0.96525	D	0.965;.	0.99518	0.86;.;	0.95774	Q9BQB6;.;	C135G;.;	Loss of stability (P = 0.0189);.;	0.967711290523;0.967711290523	0.96736	0.8978998704228284;.	0.89760	1.28053249883;.	0.82507	0.678943097591	0.64116	T	0.963533;.	0.99547	D;.	0.541371	0.95484	D	0.539866	0.95417	D	0.999461948871613	0.97510	D	0.918008;0.953005	0.82069	D;D	0.98589754;.	0.99525	0.97142655;.	0.99525	0.98589754;.	0.99525	0.97142655;.	0.99526	-3.773;.	0.38610	T;.	0.6393832722269561;.	0.70986	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	0.8207;0.7805	0.78270	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.193095	0.85229	28.6	3.936305	0.80057	27.2	0.98281469740514904	0.39861	0.98626	0.84855	D	AEFBI	0.967216	0.98969	D	0.929647181809254	0.93134	11.84311	0.87608070251717	0.94443	12.76526	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.921000	0.45669	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091223	A	T	C	S	.	16	31102544	16	31010045	135;30	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.403T>A;.	p.C135S;.	c.403T>A;c.88T>A	p.Cys135Ser;p.Cys30Ser	c.403T>A;c.88T>A	p.Cys135Ser;p.Cys30Ser	principal1;.	Y;.	1;2	YES;.	-;-	TGT;TGT	1;1	0;0	A	A/A	A/A	A/A	A/A	0.026;.	0.46910	D;.	0.106;0.0	0.92824	T;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C135S;.;.;.;.;.	2.63;.	0.76995	M;.	-7.2;-7.2	0.99853	D;D	-8.68;.	0.97599	D;.	0.92;.	0.92317	0.9546	0.96464	D	0.9935	0.99850	D	10	0.98202527;0.98202527	0.98260	D;D	0.525519	0.95511	D	0.925;.	0.98154	0.879;.;	0.96784	Q9BQB6;.;	C135S;.;	Loss of stability (P = 0.0587);.;	0.980668466378;0.980668466378	0.98045	0.8796074059852166;.	0.87928	1.26176195627;.	0.82047	0.700263142586	0.67181	T	0.961027;.	0.99499	D;.	0.523201	0.95003	D	0.513765	0.94929	D	0.991770148277283	0.82119	D	0.915608;0.89481	0.69895	D;D	0.9240334;.	0.93642	0.9277174;.	0.96937	0.9240334;.	0.93643	0.9277174;.	0.96937	-2.754;.	0.16113	T;.	0.6017311926984502;.	0.66878	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	0.8989;0.8643	0.82674	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.163266	0.84262	28.3	4.016091	0.82845	27.8	0.99408908210358793	0.63169	0.98562	0.84121	D	AEFBI	0.969575	0.99195	D	0.879200329633068	0.90704	10.52633	0.840989446084897	0.92478	11.44996	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.921000	0.45669	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091225	A	C	V	G	.	16	31102546	16	31010047	134;29	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.401T>G;.	p.V134G;.	c.401T>G;c.86T>G	p.Val134Gly;p.Val29Gly	c.401T>G;c.86T>G	p.Val134Gly;p.Val29Gly	principal1;.	Y;.	1;2	YES;.	-;-	GTT;GTT	2;2	0;0	A	A/A	A/A	A/A	A/A	0.001;.	0.78490	D;.	0.001;0.002	0.83351	D;D	0.999;.	0.77913	D;.	0.977;.	0.73820	D;.	0.000360	0.45440	D	0.093960	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	V134G;.;.;.;.;.	2.79;.	0.81396	M;.	-4.79;-4.79	0.98155	D;D	-6.39;.	0.91141	D;.	0.468;.	0.50418	1.1007	0.99690	D	0.9654	0.98897	D	10	0.9196942;0.9196942	0.91325	D;D	0.602001	0.96499	D	0.909;.	0.97549	0.577;.;	0.70217	Q9BQB6;.;	V134G;.;	Loss of sheet (P = 0.0084);.;	0.995559530204;0.995559530204	0.99551	0.750936519855229;.	0.75040	1.3436498133;.	0.83914	0.559035897255	0.47132	T	0.948807;.	0.99248	D;.	0.391576	0.89421	D	0.324696	0.89288	D	0.99147230386734	0.81774	D	0.860114;0.856014	0.55285	D;D	0.95626664;.	0.96902	0.9551567;.	0.98702	0.95626664;.	0.96902	0.9551567;.	0.98703	-3.773;.	0.38610	T;.	0.5470858323822163;.	0.61608	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	0.7736;0.8084	0.77678	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.145506	0.83657	28.2	3.969405	0.81229	27.4	0.99724035444768244	0.82266	0.98626	0.84855	D	AEFBI	0.952168	0.96739	D	0.893152993265546	0.91420	10.87465	0.851841846353922	0.93124	11.83893	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	0.997000	0.40164	1.000000	0.68203	0.902000	0.43815	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091225	A	G	V	A	.	16	31102546	16	31010047	134;29	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.401T>C;.	p.V134A;.	c.401T>C;c.86T>C	p.Val134Ala;p.Val29Ala	c.401T>C;c.86T>C	p.Val134Ala;p.Val29Ala	principal1;.	Y;.	1;2	YES;.	-;-	GTT;GTT	2;2	0;0	A	A/A	A/A	A/A	A/A	0.001;.	0.78490	D;.	0.003;0.008	0.76473	D;D	0.987;.	0.61912	D;.	0.856;.	0.61001	P;.	0.000360	0.45440	D	0.093960	0.99976;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	V134A;.;.;.;.;.	2.79;.	0.81396	M;.	-4.74;-4.74	0.98081	D;D	-3.59;.	0.69236	D;.	0.481;.	0.51583	1.0658	0.98481	D	0.9448	0.98194	D	10	0.85264784;0.85264784	0.84448	D;D	0.405298	0.93484	D	0.827;.	0.94503	0.51;.;	0.60693	Q9BQB6;.;	V134A;.;	Loss of sheet (P = 0.0084);.;	0.987762279203;0.987762279203	0.98763	0.5819220249325681;.	0.58121	1.28454726725;.	0.82622	0.642411351204	0.58906	T	0.935217;.	0.98936	D;.	0.277314	0.81086	D	0.160566	0.80843	D	0.979467153549194	0.72845	D	0.907309;0.90461	0.67223	D;D	0.8314755;.	0.86005	0.84748316;.	0.91336	0.8314755;.	0.86006	0.84748316;.	0.91336	-3.435;.	0.30034	T;.	0.5617506785927335;.	0.62947	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	0.7664;0.7027	0.75767	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.032459	0.79726	27.2	3.863019	0.77535	26.7	0.99826062581271857	0.90852	0.98536	0.83832	D	AEFBI	0.938098	0.93681	D	0.79467753661111	0.85772	8.676783	0.781549535908324	0.88483	9.598791	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	0.997000	0.40164	1.000000	0.68203	0.902000	0.43815	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091226	C	A	V	F	.	16	31102547	16	31010048	134;29	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.400G>T;.	p.V134F;.	c.400G>T;c.85G>T	p.Val134Phe;p.Val29Phe	c.400G>T;c.85G>T	p.Val134Phe;p.Val29Phe	principal1;.	Y;.	1;2	YES;.	-;-	GTT;GTT	1;1	0;0	C	C/C	C/C	C/C	C/C	0.002;.	0.72154	D;.	0.004;0.008	0.74150	D;D	0.998;.	0.73220	D;.	0.969;.	0.72001	D;.	0.000360	0.45440	D	0.093960	0.999901;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	V134F;.;.;.;.;.	2.24;.	0.63355	M;.	-4.66;-4.66	0.97956	D;D	-3.9;.	0.72932	D;.	0.633;.	0.64648	1.0364	0.97840	D	0.9419	0.98095	D	10	0.8243526;0.8243526	0.81622	D;D	0.521429	0.95452	D	0.691;.	0.88773	0.502;.;	0.59460	Q9BQB6;.;	V134F;.;	Loss of sheet (P = 0.0357);.;	0.990683011835;0.990683011835	0.99058	0.8120760156695643;.	0.81163	1.35631030607;.	0.84190	0.610448002815	0.54379	T	0.833682;.	0.96054	D;.	0.312949	0.83965	D	0.211753	0.83757	D	0.95046854019165	0.63341	D	0.952805;0.951205	0.82030	D;D	0.8071561;.	0.84367	0.6468767;.	0.79351	0.8071561;.	0.84368	0.6468767;.	0.79352	-5.86;.	0.72623	T;.	0.33974025939902225;.	0.43754	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	0.5977;0.5414	0.68784	P;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.540179	0.65126	24.8	3.904032	0.78932	26.9	0.9966346208046043	0.78074	0.90401	0.51547	D	AEFBI	0.562550	0.57010	D	0.714187909151801	0.80561	7.321836	0.689741101212352	0.81599	7.564641	0.999998049342593	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	1.372000	0.33866	.	.	0.590000	0.31872	0.957000	0.33433	1.000000	0.68203	0.879000	0.42020	0.0:0.8459:0.0:0.1541	9.1962	0.36390	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091226	C	G	V	L	.	16	31102547	16	31010048	134;29	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.400G>C;.	p.V134L;.	c.400G>C;c.85G>C	p.Val134Leu;p.Val29Leu	c.400G>C;c.85G>C	p.Val134Leu;p.Val29Leu	principal1;.	Y;.	1;2	YES;.	-;-	GTT;GTT	1;1	0;0	C	C/C	C/C	C/C	C/C	0.043;.	0.41364	D;.	0.056;0.041	0.50514	T;D	0.948;.	0.53620	P;.	0.653;.	0.52567	P;.	0.000360	0.45440	D	0.093960	0.998909;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	V134L;.;.;.;.;.	2.24;.	0.63355	M;.	-4.6;-4.6	0.97849	D;D	-1.87;.	0.43717	N;.	0.286;.	0.32370	0.8841	0.95458	D	0.9051	0.96852	D	10	0.6978851;0.6978851	0.72258	D;D	0.27524	0.90030	D	0.568;.	0.82403	0.5;.;	0.59147	Q9BQB6;.;	V134L;.;	Loss of sheet (P = 0.0357);.;	0.976162945562;0.976162945562	0.97590	0.5487890399531586;.	0.54804	1.1526068558;.	0.79254	0.626965880394	0.56714	T	0.667849;.	0.90107	D;.	0.184123	0.72422	D	0.0267037	0.72065	D	0.82803750038147	0.48378	D	0.90061;0.893911	0.65471	D;D	0.46843225;.	0.65194	0.32373646;.	0.58303	0.46843225;.	0.65195	0.32373646;.	0.58302	-4.726;.	0.59903	T;.	0.20810227567956707;.	0.27829	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	0.4044;0.3836	0.59821	A;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.248619	0.57761	24.0	3.581988	0.69242	25.3	0.995217002027868	0.69284	0.91013	0.52691	D	AEFBI	0.562550	0.57010	D	0.560684676598184	0.70734	5.545364	0.580665171326689	0.73554	5.989617	0.999998049342593	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	1.372000	0.33866	.	.	0.590000	0.31872	0.957000	0.33433	1.000000	0.68203	0.879000	0.42020	0.0:0.8459:0.0:0.1541	9.1962	0.36390	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091228	A	C	I	S	.	16	31102549	16	31010050	133;28	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.398T>G;.	p.I133S;.	c.398T>G;c.83T>G	p.Ile133Ser;p.Ile28Ser	c.398T>G;c.83T>G	p.Ile133Ser;p.Ile28Ser	principal1;.	Y;.	1;2	YES;.	-;-	ATT;ATT	2;2	0;0	A	A/A	A/A	A/A	A/A	0.001;.	0.78490	D;.	0.002;0.006	0.79402	D;D	0.959;.	0.55135	D;.	0.703;.	0.54270	P;.	0.009844	0.30173	N	0.285167	0.926055;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	I133S;.;.;.;.;.	2.42;.	0.70002	M;.	-4.81;-4.81	0.98183	D;D	-4.31;.	0.76576	D;.	0.631;.	0.64478	1.0739	0.98698	D	0.9392	0.98003	D	10	0.8111131;0.8111131	0.80395	D;D	0.323837	0.91553	D	0.809;.	0.93816	0.55;.;	0.66576	Q9BQB6;.;	I133S;.;	Loss of sheet (P = 0.0084);.;	0.980573810218;0.980573810218	0.98036	0.7099393790800305;.	0.70935	0.699661806568;.	0.61046	0.552097678185	0.46153	T	0.859152;.	0.96860	D;.	0.356955	0.87020	D	0.274964	0.86850	D	0.978971064090729	0.72594	D	0.955004;0.972103	0.89869	D;D	0.87201715;.	0.89022	0.9021947;.	0.95132	0.87201715;.	0.89023	0.9021947;.	0.95133	-2.754;.	0.16113	T;.	0.3320626838422733;.	0.43005	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	0.7018;0.4964	0.73033	P;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.166317	0.84366	28.3	3.991712	0.82021	27.6	0.99160594917625833	0.54099	0.98623	0.84820	D	AEFBI	0.949821	0.96284	D	0.721029530986414	0.81010	7.423298	0.73327035136902	0.84902	8.423797	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.858000	0.40661	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091230	G	C	C	W	.	16	31102551	16	31010052	132;27	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.396C>G;.	p.C132W;.	c.396C>G;c.81C>G	p.Cys132Trp;p.Cys27Trp	c.396C>G;c.81C>G	p.Cys132Trp;p.Cys27Trp	principal1;.	Y;.	1;2	YES;.	-;-	TGC;TGC	3;3	2;2	G	G/G	G/G	G/G	G/G	0.0;.	0.91255	D;.	0.0;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C132W;.;.;.;.;.	2.985;.	0.85602	M;.	-8.6;-8.6	0.99944	D;D	-10.26;.	0.98946	D;.	0.895;.	0.89465	0.8979	0.95644	D	0.9973	0.99934	D	10	0.9706408;0.9706408	0.96655	D;D	0.835955	0.98730	D	0.902;.	0.97286	0.758;.;	0.88730	Q9BQB6;.;	C132W;.;	Gain of sheet (P = 0.0827);.;	0.973777975627;0.973777975627	0.97349	0.9215427673384002;.	0.92130	1.36121493711;.	0.84342	0.659344315529	0.61315	T	0.963058;.	0.99538	D;.	0.524651	0.95026	D	0.515849	0.94953	D	0.999588549137115	0.98022	D	0.920008;0.958704	0.84427	D;D	0.98283064;.	0.99318	0.97944516;.	0.99804	0.98283064;.	0.99318	0.97944516;.	0.99804	-6.696;.	0.77767	T;.	0.7681223884168424;.	0.84934	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	0.9619;0.94	0.88297	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.779950	0.71607	25.7	3.477733	0.66549	24.9	0.99391838559028012	0.62383	0.94518	0.61425	D	AEFBI	0.801230	0.72699	D	0.479700745777912	0.65907	4.881779	0.387040870198471	0.60765	4.267875	0.997642363479924	0.35855	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	2.86	0.32427	2.834000	0.47869	.	.	-0.147000	0.12262	1.000000	0.71638	0.998000	0.33993	0.885000	0.42453	0.2753:0.0:0.7247:0.0	10.2607	0.42604	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091231	C	G	C	S	.	16	31102552	16	31010053	132;27	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.395G>C;.	p.C132S;.	c.395G>C;c.80G>C	p.Cys132Ser;p.Cys27Ser	c.395G>C;c.80G>C	p.Cys132Ser;p.Cys27Ser	principal1;.	Y;.	1;2	YES;.	-;-	TGC;TGC	2;2	0;0	C	C/C	C/C	C/C	C/C	0.0;.	0.91255	D;.	0.082;0.0	0.92824	T;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C132S;.;.;.;.;.	2.985;.	0.85602	M;.	-8.59;-8.59	0.99944	D;D	-9.33;.	0.98332	D;.	0.912;.	0.91391	0.9242	0.96018	D	0.9980	0.99949	D	10	0.9679865;0.9679865	0.96323	D;D	0.403539	0.93448	D	0.896;.	0.97060	0.799;.;	0.91874	Q9BQB6;.;	C132S;.;	Gain of glycosylation at C132 (P = 0.0219);.;	0.966968392209;0.966968392209	0.96661	0.8640419231051325;.	0.86368	1.2879892462;.	0.82714	0.604207277298	0.53498	T	0.964224;.	0.99560	D;.	0.550348	0.95807	D	0.552761	0.95744	D	0.999089121818542	0.96125	D	0.907509;0.952005	0.81587	D;D	0.96817636;.	0.98088	0.9521085;.	0.98525	0.96817636;.	0.98088	0.9521085;.	0.98526	-2.754;.	0.16113	T;.	0.6799060593213776;.	0.75615	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	0.9497;0.861	0.86878	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.891294	0.74997	26.3	4.001728	0.82359	27.7	0.99521351089223686	0.69284	0.98276	0.81177	D	AEFBI	0.940433	0.94237	D	0.954336518329861	0.94156	12.54331	0.904654585009989	0.95771	13.95262	0.999999999996755	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.416000	0.73240	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.927000	0.46353	0.0:1.0:0.0:0.0	19.1019	0.93261	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091232	A	C	C	G	.	16	31102553	16	31010054	132;27	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.394T>G;.	p.C132G;.	c.394T>G;c.79T>G	p.Cys132Gly;p.Cys27Gly	c.394T>G;c.79T>G	p.Cys132Gly;p.Cys27Gly	principal1;.	Y;.	1;2	YES;.	-;-	TGC;TGC	1;1	0;0	A	A/A	A/A	A/A	A/A	0.0;.	0.91255	D;.	0.01;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C132G;.;.;.;.;.	2.985;.	0.85602	M;.	-8.59;-8.59	0.99944	D;D	-11.25;.	0.99385	D;.	0.916;.	0.91852	0.8632	0.95192	D	0.9978	0.99945	D	10	0.9708066;0.9708066	0.96676	D;D	0.65348	0.97073	D	0.944;.	0.98851	0.766;.;	0.89373	Q9BQB6;.;	C132G;.;	Loss of stability (P = 0.0189);.;	0.968367701688;0.968367701688	0.96803	0.8830858040382347;.	0.88276	1.29661177866;.	0.82915	0.582232296467	0.50399	T	0.963564;.	0.99548	D;.	0.560622	0.96249	D	0.567518	0.96190	D	0.999652028083801	0.98346	D	0.909109;0.953005	0.82069	D;D	0.99364;.	0.99923	0.97800833;.	0.99762	0.99364;.	0.99923	0.97800833;.	0.99762	-3.773;.	0.38610	T;.	0.7197421890325962;.	0.80075	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	0.9162;0.8208	0.83907	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.198947	0.85415	28.6	3.971571	0.81304	27.4	0.98334146104311981	0.40368	0.98626	0.84855	D	AEFBI	0.969753	0.99211	D	0.938483876297434	0.93514	12.08962	0.886780447691045	0.94970	13.19768	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.954000	0.50415	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091232	A	G	C	R	.	16	31102553	16	31010054	132;27	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.394T>C;.	p.C132R;.	c.394T>C;c.79T>C	p.Cys132Arg;p.Cys27Arg	c.394T>C;c.79T>C	p.Cys132Arg;p.Cys27Arg	principal1;.	Y;.	1;2	YES;.	-;-	TGC;TGC	1;1	0;0	A	A/A	A/A	A/A	A/A	0.0;.	0.91255	D;.	0.002;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C132R;.;.;.;.;.	2.985;.	0.85602	M;.	-8.6;-8.6	0.99944	D;D	-11.18;.	0.99365	D;.	0.915;.	0.91736	0.8600	0.95152	D	0.9978	0.99945	D	10	0.9795747;0.9795747	0.97887	D;D	0.671674	0.97263	D	0.962;.	0.99434	0.809;.;	0.92581	Q9BQB6;.;	C132R;.;	Gain of sheet (P = 0.039);.;	0.95760778915;0.95760778915	0.95716	0.9376120084301867;.	0.93741	1.57610209646;.	0.88303	0.689551591873	0.65641	T	0.963058;.	0.99538	D;.	0.56062	0.96249	D	0.567515	0.96190	D	0.999716460704803	0.98628	D	0.89481;0.943706	0.78720	D;D	0.99622273;.	0.99985	0.9891089;.	0.99972	0.99622273;.	0.99985	0.9891089;.	0.99972	-3.776;.	0.38690	T;.	0.7953954062035121;.	0.87316	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	0.9569;0.9411	0.87684	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.262045	0.87271	29.2	4.116861	0.86114	28.7	0.99738618748676144	0.83337	0.98536	0.83832	D	AEFBI	0.969902	0.99224	D	0.940688304287334	0.93605	12.15157	0.888663975918685	0.95060	13.27538	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.954000	0.50415	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091232	A	T	C	S	.	16	31102553	16	31010054	132;27	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.394T>A;.	p.C132S;.	c.394T>A;c.79T>A	p.Cys132Ser;p.Cys27Ser	c.394T>A;c.79T>A	p.Cys132Ser;p.Cys27Ser	principal1;.	Y;.	1;2	YES;.	-;-	TGC;TGC	1;1	0;0	A	A/A	A/A	A/A	A/A	0.0;.	0.91255	D;.	0.082;0.0	0.92824	T;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	C132S;.;.;.;.;.	2.985;.	0.85602	M;.	-8.59;-8.59	0.99944	D;D	-9.33;.	0.98332	D;.	0.912;.	0.91391	0.8765	0.95359	D	0.9978	0.99945	D	10	0.97218573;0.97218573	0.96854	D;D	0.560501	0.95986	D	0.945;.	0.98886	0.799;.;	0.91874	Q9BQB6;.;	C132S;.;	Gain of glycosylation at C132 (P = 0.0219);.;	0.965630039209;0.965630039209	0.96526	0.8640419093340981;.	0.86368	1.2879892462;.	0.82714	0.604207277298	0.53498	T	0.964224;.	0.99560	D;.	0.56034	0.96244	D	0.567113	0.96185	D	0.999349772930145	0.97042	D	0.907509;0.952005	0.81587	D;D	0.9706953;.	0.98325	0.9554072;.	0.98717	0.9706953;.	0.98325	0.9554072;.	0.98718	-2.754;.	0.16113	T;.	0.6799060593213776;.	0.75615	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	0.9497;0.861	0.86878	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.087955	0.81669	27.7	3.959491	0.80888	27.4	0.99498371532012431	0.67859	0.98562	0.84121	D	AEFBI	0.968240	0.99071	D	0.929368330549537	0.93122	11.83545	0.879036010121588	0.94594	12.88326	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.954000	0.50415	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091235	A	C	F	V	.	16	31102556	16	31010057	131;26	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.391T>G;.	p.F131V;.	c.391T>G;c.76T>G	p.Phe131Val;p.Phe26Val	c.391T>G;c.76T>G	p.Phe131Val;p.Phe26Val	principal1;.	Y;.	1;2	YES;.	-;-	TTC;TTC	1;1	0;0	A	A/A	A/A	A/A	A/A	0.244;.	0.17468	T;.	0.171;0.02	0.58613	T;D	0.716;.	0.42206	P;.	0.57;.	0.49854	P;.	0.000045	0.53742	D	0.076715	0.999917;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	F131V;.;.;.;.;.	1.87;.	0.49600	L;.	-4.69;-4.69	0.98005	D;D	-3.33;.	0.66206	D;.	0.556;.	0.58117	1.0062	0.97292	D	0.9241	0.97490	D	10	0.7921522;0.7921522	0.78754	D;D	0.300588	0.90869	D	0.797;.	0.93346	0.514;.;	0.61307	Q9BQB6;.;	F131V;.;	Gain of sheet (P = 0.1208);.;	0.947349779058;0.947349779058	0.94679	0.5244271297861884;.	0.52366	1.09524790985;.	0.77555	0.665021955967	0.62127	T	0.79654;.	0.94767	D;.	0.444281	0.92224	D	0.400403	0.92127	D	0.967742383480072	0.68010	D	0.881212;0.89741	0.64114	D;D	0.6903445;.	0.77530	0.6396703;.	0.78952	0.6903445;.	0.77532	0.6396703;.	0.78953	-4.523;.	0.56265	T;.	0.1813055433227181;.	0.23372	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1786;0.1554	0.38941	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.180091	0.56118	23.8	3.403607	0.64656	24.7	0.99052954388521486	0.51298	0.96486	0.69378	D	AEFBI	0.822307	0.74267	D	0.484540250684414	0.66187	4.917797	0.534750340551442	0.70343	5.49136	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	4.645000	0.61100	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.982000	0.59238	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091237	T	A	D	V	.	16	31102558	16	31010059	130;25	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.389A>T;.	p.D130V;.	c.389A>T;c.74A>T	p.Asp130Val;p.Asp25Val	c.389A>T;c.74A>T	p.Asp130Val;p.Asp25Val	principal1;.	Y;.	1;2	YES;.	-;-	GAT;GAT	2;2	0;0	T	T/T	T/T	T/T	T/T	0.001;.	0.78490	D;.	0.09;0.0	0.92824	T;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000002	0.62929	D	0.000000	1;1;1;1;1;1	0.81001	D;N;N;N;N;N	simple_aae;complex_aae;complex_aae;complex_aae;complex_aae;complex_aae	D130V;*93C;*157C;*150C;*162C;*161C	.;.	.	.;.	-4.76;-4.76	0.98111	D;D	-7.81;.	0.95950	D;.	0.695;.	0.70000	-0.9040	0.47561	T	0.1714	0.51309	T	9	0.83001137;0.83001137	0.82166	D;D	.	.	.	0.905;.	0.97398	0.582;.;	0.70861	Q9BQB6;.;	D130V;.;	Gain of helix (P = 0.132);.;	0.996715896902;0.996715896902	0.99667	0.7606099967850143;.	0.76008	1.40697242767;.	0.85345	0.598392963409	0.52677	T	0.829301;.	0.95907	D;.	0.553306	0.95857	D	0.557009	0.95794	D	0.994075059890747	0.85163	D	0.962404;0.965903	0.87416	D;D	0.9580524;.	0.97084	0.9510497;.	0.98463	0.9580524;.	0.97084	0.9510497;.	0.98463	-4.523;.	0.56265	T;.	0.34836274672452217;.	0.44573	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	0.893;0.9423	0.86127	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.270557	0.87497	29.3	4.214947	0.88563	29.6	0.99415199433291901	0.63501	0.97838	0.77507	D	AEFBI	0.960855	0.98186	D	0.425796165679696	0.62843	4.507299	0.524211598461028	0.69622	5.38695	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.507000	0.73628	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.990000	0.65344	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091237	T	C	D	G	.	16	31102558	16	31010059	130;25	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.389A>G;.	p.D130G;.	c.389A>G;c.74A>G	p.Asp130Gly;p.Asp25Gly	c.389A>G;c.74A>G	p.Asp130Gly;p.Asp25Gly	principal1;.	Y;.	1;2	YES;.	-;-	GAT;GAT	2;2	0;0	T	T/T	T/T	T/T	T/T	0.002;.	0.72154	D;.	0.006;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000002	0.62929	D	0.000000	0.999997;1;1;1;1;1	0.58761	D;N;N;N;N;N	simple_aae;complex_aae;complex_aae;complex_aae;complex_aae;complex_aae	D130G;*93W;*157W;*162W;*150W;*161W	.;.	.	.;.	-4.76;-4.76	0.98111	D;D	-6.12;.	0.90060	D;.	0.568;.	0.59138	-0.9040	0.47561	T	0.1714	0.51309	T	9	0.8315908;0.8315908	0.82321	D;D	.	.	.	0.934;.	0.98489	0.607;.;	0.73945	Q9BQB6;.;	D130G;.;	Loss of stability (P = 0.1306);.;	0.998061836846;0.998061836846	0.99804	0.6846065558992591;.	0.68399	1.34759586193;.	0.84011	0.611857235432	0.54579	T	0.870423;.	0.97196	D;.	0.545951	0.95639	D	0.546444	0.95575	D	0.981693096833659	0.74058	D	0.950905;0.955504	0.83071	D;D	0.9844136;.	0.99428	0.9708563;.	0.99501	0.9844136;.	0.99428	0.9708563;.	0.99502	-3.773;.	0.38610	T;.	0.5555267020618887;.	0.62371	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	0.8805;0.9035	0.82987	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.254393	0.87064	29.2	4.163042	0.87376	29.1	0.99852128161473253	0.93102	0.97535	0.75383	D	AEFBI	0.971317	0.99341	D	0.425796165679696	0.62843	4.507299	0.524211598461028	0.69622	5.38695	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.507000	0.73628	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.990000	0.65344	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091238	C	G	D	H	.	16	31102559	16	31010060	130;25	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.388G>C;.	p.D130H;.	c.388G>C;c.73G>C	p.Asp130His;p.Asp25His	c.388G>C;c.73G>C	p.Asp130His;p.Asp25His	principal1;.	Y;.	1;2	YES;.	-;-	GAT;GAT	1;1	0;0	C	C/C	C/C	C/C	C/C	0.001;.	0.78490	D;.	0.004;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000002	0.62929	D	0.000000	0.999999;1;1;1;1;1	0.58761	D;N;N;N;N;N	simple_aae;complex_aae;complex_aae;complex_aae;complex_aae;complex_aae	D130H;*162S;*161S;*93S;*157S;*150S	.;.	.	.;.	-4.73;-4.73	0.98066	D;D	-5.92;.	0.88963	D;.	0.616;.	0.63204	-0.8786	0.49872	T	0.2005	0.55681	T	9	0.8514359;0.8514359	0.84324	D;D	.	.	.	0.915;.	0.97776	0.648;.;	0.78542	Q9BQB6;.;	D130H;.;	Gain of helix (P = 0.132);.;	0.998588587538;0.998588587538	0.99857	0.6825908069586579;.	0.68198	1.27448055317;.	0.82373	0.671909809113	0.63110	T	0.905781;.	0.98187	D;.	0.550401	0.95808	D	0.552836	0.95745	D	0.993078529834747	0.83739	D	0.954105;0.958004	0.84234	D;D	0.96153086;.	0.97434	0.96071786;.	0.99010	0.96153086;.	0.97435	0.96071786;.	0.99010	0.0;.	0.02703	T;.	0.4139012532681516;.	0.50377	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	0.8846;0.8854	0.81802	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.016175	0.79168	27.1	4.232784	0.88927	29.7	0.99617839241129302	0.75233	0.98276	0.81177	D	AEFBI	0.941897	0.94578	D	0.486796921053945	0.66317	4.934686	0.588680672628406	0.74124	6.084438	0.999999999996755	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	6.416000	0.73240	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.994000	0.71098	0.0:1.0:0.0:0.0	19.1019	0.93261	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091240	T	C	Y	C	rs2057287095	16	31102561	16	31010062	129;24	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.386A>G;.	p.Y129C;.	c.386A>G;c.71A>G	p.Tyr129Cys;p.Tyr24Cys	c.386A>G;c.71A>G	p.Tyr129Cys;p.Tyr24Cys	principal1;.	Y;.	1;2	YES;.	-;-	TAT;TAT	2;2	0;0	T	T/T	T/T	T/T	T/T	0.018;.	0.50676	D;.	0.082;0.153	0.41573	T;T	0.978;.	0.58756	D;.	0.733;.	0.55393	P;.	0.064155	0.21973	N	0.429556	0.966823;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	Y129C;.;.;.;.;.	.;.	.	.;.	-4.7;-4.7	0.98020	D;D	-3.2;.	0.64710	D;.	0.446;.	0.48411	1.0488	0.98092	D	0.9321	0.97760	D	9	0.7909157;0.7909157	0.78652	D;D	0.595353	0.96419	D	0.655;.	0.87035	0.466;.;	0.53729	Q9BQB6;.;	Y129C;.;	Loss of catalytic residue at L124 (P = 0.0746);.;	0.991474181579;0.991474181579	0.99138	0.4926200888600787;.	0.49183	1.28677131276;.	0.82676	0.503075778484	0.39257	T	0.829483;.	0.95913	D;.	0.225458	0.76291	D	0.0860782	0.75983	D	0.905043017092351	0.55867	D	0.952405;0.956004	0.83260	D;D	0.7933219;.	0.83481	0.65401214;.	0.79747	0.7933219;.	0.83483	0.65401214;.	0.79748	-5.942;.	0.73235	T;.	0.2480240665773276;.	0.33582	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.2027;0.1995	0.42749	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.122306	0.82872	27.9	4.032841	0.83436	28.0	0.99765241411489991	0.85417	0.94464	0.61249	D	AEFBI	0.805055	0.72975	D	0.565139817881174	0.71010	5.586171	0.601986116884264	0.75084	6.248362	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	4.823000	0.62385	.	.	0.654000	0.53741	0.998000	0.41325	1.000000	0.68203	0.997000	0.79791	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	24516	4.078968836678088E-5	0	108	0	0	84	0	0	2728	0	0	500	0	0	628	0	0	24	0	0	94	0	0	4562	0	0	2836	0	0	108	0	1	33244	3.0080616051016725E-5	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091240	T	G	Y	S	.	16	31102561	16	31010062	129;24	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.386A>C;.	p.Y129S;.	c.386A>C;c.71A>C	p.Tyr129Ser;p.Tyr24Ser	c.386A>C;c.71A>C	p.Tyr129Ser;p.Tyr24Ser	principal1;.	Y;.	1;2	YES;.	-;-	TAT;TAT	2;2	0;0	T	T/T	T/T	T/T	T/T	0.128;.	0.26965	T;.	0.528;0.515	0.10643	T;T	0.351;.	0.33667	B;.	0.174;.	0.35540	B;.	0.064155	0.21973	N	0.429556	0.948406;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	Y129S;.;.;.;.;.	.;.	.	.;.	-4.58;-4.58	0.97812	D;D	-1.14;.	0.29323	N;.	0.416;.	0.45615	0.7508	0.93803	D	0.8509	0.95028	D	9	0.69979227;0.69979227	0.72371	D;D	0.486077	0.94921	D	0.466;.	0.76156	0.484;.;	0.56621	Q9BQB6;.;	Y129S;.;	Gain of glycosylation at Y129 (P = 0.0523);.;	0.979114708393;0.979114708393	0.97889	0.5012933204726561;.	0.50051	1.27794266167;.	0.82456	0.444368422031	0.31174	T	0.553084;.	0.84903	D;.	0.215155	0.75316	D	0.0712783	0.74994	D	0.906186580657959	0.56013	D	0.913409;0.919808	0.70989	D;D	0.5413112;.	0.69469	0.45443016;.	0.68277	0.5413112;.	0.69470	0.45443016;.	0.68277	-2.754;.	0.16113	T;.	0.09865989112605306;.	0.07079	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.2165;0.1445	0.44617	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	2.886239	0.49582	23.2	2.864612	0.51710	23.3	0.9863285605385167	0.43933	0.96165	0.67831	D	AEFBI	0.812140	0.73494	D	0.140144469095457	0.48345	3.048002	0.291629083266991	0.55048	3.668466	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	4.823000	0.62385	.	.	0.654000	0.53741	0.998000	0.41325	1.000000	0.68203	0.997000	0.79791	0.0:0.0:0.0:1.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091243	A	G	L	P	.	16	31102564	16	31010065	128;23	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.383T>C;.	p.L128P;.	c.383T>C;c.68T>C	p.Leu128Pro;p.Leu23Pro	c.383T>C;c.68T>C	p.Leu128Pro;p.Leu23Pro	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	2;2	0;0	A	A/A	A/A	A/A	A/A	0.001;.	0.78490	D;.	0.0;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000049	0.53742	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L128P;.;.;.;.;.	.;.	.	.;.	-5.1;-5.1	0.98700	D;D	-6.15;.	0.90178	D;.	0.936;.	0.94196	1.0998	0.99653	D	0.9695	0.99037	D	9	0.9546083;0.9546083	0.94815	D;D	0.70062	0.97550	D	0.979;.	0.99840	0.804;.;	0.92230	Q9BQB6;.;	L128P;.;	Gain of sheet (P = 0.0149);.;	0.979605310708;0.979605310708	0.97938	0.955739468332859;.	0.95558	1.23012436394;.	0.81310	0.750862002373	0.74573	T	0.958505;.	0.99450	D;.	0.562149	0.96278	D	0.569712	0.96219	D	0.995353102684021	0.87274	D	0.925008;0.941006	0.77964	D;D	0.98560876;.	0.99506	0.9720445;.	0.99551	0.98560876;.	0.99506	0.9720445;.	0.99551	-4.659;.	0.58755	T;.	0.7449997435440863;.	0.82709	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	0.8396;0.9026	0.82925	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.286142	0.87894	29.5	4.180772	0.87798	29.3	0.9978140529518591	0.86780	0.98531	0.83777	D	AEFBI	0.965025	0.98726	D	0.77275486712316	0.84378	8.27071	0.7877673499285	0.88930	9.771253	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091243	A	T	L	H	.	16	31102564	16	31010065	128;23	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.383T>A;.	p.L128H;.	c.383T>A;c.68T>A	p.Leu128His;p.Leu23His	c.383T>A;c.68T>A	p.Leu128His;p.Leu23His	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	2;2	0;0	A	A/A	A/A	A/A	A/A	0.01;.	0.56456	D;.	0.0;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000049	0.53742	D	0.000000	0.999458;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L128H;.;.;.;.;.	.;.	.	.;.	-5.1;-5.1	0.98700	D;D	-6.43;.	0.91311	D;.	0.921;.	0.92433	1.0998	0.99653	D	0.9695	0.99037	D	9	0.95643955;0.95643955	0.95009	D;D	0.780505	0.98271	D	0.984;.	0.99918	0.8;.;	0.91946	Q9BQB6;.;	L128H;.;	Gain of sheet (P = 0.0344);.;	0.987159157288;0.987159157288	0.98701	0.8404802615218596;.	0.84008	0.504819141512;.	0.48747	0.722283959389	0.70379	T	0.958524;.	0.99450	D;.	0.548339	0.95679	D	0.549875	0.95615	D	0.99335640668869	0.84121	D	0.727127;0.743726	0.36333	T;T	0.93524706;.	0.94765	0.9008585;.	0.95037	0.93524706;.	0.94765	0.9008585;.	0.95037	0.0;.	0.02703	T;.	0.6991698248066807;.	0.77790	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	0.8419;0.9392	0.85832	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.187699	0.85057	28.5	4.128640	0.86454	28.8	0.96932199547033715	0.31660	0.98557	0.84065	D	AEFBI	0.928804	0.91359	D	0.77275486712316	0.84378	8.27071	0.7877673499285	0.88930	9.771253	0.99999999872791	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	5.9	0.94952	7.522000	0.80772	.	.	0.743000	0.86499	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.3526	0.74116	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091244	G	C	L	V	.	16	31102565	16	31010066	128;23	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.382C>G;.	p.L128V;.	c.382C>G;c.67C>G	p.Leu128Val;p.Leu23Val	c.382C>G;c.67C>G	p.Leu128Val;p.Leu23Val	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	1;1	0;0	G	G/G	G/G	G/G	G/G	0.003;.	0.68238	D;.	0.0;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000049	0.53742	D	0.000000	0.979168;0.982195;0.989809;0.989809;0.989809;0.989809	0.39534	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	L128V;A148G;A155G;A91G;A159G;A160G	.;.	.	.;.	-4.96;-4.96	0.98448	D;D	-2.78;.	0.58896	D;.	0.622;.	0.63713	0.8472	0.94994	D	0.9543	0.98517	D	9	0.72312164;0.72312164	0.73795	D;D	0.207458	0.87094	D	0.779;.	0.92623	0.599;.;	0.72984	Q9BQB6;.;	L128V;.;	Gain of sheet (P = 0.1208);.;	0.954471892389;0.954471892389	0.95399	0.6122126133146129;.	0.61153	0.612275665354;.	0.55827	0.611491680145	0.54527	T	0.927761;.	0.98755	D;.	0.047028	0.57958	T	-0.170224	0.57423	T	0.975364506244659	0.70902	D	0.950305;0.960904	0.85339	D;D	0.8707631;.	0.88922	0.7224216;.	0.83608	0.8707631;.	0.88923	0.7224216;.	0.83609	-4.523;.	0.56265	T;.	0.4011829670322166;.	0.49296	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	0.5386;0.6562	0.71172	A;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.583064	0.66244	25.0	3.477812	0.66549	24.9	0.99668014802040161	0.78394	0.96562	0.69761	D	AEFBI	0.773399	0.70743	D	0.611976804222263	0.73930	6.04734	0.606000865092173	0.75376	6.299402	0.999985929576201	0.51787	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.9	4.93	0.64394	4.245000	0.58529	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.1504:0.0:0.8496:0.0	10.6835	0.45024	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091252	A	G	F	S	.	16	31102573	16	31010074	125;20	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.374T>C;.	p.F125S;.	c.374T>C;c.59T>C	p.Phe125Ser;p.Phe20Ser	c.374T>C;c.59T>C	p.Phe125Ser;p.Phe20Ser	principal1;.	Y;.	1;2	YES;.	-;-	TTC;TTC	2;2	0;0	A	A/A	A/A	A/A	A/A	0.044;.	0.41096	D;.	0.017;0.022	0.60337	D;D	0.999;.	0.77913	D;.	0.958;.	0.70027	D;.	0.000087	0.51296	D	0.080665	1;1;1;1;1;0.864813	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;F125S	.;.	.	.;.	-4.72;-4.72	0.98051	D;D	-3.74;.	0.71042	D;.	0.639;.	0.65159	1.0565	0.98259	D	0.9451	0.98204	D	9	0.85115165;0.85115165	0.84294	D;D	0.562807	0.96016	D	0.804;.	0.93621	0.627;.;	0.76254	Q9BQB6;.;	F125S;.;	Loss of stability (P = 0.0649);.;	0.96523044008;0.96523044008	0.96486	0.5671849524016588;.	0.56646	1.5511798655;.	0.87904	0.66208589077	0.61708	T	0.805974;.	0.95100	D;.	0.363917	0.87550	D	0.284965	0.87388	D	0.9671590924263	0.67815	D	0.905509;0.906109	0.66926	D;D	0.8518037;.	0.87469	0.87971383;.	0.93542	0.8518037;.	0.87470	0.87971383;.	0.93542	-2.754;.	0.16113	T;.	0.2648495314875965;.	0.35714	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	0.6372;0.4503	0.70402	P;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.532941	0.64941	24.8	3.671975	0.71654	25.6	0.9986158094564016	0.94002	0.93908	0.59540	D	AEFBI	0.634821	0.61455	D	0.580967649846302	0.71989	5.735386	0.604380905805849	0.75257	6.278774	0.999996527039517	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	2.703000	0.46778	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	1.000000	0.97212	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091252	A	T	F	Y	.	16	31102573	16	31010074	125;20	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.374T>A;.	p.F125Y;.	c.374T>A;c.59T>A	p.Phe125Tyr;p.Phe20Tyr	c.374T>A;c.59T>A	p.Phe125Tyr;p.Phe20Tyr	principal1;.	Y;.	1;2	YES;.	-;-	TTC;TTC	2;2	0;0	A	A/A	A/A	A/A	A/A	1.0;.	0.00964	T;.	1.0;0.835	0.03663	T;T	0.659;.	0.40886	P;.	0.284;.	0.40463	B;.	0.000087	0.51296	D	0.080665	1;1;1;1;1;0.98112	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;F125Y	.;.	.	.;.	-4.74;-4.74	0.98081	D;D	1.14;.	0.01166	N;.	0.284;.	0.32148	0.6429	0.92453	D	0.7885	0.92825	D	9	0.5454415;0.5454415	0.63957	D;D	0.645398	0.96987	D	0.458;.	0.75619	0.605;.;	0.73706	Q9BQB6;.;	F125Y;.;	Loss of stability (P = 0.1899);.;	0.785822634789;0.785822634789	0.78383	0.32529505198744535;.	0.32442	0.642306294363;.	0.57800	0.683534026146	0.64776	T	0.410825;.	0.76545	T;.	0.196598	0.73574	D	0.0446232	0.73230	D	0.932181060314178	0.59806	D	0.830817;0.827917	0.49719	T;T	0.37770134;.	0.59149	0.21235207;.	0.45700	0.37770134;.	0.59150	0.21235207;.	0.45699	-5.692;.	0.71313	T;.	0.09047633693330748;.	0.05638	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.2398;0.1154	0.47382	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.984761	0.30292	19.14	2.238748	0.37979	21.7	0.9519344895592422	0.26379	0.89398	0.49838	D	AEFBI	0.527037	0.54914	D	0.114350741481227	0.47132	2.943215	0.250681116084321	0.52689	3.441992	0.999996527039517	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	2.703000	0.46778	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	1.000000	0.97212	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091253	A	C	F	V	.	16	31102574	16	31010075	125;20	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.373T>G;.	p.F125V;.	c.373T>G;c.58T>G	p.Phe125Val;p.Phe20Val	c.373T>G;c.58T>G	p.Phe125Val;p.Phe20Val	principal1;.	Y;.	1;2	YES;.	-;-	TTC;TTC	1;1	0;0	A	A/A	A/A	A/A	A/A	0.177;.	0.22224	T;.	0.102;0.039	0.51112	T;D	0.98;.	0.59353	D;.	0.714;.	0.54635	P;.	0.000087	0.51296	D	0.080665	0.990644;0.990644;0.990644;0.990644;0.994665;0.7995	0.42368	D;D;D;D;D;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	V157G;V156G;V88G;V152G;V145G;F125V	.;.	.	.;.	-4.55;-4.55	0.97753	D;D	-2.65;.	0.56787	D;.	0.376;.	0.41754	1.0170	0.97480	D	0.9164	0.97230	D	9	0.7003906;0.7003906	0.72406	D;D	0.469941	0.94662	D	0.752;.	0.91498	0.538;.;	0.64874	Q9BQB6;.;	F125V;.;	Loss of helix (P = 0.4763);.;	0.956517798178;0.956517798178	0.95605	0.4294480847562002;.	0.42861	1.23012436394;.	0.81310	0.645170748234	0.59299	T	0.768325;.	0.93779	D;.	0.332753	0.85347	D	0.2402	0.85156	D	0.976411938667297	0.71369	D	0.840516;0.835616	0.51562	T;T	0.559512;.	0.70483	0.32438037;.	0.58363	0.559512;.	0.70484	0.32438037;.	0.58362	-4.523;.	0.56265	T;.	0.14448002287613634;.	0.16509	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.2309;0.1823	0.46378	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.120796	0.54742	23.7	3.285375	0.61647	24.3	0.98772814228039596	0.46002	0.90727	0.52147	D	AEFBI	0.481662	0.52286	N	0.377624049321553	0.60211	4.207615	0.432114239759629	0.63578	4.594167	0.999992788536573	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	4.83	0.61880	2.278000	0.43085	.	.	0.678000	0.82376	0.994000	0.38300	1.000000	0.68203	1.000000	0.97212	0.9269:0.0:0.073:0.0	11.4092	0.49157	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091255	A	C	L	R	.	16	31102576	16	31010077	124;19	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.371T>G;.	p.L124R;.	c.371T>G;c.56T>G	p.Leu124Arg;p.Leu19Arg	c.371T>G;c.56T>G	p.Leu124Arg;p.Leu19Arg	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	2;2	0;0	A	A/A	A/A	A/A	A/A	0.0;.	0.91255	D;.	0.001;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000085	0.51296	D	0.000000	0.999847;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L124R;.;.;.;.;.	.;.	.	.;.	-4.89;-4.89	0.98313	D;D	-5.59;.	0.86527	D;.	0.881;.	0.87917	1.1045	0.99805	D	0.9635	0.98831	D	9	0.92087114;0.92087114	0.91441	D;D	0.690464	0.97451	D	0.958;.	0.99315	0.693;.;	0.83032	Q9BQB6;.;	L124R;.;	Loss of stability (P = 0.0229);.;	0.959672100304;0.959672100304	0.95924	0.9483680401501671;.	0.94819	1.42526408802;.	0.85695	0.747531235218	0.74082	T	0.96101;.	0.99499	D;.	0.568429	0.96580	D	0.578733	0.96523	D	0.997565627098083	0.91863	D	0.957704;0.966503	0.87759	D;D	0.99020445;.	0.99775	0.98023623;.	0.99824	0.99020445;.	0.99775	0.98023623;.	0.99825	-3.776;.	0.38690	T;.	0.7918450754741106;.	0.87014	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	0.8777;0.9162	0.83907	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.215635	0.85942	28.8	4.167258	0.87484	29.2	0.99759478608595054	0.84931	0.98800	0.87016	D	AEFBI	0.949391	0.96198	D	0.765844833148895	0.83931	8.148833	0.782676203498349	0.88562	9.62965	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091255	A	G	L	P	.	16	31102576	16	31010077	124;19	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.371T>C;.	p.L124P;.	c.371T>C;c.56T>C	p.Leu124Pro;p.Leu19Pro	c.371T>C;c.56T>C	p.Leu124Pro;p.Leu19Pro	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	2;2	0;0	A	A/A	A/A	A/A	A/A	0.0;.	0.91255	D;.	0.001;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000085	0.51296	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L124P;.;.;.;.;.	.;.	.	.;.	-4.92;-4.92	0.98371	D;D	-6.4;.	0.91184	D;.	0.92;.	0.92317	1.0993	0.99632	D	0.9613	0.98756	D	8	0.92487884;0.92487884	0.91837	D;D	0.685364	0.97400	D	0.961;.	0.99405	0.7;.;	0.83684	Q9BQB6;.;	L124P;.;	Loss of stability (P = 0.0092);.;	0.968246250369;0.968246250369	0.96790	0.9630155734149959;.	0.96288	1.50425018939;.	0.87093	0.770728588104	0.77534	T	0.960106;.	0.99481	D;.	0.568679	0.96584	D	0.579092	0.96527	D	0.99785041809082	0.92591	D	0.941806;0.955104	0.82903	D;D	0.9905668;.	0.99793	0.9795518;.	0.99807	0.9905668;.	0.99793	0.9795518;.	0.99807	-4.659;.	0.58755	T;.	0.8387814237682711;.	0.90779	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	P;.	0.9399;0.9553	0.87497	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.274919	0.87613	29.4	4.174065	0.87644	29.2	0.99915730949885551	0.98379	0.98714	0.85918	D	AEFBI	0.949634	0.96248	D	0.715851338543478	0.80673	7.346359	0.739960288658275	0.85405	8.570795	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091256	G	C	L	V	rs1361180864	16	31102577	16	31010078	124;19	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.370C>G;.	p.L124V;.	c.370C>G;c.55C>G	p.Leu124Val;p.Leu19Val	c.370C>G;c.55C>G	p.Leu124Val;p.Leu19Val	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	1;1	2;2	G	G/G	G/G	G/G	G/G	0.0;.	0.91255	D;.	0.075;0.0	0.92824	T;D	1.0;.	0.90584	D;.	0.998;.	0.88582	D;.	0.000085	0.51296	D	0.000000	0.970671;0.991331;0.995058;0.995058;0.995058;0.995058	0.38815	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	L124V;P144R;P151R;P87R;P155R;P156R	.;.	.	.;.	-4.86;-4.86	0.98263	D;D	-2.78;.	0.58896	D;.	0.534;.	0.56231	0.7219	0.93447	D	0.9335	0.97809	D	9	0.8357793;0.8357793	0.82735	D;D	0.152074	0.83354	D	0.762;.	0.91920	0.673;.;	0.81101	Q9BQB6;.;	L124V;.;	Loss of stability (P = 0.1523);.;	0.926276339266;0.926276339266	0.92552	0.671090134092143;.	0.67047	1.16937237842;.	0.79717	0.628590226173	0.56944	T	0.946577;.	0.99199	D;.	0.460134	0.92932	D	0.423174	0.92845	D	0.988899290561676	0.79172	D	0.961704;0.969436	0.89015	D;D	0.9404492;.	0.95293	0.8860992;.	0.93990	0.9404492;.	0.95294	0.8860992;.	0.93991	-4.523;.	0.56265	T;.	0.7367344631962318;.	0.81866	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	0.6855;0.7223	0.73884	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.430756	0.62317	24.5	2.998239	0.54688	23.6	0.99810789023301993	0.89442	0.95171	0.63699	D	AEFBI	0.676623	0.64160	D	0.268952216904352	0.54583	3.62346	0.240257494419778	0.52097	3.38694	0.990109050517139	0.32040	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	0.618	0.16800	3.940000	0.56310	.	.	0.607000	0.46521	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.3368:0.0:0.6632:0.0	10.243	0.42501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	251206	3.980800e-06	0	0	16212	0.000000e+00	0	0	34572	0.000000e+00	0	0	10074	0.000000e+00	0	0	18388	0.000000e+00	0	0	21634	0.000000e+00	0	1	113588	8.803750e-06	0	0	30602	0.000000e+00	0	1	113588	8.803750e-06	0	0	109368	0.000000e+00	0	1	207944	4.808990e-06	0	1	236804	4.222900e-06	0	1	244590	4.088470e-06	0	0	7158	0.000000e+00	0	0	17106	0.000000e+00	0	0	2320	0.000000e+00	0	0	9046	0.000000e+00	0	0	13380	0.000000e+00	0	0	42766	0.000000e+00	0	0	15678	0.000000e+00	0	.	.	.	.	0	16174	0.000000e+00	0	0	30506	0.000000e+00	0	0	6212	0.000000e+00	0	0	13410	0.000000e+00	0	0	16720	0.000000e+00	0	1	89466	1.117740e-05	0	0	30594	0.000000e+00	0	1	89466	1.117740e-05	0	0	14894	0.000000e+00	0	0	34242	0.000000e+00	0	0	9566	0.000000e+00	0	0	17692	0.000000e+00	0	0	21618	0.000000e+00	0	1	102658	9.741080e-06	0	0	30514	0.000000e+00	0	1	102658	9.741080e-06	0	0	11984	0.000000e+00	0	0	34438	0.000000e+00	0	0	9992	0.000000e+00	0	0	18384	0.000000e+00	0	0	21632	0.000000e+00	0	1	111498	8.968770e-06	0	0	30602	0.000000e+00	0	1	111498	8.968770e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091257	G	C	I	M	.	16	31102578	16	31010079	123;18	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.369C>G;.	p.I123M;.	c.369C>G;c.54C>G	p.Ile123Met;p.Ile18Met	c.369C>G;c.54C>G	p.Ile123Met;p.Ile18Met	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	3;3	3;3	G	G/G	G/G	G/G	G/G	0.001;.	0.78490	D;.	0.004;0.008	0.74150	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000002	0.62929	D	0.000000	0.998554;0.895872;0.938074;0.938074;0.938074;0.938074	0.45078	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	I123M;P144A;P151A;P87A;P155A;P156A	.;.	.	.;.	-5.04;-5.04	0.98594	D;D	-2.64;.	0.56630	D;.	0.495;.	0.52829	0.5766	0.91591	D	0.8658	0.95536	D	9	0.729086;0.729086	0.74174	D;D	0.331009	0.91750	D	0.815;.	0.94046	0.598;.;	0.72862	Q9BQB6;.;	I123M;.;	Loss of catalytic residue at L128 (P = 0.0354);.;	0.935391410347;0.935391410347	0.93472	0.7032431309460401;.	0.70266	1.14435117917;.	0.79029	0.69298106432	0.66134	T	0.927944;.	0.98759	D;.	0.450568	0.92507	D	0.409433	0.92414	D	0.992612957954407	0.83140	D	0.809719;0.814119	0.46793	T;T	0.9514583;.	0.96415	0.86692035;.	0.92653	0.9514583;.	0.96415	0.86692035;.	0.92654	-6.249;.	0.75275	T;.	0.5096675286513722;.	0.58360	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	0.3809;0.266	0.58481	A;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.390257	0.61289	24.4	3.538462	0.68094	25.1	0.99733473015463869	0.82975	0.96646	0.70192	D	AEFBI	0.693817	0.65302	D	0.272757538464976	0.54772	3.642055	0.359419868622612	0.59076	4.082605	0.999999839135514	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	4.97	0.65419	4.223000	0.58384	.	.	0.607000	0.46521	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.074:0.0:0.926:0.0	13.966	0.63721	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091259	T	C	I	V	rs2057287440	16	31102580	16	31010081	123;18	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.367A>G;.	p.I123V;.	c.367A>G;c.52A>G	p.Ile123Val;p.Ile18Val	c.367A>G;c.52A>G	p.Ile123Val;p.Ile18Val	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	1;1	0;0	T	T/T	T/T	T/T	T/T	0.134;.	0.26300	T;.	0.077;0.067	0.44302	T;T	0.997;.	0.70673	D;.	0.994;.	0.82059	D;.	0.000002	0.62929	D	0.000000	0.603751;0.99862;0.536087;0.536087;0.536087;0.536087	0.45182	D;D;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	D143G;I123V;D150G;D86G;D154G;D155G	.;.	.	.;.	-4.91;-4.91	0.98352	D;D	-0.69;.	0.19720	N;.	0.279;.	0.31590	1.1636	0.99954	D	0.9537	0.98497	D	9	0.6184296;0.6184296	0.67839	D;D	0.247705	0.88980	D	0.599;.	0.84128	0.574;.;	0.69826	Q9BQB6;.;	I123V;.;	Loss of catalytic residue at L128 (P = 0.0365);.;	0.914196117809;0.914196117809	0.91333	0.412186230766788;.	0.41134	0.355704073165;.	0.37328	0.649737894535	0.59950	T	0.520801;.	0.83238	D;.	0.225076	0.76256	D	0.0855298	0.75947	D	0.956607401371002	0.64799	D	0.827917;0.830817	0.49719	T;T	0.25509763;.	0.48542	0.2610544;.	0.51877	0.25509763;.	0.48542	0.2610544;.	0.51876	-4.523;.	0.56265	T;.	0.1144535562302512;.	0.10129	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1981;0.1582	0.42082	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.351832	0.60316	24.3	3.364609	0.63671	24.5	0.99661046427272648	0.77947	0.96659	0.70259	D	AEFBI	0.861945	0.78012	D	0.627669990821666	0.74930	6.217326	0.650015591660229	0.78612	6.91134	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	4.830000	0.62434	.	.	0.598000	0.34611	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.0:0.0:1.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091259	T	G	I	L	.	16	31102580	16	31010081	123;18	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.367A>C;.	p.I123L;.	c.367A>C;c.52A>C	p.Ile123Leu;p.Ile18Leu	c.367A>C;c.52A>C	p.Ile123Leu;p.Ile18Leu	principal1;.	Y;.	1;2	YES;.	-;-	ATC;ATC	1;1	0;0	T	T/T	T/T	T/T	T/T	0.007;.	0.59928	D;.	0.249;0.034	0.52727	T;D	0.997;.	0.70673	D;.	0.994;.	0.82059	D;.	0.000002	0.62929	D	0.000000	0.545287;0.999462;0.594855;0.594855;0.594855;0.594855	0.47157	D;D;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	D143A;I123L;D150A;D86A;D154A;D155A	.;.	.	.;.	-4.72;-4.72	0.98051	D;D	-1.85;.	0.43334	N;.	0.443;.	0.48134	1.1125	0.99880	D	0.9445	0.98184	D	9	0.6863258;0.6863258	0.71584	D;D	0.425183	0.93872	D	0.709;.	0.89605	0.583;.;	0.70990	Q9BQB6;.;	I123L;.;	Loss of catalytic residue at L128 (P = 0.0365);.;	0.948994781086;0.948994781086	0.94845	0.6751796906546428;.	0.67455	0.772997564136;.	0.64872	0.72188615799	0.70321	T	0.651605;.	0.89435	D;.	0.219344	0.75713	D	0.0772955	0.75398	D	0.960191905498505	0.65738	D	0.918808;0.920308	0.71149	D;D	0.81372446;.	0.84800	0.64076567;.	0.79012	0.81372446;.	0.84801	0.64076567;.	0.79013	-4.726;.	0.59903	T;.	0.17138906402251738;.	0.21600	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.273;0.1621	0.50690	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.028694	0.79601	27.2	4.015642	0.82845	27.8	0.9892240491654094	0.48583	0.97432	0.74713	D	AEFBI	0.820344	0.74116	D	0.625465562831766	0.74788	6.192808	0.64813206343259	0.78471	6.883108	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	4.830000	0.62434	.	.	0.598000	0.34611	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.0:0.0:1.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091261	C	A	W	L	.	16	31102582	16	31010083	122;17	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.365G>T;.	p.W122L;.	c.365G>T;c.50G>T	p.Trp122Leu;p.Trp17Leu	c.365G>T;c.50G>T	p.Trp122Leu;p.Trp17Leu	principal1;.	Y;.	1;2	YES;.	-;-	TGG;TGG	2;2	0;0	C	C/C	C/C	C/C	C/C	0.165;.	0.23271	T;.	0.234;0.143	0.33219	T;T	0.906;.	0.49993	P;.	0.523;.	0.48316	P;.	0.001828	0.37892	N	0.189048	1;1;1;1;1;0.590412	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;W122L	.;.	.	.;.	-4.46;-4.46	0.97560	D;D	-3.2;.	0.64710	D;.	0.449;.	0.48689	0.7003	0.93179	D	0.8553	0.95179	D	8	0.7191402;0.7191402	0.73544	D;D	0.590841	0.96365	D	0.638;.	0.86181	0.621;.;	0.75576	Q9BQB6;.;	W122L;.;	Loss of catalytic residue at L120 (P = 0.003);.;	0.991219898523;0.991219898523	0.99112	0.6334554254887471;.	0.63279	1.5806642636;.	0.88385	0.702716052532	0.67536	T	0.791231;.	0.94579	D;.	0.194808	0.73408	D	0.0420513	0.73061	D	0.807316994483493	0.46858	D	0.938006;0.936606	0.76748	D;D	0.23246229;.	0.46034	0.24544927;.	0.50033	0.23246229;.	0.46034	0.24544927;.	0.50032	-4.726;.	0.59903	T;.	0.10186021189871663;.	0.07676	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.3145;0.2606	0.54101	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.188743	0.56330	23.8	3.470501	0.66357	24.9	0.98506704659607369	0.42288	0.81683	0.41038	D	AEFBI	0.211955	0.33768	N	0.427935268525743	0.62965	4.521255	0.49799820975388	0.67858	5.140486	0.99995167387799	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	1.476000	0.35028	.	.	0.539000	0.25131	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.8465:0.0:0.1535	9.2336	0.36614	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091261	C	G	W	S	.	16	31102582	16	31010083	122;17	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.365G>C;.	p.W122S;.	c.365G>C;c.50G>C	p.Trp122Ser;p.Trp17Ser	c.365G>C;c.50G>C	p.Trp122Ser;p.Trp17Ser	principal1;.	Y;.	1;2	YES;.	-;-	TGG;TGG	2;2	0;0	C	C/C	C/C	C/C	C/C	0.169;.	0.22920	T;.	0.195;0.216	0.28032	T;T	0.994;.	0.66517	D;.	0.879;.	0.62418	P;.	0.001828	0.37892	N	0.189048	0.999705;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	W122S;.;.;.;.;.	.;.	.	.;.	-4.6;-4.6	0.97849	D;D	-3.61;.	0.69477	D;.	0.369;.	0.41063	0.9788	0.96840	D	0.9318	0.97750	D	9	0.72250307;0.72250307	0.73756	D;D	0.403491	0.93447	D	0.700;.	0.89192	0.667;.;	0.80502	Q9BQB6;.;	W122S;.;	Loss of catalytic residue at L120 (P = 0.0026);.;	0.996294982073;0.996294982073	0.99625	0.6845757225530958;.	0.68396	1.5059257103;.	0.87137	0.686748564243	0.65238	T	0.811703;.	0.95302	D;.	0.228952	0.76622	D	0.091097	0.76319	D	0.921972936129183	0.58189	D	0.822218;0.808619	0.48193	T;T	0.3595006;.	0.57797	0.4302536;.	0.66682	0.3595006;.	0.57797	0.4302536;.	0.66682	-2.754;.	0.16113	T;.	0.09765134330737586;.	0.06895	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.257;0.2313	0.49177	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.335127	0.59901	24.2	3.549016	0.68372	25.2	0.98828031208525302	0.46902	0.83231	0.42365	D	AEFBI	0.185710	0.31303	N	0.589570551291553	0.72524	5.819155	0.616443150702641	0.76134	6.435289	0.99995167387799	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	1.476000	0.35028	.	.	0.539000	0.25131	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.8465:0.0:0.1535	9.2336	0.36614	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091262	A	G	W	R	.	16	31102583	16	31010084	122;17	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.364T>C;.	p.W122R;.	c.364T>C;c.49T>C	p.Trp122Arg;p.Trp17Arg	c.364T>C;c.49T>C	p.Trp122Arg;p.Trp17Arg	principal1;.	Y;.	1;2	YES;.	-;-	TGG;TGG	1;1	0;0	A	A/A	A/A	A/A	A/A	0.052;.	0.39097	T;.	0.106;0.055	0.46862	T;T	0.998;.	0.73220	D;.	0.916;.	0.65201	D;.	0.001828	0.37892	N	0.189048	0.999996;0.999996;0.999993;0.991819;0.999993;0.999993	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	L142P;L149P;L85P;W122R;L153P;L154P	.;.	.	.;.	-4.65;-4.65	0.97938	D;D	-4.32;.	0.76655	D;.	0.519;.	0.54932	1.0882	0.99168	D	0.9494	0.98352	D	9	0.89467645;0.89467645	0.88818	D;D	0.27371	0.89975	D	0.874;.	0.96243	0.719;.;	0.85408	Q9BQB6;.;	W122R;.;	Loss of catalytic residue at L120 (P = 0.0013);.;	0.996093747413;0.996093747413	0.99604	0.7572631671952587;.	0.75674	1.5806642636;.	0.88385	0.736897289753	0.72516	T	0.847322;.	0.96492	D;.	0.278808	0.81214	D	0.162712	0.80972	D	0.970481694437679	0.68965	D	0.849815;0.846715	0.53298	T;T	0.55317926;.	0.70132	0.709468;.	0.82864	0.55317926;.	0.70133	0.709468;.	0.82865	-3.776;.	0.38690	T;.	0.17380316449788305;.	0.22038	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.897;0.8499	0.82547	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.826408	0.72990	26.0	3.697267	0.72385	25.8	0.99650521127352898	0.77254	0.98714	0.85918	D	AEFBI	0.980325	0.99839	D	0.733635037975122	0.81837	7.616724	0.758953683795461	0.86823	9.014909	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091262	A	T	W	R	.	16	31102583	16	31010084	122;17	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.364T>A;.	p.W122R;.	c.364T>A;c.49T>A	p.Trp122Arg;p.Trp17Arg	c.364T>A;c.49T>A	p.Trp122Arg;p.Trp17Arg	principal1;.	Y;.	1;2	YES;.	-;-	TGG;TGG	1;1	0;0	A	A/A	A/A	A/A	A/A	0.052;.	0.39097	T;.	0.106;0.055	0.46862	T;T	0.998;.	0.73220	D;.	0.916;.	0.65201	D;.	0.001828	0.37892	N	0.189048	0.825018;0.825018;0.7281;0.990928;0.7281;0.7281	0.41267	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	L142Q;L149Q;L85Q;W122R;L153Q;L154Q	.;.	.	.;.	-4.65;-4.65	0.97938	D;D	-4.32;.	0.76655	D;.	0.533;.	0.56145	1.2399	0.99978	D	0.9473	0.98280	D	9	0.8969239;0.8969239	0.89047	D;D	0.243935	0.88823	D	0.805;.	0.93660	0.719;.;	0.85408	Q9BQB6;.;	W122R;.;	Loss of catalytic residue at L120 (P = 0.0013);.;	0.996093747413;0.996093747413	0.99604	0.7572631809662931;.	0.75674	1.5806642636;.	0.88385	0.736897289753	0.72516	T	0.847322;.	0.96492	D;.	0.265982	0.80079	D	0.144288	0.79821	D	0.969473541118303	0.68603	D	0.849815;0.846715	0.53298	T;T	0.55317926;.	0.70132	0.709468;.	0.82864	0.55317926;.	0.70133	0.709468;.	0.82865	-3.776;.	0.38690	T;.	0.17380316449788305;.	0.22038	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.897;0.8499	0.82547	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.817819	0.72719	25.9	3.720427	0.73036	25.9	0.9963394741105952	0.76203	0.98750	0.86373	D	AEFBI	0.955915	0.97408	D	0.733635037975122	0.81837	7.616724	0.758953683795461	0.86823	9.014909	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091264	G	C	A	G	.	16	31102585	16	31010086	121;16	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.362C>G;.	p.A121G;.	c.362C>G;c.47C>G	p.Ala121Gly;p.Ala16Gly	c.362C>G;c.47C>G	p.Ala121Gly;p.Ala16Gly	principal1;.	Y;.	1;2	YES;.	-;-	GCC;GCC	2;2	0;0	G	G/G	G/G	G/G	G/G	0.102;.	0.30235	T;.	0.225;0.253	0.25514	T;T	0.767;.	0.43786	P;.	0.279;.	0.40265	B;.	0.000004	0.62929	D	0.000000	0.999338;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	A121G;.;.;.;.;.	.;.	.	.;.	-4.72;-4.72	0.98051	D;D	-2.13;.	0.48354	N;.	0.396;.	0.43706	0.8241	0.94709	D	0.8679	0.95607	D	8	0.8490795;0.8490795	0.84081	D;D	0.683117	0.97378	D	0.622;.	0.85354	0.717;.;	0.85230	Q9BQB6;.;	A121G;.;	Loss of stability (P = 0.0662);.;	0.938102117097;0.938102117097	0.93746	0.6668481872622724;.	0.66622	1.15193762352;.	0.79231	0.644252598286	0.59169	T	0.81845;.	0.95535	D;.	0.238438	0.77513	D	0.104723	0.77221	D	0.932952702045441	0.59936	D	0.929807;0.939106	0.77081	D;D	0.41813126;.	0.61967	0.3683382;.	0.62125	0.41813126;.	0.61967	0.3683382;.	0.62125	-3.773;.	0.38610	T;.	0.16423629511584864;.	0.20284	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1333;0.1099	0.28863	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	2.821186	0.48193	23.1	2.785851	0.49971	23.1	0.99760666822459809	0.85011	0.94234	0.60522	D	AEFBI	0.787453	0.71723	D	0.414928695964942	0.62242	4.437018	0.52247008208351	0.69503	5.369955	0.999999841859695	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	4.844000	0.62544	.	.	0.607000	0.46521	1.000000	0.71638	1.000000	0.68203	0.998000	0.85391	0.0:0.0:1.0:0.0	19.1531	0.93481	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091267	A	G	L	P	.	16	31102588	16	31010089	120;15	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.359T>C;.	p.L120P;.	c.359T>C;c.44T>C	p.Leu120Pro;p.Leu15Pro	c.359T>C;c.44T>C	p.Leu120Pro;p.Leu15Pro	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	2;2	0;0	A	A/A	A/A	A/A	A/A	0.0;.	0.91255	D;.	0.0;0.0	0.92824	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000122	0.49741	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L120P;.;.;.;.;.	.;.	.	.;.	-6.09;-6.09	0.99521	D;D	-6.37;.	0.91058	D;.	0.919;.	0.92200	1.0686	0.98554	D	0.9821	0.99453	D	8	0.97649086;0.97649086	0.97440	D;D	0.747103	0.97980	D	0.980;.	0.99858	0.858;.;	0.95662	Q9BQB6;.;	L120P;.;	Loss of catalytic residue at L120 (P = 0.0029);.;	0.969933984153;0.969933984153	0.96961	0.9878976706377831;.	0.98783	1.50425018939;.	0.87093	0.785093188286	0.79697	T	0.959281;.	0.99465	D;.	0.568671	0.96584	D	0.57908	0.96527	D	0.99785041809082	0.92591	D	0.907009;0.957804	0.84101	D;D	0.9872924;.	0.99612	0.9798543;.	0.99815	0.9872924;.	0.99612	0.9798543;.	0.99815	-4.659;.	0.58755	T;.	0.8197946440229426;.	0.89302	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	P;.	0.9327;0.9558	0.87554	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.288917	0.87959	29.5	4.161458	0.87322	29.1	0.99914581589552531	0.98309	0.98714	0.85918	D	AEFBI	0.956314	0.97476	D	0.715098070777266	0.80622	7.335244	0.738952524271538	0.85331	8.548215	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.997000	0.79791	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091271	A	G	Y	H	.	16	31102592	16	31010093	119;14	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.355T>C;.	p.Y119H;.	c.355T>C;c.40T>C	p.Tyr119His;p.Tyr14His	c.355T>C;c.40T>C	p.Tyr119His;p.Tyr14His	principal1;.	Y;.	1;2	YES;.	-;-	TAC;TAC	1;1	0;0	A	./.	./.	./.	./.	0.0;.	0.91255	D;.	0.0;0.0	0.92824	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000013	0.62929	D	0.000000	0.999983;0.999956;0.999983;0.99999;0.99999;0.999983	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	L150P;Y119H;L82P;L146P;L139P;L151P	.;.	.	.;.	-5.03;-5.03	0.98578	D;D	-4.56;.	0.78636	D;.	0.725;.	0.72656	1.0996	0.99645	D	0.9695	0.99037	D	9	0.976176;0.976176	0.97395	D;D	0.462725	0.94542	D	0.951;.	0.99091	0.88;.;	0.96835	Q9BQB6;.;	Y119H;.;	Loss of catalytic residue at L114 (P = 0.1206);.;	0.961466171733;0.961466171733	0.96105	0.8724533122684246;.	0.87211	1.33859581361;.	0.83798	0.770447850227	0.77492	T	0.958452;.	0.99448	D;.	0.249736	0.78575	D	0.120952	0.78297	D	0.996223568916321	0.88912	D	0.945305;0.982402	0.94055	D;D	0.9605728;.	0.97338	0.94624;.	0.98168	0.9605728;.	0.97338	0.94624;.	0.98168	0.0;.	0.02703	T;.	0.7104120017051829;.	0.79055	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	0.8525;0.7905	0.79900	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.157038	0.84051	28.3	4.045023	0.83836	28.1	0.99853837518461985	0.93279	0.98709	0.85857	D	AEFBI	0.981206	0.99867	D	0.758713562166405	0.83471	8.026246	0.774353360399362	0.87959	9.406329	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.995000	0.73285	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091276	G	T	S	Y	.	16	31102597	16	31010098	117;12	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.350C>A;.	p.S117Y;.	c.350C>A;c.35C>A	p.Ser117Tyr;p.Ser12Tyr	c.350C>A;c.35C>A	p.Ser117Tyr;p.Ser12Tyr	principal1;.	Y;.	1;2	YES;.	-;-	TCT;TCT	2;2	0;0	G	./.	./.	./.	./.	0.002;.	0.72154	D;.	0.002;0.0	0.92824	D;D	0.999;.	0.77913	D;.	0.967;.	0.71530	D;.	0.000005	0.62929	D	0.000000	0.991649;0.988357;0.988357;0.993354;0.988357;0.988357	0.41438	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	S117Y;F137L;F144L;F80L;F148L;F149L	.;.	.	.;.	-5.01;-5.01	0.98544	D;D	-5.03;.	0.82575	D;.	0.803;.	0.79889	0.8587	0.95136	D	0.9621	0.98783	D	9	0.93320966;0.93320966	0.92655	D;D	0.038187	0.58072	D	0.900;.	0.97210	0.86;.;	0.95774	Q9BQB6;.;	S117Y;.;	Gain of relative solvent accessibility (P = 0.1259);.;	0.995676345058;0.995676345058	0.99562	0.9488673227756688;.	0.94869	1.29869024389;.	0.82957	0.654633879662	0.60643	T	0.952921;.	0.99335	D;.	0.0778098	0.61783	D	-0.126008	0.61307	T	0.983525791790728	0.75159	D	0.919908;0.967103	0.88031	D;D	0.97779787;.	0.98937	0.95754975;.	0.98838	0.97779787;.	0.98937	0.95754975;.	0.98839	-5.692;.	0.71313	T;.	0.7649764059678956;.	0.84648	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	P;.	0.8918;0.8543	0.82207	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.009540	0.78936	27.0	3.913259	0.79269	27.0	0.99470781799523655	0.66312	0.97168	0.73090	D	AEFBI	0.897281	0.83928	D	0.762243841411062	0.83701	8.086482	0.778876723855618	0.88287	9.52647	0.999999842598817	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	6.141000	0.71499	.	.	0.607000	0.46521	1.000000	0.71638	1.000000	0.68203	0.990000	0.65344	0.0:0.0:1.0:0.0	19.1531	0.93481	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091277	A	G	S	P	.	16	31102598	16	31010099	117;12	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.349T>C;.	p.S117P;.	c.349T>C;c.34T>C	p.Ser117Pro;p.Ser12Pro	c.349T>C;c.34T>C	p.Ser117Pro;p.Ser12Pro	principal1;.	Y;.	1;2	YES;.	-;-	TCT;TCT	1;1	0;0	A	./.	./.	./.	./.	0.008;.	0.58626	D;.	0.009;0.0	0.92824	D;D	0.994;.	0.66517	D;.	0.936;.	0.67150	D;.	0.000005	0.62929	D	0.000000	0.954861;0.993217;0.993217;0.996136;0.993217;0.993217	0.37898	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	S117P;F137S;F144S;F80S;F148S;F149S	.;.	.	.;.	-5.02;-5.02	0.98562	D;D	-4.31;.	0.76576	D;.	0.842;.	0.83781	0.8498	0.95027	D	0.9522	0.98446	D	9	0.945397;0.945397	0.93865	D;D	0.414423	0.93665	D	0.879;.	0.96428	0.86;.;	0.95774	Q9BQB6;.;	S117P;.;	Loss of helix (P = 0.0376);.;	0.996756119749;0.996756119749	0.99672	0.9759005382078315;.	0.97580	1.31051713131;.	0.83204	0.61067378521	0.54411	T	0.953563;.	0.99348	D;.	0.180625	0.72100	D	0.0216786	0.71739	D	0.968971371650696	0.68428	D	0.867113;0.941406	0.78138	D;D	0.9859518;.	0.99528	0.9657637;.	0.99269	0.9859518;.	0.99528	0.9657637;.	0.99269	-4.659;.	0.58755	T;.	0.7556702427410077;.	0.83764	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	0.9023;0.8865	0.82904	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.071865	0.81105	27.5	3.603275	0.69783	25.4	0.99854502736599893	0.93368	0.96081	0.67446	D	AEFBI	0.924888	0.90358	D	0.551056900878209	0.70148	5.458953	0.545862713375297	0.71108	5.605147	0.999819044149291	0.43459	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	4.81	0.61401	5.597000	0.67267	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.988000	0.63387	0.8655:0.0:0.0:0.1344	11.5316	0.49866	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091280	C	G	G	R	.	16	31102601	16	31010102	116;11	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.346G>C;.	p.G116R;.	c.346G>C;c.31G>C	p.Gly116Arg;p.Gly11Arg	c.346G>C;c.31G>C	p.Gly116Arg;p.Gly11Arg	principal1;.	Y;.	1;2	YES;.	-;-	GGT;GGT	1;1	0;0	C	./.	./.	./.	./.	0.001;.	0.78490	D;.	0.031;0.006	0.70582	D;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000002	0.62929	D	0.000000	0.999993;0.999993;0.999987;0.999997;0.999993;0.999993	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	W136S;W143S;W79S;G116R;W147S;W148S	.;.	.	.;.	-4.78;-4.78	0.98140	D;D	-6.03;.	0.89722	D;.	0.812;.	0.80767	1.0308	0.97733	D	0.9141	0.97153	D	9	0.93057334;0.93057334	0.92397	D;D	0.172622	0.84955	D	0.899;.	0.97173	0.808;.;	0.92512	Q9BQB6;.;	G116R;.;	Gain of methylation at G116 (P = 0.0375);.;	0.996573952805;0.996573952805	0.99653	0.9461573484457033;.	0.94597	1.28073235823;.	0.82515	0.710554897785	0.68674	T	0.929143;.	0.98788	D;.	0.547159	0.95659	D	0.54818	0.95595	D	0.98739093542099	0.77899	D	0.929807;0.966603	0.87805	D;D	0.96089023;.	0.97370	0.91690713;.	0.96180	0.96089023;.	0.97370	0.91690713;.	0.96180	-3.776;.	0.38690	T;.	0.6676582370441321;.	0.74212	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	0.9417;0.9112	0.86069	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.980982	0.77955	26.8	4.218125	0.88629	29.6	0.99930029927795183	0.99334	0.98465	0.83062	D	AEFBI	0.938074	0.93676	D	0.531575762262106	0.68969	5.29075	0.618360336952147	0.76273	6.460799	0.999999999997103	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	6.416000	0.73240	.	.	0.539000	0.25131	1.000000	0.71638	1.000000	0.68203	0.984000	0.60418	0.0:1.0:0.0:0.0	19.1531	0.93481	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091280	C	T	G	S	.	16	31102601	16	31010102	116;11	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.346G>A;.	p.G116S;.	c.346G>A;c.31G>A	p.Gly116Ser;p.Gly11Ser	c.346G>A;c.31G>A	p.Gly116Ser;p.Gly11Ser	principal1;.	Y;.	1;2	YES;.	-;-	GGT;GGT	1;1	0;0	C	./.	./.	./.	./.	0.006;.	0.61437	D;.	0.132;0.024	0.56640	T;D	1.0;.	0.90584	D;.	1.0;.	0.97372	D;.	0.000002	0.62929	D	0.000000	0.999412;0.999412;0.999785;0.999412;0.999412;0.999993	0.58761	D;D;D;D;D;D	complex_aae;complex_aae;complex_aae;complex_aae;complex_aae;simple_aae	W148*;W147*;W79*;W143*;W136*;G116S	.;.	.	.;.	-4.74;-4.74	0.98081	D;D	-4.26;.	0.76174	D;.	0.534;.	0.56231	-0.9783	0.35390	T	0.1458	0.46985	T	9	0.7934996;0.7934996	0.78865	D;D	.	.	.	0.760;.	0.91837	0.656;.;	0.79379	Q9BQB6;.;	G116S;.;	Gain of glycosylation at G116 (P = 0.1172);.;	0.996007300407;0.996007300407	0.99596	0.7950172982095204;.	0.79454	1.16132611022;.	0.79496	0.613062262535	0.54749	T	0.861995;.	0.96946	D;.	0.376995	0.88515	D	0.303751	0.88369	D	0.989611566317438	0.79841	D	0.90461;0.952305	0.81786	D;D	0.73472637;.	0.79991	0.6929704;.	0.81928	0.73472637;.	0.79993	0.6929704;.	0.81929	-2.754;.	0.16113	T;.	0.2905995320410195;.	0.38710	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	0.2561;0.1484	0.49088	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.038467	0.79945	27.3	4.301404	0.90053	31	0.99826312879665369	0.90852	0.98034	0.79045	D	AEFBI	0.963401	0.98528	D	0.294227088989903	0.55855	3.749685	0.418418045325702	0.62713	4.491389	0.999999999997103	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	6.416000	0.73240	.	.	0.539000	0.25131	1.000000	0.71638	1.000000	0.68203	0.984000	0.60418	0.0:1.0:0.0:0.0	19.1531	0.93481	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091282	G	A	A	V	rs760391247	16	31102603	16	31010104	115;10	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.344C>T;.	p.A115V;.	c.344C>T;c.29C>T	p.Ala115Val;p.Ala10Val	c.344C>T;c.29C>T	p.Ala115Val;p.Ala10Val	principal1;.	Y;.	1;2	YES;.	-;-	GCT;GCT	2;2	0;0	G	./.	./.	./.	./.	0.998;.	0.01934	T;.	1.0;1.0	0.01155	T;T	0.001;.	0.07471	B;.	0.007;.	0.12992	B;.	0.162234	0.17628	N	0.534171	1;0.999988;0.999988;0.999988;0.999988;0.999988	0.18198	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	A115V;.;.;.;.;.	.;.	.	.;.	-4.51;-4.51	0.97672	D;D	1.3;.	0.00948	N;.	0.053;.	0.02462	-0.2334	0.76798	T	0.7149	0.90214	D	9	0.15198347;0.15198347	0.28717	T;T	0.046919	0.62681	D	0.331;.	0.65325	0.33;.;	0.31519	Q9BQB6;.;	A115V;.;	Loss of helix (P = 0.1299);.;	0.917214898647;0.917214898647	0.91637	0.49100849223890664;.	0.49021	0.368897684081;.	0.38427	0.43783390522	0.30281	T	0.397007;.	0.75548	T;.	0.0889422	0.63069	D	-0.0945312	0.63818	T	0.0254600830376148	0.01334	T	0.838216;0.869313	0.57326	T;D	0.059887063;.	0.12225	0.07090318;.	0.15120	0.059887063;.	0.12224	0.07090318;.	0.15120	-4.523;.	0.56265	T;.	0.1039930904130799;.	0.08083	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0793;0.0782	0.07460	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.725915	0.11713	8.692	0.989508	0.16788	13.36	0.79992385055649995	0.12995	0.13701	0.18004	N	AEFBI	0.163786	0.29011	N	-0.7108087943035	0.15716	0.7945474	-0.632402058541325	0.18662	0.9979728	0.98697017997824	0.31161	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	1.3	0.20778	0.857000	0.27486	.	.	0.607000	0.46521	0.002000	0.15269	0.146000	0.23136	0.978000	0.57271	0.2986:0.0:0.7014:0.0	11.3892	0.49045	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	1.647e-05	2	1.672e-05	0	0	0	0	0	0	0	0	2	3.035e-05	0	0	2	1.883e-05	2	1.903e-05	0	0	0	0	0	0	0	0	2	3.705e-05	0	0	2	2.204e-05	2	2.241e-05	0	0	0	0	0	0	0	0	2	4.829e-05	0	0	segdup	2	251040	7.966860e-06	0	0	16198	0.000000e+00	0	0	34558	0.000000e+00	0	0	10070	0.000000e+00	0	0	18382	0.000000e+00	0	0	21636	0.000000e+00	0	2	113474	1.762520e-05	0	0	30590	0.000000e+00	0	2	113474	1.762520e-05	0	1	109344	9.145450e-06	0	2	207886	9.620660e-06	0	2	236664	8.450800e-06	0	2	244424	8.182500e-06	0	0	7150	0.000000e+00	0	0	17102	0.000000e+00	0	0	2320	0.000000e+00	0	0	9044	0.000000e+00	0	0	13386	0.000000e+00	0	1	42758	2.338740e-05	0	0	15670	0.000000e+00	0	1	42758	2.338740e-05	0	0	16160	0.000000e+00	0	0	30496	0.000000e+00	0	0	6208	0.000000e+00	0	0	13406	0.000000e+00	0	0	16726	0.000000e+00	0	2	89446	2.235990e-05	0	0	30584	0.000000e+00	0	2	89446	2.235990e-05	0	0	14882	0.000000e+00	0	0	34232	0.000000e+00	0	0	9566	0.000000e+00	0	0	17688	0.000000e+00	0	0	21620	0.000000e+00	0	2	102554	1.950190e-05	0	0	30504	0.000000e+00	0	2	102554	1.950190e-05	0	0	11970	0.000000e+00	0	0	34424	0.000000e+00	0	0	9988	0.000000e+00	0	0	18378	0.000000e+00	0	0	21634	0.000000e+00	0	2	111384	1.795590e-05	0	0	30590	0.000000e+00	0	2	111384	1.795590e-05	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091282	G	C	A	G	rs760391247	16	31102603	16	31010104	115;10	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.344C>G;.	p.A115G;.	c.344C>G;c.29C>G	p.Ala115Gly;p.Ala10Gly	c.344C>G;c.29C>G	p.Ala115Gly;p.Ala10Gly	principal1;.	Y;.	1;2	YES;.	-;-	GCT;GCT	2;2	0;0	G	./.	./.	./.	./.	0.036;.	0.43393	D;.	0.117;0.024	0.56640	T;D	0.492;.	0.36976	P;.	0.378;.	0.43788	B;.	0.162234	0.17628	N	0.534171	1;0.999987;0.999987;0.999987;0.999987;0.999987	0.18198	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	A115G;.;.;.;.;.	.;.	.	.;.	-4.76;-4.76	0.98111	D;D	-2.37;.	0.52289	N;.	0.216;.	0.24135	0.5996	0.91896	D	0.8920	0.96415	D	9	0.38583416;0.38583416	0.54533	T;T	0.207262	0.87084	D	0.351;.	0.67234	0.431;.;	0.48007	Q9BQB6;.;	A115G;.;	Loss of helix (P = 0.0376);.;	0.966195828542;0.966195828542	0.96582	0.5393276644961772;.	0.53857	0.545423859402;.	0.51576	0.414226025343	0.27041	T	0.646961;.	0.89240	D;.	0.118403	0.66210	D	-0.0676982	0.65789	T	0.766972184181213	0.44259	D	0.833717;0.891811	0.62701	T;D	0.26151896;.	0.49211	0.23101683;.	0.48221	0.26151896;.	0.49211	0.23101683;.	0.48220	-3.773;.	0.38610	T;.	0.15847641202487026;.	0.19205	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1266;0.1151	0.26886	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.867137	0.28043	18.23	2.032904	0.33616	20.0	0.98622393886393112	0.43798	0.31869	0.24445	N	AEFBI	0.268899	0.38529	N	-0.266512105371058	0.30451	1.69797	-0.291159722689035	0.28389	1.582521	0.98697017997824	0.31161	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	1.3	0.20778	0.857000	0.27486	.	.	0.607000	0.46521	0.002000	0.15269	0.146000	0.23136	0.978000	0.57271	0.2986:0.0:0.7014:0.0	11.3892	0.49045	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	8.237e-06	1	8.359e-06	0	0	0	0	0	0	0	0	1	1.518e-05	0	0	1	9.415e-06	1	9.514e-06	0	0	0	0	0	0	0	0	1	1.853e-05	0	0	1	1.102e-05	1	1.121e-05	0	0	0	0	0	0	0	0	1	2.415e-05	0	0	segdup	1	251040	3.983430e-06	0	0	16198	0.000000e+00	0	0	34558	0.000000e+00	0	0	10070	0.000000e+00	0	0	18382	0.000000e+00	0	0	21636	0.000000e+00	0	1	113474	8.812590e-06	0	0	30590	0.000000e+00	0	1	113474	8.812590e-06	0	0	109344	0.000000e+00	0	1	207886	4.810330e-06	0	1	236664	4.225400e-06	0	1	244424	4.091250e-06	0	0	7150	0.000000e+00	0	0	17102	0.000000e+00	0	0	2320	0.000000e+00	0	0	9044	0.000000e+00	0	0	13386	0.000000e+00	0	0	42758	0.000000e+00	0	0	15670	0.000000e+00	0	.	.	.	.	0	16160	0.000000e+00	0	0	30496	0.000000e+00	0	0	6208	0.000000e+00	0	0	13406	0.000000e+00	0	0	16726	0.000000e+00	0	1	89446	1.117990e-05	0	0	30584	0.000000e+00	0	1	89446	1.117990e-05	0	0	14882	0.000000e+00	0	0	34232	0.000000e+00	0	0	9566	0.000000e+00	0	0	17688	0.000000e+00	0	0	21620	0.000000e+00	0	1	102554	9.750960e-06	0	0	30504	0.000000e+00	0	1	102554	9.750960e-06	0	0	11970	0.000000e+00	0	0	34424	0.000000e+00	0	0	9988	0.000000e+00	0	0	18378	0.000000e+00	0	0	21634	0.000000e+00	0	1	111384	8.977950e-06	0	0	30590	0.000000e+00	0	1	111384	8.977950e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091282	G	T	A	D	.	16	31102603	16	31010104	115;10	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.344C>A;.	p.A115D;.	c.344C>A;c.29C>A	p.Ala115Asp;p.Ala10Asp	c.344C>A;c.29C>A	p.Ala115Asp;p.Ala10Asp	principal1;.	Y;.	1;2	YES;.	-;-	GCT;GCT	2;2	0;0	G	./.	./.	./.	./.	0.012;.	0.54683	D;.	0.044;0.033	0.53072	D;D	0.773;.	0.44016	P;.	0.678;.	0.53406	P;.	0.162234	0.17628	N	0.534171	0.999998;0.999987;0.999987;0.999987;0.999987;0.999987	0.18198	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	A115D;.;.;.;.;.	.;.	.	.;.	-4.83;-4.83	0.98213	D;D	-3.21;.	0.64826	D;.	0.661;.	0.67045	0.7681	0.94016	D	0.9281	0.97625	D	9	0.5952921;0.5952921	0.66607	D;D	0.242011	0.88741	D	0.639;.	0.86232	0.525;.;	0.62967	Q9BQB6;.;	A115D;.;	Loss of helix (P = 0.0167);.;	0.992674725165;0.992674725165	0.99259	0.9044871483611105;.	0.90421	0.933610159477;.	0.71939	0.502891421318	0.39231	T	0.894707;.	0.97888	D;.	0.42874	0.91467	D	0.378079	0.91361	D	0.778255981769443	0.44942	D	0.917708;0.914809	0.70434	D;D	0.72989506;.	0.79717	0.5858599;.	0.75982	0.72989506;.	0.79719	0.5858599;.	0.75983	-0.64;.	0.05512	T;.	0.6631792804255571;.	0.73700	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	0.8137;0.7761	0.77931	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	2.458492	0.40329	22.3	2.643564	0.46876	22.8	0.99383953367883815	0.62024	0.29406	0.23813	N	AEFBI	0.279676	0.39367	N	-0.0694333783042844	0.38738	2.273551	-0.148604740302957	0.33462	1.914349	0.98697017997824	0.31161	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	1.3	0.20778	0.857000	0.27486	.	.	0.607000	0.46521	0.002000	0.15269	0.146000	0.23136	0.978000	0.57271	0.2986:0.0:0.7014:0.0	11.3892	0.49045	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091283	C	A	A	S	.	16	31102604	16	31010105	115;10	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.343G>T;.	p.A115S;.	c.343G>T;c.28G>T	p.Ala115Ser;p.Ala10Ser	c.343G>T;c.28G>T	p.Ala115Ser;p.Ala10Ser	principal1;.	Y;.	1;2	YES;.	-;-	GCT;GCT	1;1	0;0	C	./.	./.	./.	./.	0.024;.	0.47745	D;.	0.155;0.085	0.41074	T;T	0.549;.	0.38101	P;.	0.449;.	0.46066	P;.	0.162234	0.17628	N	0.534171	1;1;1;1;1;1	0.08975	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R135L;R142L;R78L;A115S;R146L;R147L	.;.	.	.;.	-4.76;-4.76	0.98111	D;D	-1.59;.	0.38345	N;.	0.242;.	0.27316	0.5332	0.91006	D	0.8524	0.95080	D	9	0.36553454;0.36553454	0.53070	T;T	0.177506	0.85293	D	0.368;.	0.68757	0.454;.;	0.51775	Q9BQB6;.;	A115S;.;	Gain of glycosylation at A115 (P = 0.0155);.;	0.92806123812;0.92806123812	0.92732	0.5163249967438389;.	0.51555	0.49715111449;.	0.48212	0.398115307093	0.24806	T	0.641733;.	0.89022	D;.	0.104951	0.64822	D	-0.087021	0.64386	T	0.908409178256989	0.56298	D	0.929307;0.927007	0.73951	D;D	0.30577463;.	0.53417	0.27822483;.	0.53781	0.30577463;.	0.53417	0.27822483;.	0.53780	-2.754;.	0.16113	T;.	0.333724095040234;.	0.43169	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	0.1603;0.1397	0.35435	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	2.399378	0.39027	22.1	2.769125	0.49620	23.1	0.99291131241552322	0.58255	0.27015	0.23158	N	AEFBI	0.387722	0.46760	N	-0.343377123377682	0.27516	1.510316	-0.266623962961141	0.29205	1.634383	0.999559742083766	0.40362	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	3.8	0.42887	1.281000	0.32819	.	.	0.539000	0.25131	0.002000	0.15269	0.106000	0.22736	0.971000	0.54645	0.1296:0.7981:0.0:0.0723	11.993	0.52477	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091285	A	C	L	R	.	16	31102606	16	31010107	114;9	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.341T>G;.	p.L114R;.	c.341T>G;c.26T>G	p.Leu114Arg;p.Leu9Arg	c.341T>G;c.26T>G	p.Leu114Arg;p.Leu9Arg	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	2;2	0;0	A	./.	./.	./.	./.	0.014;.	0.53172	D;.	0.015;0.025	0.61642	D;D	0.879;.	0.48338	P;.	0.745;.	0.55870	P;.	0.104187	0.19714	N	0.460872	1;1;1;1;1;0.999944	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;L114R	.;.	.	.;.	-4.8;-4.8	0.98169	D;D	-2.49;.	0.54217	N;.	0.747;.	0.74644	1.0851	0.99053	D	0.9471	0.98273	D	9	0.9464296;0.9464296	0.93969	D;D	0.695865	0.97503	D	0.786;.	0.92908	0.779;.;	0.90388	Q9BQB6;.;	L114R;.;	Loss of stability (P = 0.0328);.;	0.990461063612;0.990461063612	0.99035	0.8200146865328344;.	0.81958	1.29156118664;.	0.82799	0.553940117359	0.46412	T	0.905059;.	0.98167	D;.	0.448117	0.92396	D	0.405913	0.92302	D	0.863553361474377	0.51379	D	0.868613;0.861114	0.57103	D;D	0.6954056;.	0.77805	0.47519943;.	0.69588	0.6954056;.	0.77807	0.47519943;.	0.69588	-3.776;.	0.38690	T;.	0.7085181896404587;.	0.78842	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	0.7942;0.7048	0.77016	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.707227	0.69557	25.4	3.399547	0.64546	24.7	0.99607144537091918	0.74575	0.96651	0.70217	D	AEFBI	0.948945	0.96110	D	0.481578500767202	0.66015	4.895731	0.472452406697419	0.66171	4.917487	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	0.815000	0.29920	1.000000	0.68203	0.966000	0.53164	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091285	A	G	L	P	.	16	31102606	16	31010107	114;9	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.341T>C;.	p.L114P;.	c.341T>C;c.26T>C	p.Leu114Pro;p.Leu9Pro	c.341T>C;c.26T>C	p.Leu114Pro;p.Leu9Pro	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	2;2	0;0	A	./.	./.	./.	./.	0.025;.	0.47320	D;.	0.031;0.025	0.56192	D;D	0.957;.	0.54824	D;.	0.812;.	0.58704	P;.	0.104187	0.19714	N	0.460872	0.686581;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L114P;.;.;.;.;.	.;.	.	.;.	-4.76;-4.76	0.98111	D;D	-2.49;.	0.54217	N;.	0.713;.	0.71587	1.0858	0.99078	D	0.9513	0.98416	D	9	0.95393103;0.95393103	0.94743	D;D	0.669345	0.97239	D	0.777;.	0.92542	0.782;.;	0.90617	Q9BQB6;.;	L114P;.;	Loss of stability (P = 0.0105);.;	0.994863558545;0.994863558545	0.99481	0.9058156262847514;.	0.90554	1.40417438636;.	0.85273	0.579805016518	0.50059	T	0.904603;.	0.98155	D;.	0.40168	0.90011	D	0.339209	0.89886	D	0.901544451713562	0.55430	D	0.561144;0.819518	0.47762	T;T	0.9076184;.	0.92074	0.7650786;.	0.86123	0.9076184;.	0.92075	0.7650786;.	0.86124	-4.659;.	0.58755	T;.	0.4474248509849119;.	0.53183	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	0.775;0.7234	0.76147	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.783028	0.71699	25.8	3.422990	0.65150	24.7	0.9984903810628587	0.92838	0.96416	0.69031	D	AEFBI	0.975192	0.99604	D	0.519684955103355	0.68255	5.192019	0.49855898561545	0.67894	5.145588	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	7.522000	0.80772	.	.	0.678000	0.82376	0.815000	0.29920	1.000000	0.68203	0.966000	0.53164	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091286	G	T	L	I	.	16	31102607	16	31010108	114;9	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.340C>A;.	p.L114I;.	c.340C>A;c.25C>A	p.Leu114Ile;p.Leu9Ile	c.340C>A;c.25C>A	p.Leu114Ile;p.Leu9Ile	principal1;.	Y;.	1;2	YES;.	-;-	CTC;CTC	1;1	0;0	G	./.	./.	./.	./.	0.469;.	0.08508	T;.	0.458;0.951	0.12668	T;T	0.001;.	0.07471	B;.	0.009;.	0.14300	B;.	0.104187	0.19714	N	0.460872	1;1;1;1;1;1	0.08975	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	S134Y;S141Y;S77Y;L114I;S145Y;S146Y	.;.	.	.;.	-4.7;-4.7	0.98020	D;D	0.42;.	0.03352	N;.	0.093;.	0.07262	0.3717	0.88669	D	0.8536	0.95121	D	9	0.22476986;0.22476986	0.39289	T;T	0.05003	0.64070	D	0.202;.	0.48754	0.465;.;	0.53566	Q9BQB6;.;	L114I;.;	Loss of helix (P = 0.0626);.;	0.837807051206;0.837807051206	0.83626	0.27563750043275476;.	0.27476	0.416021963706;.	0.42244	0.479140341282	0.35938	T	0.451622;.	0.79227	T;.	0.0403538	0.57092	T	-0.179811	0.56541	T	0.0341301709413528	0.02660	T	0.670133;0.656934	0.27879	T;T	0.06807901;.	0.14802	0.048785303;.	0.07318	0.06807901;.	0.14802	0.048785303;.	0.07318	-5.673;.	0.71160	T;.	0.08828682441459239;.	0.05275	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1149;0.0685	0.23005	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.735749	0.11829	8.782	0.944440	0.16214	13.04	0.9155975987867051	0.20838	0.21128	0.21291	N	AEFBI	0.271691	0.38748	N	-0.204763915109398	0.32937	1.863125	-0.236182909894317	0.30249	1.701601	0.992816210105125	0.32978	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	2.74	0.31352	0.471000	0.21811	.	.	0.607000	0.46521	0.207000	0.24389	0.993000	0.31925	0.968000	0.53726	0.0:0.2502:0.3524:0.3974	8.6701	0.33307	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091288	G	T	S	Y	.	16	31102609	16	31010110	113;8	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.338C>A;.	p.S113Y;.	c.338C>A;c.23C>A	p.Ser113Tyr;p.Ser8Tyr	c.338C>A;c.23C>A	p.Ser113Tyr;p.Ser8Tyr	principal1;.	Y;.	1;2	YES;.	-;-	TCT;TCT	2;2	0;0	G	./.	./.	./.	./.	0.0;.	0.91255	D;.	0.001;0.002	0.83351	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000004	0.62929	D	0.000000	0.999992;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	S113Y;.;.;.;.;.	.;.	.	.;.	-4.75;-4.75	0.98096	D;D	-5.03;.	0.82575	D;.	0.629;.	0.64308	1.0921	0.99324	D	0.9594	0.98690	D	9	0.9470395;0.9470395	0.94031	D;D	0.204496	0.86934	D	0.933;.	0.98452	0.834;.;	0.94231	Q9BQB6;.;	S113Y;.;	Gain of catalytic residue at L108 (P = 0.0509);.;	0.997218441629;0.997218441629	0.99718	0.9562730959183122;.	0.95612	1.32510383089;.	0.83540	0.682019352913	0.64558	T	0.868474;.	0.97139	D;.	0.554093	0.95871	D	0.55814	0.95808	D	0.994911372661591	0.86513	D	0.916808;0.80342	0.70203	D;T	0.97342956;.	0.98570	0.9513231;.	0.98479	0.97342956;.	0.98570	0.9513231;.	0.98479	-5.692;.	0.71313	T;.	0.7275069801189951;.	0.80901	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	P;.	0.8198;0.8219	0.78329	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.706293	0.69532	25.4	3.999748	0.82284	27.7	0.99466755896276626	0.66102	0.98174	0.80243	D	AEFBI	0.902463	0.85038	D	0.763623783276102	0.83790	8.110346	0.778023976700529	0.88228	9.503762	0.999999999997103	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	6.238000	0.72305	.	.	0.607000	0.46521	1.000000	0.71638	1.000000	0.68203	0.966000	0.53164	0.0:0.0:1.0:0.0	19.1531	0.93481	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091289	A	G	S	P	.	16	31102610	16	31010111	113;8	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.337T>C;.	p.S113P;.	c.337T>C;c.22T>C	p.Ser113Pro;p.Ser8Pro	c.337T>C;c.22T>C	p.Ser113Pro;p.Ser8Pro	principal1;.	Y;.	1;2	YES;.	-;-	TCT;TCT	1;1	0;0	A	./.	./.	./.	./.	0.002;.	0.72154	D;.	0.006;0.013	0.70582	D;D	1.0;.	0.90584	D;.	0.999;.	0.92359	D;.	0.000004	0.62929	D	0.000000	0.999943;0.6202;0.6202;0.741947;0.6202;0.6202	0.51968	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	S113P;V133A;V140A;V76A;V144A;V145A	.;.	.	.;.	-4.78;-4.78	0.98140	D;D	-4.26;.	0.76174	D;.	0.746;.	0.74553	0.9544	0.96461	D	0.8538	0.95128	D	9	0.97180986;0.97180986	0.96805	D;D	0.200549	0.86715	D	0.945;.	0.98886	0.889;.;	0.97273	Q9BQB6;.;	S113P;.;	Loss of glycosylation at S113 (P = 0.0714);.;	0.989579894245;0.989579894245	0.98946	0.9818629829994101;.	0.98178	0.686615846402;.	0.60338	0.634015440941	0.57714	T	0.943869;.	0.99139	D;.	0.537785	0.95357	D	0.534715	0.95287	D	0.975759327411652	0.71074	D	0.863014;0.70483	0.55864	D;T	0.98324156;.	0.99347	0.9647057;.	0.99217	0.98324156;.	0.99347	0.9647057;.	0.99217	-4.659;.	0.58755	T;.	0.5829310878487804;.	0.64975	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	0.7002;0.7112	0.73421	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	4.033967	0.79789	27.2	4.005028	0.82471	27.7	0.99879670888086647	0.95572	0.97598	0.75804	D	AEFBI	0.940797	0.94325	D	0.239704776846091	0.53133	3.483499	0.385545577533609	0.60674	4.257501	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	5.722000	0.68134	.	.	0.678000	0.82376	1.000000	0.71638	1.000000	0.68203	0.961000	0.51904	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091294	A	C	L	R	rs201545927	16	31102615	16	31010116	111;6	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.332T>G;.	p.L111R;.	c.332T>G;c.17T>G	p.Leu111Arg;p.Leu6Arg	c.332T>G;c.17T>G	p.Leu111Arg;p.Leu6Arg	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	2;2	0;0	A	./.	./.	./.	./.	0.011;.	0.55530	D;.	0.017;0.027	0.60337	D;D	0.999;.	0.77913	D;.	0.985;.	0.76457	D;.	0.004528	0.33648	N	0.128914	0.749204;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L111R;.;.;.;.;.	.;.	.	.;.	-4.98;-4.98	0.98487	D;D	-3.85;.	0.72353	D;.	0.884;.	0.88246	1.1007	0.99690	D	0.9623	0.98790	D	9	0.92442775;0.92442775	0.91793	D;D	0.706775	0.97609	D	0.894;.	0.96985	0.748;.;	0.87905	Q9BQB6;.;	L111R;.;	Gain of methylation at L111 (P = 0.0113);.;	0.965990700052;0.965990700052	0.96562	0.8365079928598839;.	0.83610	0.76600582791;.	0.64516	0.548640370369	0.45666	T	0.906391;.	0.98203	D;.	0.515032	0.94731	D	0.502032	0.94654	D	0.930153852170436	0.59468	D	0.856214;0.665633	0.54490	D;T	0.83045757;.	0.85934	0.76052964;.	0.85851	0.83045757;.	0.85935	0.76052964;.	0.85852	-3.776;.	0.38690	T;.	0.386204090131135;.	0.47997	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	0.5426;0.5107	0.66467	A;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.412958	0.61871	24.4	3.543393	0.68233	25.1	0.99685033510788079	0.79507	0.94599	0.61692	D	AEFBI	0.657297	0.62898	D	0.60316868249379	0.73374	5.955826	0.607295538359903	0.75470	6.315942	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	4.333000	0.59070	.	.	0.678000	0.82376	0.885000	0.31090	1.000000	0.68203	0.925000	0.46118	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	152224	6.569270e-06	0	1	68042	1.469680e-05	0	0	41458	0.000000e+00	0	0	912	0.000000e+00	0	0	15282	0.000000e+00	0	0	3470	0.000000e+00	0	0	5194	0.000000e+00	0	0	10628	0.000000e+00	0	0	316	0.000000e+00	0	1	68042	1.469680e-05	0	0	4828	0.000000e+00	0	0	32904	0.000000e+00	0	1	134810	7.417850e-06	0	1	147970	6.758130e-06	0	0	80782	0.000000e+00	0	0	9098	0.000000e+00	0	0	60	0.000000e+00	0	0	4686	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5496	0.000000e+00	0	0	246	0.000000e+00	0	0	6852	0.000000e+00	0	0	3110	0.000000e+00	0	0	32488	0.000000e+00	0	0	862	0.000000e+00	0	0	14836	0.000000e+00	0	0	3386	0.000000e+00	0	0	5194	0.000000e+00	0	0	6986	0.000000e+00	0	0	310	0.000000e+00	0	1	63918	1.564500e-05	0	0	4826	0.000000e+00	0	0	41138	0.000000e+00	0	0	912	0.000000e+00	0	0	15094	0.000000e+00	0	0	3302	0.000000e+00	0	0	4960	0.000000e+00	0	0	10628	0.000000e+00	0	0	304	0.000000e+00	0	1	64812	1.542920e-05	0	0	4796	0.000000e+00	0	0	24832	0.000000e+00	0	0	112	0.000000e+00	0	0	12908	0.000000e+00	0	0	996	0.000000e+00	0	0	3754	0.000000e+00	0	0	10536	0.000000e+00	0	0	272	0.000000e+00	0	0	21052	0.000000e+00	0	0	4800	0.000000e+00	0	0	7618	0	0	108	0	0	84	0	0	2708	0	0	146	0	0	610	0	0	24	0	0	94	0	0	470	0	0	2816	0	0	108	0	0	11862	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091294	A	G	L	P	rs201545927	16	31102615	16	31010116	111;6	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.332T>C;.	p.L111P;.	c.332T>C;c.17T>C	p.Leu111Pro;p.Leu6Pro	c.332T>C;c.17T>C	p.Leu111Pro;p.Leu6Pro	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	2;2	0;0	A	./.	./.	./.	./.	0.089;.	0.32141	T;.	0.118;0.095	0.39492	T;T	0.999;.	0.77913	D;.	0.989;.	0.78396	D;.	0.004528	0.33648	N	0.128914	0.999991;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L111P;.;.;.;.;.	.;.	.	.;.	-4.99;-4.99	0.98507	D;D	-3.65;.	0.69950	D;.	0.836;.	0.83167	1.0984	0.99594	D	0.9608	0.98738	D	8	0.93114346;0.93114346	0.92453	D;D	0.793964	0.98384	D	0.873;.	0.96207	0.798;.;	0.91802	Q9BQB6;.;	L111P;.;	Loss of stability (P = 0.0182);.;	0.969405125976;0.969405125976	0.96907	0.8981099750956351;.	0.89781	1.4902633655;.	0.86861	0.579736769199	0.50049	T	0.906576;.	0.98208	D;.	0.49785	0.94236	D	0.477351	0.94160	D	0.942082721651652	0.61594	D	0.611839;0.457954	0.23263	T;T	0.92091477;.	0.93337	0.8766876;.	0.93331	0.92091477;.	0.93338	0.8766876;.	0.93332	-4.659;.	0.58755	T;.	0.3184956568052584;.	0.41659	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	0.3465;0.2465	0.56344	A;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.963003	0.77348	26.7	4.020912	0.83031	27.9	0.996103649021161	0.74753	0.94261	0.60606	D	AEFBI	0.658437	0.62971	D	0.560979807011259	0.70754	5.548051	0.571071506838342	0.72876	5.879285	0.999999998832748	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	4.333000	0.59070	.	.	0.678000	0.82376	0.885000	0.31090	1.000000	0.68203	0.925000	0.46118	1.0:0.0:0.0:0.0	15.3945	0.74501	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091295	G	C	L	V	rs1355041443	16	31102616	16	31010117	111;6	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.331C>G;.	p.L111V;.	c.331C>G;c.16C>G	p.Leu111Val;p.Leu6Val	c.331C>G;c.16C>G	p.Leu111Val;p.Leu6Val	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	1;1	2;2	G	./.	./.	./.	./.	0.523;.	0.07187	T;.	0.704;0.62	0.07444	T;T	0.775;.	0.44108	P;.	0.306;.	0.41250	B;.	0.004528	0.33648	N	0.128914	0.996444;0.996444;0.997977;0.993089;0.996444;0.996444	0.23774	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	P131R;P138R;P74R;L111V;P142R;P143R	.;.	.	.;.	-4.84;-4.84	0.98229	D;D	0.1;.	0.05810	N;.	0.092;.	0.07125	0.4607	0.89987	D	0.8501	0.95001	D	9	0.29138628;0.29138628	0.46717	T;T	0.155436	0.83638	D	0.304;.	0.62510	0.608;.;	0.74063	Q9BQB6;.;	L111V;.;	Gain of catalytic residue at L111 (P = 0.0189);.;	0.856093292597;0.856093292597	0.85470	0.44297124059916887;.	0.44214	0.582582740408;.	0.54013	0.444079577923	0.31134	T	0.425679;.	0.77572	T;.	0.0461014	0.57840	T	-0.171555	0.57301	T	0.13883985771153	0.16175	T	0.779122;0.594141	0.41282	T;T	0.0685984;.	0.14958	0.041642968;.	0.04779	0.0685984;.	0.14958	0.041642968;.	0.04778	-4.523;.	0.56265	T;.	0.08223904402275113;.	0.04325	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0675;0.059	0.02639	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.777859	0.12327	9.174	0.921509	0.15929	12.88	0.91445354884897745	0.20715	0.52275	0.29093	D	AEFBI	0.402756	0.47672	N	-0.604710011634584	0.18802	0.9790781	-0.537135929896058	0.21148	1.142678	0.983711716366084	0.30603	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	-0.804	0.10333	-0.859000	0.04385	.	.	-0.199000	0.08999	0.185000	0.24126	0.999000	0.35428	0.905000	0.44082	0.4032:0.1139:0.4829:0.0	6.6652	0.22227	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	152204	6.570130e-06	0	1	41446	2.412780e-05	0	1	41446	2.412780e-05	0	0	912	0.000000e+00	0	0	15282	0.000000e+00	0	0	3470	0.000000e+00	0	0	5200	0.000000e+00	0	0	10622	0.000000e+00	0	0	316	0.000000e+00	0	0	68036	0.000000e+00	0	0	4828	0.000000e+00	0	0	32896	0.000000e+00	0	0	134794	0.000000e+00	0	1	147950	6.759040e-06	0	1	80768	1.238110e-05	0	0	9090	0.000000e+00	0	0	60	0.000000e+00	0	0	4688	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5492	0.000000e+00	0	0	246	0.000000e+00	0	0	6852	0.000000e+00	0	0	3112	0.000000e+00	0	0	32478	0.000000e+00	0	0	862	0.000000e+00	0	0	14836	0.000000e+00	0	0	3386	0.000000e+00	0	0	5200	0.000000e+00	0	0	6982	0.000000e+00	0	0	310	0.000000e+00	0	0	63912	0.000000e+00	0	0	4826	0.000000e+00	0	1	41126	2.431550e-05	0	0	912	0.000000e+00	0	0	15096	0.000000e+00	0	0	3302	0.000000e+00	0	0	4964	0.000000e+00	0	0	10622	0.000000e+00	0	0	304	0.000000e+00	0	0	64804	0.000000e+00	0	0	4796	0.000000e+00	0	1	24822	4.028680e-05	0	0	112	0.000000e+00	0	0	12908	0.000000e+00	0	0	996	0.000000e+00	0	0	3758	0.000000e+00	0	0	10530	0.000000e+00	0	0	272	0.000000e+00	0	0	21052	0.000000e+00	0	0	4800	0.000000e+00	0	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091297	G	T	S	Y	.	16	31102618	16	31010119	110;5	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.329C>A;.	p.S110Y;.	c.329C>A;c.14C>A	p.Ser110Tyr;p.Ser5Tyr	c.329C>A;c.14C>A	p.Ser110Tyr;p.Ser5Tyr	principal1;.	Y;.	1;2	YES;.	-;-	TCC;TCC	2;2	0;0	G	./.	./.	./.	./.	0.0;.	0.91255	D;.	0.039;0.003	0.76473	D;D	0.998;.	0.73220	D;.	0.946;.	0.68276	D;.	0.000176	0.48594	D	0.088849	0.999536;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	S110Y;.;.;.;.;.	.;.	.	.;.	-4.88;-4.88	0.98296	D;D	-5.06;.	0.82764	D;.	0.634;.	0.64733	1.0944	0.99422	D	0.9609	0.98742	D	9	0.9156432;0.9156432	0.90925	D;D	0.675251	0.97299	D	0.918;.	0.97890	0.728;.;	0.86198	Q9BQB6;.;	S110Y;.;	Gain of catalytic residue at S110 (P = 0.0598);.;	0.996738416879;0.996738416879	0.99670	0.938105424595007;.	0.93790	1.28972051973;.	0.82754	0.619179010391	0.55613	T	0.938058;.	0.99005	D;.	0.505886	0.94462	D	0.488894	0.94383	D	0.995538351878755	0.87601	D	0.854015;0.555844	0.53996	D;T	0.98625714;.	0.99548	0.97820175;.	0.99768	0.98625714;.	0.99548	0.97820175;.	0.99769	-5.692;.	0.71313	T;.	0.6899590306917052;.	0.76755	U;.	U;.	U;.	U;.	U;.	U;.	U;.	P;.	P;.	P;.	P;.	0.8241;0.6393	0.78437	P;P	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.695667	0.69237	25.4	3.511700	0.67403	25.0	0.99441789836577121	0.64820	0.97801	0.77233	D	AEFBI	0.902911	0.85137	D	0.594712059352216	0.72845	5.870065	0.581236763555701	0.73597	5.996276	0.999999834890698	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	4.96	0.65153	6.288000	0.72696	.	.	0.607000	0.46521	1.000000	0.71638	1.000000	0.68203	0.883000	0.42306	0.0:0.1344:0.8656:0.0	16.1127	0.81082	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091301	T	A	S	C	.	16	31102622	16	31010123	109;4	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.325A>T;.	p.S109C;.	c.325A>T;c.10A>T	p.Ser109Cys;p.Ser4Cys	c.325A>T;c.10A>T	p.Ser109Cys;p.Ser4Cys	principal1;.	Y;.	1;2	YES;.	-;-	AGC;AGC	1;1	0;0	T	./.	./.	./.	./.	0.015;.	0.52492	D;.	0.011;0.028	0.64786	D;D	1.0;.	0.90584	D;.	0.979;.	0.74454	D;.	0.000030	0.55875	D	0.074843	0.92716;0.996567;0.996567;0.998047;0.996567;0.996567	0.36856	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	S109C;E129V;E136V;E72V;E140V;E141V	.;.	.	.;.	-4.73;-4.73	0.98066	D;D	-2.62;.	0.56301	D;.	0.536;.	0.56403	0.8065	0.94491	D	0.9414	0.98078	D	9	0.7688668;0.7688668	0.76920	D;D	0.552361	0.95879	D	0.657;.	0.87135	0.603;.;	0.73466	Q9BQB6;.;	S109C;.;	Gain of catalytic residue at S113 (P = 0.1005);.;	0.993126569838;0.993126569838	0.99304	0.6630121003601043;.	0.66238	1.11159318342;.	0.78070	0.509529352188	0.40156	T	0.824058;.	0.95729	D;.	0.135633	0.67907	D	-0.0429495	0.67503	D	0.967925548553467	0.68070	D	0.740526;0.329867	0.35940	T;T	0.4712065;.	0.65364	0.22502558;.	0.47433	0.4712065;.	0.65365	0.22502558;.	0.47432	-5.942;.	0.73235	T;.	0.1837267506043322;.	0.23799	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1212;0.1215	0.25265	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.258590	0.58002	24.0	3.068341	0.56306	23.7	0.99138109175518785	0.53464	0.96771	0.70851	D	AEFBI	0.780170	0.71214	D	0.506618200107753	0.67479	5.087274	0.495617577284477	0.67699	5.119124	0.999967471338019	0.48965	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	2.999000	0.49161	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.783000	0.37026	0.0:0.0765:0.0:0.9235	10.3381	0.43044	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091301	T	C	S	G	.	16	31102622	16	31010123	109;4	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.325A>G;.	p.S109G;.	c.325A>G;c.10A>G	p.Ser109Gly;p.Ser4Gly	c.325A>G;c.10A>G	p.Ser109Gly;p.Ser4Gly	principal1;.	Y;.	1;2	YES;.	-;-	AGC;AGC	1;1	0;0	T	./.	./.	./.	./.	0.015;.	0.52492	D;.	0.017;0.056	0.60337	D;T	0.061;.	0.23190	B;.	0.069;.	0.27757	B;.	0.000030	0.55875	D	0.074843	0.751554;0.998248;0.998248;0.999004;0.998248;0.998248	0.33935	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	S109G;E129G;E136G;E72G;E140G;E141G	.;.	.	.;.	-4.44;-4.44	0.97515	D;D	-2.56;.	0.55339	D;.	0.224;.	0.25130	0.0379	0.83009	D	0.7864	0.92750	D	8	0.43168765;0.43168765	0.57532	T;T	0.180594	0.85500	D	0.428;.	0.73517	0.486;.;	0.56939	Q9BQB6;.;	S109G;.;	Loss of helix (P = 0.1299);.;	0.965884241979;0.965884241979	0.96552	0.6602261099199014;.	0.65959	0.883452538917;.	0.69856	0.47099173069	0.34817	T	0.750903;.	0.93173	D;.	0.0616385	0.59820	T	-0.149237	0.59311	T	0.952884137630463	0.63897	D	0.757724;0.323768	0.38135	T;T	0.62405896;.	0.73980	0.29938942;.	0.55972	0.62405896;.	0.73982	0.29938942;.	0.55971	-3.773;.	0.38610	T;.	0.1912825343212341;.	0.25092	U;.	U;.	U;.	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.1398;0.0915	0.30634	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	2.940321	0.50746	23.3	2.711842	0.48379	23.0	0.99776067308839633	0.86346	0.91729	0.54139	D	AEFBI	0.497475	0.53198	N	-0.0705661133999778	0.38687	2.269758	0.0847013262061719	0.43779	2.67262	0.999967471338019	0.48965	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	2.999000	0.49161	.	.	0.654000	0.53741	1.000000	0.71638	1.000000	0.68203	0.783000	0.37026	0.0:0.0765:0.0:0.9235	10.3381	0.43044	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091303	A	C	L	R	.	16	31102624	16	31010125	108;3	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.323T>G;.	p.L108R;.	c.323T>G;c.8T>G	p.Leu108Arg;p.Leu3Arg	c.323T>G;c.8T>G	p.Leu108Arg;p.Leu3Arg	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	2;2	0;0	A	./.	./.	./.	./.	0.215;.	0.19293	T;.	0.352;0.315	0.19421	T;T	0.998;.	0.73220	D;.	0.948;.	0.68536	D;.	0.074546	0.21277	N	0.398425	1;1;1;1;1;0.75103	0.81001	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;L108R	.;.	.	.;.	-4.9;-4.9	0.98333	D;D	-2.37;.	0.52289	N;.	0.864;.	0.86085	1.0484	0.98083	D	0.9501	0.98375	D	9	0.8869981;0.8869981	0.88030	D;D	0.781121	0.98276	D	0.736;.	0.90808	0.554;.;	0.67133	Q9BQB6;.;	L108R;.;	Gain of methylation at L108 (P = 0.0086);.;	0.960082578066;0.960082578066	0.95966	0.8694402374699216;.	0.86909	1.42345539463;.	0.85657	0.562161803246	0.47572	T	0.886654;.	0.97664	D;.	0.481992	0.93766	D	0.454572	0.93687	D	0.826803028583527	0.48284	D	0.765223;0.355164	0.39255	T;T	0.6187875;.	0.73698	0.5702846;.	0.75118	0.6187875;.	0.73699	0.5702846;.	0.75118	-3.776;.	0.38690	T;.	0.34156986471728745;.	0.43929	U;.	U;.	U;.	U;.	U;.	U;.	U;.	U;.	B;.	B;.	B;.	0.5229;0.3453	0.65607	A;A	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	3.025546	0.52602	23.5	2.901211	0.52516	23.3	0.99564335386968217	0.71953	0.98165	0.80163	D	AEFBI	0.834742	0.75275	D	0.563995131226667	0.70939	5.575684	0.558143143599285	0.71965	5.736017	0.999956883114256	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.92	5.92	0.95557	2.639000	0.46236	.	.	0.743000	0.86499	0.997000	0.40164	1.000000	0.68203	0.675000	0.33396	0.8489:0.1511:0.0:0.0	11.401	0.49112	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091307	G	C	L	V	.	16	31102628	16	31010129	107;2	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.319C>G;.	p.L107V;.	c.319C>G;c.4C>G	p.Leu107Val;p.Leu2Val	c.319C>G;c.4C>G	p.Leu107Val;p.Leu2Val	principal1;.	Y;.	1;2	YES;.	-;-	CTG;CTG	1;1	2;2	G	./.	./.	./.	./.	0.678;.	0.04456	T;.	0.387;0.442	0.15650	T;T	0.001;.	0.07471	B;.	0.004;.	0.10090	B;.	0.276978	0.03808	N	1.508260	1;1;1;0.999996;1;1	0.08975	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	A127G;A134G;A70G;L107V;A138G;A139G	.;.	.	.;.	-4.8;-4.8	0.98169	D;D	-0.74;.	0.20791	N;.	0.041;.	0.01421	0.2917	0.87425	D	0.7867	0.92761	D	9	0.16637972;0.16637972	0.31071	T;T	0.018373	0.40411	T	0.385;.	0.70194	0.608;.;	0.74063	Q9BQB6;.;	L107V;.;	Loss of loop (P = 0.0804);.;	0.698756590179;0.698756590179	0.69615	0.4801549478238915;.	0.47935	0.371439831053;.	0.38641	0.361664324999	0.19629	T	0.590625;.	0.86733	D;.	-0.0671689	0.41778	T	-0.33426	0.40992	T	0.0246951727875225	0.01233	T	0.556544;0.281772	0.19325	T;T	0.057642292;.	0.11498	0.038372457;.	0.03691	0.057642292;.	0.11498	0.038372457;.	0.03690	-4.523;.	0.56265	T;.	0.11803213378731485;.	0.10847	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0751;0.0652	0.05535	B;B	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	-0.353057	0.02107	0.241	-0.657630	0.01000	0.027	0.58212848140267448	0.05942	0.11132	0.16429	N	AEFBI	0.192302	0.31947	N	-1.16568803214645	0.05527	0.2521828	-1.21372375296053	0.05689	0.27176	0.999973986336773	0.50053	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.62	-6.75	0.01575	-0.279000	0.08512	.	.	-0.193000	0.09282	0.393000	0.26112	0.000000	0.08366	0.303000	0.24570	0.0807:0.2172:0.4084:0.2937	4.5783	0.11640	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091310	T	A	M	L	rs2057288266	16	31102631	16	31010132	106;1	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.316A>T;.	p.M106L;.	c.316A>T;c.1A>T	p.Met106Leu;p.Met1?	c.316A>T;c.1A>T	p.Met106Leu;p.Met1?	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	1;1	0;0	T	T/T	T/T	T/T	T/T	1.0;.	0.00964	T;.	1.0;1.0	0.01155	T;T	0.0;.	0.02946	B;.	0.0;.	0.01387	B;.	0.002540	0.36389	N	0.118551	0.847157;0.758918;0.847157;0.758918;0.847157;0.999905	0.35161	D;D;D;D;D;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	D133V;D126V;D138V;D69V;D137V;M106L	.;.	.	.;.	-4.16;-1.73	0.96826	D;D	0.98;.	0.01447	N;.	0.162;.	0.17002	-0.1506	0.78901	T	0.6202	0.86613	D	9	0.19461522;0.29654235	0.47218	T;T	0.013445	0.32845	T	0.293;.	0.61272	0.52;.;	0.62217	Q9BQB6;.;	M106L;.;	Loss of catalytic residue at M106 (P = 0.0191);.;	0.744920796819;0.744920796819	0.74262	0.5437344092954703;.	0.54299	0.343187920697;.	0.36250	0.512627124786	0.40590	T	0.408093;.	0.76352	T;.	0.0780083	0.61807	D	-0.125723	0.61330	T	0.0791885405778885	0.09883	T	0.454955;0.9	0.65058	T;D	0.108931765;.	0.25753	0.07376244;.	0.16063	0.108931765;.	0.25753	0.07376244;.	0.16063	-4.726;.	0.59903	T;.	0.03807224674863503;.	0.00272	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0421;.	0.00024	B;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.789826	0.12472	9.291	0.380775	0.09357	8.187	0.68564812885116988	0.08697	0.66640	0.33148	D	AEFBI	0.603360	0.59487	D	-0.843998910961754	0.12197	0.5931296	-0.716543476089925	0.16549	0.8759736	0.992899383669769	0.33008	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	2.68	0.30839	2.480000	0.44865	.	.	-0.746000	0.03629	1.000000	0.71638	1.000000	0.68203	0.164000	0.20782	0.1508:0.0:0.7115:0.1377	7.7169	0.27876	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091310	T	C	M	V	.	16	31102631	16	31010132	106;1	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.316A>G;.	p.M106V;.	c.316A>G;c.1A>G	p.Met106Val;p.Met1?	c.316A>G;c.1A>G	p.Met106Val;p.Met1?	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	1;1	0;0	T	T/T	T/T	T/T	T/T	0.047;.	0.40319	D;.	0.039;0.015	0.61642	D;D	0.0;.	0.02946	B;.	0.0;.	0.01387	B;.	0.002540	0.36389	N	0.118551	0.999679;0.999434;0.999679;0.999877;0.999434;0.999434	0.21199	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	D126G;D133G;D69G;M106V;D137G;D138G	.;.	.	.;.	-4.56;-1.96	0.97772	D;D	-0.86;.	0.23372	N;.	0.087;.	0.06454	0.2485	0.86719	D	0.8056	0.93429	D	9	0.36740077;0.53511083	0.63403	T;D	0.055612	0.66300	D	0.322;.	0.64420	0.594;.;	0.72371	Q9BQB6;.;	M106V;.;	Loss of catalytic residue at M106 (P = 0.0601);.;	0.847838978391;0.847838978391	0.84637	0.6148105051950814;.	0.61413	0.373056351896;.	0.38782	0.484668791294	0.36700	T	0.552778;.	0.84887	D;.	0.0357257	0.56481	T	-0.186459	0.55921	T	0.242088034749031	0.22515	T	0.687731;0.9	0.65058	T;D	0.17097925;.	0.37705	0.11232415;.	0.27102	0.17097925;.	0.37705	0.11232415;.	0.27102	-4.523;.	0.56265	T;.	0.1001872491830012;.	0.07363	U;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0937;.	0.14339	B;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	1.212897	0.17803	13.74	0.738893	0.13658	11.47	0.54944048975705728	0.05240	0.76509	0.37529	D	AEFBI	0.836392	0.75416	D	-0.652213675840437	0.17396	0.894795	-0.552676520285277	0.20735	1.118489	0.992899383669769	0.33008	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	2.68	0.30839	2.480000	0.44865	.	.	-0.746000	0.03629	1.000000	0.71638	1.000000	0.68203	0.164000	0.20782	0.1508:0.0:0.7115:0.1377	7.7169	0.27876	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091310	T	G	M	L	.	16	31102631	16	31010132	106;1	VKORC1;VKORC1	ENSG00000167397;ENSG00000167397	ENST00000394975;ENST00000472468	ENSP00000378426;ENSP00000458994	Q9BQB6;I3L1P9	VKOR1_HUMAN;I3L1P9_HUMAN	c.316A>C;.	p.M106L;.	c.316A>C;c.1A>C	p.Met106Leu;p.Met1?	c.316A>C;c.1A>C	p.Met106Leu;p.Met1?	principal1;.	Y;.	1;2	YES;.	-;-	ATG;ATG	1;1	0;0	T	T/T	T/T	T/T	T/T	1.0;.	0.00964	T;.	1.0;1.0	0.01155	T;T	0.0;.	0.02946	B;.	0.0;.	0.01387	B;.	0.002540	0.36389	N	0.118551	0.999782;0.999616;0.999782;0.999905;0.999616;0.999616	0.20864	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	D126A;D133A;D69A;M106L;D137A;D138A	.;.	.	.;.	-4.16;-1.73	0.96826	D;D	0.98;.	0.01447	N;.	0.158;.	0.16447	-0.3979	0.72093	T	0.6095	0.86166	D	9	0.17344058;0.2754825	0.45107	T;T	0.013647	0.33213	T	0.288;.	0.60691	0.52;.;	0.62217	Q9BQB6;.;	M106L;.;	Loss of catalytic residue at M106 (P = 0.0191);.;	0.744920796819;0.744920796819	0.74262	0.5437343955244358;.	0.54299	0.343187920697;.	0.36250	0.512627124786	0.40590	T	0.408093;.	0.76352	T;.	0.0418074	0.57282	T	-0.177723	0.56732	T	0.0791885405778885	0.09883	T	0.454955;0.9	0.65058	T;D	0.108931765;.	0.25753	0.07376244;.	0.16063	0.108931765;.	0.25753	0.07376244;.	0.16063	-4.726;.	0.59903	T;.	0.03807224674863503;.	0.00272	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	B;.	0.0421;.	0.00024	B;.	.;.;	.;.;	.;.;	.;.;	.;.;	.;.;	0.725901	0.11713	8.692	0.282094	0.08183	6.980	0.52668562858334877	0.04792	0.04693	0.10379	N	AEFBI	0.284045	0.39701	N	-0.843998910961754	0.12197	0.5931296	-0.716543476089925	0.16549	0.8759736	0.992899383669769	0.33008	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	2.68	0.30839	2.480000	0.44865	.	.	-0.746000	0.03629	1.000000	0.71638	1.000000	0.68203	0.164000	0.20782	0.1508:0.0:0.7115:0.1377	7.7169	0.27876	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase;.	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091312	A	C	L	R	.	16	31102633	16	31010134	105	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.314T>G	p.L105R	c.314T>G	p.Leu105Arg	c.314T>G	p.Leu105Arg	principal1	Y	1	YES	-	CTG	2	0	A	A/A	A/A	A/A	A/A	0.004	0.65419	D	0.011	0.64786	D	0.999	0.77913	D	0.985	0.76457	D	0.022940	0.26539	N	0.254138	0.999992;0.999992;0.999992;0.999992;0.999992;0.998055	0.58761	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;L105R	.	.	.	-4.86	0.98263	D	-3.82	0.71997	D	0.86	0.85660	1.0837	0.99004	D	0.9521	0.98443	D	9	0.8924295	0.88589	D	0.753503	0.98037	D	0.638	0.86181	0.403;	0.43408	Q9BQB6;	L105R;	Gain of methylation at L105 (P = 0.0068);	0.954767482141	0.95429	0.8926366085930209	0.89233	1.41889764318	0.85580	0.556579589844	0.46785	T	0.873393	0.97284	D	0.470888	0.93370	D	0.438622	0.93286	D	0.937143231177928	0.60670	D	0.780822	0.41560	T	0.8265494	0.85664	0.6842296	0.81436	0.8265494	0.85665	0.6842296	0.81437	-3.776	0.38690	T	0.36954093638105	0.46520	U	U	U	U	U	U	U	U	U	B	B	0.5368	0.66216	A	.;	.;	.;	.;	.;	.;	3.529243	0.64848	24.8	3.167270	0.58690	24.0	0.99635446891378254	0.76326	0.95150	0.63621	D	AEFBI	0.720245	0.67087	D	0.439407474053003	0.63605	4.597465	0.386342034342937	0.60721	4.263044	0.999953546297605	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	5.71	0.89031	5.786000	0.68654	.	.	0.743000	0.86499	0.989000	0.36753	1.000000	0.68203	0.151000	0.20341	0.8451:0.0:0.1549:0.0	7.4754	0.26543	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091312	A	G	L	P	rs2057288295	16	31102633	16	31010134	105	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.314T>C	p.L105P	c.314T>C	p.Leu105Pro	c.314T>C	p.Leu105Pro	principal1	Y	1	YES	-	CTG	2	0	A	A/A	A/A	A/A	A/A	0.005	0.63226	D	0.016	0.60972	D	0.999	0.77913	D	0.985	0.76457	D	0.022940	0.26539	N	0.254138	0.986152;0.999992;0.999992;0.999992;0.999992;0.999992	0.58761	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L105P;.;.;.;.;.	.	.	.	-4.87	0.98279	D	-4.06	0.74582	D	0.868	0.86511	1.0650	0.98461	D	0.9495	0.98355	D	8	0.8919298	0.88537	D	0.76008	0.98095	D	0.654	0.86986	0.452;	0.51448	Q9BQB6;	L105P;	Loss of helix (P = 0.0304);	0.96371562038	0.96332	0.9408411369883843	0.94065	1.49794151947	0.86986	0.578692317009	0.49901	T	0.901875	0.98081	D	0.498675	0.94257	D	0.478536	0.94178	D	0.943369397050126	0.61845	D	0.728327	0.34315	T	0.8297741	0.85887	0.75602293	0.85582	0.8297741	0.85888	0.75602293	0.85582	-4.659	0.58755	T	0.27002736294026164	0.36341	U	U	U	U	U	U	B	B	B	B	B	0.3274	0.55039	B	.;	.;	.;	.;	.;	.;	3.585383	0.66303	25.0	3.171612	0.58795	24.0	0.99804389909165858	0.88906	0.68733	0.33914	D	AEFBI	0.371759	0.45765	N	0.391618407437486	0.60966	4.29178	0.345509647730503	0.58239	3.993185	0.999953546297605	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	5.71	0.89031	5.786000	0.68654	.	.	0.743000	0.86499	0.989000	0.36753	1.000000	0.68203	0.151000	0.20341	0.8451:0.0:0.1549:0.0	7.4754	0.26543	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	152234	1.313770e-05	0	2	15288	1.308220e-04	0	0	41458	0.000000e+00	0	0	912	0.000000e+00	0	2	15288	1.308220e-04	0	0	3468	0.000000e+00	0	0	5190	0.000000e+00	0	0	10630	0.000000e+00	0	0	316	0.000000e+00	0	0	68048	0.000000e+00	0	0	4830	0.000000e+00	0	0	32906	0.000000e+00	0	2	134812	1.483550e-05	0	2	147980	1.351530e-05	0	2	80790	2.475550e-05	0	0	9092	0.000000e+00	0	0	60	0.000000e+00	0	0	4690	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5498	0.000000e+00	0	0	246	0.000000e+00	0	0	6854	0.000000e+00	0	0	3110	0.000000e+00	0	0	32480	0.000000e+00	0	0	862	0.000000e+00	0	2	14842	1.347530e-04	0	0	3384	0.000000e+00	0	0	5190	0.000000e+00	0	0	6988	0.000000e+00	0	0	310	0.000000e+00	0	0	63924	0.000000e+00	0	0	4828	0.000000e+00	0	0	41136	0.000000e+00	0	0	912	0.000000e+00	0	2	15100	1.324500e-04	0	0	3302	0.000000e+00	0	0	4956	0.000000e+00	0	0	10630	0.000000e+00	0	0	304	0.000000e+00	0	0	64818	0.000000e+00	0	0	4798	0.000000e+00	0	0	24834	0.000000e+00	0	0	112	0.000000e+00	0	2	12914	1.548710e-04	0	0	994	0.000000e+00	0	0	3748	0.000000e+00	0	0	10538	0.000000e+00	0	0	272	0.000000e+00	0	0	21056	0.000000e+00	0	0	4802	0.000000e+00	0	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091313	G	C	L	V	.	16	31102634	16	31010135	105	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.313C>G	p.L105V	c.313C>G	p.Leu105Val	c.313C>G	p.Leu105Val	principal1	Y	1	YES	-	CTG	1	2	G	G/G	G/G	G/G	G/G	0.329	0.13175	T	0.451	0.12920	T	0.775	0.44108	P	0.306	0.41250	B	0.022940	0.26539	N	0.254138	0.999981;0.999454;0.999981;0.999883;0.999966;0.999966	0.21167	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	P125R;P132R;P68R;L105V;P136R;P137R	.	.	.	-4.65	0.97938	D	-0.4	0.13805	N	0.17	0.18103	0.5428	0.91138	D	0.8771	0.95918	D	9	0.29192644	0.46770	T	0.176401	0.85217	D	0.291	0.61040	0.266;	0.21261	Q9BQB6;	L105V;	Loss of helix (P = 0.0795);	0.896335046357	0.89530	0.5951082311042886	0.59440	0.576200766118	0.53580	0.466236352921	0.34165	T	0.553377	0.84917	D	0.071089	0.60982	D	-0.135662	0.60492	T	0.539718925952911	0.34093	D	0.651035	0.26183	T	0.10337045	0.24431	0.059816495	0.11290	0.10337045	0.24431	0.059816495	0.11290	-4.523	0.56265	T	0.09299340168748203	0.06069	U	B	B	B	B	B	B	B	B	B	B	0.0911	0.13127	B	.;	.;	.;	.;	.;	.;	0.869714	0.13433	10.12	1.339188	0.21479	15.40	0.90615452656108775	0.19868	0.32056	0.24491	N	AEFBI	0.244855	0.36589	N	-0.253052280917989	0.30981	1.732763	-0.176260296738719	0.32412	1.843732	0.999906299831415	0.45458	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	4.69	0.58546	0.697000	0.25234	.	.	-0.118000	0.14412	0.524000	0.27143	1.000000	0.68203	0.131000	0.19607	0.0:0.3244:0.6756:0.0	12.8222	0.57083	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091315	A	C	V	G	rs1389762752	16	31102636	16	31010137	104	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.311T>G	p.V104G	c.311T>G	p.Val104Gly	c.311T>G	p.Val104Gly	principal1	Y	1	YES	-	GTC	2	0	A	A/A	A/A	A/A	A/A	0.184	0.21634	T	0.243	0.24193	T	0.007	0.14184	B	0.023	0.19966	B	0.718029	0.06297	N	1.138390	1;1;1;1;0.999999;1	0.08975	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	C124W;C131W;C67W;V104G;C135W;C136W	.	.	.	-4.68	0.97989	D	-2.44	0.53420	N	0.164	0.17278	0.1638	0.85293	D	0.8210	0.93980	D	9	0.267896	0.44305	T	0.137508	0.82001	D	0.513	0.79156	0.647;	0.78436	Q9BQB6;	V104G;	Loss of stability (P = 0.0197);	0.749761708737	0.74749	0.58225926379554	0.58154	0.534207440331	0.50835	0.309200167656	0.11786	T	0.748021	0.93073	D	0.00552651	0.52414	T	-0.129208	0.61038	T	0.0311039106770144	0.02162	T	0.462854	0.13445	T	0.47328514	0.65492	0.22816439	0.47849	0.47328514	0.65492	0.22816439	0.47848	-3.773	0.38610	T	0.15886073935424916	0.19278	U	U	U	B	B	B	B	B	B	B	B	0.1022	0.18080	B	.;	.;	.;	.;	.;	.;	0.544824	0.09627	6.966	0.701469	0.13199	11.16	0.84982832844489276	0.15614	0.21909	0.21566	N	AEFBI	0.699851	0.65707	D	-0.803396885063511	0.13223	0.6499091	-0.82010076134945	0.14008	0.7297585	0.984385450738884	0.30709	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	1.02	0.19102	0.489000	0.22096	.	.	0.743000	0.86499	0.000000	0.06391	0.990000	0.31317	0.105000	0.18517	0.6334:0.0:0.3666:0.0	9.5293	0.38349	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	250342	3.994540e-06	0	0	16082	0.000000e+00	0	0	34500	0.000000e+00	0	0	10040	0.000000e+00	0	0	18368	0.000000e+00	0	0	21590	0.000000e+00	0	0	113082	0.000000e+00	0	1	30566	3.271610e-05	0	1	30566	3.271610e-05	0	0	109192	0.000000e+00	0	1	207430	4.820900e-06	0	1	236160	4.234420e-06	0	1	243776	4.102130e-06	0	0	7114	0.000000e+00	0	0	17082	0.000000e+00	0	0	2316	0.000000e+00	0	0	9038	0.000000e+00	0	0	13374	0.000000e+00	0	0	42708	0.000000e+00	0	0	15652	0.000000e+00	0	.	.	.	.	0	16044	0.000000e+00	0	0	30440	0.000000e+00	0	0	6194	0.000000e+00	0	0	13394	0.000000e+00	0	0	16712	0.000000e+00	0	0	89238	0.000000e+00	0	1	30560	3.272250e-05	0	1	30560	3.272250e-05	0	0	14802	0.000000e+00	0	0	34184	0.000000e+00	0	0	9546	0.000000e+00	0	0	17682	0.000000e+00	0	0	21574	0.000000e+00	0	0	102288	0.000000e+00	0	1	30480	3.280840e-05	0	1	30480	3.280840e-05	0	0	11894	0.000000e+00	0	0	34366	0.000000e+00	0	0	9958	0.000000e+00	0	0	18364	0.000000e+00	0	0	21588	0.000000e+00	0	0	111002	0.000000e+00	0	1	30566	3.271610e-05	0	1	30566	3.271610e-05	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091315	A	T	V	D	.	16	31102636	16	31010137	104	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.311T>A	p.V104D	c.311T>A	p.Val104Asp	c.311T>A	p.Val104Asp	principal1	Y	1	YES	-	GTC	2	0	A	A/A	A/A	A/A	A/A	0.123	0.27544	T	0.153	0.32144	T	0.001	0.07471	B	0.006	0.12133	B	0.718029	0.06297	N	1.138390	0.813971;0.813971;0.813971;0.813971;0.813971;1	0.28966	N;N;N;N;N;N	complex_aae;complex_aae;complex_aae;complex_aae;complex_aae;simple_aae	.;.;.;.;.;V104D	.	.	.	-4.73	0.98066	D	-2.28	0.50830	N	0.307	0.34659	0.3122	0.87750	D	0.8304	0.94313	D	9	0.36451513	0.52994	T	.	.	.	0.609	0.84666	0.635;	0.77142	Q9BQB6;	V104D;	Loss of methylation at R100 (P = 0.0496);	0.719891548447	0.71742	0.786517829509801	0.78603	0.7593053508	0.64165	0.333436250687	0.15453	T	0.774902	0.94005	D	-0.376727	0.03266	T	-0.778919	0.02486	T	0.0356493628269792	0.02920	T	0.744825	0.36507	T	0.670996	0.76486	0.5812023	0.75724	0.670996	0.76487	0.5812023	0.75725	-0.64	0.05512	T	0.27921950632395204	0.37425	U	U	U	U	U	U	B	B	B	B	B	0.2554	0.49018	B	.;	.;	.;	.;	.;	.;	0.665899	0.11012	8.139	0.864185	0.15217	12.45	0.97373034906511735	0.33632	0.26149	0.22909	N	AEFBI	0.823520	0.74361	D	-0.783742342547292	0.13734	0.6787078	-0.802287932836519	0.14441	0.7545105	0.984385450738884	0.30709	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	1.02	0.19102	0.489000	0.22096	.	.	0.743000	0.86499	0.000000	0.06391	0.990000	0.31317	0.105000	0.18517	0.6334:0.0:0.3666:0.0	9.5293	0.38349	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091318	G	T	S	Y	.	16	31102639	16	31010140	103	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.308C>A	p.S103Y	c.308C>A	p.Ser103Tyr	c.308C>A	p.Ser103Tyr	principal1	Y	1	YES	-	TCT	2	0	G	G/G	G/G	G/G	G/G	0.003	0.68238	D	0.013	0.63109	D	0.484	0.36838	P	0.452	0.46163	P	0.000176	0.48594	D	0.089585	0.994057;0.994057;0.994057;0.994057;0.994057;1	0.42145	D;D;D;D;D;N	without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	.;.;.;.;.;S103Y	.	.	.	-4.74	0.98081	D	-3.36	0.66549	D	0.405	0.44570	0.9989	0.97170	D	0.9200	0.97352	D	9	0.8168863	0.80920	D	0.640302	0.96932	D	0.534	0.80426	0.708;	0.84418	Q9BQB6;	S103Y;	Gain of methylation at R98 (P = 0.1441);	0.988583977366	0.98846	0.655205452404234	0.65456	1.32510383089	0.83540	0.535575509071	0.43821	T	0.870733	0.97206	D	0.225404	0.76288	D	0.0860011	0.75979	D	0.949174284934998	0.63056	D	0.675332	0.28377	T	0.9440762	0.95662	0.8816661	0.93679	0.9440762	0.95663	0.8816661	0.93679	-5.692	0.71313	T	0.2391212835280437	0.32388	U	U	U	U	U	B	B	B	B	B	B	0.1528	0.33800	B	.;	.;	.;	.;	.;	.;	2.905117	0.49985	23.2	2.675471	0.47581	22.9	0.99282923890644947	0.57973	0.89604	0.50175	D	AEFBI	0.584674	0.58340	D	0.170971681882889	0.49810	3.177246	0.209300005347926	0.50363	3.22914	0.999991416280881	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	5.71	0.89031	3.874000	0.55814	.	.	0.665000	0.62972	0.999000	0.42656	1.000000	0.68203	0.090000	0.17789	0.0:0.0:1.0:0.0	19.0627	0.93081	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091319	A	T	S	T	.	16	31102640	16	31010141	103	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.307T>A	p.S103T	c.307T>A	p.Ser103Thr	c.307T>A	p.Ser103Thr	principal1	Y	1	YES	-	TCT	1	0	A	A/A	A/A	A/A	A/A	0.08	0.33585	T	0.165	0.30926	T	0.027	0.19556	B	0.055	0.25995	B	0.000176	0.48594	D	0.089585	1;1;1;1;1;1	0.08975	N;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	L123H;L130H;L66H;S103T;L134H;L135H	.	.	.	-4.68	0.97989	D	-1.32	0.32991	N	0.27	0.30574	0.2901	0.87399	D	0.8502	0.95004	D	9	0.3867206	0.54595	T	0.24132	0.88712	D	0.354	0.67510	0.688;	0.82558	Q9BQB6;	S103T;	Loss of methylation at R100 (P = 0.174);	0.91263525459	0.91175	0.4183871623332021	0.41754	1.10155356664	0.77751	0.492815494537	0.37829	T	0.580927	0.86276	D	0.109736	0.65323	D	-0.0801488	0.64893	T	0.924240350723267	0.58530	D	0.667533	0.27667	T	0.25444627	0.48473	0.21825275	0.46522	0.25444627	0.48473	0.21825275	0.46521	-4.093	0.46692	T	0.1114562068521636	0.09533	U	B	B	B	B	B	B	B	B	B	B	0.0926	0.13830	B	.;	.;	.;	.;	.;	.;	1.490300	0.21739	15.67	0.843963	0.14962	12.29	0.98248799573270496	0.39548	0.77291	0.37986	D	AEFBI	0.223963	0.34825	N	-0.555551591070593	0.20309	1.069715	-0.470150207426472	0.22981	1.250932	0.995539512262621	0.34180	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	3.42	0.38259	3.107000	0.50021	.	.	-0.065000	0.16512	0.998000	0.41325	1.000000	0.68203	0.101000	0.18331	0.4724:0.5276:0.0:0.0	13.1632	0.58978	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091321	G	A	A	V	.	16	31102642	16	31010143	102	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.305C>T	p.A102V	c.305C>T	p.Ala102Val	c.305C>T	p.Ala102Val	principal1	Y	1	YES	-	GCC	2	0	G	G/G	G/G	G/G	G/G	0.04	0.42199	D	0.077	0.42436	T	0.032	0.20242	B	0.042	0.24114	B	0.001273	0.39594	N	0.169796	0.995319;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	A102V;.;.;.;.;.	.	.	.	-4.74	0.98081	D	-2.33	0.51646	N	0.076	0.05037	0.6330	0.92327	D	0.8440	0.94791	D	9	0.50007033	0.61495	D	0.754841	0.98049	D	0.580	0.83081	0.65;	0.78753	Q9BQB6;	A102V;	Loss of methylation at R100 (P = 0.0974);	0.958068906754	0.95761	0.7544868577922834	0.75395	0.39927481172	0.40956	0.402112662792	0.25363	T	0.667842	0.90107	D	0.207869	0.74630	D	0.0608126	0.74300	D	0.781769275665283	0.45161	D	0.722228	0.33571	T	0.35083112	0.57132	0.17216009	0.39450	0.35083112	0.57132	0.17216009	0.39449	-4.523	0.56265	T	0.2078704229811936	0.27793	U	U	U	U	U	B	B	B	B	B	B	0.1222	0.25495	B	.;	.;	.;	.;	.;	.;	1.704392	0.25153	17.06	2.236861	0.37933	21.7	0.99642758842342982	0.76756	0.96065	0.67374	D	AEFBI	0.597703	0.59138	D	-0.161096576961547	0.34763	1.988287	-0.0320629953719188	0.38274	2.252724	0.999999798343653	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	4.77	0.60425	2.221000	0.42559	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.168000	0.20914	0.0744:0.0:0.9256:0.0	13.9011	0.63308	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091322	C	A	A	S	.	16	31102643	16	31010144	102	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.304G>T	p.A102S	c.304G>T	p.Ala102Ser	c.304G>T	p.Ala102Ser	principal1	Y	1	YES	-	GCC	1	0	C	C/C	C/C	C/C	C/C	0.054	0.38633	T	0.102	0.38450	T	0.294	0.32391	B	0.123	0.32463	B	0.001273	0.39594	N	0.169796	0.999026;0.999026;0.998286;0.969146;0.999026;0.999026	0.45899	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	G122V;G129V;G65V;A102S;G133V;G134V	.	.	.	-4.78	0.98140	D	-1.51	0.36787	N	0.129	0.12341	1.0545	0.98215	D	0.9444	0.98180	D	9	0.4385173	0.57950	T	0.462001	0.94530	D	0.403	0.71636	0.623;	0.75803	Q9BQB6;	A102S;	Loss of methylation at R100 (P = 0.1104);	0.956455797992	0.95599	0.6387739642508903	0.63811	0.415885500396	0.42230	0.372487187386	0.21188	T	0.638951	0.88904	D	0.122662	0.66638	D	-0.0615806	0.66221	T	0.872174024581909	0.52205	D	0.655434	0.26547	T	0.39076945	0.60086	0.15034565	0.35461	0.39076945	0.60087	0.15034565	0.35460	-2.754	0.16113	T	0.3066160613538081	0.40430	U	U	U	U	U	U	U	B	B	B	B	0.1175	0.23918	B	.;	.;	.;	.;	.;	.;	1.533964	0.22401	15.95	1.987166	0.32697	19.63	0.99451571511017445	0.65325	0.70793	0.34739	D	AEFBI	0.314788	0.41955	N	0.339530203544479	0.58188	3.989781	0.310542607842477	0.56158	3.778844	0.999956196435989	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	3.72	0.41857	2.290000	0.43193	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.193000	0.21690	0.1429:0.7826:0.0:0.0744	9.74	0.39580	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091322	C	G	A	P	.	16	31102643	16	31010144	102	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.304G>C	p.A102P	c.304G>C	p.Ala102Pro	c.304G>C	p.Ala102Pro	principal1	Y	1	YES	-	GCC	1	0	C	C/C	C/C	C/C	C/C	0.065	0.36310	T	0.076	0.42614	T	0.99	0.63424	D	0.845	0.60432	P	0.001273	0.39594	N	0.169796	0.996074;0.982848;0.982848;0.990186;0.982848;0.982848	0.43003	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	A102P;G122A;G129A;G65A;G133A;G134A	.	.	.	-4.76	0.98111	D	-2.67	0.57110	D	0.635	0.64818	0.7589	0.93905	D	0.9438	0.98160	D	9	0.9447342	0.93798	D	0.323018	0.91530	D	0.822	0.94315	0.798;	0.91802	Q9BQB6;	A102P;	Loss of helix (P = 0.0304);	0.987083769558	0.98694	0.9416532286617201	0.94146	1.23315952786	0.81401	0.421161413193	0.27996	T	0.813695	0.95371	D	0.36791	0.87870	D	0.290701	0.87716	D	0.952493488788605	0.63804	D	0.748825	0.36981	T	0.9428932	0.95542	0.7991708	0.88217	0.9428932	0.95542	0.7991708	0.88218	-4.659	0.58755	T	0.3061681927664547	0.40383	U	U	U	U	U	U	U	B	B	B	B	0.2212	0.45211	B	.;	.;	.;	.;	.;	.;	2.905556	0.49995	23.2	3.248996	0.60724	24.2	0.99701563677335636	0.80660	0.92487	0.55826	D	AEFBI	0.668137	0.63602	D	0.366731368698404	0.59628	4.143851	0.325139819839772	0.57021	3.866623	0.999956196435989	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	3.72	0.41857	2.290000	0.43193	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.193000	0.21690	0.1429:0.7826:0.0:0.0744	9.74	0.39580	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091322	C	T	A	T	.	16	31102643	16	31010144	102	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.304G>A	p.A102T	c.304G>A	p.Ala102Thr	c.304G>A	p.Ala102Thr	principal1	Y	1	YES	-	GCC	1	0	C	C/C	C/C	C/C	C/C	0.006	0.61437	D	0.169	0.30534	T	0.294	0.32391	B	0.123	0.32463	B	0.001273	0.39594	N	0.169796	0.984858;0.945741;0.945741;0.968444;0.945741;0.945741	0.40202	D;N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	A102T;G122D;G129D;G65D;G133D;G134D	.	.	.	-4.65	0.97938	D	-2.1	0.47852	N	0.09	0.06854	0.7783	0.94143	D	0.9417	0.98088	D	9	0.37691587	0.53902	T	0.247959	0.88990	D	0.476	0.76816	0.627;	0.76254	Q9BQB6;	A102T;	Loss of methylation at R100 (P = 0.118);	0.971868574619	0.97156	0.7097538694747753	0.70917	0.405011907542	0.41392	0.390198796988	0.23698	T	0.57849	0.86159	D	0.151106	0.69371	D	-0.0207227	0.68981	D	0.854859054088593	0.50589	D	0.706729	0.31713	T	0.41558424	0.61797	0.23668653	0.48947	0.41558424	0.61797	0.23668653	0.48946	-4.093	0.46692	T	0.21741588882653745	0.29261	U	U	U	U	U	B	B	B	B	B	B	0.1325	0.28636	B	.;	.;	.;	.;	.;	.;	2.211636	0.34951	21.0	2.611415	0.46169	22.8	0.99750762208041988	0.84228	0.66293	0.33028	D	AEFBI	0.317646	0.42158	N	0.314214337084195	0.56877	3.853277	0.292031587572712	0.55074	3.670762	0.999956196435989	0.48110	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	3.72	0.41857	2.290000	0.43193	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.193000	0.21690	0.1429:0.7826:0.0:0.0744	9.74	0.39580	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091324	C	A	W	L	.	16	31102645	16	31010146	101	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.302G>T	p.W101L	c.302G>T	p.Trp101Leu	c.302G>T	p.Trp101Leu	principal1	Y	1	YES	-	TGG	2	0	C	C/C	C/C	C/C	C/C	0.746	0.03631	T	0.662	0.06469	T	0.068	0.23728	B	0.05	0.25278	B	0.000533	0.43581	D	0.107337	0.952867;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	W101L;.;.;.;.;.	.	.	.	-4.71	0.98035	D	-1.22	0.30964	N	0.504	0.53620	0.5352	0.91034	D	0.8369	0.94543	D	8	0.72941303	0.74195	D	0.821674	0.98613	D	0.466	0.76156	0.586;	0.71371	Q9BQB6;	W101L;	Gain of methylation at R98 (P = 0.0379);	0.990384852959	0.99027	0.6042991159023416	0.60360	1.5806642636	0.88385	0.57511973381	0.49399	T	0.599194	0.87130	D	0.178713	0.71925	D	0.0189326	0.71562	D	0.962974548339844	0.66523	D	0.816718	0.47282	T	0.29021263	0.52012	0.1616191	0.37583	0.29021263	0.52012	0.1616191	0.37582	-4.726	0.59903	T	0.08167731514630372	0.04241	B	B	B	B	B	B	B	B	B	B	B	0.1916	0.41094	B	.;	.;	.;	.;	.;	.;	1.972804	0.30063	19.05	2.479728	0.43275	22.5	0.97416074284632703	0.33850	0.97630	0.76021	D	AEFBI	0.865971	0.78525	D	0.0559465480167467	0.44416	2.716119	0.216141774591707	0.50743	3.263123	0.999999858121823	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	5.71	0.89031	4.523000	0.60261	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.216000	0.22352	0.1469:0.8531:0.0:0.0	14.5629	0.67745	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091324	C	G	W	S	.	16	31102645	16	31010146	101	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.302G>C	p.W101S	c.302G>C	p.Trp101Ser	c.302G>C	p.Trp101Ser	principal1	Y	1	YES	-	TGG	2	0	C	C/C	C/C	C/C	C/C	0.899	0.02430	T	0.429	0.13752	T	0.979	0.59044	D	0.871	0.61869	P	0.000533	0.43581	D	0.107337	0.999989;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	W101S;.;.;.;.;.	.	.	.	-4.79	0.98155	D	-1.16	0.29727	N	0.565	0.58883	0.9472	0.96353	D	0.9351	0.97863	D	9	0.87150526	0.86419	D	0.714262	0.97680	D	0.704	0.89376	0.617;	0.75116	Q9BQB6;	W101S;	Gain of methylation at R98 (P = 0.0421);	0.9984055776	0.99839	0.69712227794503	0.69653	1.5059257103	0.87137	0.564784705639	0.47942	T	0.635088	0.88739	D	0.282153	0.81499	D	0.167517	0.81262	D	0.972962021827698	0.69906	D	0.744526	0.36463	T	0.44626144	0.63804	0.29593736	0.55626	0.44626144	0.63805	0.29593736	0.55625	-2.754	0.16113	T	0.1156636359470136	0.10373	U	B	B	B	B	B	B	B	B	B	B	0.1906	0.40937	B	.;	.;	.;	.;	.;	.;	2.706519	0.45735	22.8	3.124652	0.57640	23.9	0.9803438547194836	0.37735	0.96613	0.70021	D	AEFBI	0.734934	0.68091	D	0.51475676892935	0.67962	5.152157	0.531099766962875	0.70093	5.454808	0.999999858121823	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	5.71	0.89031	4.523000	0.60261	.	.	0.590000	0.31872	1.000000	0.71638	1.000000	0.68203	0.216000	0.22352	0.1469:0.8531:0.0:0.0	14.5629	0.67745	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31091336	A	G	L	P	.	16	31102657	16	31010158	97	VKORC1	ENSG00000167397	ENST00000394975	ENSP00000378426	Q9BQB6	VKOR1_HUMAN	c.290T>C	p.L97P	c.290T>C	p.Leu97Pro	c.290T>C	p.Leu97Pro	principal1	Y	1	YES	-	CTG	2	0	A	A/A	A/A	A/A	A/A	0.173	0.22573	T	0.204	0.27235	T	0.979	0.59044	D	0.602	0.50862	P	0.450975	0.12507	N	0.727512	0.999918;0.999997;0.999997;0.999997;0.999997;0.999997	0.19599	N;N;N;N;N;N	simple_aae;without_aae;without_aae;without_aae;without_aae;without_aae	L97P;.;.;.;.;.	.	.	.	-4.68	0.97989	D	-1.35	0.33598	N	0.408	0.44857	0.4610	0.89992	D	0.8626	0.95428	D	8	0.61511946	0.67662	D	0.473378	0.94718	D	0.592	0.83747	0.595;	0.72494	Q9BQB6;	L97P;	Loss of helix (P = 0.0068);	0.99148313337	0.99139	0.8249376661010536	0.82451	1.44073316277	0.85972	0.543370127678	0.44922	T	0.611177	0.87679	D	0.289059	0.82078	D	0.177437	0.81847	D	0.934950113296509	0.60279	D	0.464354	0.13557	T	0.4162608	0.61842	0.18192725	0.41087	0.4162608	0.61843	0.18192725	0.41086	-4.659	0.58755	T	0.13093528288083098	0.13822	U	U	B	B	B	B	B	B	B	B	B	0.2825	0.51532	B	.;	.;	.;	.;	.;	.;	2.809050	0.47934	23.0	2.760511	0.49433	23.1	0.9969073482239571	0.79909	0.12747	0.17455	N	AEFBI	0.178167	0.30543	N	0.118375235980155	0.47320	2.959393	0.0826328583646011	0.43676	2.664425	0.996423544263545	0.34736	0.706548	0.73137	0	0.724815	0.89359	0	0.702456	0.68683	0	0.714379	0.83352	0	.	.	5.71	3.4	0.38031	0.814000	0.26897	.	.	0.743000	0.86499	0.339000	0.25666	0.999000	0.35428	0.581000	0.30918	0.5358:0.0:0.1428:0.3214	2.9656	0.05546	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	VKCFD2	.	Q9BQB6	VKOR1_HUMAN	79001	CCDS10703;CCDS10704	NM_024006;NM_001311311	uc002eas.4	608547	608547	vitamin K epoxide reductase complex subunit 1	.	.	.	Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Warfarin Pathway, Pharmacodynamics;Aminocaproic Acid Action Pathway;Tranexamic Acid Action Pathway;Urokinase Action Pathway;Reteplase Action Pathway;Streptokinase Action Pathway;Tenecteplase Action Pathway;Alteplase Action Pathway;Anistreplase Action Pathway;Aprotinin Action Pathway;Phenindione Action Pathway;Dicoumarol Action Pathway;Warfarin Action Pathway;Acenocoumarol Action Pathway;Vitamin K Metabolism;Coagulation ;Bivalirudin Action Pathway;Argatroban Action Pathway;Ardeparin Action Pathway;Heparin Action Pathway;Fondaparinux Action Pathway;Enoxaparin Action Pathway;Phenprocoumon Action Pathway;Dicumarol Action Pathway;Ximelagatran Action Pathway;Lepirudin Action Pathway;Metabolism of fat-soluble vitamins;Metabolism;Metabolism of vitamins and cofactors;Metabolism of vitamin K	hsa00100	Biosynthesis of steroids	FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195, ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.; 	DISEASE: Combined deficiency of vitamin K-dependent clotting factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:16270630}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti- coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement. {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:20946155}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	122700;607473;	[MIM:607473]Combined deficiency of vitamin K-dependent clotting factors 2;[MIM:122700]Coumarin resistance;	413674;413684;98434	Vitamin K antagonists toxicity or dose selection;Resistance to vitamin K antagonists;Hereditary combined deficiency of vitamin K-dependent clotting factors	Biomarker tested in;Biomarker tested in;Disease-causing germline mutation(s) in	Warfarin maintenance dose[20833655;18535201;19300499;26265036];	HP:0001871;HP:0001939;HP:0000006;HP:0001892;HP:0000007;HP:0011858;HP:0008321;HP:0008169;HP:0040250	Abnormality of blood and blood-forming tissues;Abnormality of metabolism/homeostasis;Autosomal dominant inheritance;Abnormal bleeding;Autosomal recessive inheritance;Reduced factor IX activity;Reduced factor X activity;Reduced factor VII activity;Reduced prothrombin antigen	blood coagulation;response to organonitrogen compound;response to organic cyclic compound;drug metabolic process;peptidyl-glutamic acid carboxylation;regulation of blood coagulation;vitamin K metabolic process;response to antibiotic;oxidation-reduction process;bone development	endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane	vitamin-K-epoxide reductase (warfarin-sensitive) activity;vitamin-K-epoxide reductase (warfarin-insensitive) activity;quinone binding	Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas. {ECO:0000269|PubMed:14765194}.;	pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;pancreas;skeletal muscle;trophoblast;islets of Langerhans;visual apparatus;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;amnion;intestine;tongue;alveolus;skin;smooth muscle;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;head and neck;mammary gland;pineal body;cartilage;endometrium;bone;parathyroid;brain;ciliary body;blood;duodenum;ovary;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	thyroid;liver;adipose tissue;heart;	18	94	1237	0.17686	0.139342904090881	N	0.457964957	.	.	0.19	66.57	0.7559028	0.844696844	88.29588579	0.0818030758329219	0.756312664876125	0.161884259290953	0.0740832824797881	0.745856683564723	0.180060033955489	0.0760505292416963	0.725719953206779	0.198229517551525	5.4723e-04	7.1478e-01	2.8468e-01	0.399298248823966	0.399769465855976	0.548290021659949	N	5.70432	0.21368	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	Medium	.	0.0	0.0	0.0	0.0	0.011182108626198083	3.9936102236421724E-4	0.004792332268370607	3.9936102236421724E-4	N	N	N	N	0.979261817039582	E	Vkorc1	homeostasis/metabolism phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	.	.	.	.
16	31093323	T	C	Q	R	.	16	31104644	16	31012145	91;91;91	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.272A>G;c.272A>G;c.272A>G	p.Q91R;p.Q91R;p.Q91R	c.272A>G;c.272A>G;c.272A>G	p.Gln91Arg;p.Gln91Arg;p.Gln91Arg	c.272A>G;c.272A>G;c.272A>G	p.Gln91Arg;p.Gln91Arg;p.Gln91Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAG;CAG;CAG	2;2;2	0;0;0	T	T/T	T/T	T/T	T/T	0.355;0.147;0.005	0.63226	T;T;D	0.036;0.036;0.025	0.56192	D;D;D	.;0.996;0.997	0.70673	.;D;D	.;0.986;0.992	0.80445	.;D;D	0.000011	0.62929	D	0.000000	0.995292;0.995292;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	Q91R;Q91R;.;.;.;.	.;2.705;2.705	0.79137	.;M;M	-4.72;-4.72;-4.72	0.98051	D;D;D	-2.7;-2.72;-3.04	0.62863	D;D;D	.;0.765;0.741	0.76296	1.1306	0.99925	D	0.9511	0.98409	D	10	0.8824024;0.8824024;0.8824024	0.87555	D;D;D	0.093349	0.76057	D	0.798;0.798;0.798	0.93385	0.786;0.786;0.786;	0.90919	Q9BQB6;Q9BQB6;Q9BQB6;	Q91R;Q91R;Q91R;	Gain of methylation at Q91 (P = 0.0101);Gain of methylation at Q91 (P = 0.0101);Gain of methylation at Q91 (P = 0.0101);	0.853893600655;0.853893600655;0.853893600655	0.85248	.;.;0.9166490649894502	0.91639	.;.;1.17859640205	0.79955	0.561985969543	0.47547	T	.;.;0.899651	0.98022	.;.;D	0.389241	0.89284	D	0.321342	0.89150	D	0.985655426979065	0.76584	D	0.953805;0.915608;0.927007	0.82399	D;D;D	.;.;0.96607256	0.97884	.;.;0.87226886	0.93022	.;.;0.96607256	0.97884	.;.;0.87226886	0.93023	.;-3.938;-3.776	0.42755	.;T;T	.;.;0.5731619145852148	0.64023	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	0.8398;0.6603;0.8186	0.79230	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.146176	0.83688	28.2	4.131666	0.86544	28.9	0.99825565707480413	0.90764	0.91598	0.53864	D	ALL	0.873430	0.79579	D	0.732442891085708	0.81758	7.598011	0.727371592270405	0.84457	8.297184	0.999999999999992	0.74766	0.72623	0.87236	0	0.504199	0.08210	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.196000	0.58203	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.960000	0.51673	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093332	T	G	Y	S	.	16	31104653	16	31012154	88;88;88	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.263A>C;c.263A>C;c.263A>C	p.Y88S;p.Y88S;p.Y88S	c.263A>C;c.263A>C;c.263A>C	p.Tyr88Ser;p.Tyr88Ser;p.Tyr88Ser	c.263A>C;c.263A>C;c.263A>C	p.Tyr88Ser;p.Tyr88Ser;p.Tyr88Ser	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TAC;TAC;TAC	2;2;2	0;0;0	T	T/T	T/T	T/T	T/T	0.164;0.026;0.0	0.91255	T;D;D	0.012;0.014;0.001	0.83351	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.998;0.999	0.92359	.;D;D	0.000021	0.62929	D	0.000000	0.999947;0.999947;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	Y88S;Y88S;.;.;.;.	.;2.965;2.965	0.85198	.;M;M	-5.51;-5.51;-5.51	0.99156	D;D;D	-6.42;-7.75;-7.73	0.95789	D;D;D	.;0.91;0.833	0.91162	1.1524	0.99947	D	0.9779	0.99316	D	10	0.9186821;0.9186821;0.9186821	0.91225	D;D;D	0.11837	0.79840	D	0.824;0.824;0.824	0.94390	0.742;0.742;0.742;	0.87401	Q9BQB6;Q9BQB6;Q9BQB6;	Y88S;Y88S;Y88S;	Loss of stability (P = 0.1676);Loss of stability (P = 0.1676);Loss of stability (P = 0.1676);	0.887824502181;0.887824502181;0.887824502181	0.88672	.;.;0.9711881039855219	0.97107	.;.;1.29207387054	0.82819	0.685018777847	0.64990	T	.;.;0.964009	0.99556	.;.;D	0.529921	0.95167	D	0.523418	0.95095	D	0.976727216873264	0.71511	D	0.973403;0.974203;0.90311	0.90777	D;D;D	.;.;0.9959352	0.99980	.;.;0.98800474	0.99962	.;.;0.9959352	0.99980	.;.;0.98800474	0.99962	.;-3.704;-2.754	0.36822	.;T;T	.;.;0.6217629267735303	0.69021	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	.;.;P	0.8453;0.8167;0.8569	0.80139	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.470399	0.90963	32	4.284946	0.89805	31	0.99219285450595429	0.55839	0.92573	0.56029	D	AEFDGBHCI	0.895337	0.83524	D	0.846131263875068	0.88885	9.750506	0.816634649146105	0.90927	10.63417	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.807000	0.68825	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093333	A	C	Y	D	.	16	31104654	16	31012155	88;88;88	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.262T>G;c.262T>G;c.262T>G	p.Y88D;p.Y88D;p.Y88D	c.262T>G;c.262T>G;c.262T>G	p.Tyr88Asp;p.Tyr88Asp;p.Tyr88Asp	c.262T>G;c.262T>G;c.262T>G	p.Tyr88Asp;p.Tyr88Asp;p.Tyr88Asp	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TAC;TAC;TAC	1;1;1	0;0;0	A	A/A	A/A	A/A	A/A	0.359;0.095;0.0	0.91255	T;T;D	0.005;0.011;0.0	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.998;0.999	0.92359	.;D;D	0.000021	0.62929	D	0.000000	0.999959;0.999959;1;0.6306;0.6306;0.6306	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	Y88D;Y88D;.;L108R;L119R;L120R	.;2.965;2.965	0.85198	.;M;M	-5.52;-5.52;-5.52	0.99165	D;D;D	-7.32;-8.44;-8.64	0.97530	D;D;D	.;0.882;0.813	0.88027	1.1536	0.99948	D	0.9787	0.99342	D	10	0.9480189;0.9480189;0.9480189	0.94131	D;D;D	0.19354	0.86310	D	0.864;0.864;0.864	0.95876	0.785;0.785;0.785;	0.90844	Q9BQB6;Q9BQB6;Q9BQB6;	Y88D;Y88D;Y88D;	Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);	0.88952062576;0.88952062576;0.88952062576	0.88843	.;.;0.989223917653841	0.98916	.;.;1.48240043888	0.86736	0.726720094681	0.71027	T	.;.;0.963807	0.99552	.;.;D	0.220624	0.75835	D	0.0791347	0.75520	D	0.99906200170517	0.96056	D	0.959304;0.960504;0.861914	0.85148	D;D;D	.;.;0.9959778	0.99981	.;.;0.99092495	0.99984	.;.;0.9959778	0.99981	.;.;0.99092495	0.99985	.;-4.729;-0.64	0.59955	.;T;T	.;.;0.8497219928618727	0.91620	.;.;U	.;.;U	.;.;U	.;.;P	.;.;P	.;.;P	.;.;P	.;.;P	.;.;P	.;.;P	.;.;P	0.9679;0.9253;0.942	0.89111	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.432834	0.90540	31	4.356587	0.90716	31	0.99409824177954587	0.63216	0.94384	0.60994	D	AEFDGBHCI	0.956952	0.97582	D	0.910838870704705	0.92281	11.33388	0.87752444780755	0.94517	12.82295	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.924000	0.63118	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	1.000000	0.97212	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093334	G	C	F	L	.	16	31104655	16	31012156	87;87;87	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.261C>G;c.261C>G;c.261C>G	p.F87L;p.F87L;p.F87L	c.261C>G;c.261C>G;c.261C>G	p.Phe87Leu;p.Phe87Leu;p.Phe87Leu	c.261C>G;c.261C>G;c.261C>G	p.Phe87Leu;p.Phe87Leu;p.Phe87Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	3;3;3	2;2;2	G	G/G	G/G	G/G	G/G	0.241;0.017;0.006	0.61437	T;D;D	0.087;0.016;0.005	0.72224	T;D;D	.;0.998;0.999	0.77913	.;D;D	.;0.987;0.992	0.80445	.;D;D	0.000002	0.62929	D	0.000000	0.999502;0.999502;1;0.991546;0.991546;0.991546	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	F87L;F87L;.;L108V;L119V;L120V	.;2.92;2.92	0.84325	.;M;M	-4.74;-4.74;-4.74	0.98081	D;D;D	-4.09;-5.09;-5.2	0.83695	D;D;D	.;0.762;0.699	0.76019	0.7407	0.93679	D	0.9158	0.97210	D	10	0.756426;0.756426;0.756426	0.76017	D;D;D	0.259765	0.89459	D	0.685;0.685;0.685	0.88490	0.591;0.591;0.591;	0.71999	Q9BQB6;Q9BQB6;Q9BQB6;	F87L;F87L;F87L;	Gain of catalytic residue at F87 (P = 0.0756);Gain of catalytic residue at F87 (P = 0.0756);Gain of catalytic residue at F87 (P = 0.0756);	0.813716657062;0.813716657062;0.813716657062	0.81196	.;.;0.9081570326483409	0.90788	.;.;1.21149271969	0.80847	0.723114073277	0.70500	T	.;.;0.850285	0.96587	.;.;D	0.368568	0.87928	D	0.291646	0.87774	D	0.995601534843445	0.87730	D	0.959504;0.958704;0.873013	0.84742	D;D;D	.;.;0.94521177	0.95778	.;.;0.87452525	0.93180	.;.;0.94521177	0.95779	.;.;0.87452525	0.93180	.;0.0;-4.726	0.59903	.;T;T	.;.;0.3497431994818746	0.44703	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	0.9814;0.9798;0.9797	0.91427	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.233422	0.86467	29.0	4.540044	0.92003	32	0.99881190542737353	0.95733	0.86733	0.46077	D	AEFDGBHCI	0.709576	0.66362	D	0.528486326366137	0.68780	5.26473	0.587518378910036	0.74043	6.070606	0.999999999999694	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	2.744000	0.47126	.	.	0.676000	0.76740	1.000000	0.71638	1.000000	0.68203	1.000000	0.97212	0.0738:0.0:0.9262:0.0	13.5813	0.61370	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093334	G	T	F	L	rs1385518753	16	31104655	16	31012156	87;87;87	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.261C>A;c.261C>A;c.261C>A	p.F87L;p.F87L;p.F87L	c.261C>A;c.261C>A;c.261C>A	p.Phe87Leu;p.Phe87Leu;p.Phe87Leu	c.261C>A;c.261C>A;c.261C>A	p.Phe87Leu;p.Phe87Leu;p.Phe87Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	3;3;3	2;2;2	G	G/G	G/G	G/G	G/G	0.241;0.017;0.006	0.61437	T;D;D	0.087;0.016;0.005	0.72224	T;D;D	.;0.998;0.999	0.77913	.;D;D	.;0.987;0.992	0.80445	.;D;D	0.000002	0.62929	D	0.000000	0.999553;0.999553;1;0.994753;0.994753;0.994753	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	F87L;F87L;.;L108I;L119I;L120I	.;2.92;2.92	0.84325	.;M;M	-4.74;-4.74;-4.74	0.98081	D;D;D	-4.09;-5.09;-5.2	0.83695	D;D;D	.;0.762;0.699	0.76019	0.7003	0.93179	D	0.9109	0.97046	D	10	0.7526405;0.7526405;0.7526405	0.75750	D;D;D	0.291365	0.90575	D	0.684;0.684;0.684	0.88443	0.591;0.591;0.591;	0.71999	Q9BQB6;Q9BQB6;Q9BQB6;	F87L;F87L;F87L;	Gain of catalytic residue at F87 (P = 0.0756);Gain of catalytic residue at F87 (P = 0.0756);Gain of catalytic residue at F87 (P = 0.0756);	0.807866681576;0.807866681576;0.807866681576	0.80606	.;.;0.9081570464193754	0.90788	.;.;1.21149271969	0.80847	0.723114073277	0.70500	T	.;.;0.850285	0.96587	.;.;D	0.301139	0.83061	D	0.291643	0.87774	D	0.977973282337189	0.72100	D	0.959504;0.958704;0.873013	0.84742	D;D;D	.;.;0.94521177	0.95778	.;.;0.87452525	0.93180	.;.;0.94521177	0.95779	.;.;0.87452525	0.93180	.;0.0;-4.726	0.59903	.;T;T	.;.;0.3497431994818746	0.44703	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	0.9814;0.9798;0.9797	0.91427	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.390821	0.89960	31	4.738423	0.92664	32	0.99882141921328993	0.95813	0.85800	0.44973	D	AEFDGBHCI	0.701277	0.65802	D	0.502033190487334	0.67208	5.051365	0.56491604017836	0.72443	5.810384	0.999999999999694	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	2.744000	0.47126	.	.	0.676000	0.76740	1.000000	0.71638	1.000000	0.68203	1.000000	0.97212	0.0738:0.0:0.9262:0.0	13.5813	0.61370	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	250966	3.984600e-06	0	0	16250	0.000000e+00	0	0	34592	0.000000e+00	0	0	10076	0.000000e+00	0	0	18390	0.000000e+00	0	0	21562	0.000000e+00	0	0	113350	0.000000e+00	0	1	30616	3.266270e-05	0	1	30616	3.266270e-05	0	1	109298	9.149300e-06	0	1	207714	4.814310e-06	0	1	236454	4.229150e-06	0	1	244348	4.092520e-06	0	0	7158	0.000000e+00	0	0	17112	0.000000e+00	0	0	2320	0.000000e+00	0	0	9042	0.000000e+00	0	0	13308	0.000000e+00	0	0	42760	0.000000e+00	0	1	15690	6.373490e-05	0	1	15690	6.373490e-05	0	0	16212	0.000000e+00	0	0	30524	0.000000e+00	0	0	6210	0.000000e+00	0	0	13412	0.000000e+00	0	0	16648	0.000000e+00	0	0	89240	0.000000e+00	0	1	30608	3.267120e-05	0	1	30608	3.267120e-05	0	0	14896	0.000000e+00	0	0	34260	0.000000e+00	0	0	9568	0.000000e+00	0	0	17688	0.000000e+00	0	0	21546	0.000000e+00	0	0	102360	0.000000e+00	0	1	30526	3.275900e-05	0	1	30526	3.275900e-05	0	0	12020	0.000000e+00	0	0	34458	0.000000e+00	0	0	9994	0.000000e+00	0	0	18386	0.000000e+00	0	0	21560	0.000000e+00	0	0	111260	0.000000e+00	0	1	30616	3.266270e-05	0	1	30616	3.266270e-05	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093336	A	C	F	V	.	16	31104657	16	31012158	87;87;87	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.259T>G;c.259T>G;c.259T>G	p.F87V;p.F87V;p.F87V	c.259T>G;c.259T>G;c.259T>G	p.Phe87Val;p.Phe87Val;p.Phe87Val	c.259T>G;c.259T>G;c.259T>G	p.Phe87Val;p.Phe87Val;p.Phe87Val	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	1;1;1	0;0;0	A	A/A	A/A	A/A	A/A	0.179;0.036;0.053	0.43393	T;D;T	0.031;0.01;0.002	0.79402	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.996;0.998	0.88582	.;D;D	0.000002	0.62929	D	0.000000	0.999941;0.999941;1;0.6306;0.6306;0.6306	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	F87V;F87V;.;L107R;L118R;L119R	.;2.575;2.575	0.75298	.;M;M	-4.76;-4.76;-4.76	0.98111	D;D;D	-4.87;-5.72;-5.97	0.89272	D;D;D	.;0.73;0.702	0.73105	1.1569	0.99950	D	0.9555	0.98558	D	10	0.8178027;0.8178027;0.8178027	0.81005	D;D;D	0.117461	0.79724	D	0.828;0.828;0.828	0.94541	0.589;0.589;0.589;	0.71749	Q9BQB6;Q9BQB6;Q9BQB6;	F87V;F87V;F87V;	Gain of catalytic residue at F87 (P = 0.0707);Gain of catalytic residue at F87 (P = 0.0707);Gain of catalytic residue at F87 (P = 0.0707);	0.853130570847;0.853130570847;0.853130570847	0.85171	.;.;0.9224945386142974	0.92226	.;.;1.32832619183	0.83597	0.680807232857	0.64385	T	.;.;0.899276	0.98012	.;.;D	0.382183	0.88848	D	0.311203	0.88708	D	0.995389103889465	0.87327	D	0.957404;0.956938;0.867913	0.83962	D;D;D	.;.;0.93048865	0.94286	.;.;0.86706674	0.92664	.;.;0.93048865	0.94286	.;.;0.86706674	0.92664	.;-3.811;-4.523	0.56265	.;T;T	.;.;0.3568639267483428	0.45364	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	0.7997;0.768;0.8313	0.78797	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.323376	0.88744	29.8	4.263890	0.89482	29.9	0.99221063149534827	0.55901	0.94384	0.60994	D	ALL	0.955621	0.97359	D	0.660324234342563	0.77039	6.598495	0.704878887287553	0.82748	7.844843	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.924000	0.63118	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093336	A	G	F	L	.	16	31104657	16	31012158	87;87;87	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.259T>C;c.259T>C;c.259T>C	p.F87L;p.F87L;p.F87L	c.259T>C;c.259T>C;c.259T>C	p.Phe87Leu;p.Phe87Leu;p.Phe87Leu	c.259T>C;c.259T>C;c.259T>C	p.Phe87Leu;p.Phe87Leu;p.Phe87Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	1;1;1	0;0;0	A	A/A	A/A	A/A	A/A	0.241;0.017;0.006	0.61437	T;D;D	0.087;0.016;0.005	0.72224	T;D;D	.;0.998;0.999	0.77913	.;D;D	.;0.987;0.992	0.80445	.;D;D	0.000002	0.62929	D	0.000000	0.999958;0.999885;0.999885;0.999958;0.999958;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;without_aae	L107P;F87L;F87L;L118P;L119P;.	.;2.92;2.92	0.84325	.;M;M	-4.74;-4.74;-4.74	0.98081	D;D;D	-4.09;-5.09;-5.2	0.83695	D;D;D	.;0.762;0.699	0.76019	1.0614	0.98374	D	0.9480	0.98304	D	10	0.8055999;0.8055999;0.8055999	0.79903	D;D;D	0.256082	0.89316	D	0.824;0.824;0.824	0.94390	0.591;0.591;0.591;	0.71999	Q9BQB6;Q9BQB6;Q9BQB6;	F87L;F87L;F87L;	Gain of catalytic residue at F87 (P = 0.0756);Gain of catalytic residue at F87 (P = 0.0756);Gain of catalytic residue at F87 (P = 0.0756);	0.823294612019;0.823294612019;0.823294612019	0.82162	.;.;0.9081570601904099	0.90788	.;.;1.21149271969	0.80847	0.723114073277	0.70500	T	.;.;0.850285	0.96587	.;.;D	0.377382	0.88538	D	0.304306	0.88394	D	0.998378992080688	0.93972	D	0.959504;0.958704;0.873013	0.84742	D;D;D	.;.;0.9360849	0.94849	.;.;0.9060308	0.95406	.;.;0.9360849	0.94849	.;.;0.9060308	0.95407	.;0.0;-4.726	0.59903	.;T;T	.;.;0.3497431994818746	0.44703	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	0.9814;0.9798;0.9797	0.91427	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.438802	0.90612	31	4.381375	0.90962	31	0.9987507916622882	0.95244	0.94089	0.60079	D	ALL	0.979914	0.99825	D	0.588130936055672	0.72432	5.805034	0.651162673237782	0.78697	6.928636	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.924000	0.63118	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093339	T	A	I	F	.	16	31104660	16	31012161	86;86;86	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.256A>T;c.256A>T;c.256A>T	p.I86F;p.I86F;p.I86F	c.256A>T;c.256A>T;c.256A>T	p.Ile86Phe;p.Ile86Phe;p.Ile86Phe	c.256A>T;c.256A>T;c.256A>T	p.Ile86Phe;p.Ile86Phe;p.Ile86Phe	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	ATC;ATC;ATC	1;1;1	0;0;0	T	T/T	T/T	T/T	T/T	0.074;0.226;0.041	0.41915	T;T;D	0.205;0.397;0.244	0.27145	T;T;T	.;0.97;0.379	0.56973	.;D;B	.;0.51;0.255	0.47925	.;P;B	0.040865	0.24011	N	0.389237	0.974905;0.974905;1;0.998409;0.998409;0.998409	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	I86F;I86F;.;H106L;H117L;H118L	.;1.38;1.38	0.34346	.;L;L	-4.73;-4.73;-4.73	0.98066	D;D;D	-2.61;-2.1;-2.4	0.56144	D;N;N	.;0.613;0.628	0.64223	0.2991	0.87545	D	0.8223	0.94026	D	10	0.3337291;0.3337291;0.3337291	0.50558	T;T;T	0.237594	0.88551	D	0.611;0.611;0.611	0.84773	0.37;0.37;0.37;	0.38013	Q9BQB6;Q9BQB6;Q9BQB6;	I86F;I86F;I86F;	Loss of helix (P = 0.1299);Loss of helix (P = 0.1299);Loss of helix (P = 0.1299);	0.600719443016;0.600719443016;0.600719443016	0.59754	.;.;0.7571162577996041	0.75659	.;.;1.04843531002	0.76047	0.5677921772	0.48365	T	.;.;0.662373	0.89884	.;.;D	0.133243	0.67676	D	-0.0463828	0.67269	D	0.865565240383148	0.51567	D	0.89741;0.89741;0.859914	0.64114	D;D;D	.;.;0.42995232	0.62749	.;.;0.29495737	0.55527	.;.;0.42995232	0.62750	.;.;0.29495737	0.55526	.;-5.207;-5.86	0.72623	.;T;T	.;.;0.16608465487055013	0.20629	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.2207;0.2678;0.1905	0.50213	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	2.793533	0.47599	23.0	2.237452	0.37956	21.7	0.962955604795114	0.29328	0.68629	0.33875	D	ALL	0.443880	0.50101	N	-0.277985825420284	0.30000	1.668779	-0.187539421247795	0.31994	1.815899	0.999999998098237	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	2.47	0.29113	0.684000	0.25043	.	.	-0.147000	0.12262	1.000000	0.71638	0.997000	0.33255	0.996000	0.76049	0.0:0.0713:0.5256:0.4031	9.0015	0.35247	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093339	T	G	I	L	.	16	31104660	16	31012161	86;86;86	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.256A>C;c.256A>C;c.256A>C	p.I86L;p.I86L;p.I86L	c.256A>C;c.256A>C;c.256A>C	p.Ile86Leu;p.Ile86Leu;p.Ile86Leu	c.256A>C;c.256A>C;c.256A>C	p.Ile86Leu;p.Ile86Leu;p.Ile86Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	ATC;ATC;ATC	1;1;1	0;0;0	T	T/T	T/T	T/T	T/T	0.444;0.465;0.255	0.16848	T;T;T	0.438;0.333;0.31	0.19721	T;T;T	.;0.012;0.001	0.16265	.;B;B	.;0.004;0.003	0.10090	.;B;B	0.040865	0.24011	N	0.389237	1;0.998482;0.698086;0.698086;0.998482;0.998482	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;H106P;I86L;I86L;H117P;H118P	.;1.585;1.585	0.39878	.;L;L	-4.57;-4.57;-4.57	0.97792	D;D;D	-1.09;-0.88;-1.03	0.28290	N;N;N	.;0.289;0.304	0.34336	-0.1902	0.77923	T	0.7538	0.91609	D	10	0.1427879;0.1427879;0.1427879	0.27118	T;T;T	0.097668	0.76812	D	0.287;0.287;0.287	0.60574	0.35;0.35;0.35;	0.34760	Q9BQB6;Q9BQB6;Q9BQB6;	I86L;I86L;I86L;	Gain of catalytic residue at I86 (P = 0.0915);Gain of catalytic residue at I86 (P = 0.0915);Gain of catalytic residue at I86 (P = 0.0915);	0.409262747536;0.409262747536;0.409262747536	0.40539	.;.;0.633727926718707	0.63306	.;.;0.373551147566	0.38820	0.56084561348	0.47387	T	.;.;0.507113	0.82500	.;.;D	0.0804031	0.62087	D	-0.122283	0.61614	T	0.310927420854568	0.25452	T	0.783522;0.783522;0.746025	0.42019	T;T;T	.;.;0.32171065	0.54784	.;.;0.16948256	0.38985	.;.;0.32171065	0.54784	.;.;0.16948256	0.38984	.;0.0;-4.726	0.59903	.;T;T	.;.;0.09699399064791804	0.06775	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.0874;0.0977;0.0807	0.16143	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	2.509840	0.41462	22.4	1.917978	0.31320	19.09	0.94924298286701059	0.25802	0.64839	0.32538	D	ALL	0.501440	0.53428	D	-0.686682126489986	0.16400	0.835233	-0.478879644463073	0.22735	1.236407	0.999999998098237	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	2.47	0.29113	0.684000	0.25043	.	.	-0.147000	0.12262	1.000000	0.71638	0.997000	0.33255	0.996000	0.76049	0.0:0.0713:0.5256:0.4031	9.0015	0.35247	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093341	C	G	C	S	.	16	31104662	16	31012163	85;85;85	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.254G>C;c.254G>C;c.254G>C	p.C85S;p.C85S;p.C85S	c.254G>C;c.254G>C;c.254G>C	p.Cys85Ser;p.Cys85Ser;p.Cys85Ser	c.254G>C;c.254G>C;c.254G>C	p.Cys85Ser;p.Cys85Ser;p.Cys85Ser	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TGC;TGC;TGC	2;2;2	0;0;0	C	C/C	C/C	C/C	C/C	0.199;0.056;0.009	0.57480	T;T;D	0.013;0.031;0.019	0.63109	D;D;D	.;0.991;0.986	0.64070	.;D;D	.;0.73;0.715	0.55268	.;P;P	0.010632	0.29847	N	0.286819	1;0.996064;0.532242;0.532242;0.996064;0.996064	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;L105F;C85S;C85S;L116F;L117F	.;1.67;1.67	0.42885	.;L;L	-4.66;-4.66;-4.66	0.97956	D;D;D	-1.69;-1.8;-1.53	0.42384	N;N;N	.;0.51;0.55	0.57604	0.5129	0.90727	D	0.8663	0.95553	D	10	0.8146703;0.8146703;0.8146703	0.80717	D;D;D	0.274062	0.89988	D	0.625;0.625;0.625	0.85511	0.616;0.616;0.616;	0.75000	Q9BQB6;Q9BQB6;Q9BQB6;	C85S;C85S;C85S;	Gain of disorder (P = 0.0412);Gain of disorder (P = 0.0412);Gain of disorder (P = 0.0412);	0.717866958359;0.717866958359;0.717866958359	0.71538	.;.;0.763598751936655	0.76307	.;.;1.15193762352	0.79231	0.411068499088	0.26605	T	.;.;0.663599	0.89934	.;.;D	0.228847	0.76612	D	0.0909459	0.76308	D	0.932633757591248	0.59882	D	0.892111;0.892111;0.877412	0.62800	D;D;D	.;.;0.58431816	0.71843	.;.;0.33730718	0.59522	.;.;0.58431816	0.71844	.;.;0.33730718	0.59521	.;-3.704;-2.754	0.36822	.;T;T	.;.;0.08476460069532503	0.04711	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.3987;0.5693;0.3775	0.67606	A;P;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.932916	0.76348	26.5	3.822155	0.76184	26.4	0.99513614711503029	0.68799	0.81740	0.41084	D	ALL	0.915072	0.87934	D	0.449440755432326	0.64171	4.665779	0.551026974926862	0.71467	5.659541	0.99999999999741	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	5.17	0.70848	4.484000	0.60002	.	.	0.599000	0.40250	1.000000	0.71638	1.000000	0.68203	0.996000	0.76049	0.3247:0.6753:0.0:0.0	11.666	0.50636	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093342	A	C	C	G	.	16	31104663	16	31012164	85;85;85	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.253T>G;c.253T>G;c.253T>G	p.C85G;p.C85G;p.C85G	c.253T>G;c.253T>G;c.253T>G	p.Cys85Gly;p.Cys85Gly;p.Cys85Gly	c.253T>G;c.253T>G;c.253T>G	p.Cys85Gly;p.Cys85Gly;p.Cys85Gly	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TGC;TGC;TGC	1;1;1	0;0;0	A	A/A	A/A	A/A	A/A	0.003;0.002;0.004	0.72154	D;D;D	0.001;0.015;0.001	0.83351	D;D;D	.;0.991;0.986	0.64070	.;D;D	.;0.791;0.778	0.57754	.;P;P	0.010632	0.29847	N	0.286819	1;0.998192;0.601284;0.601284;0.998192;0.998192	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;L105W;C85G;C85G;L116W;L117W	.;2.015;2.015	0.55033	.;M;M	-4.68;-4.68;-4.68	0.97989	D;D;D	-3.28;-3.28;-3.0	0.65627	D;D;D	.;0.549;0.564	0.58798	0.4941	0.90464	D	0.8544	0.95149	D	10	0.7812015;0.7812015;0.7812015	0.77868	D;D;D	0.360032	0.92488	D	0.641;0.641;0.641	0.86333	0.62;0.62;0.62;	0.75461	Q9BQB6;Q9BQB6;Q9BQB6;	C85G;C85G;C85G;	Loss of stability (P = 0.0084);Loss of stability (P = 0.0084);Loss of stability (P = 0.0084);	0.876754066858;0.876754066858;0.876754066858	0.87554	.;.;0.7975472438059471	0.79707	.;.;1.22941327989	0.81299	0.394065290689	0.24241	T	.;.;0.837098	0.96166	.;.;D	0.228929	0.76620	D	0.0910641	0.76316	D	0.905063092708588	0.55870	D	0.89481;0.89481;0.880112	0.63428	D;D;D	.;.;0.61984086	0.73755	.;.;0.436177	0.67079	.;.;0.61984086	0.73756	.;.;0.436177	0.67079	.;-3.327;-3.773	0.38610	.;T;T	.;.;0.1001872491830012	0.07363	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.2176;0.3473;0.2255	0.56396	B;A;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.033468	0.79758	27.2	3.780266	0.74853	26.2	0.98053619980053608	0.37890	0.59810	0.31018	D	ALL	0.797814	0.72454	D	0.301803019335496	0.56240	3.788513	0.371888478841962	0.59838	4.16511	0.999999999890126	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	5.07	0.68106	1.013000	0.29540	.	.	0.756000	0.94297	0.659000	0.28251	1.000000	0.68203	0.995000	0.73285	0.5471:0.0:0.1123:0.3406	3.1553	0.06112	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093342	A	T	C	S	.	16	31104663	16	31012164	85;85;85	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.253T>A;c.253T>A;c.253T>A	p.C85S;p.C85S;p.C85S	c.253T>A;c.253T>A;c.253T>A	p.Cys85Ser;p.Cys85Ser;p.Cys85Ser	c.253T>A;c.253T>A;c.253T>A	p.Cys85Ser;p.Cys85Ser;p.Cys85Ser	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TGC;TGC;TGC	1;1;1	0;0;0	A	A/A	A/A	A/A	A/A	0.199;0.056;0.009	0.57480	T;T;D	0.013;0.031;0.019	0.63109	D;D;D	.;0.991;0.986	0.64070	.;D;D	.;0.73;0.715	0.55268	.;P;P	0.010632	0.29847	N	0.286819	0.999995;0.999995;0.999995;1;0.743578;0.743578	0.81001	D;D;D;D;N;N	complex_aae;complex_aae;complex_aae;without_aae;simple_aae;simple_aae	L117*;L116*;L105*;.;C85S;C85S	.;1.67;1.67	0.42885	.;L;L	-4.66;-4.66;-4.66	0.97956	D;D;D	-1.69;-1.8;-1.53	0.42384	N;N;N	.;0.51;0.55	0.57604	-0.9561	0.39898	T	0.1022	0.37743	T	10	0.6865089;0.6865089;0.6865089	0.71594	D;D;D	.	.	.	0.590;0.590;0.590	0.83636	0.616;0.616;0.616;	0.75000	Q9BQB6;Q9BQB6;Q9BQB6;	C85S;C85S;C85S;	Gain of disorder (P = 0.0412);Gain of disorder (P = 0.0412);Gain of disorder (P = 0.0412);	0.634685629852;0.634685629852;0.634685629852	0.63168	.;.;0.7635987243945861	0.76307	.;.;1.15193762352	0.79231	0.411068499088	0.26605	T	.;.;0.663599	0.89934	.;.;D	0.206994	0.74547	D	0.0595566	0.74216	D	0.937769711017609	0.60782	D	0.892111;0.892111;0.877412	0.62800	D;D;D	.;.;0.43888664	0.63330	.;.;0.2776668	0.53721	.;.;0.43888664	0.63331	.;.;0.2776668	0.53720	.;-3.704;-2.754	0.36822	.;T;T	.;.;0.08476460069532503	0.04711	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.3987;0.5693;0.3775	0.67606	A;P;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.987765	0.78184	26.9	3.840689	0.76782	26.5	0.99375654814909309	0.61628	0.47479	0.27992	N	ALL	0.783682	0.71459	D	0.0488466258767889	0.44090	2.689421	0.163722950125741	0.47873	3.011141	0.999999999890126	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	5.07	0.68106	1.013000	0.29540	.	.	0.756000	0.94297	0.659000	0.28251	1.000000	0.68203	0.995000	0.73285	0.5471:0.0:0.1123:0.3406	3.1553	0.06112	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093344	C	A	G	V	.	16	31104665	16	31012166	84;84;84	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.251G>T;c.251G>T;c.251G>T	p.G84V;p.G84V;p.G84V	c.251G>T;c.251G>T;c.251G>T	p.Gly84Val;p.Gly84Val;p.Gly84Val	c.251G>T;c.251G>T;c.251G>T	p.Gly84Val;p.Gly84Val;p.Gly84Val	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GGT;GGT;GGT	2;2;2	0;0;0	C	C/C	C/C	C/C	C/C	0.004;0.003;0.002	0.72154	D;D;D	0.005;0.007;0.003	0.76473	D;D;D	.;0.999;0.996	0.77913	.;D;D	.;0.967;0.937	0.71530	.;D;D	0.000300	0.46274	D	0.091737	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	G84V;G84V;.;.;.;.	.;2.985;2.985	0.85602	.;M;M	-6.41;-6.41;-6.41	0.99684	D;D;D	-6.57;-7.95;-8.18	0.96794	D;D;D	.;0.924;0.926	0.93018	1.2027	0.99970	D	0.9895	0.99708	D	10	0.9676671;0.9676671;0.9676671	0.96284	D;D;D	0.127138	0.80890	D	0.807;0.807;0.807	0.93738	0.881;0.881;0.881;	0.96884	Q9BQB6;Q9BQB6;Q9BQB6;	G84V;G84V;G84V;	Loss of stability (P = 0.0869);Loss of stability (P = 0.0869);Loss of stability (P = 0.0869);	0.897855245161;0.897855245161;0.897855245161	0.89684	.;.;0.9768478889816659	0.97674	.;.;1.31148163518	0.83232	0.710389256477	0.68650	T	.;.;0.963927	0.99555	.;.;D	0.531059	0.95185	D	0.525053	0.95114	D	0.96611180334365	0.67480	D	0.973753;0.972478;0.893511	0.90539	D;D;D	.;.;0.98648584	0.99562	.;.;0.95242393	0.98544	.;.;0.98648584	0.99562	.;.;0.95242393	0.98544	.;-3.811;-4.523	0.56265	.;T;T	.;.;0.5219782938257723	0.59410	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	0.9369;0.8602;0.9025	0.85620	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.972382	0.77666	26.8	4.289389	0.89869	31	0.99804365260103001	0.88906	0.93067	0.57244	D	ALL	0.908297	0.86343	D	0.834440891642858	0.88205	9.491644	0.812676546670864	0.90662	10.50976	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.124000	0.57676	.	.	0.599000	0.40250	0.997000	0.40164	1.000000	0.68203	0.990000	0.65344	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093344	C	G	G	A	.	16	31104665	16	31012166	84;84;84	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.251G>C;c.251G>C;c.251G>C	p.G84A;p.G84A;p.G84A	c.251G>C;c.251G>C;c.251G>C	p.Gly84Ala;p.Gly84Ala;p.Gly84Ala	c.251G>C;c.251G>C;c.251G>C	p.Gly84Ala;p.Gly84Ala;p.Gly84Ala	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GGT;GGT;GGT	2;2;2	0;0;0	C	C/C	C/C	C/C	C/C	0.018;0.017;0.008	0.58626	D;D;D	0.037;0.038;0.012	0.63918	D;D;D	.;0.994;0.984	0.66517	.;D;D	.;0.858;0.69	0.61127	.;P;P	0.000300	0.46274	D	0.091737	0.999932;0.999932;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	G84A;G84A;.;.;.;.	.;2.985;2.985	0.85602	.;M;M	-6.22;-6.22;-6.22	0.99576	D;D;D	-4.43;-5.32;-5.46	0.85541	D;D;D	.;0.878;0.842	0.87590	1.1889	0.99966	D	0.9837	0.99505	D	10	0.97107923;0.97107923;0.97107923	0.96711	D;D;D	0.060639	0.68070	D	0.747;0.747;0.747	0.91285	0.924;0.924;0.924;	0.98707	Q9BQB6;Q9BQB6;Q9BQB6;	G84A;G84A;G84A;	Gain of catalytic residue at G84 (P = 0.1284);Gain of catalytic residue at G84 (P = 0.1284);Gain of catalytic residue at G84 (P = 0.1284);	0.851790270932;0.851790270932;0.851790270932	0.85036	.;.;0.9557134686197923	0.95556	.;.;1.20313658712	0.80601	0.703648924828	0.67672	T	.;.;0.965362	0.99582	.;.;D	0.407968	0.90367	D	0.348242	0.90245	D	0.953401887576146	0.64018	D	0.975469;0.974503;0.89951	0.91344	D;D;D	.;.;0.8861462	0.90179	.;.;0.8288658	0.90111	.;.;0.8861462	0.90181	.;.;0.8288658	0.90112	.;-3.364;-3.435	0.30034	.;T;T	.;.;0.3394420712538176	0.43725	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	0.727;0.6866;0.7027	0.74080	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.757076	0.70949	25.6	3.969071	0.81229	27.4	0.99799881548698299	0.88461	0.93316	0.57891	D	ALL	0.884269	0.81383	D	0.748658800651803	0.82818	7.857445	0.755589759054221	0.86572	8.933038	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.124000	0.57676	.	.	0.599000	0.40250	0.997000	0.40164	1.000000	0.68203	0.990000	0.65344	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093345	C	G	G	R	.	16	31104666	16	31012167	84;84;84	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.250G>C;c.250G>C;c.250G>C	p.G84R;p.G84R;p.G84R	c.250G>C;c.250G>C;c.250G>C	p.Gly84Arg;p.Gly84Arg;p.Gly84Arg	c.250G>C;c.250G>C;c.250G>C	p.Gly84Arg;p.Gly84Arg;p.Gly84Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GGT;GGT;GGT	1;1;1	0;0;0	C	C/C	C/C	C/C	C/C	0.038;0.036;0.052	0.43393	D;D;T	0.056;0.071;0.053	0.47336	T;T;T	.;0.876;0.728	0.48154	.;P;P	.;0.414;0.334	0.44907	.;B;B	0.000300	0.46274	N	0.091737	0.999912;0.999912;1;0.763096;0.763096;0.763096	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	G84R;G84R;.;R104P;R115P;R116P	.;2.985;2.985	0.85602	.;M;M	-6.42;-6.42;-6.42	0.99687	D;D;D	-6.08;-7.05;-7.28	0.94430	D;D;D	.;0.9;0.91	0.91162	1.0109	0.97373	D	0.9422	0.98105	D	10	0.9855272;0.9855272;0.9855272	0.98811	D;D;D	0.42767	0.93919	D	0.824;0.824;0.824	0.94390	0.921;0.921;0.921;	0.98604	Q9BQB6;Q9BQB6;Q9BQB6;	G84R;G84R;G84R;	Loss of catalytic residue at C85 (P = 0.0408);Loss of catalytic residue at C85 (P = 0.0408);Loss of catalytic residue at C85 (P = 0.0408);	0.858007952282;0.858007952282;0.858007952282	0.85663	.;.;0.9878072913386005	0.98774	.;.;1.27675254131	0.82425	0.768191635609	0.77154	T	.;.;0.963175	0.99540	.;.;D	0.515467	0.94739	D	0.502656	0.94661	D	0.987603604793549	0.78068	D	0.980402;0.979602;0.915608	0.93314	D;D;D	.;.;0.9743114	0.98647	.;.;0.92615056	0.96827	.;.;0.9743114	0.98647	.;.;0.92615056	0.96827	.;-3.938;-3.776	0.42755	.;T;T	.;.;0.7433868686025936	0.82547	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	.;.;P	.;.;P	.;.;P	.;.;P	0.9801;0.9221;0.9401	0.91161	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.394296	0.61391	24.4	3.324756	0.62631	24.4	0.99838703160031583	0.91972	0.92137	0.55027	D	ALL	0.966459	0.98889	D	0.52317685345986	0.68465	5.220709	0.539978571183226	0.70702	5.544326	0.999999999999232	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	5.23	0.72570	4.124000	0.57676	.	.	0.599000	0.40250	0.999000	0.42656	1.000000	0.68203	0.985000	0.61073	0.0:0.9292:0.0:0.0708	14.5279	0.67489	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093346	G	C	F	L	rs754924004	16	31104667	16	31012168	83;83;83	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.249C>G;c.249C>G;c.249C>G	p.F83L;p.F83L;p.F83L	c.249C>G;c.249C>G;c.249C>G	p.Phe83Leu;p.Phe83Leu;p.Phe83Leu	c.249C>G;c.249C>G;c.249C>G	p.Phe83Leu;p.Phe83Leu;p.Phe83Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	3;3;3	2;2;2	G	G/G	G/G	G/G	G/G	0.185;0.358;0.233	0.21550	T;T;T	0.264;0.329;0.394	0.22761	T;T;T	.;0.989;0.913	0.62824	.;D;P	.;0.639;0.542	0.52057	.;P;P	0.000143	0.49130	D	0.084080	1;0.999616;0.995366;0.995366;0.999616;0.999616	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;R104G;F83L;F83L;R115G;R116G	.;1.615;1.615	0.41426	.;L;L	-4.5;-4.5;-4.5	0.97650	D;D;D	-2.93;-3.39;-3.29	0.66896	D;D;D	.;0.405;0.388	0.44570	-0.1976	0.77732	T	0.7224	0.90488	D	10	0.56179947;0.56179947;0.56179947	0.64829	D;D;D	0.118333	0.79835	D	0.593;0.593;0.593	0.83802	0.449;0.449;0.449;	0.50957	Q9BQB6;Q9BQB6;Q9BQB6;	F83L;F83L;F83L;	Loss of stability (P = 0.0636);Loss of stability (P = 0.0636);Loss of stability (P = 0.0636);	0.341460817117;0.341460817117;0.341460817117	0.33762	.;.;0.5905532686610668	0.58985	.;.;0.646787645199	0.58085	0.723393976688	0.70541	T	.;.;0.793435	0.94657	.;.;D	0.197176	0.73627	D	0.0454532	0.73285	D	0.915076792240143	0.57196	D	0.856014;0.868913;0.89491	0.63503	D;D;D	.;.;0.6052066	0.72971	.;.;0.42501062	0.66323	.;.;0.6052066	0.72972	.;.;0.42501062	0.66323	.;0.0;-4.726	0.59903	.;T;T	.;.;0.1014318351153291	0.07596	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.8617;0.8935;0.8299	0.82317	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.387787	0.20227	15.00	1.012315	0.17077	13.51	0.97986592146378115	0.37371	0.33863	0.24931	N	ALL	0.409772	0.48092	N	-1.1790626529057	0.05317	0.242106	-1.19834684378125	0.05938	0.2843596	0.999999999800546	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	-4.71	0.03042	-0.211000	0.09336	.	.	-0.764000	0.03494	0.789000	0.29582	0.000000	0.08366	0.977000	0.56843	0.6142:0.0:0.3858:0.0	15.3174	0.73800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	152128	6.573410e-06	0	1	41416	2.414530e-05	0	1	41416	2.414530e-05	0	0	912	0.000000e+00	0	0	15264	0.000000e+00	0	0	3472	0.000000e+00	0	0	5184	0.000000e+00	0	0	10620	0.000000e+00	0	0	316	0.000000e+00	0	0	68024	0.000000e+00	0	0	4828	0.000000e+00	0	0	32868	0.000000e+00	0	1	134730	7.422250e-06	0	1	147870	6.762700e-06	0	0	80696	0.000000e+00	0	0	9080	0.000000e+00	0	0	60	0.000000e+00	0	0	4686	0.000000e+00	0	0	136	0.000000e+00	0	0	2426	0.000000e+00	0	0	5490	0.000000e+00	0	0	246	0.000000e+00	0	0	6848	0.000000e+00	0	0	3108	0.000000e+00	0	1	32456	3.081090e-05	0	0	862	0.000000e+00	0	0	14818	0.000000e+00	0	0	3388	0.000000e+00	0	0	5184	0.000000e+00	0	0	6980	0.000000e+00	0	0	310	0.000000e+00	0	0	63904	0.000000e+00	0	0	4826	0.000000e+00	0	1	41094	2.433450e-05	0	0	912	0.000000e+00	0	0	15076	0.000000e+00	0	0	3302	0.000000e+00	0	0	4952	0.000000e+00	0	0	10620	0.000000e+00	0	0	304	0.000000e+00	0	0	64792	0.000000e+00	0	0	4796	0.000000e+00	0	0	24792	0.000000e+00	0	0	112	0.000000e+00	0	0	12890	0.000000e+00	0	0	998	0.000000e+00	0	0	3742	0.000000e+00	0	0	10528	0.000000e+00	0	0	272	0.000000e+00	0	0	21044	0.000000e+00	0	0	4800	0.000000e+00	0	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093346	G	T	F	L	.	16	31104667	16	31012168	83;83;83	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.249C>A;c.249C>A;c.249C>A	p.F83L;p.F83L;p.F83L	c.249C>A;c.249C>A;c.249C>A	p.Phe83Leu;p.Phe83Leu;p.Phe83Leu	c.249C>A;c.249C>A;c.249C>A	p.Phe83Leu;p.Phe83Leu;p.Phe83Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	3;3;3	2;2;2	G	G/G	G/G	G/G	G/G	0.185;0.358;0.233	0.21550	T;T;T	0.264;0.329;0.394	0.22761	T;T;T	.;0.989;0.913	0.62824	.;D;P	.;0.639;0.542	0.52057	.;P;P	0.000143	0.49130	D	0.084080	1;1;1;1;0.995366;0.995366	0.81001	D;D;D;D;N;N	without_aae;without_aae;without_aae;without_aae;simple_aae;simple_aae	.;.;.;.;F83L;F83L	.;1.615;1.615	0.41426	.;L;L	-4.5;-4.5;-4.5	0.97650	D;D;D	-2.93;-3.39;-3.29	0.66896	D;D;D	.;0.405;0.388	0.44570	0.3718	0.88671	D	0.7962	0.93096	D	10	0.54290247;0.54290247;0.54290247	0.63820	D;D;D	0.133773	0.81617	D	0.593;0.593;0.593	0.83802	0.449;0.449;0.449;	0.50957	Q9BQB6;Q9BQB6;Q9BQB6;	F83L;F83L;F83L;	Loss of stability (P = 0.0636);Loss of stability (P = 0.0636);Loss of stability (P = 0.0636);	0.345405024496;0.345405024496;0.345405024496	0.34151	.;.;0.5905532824321013	0.58985	.;.;0.646787645199	0.58085	0.723393976688	0.70541	T	.;.;0.793435	0.94657	.;.;D	0.197176	0.73627	D	0.0454533	0.73285	D	0.915076792240143	0.57196	D	0.856014;0.868913;0.89491	0.63503	D;D;D	.;.;0.6052066	0.72971	.;.;0.42501062	0.66323	.;.;0.6052066	0.72972	.;.;0.42501062	0.66323	.;0.0;-4.726	0.59903	.;T;T	.;.;0.1014318351153291	0.07596	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.8617;0.8935;0.8299	0.82317	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.672570	0.24618	16.84	1.363280	0.21836	15.52	0.9806037391379292	0.37944	0.34223	0.25016	N	ALL	0.225909	0.34993	N	-1.09818494807403	0.06676	0.3080341	-1.14876253276142	0.06790	0.3280443	0.999999999800546	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	-4.71	0.03042	-0.211000	0.09336	.	.	-0.764000	0.03494	0.789000	0.29582	0.000000	0.08366	0.977000	0.56843	0.6142:0.0:0.3858:0.0	15.3174	0.73800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093348	A	G	F	L	.	16	31104669	16	31012170	83;83;83	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.247T>C;c.247T>C;c.247T>C	p.F83L;p.F83L;p.F83L	c.247T>C;c.247T>C;c.247T>C	p.Phe83Leu;p.Phe83Leu;p.Phe83Leu	c.247T>C;c.247T>C;c.247T>C	p.Phe83Leu;p.Phe83Leu;p.Phe83Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	1;1;1	0;0;0	A	A/A	A/A	A/A	A/A	0.185;0.358;0.233	0.21550	T;T;T	0.264;0.329;0.394	0.22761	T;T;T	.;0.972;0.805	0.57405	.;D;P	.;0.488;0.389	0.47288	.;P;B	0.000143	0.49130	D	0.084080	1;0.972859;0.754804;0.754804;0.972859;0.972859	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;I103T;F83L;F83L;I114T;I115T	.;1.615;1.615	0.41426	.;L;L	-4.5;-4.5;-4.5	0.97650	D;D;D	-2.93;-3.39;-3.29	0.66896	D;D;D	.;0.405;0.388	0.44570	-0.1410	0.79140	T	0.7363	0.90987	D	10	0.6997628;0.6997628;0.6997628	0.72369	D;D;D	0.141974	0.82437	D	0.585;0.585;0.585	0.83360	0.449;0.449;0.449;	0.50957	Q9BQB6;Q9BQB6;Q9BQB6;	F83L;F83L;F83L;	Loss of stability (P = 0.0636);Loss of stability (P = 0.0636);Loss of stability (P = 0.0636);	0.71246766341;0.71246766341;0.71246766341	0.70995	.;.;0.5905532962031358	0.58985	.;.;0.646787645199	0.58085	0.723393976688	0.70541	T	.;.;0.793435	0.94657	.;.;D	0.251781	0.78769	D	0.12389	0.78493	D	0.964410006999969	0.66948	D	0.856014;0.868913;0.89491	0.63503	D;D;D	.;.;0.5594713	0.70481	.;.;0.44791675	0.67854	.;.;0.5594713	0.70482	.;.;0.44791675	0.67855	.;0.0;-4.726	0.59903	.;T;T	.;.;0.1014318351153291	0.07596	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.8617;0.8935;0.8299	0.82317	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.128815	0.54927	23.7	3.065053	0.56230	23.7	0.99847919829843046	0.92750	0.85644	0.44799	D	ALL	0.788741	0.71814	D	0.108955383485385	0.46879	2.921727	0.276578499658701	0.54176	3.583282	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.924000	0.63118	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.989000	0.64315	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093350	A	C	I	R	.	16	31104671	16	31012172	82;82;82	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.245T>G;c.245T>G;c.245T>G	p.I82R;p.I82R;p.I82R	c.245T>G;c.245T>G;c.245T>G	p.Ile82Arg;p.Ile82Arg;p.Ile82Arg	c.245T>G;c.245T>G;c.245T>G	p.Ile82Arg;p.Ile82Arg;p.Ile82Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	ATA;ATA;ATA	2;2;2	0;0;0	A	A/A	A/A	A/A	A/A	0.008;0.004;0.001	0.78490	D;D;D	0.001;0.002;0.003	0.83351	D;D;D	.;0.993;0.97	0.65571	.;D;D	.;0.804;0.828	0.59497	.;P;P	0.001212	0.39820	N	0.176670	0.999362;0.999362;1;0.988997;0.988997;0.988997	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	I82R;I82R;.;H102Q;H113Q;H114Q	.;2.255;2.255	0.64187	.;M;M	-4.74;-4.74;-4.74	0.98081	D;D;D	-4.56;-5.59;-5.57	0.86527	D;D;D	.;0.778;0.788	0.78451	0.7922	0.94313	D	0.9308	0.97716	D	10	0.9395658;0.9395658;0.9395658	0.93283	D;D;D	0.281013	0.90231	D	0.770;0.770;0.770	0.92253	0.791;0.791;0.791;	0.91291	Q9BQB6;Q9BQB6;Q9BQB6;	I82R;I82R;I82R;	Gain of methylation at I82 (P = 0.0173);Gain of methylation at I82 (P = 0.0173);Gain of methylation at I82 (P = 0.0173);	0.900832558732;0.900832558732;0.900832558732	0.89984	.;.;0.8659912681175517	0.86564	.;.;1.11718123283	0.78204	0.591682910919	0.51732	T	.;.;0.91454	0.98418	.;.;D	0.147835	0.69065	D	-0.025422	0.68671	D	0.977610409259796	0.71928	D	0.889911;0.89941;0.937406	0.76468	D;D;D	.;.;0.91157395	0.92441	.;.;0.9315002	0.97198	.;.;0.91157395	0.92442	.;.;0.9315002	0.97198	.;-3.938;-3.776	0.42755	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.9002;0.8751;0.7873	0.82761	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.230002	0.86374	28.9	4.010297	0.82658	27.8	0.98961078063910213	0.49324	0.94384	0.60994	D	ALL	0.956952	0.97582	D	0.727921572214257	0.81463	7.527963	0.755402048436224	0.86559	8.928507	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.913000	0.63039	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.996000	0.76049	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093350	A	G	I	T	rs1454769993	16	31104671	16	31012172	82;82;82	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.245T>C;c.245T>C;c.245T>C	p.I82T;p.I82T;p.I82T	c.245T>C;c.245T>C;c.245T>C	p.Ile82Thr;p.Ile82Thr;p.Ile82Thr	c.245T>C;c.245T>C;c.245T>C	p.Ile82Thr;p.Ile82Thr;p.Ile82Thr	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	ATA;ATA;ATA	2;2;2	0;0;0	A	A/A	A/A	A/A	A/A	0.182;0.03;0.002	0.72154	T;D;D	0.003;0.006;0.01	0.76473	D;D;D	.;0.952;0.822	0.54136	.;P;P	.;0.466;0.419	0.46637	.;P;B	0.001212	0.39820	N	0.176670	1;1;1;1;0.599464;0.599464	0.81001	D;D;D;D;N;N	without_aae;without_aae;without_aae;without_aae;simple_aae;simple_aae	.;.;.;.;I82T;I82T	.;2.255;2.255	0.64187	.;M;M	-4.71;-4.71;-4.71	0.98035	D;D;D	-2.8;-3.51;-3.5	0.68298	D;D;D	.;0.678;0.665	0.68516	0.8665	0.95234	D	0.8877	0.96271	D	10	0.8663575;0.8663575;0.8663575	0.85882	D;D;D	0.120184	0.80066	D	0.717;0.717;0.717	0.89966	0.665;0.665;0.665;	0.80300	Q9BQB6;Q9BQB6;Q9BQB6;	I82T;I82T;I82T;	Loss of stability (P = 0.0089);Loss of stability (P = 0.0089);Loss of stability (P = 0.0089);	0.728469231058;0.728469231058;0.728469231058	0.72605	.;.;0.6122049290773823	0.61152	.;.;0.708055894707	0.61527	0.648100733757	0.59717	T	.;.;0.855733	0.96756	.;.;D	0.178454	0.71901	D	0.187688	0.82436	D	0.942569673061371	0.61687	D	0.912409;0.920508;0.952205	0.81731	D;D;D	.;.;0.58622706	0.71947	.;.;0.63122284	0.78486	.;.;0.58622706	0.71948	.;.;0.63122284	0.78487	.;-4.272;-4.093	0.50911	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.7691;0.7951;0.6416	0.77057	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.517577	0.64547	24.8	3.425576	0.65204	24.7	0.99635256308945253	0.76326	0.94089	0.60079	D	ALL	0.944245	0.95108	D	0.507783968014927	0.67547	5.096467	0.588034885389797	0.74081	6.076737	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.913000	0.63039	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.996000	0.76049	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	251214	3.980670e-06	0	0	16256	0.000000e+00	0	0	34592	0.000000e+00	0	0	10076	0.000000e+00	0	1	18394	5.436560e-05	0	0	21622	0.000000e+00	0	0	113522	0.000000e+00	0	0	30616	0.000000e+00	0	1	18394	5.436560e-05	0	1	109378	9.142610e-06	0	1	207940	4.809080e-06	0	1	236688	4.224970e-06	0	1	244596	4.088370e-06	0	0	7164	0.000000e+00	0	0	17112	0.000000e+00	0	0	2320	0.000000e+00	0	1	9046	1.105460e-04	0	0	13368	0.000000e+00	0	0	42766	0.000000e+00	0	0	15690	0.000000e+00	0	1	9046	1.105460e-04	0	0	16218	0.000000e+00	0	0	30524	0.000000e+00	0	0	6210	0.000000e+00	0	1	13416	7.453790e-05	0	0	16708	0.000000e+00	0	0	89392	0.000000e+00	0	0	30608	0.000000e+00	0	1	13416	7.453790e-05	0	0	14902	0.000000e+00	0	0	34260	0.000000e+00	0	0	9568	0.000000e+00	0	1	17692	5.652270e-05	0	0	21606	0.000000e+00	0	0	102518	0.000000e+00	0	0	30526	0.000000e+00	0	1	17692	5.652270e-05	0	0	12026	0.000000e+00	0	0	34458	0.000000e+00	0	0	9994	0.000000e+00	0	1	18390	5.437740e-05	0	0	21620	0.000000e+00	0	0	111432	0.000000e+00	0	0	30616	0.000000e+00	0	1	18390	5.437740e-05	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093350	A	T	I	K	.	16	31104671	16	31012172	82;82;82	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.245T>A;c.245T>A;c.245T>A	p.I82K;p.I82K;p.I82K	c.245T>A;c.245T>A;c.245T>A	p.Ile82Lys;p.Ile82Lys;p.Ile82Lys	c.245T>A;c.245T>A;c.245T>A	p.Ile82Lys;p.Ile82Lys;p.Ile82Lys	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	ATA;ATA;ATA	2;2;2	0;0;0	A	A/A	A/A	A/A	A/A	0.008;0.004;0.001	0.78490	D;D;D	0.001;0.002;0.004	0.83351	D;D;D	.;0.993;0.97	0.65571	.;D;D	.;0.804;0.828	0.59497	.;P;P	0.001212	0.39820	N	0.176670	0.999562;0.999562;1;0.988997;0.988997;0.988997	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	I82K;I82K;.;H102Q;H113Q;H114Q	.;2.255;2.255	0.64187	.;M;M	-4.74;-4.74;-4.74	0.98081	D;D;D	-4.19;-5.2;-5.18	0.83695	D;D;D	.;0.798;0.804	0.79986	0.7922	0.94313	D	0.9308	0.97716	D	10	0.9390017;0.9390017;0.9390017	0.93227	D;D;D	0.294684	0.90682	D	0.778;0.778;0.778	0.92583	0.79;0.79;0.79;	0.91217	Q9BQB6;Q9BQB6;Q9BQB6;	I82K;I82K;I82K;	Loss of stability (P = 0.0071);Loss of stability (P = 0.0071);Loss of stability (P = 0.0071);	0.900832558732;0.900832558732;0.900832558732	0.89984	.;.;0.8871601986917903	0.88685	.;.;0.713057731645	0.61797	0.606908500195	0.53880	T	.;.;0.91219	0.98355	.;.;D	0.147833	0.69065	D	-0.0254243	0.68671	D	0.988917350769043	0.79191	D	0.89531;0.90401;0.940506	0.77585	D;D;D	.;.;0.8587285	0.87989	.;.;0.9059709	0.95402	.;.;0.8587285	0.87990	.;.;0.9059709	0.95403	.;-5.29;-3.305	0.67544	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.9545;0.9397;0.8844	0.87405	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.117063	0.82686	27.9	4.061203	0.84373	28.2	0.96484170012481363	0.29981	0.94171	0.60328	D	ALL	0.958256	0.97793	D	0.727921572214257	0.81463	7.527963	0.755402048436224	0.86559	8.928507	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.913000	0.63039	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.996000	0.76049	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093351	T	A	I	L	.	16	31104672	16	31012173	82;82;82	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.244A>T;c.244A>T;c.244A>T	p.I82L;p.I82L;p.I82L	c.244A>T;c.244A>T;c.244A>T	p.Ile82Leu;p.Ile82Leu;p.Ile82Leu	c.244A>T;c.244A>T;c.244A>T	p.Ile82Leu;p.Ile82Leu;p.Ile82Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	ATA;ATA;ATA	1;1;1	0;0;0	T	T/T	T/T	T/T	T/T	0.405;0.388;0.082	0.33254	T;T;T	0.131;0.156;0.232	0.34596	T;T;T	.;0.025;0.006	0.19245	.;B;B	.;0.013;0.015	0.17295	.;B;B	0.001212	0.39820	N	0.176670	1;0.992672;0.983634;0.983634;0.992672;0.992672	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;H102L;I82L;I82L;H113L;H114L	.;1.22;1.22	0.30592	.;L;L	-4.35;-4.35;-4.35	0.97292	D;D;D	-1.15;-1.26;-1.29	0.32387	N;N;N	.;0.283;0.279	0.32037	-0.2600	0.76088	T	0.7021	0.89746	D	10	0.25480944;0.25480944;0.25480944	0.42865	T;T;T	0.074234	0.71990	D	0.274;0.274;0.274	0.59007	0.42;0.42;0.42;	0.46200	Q9BQB6;Q9BQB6;Q9BQB6;	I82L;I82L;I82L;	Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);	0.474798811001;0.474798811001;0.474798811001	0.47109	.;.;0.5792415894715264	0.57853	.;.;0.372969820583	0.38776	0.550356388092	0.45908	T	.;.;0.544892	0.84484	.;.;D	0.123102	0.66682	D	-0.0609487	0.66266	T	0.495929390192032	0.32481	T	0.763424;0.772923;0.825517	0.48813	T;T;T	.;.;0.23161356	0.45935	.;.;0.1252684	0.30185	.;.;0.23161356	0.45935	.;.;0.1252684	0.30185	.;0.0;-4.726	0.59903	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.1378;0.1632;0.1149	0.36033	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	2.295797	0.36763	21.5	2.284068	0.38964	21.9	0.97473023184152263	0.34147	0.65869	0.32883	D	ALL	0.411322	0.48184	N	-0.478986871361225	0.22771	1.2182	-0.287337239554473	0.28514	1.5905	0.999999998566776	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	2.71	0.31092	0.409000	0.20803	.	.	0.665000	0.62972	0.998000	0.41325	0.013000	0.20296	0.997000	0.79791	0.143:0.2185:0.0:0.6385	4.1108	0.09530	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093351	T	G	I	L	.	16	31104672	16	31012173	82;82;82	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.244A>C;c.244A>C;c.244A>C	p.I82L;p.I82L;p.I82L	c.244A>C;c.244A>C;c.244A>C	p.Ile82Leu;p.Ile82Leu;p.Ile82Leu	c.244A>C;c.244A>C;c.244A>C	p.Ile82Leu;p.Ile82Leu;p.Ile82Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	ATA;ATA;ATA	1;1;1	0;0;0	T	T/T	T/T	T/T	T/T	0.405;0.388;0.082	0.33254	T;T;T	0.131;0.156;0.232	0.34596	T;T;T	.;0.025;0.006	0.19245	.;B;B	.;0.013;0.015	0.17295	.;B;B	0.001212	0.39820	N	0.176670	1;0.993276;0.983634;0.983634;0.993276;0.993276	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;H102P;I82L;I82L;H113P;H114P	.;1.22;1.22	0.30592	.;L;L	-4.35;-4.35;-4.35	0.97292	D;D;D	-1.15;-1.26;-1.29	0.32387	N;N;N	.;0.283;0.279	0.32037	-0.2600	0.76088	T	0.7021	0.89746	D	10	0.27011442;0.27011442;0.27011442	0.44540	T;T;T	0.071474	0.71278	D	0.274;0.274;0.274	0.59007	0.42;0.42;0.42;	0.46200	Q9BQB6;Q9BQB6;Q9BQB6;	I82L;I82L;I82L;	Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);	0.474798811001;0.474798811001;0.474798811001	0.47109	.;.;0.579241575700492	0.57853	.;.;0.372969820583	0.38776	0.550356388092	0.45908	T	.;.;0.544892	0.84484	.;.;D	0.118416	0.66212	D	-0.0676805	0.65791	T	0.377232521772385	0.28076	T	0.763424;0.772923;0.825517	0.48813	T;T;T	.;.;0.23161356	0.45935	.;.;0.1252684	0.30185	.;.;0.23161356	0.45935	.;.;0.1252684	0.30185	.;0.0;-4.726	0.59903	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.1378;0.1632;0.1149	0.36033	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	2.204319	0.34799	20.9	2.155686	0.36201	21.1	0.97334037004560958	0.33437	0.68659	0.33886	D	ALL	0.637296	0.61613	D	-0.478986871361225	0.22771	1.2182	-0.287337239554473	0.28514	1.5905	0.999999998566776	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	2.71	0.31092	0.409000	0.20803	.	.	0.665000	0.62972	0.998000	0.41325	0.013000	0.20296	0.997000	0.79791	0.143:0.2185:0.0:0.6385	4.1108	0.09530	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093352	G	C	S	R	.	16	31104673	16	31012174	81;81;81	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.243C>G;c.243C>G;c.243C>G	p.S81R;p.S81R;p.S81R	c.243C>G;c.243C>G;c.243C>G	p.Ser81Arg;p.Ser81Arg;p.Ser81Arg	c.243C>G;c.243C>G;c.243C>G	p.Ser81Arg;p.Ser81Arg;p.Ser81Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AGC;AGC;AGC	3;3;3	2;2;2	G	G/G	G/G	G/G	G/G	0.037;0.01;0.001	0.78490	D;D;D	0.002;0.004;0.007	0.79402	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.997;0.999	0.92359	.;D;D	0.000000	0.84330	D	0.000000	0.98276;0.98276;1;0.986644;0.986644;0.986644	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	S81R;S81R;.;H102D;H113D;H114D	.;2.755;2.755	0.80505	.;M;M	-5.01;-5.01;-5.01	0.98544	D;D;D	-3.83;-4.36;-4.35	0.76980	D;D;D	.;0.889;0.881	0.88798	0.8629	0.95188	D	0.9588	0.98670	D	10	0.9755095;0.9755095;0.9755095	0.97302	D;D;D	0.203975	0.86905	D	0.859;0.859;0.859	0.95691	0.934;0.934;0.934;	0.99018	Q9BQB6;Q9BQB6;Q9BQB6;	S81R;S81R;S81R;	Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);	0.73732307442;0.73732307442;0.73732307442	0.73497	.;.;0.9784047181987774	0.97831	.;.;1.2154307609	0.80945	0.646290659904	0.59458	T	.;.;0.929734	0.98803	.;.;D	0.113464	0.65710	D	-0.0747928	0.65283	T	0.994266450405121	0.85453	D	0.957704;0.965203;0.90081	0.87125	D;D;D	.;.;0.9952733	0.99968	.;.;0.9804357	0.99830	.;.;0.9952733	0.99968	.;.;0.9804357	0.99830	.;-3.938;-3.776	0.42755	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.9917;0.9807;0.9822	0.94165	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.620803	0.67233	25.1	3.789245	0.75121	26.2	0.99809563559795034	0.89353	0.81774	0.41111	D	AEFDGBHCI	0.536332	0.55459	D	0.516300057244818	0.68053	5.164581	0.436638386352168	0.63864	4.628808	0.999999999624912	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	3.2	0.35826	0.619000	0.24083	.	.	0.676000	0.76740	0.999000	0.42656	0.996000	0.32793	0.998000	0.85391	0.2069:0.0:0.7931:0.0	10.7787	0.45565	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093352	G	T	S	R	.	16	31104673	16	31012174	81;81;81	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.243C>A;c.243C>A;c.243C>A	p.S81R;p.S81R;p.S81R	c.243C>A;c.243C>A;c.243C>A	p.Ser81Arg;p.Ser81Arg;p.Ser81Arg	c.243C>A;c.243C>A;c.243C>A	p.Ser81Arg;p.Ser81Arg;p.Ser81Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AGC;AGC;AGC	3;3;3	2;2;2	G	G/G	G/G	G/G	G/G	0.037;0.01;0.001	0.78490	D;D;D	0.002;0.004;0.007	0.79402	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.997;0.999	0.92359	.;D;D	0.000000	0.84330	D	0.000000	0.98276;0.98276;1;0.996017;0.996017;0.996017	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	S81R;S81R;.;H102N;H113N;H114N	.;2.755;2.755	0.80505	.;M;M	-5.01;-5.01;-5.01	0.98544	D;D;D	-3.83;-4.36;-4.35	0.76980	D;D;D	.;0.889;0.881	0.88798	0.8591	0.95141	D	0.9588	0.98670	D	10	0.9754013;0.9754013;0.9754013	0.97287	D;D;D	0.208608	0.87156	D	0.859;0.859;0.859	0.95691	0.934;0.934;0.934;	0.99018	Q9BQB6;Q9BQB6;Q9BQB6;	S81R;S81R;S81R;	Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);	0.73732307442;0.73732307442;0.73732307442	0.73497	.;.;0.9784047044277429	0.97831	.;.;1.2154307609	0.80945	0.646290659904	0.59458	T	.;.;0.929734	0.98803	.;.;D	0.0667867	0.60455	T	-0.141842	0.59959	T	0.994266450405121	0.85453	D	0.957704;0.965203;0.90081	0.87125	D;D;D	.;.;0.9952733	0.99968	.;.;0.9804357	0.99830	.;.;0.9952733	0.99968	.;.;0.9804357	0.99830	.;-3.938;-3.776	0.42755	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.9917;0.9807;0.9822	0.94165	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.434214	0.62408	24.5	3.612995	0.70040	25.4	0.99817779265014572	0.90061	0.80502	0.40123	D	AEFDGBHCI	0.523782	0.54724	D	0.516300057244818	0.68053	5.164581	0.436638386352168	0.63864	4.628808	0.999999999624912	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	3.2	0.35826	0.619000	0.24083	.	.	0.676000	0.76740	0.999000	0.42656	0.996000	0.32793	0.998000	0.85391	0.2069:0.0:0.7931:0.0	10.7787	0.45565	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093354	T	G	S	R	.	16	31104675	16	31012176	81;81;81	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.241A>C;c.241A>C;c.241A>C	p.S81R;p.S81R;p.S81R	c.241A>C;c.241A>C;c.241A>C	p.Ser81Arg;p.Ser81Arg;p.Ser81Arg	c.241A>C;c.241A>C;c.241A>C	p.Ser81Arg;p.Ser81Arg;p.Ser81Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AGC;AGC;AGC	1;1;1	0;0;0	T	T/T	T/T	T/T	T/T	0.037;0.01;0.001	0.78490	D;D;D	0.002;0.004;0.007	0.79402	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.997;0.999	0.92359	.;D;D	0.000000	0.84330	D	0.000000	0.999481;0.999481;1;0.526608;0.526608;0.526608	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	S81R;S81R;.;Q101P;Q112P;Q113P	.;2.755;2.755	0.80505	.;M;M	-5.01;-5.01;-5.01	0.98544	D;D;D	-3.83;-4.36;-4.35	0.76980	D;D;D	.;0.889;0.881	0.88798	1.1837	0.99964	D	0.9660	0.98917	D	10	0.98382306;0.98382306;0.98382306	0.98542	D;D;D	0.104938	0.77978	D	0.863;0.863;0.863	0.95839	0.934;0.934;0.934;	0.99018	Q9BQB6;Q9BQB6;Q9BQB6;	S81R;S81R;S81R;	Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);	0.851242385182;0.851242385182;0.851242385182	0.84981	.;.;0.9784046631146395	0.97831	.;.;1.2154307609	0.80945	0.646290659904	0.59458	T	.;.;0.929734	0.98803	.;.;D	0.153482	0.69594	D	-0.01731	0.69206	D	0.992568790912628	0.83076	D	0.957704;0.965203;0.90081	0.87125	D;D;D	.;.;0.98711455	0.99601	.;.;0.96662235	0.99310	.;.;0.98711455	0.99601	.;.;0.96662235	0.99311	.;-3.938;-3.776	0.42755	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.9917;0.9807;0.9822	0.94165	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.269959	0.87485	29.3	4.187487	0.87975	29.4	0.99837226644425414	0.91800	0.92579	0.56044	D	ALL	0.955392	0.97320	D	0.868368718314802	0.90127	10.26496	0.841862746189193	0.92531	11.48093	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.146000	0.57840	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093356	T	G	N	T	.	16	31104677	16	31012178	80;80;80	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.239A>C;c.239A>C;c.239A>C	p.N80T;p.N80T;p.N80T	c.239A>C;c.239A>C;c.239A>C	p.Asn80Thr;p.Asn80Thr;p.Asn80Thr	c.239A>C;c.239A>C;c.239A>C	p.Asn80Thr;p.Asn80Thr;p.Asn80Thr	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AAC;AAC;AAC	2;2;2	0;0;0	T	./.	./.	./.	./.	0.004;0.002;0.0	0.91255	D;D;D	0.023;0.0;0.0	0.92824	D;D;D	.;0.998;0.999	0.77913	.;D;D	.;0.995;0.997	0.86255	.;D;D	0.000001	0.84330	D	0.000000	0.999813;0.999813;1;0.926791;0.8779;0.8779	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	N80T;N80T;.;Q100H;Q111H;Q112H	.;2.985;2.985	0.85602	.;M;M	-4.9;-4.9;-4.9	0.98333	D;D;D	-4.53;-5.45;-5.46	0.85541	D;D;D	.;0.885;0.815	0.88356	0.8581	0.95129	D	0.9239	0.97483	D	10	0.9773512;0.9773512;0.9773512	0.97562	D;D;D	0.185742	0.85831	D	0.888;0.888;0.888	0.96762	0.953;0.953;0.953;	0.99466	Q9BQB6;Q9BQB6;Q9BQB6;	N80T;N80T;N80T;	Gain of catalytic residue at N80 (P = 0.1295);Gain of catalytic residue at N80 (P = 0.1295);Gain of catalytic residue at N80 (P = 0.1295);	0.797373355788;0.797373355788;0.797373355788	0.79549	.;.;0.9713425461370279	0.97123	.;.;1.17709788151	0.79901	0.638608932495	0.58366	T	.;.;0.91321	0.98382	.;.;D	0.285677	0.81796	D	0.172579	0.81562	D	0.991755485534668	0.82096	D	0.960254;0.966303;0.906909	0.87634	D;D;D	.;.;0.98730135	0.99613	.;.;0.96560794	0.99261	.;.;0.98730135	0.99613	.;.;0.96560794	0.99261	.;-4.272;-4.093	0.50911	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.8945;0.8895;0.8566	0.82382	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.124392	0.82934	28.0	4.013610	0.82770	27.8	0.99651702122998009	0.77317	0.92579	0.56044	D	ALL	0.895853	0.83631	D	0.53719737497797	0.69307	5.338244	0.591709468106038	0.74342	6.121081	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.196000	0.58203	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093357	T	A	N	Y	.	16	31104678	16	31012179	80;80;80	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.238A>T;c.238A>T;c.238A>T	p.N80Y;p.N80Y;p.N80Y	c.238A>T;c.238A>T;c.238A>T	p.Asn80Tyr;p.Asn80Tyr;p.Asn80Tyr	c.238A>T;c.238A>T;c.238A>T	p.Asn80Tyr;p.Asn80Tyr;p.Asn80Tyr	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AAC;AAC;AAC	1;1;1	0;0;0	T	./.	./.	./.	./.	0.002;0.001;0.0	0.91255	D;D;D	0.001;0.0;0.0	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;0.999	0.92359	.;D;D	0.000001	0.84330	D	0.000000	0.999931;0.999931;1;0.84777;0.759784;0.759784	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	N80Y;N80Y;.;Q100L;Q111L;Q112L	.;2.985;2.985	0.85602	.;M;M	-4.93;-4.93;-4.93	0.98390	D;D;D	-5.65;-7.12;-7.28	0.94430	D;D;D	.;0.967;0.906	0.97750	0.9529	0.96438	D	0.9227	0.97443	D	10	0.9825621;0.9825621;0.9825621	0.98342	D;D;D	0.223189	0.87890	D	0.927;0.927;0.927	0.98229	0.944;0.944;0.944;	0.99279	Q9BQB6;Q9BQB6;Q9BQB6;	N80Y;N80Y;N80Y;	Loss of disorder (P = 0.0852);Loss of disorder (P = 0.0852);Loss of disorder (P = 0.0852);	0.87859002705;0.87859002705;0.87859002705	0.87740	.;.;0.9893921446108448	0.98933	.;.;1.29351261363	0.82853	0.675493955612	0.63624	T	.;.;0.959555	0.99471	.;.;D	0.556711	0.96033	D	0.5619	0.95973	D	0.997923612594604	0.92772	D	0.957004;0.963604;0.89971	0.86445	D;D;D	.;.;0.97779673	0.98937	.;.;0.9763949	0.99711	.;.;0.97779673	0.98937	.;.;0.9763949	0.99711	.;-5.902;-5.692	0.72943	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.9582;0.939;0.9179	0.87839	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.322779	0.88734	29.8	4.220975	0.88695	29.6	0.9950208526287514	0.68089	0.92333	0.55470	D	ALL	0.901542	0.84834	D	0.519712604612011	0.68255	5.192245	0.576842795162268	0.73284	5.945273	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.807000	0.68825	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093357	T	C	N	D	.	16	31104678	16	31012179	80;80;80	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.238A>G;c.238A>G;c.238A>G	p.N80D;p.N80D;p.N80D	c.238A>G;c.238A>G;c.238A>G	p.Asn80Asp;p.Asn80Asp;p.Asn80Asp	c.238A>G;c.238A>G;c.238A>G	p.Asn80Asp;p.Asn80Asp;p.Asn80Asp	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AAC;AAC;AAC	1;1;1	0;0;0	T	./.	./.	./.	./.	0.011;0.008;0.0	0.91255	D;D;D	0.006;0.0;0.0	0.92824	D;D;D	.;0.998;0.999	0.77913	.;D;D	.;0.994;0.996	0.84481	.;D;D	0.000001	0.84330	D	0.000000	0.999403;0.999403;1;0.987786;0.978693;0.978693	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	N80D;N80D;.;Q100R;Q111R;Q112R	.;2.985;2.985	0.85602	.;M;M	-4.85;-4.85;-4.85	0.98245	D;D;D	-3.96;-4.52;-4.55	0.78553	D;D;D	.;0.926;0.894	0.93018	0.8087	0.94518	D	0.9292	0.97662	D	10	0.9744252;0.9744252;0.9744252	0.97154	D;D;D	0.179338	0.85416	D	0.878;0.878;0.878	0.96391	0.951;0.951;0.951;	0.99428	Q9BQB6;Q9BQB6;Q9BQB6;	N80D;N80D;N80D;	Gain of relative solvent accessibility (P = 0.1571);Gain of relative solvent accessibility (P = 0.1571);Gain of relative solvent accessibility (P = 0.1571);	0.811439811116;0.811439811116;0.811439811116	0.80967	.;.;0.9874541331597889	0.98739	.;.;1.24671669399	0.81698	0.682764649391	0.64666	T	.;.;0.957886	0.99437	.;.;D	0.288613	0.82041	D	0.176796	0.81810	D	0.995361149311066	0.87292	D	0.958304;0.964804;0.90281	0.86967	D;D;D	.;.;0.9874849	0.99623	.;.;0.9698052	0.99456	.;.;0.9874849	0.99623	.;.;0.9698052	0.99457	.;-4.729;-0.64	0.59955	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.9482;0.9165;0.8759	0.86720	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.259018	0.87186	29.2	4.109134	0.85892	28.7	0.99792133367884861	0.87750	0.91598	0.53864	D	ALL	0.904334	0.85449	D	0.577027732349416	0.71743	5.697442	0.625814529080899	0.76820	6.562032	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.807000	0.68825	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.999000	0.91618	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093360	A	T	S	T	rs1186082539	16	31104681	16	31012182	79;79;79	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.235T>A;c.235T>A;c.235T>A	p.S79T;p.S79T;p.S79T	c.235T>A;c.235T>A;c.235T>A	p.Ser79Thr;p.Ser79Thr;p.Ser79Thr	c.235T>A;c.235T>A;c.235T>A	p.Ser79Thr;p.Ser79Thr;p.Ser79Thr	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TCC;TCC;TCC	1;1;1	0;0;0	A	./.	./.	./.	./.	0.01;0.033;0.006	0.61437	D;D;D	0.004;0.015;0.006	0.74150	D;D;D	.;0.933;0.722	0.52105	.;P;P	.;0.517;0.285	0.48105	.;P;B	0.001221	0.39820	N	0.175833	1;0.971441;0.982036;0.982036;0.950784;0.950784	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;I99N;S79T;S79T;I110N;I111N	.;2.175;2.175	0.60977	.;M;M	-4.68;-4.68;-4.68	0.97989	D;D;D	-0.63;-0.59;-0.59	0.18459	N;N;N	.;0.472;0.401	0.50778	0.5998	0.91899	D	0.8794	0.95995	D	10	0.6934204;0.6934204;0.6934204	0.71996	D;D;D	0.447349	0.94277	D	0.564;0.564;0.564	0.82175	0.523;0.523;0.523;	0.62668	Q9BQB6;Q9BQB6;Q9BQB6;	S79T;S79T;S79T;	Loss of disorder (P = 0.0809);Loss of disorder (P = 0.0809);Loss of disorder (P = 0.0809);	0.746830719681;0.746830719681;0.746830719681	0.74454	.;.;0.5201387057150041	0.51936	.;.;1.06199324863	0.76512	0.649664163589	0.59938	T	.;.;0.649913	0.89364	.;.;D	0.133859	0.67736	D	-0.0454977	0.67329	D	0.906593859195709	0.56065	D	0.80432;0.80172;0.919808	0.70989	T;T;D	.;.;0.8461488	0.87052	.;.;0.6164484	0.77671	.;.;0.8461488	0.87053	.;.;0.6164484	0.77672	.;-4.272;-4.093	0.50911	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.3622;0.3964;0.3523	0.59375	A;A;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.328455	0.59733	24.2	2.932360	0.53208	23.4	0.99560602326087166	0.71769	0.77361	0.38027	D	ALL	0.713031	0.66596	D	0.324813955288073	0.57425	3.909734	0.364336501531185	0.59377	4.11488	0.999999999815132	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	3.97	0.45241	3.854000	0.55657	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.998000	0.85391	0.7025:0.0:0.2975:0.0	6.3753	0.20707	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093361	T	A	Q	H	.	16	31104682	16	31012183	78;78;78	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.234A>T;c.234A>T;c.234A>T	p.Q78H;p.Q78H;p.Q78H	c.234A>T;c.234A>T;c.234A>T	p.Gln78His;p.Gln78His;p.Gln78His	c.234A>T;c.234A>T;c.234A>T	p.Gln78His;p.Gln78His;p.Gln78His	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAA;CAA;CAA	3;3;3	2;2;2	T	./.	./.	./.	./.	0.532;0.53;0.001	0.78490	T;T;D	0.003;0.009;0.019	0.76473	D;D;D	.;0.999;0.999	0.77913	.;D;D	.;0.997;0.998	0.88582	.;D;D	0.000006	0.62929	D	0.000000	0.962739;0.962739;1;0.933733;0.888923;0.888923	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	Q78H;Q78H;.;I99F;I110F;I111F	.;2.69;2.69	0.78713	.;M;M	-4.75;-4.75;-4.75	0.98096	D;D;D	-3.47;-3.46;-3.65	0.69950	D;D;D	.;0.817;0.795	0.81261	0.6538	0.92591	D	0.9379	0.97958	D	10	0.7537719;0.7537719;0.7537719	0.75830	D;D;D	0.223317	0.87896	D	0.807;0.807;0.807	0.93738	0.683;0.683;0.683;	0.82078	Q9BQB6;Q9BQB6;Q9BQB6;	Q78H;Q78H;Q78H;	Gain of catalytic residue at Q78 (P = 0.0287);Gain of catalytic residue at Q78 (P = 0.0287);Gain of catalytic residue at Q78 (P = 0.0287);	0.746547232912;0.746547232912;0.746547232912	0.74425	.;.;0.8908099221845664	0.89050	.;.;1.12353754933	0.78372	0.547534942627	0.45509	T	.;.;0.930208	0.98814	.;.;D	0.136044	0.67947	D	-0.0423592	0.67542	D	0.987248241901398	0.77778	D	0.959304;0.959304;0.940306	0.84657	D;D;D	.;.;0.96540403	0.97819	.;.;0.8933194	0.94502	.;.;0.96540403	0.97819	.;.;0.8933194	0.94503	.;-4.422;0.0	0.54223	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.8708;0.9052;0.8207	0.83105	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.660141	0.68278	25.3	3.797217	0.75391	26.3	0.99690691166288592	0.79909	0.74149	0.36269	D	ALL	0.507687	0.53788	D	0.400675478213947	0.61461	4.347386	0.347445169061989	0.58353	4.005424	0.999999999876683	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	3.99	0.45527	0.596000	0.23744	.	.	0.665000	0.62972	1.000000	0.71638	0.995000	0.32472	0.997000	0.79791	0.0:0.437:0.0:0.563	5.1984	0.14575	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093361	T	G	Q	H	.	16	31104682	16	31012183	78;78;78	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.234A>C;c.234A>C;c.234A>C	p.Q78H;p.Q78H;p.Q78H	c.234A>C;c.234A>C;c.234A>C	p.Gln78His;p.Gln78His;p.Gln78His	c.234A>C;c.234A>C;c.234A>C	p.Gln78His;p.Gln78His;p.Gln78His	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAA;CAA;CAA	3;3;3	2;2;2	T	./.	./.	./.	./.	0.532;0.53;0.001	0.78490	T;T;D	0.003;0.009;0.019	0.76473	D;D;D	.;0.999;0.999	0.77913	.;D;D	.;0.997;0.998	0.88582	.;D;D	0.000006	0.62929	D	0.000000	0.962739;0.962739;1;0.999241;0.998664;0.998664	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	Q78H;Q78H;.;I99L;I110L;I111L	.;2.69;2.69	0.78713	.;M;M	-4.75;-4.75;-4.75	0.98096	D;D;D	-3.47;-3.46;-3.65	0.69950	D;D;D	.;0.817;0.795	0.81261	0.5828	0.91672	D	0.9379	0.97958	D	10	0.7507317;0.7507317;0.7507317	0.75617	D;D;D	0.218508	0.87662	D	0.807;0.807;0.807	0.93738	0.683;0.683;0.683;	0.82078	Q9BQB6;Q9BQB6;Q9BQB6;	Q78H;Q78H;Q78H;	Gain of catalytic residue at Q78 (P = 0.0287);Gain of catalytic residue at Q78 (P = 0.0287);Gain of catalytic residue at Q78 (P = 0.0287);	0.746547232912;0.746547232912;0.746547232912	0.74425	.;.;0.8908098946424975	0.89050	.;.;1.12353754933	0.78372	0.547534942627	0.45509	T	.;.;0.930208	0.98814	.;.;D	0.13346	0.67696	D	-0.0460703	0.67289	D	0.985133409500122	0.76219	D	0.959304;0.959304;0.940306	0.84657	D;D;D	.;.;0.96540403	0.97819	.;.;0.8933194	0.94502	.;.;0.96540403	0.97819	.;.;0.8933194	0.94503	.;-4.422;0.0	0.54223	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.8708;0.9052;0.8207	0.83105	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.540303	0.65138	24.8	3.639999	0.70794	25.5	0.99676735434341857	0.78977	0.75233	0.36826	D	ALL	0.515830	0.54262	D	0.400675478213947	0.61461	4.347386	0.347445169061989	0.58353	4.005424	0.999999999876683	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	3.99	0.45527	0.596000	0.23744	.	.	0.665000	0.62972	1.000000	0.71638	0.995000	0.32472	0.997000	0.79791	0.0:0.437:0.0:0.563	5.1984	0.14575	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093362	T	A	Q	L	.	16	31104683	16	31012184	78;78;78	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.233A>T;c.233A>T;c.233A>T	p.Q78L;p.Q78L;p.Q78L	c.233A>T;c.233A>T;c.233A>T	p.Gln78Leu;p.Gln78Leu;p.Gln78Leu	c.233A>T;c.233A>T;c.233A>T	p.Gln78Leu;p.Gln78Leu;p.Gln78Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAA;CAA;CAA	2;2;2	0;0;0	T	./.	./.	./.	./.	0.889;1.0;0.124	0.27426	T;T;T	0.292;0.649;1.0	0.20877	T;T;T	.;0.996;0.997	0.70673	.;D;D	.;0.99;0.994	0.82059	.;D;D	0.000006	0.62929	D	0.000000	0.999637;0.999637;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	Q78L;Q78L;.;.;.;.	.;1.65;1.65	0.42232	.;L;L	-4.6;-4.6;-4.6	0.97849	D;D;D	-3.5;-3.18;-3.87	0.72594	D;D;D	.;0.796;0.773	0.79214	1.0347	0.97806	D	0.9371	0.97930	D	10	0.83033836;0.83033836;0.83033836	0.82198	D;D;D	0.08163	0.73724	D	0.786;0.786;0.786	0.92908	0.723;0.723;0.723;	0.85761	Q9BQB6;Q9BQB6;Q9BQB6;	Q78L;Q78L;Q78L;	Loss of disorder (P = 0.0499);Loss of disorder (P = 0.0499);Loss of disorder (P = 0.0499);	0.878445433544;0.878445433544;0.878445433544	0.87725	.;.;0.8658526901977474	0.86550	.;.;1.11711265099	0.78202	0.507340788841	0.39851	T	.;.;0.819703	0.95578	.;.;D	0.414849	0.90746	D	0.358126	0.90630	D	0.974132657051086	0.70382	D	0.911209;0.911209;0.888711	0.68535	D;D;D	.;.;0.54568493	0.69714	.;.;0.36875755	0.62159	.;.;0.54568493	0.69716	.;.;0.36875755	0.62159	.;0.0;-4.726	0.59903	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.5017;0.5298;0.4231	0.65911	A;A;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.982466	0.78016	26.9	3.871321	0.77826	26.7	0.99625625581089261	0.75716	0.92333	0.55470	D	ALL	0.885188	0.81550	D	0.618333054140069	0.74334	6.115137	0.644371076600935	0.78192	6.827043	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.807000	0.68825	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.995000	0.73285	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093362	T	C	Q	R	.	16	31104683	16	31012184	78;78;78	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.233A>G;c.233A>G;c.233A>G	p.Q78R;p.Q78R;p.Q78R	c.233A>G;c.233A>G;c.233A>G	p.Gln78Arg;p.Gln78Arg;p.Gln78Arg	c.233A>G;c.233A>G;c.233A>G	p.Gln78Arg;p.Gln78Arg;p.Gln78Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAA;CAA;CAA	2;2;2	0;0;0	T	./.	./.	./.	./.	0.374;0.363;0.003	0.68238	T;T;D	0.006;0.018;0.035	0.70582	D;D;D	.;0.996;0.997	0.70673	.;D;D	.;0.986;0.992	0.80445	.;D;D	0.000006	0.62929	D	0.000000	0.994753;0.994753;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	Q78R;Q78R;.;.;.;.	.;2.69;2.69	0.78713	.;M;M	-4.75;-4.75;-4.75	0.98096	D;D;D	-2.44;-2.62;-2.8	0.59226	N;D;D	.;0.818;0.799	0.81360	1.0918	0.99311	D	0.9482	0.98311	D	10	0.84265375;0.84265375;0.84265375	0.83423	D;D;D	0.065702	0.69658	D	0.783;0.783;0.783	0.92787	0.706;0.706;0.706;	0.84236	Q9BQB6;Q9BQB6;Q9BQB6;	Q78R;Q78R;Q78R;	Loss of helix (P = 0.0558);Loss of helix (P = 0.0558);Loss of helix (P = 0.0558);	0.853848861771;0.853848861771;0.853848861771	0.85244	.;.;0.9095331858932938	0.90927	.;.;1.08736435357	0.77331	0.549975275993	0.45854	T	.;.;0.920622	0.98577	.;.;D	0.50576	0.94459	D	0.488713	0.94380	D	0.973663747310638	0.70189	D	0.947205;0.947205;0.921108	0.79675	D;D;D	.;.;0.86431855	0.88417	.;.;0.7962105	0.88032	.;.;0.86431855	0.88418	.;.;0.7962105	0.88033	.;-3.938;-3.776	0.42755	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.5094;0.4362;0.3124	0.65006	A;A;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.162808	0.84247	28.3	4.027535	0.83253	27.9	0.99848803778133277	0.92838	0.91598	0.53864	D	ALL	0.888386	0.82145	D	0.722699270910575	0.81122	7.448533	0.725709240088604	0.84330	8.262184	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.807000	0.68825	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.995000	0.73285	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093363	G	C	Q	E	.	16	31104684	16	31012185	78;78;78	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.232C>G;c.232C>G;c.232C>G	p.Q78E;p.Q78E;p.Q78E	c.232C>G;c.232C>G;c.232C>G	p.Gln78Glu;p.Gln78Glu;p.Gln78Glu	c.232C>G;c.232C>G;c.232C>G	p.Gln78Glu;p.Gln78Glu;p.Gln78Glu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAA;CAA;CAA	1;1;1	0;0;0	G	./.	./.	./.	./.	0.286;0.285;0.002	0.72154	T;T;D	0.028;0.018;0.042	0.59732	D;D;D	.;0.99;0.992	0.64738	.;D;D	.;0.979;0.987	0.77487	.;D;D	0.000006	0.62929	D	0.000000	1;1;1;0.997813;0.997813;1	0.81001	D;D;D;D;D;D	complex_aae;complex_aae;complex_aae;simple_aae;simple_aae;without_aae	S110*;S109*;S98*;Q78E;Q78E;.	.;2.69;2.69	0.78713	.;M;M	-4.75;-4.75;-4.75	0.98096	D;D;D	-2.07;-2.09;-2.2	0.49519	N;N;N	.;0.773;0.763	0.77039	-0.3222	0.74360	T	0.4724	0.79721	T	10	0.8179873;0.8179873;0.8179873	0.81022	D;D;D	.	.	.	0.714;0.714;0.714	0.89831	0.721;0.721;0.721;	0.85585	Q9BQB6;Q9BQB6;Q9BQB6;	Q78E;Q78E;Q78E;	Loss of helix (P = 0.0558);Loss of helix (P = 0.0558);Loss of helix (P = 0.0558);	0.77048865801;0.77048865801;0.77048865801	0.76838	.;.;0.8843834761577811	0.88406	.;.;1.11403762411	0.78128	0.514942526817	0.40914	T	.;.;0.805939	0.95099	.;.;D	0.387367	0.89169	D	0.31865	0.89032	D	0.976522088050842	0.71419	D	0.966503;0.966503;0.951605	0.87759	D;D;D	.;.;0.94843537	0.96107	.;.;0.8482187	0.91385	.;.;0.94843537	0.96107	.;.;0.8482187	0.91385	.;-4.511;-2.298	0.56022	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.3487;0.3659;0.2528	0.57579	A;A;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.968934	0.77544	26.8	3.876541	0.77973	26.7	0.9948245701227092	0.66959	0.94967	0.62957	D	ALL	0.982652	0.99906	D	0.586429745408769	0.72326	5.788311	0.661002770416033	0.79433	7.081303	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	7.187000	0.77268	.	.	0.676000	0.76740	1.000000	0.71638	1.000000	0.68203	0.991000	0.66497	0.0:0.0:1.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093365	T	A	N	I	.	16	31104686	16	31012187	77;77;77	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.230A>T;c.230A>T;c.230A>T	p.N77I;p.N77I;p.N77I	c.230A>T;c.230A>T;c.230A>T	p.Asn77Ile;p.Asn77Ile;p.Asn77Ile	c.230A>T;c.230A>T;c.230A>T	p.Asn77Ile;p.Asn77Ile;p.Asn77Ile	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AAT;AAT;AAT	2;2;2	0;0;0	T	./.	./.	./.	./.	0.035;0.035;0.035	0.43708	D;D;D	0.0;0.0;0.0	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;0.999	0.92359	.;D;D	0.000001	0.62929	D	0.000000	0.999938;0.999938;1;0.926791;0.8779;0.8779	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	N77I;N77I;.;Q97H;Q108H;Q109H	.;2.36;2.36	0.67893	.;M;M	-3.09;-4.6;-4.9	0.98333	D;D;D	-6.84;-7.65;-7.65	0.95483	D;D;D	.;0.904;0.855	0.90476	0.8293	0.94773	D	0.9108	0.97043	D	10	0.95803857;0.95803857;0.95803857	0.95183	D;D;D	0.18185	0.85582	D	0.785;0.785;0.785	0.92868	0.855;0.855;0.855;	0.95491	Q9BQB6;Q9BQB6;Q9BQB6;	N77I;N77I;N77I;	Gain of sheet (P = 0.0221);Gain of sheet (P = 0.0221);Gain of sheet (P = 0.0221);	0.890129106707;0.890129106707;0.890129106707	0.88904	.;.;0.9797879635264788	0.97969	.;.;1.30182671262	0.83034	0.68795132637	0.65411	T	.;.;0.896073	0.97925	.;.;D	0.35539	0.86893	D	0.272716	0.86722	D	0.99533599615097	0.87239	D	0.935306;0.935306;0.936706	0.76258	D;D;D	.;.;0.95030504	0.96296	.;.;0.8573254	0.91997	.;.;0.95030504	0.96296	.;.;0.8573254	0.91998	.;-5.331;-5.673	0.71160	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.8408;0.6896;0.6161	0.79281	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.319065	0.88648	29.7	4.282514	0.89773	31	0.99175419715588697	0.54527	0.92333	0.55470	D	ALL	0.899598	0.84418	D	0.536598604169088	0.69271	5.333197	0.607569207060665	0.75490	6.319495	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.196000	0.58203	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.983000	0.59808	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093365	T	C	N	S	rs2057303532	16	31104686	16	31012187	77;77;77	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.230A>G;c.230A>G;c.230A>G	p.N77S;p.N77S;p.N77S	c.230A>G;c.230A>G;c.230A>G	p.Asn77Ser;p.Asn77Ser;p.Asn77Ser	c.230A>G;c.230A>G;c.230A>G	p.Asn77Ser;p.Asn77Ser;p.Asn77Ser	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AAT;AAT;AAT	2;2;2	0;0;0	T	./.	./.	./.	./.	0.019;0.021;0.005	0.63226	D;D;D	0.003;0.0;0.006	0.92824	D;D;D	.;0.998;0.999	0.77913	.;D;D	.;0.994;0.996	0.84481	.;D;D	0.000001	0.62929	D	0.000000	0.999426;0.999426;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	N77S;N77S;.;.;.;.	.;2.91;2.91	0.84121	.;M;M	-3.06;-4.57;-4.88	0.98296	D;D;D	-3.82;-4.19;-4.35	0.76900	D;D;D	.;0.729;0.7	0.73015	1.1095	0.99861	D	0.9678	0.98979	D	10	0.96545005;0.96545005;0.96545005	0.96019	D;D;D	0.055809	0.66374	D	0.754;0.754;0.754	0.91583	0.91;0.91;0.91;	0.98190	Q9BQB6;Q9BQB6;Q9BQB6;	N77S;N77S;N77S;	Gain of disorder (P = 0.0683);Gain of disorder (P = 0.0683);Gain of disorder (P = 0.0683);	0.862475478164;0.862475478164;0.862475478164	0.86113	.;.;0.9280195740382179	0.92779	.;.;1.00448479125	0.74533	0.644124567509	0.59149	T	.;.;0.897457	0.97963	.;.;D	0.156188	0.69846	D	-0.0134238	0.69461	D	0.992299914360046	0.82739	D	0.872113;0.872113;0.868113	0.57861	D;D;D	.;.;0.8920186	0.90681	.;.;0.72575235	0.83801	.;.;0.8920186	0.90682	.;.;0.72575235	0.83802	.;-3.704;-2.754	0.36822	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.5696;0.4821;0.3293	0.67618	P;A;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.912631	0.75689	26.4	3.816356	0.76009	26.4	0.99884554010665405	0.95970	0.91598	0.53864	D	ALL	0.887027	0.81891	D	0.852521954565484	0.89252	9.895747	0.821944204060421	0.91275	10.80544	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.196000	0.58203	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.983000	0.59808	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	152184	6.570990e-06	0	1	68016	1.470240e-05	0	0	41452	0.000000e+00	0	0	910	0.000000e+00	0	0	15276	0.000000e+00	0	0	3472	0.000000e+00	0	0	5184	0.000000e+00	0	0	10630	0.000000e+00	0	0	316	0.000000e+00	0	1	68016	1.470240e-05	0	0	4836	0.000000e+00	0	0	32910	0.000000e+00	0	1	134770	7.420050e-06	0	1	147934	6.759770e-06	0	0	80754	0.000000e+00	0	0	9100	0.000000e+00	0	0	60	0.000000e+00	0	0	4688	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5498	0.000000e+00	0	0	246	0.000000e+00	0	0	6848	0.000000e+00	0	0	3114	0.000000e+00	0	0	32478	0.000000e+00	0	0	860	0.000000e+00	0	0	14830	0.000000e+00	0	0	3388	0.000000e+00	0	0	5184	0.000000e+00	0	0	6988	0.000000e+00	0	0	310	0.000000e+00	0	1	63896	1.565040e-05	0	0	4834	0.000000e+00	0	0	41130	0.000000e+00	0	0	910	0.000000e+00	0	0	15088	0.000000e+00	0	0	3302	0.000000e+00	0	0	4948	0.000000e+00	0	0	10630	0.000000e+00	0	0	304	0.000000e+00	0	1	64796	1.543310e-05	0	0	4804	0.000000e+00	0	0	24828	0.000000e+00	0	0	112	0.000000e+00	0	0	12904	0.000000e+00	0	0	998	0.000000e+00	0	0	3742	0.000000e+00	0	0	10538	0.000000e+00	0	0	272	0.000000e+00	0	0	21034	0.000000e+00	0	0	4808	0.000000e+00	0	0	7618	0	0	108	0	0	84	0	0	2708	0	0	146	0	0	610	0	0	24	0	0	94	0	0	470	0	0	2816	0	0	108	0	0	11862	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093368	A	C	L	R	.	16	31104689	16	31012190	76;76;76	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.227T>G;c.227T>G;c.227T>G	p.L76R;p.L76R;p.L76R	c.227T>G;c.227T>G;c.227T>G	p.Leu76Arg;p.Leu76Arg;p.Leu76Arg	c.227T>G;c.227T>G;c.227T>G	p.Leu76Arg;p.Leu76Arg;p.Leu76Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTC;CTC;CTC	2;2;2	0;0;0	A	./.	./.	./.	./.	0.086;0.001;0.001	0.78490	T;D;D	0.001;0.001;0.001	0.83351	D;D;D	.;0.996;0.971	0.68779	.;D;D	.;0.919;0.845	0.65474	.;D;P	0.000752	0.42006	D	0.102660	0.99882;0.99882;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	L76R;L76R;.;.;.;.	.;2.765;2.765	0.80766	.;M;M	-3.52;-4.78;-5.16	0.98796	D;D;D	-4.51;-4.98;-4.91	0.82141	D;D;D	.;0.885;0.896	0.89577	1.0921	0.99324	D	0.9704	0.99068	D	10	0.9559293;0.9559293;0.9559293	0.94955	D;D;D	0.242647	0.88769	D	0.849;0.849;0.849	0.95323	0.87;0.87;0.87;	0.96319	Q9BQB6;Q9BQB6;Q9BQB6;	L76R;L76R;L76R;	Gain of disorder (P = 0.0182);Gain of disorder (P = 0.0182);Gain of disorder (P = 0.0182);	0.881210493322;0.881210493322;0.881210493322	0.88004	.;.;0.9617284223657795	0.96158	.;.;1.38877873736	0.84944	0.615379095078	0.55075	T	.;.;0.939571	0.99041	.;.;D	0.499317	0.94271	D	0.479458	0.94192	D	0.985166251659393	0.76240	D	0.944306;0.944306;0.937306	0.78939	D;D;D	.;.;0.9284756	0.94084	.;.;0.90968996	0.95666	.;.;0.9284756	0.94085	.;.;0.90968996	0.95667	.;-3.938;-3.776	0.42755	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.855;0.7899;0.7991	0.80035	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.172195	0.84559	28.4	4.183794	0.87875	29.3	0.99693564352379804	0.80112	0.92300	0.55394	D	ALL	0.841662	0.75883	D	0.82656253453497	0.87736	9.32251	0.800925404684685	0.89858	10.15104	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	3.624000	0.53971	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.966000	0.53164	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093368	A	T	L	H	.	16	31104689	16	31012190	76;76;76	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.227T>A;c.227T>A;c.227T>A	p.L76H;p.L76H;p.L76H	c.227T>A;c.227T>A;c.227T>A	p.Leu76His;p.Leu76His;p.Leu76His	c.227T>A;c.227T>A;c.227T>A	p.Leu76His;p.Leu76His;p.Leu76His	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTC;CTC;CTC	2;2;2	0;0;0	A	./.	./.	./.	./.	0.001;0.0;0.0	0.91255	D;D;D	0.0;0.001;0.001	0.92824	D;D;D	.;0.999;0.997	0.77913	.;D;D	.;0.939;0.916	0.67449	.;D;D	0.000752	0.42006	D	0.102660	0.997835;0.997835;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	L76H;L76H;.;.;.;.	.;2.765;2.765	0.80766	.;M;M	-3.52;-4.87;-5.17	0.98809	D;D;D	-4.95;-5.45;-5.38	0.85468	D;D;D	.;0.684;0.748	0.74735	1.0924	0.99336	D	0.9711	0.99091	D	10	0.94793534;0.94793534;0.94793534	0.94122	D;D;D	0.256186	0.89320	D	0.842;0.842;0.842	0.95063	0.82;0.82;0.82;	0.93328	Q9BQB6;Q9BQB6;Q9BQB6;	L76H;L76H;L76H;	Gain of disorder (P = 0.0132);Gain of disorder (P = 0.0132);Gain of disorder (P = 0.0132);	0.895060038319;0.895060038319;0.895060038319	0.89402	.;.;0.9067593415054875	0.90648	.;.;1.30509170409	0.83107	0.613869071007	0.54863	T	.;.;0.940229	0.99057	.;.;D	0.370672	0.88097	D	0.294668	0.87946	D	0.989101350307465	0.79363	D	0.915608;0.915608;0.906409	0.69895	D;D;D	.;.;0.9258829	0.93826	.;.;0.9100582	0.95692	.;.;0.9258829	0.93827	.;.;0.9100582	0.95692	.;-4.422;0.0	0.54223	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.8941;0.8787;0.8413	0.82356	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.156925	0.84051	28.3	4.177840	0.87747	29.3	0.98054223015959929	0.37890	0.91900	0.54506	D	ALL	0.841662	0.75883	D	0.842103473069621	0.88654	9.66019	0.811545460062482	0.90585	10.47441	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	3.624000	0.53971	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.966000	0.53164	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093375	T	C	S	G	.	16	31104696	16	31012197	74;74;74	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.220A>G;c.220A>G;c.220A>G	p.S74G;p.S74G;p.S74G	c.220A>G;c.220A>G;c.220A>G	p.Ser74Gly;p.Ser74Gly;p.Ser74Gly	c.220A>G;c.220A>G;c.220A>G	p.Ser74Gly;p.Ser74Gly;p.Ser74Gly	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AGC;AGC;AGC	1;1;1	0;0;0	T	./.	./.	./.	./.	0.218;0.168;0.121	0.27783	T;T;T	0.367;0.247;0.359	0.23914	T;T;T	.;0.993;0.989	0.65571	.;D;D	.;0.826;0.813	0.59373	.;P;P	0.000006	0.62929	D	0.063358	0.993412;0.993412;1;0.993739;0.989028;0.989028	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	S74G;S74G;.;Q94R;Q105R;Q106R	.;2.525;2.525	0.73725	.;M;M	-3.18;-4.64;-5.0	0.98525	D;D;D	-2.37;-2.57;-2.35	0.55501	N;D;N	.;0.583;0.586	0.60664	0.8610	0.95165	D	0.9445	0.98184	D	10	0.86816156;0.86816156;0.86816156	0.86069	D;D;D	0.2142	0.87445	D	0.707;0.707;0.707	0.89514	0.739;0.739;0.739;	0.87147	Q9BQB6;Q9BQB6;Q9BQB6;	S74G;S74G;S74G;	Gain of sheet (P = 0.0827);Gain of sheet (P = 0.0827);Gain of sheet (P = 0.0827);	0.828733045965;0.828733045965;0.828733045965	0.82711	.;.;0.8760360809916401	0.87570	.;.;0.724457622991	0.62389	0.418246388435	0.27596	T	.;.;0.843416	0.96368	.;.;D	0.15175	0.69432	D	-0.0197982	0.69042	D	0.964844167232513	0.67083	D	0.552645;0.581242;0.588241	0.21547	T;T;T	.;.;0.5094649	0.67648	.;.;0.23006172	0.48097	.;.;0.5094649	0.67649	.;.;0.23006172	0.48096	.;-3.327;-3.773	0.38610	.;T;T	.;.;.	.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	.;.;.	0.2178;0.2539;0.1742	0.48867	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.287884	0.58729	24.1	3.360009	0.63535	24.5	0.99769175696201695	0.85750	0.91364	0.53385	D	ALL	0.914012	0.87680	D	0.683732690363635	0.78567	6.897628	0.693440075743645	0.81880	7.631367	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	3.813000	0.55340	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.886000	0.42526	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093377	T	A	D	V	.	16	31104698	16	31012199	73;73;73	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.218A>T;c.218A>T;c.218A>T	p.D73V;p.D73V;p.D73V	c.218A>T;c.218A>T;c.218A>T	p.Asp73Val;p.Asp73Val;p.Asp73Val	c.218A>T;c.218A>T;c.218A>T	p.Asp73Val;p.Asp73Val;p.Asp73Val	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GAC;GAC;GAC	2;2;2	0;0;0	T	./.	./.	./.	./.	0.005;0.012;0.001	0.78490	D;D;D	0.001;0.001;0.002	0.83351	D;D;D	.;0.999;0.999	0.77913	.;D;D	.;0.974;0.985	0.76457	.;D;D	0.000661	0.42516	D	0.164354	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	D73V;D73V;.;.;.;.	.;2.79;2.79	0.81396	.;M;M	-3.19;-4.71;-4.94	0.98409	D;D;D	-6.21;-6.92;-7.0	0.93697	D;D;D	.;0.587;0.695	0.70000	1.1001	0.99666	D	0.9645	0.98866	D	10	0.8883791;0.8883791;0.8883791	0.88174	D;D;D	0.231512	0.88279	D	0.820;0.820;0.820	0.94238	0.701;0.701;0.701;	0.83777	Q9BQB6;Q9BQB6;Q9BQB6;	D73V;D73V;D73V;	Loss of disorder (P = 0.0388);Loss of disorder (P = 0.0388);Loss of disorder (P = 0.0388);	0.889154365029;0.889154365029;0.889154365029	0.88806	.;.;0.8640863346912767	0.86372	.;.;1.21983900226	0.81051	0.467226207256	0.34300	T	.;.;0.933891	0.98904	.;.;D	0.482601	0.93795	D	0.455446	0.93717	D	0.976366698741913	0.71346	D	0.913109;0.90401;0.90031	0.69007	D;D;D	.;.;0.8525071	0.87521	.;.;0.8889241	0.94191	.;.;0.8525071	0.87523	.;.;0.8889241	0.94191	.;-3.811;-4.523	0.56265	.;T;T	.;.;0.2363670699409572	0.32007	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.4358;0.4423;0.3472	0.61822	A;A;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.354626	0.89360	30	4.575924	0.92158	32	0.99398310224998665	0.62656	0.87007	0.46420	D	ALL	0.719595	0.67043	D	0.748371112698959	0.82797	7.852665	0.711247925872859	0.83231	7.968223	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	3.051000	0.49576	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.897000	0.43391	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093377	T	C	D	G	.	16	31104698	16	31012199	73;73;73	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.218A>G;c.218A>G;c.218A>G	p.D73G;p.D73G;p.D73G	c.218A>G;c.218A>G;c.218A>G	p.Asp73Gly;p.Asp73Gly;p.Asp73Gly	c.218A>G;c.218A>G;c.218A>G	p.Asp73Gly;p.Asp73Gly;p.Asp73Gly	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GAC;GAC;GAC	2;2;2	0;0;0	T	./.	./.	./.	./.	0.055;0.193;0.059	0.38407	T;T;T	0.075;0.079;0.087	0.42794	T;T;T	.;0.986;0.989	0.62824	.;D;D	.;0.793;0.869	0.61749	.;P;P	0.000661	0.42516	D	0.164354	0.996714;0.996714;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	D73G;D73G;.;.;.;.	.;2.79;2.79	0.81396	.;M;M	-3.17;-4.69;-4.93	0.98390	D;D;D	-4.82;-5.24;-5.33	0.84601	D;D;D	.;0.316;0.469	0.50508	1.0736	0.98690	D	0.9494	0.98352	D	10	0.8308002;0.8308002;0.8308002	0.82244	D;D;D	0.082277	0.73867	D	0.719;0.719;0.719	0.90056	0.685;0.685;0.685;	0.82271	Q9BQB6;Q9BQB6;Q9BQB6;	D73G;D73G;D73G;	Gain of sheet (P = 0.0827);Gain of sheet (P = 0.0827);Gain of sheet (P = 0.0827);	0.781583760937;0.781583760937;0.781583760937	0.77956	.;.;0.7809637372031629	0.78047	.;.;0.497562604243	0.48255	0.478959679604	0.35914	T	.;.;0.871006	0.97213	.;.;D	0.334736	0.85482	D	0.243049	0.85291	D	0.955225646495819	0.64455	D	0.775922;0.747625;0.752425	0.40781	T;T;T	.;.;0.50130194	0.67171	.;.;0.5942718	0.76448	.;.;0.50130194	0.67172	.;.;0.5942718	0.76449	.;-3.327;-3.773	0.38610	.;T;T	.;.;0.15369339546991428	0.18301	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.1273;0.1397;0.1124	0.30608	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.093812	0.81874	27.7	4.611905	0.92289	32	0.99448224019386688	0.65122	0.82345	0.41586	D	ALL	0.663444	0.63296	D	0.622114846024982	0.74575	6.156029	0.623145218283617	0.76624	6.525527	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	3.051000	0.49576	.	.	0.665000	0.62972	1.000000	0.71638	1.000000	0.68203	0.897000	0.43391	0.0:0.0:0.0:1.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093378	C	T	D	N	.	16	31104699	16	31012200	73;73;73	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.217G>A;c.217G>A;c.217G>A	p.D73N;p.D73N;p.D73N	c.217G>A;c.217G>A;c.217G>A	p.Asp73Asn;p.Asp73Asn;p.Asp73Asn	c.217G>A;c.217G>A;c.217G>A	p.Asp73Asn;p.Asp73Asn;p.Asp73Asn	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GAC;GAC;GAC	1;1;1	0;0;0	C	./.	./.	./.	./.	0.084;0.107;0.01	0.56456	T;T;D	0.048;0.056;0.078	0.48594	D;T;T	.;0.687;0.733	0.42736	.;P;P	.;0.189;0.287	0.40572	.;B;B	0.000661	0.42516	D	0.164354	0.964319;0.964319;1;0.984987;0.973865;0.973865	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	D73N;D73N;.;G93E;G104E;G105E	.;1.89;1.89	0.50145	.;L;L	-3.13;-4.66;-4.9	0.98333	D;D;D	-3.02;-3.09;-3.19	0.64593	D;D;D	.;0.189;0.256	0.28965	0.7641	0.93967	D	0.9120	0.97083	D	10	0.65582436;0.65582436;0.65582436	0.69867	D;D;D	0.24924	0.89042	D	0.386;0.386;0.386	0.70276	0.663;0.663;0.663;	0.80098	Q9BQB6;Q9BQB6;Q9BQB6;	D73N;D73N;D73N;	Gain of helix (P = 0.1736);Gain of helix (P = 0.1736);Gain of helix (P = 0.1736);	0.662036563411;0.662036563411;0.662036563411	0.65920	.;.;0.6446878936880546	0.64403	.;.;0.375896712057	0.39039	0.508311331272	0.39986	T	.;.;0.826901	0.95827	.;.;D	0.112022	0.65562	D	-0.0768642	0.65133	T	0.894602239131927	0.54602	D	0.89841;0.888511;0.80202	0.64469	D;D;T	.;.;0.35002804	0.57069	.;.;0.23685376	0.48968	.;.;0.35002804	0.57069	.;.;0.23685376	0.48967	.;-5.236;-2.908	0.66936	.;T;T	.;.;0.1531748410509232	0.18199	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.1377;0.1384;0.1063	0.30264	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	2.940376	0.50746	23.3	3.164586	0.58637	24.0	0.9987092067364719	0.94815	0.77852	0.38329	D	ALL	0.481374	0.52269	N	0.239660349120496	0.53130	3.483293	0.295494374951467	0.55275	3.690784	0.999999999979915	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	5.23	0.72570	2.364000	0.43840	.	.	0.599000	0.40250	0.975000	0.34726	1.000000	0.68203	0.895000	0.43227	0.0:0.7921:0.136:0.072	10.2115	0.42319	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093383	C	G	G	A	.	16	31104704	16	31012205	71;71;71	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.212G>C;c.212G>C;c.212G>C	p.G71A;p.G71A;p.G71A	c.212G>C;c.212G>C;c.212G>C	p.Gly71Ala;p.Gly71Ala;p.Gly71Ala	c.212G>C;c.212G>C;c.212G>C	p.Gly71Ala;p.Gly71Ala;p.Gly71Ala	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GGA;GGA;GGA	2;2;2	0;0;0	C	./.	./.	./.	./.	0.048;0.028;0.052	0.46129	D;D;T	0.031;0.033;0.037	0.53788	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;0.999	0.92359	.;D;D	0.000003	0.62929	D	0.000000	0.995067;0.995067;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	G71A;G71A;.;.;.;.	.;2.295;2.295	0.65404	.;M;M	-3.1;-4.75;-4.98	0.98487	D;D;D	-4.17;-4.57;-4.74	0.80172	D;D;D	.;0.539;0.629	0.64308	1.0541	0.98206	D	0.9504	0.98385	D	10	0.96968925;0.96968925;0.96968925	0.96534	D;D;D	0.081688	0.73737	D	0.777;0.777;0.777	0.92542	0.855;0.855;0.855;	0.95491	Q9BQB6;Q9BQB6;Q9BQB6;	G71A;G71A;G71A;	Loss of sheet (P = 0.0457);Loss of sheet (P = 0.0457);Loss of sheet (P = 0.0457);	0.824805036109;0.824805036109;0.824805036109	0.82314	.;.;0.796896300777901	0.79642	.;.;1.18777844559	0.80193	0.539130330086	0.44322	T	.;.;0.870811	0.97208	.;.;D	0.494847	0.94146	D	0.473037	0.94069	D	0.926039756500507	0.58809	D	0.845515;0.845515;0.831217	0.52437	T;T;T	.;.;0.7882955	0.83166	.;.;0.670462	0.80664	.;.;0.7882955	0.83168	.;.;0.670462	0.80665	.;-3.364;-3.435	0.30034	.;T;T	.;.;0.2648676221477512	0.35717	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.5501;0.6213;0.5481	0.69755	A;P;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.071244	0.53623	23.6	3.466566	0.66247	24.9	0.99846341585281129	0.92576	0.94982	0.63010	D	AEFDGBHCI	0.876626	0.80074	D	0.747796516303636	0.82761	7.843102	0.76535121807407	0.87300	9.17445	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	2.907000	0.48440	.	.	0.599000	0.40250	0.990000	0.36992	1.000000	0.68203	0.966000	0.53164	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093386	A	G	L	P	.	16	31104707	16	31012208	70;70;70	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.209T>C;c.209T>C;c.209T>C	p.L70P;p.L70P;p.L70P	c.209T>C;c.209T>C;c.209T>C	p.Leu70Pro;p.Leu70Pro;p.Leu70Pro	c.209T>C;c.209T>C;c.209T>C	p.Leu70Pro;p.Leu70Pro;p.Leu70Pro	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTG;CTG;CTG	2;2;2	0;0;0	A	./.	./.	./.	./.	0.011;0.005;0.008	0.63226	D;D;D	0.008;0.008;0.009	0.67890	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;1.0	0.97372	.;D;D	0.000102	0.50451	D	0.000000	0.999998;0.999978;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	L70P;L70P;.;.;.;.	.;2.51;2.51	0.73131	.;M;M	-3.27;-4.75;-5.09	0.98684	D;D;D	-3.88;-4.67;-4.52	0.79571	D;D;D	.;0.91;0.921	0.92433	1.1027	0.99763	D	0.9672	0.98958	D	10	0.9425433;0.9425433;0.9425433	0.93579	D;D;D	0.225371	0.87994	D	0.859;0.859;0.859	0.95691	0.803;0.803;0.803;	0.92160	Q9BQB6;Q9BQB6;Q9BQB6;	L70P;L70P;L70P;	Loss of catalytic residue at L70 (P = 0.0048);Loss of catalytic residue at L70 (P = 0.0048);Loss of catalytic residue at L70 (P = 0.0048);	0.879020957448;0.879020957448;0.879020957448	0.87783	.;.;0.9423296756455923	0.94213	.;.;1.50258110785	0.87060	0.615283787251	0.55062	T	.;.;0.89522	0.97902	.;.;D	0.517896	0.94822	D	0.506146	0.94745	D	0.997792720794678	0.92438	D	0.826617;0.826617;0.80432	0.49005	T;T;T	.;.;0.9719428	0.98439	.;.;0.9368798	0.97561	.;.;0.9719428	0.98439	.;.;0.9368798	0.97561	.;-3.663;-4.659	0.58755	.;T;T	.;.;0.3019417174725089	0.39935	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	0.7663;0.6676;0.5782	0.75762	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.149235	0.83794	28.2	4.201163	0.88265	29.5	0.99918335609795028	0.98586	0.88979	0.49177	D	ALL	0.853035	0.76997	D	0.747386450702895	0.82732	7.836422	0.724890679057941	0.84268	8.24511	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.798000	0.62203	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.981000	0.58702	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093386	A	T	L	Q	rs1209106306	16	31104707	16	31012208	70;70;70	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.209T>A;c.209T>A;c.209T>A	p.L70Q;p.L70Q;p.L70Q	c.209T>A;c.209T>A;c.209T>A	p.Leu70Gln;p.Leu70Gln;p.Leu70Gln	c.209T>A;c.209T>A;c.209T>A	p.Leu70Gln;p.Leu70Gln;p.Leu70Gln	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTG;CTG;CTG	2;2;2	0;0;0	A	./.	./.	./.	./.	0.007;0.003;0.006	0.68238	D;D;D	0.008;0.008;0.009	0.67890	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;1.0	0.97372	.;D;D	0.000102	0.50451	D	0.000000	0.893357;1;1;1;1;0.535592	0.81001	D;D;D;D;D;N	simple_aae;without_aae;without_aae;without_aae;without_aae;simple_aae	L70Q;.;.;.;.;L70Q	.;2.51;2.51	0.73131	.;M;M	-3.26;-4.74;-5.08	0.98667	D;D;D	-3.6;-4.04;-3.91	0.74427	D;D;D	.;0.857;0.889	0.88798	1.1039	0.99794	D	0.9674	0.98965	D	10	0.94969743;0.94969743;0.94969743	0.94302	D;D;D	0.255728	0.89302	D	0.854;0.854;0.854	0.95507	0.779;0.779;0.779;	0.90388	Q9BQB6;Q9BQB6;Q9BQB6;	L70Q;L70Q;L70Q;	Gain of disorder (P = 0.0152);Gain of disorder (P = 0.0152);Gain of disorder (P = 0.0152);	0.886972516455;0.886972516455;0.886972516455	0.88586	.;.;0.8072776915053071	0.80682	.;.;1.19109956105	0.80279	0.533851861954	0.43577	T	.;.;0.894694	0.97888	.;.;D	0.523628	0.95010	D	0.514379	0.94936	D	0.989123821258545	0.79382	D	0.883312;0.883312;0.867413	0.60567	D;D;D	.;.;0.95361924	0.96634	.;.;0.8636282	0.92427	.;.;0.95361924	0.96635	.;.;0.8636282	0.92428	.;-3.867;-3.169	0.41014	.;T;T	.;.;0.6276628751850951	0.69670	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	.;.;P	0.6551;0.6415;0.5897	0.71128	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.219066	0.86038	28.8	4.308138	0.90140	31	0.99560262950770206	0.71707	0.91487	0.53635	D	ALL	0.801826	0.72742	D	0.753999734672596	0.83165	7.946412	0.73054126374086	0.84697	8.364962	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.798000	0.62203	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.981000	0.58702	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	251256	3.980000e-06	0	0	16256	0.000000e+00	0	0	34592	0.000000e+00	0	0	10076	0.000000e+00	0	0	18394	0.000000e+00	0	0	21636	0.000000e+00	0	1	113550	8.806690e-06	0	0	30616	0.000000e+00	0	1	113550	8.806690e-06	0	0	109396	0.000000e+00	0	0	207966	0.000000e+00	0	1	236732	4.224190e-06	0	1	244638	4.087670e-06	0	0	7164	0.000000e+00	0	0	17112	0.000000e+00	0	0	2320	0.000000e+00	0	0	9046	0.000000e+00	0	0	13382	0.000000e+00	0	0	42768	0.000000e+00	0	0	15690	0.000000e+00	0	.	.	.	.	0	16218	0.000000e+00	0	0	30524	0.000000e+00	0	0	6210	0.000000e+00	0	0	13416	0.000000e+00	0	0	16722	0.000000e+00	0	0	89404	0.000000e+00	0	0	30608	0.000000e+00	0	.	.	.	.	0	14902	0.000000e+00	0	0	34260	0.000000e+00	0	0	9568	0.000000e+00	0	0	17692	0.000000e+00	0	0	21620	0.000000e+00	0	1	102548	9.751530e-06	0	0	30526	0.000000e+00	0	1	102548	9.751530e-06	0	0	12026	0.000000e+00	0	0	34458	0.000000e+00	0	0	9994	0.000000e+00	0	0	18390	0.000000e+00	0	0	21634	0.000000e+00	0	1	111460	8.971830e-06	0	0	30616	0.000000e+00	0	1	111460	8.971830e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093387	G	T	L	M	.	16	31104708	16	31012209	70;70;70	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.208C>A;c.208C>A;c.208C>A	p.L70M;p.L70M;p.L70M	c.208C>A;c.208C>A;c.208C>A	p.Leu70Met;p.Leu70Met;p.Leu70Met	c.208C>A;c.208C>A;c.208C>A	p.Leu70Met;p.Leu70Met;p.Leu70Met	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTG;CTG;CTG	1;1;1	2;2;2	G	./.	./.	./.	./.	0.038;0.028;0.025	0.47320	D;D;D	0.05;0.046;0.052	0.49120	T;D;T	.;1.0;1.0	0.90584	.;D;D	.;0.999;0.999	0.92359	.;D;D	0.000102	0.50451	D	0.000000	1;0.996873;0.947563;0.994305;0.994508;0.994508	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;A90D;L70M;L70M;A101D;A102D	.;2.51;2.51	0.73131	.;M;M	-3.23;-4.71;-5.05	0.98611	D;D;D	-0.82;-0.93;-0.82	0.24898	N;N;N	.;0.44;0.464	0.50056	0.9004	0.95678	D	0.9566	0.98595	D	10	0.7445619;0.7445619;0.7445619	0.75195	D;D;D	0.197919	0.86566	D	0.629;0.629;0.629	0.85718	0.709;0.709;0.709;	0.84509	Q9BQB6;Q9BQB6;Q9BQB6;	L70M;L70M;L70M;	Gain of catalytic residue at V66 (P = 0.0182);Gain of catalytic residue at V66 (P = 0.0182);Gain of catalytic residue at V66 (P = 0.0182);	0.518038692251;0.518038692251;0.518038692251	0.51447	.;.;0.5797233140280873	0.57901	.;.;1.14173055416	0.78954	0.513619542122	0.40728	T	.;.;0.662733	0.89900	.;.;D	0.121764	0.66549	D	-0.0628704	0.66132	T	0.900982916355133	0.55362	D	0.785921;0.785921;0.766923	0.42389	T;T;T	.;.;0.92841864	0.94078	.;.;0.62771165	0.78291	.;.;0.92841864	0.94079	.;.;0.62771165	0.78292	.;-5.818;-6.249	0.75275	.;T;T	.;.;0.2631760894170912	0.35508	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.2152;0.2366;0.1928	0.47027	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.093380	0.54119	23.6	3.028692	0.55379	23.6	0.99450206556515486	0.65223	0.74676	0.36537	D	ALL	0.434136	0.49531	N	0.310876481650631	0.56706	3.835805	0.201473798929493	0.49929	3.190453	0.999999996471685	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	0.769	0.17638	0.246000	0.17935	.	.	0.676000	0.76740	0.984000	0.35821	1.000000	0.68203	0.982000	0.59238	0.4261:0.0:0.5738:0.0	10.007	0.41135	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093392	T	A	H	L	.	16	31104713	16	31012214	68;68;68	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.203A>T;c.203A>T;c.203A>T	p.H68L;p.H68L;p.H68L	c.203A>T;c.203A>T;c.203A>T	p.His68Leu;p.His68Leu;p.His68Leu	c.203A>T;c.203A>T;c.203A>T	p.His68Leu;p.His68Leu;p.His68Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAT;CAT;CAT	2;2;2	0;0;0	T	./.	./.	./.	./.	0.655;0.663;0.643	0.04957	T;T;T	0.653;0.651;0.65	0.06738	T;T;T	.;0.228;0.042	0.30509	.;B;B	.;0.083;0.061	0.29179	.;B;B	0.168167	0.17455	N	0.567843	1;1;0.99915;0.99915;0.99915;0.99915	0.21576	N;N;N;N;N;N	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	H68L;H68L;.;.;.;.	.;0.73;0.73	0.18813	.;N;N	-2.93;-4.44;-4.66	0.97956	D;D;D	-2.17;-2.09;-2.07	0.49018	N;N;N	.;0.224;0.493	0.52651	-0.0510	0.81185	T	0.6904	0.89316	D	10	0.17327535;0.17327535;0.17327535	0.32145	T;T;T	0.048349	0.63331	D	0.388;0.388;0.388	0.70440	0.477;0.477;0.477;	0.55502	Q9BQB6;Q9BQB6;Q9BQB6;	H68L;H68L;H68L;	Loss of disorder (P = 0.0834);Loss of disorder (P = 0.0834);Loss of disorder (P = 0.0834);	0.775060895764;0.775060895764;0.775060895764	0.77299	.;.;0.6440846948364928	0.64343	.;.;0.540378755442	0.51234	0.409976601601	0.26454	T	.;.;0.64586	0.89194	.;.;D	0.142845	0.68595	D	-0.032589	0.68198	D	0.349019706249237	0.26980	T	0.20278;0.212779;0.555844	0.19272	T;T;T	.;.;0.34408122	0.56602	.;.;0.15080237	0.35549	.;.;0.34408122	0.56602	.;.;0.15080237	0.35548	.;0.0;-4.726	0.59903	.;T;T	.;.;0.084225945590808	0.04627	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.1292;0.1397;0.1029	0.30608	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.047834	0.15648	12.21	1.463036	0.23326	16.06	0.88590665040411531	0.18097	0.10696	0.16128	N	ALL	0.099625	0.20050	N	-0.68113795387209	0.16559	0.8447728	-0.541346818892079	0.21036	1.136113	0.999999998224349	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	2.61	0.30255	0.252000	0.18046	.	.	0.665000	0.62972	0.054000	0.21560	0.000000	0.08366	0.976000	0.56436	0.1181:0.0747:0.2667:0.5405	3.4846	0.07179	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093392	T	C	H	R	rs201044348	16	31104713	16	31012214	68;68;68	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.203A>G;c.203A>G;c.203A>G	p.H68R;p.H68R;p.H68R	c.203A>G;c.203A>G;c.203A>G	p.His68Arg;p.His68Arg;p.His68Arg	c.203A>G;c.203A>G;c.203A>G	p.His68Arg;p.His68Arg;p.His68Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAT;CAT;CAT	2;2;2	0;0;0	T	./.	./.	./.	./.	0.349;0.341;0.334	0.12961	T;T;T	0.342;0.345;0.346	0.17910	T;T;T	.;0.418;0.096	0.35279	.;B;B	.;0.122;0.09	0.32387	.;B;B	0.168167	0.17455	N	0.567843	1;1;0.99915;0.99915;0.99915;0.99915	0.21576	N;N;N;N;N;N	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	H68R;H68R;.;.;.;.	.;1.355;1.355	0.33814	.;L;L	-2.91;-4.39;-4.65	0.97938	D;D;D	-1.39;-1.53;-1.35	0.37178	N;N;N	.;0.291;0.483	0.51761	0.0862	0.83921	D	0.7324	0.90848	D	10	0.010351658;0.010351658;0.010351658	0.00231	T;T;T	0.040086	0.59179	D	0.333;0.333;0.333	0.65522	.;.;.;	.	.;.;.;	.;.;.;	.;.;.;	0.512942373286;0.512942373286;0.512942373286	0.50937	.;.;0.5588943627526789	0.55816	.;.;0.452611116527	0.44977	0.432187914848	0.29507	T	.;.;0.591705	0.86784	.;.;D	-0.19243	0.21904	T	-0.0449036	0.67369	D	0.0166394152287341	0.00423	T	0.262774;0.275172;0.692831	0.30243	T;T;T	.;.;0.30470008	0.53323	.;.;0.1753843	0.40001	.;.;0.30470008	0.53323	.;.;0.1753843	0.40000	.;-3.938;-3.776	0.42755	.;T;T	.;.;0.0929846689133976	0.06068	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.0932;0.1056;0.0824	0.19478	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.074668	0.15992	12.51	1.380092	0.22071	15.61	0.9310178657148005	0.22730	0.11240	0.16502	N	ALL	0.109044	0.21673	N	-0.408332423683563	0.25176	1.364772	-0.348593251393535	0.26552	1.467393	0.999999998224349	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	2.61	0.30255	0.252000	0.18046	.	.	0.665000	0.62972	0.054000	0.21560	0.000000	0.08366	0.976000	0.56436	0.1181:0.0747:0.2667:0.5405	3.4846	0.07179	41	0.97903	6	0.0011980830670926517	0	0.0	0	0.0	0	0.0	6	0.005952380952380952	0	0.0	.	.	.	.	.	.	.	.	.	.	46	3.789e-04	46	3.797e-04	0	0	0	0	42	4.872e-03	0	0	1	1.503e-05	3	1.818e-04	42	3.954e-04	42	3.956e-04	0	0	0	0	39	4.964e-03	0	0	0	0	3	1.829e-04	35	3.857e-04	35	3.868e-04	0	0	0	0	31	5.530e-03	0	0	1	2.383e-05	3	1.819e-04	segdup	110	251230	4.378460e-04	0	0	16256	0.000000e+00	0	0	34592	0.000000e+00	0	0	10076	0.000000e+00	0	105	18394	5.708380e-03	0	0	21644	0.000000e+00	0	1	113520	8.809020e-06	0	3	30616	9.798800e-05	0	105	18394	5.708380e-03	0	57	109404	5.210050e-04	0	86	207954	4.135530e-04	0	106	236710	4.478050e-04	0	110	244612	4.496920e-04	0	0	7164	0.000000e+00	0	0	17112	0.000000e+00	0	0	2320	0.000000e+00	0	55	9046	6.080040e-03	0	0	13390	0.000000e+00	0	0	42768	0.000000e+00	0	1	15690	6.373490e-05	0	55	9046	6.080040e-03	0	0	16218	0.000000e+00	0	0	30524	0.000000e+00	0	0	6210	0.000000e+00	0	81	13416	6.037570e-03	0	0	16730	0.000000e+00	0	1	89388	1.118720e-05	0	3	30608	9.801360e-05	0	81	13416	6.037570e-03	0	0	14902	0.000000e+00	0	0	34260	0.000000e+00	0	0	9568	0.000000e+00	0	102	17692	5.765320e-03	0	0	21628	0.000000e+00	0	0	102518	0.000000e+00	0	3	30526	9.827690e-05	0	102	17692	5.765320e-03	0	0	12026	0.000000e+00	0	0	34458	0.000000e+00	0	0	9994	0.000000e+00	0	105	18390	5.709620e-03	0	0	21642	0.000000e+00	0	1	111430	8.974240e-06	0	3	30616	9.798800e-05	0	105	18390	5.709620e-03	0	.	30	152132	1.971970e-04	0	29	5186	5.591980e-03	0	0	41432	0.000000e+00	0	0	912	0.000000e+00	0	0	15278	0.000000e+00	0	0	3468	0.000000e+00	0	29	5186	5.591980e-03	0	0	10616	0.000000e+00	0	0	316	0.000000e+00	0	1	68008	1.470420e-05	0	0	4828	0.000000e+00	0	15	32896	4.559820e-04	0	30	134730	2.226680e-04	0	29	147890	1.960920e-04	0	23	80702	2.849990e-04	0	0	9100	0.000000e+00	0	0	60	0.000000e+00	0	0	4684	0.000000e+00	0	0	136	0.000000e+00	0	15	2430	6.172840e-03	0	0	5492	0.000000e+00	0	0	246	0.000000e+00	0	0	6848	0.000000e+00	0	0	3110	0.000000e+00	0	0	32468	0.000000e+00	0	0	862	0.000000e+00	0	0	14832	0.000000e+00	0	0	3384	0.000000e+00	0	29	5186	5.591980e-03	0	0	6980	0.000000e+00	0	0	310	0.000000e+00	0	1	63884	1.565340e-05	0	0	4826	0.000000e+00	0	0	41110	0.000000e+00	0	0	912	0.000000e+00	0	0	15090	0.000000e+00	0	0	3300	0.000000e+00	0	28	4950	5.656570e-03	0	0	10616	0.000000e+00	0	0	304	0.000000e+00	0	1	64792	1.543400e-05	0	0	4796	0.000000e+00	0	0	24808	0.000000e+00	0	0	112	0.000000e+00	0	0	12904	0.000000e+00	0	0	996	0.000000e+00	0	22	3744	5.876070e-03	0	0	10524	0.000000e+00	0	0	272	0.000000e+00	0	1	21028	4.755560e-05	0	0	4800	0.000000e+00	0	0	146988	0	0	168	0	35	4470	0.007829977628635347	0	4172	0	0	442	0	0	950	0	13	1818	0.007150715071507151	1	280	0.0035714285714285713	17	9620	0.0017671517671517672	0	4340	0	48	6288	0.007633587786259542	66	168908	3.907452577734625E-4	887600	Benign	Vitamin_K-dependent_clotting_factors,_combined_deficiency_of,_type_2	criteria_provided,_single_submitter	NC_000016.10:g.31093392T>C	.	C1843832	607473	98434	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093392	T	G	H	P	rs201044348	16	31104713	16	31012214	68;68;68	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.203A>C;c.203A>C;c.203A>C	p.H68P;p.H68P;p.H68P	c.203A>C;c.203A>C;c.203A>C	p.His68Pro;p.His68Pro;p.His68Pro	c.203A>C;c.203A>C;c.203A>C	p.His68Pro;p.His68Pro;p.His68Pro	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAT;CAT;CAT	2;2;2	0;0;0	T	./.	./.	./.	./.	0.226;0.324;0.293	0.18562	T;T;T	0.239;0.227;0.209	0.26798	T;T;T	.;0.002;0.0	0.09854	.;B;B	.;0.002;0.001	0.06944	.;B;B	0.168167	0.17455	N	0.567843	1;1;0.99915;0.99915;0.99915;0.99915	0.21576	N;N;N;N;N;N	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	H68P;H68P;.;.;.;.	.;-0.05;-0.05	0.04954	.;N;N	-2.96;-4.44;-4.62	0.97884	D;D;D	-1.1;-0.51;-0.31	0.28497	N;N;N	.;0.206;0.254	0.28732	-0.0397	0.81424	T	0.7216	0.90459	D	10	0.15982237;0.15982237;0.15982237	0.30019	T;T;T	0.030222	0.52574	D	0.571;0.571;0.571	0.82573	.;.;.;	.	.;.;.;	.;.;.;	.;.;.;	0.596207158177;0.596207158177;0.596207158177	0.59299	.;.;0.8229705289121079	0.82254	.;.;0.582262405168	0.53989	0.403298258781	0.25528	T	.;.;0.407183	0.76287	.;.;T	0.20557	0.74413	D	0.0575106	0.74080	D	0.157501265406609	0.17685	T	0.107389;0.111589;0.440756	0.12177	T;T;T	.;.;0.5466545	0.69769	.;.;0.19458413	0.43089	.;.;0.5466545	0.69770	.;.;0.19458413	0.43088	.;-3.663;-4.659	0.58755	.;T;T	.;.;0.060397279320140114	0.01656	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.082;0.0814;0.066	0.08754	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.311041	0.19144	14.47	1.593440	0.25397	16.81	0.88445813883847191	0.17983	0.14745	0.18563	N	ALL	0.219739	0.34459	N	-0.637796779201612	0.17816	0.9200597	-0.498894030537203	0.22185	1.203707	0.999999998224349	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	2.61	0.30255	0.252000	0.18046	.	.	0.665000	0.62972	0.054000	0.21560	0.000000	0.08366	0.976000	0.56436	0.1181:0.0747:0.2667:0.5405	3.4846	0.07179	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0.0	1	1.1627906976744187E-4	1	8.236e-06	1	8.255e-06	0	0	0	0	0	0	0	0	1	1.503e-05	0	0	1	9.415e-06	1	9.420e-06	0	0	0	0	0	0	0	0	1	1.841e-05	0	0	1	1.102e-05	1	1.105e-05	0	0	0	0	0	0	0	0	1	2.383e-05	0	0	segdup	1	251230	3.980420e-06	0	0	16256	0.000000e+00	0	0	34592	0.000000e+00	0	0	10076	0.000000e+00	0	0	18394	0.000000e+00	0	0	21644	0.000000e+00	0	1	113520	8.809020e-06	0	0	30616	0.000000e+00	0	1	113520	8.809020e-06	0	0	109404	0.000000e+00	0	1	207954	4.808760e-06	0	1	236710	4.224580e-06	0	1	244612	4.088110e-06	0	0	7164	0.000000e+00	0	0	17112	0.000000e+00	0	0	2320	0.000000e+00	0	0	9046	0.000000e+00	0	0	13390	0.000000e+00	0	0	42768	0.000000e+00	0	0	15690	0.000000e+00	0	.	.	.	.	0	16218	0.000000e+00	0	0	30524	0.000000e+00	0	0	6210	0.000000e+00	0	0	13416	0.000000e+00	0	0	16730	0.000000e+00	0	1	89388	1.118720e-05	0	0	30608	0.000000e+00	0	1	89388	1.118720e-05	0	0	14902	0.000000e+00	0	0	34260	0.000000e+00	0	0	9568	0.000000e+00	0	0	17692	0.000000e+00	0	0	21628	0.000000e+00	0	1	102518	9.754380e-06	0	0	30526	0.000000e+00	0	1	102518	9.754380e-06	0	0	12026	0.000000e+00	0	0	34458	0.000000e+00	0	0	9994	0.000000e+00	0	0	18390	0.000000e+00	0	0	21642	0.000000e+00	0	1	111430	8.974240e-06	0	0	30616	0.000000e+00	0	1	111430	8.974240e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093393	G	C	H	D	.	16	31104714	16	31012215	68;68;68	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.202C>G;c.202C>G;c.202C>G	p.H68D;p.H68D;p.H68D	c.202C>G;c.202C>G;c.202C>G	p.His68Asp;p.His68Asp;p.His68Asp	c.202C>G;c.202C>G;c.202C>G	p.His68Asp;p.His68Asp;p.His68Asp	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CAT;CAT;CAT	1;1;1	0;0;0	G	./.	./.	./.	./.	0.206;0.199;0.198	0.20532	T;T;T	0.202;0.204;0.204	0.27414	T;T;T	.;0.372;0.081	0.34134	.;B;B	.;0.114;0.061	0.31755	.;B;B	0.168167	0.17455	N	0.567843	0.7623;1;0.999999;0.999999;1;1	0.34053	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;A88G;H68D;H68D;A99G;A100G	.;1.355;1.355	0.33814	.;L;L	-2.94;-4.44;-4.67	0.97973	D;D;D	-1.69;-1.67;-1.43	0.40274	N;N;N	.;0.524;0.622	0.63713	0.3611	0.88509	D	0.8408	0.94680	D	10	0.34733886;0.34733886;0.34733886	0.51670	T;T;T	0.132402	0.81472	D	0.467;0.467;0.467	0.76222	0.416;0.416;0.416;	0.45544	Q9BQB6;Q9BQB6;Q9BQB6;	H68D;H68D;H68D;	Loss of sheet (P = 0.0457);Loss of sheet (P = 0.0457);Loss of sheet (P = 0.0457);	0.600666394621;0.600666394621;0.600666394621	0.59748	.;.;0.7169165150039689	0.71634	.;.;0.635760335482	0.57380	0.433687388897	0.29713	T	.;.;0.671038	0.90236	.;.;D	0.0684707	0.60661	T	-0.139423	0.60169	T	0.771412193775177	0.44524	D	0.185281;0.194281;0.544446	0.18591	T;T;T	.;.;0.5380234	0.69285	.;.;0.30397967	0.56427	.;.;0.5380234	0.69286	.;.;0.30397967	0.56427	.;-4.729;-0.64	0.59955	.;T;T	.;.;0.09431595496949684	0.06298	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.1309;0.1712;0.1083	0.37596	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.955843	0.29730	18.92	2.223742	0.37654	21.6	0.98335260003148472	0.40378	0.55115	0.29783	D	AEFDGBHCI	0.557703	0.56722	D	-0.0377182765059371	0.40152	2.379741	0.0832621271857942	0.43706	2.66695	0.999999999964313	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	5.17	0.70848	1.706000	0.37497	.	.	0.676000	0.76740	0.212000	0.24446	0.427000	0.24836	0.977000	0.56843	0.0:0.1331:0.7295:0.1374	11.5941	0.50218	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093395	T	A	E	V	.	16	31104716	16	31012217	67;67;67	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.200A>T;c.200A>T;c.200A>T	p.E67V;p.E67V;p.E67V	c.200A>T;c.200A>T;c.200A>T	p.Glu67Val;p.Glu67Val;p.Glu67Val	c.200A>T;c.200A>T;c.200A>T	p.Glu67Val;p.Glu67Val;p.Glu67Val	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GAG;GAG;GAG	2;2;2	0;0;0	T	./.	./.	./.	./.	0.222;0.242;0.046	0.40573	T;T;D	0.031;0.037;0.051	0.53788	D;D;T	.;0.999;0.999	0.77913	.;D;D	.;0.923;0.938	0.67350	.;D;D	0.000003	0.62929	D	0.000000	0.652424;0.652424;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	E67V;E67V;.;.;.;.	.;2.455;2.455	0.71248	.;M;M	-3.08;-4.6;-4.83	0.98213	D;D;D	-3.4;-3.59;-3.76	0.71276	D;D;D	.;0.655;0.691	0.69649	1.0516	0.98152	D	0.9499	0.98368	D	10	0.8006115;0.8006115;0.8006115	0.79469	D;D;D	0.299959	0.90849	D	0.716;0.716;0.716	0.89922	0.608;0.608;0.608;	0.74063	Q9BQB6;Q9BQB6;Q9BQB6;	E67V;E67V;E67V;	Gain of sheet (P = 0.0344);Gain of sheet (P = 0.0344);Gain of sheet (P = 0.0344);	0.873314511691;0.873314511691;0.873314511691	0.87208	.;.;0.6940533753728129	0.69346	.;.;1.2566256936	0.81922	0.575700640678	0.49481	T	.;.;0.89855	0.97992	.;.;D	0.359079	0.87185	D	0.278016	0.87018	D	0.985350847244263	0.76373	D	0.771423;0.766723;0.832417	0.50060	T;T;T	.;.;0.9092775	0.92227	.;.;0.63453496	0.78668	.;.;0.9092775	0.92228	.;.;0.63453496	0.78669	.;-3.811;-4.523	0.56265	.;T;T	.;.;0.19588435528126225	0.25857	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.7853;0.7388;0.6396	0.76609	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.299136	0.88205	29.6	4.422827	0.91308	32	0.99335665499128456	0.59973	0.89898	0.50669	D	AEFDGBHCI	0.459911	0.51032	N	0.597072133262531	0.72992	5.893745	0.590704869712419	0.74272	6.108881	0.99999999999675	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	2.782000	0.47445	.	.	0.665000	0.62972	0.975000	0.34726	1.000000	0.68203	0.974000	0.55675	0.0:0.0:0.1424:0.8576	12.1849	0.53539	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093395	T	C	E	G	.	16	31104716	16	31012217	67;67;67	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.200A>G;c.200A>G;c.200A>G	p.E67G;p.E67G;p.E67G	c.200A>G;c.200A>G;c.200A>G	p.Glu67Gly;p.Glu67Gly;p.Glu67Gly	c.200A>G;c.200A>G;c.200A>G	p.Glu67Gly;p.Glu67Gly;p.Glu67Gly	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GAG;GAG;GAG	2;2;2	0;0;0	T	./.	./.	./.	./.	0.451;0.418;0.309	0.14064	T;T;T	0.348;0.188;0.199	0.28669	T;T;T	.;0.995;0.996	0.68779	.;D;D	.;0.843;0.867	0.61644	.;P;P	0.000003	0.62929	D	0.000000	0.517377;0.517377;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	E67G;E67G;.;.;.;.	.;1.26;1.26	0.31868	.;L;L	-3.04;-4.55;-4.76	0.98111	D;D;D	-1.29;-1.07;-1.12	0.32387	N;N;N	.;0.582;0.601	0.61933	0.8457	0.94976	D	0.9058	0.96875	D	10	0.592986;0.592986;0.592986	0.66485	D;D;D	0.260581	0.89490	D	0.583;0.583;0.583	0.83249	0.583;0.583;0.583;	0.70990	Q9BQB6;Q9BQB6;Q9BQB6;	E67G;E67G;E67G;	Loss of catalytic residue at E67 (P = 0.0581);Loss of catalytic residue at E67 (P = 0.0581);Loss of catalytic residue at E67 (P = 0.0581);	0.72859088309;0.72859088309;0.72859088309	0.72618	.;.;0.6378893129969674	0.63722	.;.;1.24367740306	0.81614	0.550316751003	0.45902	T	.;.;0.770523	0.93854	.;.;D	0.316256	0.84203	D	0.216504	0.83998	D	0.875675857067108	0.52555	D	0.422258;0.407759;0.547145	0.18749	T;T;T	.;.;0.46509078	0.64987	.;.;0.24926631	0.50494	.;.;0.46509078	0.64988	.;.;0.24926631	0.50493	.;-3.327;-3.773	0.38610	.;T;T	.;.;0.0959831381302762	0.06593	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.223;0.2117;0.1525	0.45433	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.517920	0.91393	32	4.665676	0.92463	32	0.99877973848473289	0.95491	0.82245	0.41502	D	AEFDGBHCI	0.274424	0.38961	N	0.34939167321533	0.58706	4.04471	0.415249565587007	0.62515	4.468078	0.99999999999675	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	2.782000	0.47445	.	.	0.665000	0.62972	0.975000	0.34726	1.000000	0.68203	0.974000	0.55675	0.0:0.0:0.1424:0.8576	12.1849	0.53539	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093398	A	T	V	E	.	16	31104719	16	31012220	66;66;66	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.197T>A;c.197T>A;c.197T>A	p.V66E;p.V66E;p.V66E	c.197T>A;c.197T>A;c.197T>A	p.Val66Glu;p.Val66Glu;p.Val66Glu	c.197T>A;c.197T>A;c.197T>A	p.Val66Glu;p.Val66Glu;p.Val66Glu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GTG;GTG;GTG	2;2;2	0;0;0	A	./.	./.	./.	./.	0.154;0.002;0.001	0.78490	T;D;D	0.001;0.002;0.003	0.83351	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.998;0.999	0.92359	.;D;D	0.000017	0.62929	D	0.000000	0.99989;0.99989;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	V66E;V66E;.;.;.;.	.;2.63;2.63	0.76995	.;M;M	-3.19;-4.76;-4.93	0.98390	D;D;D	-4.12;-4.68;-4.68	0.79659	D;D;D	.;0.868;0.875	0.87265	1.1022	0.99747	D	0.9639	0.98844	D	10	0.9412819;0.9412819;0.9412819	0.93454	D;D;D	0.287884	0.90460	D	0.911;0.911;0.911	0.97624	0.789;0.789;0.789;	0.91142	Q9BQB6;Q9BQB6;Q9BQB6;	V66E;V66E;V66E;	Gain of disorder (P = 0.0182);Gain of disorder (P = 0.0182);Gain of disorder (P = 0.0182);	0.906756978599;0.906756978599;0.906756978599	0.90582	.;.;0.9419973530419238	0.94180	.;.;1.50559008858	0.87129	0.5532143116	0.46311	T	.;.;0.907118	0.98222	.;.;D	0.537405	0.95350	D	0.534169	0.95281	D	0.995872914791107	0.88232	D	0.910309;0.911209;0.877312	0.68535	D;D;D	.;.;0.96986187	0.98247	.;.;0.94569546	0.98134	.;.;0.96986187	0.98248	.;.;0.94569546	0.98134	.;-4.511;-2.298	0.56022	.;T;T	.;.;0.5502007898671367	0.61889	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	0.9082;0.8814;0.8862	0.83316	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.052427	0.80430	27.4	4.175711	0.87696	29.3	0.98922161907542394	0.48583	0.97710	0.76577	D	AEFDGBHCI	0.958303	0.97800	D	0.86166923347255	0.89762	10.10689	0.840128327957598	0.92425	11.41966	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.998000	0.63670	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.959000	0.51448	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093399	C	T	V	M	rs72547529	16	31104720	16	31012221	66;66;66	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.196G>A;c.196G>A;c.196G>A	p.V66M;p.V66M;p.V66M	c.196G>A;c.196G>A;c.196G>A	p.Val66Met;p.Val66Met;p.Val66Met	c.196G>A;c.196G>A;c.196G>A	p.Val66Met;p.Val66Met;p.Val66Met	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GTG;GTG;GTG	1;1;1	0;0;0	C	./.	./.	./.	./.	0.035;0.015;0.004	0.65419	D;D;D	0.013;0.012;0.015	0.63918	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;0.999	0.92359	.;D;D	0.000017	0.62929	D	0.000000	0.603023;0.999003;0.999003;0.603023;0.603023;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;without_aae	G86D;V66M;V66M;G97D;G98D;.	.;1.935;1.935	0.51832	.;L;L	-3.15;-4.72;-4.89	0.98313	D;D;D	-1.21;-1.46;-1.36	0.35792	N;N;N	.;0.38;0.378	0.42149	1.0198	0.97531	D	0.9431	0.98136	D	10	0.022155285;0.022155285;0.022155285	0.00546	T;T;T	0.472576	0.94705	D	0.617;0.617;0.617	0.85091	.;.;.;	.	.;.;.;	.;.;.;	.;.;.;	0.833261688897;0.833261688897;0.833261688897	0.83167	.;.;0.7870614135531712	0.78658	.;.;1.16200997885	0.79519	0.571875095367	0.48944	T	.;.;0.690316	0.90989	.;.;D	-0.112153	0.34413	T	0.0621321	0.74387	D	0.0748806853629748	0.09320	T	0.919208;0.925707;0.907509	0.72678	D;D;D	.;.;0.52054346	0.68290	.;.;0.34258512	0.59983	.;.;0.52054346	0.68291	.;.;0.34258512	0.59982	.;-5.818;-6.249	0.75275	.;T;T	.;.;0.31578229958102794	0.41382	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	0.4551;0.4707;0.3556	0.63214	A;A;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.702033	0.69409	25.4	4.137117	0.86694	28.9	0.99909494941374533	0.97949	0.90799	0.52282	D	AEFDGBHCI	0.648027	0.62299	D	0.695118995598113	0.79312	7.051323	0.693220434973447	0.81863	7.627405	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	2.826000	0.47805	.	.	0.599000	0.40250	1.000000	0.71638	1.000000	0.68203	0.954000	0.50415	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	.	.	.	.	.	.	10	0.002275830678197542	0	0.0	32	2.636e-04	32	2.643e-04	29	2.795e-03	3	2.594e-04	0	0	0	0	0	0	0	0	28	2.636e-04	28	2.638e-04	25	2.762e-03	3	2.676e-04	0	0	0	0	0	0	0	0	32	3.526e-04	32	3.538e-04	29	2.800e-03	3	2.597e-04	0	0	0	0	0	0	0	0	segdup	49	251118	1.951270e-04	0	43	16254	2.645500e-03	0	5	34590	1.445500e-04	0	0	10076	0.000000e+00	0	0	18394	0.000000e+00	0	0	21640	0.000000e+00	0	0	113416	0.000000e+00	0	1	30616	3.266270e-05	0	43	16254	2.645500e-03	0	24	109398	2.193820e-04	0	48	207878	2.309050e-04	0	47	236606	1.986420e-04	0	43	244500	1.758690e-04	0	20	7164	2.791740e-03	0	3	17110	1.753360e-04	0	0	2320	0.000000e+00	0	0	9046	0.000000e+00	0	0	13386	0.000000e+00	0	0	42768	0.000000e+00	0	1	15690	6.373490e-05	0	20	7164	2.791740e-03	0	43	16216	2.651700e-03	0	4	30522	1.310530e-04	0	0	6210	0.000000e+00	0	0	13416	0.000000e+00	0	0	16726	0.000000e+00	0	0	89320	0.000000e+00	0	1	30608	3.267120e-05	0	43	16216	2.651700e-03	0	41	14902	2.751310e-03	0	5	34258	1.459510e-04	0	0	9568	0.000000e+00	0	0	17692	0.000000e+00	0	0	21624	0.000000e+00	0	0	102420	0.000000e+00	0	1	30526	3.275900e-05	0	41	14902	2.751310e-03	0	37	12024	3.077180e-03	0	5	34456	1.451130e-04	0	0	9994	0.000000e+00	0	0	18390	0.000000e+00	0	0	21638	0.000000e+00	0	0	111326	0.000000e+00	0	1	30616	3.266270e-05	0	37	12024	3.077180e-03	0	.	122	152156	8.018090e-04	0	116	41442	2.799090e-03	0	116	41442	2.799090e-03	0	0	912	0.000000e+00	0	6	15282	3.926190e-04	0	0	3472	0.000000e+00	0	0	5172	0.000000e+00	0	0	10624	0.000000e+00	0	0	316	0.000000e+00	0	0	68024	0.000000e+00	0	0	4822	0.000000e+00	0	32	32898	9.727040e-04	0	90	134748	6.679130e-04	0	120	147902	8.113480e-04	0	78	80720	9.663030e-04	0	31	9096	3.408090e-03	0	0	60	0.000000e+00	0	1	4690	2.132200e-04	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5496	0.000000e+00	0	0	246	0.000000e+00	0	0	6848	0.000000e+00	0	0	3106	0.000000e+00	0	84	32476	2.586530e-03	0	0	862	0.000000e+00	0	6	14836	4.044220e-04	0	0	3388	0.000000e+00	0	0	5172	0.000000e+00	0	0	6982	0.000000e+00	0	0	310	0.000000e+00	0	0	63902	0.000000e+00	0	0	4820	0.000000e+00	0	115	41122	2.796560e-03	0	0	912	0.000000e+00	0	5	15094	3.312570e-04	0	0	3302	0.000000e+00	0	0	4940	0.000000e+00	0	0	10624	0.000000e+00	0	0	304	0.000000e+00	0	0	64794	0.000000e+00	0	0	4790	0.000000e+00	0	72	24816	2.901350e-03	0	0	112	0.000000e+00	0	6	12908	4.648280e-04	0	0	998	0.000000e+00	0	0	3730	0.000000e+00	0	0	10532	0.000000e+00	0	0	272	0.000000e+00	0	0	21042	0.000000e+00	0	0	4794	0.000000e+00	0	0	179974	0	0	168	0	0	4520	0	15	4192	0.00357824427480916	0	796	0	0	968	0	0	1818	0	0	280	0	3	13942	2.1517716253048342E-4	15	4360	0.0034403669724770644	0	6338	0	18	206658	8.710042679209128E-5	692018	Conflicting_interpretations_of_pathogenicity	Warfarin_response|Vitamin_K-dependent_clotting_factors,_combined_deficiency_of,_type_2	criteria_provided,_conflicting_interpretations	NC_000016.10:g.31093399C>T	Genetic_Testing_Registry_(GTR):GTR000593349|Genetic_Testing_Registry_(GTR):GTR000593366	C0750384|C1843832	122700|607473	98434	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093401	A	G	L	P	.	16	31104722	16	31012223	65;65;65	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.194T>C;c.194T>C;c.194T>C	p.L65P;p.L65P;p.L65P	c.194T>C;c.194T>C;c.194T>C	p.Leu65Pro;p.Leu65Pro;p.Leu65Pro	c.194T>C;c.194T>C;c.194T>C	p.Leu65Pro;p.Leu65Pro;p.Leu65Pro	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTG;CTG;CTG	2;2;2	0;0;0	A	./.	./.	./.	./.	0.002;0.003;0.001	0.78490	D;D;D	0.0;0.001;0.001	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;1.0	0.97372	.;D;D	0.000088	0.51296	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	L65P;L65P;.;.;.;.	.;2.895;2.895	0.83812	.;M;M	-3.3;-4.85;-5.13	0.98748	D;D;D	-5.12;-5.91;-5.99	0.89401	D;D;D	.;0.976;0.971	0.98657	1.0905	0.99259	D	0.9734	0.99168	D	10	0.96380484;0.96380484;0.96380484	0.95827	D;D;D	0.273968	0.89985	D	0.910;0.910;0.910	0.97587	0.863;0.863;0.863;	0.95940	Q9BQB6;Q9BQB6;Q9BQB6;	L65P;L65P;L65P;	Gain of loop (P = 0.0166);Gain of loop (P = 0.0166);Gain of loop (P = 0.0166);	0.907274496501;0.907274496501;0.907274496501	0.90634	.;.;0.9654839900294405	0.96535	.;.;0.664439988566	0.59081	0.685071647167	0.64998	T	.;.;0.932836	0.98878	.;.;D	0.528499	0.95144	D	0.521376	0.95072	D	0.99890410900116	0.95536	D	0.887811;0.887111;0.887111	0.61653	D;D;D	.;.;0.98771334	0.99637	.;.;0.9799962	0.99818	.;.;0.98771334	0.99637	.;.;0.9799962	0.99819	.;-3.663;-4.659	0.58755	.;T;T	.;.;0.6593654144858067	0.73261	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	.;.;P	.;.;P	0.9127;0.8772;0.8506	0.83644	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.181175	0.84853	28.5	4.219995	0.88673	29.6	0.99918745309398604	0.98586	0.97649	0.76151	D	AEFDGBHCI	0.974719	0.99576	D	0.914314019971207	0.92442	11.42622	0.875842182332609	0.94432	12.75559	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.913000	0.63039	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.932000	0.46971	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093401	A	T	L	Q	.	16	31104722	16	31012223	65;65;65	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.194T>A;c.194T>A;c.194T>A	p.L65Q;p.L65Q;p.L65Q	c.194T>A;c.194T>A;c.194T>A	p.Leu65Gln;p.Leu65Gln;p.Leu65Gln	c.194T>A;c.194T>A;c.194T>A	p.Leu65Gln;p.Leu65Gln;p.Leu65Gln	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTG;CTG;CTG	2;2;2	0;0;0	A	./.	./.	./.	./.	0.002;0.004;0.001	0.78490	D;D;D	0.0;0.001;0.001	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;1.0	0.97372	.;D;D	0.000088	0.51296	D	0.000000	0.998735;0.999869;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	L65Q;L65Q;.;.;.;.	.;2.895;2.895	0.83812	.;M;M	-3.29;-4.84;-5.12	0.98731	D;D;D	-4.55;-5.1;-5.17	0.83489	D;D;D	.;0.918;0.897	0.92084	1.0919	0.99316	D	0.9732	0.99162	D	10	0.9587647;0.9587647;0.9587647	0.95262	D;D;D	0.25067	0.89101	D	0.878;0.878;0.878	0.96391	0.853;0.853;0.853;	0.95376	Q9BQB6;Q9BQB6;Q9BQB6;	L65Q;L65Q;L65Q;	Gain of MoRF binding (P = 0.0707);Gain of MoRF binding (P = 0.0707);Gain of MoRF binding (P = 0.0707);	0.915750979714;0.915750979714;0.915750979714	0.91490	.;.;0.8997569495043433	0.89947	.;.;0.461279298288	0.45672	0.597565889359	0.52561	T	.;.;0.917115	0.98486	.;.;D	0.50651	0.94474	D	0.48979	0.94395	D	0.997688412666321	0.92162	D	0.833717;0.833317;0.827217	0.50261	T;T;T	.;.;0.95748603	0.97026	.;.;0.94757986	0.98251	.;.;0.95748603	0.97026	.;.;0.94757986	0.98251	.;-3.867;-3.169	0.41014	.;T;T	.;.;0.6051546919025148	0.67238	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	0.8936;0.8594;0.8427	0.82324	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.216827	0.85970	28.8	4.285464	0.89821	31	0.99564658632038261	0.72014	0.97773	0.77029	D	AEFDGBHCI	0.948689	0.96058	D	0.907700736001506	0.92130	11.2507	0.87019159764969	0.94138	12.53285	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.913000	0.63039	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.932000	0.46971	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093402	G	C	L	V	.	16	31104723	16	31012224	65;65;65	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.193C>G;c.193C>G;c.193C>G	p.L65V;p.L65V;p.L65V	c.193C>G;c.193C>G;c.193C>G	p.Leu65Val;p.Leu65Val;p.Leu65Val	c.193C>G;c.193C>G;c.193C>G	p.Leu65Val;p.Leu65Val;p.Leu65Val	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	CTG;CTG;CTG	1;1;1	2;2;2	G	./.	./.	./.	./.	0.225;0.2;0.045	0.40832	T;T;D	0.002;0.005;0.039	0.79402	D;D;D	.;0.998;0.999	0.77913	.;D;D	.;0.996;0.998	0.88582	.;D;D	0.000088	0.51296	D	0.000000	0.968704;0.996667;1;0.988203;0.988203;0.988203	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	L65V;L65V;.;A85G;A96G;A97G	.;2.345;2.345	0.67358	.;M;M	-3.17;-4.72;-5.01	0.98544	D;D;D	-1.84;-2.07;-2.17	0.49018	N;N;N	.;0.532;0.48	0.56058	0.8593	0.95144	D	0.9526	0.98460	D	10	0.8924068;0.8924068;0.8924068	0.88586	D;D;D	0.287698	0.90454	D	0.657;0.657;0.657	0.87135	0.806;0.806;0.806;	0.92372	Q9BQB6;Q9BQB6;Q9BQB6;	L65V;L65V;L65V;	Gain of sheet (P = 0.0827);Gain of sheet (P = 0.0827);Gain of sheet (P = 0.0827);	0.846890128665;0.846890128665;0.846890128665	0.84542	.;.;0.7491977890438917	0.74865	.;.;0.883452538917	0.69856	0.540164351463	0.44469	T	.;.;0.84677	0.96475	.;.;D	0.14831	0.69109	D	-0.0247391	0.68717	D	0.952893495559692	0.63899	D	0.867413;0.866613;0.863714	0.56831	D;D;D	.;.;0.64095515	0.74882	.;.;0.49383393	0.70724	.;.;0.64095515	0.74883	.;.;0.49383393	0.70725	.;-3.811;-4.523	0.56265	.;T;T	.;.;0.2614670410467554	0.35298	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	.;.;B	0.1693;0.1853;0.149	0.40081	B;B;B	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.413216	0.90285	31	4.519824	0.91911	32	0.99799721738627778	0.88461	0.95191	0.63774	D	AEFDGBHCI	0.837023	0.75471	D	0.779884455739265	0.84833	8.399227	0.778472793716493	0.88259	9.515706	0.999999999999694	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.265000	0.58663	.	.	0.676000	0.76740	1.000000	0.71638	1.000000	0.68203	0.907000	0.44265	0.0738:0.0:0.9262:0.0	13.5813	0.61370	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093407	A	G	F	S	.	16	31104728	16	31012229	63;63;63	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.188T>C;c.188T>C;c.188T>C	p.F63S;p.F63S;p.F63S	c.188T>C;c.188T>C;c.188T>C	p.Phe63Ser;p.Phe63Ser;p.Phe63Ser	c.188T>C;c.188T>C;c.188T>C	p.Phe63Ser;p.Phe63Ser;p.Phe63Ser	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	2;2;2	0;0;0	A	./.	./.	./.	./.	0.001;0.0;0.001	0.91255	D;D;D	0.001;0.003;0.001	0.83351	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.997;0.999	0.92359	.;D;D	0.000002	0.62929	D	0.000000	0.999898;0.999898;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	F63S;F63S;.;.;.;.	.;2.965;2.965	0.85198	.;M;M	-5.09;-5.09;-5.09	0.98684	D;D;D	-5.94;-6.67;-6.83	0.93020	D;D;D	.;0.953;0.943	0.96187	1.0967	0.99520	D	0.9710	0.99088	D	10	0.9677782;0.9677782;0.9677782	0.96297	D;D;D	0.270248	0.89850	D	0.963;0.963;0.963	0.99463	0.858;0.858;0.858;	0.95662	Q9BQB6;Q9BQB6;Q9BQB6;	F63S;F63S;F63S;	Gain of disorder (P = 0.0026);Gain of disorder (P = 0.0026);Gain of disorder (P = 0.0026);	0.898468222075;0.898468222075;0.898468222075	0.89745	.;.;0.9606811627369137	0.96054	.;.;1.56269628182	0.88057	0.684947252274	0.64979	T	.;.;0.935717	0.98948	.;.;D	0.561026	0.96257	D	0.568098	0.96198	D	0.997824311256409	0.92514	D	0.917108;0.918408;0.949005	0.80370	D;D;D	.;.;0.95193183	0.96462	.;.;0.93439305	0.97395	.;.;0.95193183	0.96462	.;.;0.93439305	0.97395	.;-3.704;-2.754	0.36822	.;T;T	.;.;0.5894224865553643	0.65622	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	0.9825;0.9704;0.9553	0.91661	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.451784	0.90762	32	4.377778	0.90931	31	0.99832608923253918	0.91370	0.97631	0.76028	D	AEFDGBHCI	0.961825	0.98320	D	0.863512685669645	0.89864	10.1501	0.824627201553611	0.91449	10.89338	0.999999999999989	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.08	6.08	0.98982	6.715000	0.74515	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.741000	0.35472	1.0:0.0:0.0:0.0	15.6264	0.76613	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093408	A	C	F	V	.	16	31104729	16	31012230	63;63;63	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.187T>G;c.187T>G;c.187T>G	p.F63V;p.F63V;p.F63V	c.187T>G;c.187T>G;c.187T>G	p.Phe63Val;p.Phe63Val;p.Phe63Val	c.187T>G;c.187T>G;c.187T>G	p.Phe63Val;p.Phe63Val;p.Phe63Val	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TTC;TTC;TTC	1;1;1	0;0;0	A	./.	./.	./.	./.	0.005;0.001;0.005	0.78490	D;D;D	0.003;0.014;0.005	0.76473	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.996;0.998	0.88582	.;D;D	0.000002	0.62929	D	0.000000	0.999925;0.999925;1;0.828093;0.828093;0.828093	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	F63V;F63V;.;F83C;F94C;F95C	.;2.965;2.965	0.85198	.;M;M	-5.0;-5.0;-5.0	0.98525	D;D;D	-5.0;-5.71;-5.82	0.88289	D;D;D	.;0.767;0.779	0.77601	1.0053	0.97277	D	0.9653	0.98893	D	10	0.978764;0.978764;0.978764	0.97768	D;D;D	0.354764	0.92361	D	0.878;0.878;0.878	0.96391	0.912;0.912;0.912;	0.98269	Q9BQB6;Q9BQB6;Q9BQB6;	F63V;F63V;F63V;	Gain of MoRF binding (P = 0.0983);Gain of MoRF binding (P = 0.0983);Gain of MoRF binding (P = 0.0983);	0.907758374938;0.907758374938;0.907758374938	0.90683	.;.;0.9324885088291472	0.93227	.;.;1.13111999283	0.78618	0.670548737049	0.62916	T	.;.;0.94401	0.99142	.;.;D	0.129178	0.67280	D	-0.0522205	0.66871	D	0.996209621429443	0.88872	D	0.927307;0.928407;0.954805	0.82790	D;D;D	.;.;0.87842375	0.89537	.;.;0.8341811	0.90458	.;.;0.87842375	0.89539	.;.;0.8341811	0.90458	.;-3.811;-4.523	0.56265	.;T;T	.;.;0.4565595617673309	0.53946	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	0.924;0.9164;0.9175	0.84517	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	4.203452	0.85570	28.7	4.218758	0.88651	29.6	0.98891348819437019	0.48001	0.97852	0.77613	D	AEFDGBHCI	0.959670	0.98011	D	0.866039487359624	0.90002	10.20989	0.829687890490826	0.91774	11.06169	0.999999999999992	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	6.512000	0.73648	.	.	0.756000	0.94297	1.000000	0.71638	1.000000	0.68203	0.698000	0.34080	1.0:0.0:0.0:0.0	15.8048	0.78265	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093410	C	A	G	V	rs200917074	16	31104731	16	31012232	62;62;62	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.185G>T;c.185G>T;c.185G>T	p.G62V;p.G62V;p.G62V	c.185G>T;c.185G>T;c.185G>T	p.Gly62Val;p.Gly62Val;p.Gly62Val	c.185G>T;c.185G>T;c.185G>T	p.Gly62Val;p.Gly62Val;p.Gly62Val	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GGT;GGT;GGT	2;2;2	0;0;0	C	C/C	C/C	C/C	C/C	0.0;0.0;0.0	0.91255	D;D;D	0.001;0.0;0.002	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;1.0;1.0	0.97372	.;D;D	0.000104	0.50451	D	0.081458	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	G62V;G62V;.;.;.;.	.;2.985;2.985	0.85602	.;M;M	-4.56;-4.56;-4.56	0.97772	D;D;D	-7.23;-7.87;-8.17	0.96779	D;D;D	.;0.921;0.853	0.92433	1.0944	0.99422	D	0.9665	0.98934	D	10	0.9592662;0.9592662;0.9592662	0.95317	D;D;D	0.231294	0.88269	D	0.871;0.871;0.871	0.96133	0.794;0.794;0.794;	0.91511	Q9BQB6;Q9BQB6;Q9BQB6;	G62V;G62V;G62V;	Loss of methylation at R61 (P = 0.0682);Loss of methylation at R61 (P = 0.0682);Loss of methylation at R61 (P = 0.0682);	0.900634174194;0.900634174194;0.900634174194	0.89964	.;.;0.8632288536883499	0.86286	.;.;1.2898225746	0.82758	0.666072189808	0.62277	T	.;.;0.845413	0.96432	.;.;D	0.555878	0.96019	D	0.560704	0.95958	D	0.97427290005143	0.70440	D	0.950305;0.938806;0.964704	0.86917	D;D;D	.;.;0.9878227	0.99643	.;.;0.9762299	0.99705	.;.;0.9878227	0.99643	.;.;0.9762299	0.99706	.;-3.811;-4.523	0.56265	.;T;T	.;.;0.5223369070014163	0.59440	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	0.9642;0.9102;0.92	0.88599	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.773704	0.71425	25.7	4.119925	0.86208	28.8	0.99800789868783912	0.88550	0.97210	0.73340	D	AEFDGBHCI	0.932579	0.92316	D	0.931989858483062	0.93236	11.90809	0.881917176038756	0.94733	12.99905	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.554000	0.66999	.	.	0.599000	0.40250	1.000000	0.71638	1.000000	0.68203	0.580000	0.30894	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093410	C	G	G	A	rs200917074	16	31104731	16	31012232	62;62;62	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.185G>C;c.185G>C;c.185G>C	p.G62A;p.G62A;p.G62A	c.185G>C;c.185G>C;c.185G>C	p.Gly62Ala;p.Gly62Ala;p.Gly62Ala	c.185G>C;c.185G>C;c.185G>C	p.Gly62Ala;p.Gly62Ala;p.Gly62Ala	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GGT;GGT;GGT	2;2;2	0;0;0	C	C/C	C/C	C/C	C/C	0.001;0.001;0.0	0.91255	D;D;D	0.004;0.0;0.009	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.999;0.999	0.92359	.;D;D	0.000104	0.50451	N	0.081458	0.999982;0.999982;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	G62A;G62A;.;.;.;.	.;2.985;2.985	0.85602	.;M;M	-4.7;-4.7;-4.7	0.98020	D;D;D	-4.83;-5.31;-5.45	0.85468	D;D;D	.;0.752;0.604	0.75101	1.0927	0.99349	D	0.9664	0.98931	D	10	0.9446969;0.9446969;0.9446969	0.93795	D;D;D	0.155988	0.83683	D	0.774;0.774;0.774	0.92419	0.782;0.782;0.782;	0.90617	Q9BQB6;Q9BQB6;Q9BQB6;	G62A;G62A;G62A;	Gain of catalytic residue at G62 (P = 0.0699);Gain of catalytic residue at G62 (P = 0.0699);Gain of catalytic residue at G62 (P = 0.0699);	0.852724930263;0.852724930263;0.852724930263	0.85131	.;.;0.8192618929338977	0.81883	.;.;1.11917483189	0.78247	0.659267544746	0.61304	T	.;.;0.945119	0.99167	.;.;D	0.466088	0.93179	D	0.431727	0.93094	D	0.98130097627945	0.73835	D	0.953705;0.942806;0.966903	0.87955	D;D;D	.;.;0.9505088	0.96317	.;.;0.9290515	0.97029	.;.;0.9505088	0.96317	.;.;0.9290515	0.97030	.;-3.364;-3.435	0.30034	.;T;T	.;.;0.5605401164702719	0.62833	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	0.9324;0.8685;0.8731	0.85220	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.682373	0.68870	25.3	3.945334	0.80359	27.2	0.99770940366903471	0.85918	0.97277	0.73745	D	AEFDGBHCI	0.914313	0.87751	D	0.929487596704866	0.93127	11.83871	0.879823323152218	0.94631	12.91473	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.554000	0.66999	.	.	0.599000	0.40250	1.000000	0.71638	1.000000	0.68203	0.580000	0.30894	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093411	C	G	G	R	.	16	31104732	16	31012233	62;62;62	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.184G>C;c.184G>C;c.184G>C	p.G62R;p.G62R;p.G62R	c.184G>C;c.184G>C;c.184G>C	p.Gly62Arg;p.Gly62Arg;p.Gly62Arg	c.184G>C;c.184G>C;c.184G>C	p.Gly62Arg;p.Gly62Arg;p.Gly62Arg	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	GGT;GGT;GGT	1;1;1	0;0;0	C	C/C	C/C	C/C	C/C	0.001;0.001;0.0	0.91255	D;D;D	0.001;0.0;0.002	0.92824	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;1.0;1.0	0.97372	.;D;D	0.000104	0.50451	D	0.081458	0.999994;0.999994;1;0.569623;0.569623;0.569623	0.81001	D;D;D;N;N;N	simple_aae;simple_aae;without_aae;simple_aae;simple_aae;simple_aae	G62R;G62R;.;G82A;G93A;G94A	.;2.985;2.985	0.85602	.;M;M	-4.79;-4.79;-4.79	0.98155	D;D;D	-6.33;-7.17;-7.27	0.94404	D;D;D	.;0.886;0.871	0.88466	1.1142	0.99887	D	0.9714	0.99102	D	10	0.96620834;0.96620834;0.96620834	0.96109	D;D;D	0.246318	0.88923	D	0.832;0.832;0.832	0.94691	0.804;0.804;0.804;	0.92230	Q9BQB6;Q9BQB6;Q9BQB6;	G62R;G62R;G62R;	Gain of solvent accessibility (P = 0.0171);Gain of solvent accessibility (P = 0.0171);Gain of solvent accessibility (P = 0.0171);	0.895749667454;0.895749667454;0.895749667454	0.89472	.;.;0.9393871911697483	0.93919	.;.;1.25899604378	0.81981	0.737387776375	0.72588	T	.;.;0.950194	0.99277	.;.;D	0.157499	0.69968	D	-0.0115399	0.69584	D	0.965405272054127	0.67257	D	0.883312;0.873813;0.973703	0.90499	D;D;D	.;.;0.94503254	0.95759	.;.;0.9436391	0.98003	.;.;0.94503254	0.95760	.;.;0.9436391	0.98004	.;-3.938;-3.776	0.42755	.;T;T	.;.;0.7106881771361959	0.79087	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;P	.;.;P	.;.;P	.;.;P	0.9884;0.9643;0.9722	0.93122	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.877096	0.74555	26.2	4.197468	0.88194	29.4	0.99920940821597382	0.98721	0.97269	0.73696	D	AEFDGBHCI	0.896998	0.83869	D	0.904679205331171	0.91987	11.1719	0.85491650160061	0.93300	11.95274	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	5.554000	0.66999	.	.	0.599000	0.40250	1.000000	0.71638	1.000000	0.68203	0.518000	0.29429	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093412	C	A	R	S	.	16	31104733	16	31012234	61;61;61	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.183G>T;c.183G>T;c.183G>T	p.R61S;p.R61S;p.R61S	c.183G>T;c.183G>T;c.183G>T	p.Arg61Ser;p.Arg61Ser;p.Arg61Ser	c.183G>T;c.183G>T;c.183G>T	p.Arg61Ser;p.Arg61Ser;p.Arg61Ser	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AGG;AGG;AGG	3;3;3	2;2;2	C	C/C	C/C	C/C	C/C	0.044;0.273;0.005	0.63226	D;T;D	0.003;0.006;0.005	0.76473	D;D;D	.;0.763;0.379	0.43659	.;P;B	.;0.311;0.185	0.41430	.;B;B	0.721313	0.09932	N	0.856377	1;0.999998;0.99593;0.99593;0.999998;0.999998	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;G82W;R61S;R61S;G93W;G94W	.;2.675;2.675	0.78361	.;M;M	-4.61;-4.61;-4.61	0.97866	D;D;D	-3.36;-3.72;-3.79	0.71639	D;D;D	.;0.436;0.418	0.47487	0.3903	0.88951	D	0.8570	0.95237	D	10	0.57603884;0.57603884;0.57603884	0.65585	D;D;D	0.419663	0.93767	D	0.519;0.519;0.519	0.79522	0.728;0.728;0.728;	0.86198	Q9BQB6;Q9BQB6;Q9BQB6;	R61S;R61S;R61S;	Gain of glycosylation at R61 (P = 0.0175);Gain of glycosylation at R61 (P = 0.0175);Gain of glycosylation at R61 (P = 0.0175);	0.483153943251;0.483153943251;0.483153943251	0.47947	.;.;0.8324645692628363	0.83205	.;.;0.464243154752	0.45902	0.289642870426	0.08871	T	.;.;0.814306	0.95392	.;.;D	0.0925763	0.63478	D	-0.104797	0.63024	T	0.701513230800629	0.40791	D	0.892511;0.872513;0.931607	0.74555	D;D;D	.;.;0.7708954	0.82102	.;.;0.5010558	0.71155	.;.;0.7708954	0.82103	.;.;0.5010558	0.71156	.;-3.704;-2.754	0.36822	.;T;T	.;.;0.3056757948170161	0.40330	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	0.532;0.5204;0.3892	0.66007	A;A;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.312493	0.19163	14.48	1.659614	0.26507	17.22	0.96053714273887758	0.28570	0.10031	0.15647	N	AEFDGBHCI	0.402391	0.47649	N	-0.528836919076167	0.21152	1.120451	-0.676470274332233	0.17549	0.9336616	0.999999998047037	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	-2.14	0.06725	-1.435000	0.02529	.	.	0.599000	0.40250	0.000000	0.06391	0.000000	0.08366	0.419000	0.27206	0.4131:0.2368:0.1018:0.2483	1.1852	0.01740	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093412	C	G	R	S	rs1303260087	16	31104733	16	31012234	61;61;61	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.183G>C;c.183G>C;c.183G>C	p.R61S;p.R61S;p.R61S	c.183G>C;c.183G>C;c.183G>C	p.Arg61Ser;p.Arg61Ser;p.Arg61Ser	c.183G>C;c.183G>C;c.183G>C	p.Arg61Ser;p.Arg61Ser;p.Arg61Ser	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	AGG;AGG;AGG	3;3;3	2;2;2	C	C/C	C/C	C/C	C/C	0.044;0.273;0.005	0.63226	D;T;D	0.003;0.006;0.005	0.76473	D;D;D	.;0.763;0.379	0.43659	.;P;B	.;0.311;0.185	0.41430	.;B;B	0.721313	0.09932	N	0.856377	1;0.999999;0.99593;0.99593;0.999999;0.999999	0.81001	D;N;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;G82R;R61S;R61S;G93R;G94R	.;2.675;2.675	0.78361	.;M;M	-4.61;-4.61;-4.61	0.97866	D;D;D	-3.36;-3.72;-3.79	0.71639	D;D;D	.;0.436;0.418	0.47487	0.3903	0.88951	D	0.8570	0.95237	D	10	0.4573499;0.4573499;0.4573499	0.59071	T;T;T	0.16294	0.84239	D	0.519;0.519;0.519	0.79522	0.728;0.728;0.728;	0.86198	Q9BQB6;Q9BQB6;Q9BQB6;	R61S;R61S;R61S;	Gain of glycosylation at R61 (P = 0.0175);Gain of glycosylation at R61 (P = 0.0175);Gain of glycosylation at R61 (P = 0.0175);	0.483153943251;0.483153943251;0.483153943251	0.47947	.;.;0.8324645554918018	0.83205	.;.;0.464243154752	0.45902	0.289642870426	0.08871	T	.;.;0.814306	0.95392	.;.;D	0.0281827	0.55482	T	-0.197294	0.54902	T	0.475863844156265	0.31745	T	0.892511;0.872513;0.931607	0.74555	D;D;D	.;.;0.7708954	0.82102	.;.;0.5010558	0.71155	.;.;0.7708954	0.82103	.;.;0.5010558	0.71156	.;-3.704;-2.754	0.36822	.;T;T	.;.;0.3056757948170161	0.40330	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;B	.;.;B	.;.;B	.;.;B	0.532;0.5204;0.3892	0.66007	A;A;A	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	1.329745	0.19408	14.60	1.649064	0.26321	17.15	0.95760952195477578	0.27749	0.16417	0.19379	N	AEFDGBHCI	0.367883	0.45518	N	-0.528836919076167	0.21152	1.120451	-0.676470274332233	0.17549	0.9336616	0.999999998047037	0.74766	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	-2.14	0.06725	-1.435000	0.02529	.	.	0.599000	0.40250	0.000000	0.06391	0.000000	0.08366	0.419000	0.27206	0.4131:0.2368:0.1018:0.2483	1.1852	0.01740	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	152162	6.571940e-06	0	1	41434	2.413480e-05	0	1	41434	2.413480e-05	0	0	912	0.000000e+00	0	0	15274	0.000000e+00	0	0	3470	0.000000e+00	0	0	5186	0.000000e+00	0	0	10626	0.000000e+00	0	0	316	0.000000e+00	0	0	68020	0.000000e+00	0	0	4832	0.000000e+00	0	0	32904	0.000000e+00	0	0	134744	0.000000e+00	0	1	147916	6.760590e-06	0	1	80728	1.238730e-05	0	0	9094	0.000000e+00	0	0	60	0.000000e+00	0	0	4688	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5496	0.000000e+00	0	0	246	0.000000e+00	0	0	6852	0.000000e+00	0	0	3114	0.000000e+00	0	0	32462	0.000000e+00	0	0	862	0.000000e+00	0	0	14828	0.000000e+00	0	0	3386	0.000000e+00	0	0	5186	0.000000e+00	0	0	6984	0.000000e+00	0	0	310	0.000000e+00	0	0	63894	0.000000e+00	0	0	4830	0.000000e+00	0	1	41112	2.432380e-05	0	0	912	0.000000e+00	0	0	15086	0.000000e+00	0	0	3302	0.000000e+00	0	0	4952	0.000000e+00	0	0	10626	0.000000e+00	0	0	304	0.000000e+00	0	0	64800	0.000000e+00	0	0	4800	0.000000e+00	0	1	24812	4.030310e-05	0	0	112	0.000000e+00	0	0	12900	0.000000e+00	0	0	996	0.000000e+00	0	0	3744	0.000000e+00	0	0	10534	0.000000e+00	0	0	272	0.000000e+00	0	0	21036	0.000000e+00	0	0	4804	0.000000e+00	0	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31093419	C	A	W	L	.	16	31104740	16	31012241	59;59;59	AC135050.2;VKORC1;VKORC1	ENSG00000255439;ENSG00000167397;ENSG00000167397	ENST00000529564;ENST00000319788;ENST00000394975	ENSP00000431371;ENSP00000326135;ENSP00000378426	.;Q9BQB6-2;Q9BQB6	.;VKOR1_HUMAN;VKOR1_HUMAN	c.176G>T;c.176G>T;c.176G>T	p.W59L;p.W59L;p.W59L	c.176G>T;c.176G>T;c.176G>T	p.Trp59Leu;p.Trp59Leu;p.Trp59Leu	c.176G>T;c.176G>T;c.176G>T	p.Trp59Leu;p.Trp59Leu;p.Trp59Leu	principal5;.;principal1	Y;Y;Y	4;1;1	YES;.;YES	-;-;-	TGG;TGG;TGG	2;2;2	0;0;0	C	C/C	C/C	C/C	C/C	0.025;0.014;0.005	0.63226	D;D;D	0.048;0.041;0.038	0.51421	D;D;D	.;1.0;1.0	0.90584	.;D;D	.;0.997;0.998	0.88582	.;D;D	0.000006	0.62929	D	0.000000	0.999968;0.999968;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;without_aae;without_aae;without_aae;without_aae	W59L;W59L;.;.;.;.	.;2.565;2.565	0.75005	.;M;M	-4.78;-4.78;-4.78	0.98140	D;D;D	-6.87;-7.56;-7.94	0.96294	D;D;D	.;0.696;0.657	0.70088	1.0985	0.99599	D	0.9669	0.98948	D	10	0.97807324;0.97807324;0.97807324	0.97666	D;D;D	0.234837	0.88428	D	0.882;0.882;0.882	0.96539	0.887;0.887;0.887;	0.97178	Q9BQB6;Q9BQB6;Q9BQB6;	W59L;W59L;W59L;	Gain of methylation at R61 (P = 0.0346);Gain of methylation at R61 (P = 0.0346);Gain of methylation at R61 (P = 0.0346);	0.911861285934;0.911861285934;0.911861285934	0.91098	.;.;0.8473741515424674	0.84698	.;.;0.882133162261	0.69809	0.756736576557	0.75444	T	.;.;0.870708	0.97205	.;.;D	0.518336	0.94829	D	0.506777	0.94752	D	0.929309444577731	0.59328	D	0.963604;0.966503;0.959404	0.87759	D;D;D	.;.;0.9090723	0.92208	.;.;0.89773315	0.94815	.;.;0.9090723	0.92209	.;.;0.89773315	0.94815	.;0.0;-4.726	0.59903	.;T;T	.;.;0.5234803927129916	0.59539	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	.;.;U	0.7959;0.8367;0.8214	0.79071	P;P;P	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	.;.;.;	3.900997	0.75313	26.4	4.336611	0.90489	31	0.98774943105569246	0.46033	0.98033	0.79036	D	AEFDGBHCI	0.948747	0.96070	D	0.865819895305185	0.89990	10.20469	0.829295623001542	0.91750	11.04849	1.0	0.98316	0.72623	0.87236	0	0.52208	0.09955	0	0.594344	0.31042	0	0.554799	0.18163	0	.	.	6.17	6.17	0.99707	4.036000	0.57015	.	.	0.599000	0.40250	1.000000	0.71638	1.000000	0.68203	0.322000	0.25017	0.0:1.0:0.0:0.0	19.6509	0.95800	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094557	C	A	R	M	.	16	31105878	16	31013379	58;58;58;58;58;58	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.173G>T;c.173G>T;c.173G>T;c.173G>T;c.173G>T	.;p.R58M;p.R58M;p.R58M;p.R58M;p.R58M	c.173G>T;c.173G>T;c.173G>T;c.173G>T;c.173G>T;c.173G>T	p.Arg58Met;p.Arg58Met;p.Arg58Met;p.Arg58Met;p.Arg58Met;p.Arg58Met	c.173G>T;c.173G>T;c.173G>T;c.173G>T;c.173G>T;c.173G>T	p.Arg58Met;p.Arg58Met;p.Arg58Met;p.Arg58Met;p.Arg58Met;p.Arg58Met	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGG;AGG;AGG;AGG;AGG;AGG	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.04;0.001;0.007;0.001;0.001	0.78490	.;D;D;D;D;D	0.1;0.001;0.0;0.002;0.0;0.008	0.92824	T;D;D;D;D;D	.;.;.;1.0;.;0.975	0.90584	.;.;.;D;.;D	.;.;.;0.998;.;0.739	0.88582	.;.;.;D;.;P	0.000002	0.62929	D	0.000000	0.998788;0.997452;0.998788;0.998788;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R58M;R58M;R58M;R58M;.	.;.;.;2.705;2.705;2.705	0.79137	.;.;.;M;M;M	-4.78;-4.78;-4.78;-4.78;-4.78;-4.78	0.98140	D;D;D;D;D;D	.;-4.1;-3.53;-4.31;-3.89;-4.29	0.76576	.;D;D;D;D;D	.;.;0.586;0.556;0.441;0.521	0.60664	1.0452	0.98016	D	0.9587	0.98667	D	9	0.9608226;0.92125463;0.9558208;0.92125463;0.9465712;0.92125463	0.95490	D;D;D;D;D;D	0.595941	0.96426	D	.;0.863;0.863;0.863;0.863;0.863	0.95839	0.812;0.812;0.812;0.812;0.812;0.812;	0.92788	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R58M;R58M;R58M;R58M;R58M;R58M;	Gain of catalytic residue at V54 (P = 0.0379);Gain of catalytic residue at V54 (P = 0.0379);Gain of catalytic residue at V54 (P = 0.0379);Gain of catalytic residue at V54 (P = 0.0379);Gain of catalytic residue at V54 (P = 0.0379);Gain of catalytic residue at V54 (P = 0.0379);	0.716744150842;0.716744150842;0.716744150842;0.716744150842;0.716744150842;0.716744150842	0.71425	.;.;.;.;.;0.7809919540527782	0.78050	.;.;.;.;.;1.2000544037	0.80508	0.695631802082	0.66514	T	.;.;.;.;.;0.913519	0.98390	.;.;.;.;.;D	0.271942	0.80615	D	0.15285	0.80366	D	0.980623662471771	0.73460	D	0.133087;0.914708;0.159184;0.914509;0.386661;0.909809	0.69569	T;D;T;D;T;D	.;.;.;.;.;0.918187	0.93072	.;.;.;.;.;0.7858645	0.87389	.;.;.;.;.;0.918187	0.93073	.;.;.;.;.;0.7858645	0.87390	.;.;.;-5.818;-5.85;-6.249	0.75275	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.5479;0.8941;0.5943;0.8592;0.466;0.7677	0.82356	A;P;P;P;A;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	6.462410	0.96362	36	6.914752	0.97040	36	0.95900075656557515	0.28128	0.85385	0.44513	D	AEFDGBHCI	0.914971	0.87910	D	0.564329944033951	0.70959	5.578742	0.466121627086255	0.65760	4.864507	0.999999999999895	0.74766	0.733237	0.96898	0	0.52208	0.09955	0	0.52208	0.10781	0	0.621717	0.48901	0	.	.	4.63	3.61	0.40494	3.772000	0.55034	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.782000	0.36987	0.0:0.8306:0.1694:0.0	12.5064	0.55327	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094557	C	G	R	T	.	16	31105878	16	31013379	58;58;58;58;58;58	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.173G>C;c.173G>C;c.173G>C;c.173G>C;c.173G>C	.;p.R58T;p.R58T;p.R58T;p.R58T;p.R58T	c.173G>C;c.173G>C;c.173G>C;c.173G>C;c.173G>C;c.173G>C	p.Arg58Thr;p.Arg58Thr;p.Arg58Thr;p.Arg58Thr;p.Arg58Thr;p.Arg58Thr	c.173G>C;c.173G>C;c.173G>C;c.173G>C;c.173G>C;c.173G>C	p.Arg58Thr;p.Arg58Thr;p.Arg58Thr;p.Arg58Thr;p.Arg58Thr;p.Arg58Thr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGG;AGG;AGG;AGG;AGG;AGG	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.217;0.004;0.036;0.002;0.003	0.72154	.;T;D;D;D;D	0.013;0.004;0.0;0.006;0.0;0.071	0.92824	D;D;D;D;D;T	.;.;.;1.0;.;0.49	0.90584	.;.;.;D;.;P	.;.;.;0.996;.;0.229	0.84481	.;.;.;D;.;B	0.000002	0.62929	D	0.000000	0.996822;0.993335;0.996822;0.996822;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R58T;R58T;R58T;R58T;.	.;.;.;2.705;2.705;2.705	0.79137	.;.;.;M;M;M	-4.72;-4.72;-4.72;-4.72;-4.72;-4.72	0.98051	D;D;D;D;D;D	.;-3.95;-3.5;-4.31;-3.84;-4.23	0.76576	.;D;D;D;D;D	.;.;0.509;0.554;0.367;0.445	0.57946	0.9923	0.97059	D	0.9390	0.97996	D	9	0.94702506;0.8936889;0.94022965;0.8936889;0.9275398;0.8936889	0.94029	D;D;D;D;D;D	0.468069	0.94631	D	.;0.832;0.832;0.832;0.832;0.832	0.94691	0.787;0.787;0.787;0.787;0.787;0.787;	0.90993	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R58T;R58T;R58T;R58T;R58T;R58T;	Loss of MoRF binding (P = 0.0381);Loss of MoRF binding (P = 0.0381);Loss of MoRF binding (P = 0.0381);Loss of MoRF binding (P = 0.0381);Loss of MoRF binding (P = 0.0381);Loss of MoRF binding (P = 0.0381);	0.764931763366;0.764931763366;0.764931763366;0.764931763366;0.764931763366;0.764931763366	0.76279	.;.;.;.;.;0.8084676190512127	0.80801	.;.;.;.;.;1.3060442207	0.83124	0.702788710594	0.67547	T	.;.;.;.;.;0.858466	0.96839	.;.;.;.;.;D	0.337409	0.85663	D	0.246888	0.85474	D	0.989894211292267	0.80112	D	0.221078;0.958804;0.260274;0.958704;0.543046;0.956404	0.84482	T;D;T;D;T;D	.;.;.;.;.;0.8974659	0.91158	.;.;.;.;.;0.73811805	0.84521	.;.;.;.;.;0.8974659	0.91159	.;.;.;.;.;0.73811805	0.84522	.;.;.;-4.272;-4.54;-4.093	0.56583	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.23;0.6139;0.2789;0.5871;0.2534;0.4254	0.69452	B;P;B;P;B;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	5.765838	0.95250	34	6.276988	0.96144	35	0.96745729398750169	0.30943	0.84264	0.43346	D	AEFDGBHCI	0.906748	0.85990	D	0.406510901948087	0.61779	4.383787	0.358964778649617	0.59049	4.079645	0.999999999999895	0.74766	0.733237	0.96898	0	0.52208	0.09955	0	0.52208	0.10781	0	0.621717	0.48901	0	.	.	4.63	3.61	0.40494	3.772000	0.55034	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.782000	0.36987	0.0:0.8306:0.1694:0.0	12.5064	0.55327	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094558	T	C	R	G	rs104894541	16	31105879	16	31013380	58;58;58;58;58;58	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.172A>G;c.172A>G;c.172A>G;c.172A>G;c.172A>G	.;p.R58G;p.R58G;p.R58G;p.R58G;p.R58G	c.172A>G;c.172A>G;c.172A>G;c.172A>G;c.172A>G;c.172A>G	p.Arg58Gly;p.Arg58Gly;p.Arg58Gly;p.Arg58Gly;p.Arg58Gly;p.Arg58Gly	c.172A>G;c.172A>G;c.172A>G;c.172A>G;c.172A>G;c.172A>G	p.Arg58Gly;p.Arg58Gly;p.Arg58Gly;p.Arg58Gly;p.Arg58Gly;p.Arg58Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGG;AGG;AGG;AGG;AGG;AGG	1;1;1;1;1;1	2;2;2;2;2;2	T	T/T	T/T	T/T	T/T	.;0.305;0.03;0.068;0.002;0.002	0.72154	.;T;D;T;D;D	0.009;0.022;0.0;0.016;0.0;0.038	0.92824	D;D;D;D;D;D	.;.;.;1.0;.;0.001	0.90584	.;.;.;D;.;B	.;.;.;0.996;.;0.005	0.84481	.;.;.;D;.;B	0.000002	0.62929	D	0.000000	0.883587;0.883587;0.883587;0.782907;1	0.81001	A;A;A;A;A	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R58G;R58G;R58G;R58G;.	.;.;.;2.705;2.705;2.705	0.79137	.;.;.;M;M;M	-4.72;-4.72;-4.72;-4.72;-4.72;-4.72	0.98051	D;D;D;D;D;D	.;-4.77;-4.08;-5.24;-1.48;-5.04	0.83967	.;D;D;D;N;D	.;.;0.41;0.791;0.36;0.565	0.78737	0.9268	0.96056	D	0.9212	0.97392	D	9	0.980499;0.9685967;0.978927;0.9685967;0.97480273;0.9685967	0.98026	D;D;D;D;D;D	0.554898	0.95912	D	.;0.747;0.747;0.747;0.747;0.747	0.91285	0.924;0.924;0.924;0.924;0.924;0.924;	0.98707	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R58G;R58G;R58G;R58G;R58G;R58G;	Loss of MoRF binding (P = 0.0341);Loss of MoRF binding (P = 0.0341);Loss of MoRF binding (P = 0.0341);Loss of MoRF binding (P = 0.0341);Loss of MoRF binding (P = 0.0341);Loss of MoRF binding (P = 0.0341);	0.810191417597;0.810191417597;0.810191417597;0.810191417597;0.810191417597;0.810191417597	0.80840	.;.;.;.;.;0.7784730115128877	0.77797	.;.;.;.;.;1.14129531663	0.78934	0.664101719856	0.61996	T	.;.;.;.;.;0.846688	0.96472	.;.;.;.;.;D	0.365358	0.87654	D	0.287035	0.87495	D	0.991457641124725	0.81751	D	0.217978;0.859314;0.257074;0.858514;0.539746;0.865313	0.56401	T;D;T;D;T;D	.;.;.;.;.;0.9038708	0.91732	.;.;.;.;.;0.820636	0.89579	.;.;.;.;.;0.9038708	0.91733	.;.;.;.;.;0.820636	0.89580	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.1709;0.4783;0.2074;0.514;0.1635;0.3574	0.65212	B;A;B;A;B;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.572674	0.91778	32	3.806775	0.75699	26.3	0.99708365826732537	0.81143	0.73294	0.35854	D	AEFDGBHCI	0.671666	0.63833	D	0.00719696999397416	0.42181	2.536787	-0.0554828769028781	0.37253	2.178766	0.999999999976371	0.74766	0.733237	0.96898	0	0.52208	0.09955	0	0.52208	0.10781	0	0.621717	0.48901	0	.	.	4.63	0.829	0.17984	1.902000	0.39479	.	.	0.609000	0.47794	1.000000	0.71638	1.000000	0.68203	0.852000	0.40310	0.0:0.0916:0.3238:0.5846	6.0018	0.18754	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2209	Pathogenic	Warfarin_response	no_assertion_criteria_provided	NC_000016.10:g.31094558T>C	ClinGen:CA115414|Genetic_Testing_Registry_(GTR):GTR000593349|Genetic_Testing_Registry_(GTR):GTR000593366|OMIM:608547.0004|UniProtKB:Q9BQB6#VAR_021823	C0750384	122700	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094561	A	C	S	A	.	16	31105882	16	31013383	57;57;57;57;57;57	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.169T>G;c.169T>G;c.169T>G;c.169T>G;c.169T>G	.;p.S57A;p.S57A;p.S57A;p.S57A;p.S57A	c.169T>G;c.169T>G;c.169T>G;c.169T>G;c.169T>G;c.169T>G	p.Ser57Ala;p.Ser57Ala;p.Ser57Ala;p.Ser57Ala;p.Ser57Ala;p.Ser57Ala	c.169T>G;c.169T>G;c.169T>G;c.169T>G;c.169T>G;c.169T>G	p.Ser57Ala;p.Ser57Ala;p.Ser57Ala;p.Ser57Ala;p.Ser57Ala;p.Ser57Ala	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCC;TCC;TCC;TCC;TCC;TCC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.02;0.013;0.012;0.022;0.0	0.91255	.;D;D;D;D;D	0.085;0.034;0.052;0.066;0.372;0.071	0.52727	T;D;T;T;T;T	.;.;.;0.936;.;0.992	0.64738	.;.;.;P;.;D	.;.;.;0.698;.;0.989	0.78396	.;.;.;P;.;D	0.001855	0.37840	N	0.122071	0.996844;0.996844;0.996844;0.996844;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S57A;S57A;S57A;S57A;.	.;.;.;2.965;2.965;2.965	0.85198	.;.;.;M;M;M	-6.0;-6.0;-6.0;-6.0;-6.0;-6.0	0.99482	D;D;D;D;D;D	.;-2.57;-2.98;-2.81;-2.86;-2.58	0.62008	.;D;D;D;D;D	.;.;0.714;0.753;0.689;0.703	0.75192	1.0581	0.98296	D	0.9833	0.99492	D	10	0.97362816;0.9606006;0.9686424;0.9606006;0.9679924;0.9606006	0.97046	D;D;D;D;D;D	0.704283	0.97585	D	.;0.783;0.783;0.783;0.783;0.783	0.92787	0.886;0.886;0.886;0.886;0.886;0.886;	0.97130	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S57A;S57A;S57A;S57A;S57A;S57A;	Gain of helix (P = 0.027);Gain of helix (P = 0.027);Gain of helix (P = 0.027);Gain of helix (P = 0.027);Gain of helix (P = 0.027);Gain of helix (P = 0.027);	0.788892818177;0.788892818177;0.788892818177;0.788892818177;0.788892818177;0.788892818177	0.78694	.;.;.;.;.;0.9403092445532736	0.94011	.;.;.;.;.;0.609560581112	0.55682	0.728639245033	0.71307	T	.;.;.;.;.;0.954456	0.99366	.;.;.;.;.;D	0.27312	0.80718	D	0.154542	0.80469	D	0.987909555435181	0.78316	D	0.80242;0.650435;0.794021;0.649735;0.779122;0.728227	0.44873	T;T;T;T;T;T	.;.;.;.;.;0.95911974	0.97191	.;.;.;.;.;0.93823016	0.97651	.;.;.;.;.;0.95911974	0.97192	.;.;.;.;.;0.93823016	0.97651	.;.;.;-3.364;-3.477;-3.435	0.31067	.;.;.;T;T;T	.;.;.;.;.;0.6119226076763471	0.67959	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	0.3059;0.6963;0.2645;0.6827;0.2589;0.6119	0.72807	B;P;B;P;B;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.208067	0.85709	28.7	3.680088	0.71895	25.7	0.99032815447720968	0.50830	0.92176	0.55114	D	AEFDGBHCI	0.909454	0.86611	D	0.471702959280921	0.65446	4.823352	0.430293923709957	0.63460	4.580289	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.305000	0.72774	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.937000	0.47636	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094561	A	G	S	P	.	16	31105882	16	31013383	57;57;57;57;57;57	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.169T>C;c.169T>C;c.169T>C;c.169T>C;c.169T>C	.;p.S57P;p.S57P;p.S57P;p.S57P;p.S57P	c.169T>C;c.169T>C;c.169T>C;c.169T>C;c.169T>C;c.169T>C	p.Ser57Pro;p.Ser57Pro;p.Ser57Pro;p.Ser57Pro;p.Ser57Pro;p.Ser57Pro	c.169T>C;c.169T>C;c.169T>C;c.169T>C;c.169T>C;c.169T>C	p.Ser57Pro;p.Ser57Pro;p.Ser57Pro;p.Ser57Pro;p.Ser57Pro;p.Ser57Pro	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCC;TCC;TCC;TCC;TCC;TCC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.005;0.004;0.002;0.006;0.0	0.91255	.;D;D;D;D;D	0.028;0.014;0.019;0.026;0.123;0.013	0.63109	D;D;D;D;T;D	.;.;.;0.999;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.951;.;0.998	0.88582	.;.;.;D;.;D	0.001855	0.37840	N	0.122071	0.99985;0.99985;0.99985;0.99985;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S57P;S57P;S57P;S57P;.	.;.;.;2.965;2.965;2.965	0.85198	.;.;.;M;M;M	-6.05;-6.05;-6.05;-6.05;-6.05;-6.05	0.99505	D;D;D;D;D;D	.;-4.28;-4.6;-4.78;-4.65;-4.13	0.80510	.;D;D;D;D;D	.;.;0.735;0.817;0.78;0.746	0.81261	1.0476	0.98067	D	0.9838	0.99508	D	10	0.9749141;0.9618708;0.96906114;0.9618708;0.9695008;0.9618708	0.97221	D;D;D;D;D;D	0.768063	0.98164	D	.;0.920;0.920;0.920;0.920;0.920	0.97965	0.849;0.849;0.849;0.849;0.849;0.849;	0.95143	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S57P;S57P;S57P;S57P;S57P;S57P;	Gain of relative solvent accessibility (P = 0.0023);Gain of relative solvent accessibility (P = 0.0023);Gain of relative solvent accessibility (P = 0.0023);Gain of relative solvent accessibility (P = 0.0023);Gain of relative solvent accessibility (P = 0.0023);Gain of relative solvent accessibility (P = 0.0023);	0.807264362512;0.807264362512;0.807264362512;0.807264362512;0.807264362512;0.807264362512	0.80546	.;.;.;.;.;0.9864738833846217	0.98640	.;.;.;.;.;1.21397123473	0.80906	0.755066275597	0.75195	T	.;.;.;.;.;0.957769	0.99435	.;.;.;.;.;D	0.427436	0.91401	D	0.376206	0.91295	D	0.994500041007996	0.85817	D	0.882712;0.922708;0.877412;0.920908;0.866813;0.960104	0.84924	D;D;D;D;D;D	.;.;.;.;.;0.9828346	0.99318	.;.;.;.;.;0.9779717	0.99761	.;.;.;.;.;0.9828346	0.99318	.;.;.;.;.;0.9779717	0.99762	.;.;.;-3.663;-3.405;-4.659	0.58755	.;.;.;T;T;T	.;.;.;.;.;0.676546000894537	0.75233	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.5895;0.9638;0.5285;0.9386;0.4988;0.9212	0.88546	P;P;A;P;A;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.490566	0.91158	32	3.966803	0.81115	27.4	0.99806744113850832	0.89085	0.91758	0.54201	D	AEFDGBHCI	0.968208	0.99068	D	0.637442213231515	0.75559	6.327324	0.549413548699908	0.71357	5.642464	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.305000	0.72774	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.937000	0.47636	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094561	A	T	S	T	.	16	31105882	16	31013383	57;57;57;57;57;57	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.169T>A;c.169T>A;c.169T>A;c.169T>A;c.169T>A	.;p.S57T;p.S57T;p.S57T;p.S57T;p.S57T	c.169T>A;c.169T>A;c.169T>A;c.169T>A;c.169T>A;c.169T>A	p.Ser57Thr;p.Ser57Thr;p.Ser57Thr;p.Ser57Thr;p.Ser57Thr;p.Ser57Thr	c.169T>A;c.169T>A;c.169T>A;c.169T>A;c.169T>A;c.169T>A	p.Ser57Thr;p.Ser57Thr;p.Ser57Thr;p.Ser57Thr;p.Ser57Thr;p.Ser57Thr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCC;TCC;TCC;TCC;TCC;TCC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.048;0.007;0.024;0.012;0.0	0.91255	.;D;D;D;D;D	0.094;0.027;0.054;0.052;0.393;0.026	0.55759	T;D;T;T;T;D	.;.;.;0.971;.;0.997	0.70673	.;.;.;D;.;D	.;.;.;0.79;.;0.992	0.80445	.;.;.;P;.;D	0.001855	0.37840	N	0.122071	0.99903;0.99903;0.99903;0.99903;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S57T;S57T;S57T;S57T;.	.;.;.;2.415;2.415;2.415	0.69758	.;.;.;M;M;M	-5.92;-5.92;-5.92;-5.92;-5.92;-5.92	0.99447	D;D;D;D;D;D	.;-2.55;-2.98;-2.88;-2.86;-2.58	0.62008	.;D;D;D;D;D	.;.;0.659;0.695;0.624;0.654	0.70000	1.0678	0.98533	D	0.9794	0.99366	D	10	0.96736264;0.95029986;0.96029806;0.95029986;0.96049345;0.95029986	0.96248	D;D;D;D;D;D	0.725276	0.97783	D	.;0.810;0.810;0.810;0.810;0.810	0.93854	0.862;0.862;0.862;0.862;0.862;0.862;	0.95885	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S57T;S57T;S57T;S57T;S57T;S57T;	Gain of relative solvent accessibility (P = 0.0215);Gain of relative solvent accessibility (P = 0.0215);Gain of relative solvent accessibility (P = 0.0215);Gain of relative solvent accessibility (P = 0.0215);Gain of relative solvent accessibility (P = 0.0215);Gain of relative solvent accessibility (P = 0.0215);	0.782906578766;0.782906578766;0.782906578766;0.782906578766;0.782906578766;0.782906578766	0.78090	.;.;.;.;.;0.9612913021898452	0.96115	.;.;.;.;.;0.399327343636	0.40961	0.742670416832	0.73366	T	.;.;.;.;.;0.840954	0.96290	.;.;.;.;.;D	0.248999	0.78509	D	0.119894	0.78229	D	0.978644847869873	0.72429	D	0.873813;0.762724;0.868113;0.761924;0.70043;0.828317	0.58316	D;T;D;T;T;T	.;.;.;.;.;0.8210882	0.85293	.;.;.;.;.;0.83072066	0.90232	.;.;.;.;.;0.8210882	0.85294	.;.;.;.;.;0.83072066	0.90232	.;.;.;-4.272;-4.54;-4.093	0.56583	.;.;.;T;T;T	.;.;.;.;.;0.380757636888941	0.47522	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	0.2895;0.5709;0.3089;0.4852;0.2692;0.4919	0.67673	B;P;B;A;B;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.076162	0.81262	27.6	3.637593	0.70707	25.5	0.9924251146686639	0.56597	0.91799	0.54287	D	AEFDGBHCI	0.924024	0.90142	D	0.450471587825753	0.64229	4.672855	0.419422214428536	0.62774	4.498803	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.305000	0.72774	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.937000	0.47636	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094563	G	C	S	C	.	16	31105884	16	31013385	56;56;56;56;56;56	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.167C>G;c.167C>G;c.167C>G;c.167C>G;c.167C>G	.;p.S56C;p.S56C;p.S56C;p.S56C;p.S56C	c.167C>G;c.167C>G;c.167C>G;c.167C>G;c.167C>G;c.167C>G	p.Ser56Cys;p.Ser56Cys;p.Ser56Cys;p.Ser56Cys;p.Ser56Cys;p.Ser56Cys	c.167C>G;c.167C>G;c.167C>G;c.167C>G;c.167C>G;c.167C>G	p.Ser56Cys;p.Ser56Cys;p.Ser56Cys;p.Ser56Cys;p.Ser56Cys;p.Ser56Cys	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCC;TCC;TCC;TCC;TCC;TCC	2;2;2;2;2;2	0;0;0;0;0;0	G	G/G	G/G	G/G	G/G	.;0.012;0.004;0.005;0.004;0.004	0.65419	.;D;D;D;D;D	0.011;0.049;0.015;0.027;0.047;0.052	0.64786	D;D;D;D;D;T	.;.;.;0.994;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.927;.;0.969	0.72001	.;.;.;D;.;D	0.000070	0.52346	D	0.000000	0.97378;0.97378;0.97378;0.97378;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S56C;S56C;S56C;S56C;.	.;.;.;2.42;2.42;2.42	0.70002	.;.;.;M;M;M	-4.81;-4.81;-4.81;-4.81;-4.81;-4.81	0.98183	D;D;D;D;D;D	.;-2.79;-3.38;-3.16;-3.15;-2.92	0.66780	.;D;D;D;D;D	.;.;0.452;0.377;0.347;0.28	0.48963	1.0802	0.98887	D	0.9544	0.98521	D	10	0.79440475;0.79440475;0.79440475;0.79440475;0.79440475;0.79440475	0.78941	D;D;D;D;D;D	0.599656	0.96471	D	.;0.805;0.805;0.805;0.805;0.805	0.93660	0.605;0.605;0.605;0.605;0.605;0.605;	0.73706	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S56C;S56C;S56C;S56C;S56C;S56C;	Loss of phosphorylation at S56 (P = 0.0485);Loss of phosphorylation at S56 (P = 0.0485);Loss of phosphorylation at S56 (P = 0.0485);Loss of phosphorylation at S56 (P = 0.0485);Loss of phosphorylation at S56 (P = 0.0485);Loss of phosphorylation at S56 (P = 0.0485);	0.730530531519;0.730530531519;0.730530531519;0.730530531519;0.730530531519;0.730530531519	0.72813	.;.;.;.;.;0.43943224999451225	0.43860	.;.;.;.;.;1.13111999283	0.78618	0.724888026714	0.70759	T	.;.;.;.;.;0.917621	0.98499	.;.;.;.;.;D	0.256946	0.79247	D	0.131309	0.78978	D	0.992454409599304	0.82937	D	0.963704;0.915408;0.968803;0.905809;0.963804;0.957304	0.88706	D;D;D;D;D;D	.;.;.;.;.;0.80215883	0.84044	.;.;.;.;.;0.622412	0.77999	.;.;.;.;.;0.80215883	0.84045	.;.;.;.;.;0.622412	0.78000	.;.;.;-4.622;-4.455;-5.942	0.73235	.;.;.;T;T;T	.;.;.;.;.;0.6005175866630511	0.66751	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	0.6105;0.4644;0.3384;0.4422;0.3057;0.4284	0.69312	P;A;B;A;B;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.283348	0.87827	29.4	3.861893	0.77499	26.6	0.99383187725677047	0.61979	0.82586	0.41793	D	AEFDGBHCI	0.784734	0.71533	D	0.538303820624279	0.69373	5.347651	0.471292370078982	0.66096	4.907722	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	3.444000	0.52678	.	.	0.618000	0.50648	1.000000	0.71638	1.000000	0.68203	0.951000	0.49849	0.0:0.0:1.0:0.0	14.878	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094564	A	C	S	A	.	16	31105885	16	31013386	56;56;56;56;56;56	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.166T>G;c.166T>G;c.166T>G;c.166T>G;c.166T>G	.;p.S56A;p.S56A;p.S56A;p.S56A;p.S56A	c.166T>G;c.166T>G;c.166T>G;c.166T>G;c.166T>G;c.166T>G	p.Ser56Ala;p.Ser56Ala;p.Ser56Ala;p.Ser56Ala;p.Ser56Ala;p.Ser56Ala	c.166T>G;c.166T>G;c.166T>G;c.166T>G;c.166T>G;c.166T>G	p.Ser56Ala;p.Ser56Ala;p.Ser56Ala;p.Ser56Ala;p.Ser56Ala;p.Ser56Ala	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCC;TCC;TCC;TCC;TCC;TCC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.314;0.294;0.346;0.311;0.259	0.16628	.;T;T;T;T;T	0.104;0.182;0.142;0.107;0.452;0.329	0.38160	T;T;T;T;T;T	.;.;.;0.119;.;0.889	0.48869	.;.;.;B;.;P	.;.;.;0.046;.;0.525	0.48375	.;.;.;B;.;P	0.000070	0.52346	D	0.000000	1;0.818919;0.818919;0.818919;0.818919	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S56A;S56A;S56A;S56A	.;.;.;2.075;2.075;2.075	0.57047	.;.;.;M;M;M	-4.7;-4.7;-4.7;-4.7;-4.7;-4.7	0.98020	D;D;D;D;D;D	.;-1.32;-1.65;-1.49;-1.4;-1.42	0.39503	.;N;N;N;N;N	.;.;0.365;0.34;0.303;0.251	0.40665	0.6913	0.93067	D	0.8725	0.95762	D	10	0.53020775;0.53020775;0.53020775;0.53020775;0.53020775;0.53020775	0.63140	D;D;D;D;D;D	0.477418	0.94784	D	.;0.574;0.574;0.574;0.574;0.574	0.82742	0.59;0.59;0.59;0.59;0.59;0.59;	0.71874	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S56A;S56A;S56A;S56A;S56A;S56A;	Gain of helix (P = 0.0425);Gain of helix (P = 0.0425);Gain of helix (P = 0.0425);Gain of helix (P = 0.0425);Gain of helix (P = 0.0425);Gain of helix (P = 0.0425);	0.64616893142;0.64616893142;0.64616893142;0.64616893142;0.64616893142;0.64616893142	0.64323	.;.;.;.;.;0.2793076739117089	0.27843	.;.;.;.;.;0.427542606873	0.43095	0.700364589691	0.67195	T	.;.;.;.;.;0.647271	0.89253	.;.;.;.;.;D	0.182133	0.72239	D	0.0238452	0.71879	D	0.787662208080292	0.45537	D	0.816718;0.673133;0.834417;0.658834;0.817118;0.79802	0.50357	T;T;T;T;T;T	.;.;.;.;.;0.5895869	0.72128	.;.;.;.;.;0.4390213	0.67268	.;.;.;.;.;0.5895869	0.72129	.;.;.;.;.;0.4390213	0.67268	.;.;.;-3.364;-3.477;-3.435	0.31067	.;.;.;T;T;T	.;.;.;.;.;0.10533778495406476	0.08340	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.2161;0.1512;0.1768;0.1747;0.1399;0.1559	0.44566	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.509540	0.64340	24.7	2.894024	0.52350	23.3	0.99165006766691877	0.54212	0.68953	0.33998	D	AEFDGBHCI	0.521019	0.54563	D	-0.020644189216683	0.40922	2.438635	0.044572363575559	0.41809	2.518132	0.999999999999636	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	2.830000	0.47837	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.953000	0.50222	0.8147:0.0:0.0:0.1853	7.8081	0.28378	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094564	A	T	S	T	.	16	31105885	16	31013386	56;56;56;56;56;56	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.166T>A;c.166T>A;c.166T>A;c.166T>A;c.166T>A	.;p.S56T;p.S56T;p.S56T;p.S56T;p.S56T	c.166T>A;c.166T>A;c.166T>A;c.166T>A;c.166T>A;c.166T>A	p.Ser56Thr;p.Ser56Thr;p.Ser56Thr;p.Ser56Thr;p.Ser56Thr;p.Ser56Thr	c.166T>A;c.166T>A;c.166T>A;c.166T>A;c.166T>A;c.166T>A	p.Ser56Thr;p.Ser56Thr;p.Ser56Thr;p.Ser56Thr;p.Ser56Thr;p.Ser56Thr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCC;TCC;TCC;TCC;TCC;TCC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.974;0.286;0.661;0.371;0.776	0.15201	.;T;T;T;T;T	0.038;0.787;0.044;0.474;0.133;0.919	0.51421	D;T;D;T;T;T	.;.;.;0.043;.;0.098	0.25584	.;.;.;B;.;B	.;.;.;0.028;.;0.137	0.33328	.;.;.;B;.;B	0.000070	0.52346	D	0.000000	1;0.573777;0.573777;0.573777;0.573777	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S56T;S56T;S56T;S56T	.;.;.;0.57;0.57;0.57	0.15267	.;.;.;N;N;N	-4.68;-4.68;-4.68;-4.68;-4.68;-4.68	0.97989	D;D;D;D;D;D	.;0.29;-0.02;0.31;0.09;0.21	0.07299	.;N;N;N;N;N	.;.;0.266;0.218;0.209;0.151	0.30118	0.4421	0.89718	D	0.7305	0.90780	D	10	0.35501254;0.35501254;0.35501254;0.35501254;0.35501254;0.35501254	0.52272	T;T;T;T;T;T	0.387926	0.93122	D	.;0.487;0.487;0.487;0.487;0.487	0.77528	0.517;0.517;0.517;0.517;0.517;0.517;	0.61763	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S56T;S56T;S56T;S56T;S56T;S56T;	Gain of MoRF binding (P = 0.1272);Gain of MoRF binding (P = 0.1272);Gain of MoRF binding (P = 0.1272);Gain of MoRF binding (P = 0.1272);Gain of MoRF binding (P = 0.1272);Gain of MoRF binding (P = 0.1272);	0.511448588287;0.511448588287;0.511448588287;0.511448588287;0.511448588287;0.511448588287	0.50785	.;.;.;.;.;0.3148888045428329	0.31401	.;.;.;.;.;0.91655607726	0.71259	0.712147891521	0.68905	T	.;.;.;.;.;0.410138	0.76497	.;.;.;.;.;T	0.13329	0.67680	D	-0.0463139	0.67273	D	0.705508768558502	0.40982	D	0.884012;0.728227;0.89601;0.717028;0.884412;0.832317	0.63722	D;T;D;T;D;T	.;.;.;.;.;0.44292828	0.63591	.;.;.;.;.;0.1886259	0.42164	.;.;.;.;.;0.44292828	0.63591	.;.;.;.;.;0.1886259	0.42163	.;.;.;-4.272;-4.54;-4.093	0.56583	.;.;.;T;T;T	.;.;.;.;.;0.06374139352283317	0.01981	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.2163;0.169;0.2181;0.1973;0.1668;0.1623	0.44822	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.384174	0.38692	22.0	1.800364	0.29042	18.20	0.95825100369395344	0.27923	0.53776	0.29454	D	AEFDGBHCI	0.320863	0.42384	N	-0.410267437192979	0.25109	1.360595	-0.231251296252571	0.30423	1.712802	0.999999999999636	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	2.830000	0.47837	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.953000	0.50222	0.8147:0.0:0.0:0.1853	7.8081	0.28378	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094566	A	C	F	C	.	16	31105887	16	31013388	55;55;55;55;55;55	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.164T>G;c.164T>G;c.164T>G;c.164T>G;c.164T>G	.;p.F55C;p.F55C;p.F55C;p.F55C;p.F55C	c.164T>G;c.164T>G;c.164T>G;c.164T>G;c.164T>G;c.164T>G	p.Phe55Cys;p.Phe55Cys;p.Phe55Cys;p.Phe55Cys;p.Phe55Cys;p.Phe55Cys	c.164T>G;c.164T>G;c.164T>G;c.164T>G;c.164T>G;c.164T>G	p.Phe55Cys;p.Phe55Cys;p.Phe55Cys;p.Phe55Cys;p.Phe55Cys;p.Phe55Cys	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TTC;TTC;TTC;TTC;TTC;TTC	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.015;0.059;0.07;0.089;0.015	0.52492	.;D;T;T;T;D	0.053;0.028;0.0;0.08;0.127;0.029	0.92824	T;D;D;T;T;D	.;.;.;0.347;.;1.0	0.90584	.;.;.;B;.;D	.;.;.;0.156;.;0.998	0.88582	.;.;.;B;.;D	0.001290	0.39521	N	0.115558	0.999912;0.999912;0.999912;0.999912;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	F55C;F55C;F55C;F55C;.	.;.;.;2.895;2.895;2.895	0.83812	.;.;.;M;M;M	-4.77;-4.77;-4.77;-4.77;-4.77;-4.77	0.98126	D;D;D;D;D;D	.;-5.87;-6.73;-6.59;-6.4;-6.0	0.92605	.;D;D;D;D;D	.;.;0.846;0.915;0.907;0.748	0.91736	1.0935	0.99382	D	0.9646	0.98869	D	10	0.95313764;0.95313764;0.95313764;0.95313764;0.95313764;0.95313764	0.94659	D;D;D;D;D;D	0.731061	0.97836	D	.;0.914;0.914;0.914;0.914;0.914	0.97738	0.82;0.82;0.82;0.82;0.82;0.82;	0.93328	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	F55C;F55C;F55C;F55C;F55C;F55C;	Loss of MoRF binding (P = 0.0778);Loss of MoRF binding (P = 0.0778);Loss of MoRF binding (P = 0.0778);Loss of MoRF binding (P = 0.0778);Loss of MoRF binding (P = 0.0778);Loss of MoRF binding (P = 0.0778);	0.836559259824;0.836559259824;0.836559259824;0.836559259824;0.836559259824;0.836559259824	0.83499	.;.;.;.;.;0.9201358220603875	0.91989	.;.;.;.;.;1.37564790398	0.84656	0.851551055908	0.89849	D	.;.;.;.;.;0.94446	0.99152	.;.;.;.;.;D	0.499543	0.94276	D	0.479783	0.94198	D	0.9949631690979	0.86599	D	0.976902;0.939506;0.973003;0.929907;0.978602;0.959004	0.92442	D;D;D;D;D;D	.;.;.;.;.;0.95660543	0.96936	.;.;.;.;.;0.9475594	0.98250	.;.;.;.;.;0.95660543	0.96936	.;.;.;.;.;0.9475594	0.98250	.;.;.;-4.622;-4.455;-5.942	0.73235	.;.;.;T;T;T	.;.;.;.;.;0.7615560938555901	0.84332	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9712;0.9785;0.941;0.9705;0.9127;0.9658	0.90850	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.567938	0.91747	32	4.150298	0.87043	29.0	0.98799901262410539	0.46429	0.92227	0.55229	D	AEFDGBHCI	0.943025	0.94834	D	0.363515021892826	0.59456	4.125238	0.363077244891485	0.59300	4.106564	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.672000	0.61290	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.948000	0.49324	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094567	A	T	F	I	.	16	31105888	16	31013389	55;55;55;55;55;55	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.163T>A;c.163T>A;c.163T>A;c.163T>A;c.163T>A	.;p.F55I;p.F55I;p.F55I;p.F55I;p.F55I	c.163T>A;c.163T>A;c.163T>A;c.163T>A;c.163T>A;c.163T>A	p.Phe55Ile;p.Phe55Ile;p.Phe55Ile;p.Phe55Ile;p.Phe55Ile;p.Phe55Ile	c.163T>A;c.163T>A;c.163T>A;c.163T>A;c.163T>A;c.163T>A	p.Phe55Ile;p.Phe55Ile;p.Phe55Ile;p.Phe55Ile;p.Phe55Ile;p.Phe55Ile	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TTC;TTC;TTC;TTC;TTC;TTC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.057;0.01;0.039;0.016;0.041	0.56456	.;T;D;D;D;D	0.011;0.065;0.0;0.061;0.038;0.068	0.92824	D;T;D;T;D;T	.;.;.;0.996;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.895;.;0.997	0.86255	.;.;.;P;.;D	0.001290	0.39521	N	0.115558	0.999788;0.999788;0.999788;0.999788;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	F55I;F55I;F55I;F55I;.	.;.;.;2.345;2.345;2.345	0.67358	.;.;.;M;M;M	-4.7;-4.7;-4.7;-4.7;-4.7;-4.7	0.98020	D;D;D;D;D;D	.;-4.07;-4.65;-4.49;-4.45;-4.0	0.79399	.;D;D;D;D;D	.;.;0.728;0.791;0.763;0.595	0.78737	1.0685	0.98551	D	0.9476	0.98290	D	10	0.869081;0.869081;0.869081;0.869081;0.869081;0.869081	0.86166	D;D;D;D;D;D	0.708983	0.97630	D	.;0.886;0.886;0.886;0.886;0.886	0.96688	0.615;0.615;0.615;0.615;0.615;0.615;	0.74884	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	F55I;F55I;F55I;F55I;F55I;F55I;	Gain of MoRF binding (P = 0.0897);Gain of MoRF binding (P = 0.0897);Gain of MoRF binding (P = 0.0897);Gain of MoRF binding (P = 0.0897);Gain of MoRF binding (P = 0.0897);Gain of MoRF binding (P = 0.0897);	0.806424419555;0.806424419555;0.806424419555;0.806424419555;0.806424419555;0.806424419555	0.80460	.;.;.;.;.;0.9120538911255957	0.91179	.;.;.;.;.;0.98721341715	0.73952	0.837121367455	0.87655	D	.;.;.;.;.;0.843359	0.96367	.;.;.;.;.;D	0.36107	0.87335	D	0.280875	0.87171	D	0.994819700717926	0.86343	D	0.972903;0.816718;0.949605;0.805919;0.974203;0.952505	0.90777	D;T;D;T;D;D	.;.;.;.;.;0.85499376	0.87707	.;.;.;.;.;0.80705595	0.88714	.;.;.;.;.;0.85499376	0.87709	.;.;.;.;.;0.80705595	0.88714	.;.;.;-5.331;-5.948;-5.673	0.73277	.;.;.;T;T;T	.;.;.;.;.;0.4248032798307029	0.51296	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	0.9289;0.9171;0.8531;0.9131;0.7828;0.8953	0.84920	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.442563	0.90660	31	4.004244	0.82434	27.7	0.98941436526442206	0.48940	0.91852	0.54402	D	AEFDGBHCI	0.928188	0.91202	D	0.522714285367023	0.68435	5.216915	0.477495759474813	0.66502	4.960354	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.305000	0.72774	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.939000	0.47918	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094572	C	T	R	H	rs1423114055	16	31105893	16	31013394	53;53;53;53;53;53	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.158G>A;c.158G>A;c.158G>A;c.158G>A;c.158G>A	.;p.R53H;p.R53H;p.R53H;p.R53H;p.R53H	c.158G>A;c.158G>A;c.158G>A;c.158G>A;c.158G>A;c.158G>A	p.Arg53His;p.Arg53His;p.Arg53His;p.Arg53His;p.Arg53His;p.Arg53His	c.158G>A;c.158G>A;c.158G>A;c.158G>A;c.158G>A;c.158G>A	p.Arg53His;p.Arg53His;p.Arg53His;p.Arg53His;p.Arg53His;p.Arg53His	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CGC;CGC;CGC;CGC;CGC;CGC	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.042;0.016;0.015;0.013;0.014	0.53900	.;D;D;D;D;D	0.013;0.043;0.009;0.022;0.01;0.048	0.66756	D;D;D;D;D;D	.;.;.;1.0;.;1.0	0.90584	.;.;.;D;.;D	.;.;.;0.966;.;0.984	0.76113	.;.;.;D;.;D	0.000162	0.48594	D	0.000000	1;0.807862;0.807862;0.807862;0.807862	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;R53H;R53H;R53H;R53H	.;.;.;2.295;2.295;2.295	0.65404	.;.;.;M;M;M	-4.69;-4.69;-4.69;-4.69;-4.69;-4.69	0.98005	D;D;D;D;D;D	.;-3.14;-3.27;-3.38;-3.27;-3.01	0.66780	.;D;D;D;D;D	.;.;0.39;0.369;0.329;0.293	0.43126	1.0494	0.98105	D	0.9444	0.98180	D	10	0.7287482;0.7287482;0.7287482;0.7287482;0.7287482;0.7287482	0.74152	D;D;D;D;D;D	0.69122	0.97458	D	.;0.715;0.715;0.715;0.715;0.715	0.89877	0.518;0.518;0.518;0.518;0.518;0.518;	0.61915	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R53H;R53H;R53H;R53H;R53H;R53H;	Loss of MoRF binding (P = 0.0219);Loss of MoRF binding (P = 0.0219);Loss of MoRF binding (P = 0.0219);Loss of MoRF binding (P = 0.0219);Loss of MoRF binding (P = 0.0219);Loss of MoRF binding (P = 0.0219);	0.789171487838;0.789171487838;0.789171487838;0.789171487838;0.789171487838;0.789171487838	0.78721	.;.;.;.;.;0.6309317319419667	0.63027	.;.;.;.;.;1.28273602722	0.82583	0.791864752769	0.80726	T	.;.;.;.;.;0.915659	0.98448	.;.;.;.;.;D	0.238771	0.77544	D	0.105201	0.77253	D	0.993035197257996	0.83685	D	0.984801;0.983802;0.984801;0.978302;0.985201;0.982102	0.94902	D;D;D;D;D;D	.;.;.;.;.;0.7875589	0.83121	.;.;.;.;.;0.6729925	0.80807	.;.;.;.;.;0.7875589	0.83122	.;.;.;.;.;0.6729925	0.80808	.;.;.;-4.422;-4.617;0.0	0.57995	.;.;.;T;T;T	.;.;.;.;.;0.3974320543694523	0.48975	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	0.411;0.2683;0.3473;0.2524;0.2332;0.2352	0.60182	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.355653	0.89376	30	4.134679	0.86605	28.9	0.99924102657066649	0.98980	0.58230	0.30586	D	ALL	0.443532	0.50080	N	0.521178923083924	0.68343	5.204194	0.458073031360735	0.65239	4.798479	0.999999999999944	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	2.585000	0.45776	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.901000	0.43729	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	7618	0	0	108	0	0	84	0	0	2708	0	0	146	0	0	610	0	0	24	0	1	94	0.010638297872340425	0	470	0	0	2816	0	0	108	0	1	11862	8.430281571404485E-5	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094576	A	G	S	P	.	16	31105897	16	31013398	52;52;52;52;52;52	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.154T>C;c.154T>C;c.154T>C;c.154T>C;c.154T>C	.;p.S52P;p.S52P;p.S52P;p.S52P;p.S52P	c.154T>C;c.154T>C;c.154T>C;c.154T>C;c.154T>C;c.154T>C	p.Ser52Pro;p.Ser52Pro;p.Ser52Pro;p.Ser52Pro;p.Ser52Pro;p.Ser52Pro	c.154T>C;c.154T>C;c.154T>C;c.154T>C;c.154T>C;c.154T>C	p.Ser52Pro;p.Ser52Pro;p.Ser52Pro;p.Ser52Pro;p.Ser52Pro;p.Ser52Pro	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCG;TCG;TCG;TCG;TCG;TCG	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.003;0.001;0.001;0.002;0.002	0.78490	.;D;D;D;D;D	0.175;0.004;0.0;0.006;0.0;0.007	0.92824	T;D;D;D;D;D	.;.;.;0.999;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.961;.;0.998	0.88582	.;.;.;D;.;D	0.000624	0.42799	D	0.000000	0.99984;0.99984;0.99984;0.99984;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S52P;S52P;S52P;S52P;.	.;.;.;2.79;2.79;2.79	0.81396	.;.;.;M;M;M	-4.88;-4.88;-4.88;-4.88;-4.88;-4.88	0.98296	D;D;D;D;D;D	.;-4.07;-4.06;-4.08;-4.16;-3.42	0.75375	.;D;D;D;D;D	.;.;0.765;0.859;0.843;0.666	0.85554	1.0950	0.99448	D	0.9633	0.98824	D	10	0.97848505;0.97848505;0.97848505;0.97848505;0.97848505;0.97848505	0.97728	D;D;D;D;D;D	0.696372	0.97508	D	.;0.938;0.938;0.938;0.938;0.938	0.98636	0.885;0.885;0.885;0.885;0.885;0.885;	0.97081	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S52P;S52P;S52P;S52P;S52P;S52P;	Loss of MoRF binding (P = 0.0664);Loss of MoRF binding (P = 0.0664);Loss of MoRF binding (P = 0.0664);Loss of MoRF binding (P = 0.0664);Loss of MoRF binding (P = 0.0664);Loss of MoRF binding (P = 0.0664);	0.824966549705;0.824966549705;0.824966549705;0.824966549705;0.824966549705;0.824966549705	0.82331	.;.;.;.;.;0.9702697963233706	0.97015	.;.;.;.;.;0.481685419903	0.47144	0.772200763226	0.77755	T	.;.;.;.;.;0.903054	0.98113	.;.;.;.;.;D	0.422396	0.91144	D	0.368966	0.91034	D	0.994000434875488	0.85055	D	0.627737;0.653735;0.630437;0.654835;0.626737;0.628437	0.26514	T;T;T;T;T;T	.;.;.;.;.;0.963639	0.97644	.;.;.;.;.;0.9659009	0.99275	.;.;.;.;.;0.963639	0.97644	.;.;.;.;.;0.9659009	0.99276	.;.;.;-3.663;-3.405;-4.659	0.58755	.;.;.;T;T;T	.;.;.;.;.;0.7546212943322668	0.83663	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.8957;0.9366;0.8514;0.8472;0.4401;0.8688	0.85593	P;P;P;P;A;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.553905	0.91657	32	4.136055	0.86664	28.9	0.99770032971985101	0.85834	0.91786	0.54260	D	ALL	0.967182	0.98965	D	0.69915966607455	0.79577	7.107185	0.605299117295772	0.75324	6.290416	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.534000	0.60334	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.955000	0.50612	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094578	C	T	C	Y	rs1479031158	16	31105899	16	31013400	51;51;51;51;51;51	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.152G>A;c.152G>A;c.152G>A;c.152G>A;c.152G>A	.;p.C51Y;p.C51Y;p.C51Y;p.C51Y;p.C51Y	c.152G>A;c.152G>A;c.152G>A;c.152G>A;c.152G>A;c.152G>A	p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr	c.152G>A;c.152G>A;c.152G>A;c.152G>A;c.152G>A;c.152G>A	p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr;p.Cys51Tyr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGT;TGT;TGT;TGT;TGT;TGT	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.001;0.0;0.001;0.0;0.0	0.91255	.;D;D;D;D;D	0.0;0.0;0.0;0.001;0.0;0.001	0.92824	D;D;D;D;D;D	.;.;.;1.0;.;0.999	0.90584	.;.;.;D;.;D	.;.;.;0.998;.;0.998	0.88582	.;.;.;D;.;D	0.000072	0.52346	D	0.000000	0.999988;0.999988;0.999988;0.999988;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	C51Y;C51Y;C51Y;C51Y;.	.;.;.;2.985;2.985;2.985	0.85602	.;.;.;M;M;M	-6.18;-6.18;-6.18;-6.18;-6.18;-6.18	0.99560	D;D;D;D;D;D	.;-9.46;-10.83;-10.72;-10.77;-9.7	0.99217	.;D;D;D;D;D	.;.;0.865;0.945;0.946;0.938	0.95374	1.0195	0.97525	D	0.9857	0.99571	D	10	0.9908731;0.9908731;0.9908731;0.9908731;0.9908731;0.9908731	0.99601	D;D;D;D;D;D	0.749146	0.97998	D	.;0.943;0.943;0.943;0.943;0.943	0.98816	0.933;0.933;0.933;0.933;0.933;0.933;	0.98990	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	C51Y;C51Y;C51Y;C51Y;C51Y;C51Y;	Gain of MoRF binding (P = 0.0761);Gain of MoRF binding (P = 0.0761);Gain of MoRF binding (P = 0.0761);Gain of MoRF binding (P = 0.0761);Gain of MoRF binding (P = 0.0761);Gain of MoRF binding (P = 0.0761);	0.808602454585;0.808602454585;0.808602454585;0.808602454585;0.808602454585;0.808602454585	0.80680	.;.;.;.;.;0.9814582109834301	0.98137	.;.;.;.;.;1.54232769698	0.87737	0.845458507538	0.88927	D	.;.;.;.;.;0.962171	0.99521	.;.;.;.;.;D	0.552564	0.95845	D	0.555943	0.95782	D	0.99979966878891	0.99036	D	0.934906;0.940606;0.926307;0.940606;0.933507;0.934906	0.77652	D;D;D;D;D;D	.;.;.;.;.;0.98585725	0.99522	.;.;.;.;.;0.98825526	0.99965	.;.;.;.;.;0.98585725	0.99522	.;.;.;.;.;0.98825526	0.99965	.;.;.;-5.902;-6.141;-5.692	0.74603	.;.;.;T;T;T	.;.;.;.;.;0.7813566905622635	0.86118	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9858;0.9885;0.9498;0.9645;0.8501;0.9541	0.93151	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.477475	0.91035	32	4.242337	0.89108	29.8	0.99500461418766528	0.67973	0.87632	0.47235	D	ALL	0.939332	0.93980	D	0.71767140918401	0.80791	7.37315	0.631847332103774	0.77265	6.646152	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	5.369000	0.65892	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.973000	0.55318	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094579	A	G	C	R	.	16	31105900	16	31013401	51;51;51;51;51;51	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.151T>C;c.151T>C;c.151T>C;c.151T>C;c.151T>C	.;p.C51R;p.C51R;p.C51R;p.C51R;p.C51R	c.151T>C;c.151T>C;c.151T>C;c.151T>C;c.151T>C;c.151T>C	p.Cys51Arg;p.Cys51Arg;p.Cys51Arg;p.Cys51Arg;p.Cys51Arg;p.Cys51Arg	c.151T>C;c.151T>C;c.151T>C;c.151T>C;c.151T>C;c.151T>C	p.Cys51Arg;p.Cys51Arg;p.Cys51Arg;p.Cys51Arg;p.Cys51Arg;p.Cys51Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGT;TGT;TGT;TGT;TGT;TGT	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.001;0.0;0.001;0.0;0.0	0.91255	.;D;D;D;D;D	0.0;0.0;0.0;0.001;0.0;0.001	0.92824	D;D;D;D;D;D	.;.;.;1.0;.;0.999	0.90584	.;.;.;D;.;D	.;.;.;0.998;.;0.998	0.88582	.;.;.;D;.;D	0.000072	0.52346	D	0.000000	1;1;1;1;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	C51R;C51R;C51R;C51R;.	.;.;.;2.985;2.985;2.985	0.85602	.;.;.;M;M;M	-6.18;-6.18;-6.18;-6.18;-6.18;-6.18	0.99560	D;D;D;D;D;D	.;-10.32;-11.77;-11.7;-11.73;-10.59	0.99543	.;D;D;D;D;D	.;.;0.914;0.969;0.97;0.964	0.98065	1.0268	0.97657	D	0.9865	0.99599	D	10	0.9888534;0.9888534;0.9888534;0.9888534;0.9888534;0.9888534	0.99323	D;D;D;D;D;D	0.802704	0.98457	D	.;0.953;0.953;0.953;0.953;0.953	0.99157	0.908;0.908;0.908;0.908;0.908;0.908;	0.98109	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	C51R;C51R;C51R;C51R;C51R;C51R;	Gain of MoRF binding (P = 0.0032);Gain of MoRF binding (P = 0.0032);Gain of MoRF binding (P = 0.0032);Gain of MoRF binding (P = 0.0032);Gain of MoRF binding (P = 0.0032);Gain of MoRF binding (P = 0.0032);	0.884909690577;0.884909690577;0.884909690577;0.884909690577;0.884909690577;0.884909690577	0.88377	.;.;.;.;.;0.988353533191622	0.98829	.;.;.;.;.;1.57986739276	0.88370	0.827617168427	0.86197	D	.;.;.;.;.;0.961934	0.99517	.;.;.;.;.;D	0.559846	0.96090	D	0.566403	0.96028	D	0.999779880046844	0.98932	D	0.888711;0.89781;0.876912;0.89791;0.886711;0.888711	0.64303	D;D;D;D;D;D	.;.;.;.;.;0.9928778	0.99895	.;.;.;.;.;0.9953811	0.99998	.;.;.;.;.;0.9928778	0.99895	.;.;.;.;.;0.9953811	0.99999	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;0.7924185279761558	0.87062	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9856;0.9859;0.9562;0.9616;0.8658;0.9532	0.92454	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.602360	0.91950	32	4.024874	0.83142	27.9	0.99447051885453897	0.65071	0.90656	0.52014	D	ALL	0.961012	0.98208	D	0.742224192724924	0.82397	7.752561	0.641568902115467	0.77986	6.785861	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.305000	0.72774	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.977000	0.56843	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094581	C	G	S	T	.	16	31105902	16	31013403	50;50;50;50;50;50	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.149G>C;c.149G>C;c.149G>C;c.149G>C;c.149G>C	.;p.S50T;p.S50T;p.S50T;p.S50T;p.S50T	c.149G>C;c.149G>C;c.149G>C;c.149G>C;c.149G>C;c.149G>C	p.Ser50Thr;p.Ser50Thr;p.Ser50Thr;p.Ser50Thr;p.Ser50Thr;p.Ser50Thr	c.149G>C;c.149G>C;c.149G>C;c.149G>C;c.149G>C;c.149G>C	p.Ser50Thr;p.Ser50Thr;p.Ser50Thr;p.Ser50Thr;p.Ser50Thr;p.Ser50Thr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.09;0.011;0.003;0.015;0.007	0.68238	.;T;D;D;D;D	0.373;0.01;0.0;0.009;0.0;0.05	0.92824	T;D;D;D;D;T	.;.;.;0.998;.;0.997	0.73220	.;.;.;D;.;D	.;.;.;0.941;.;0.992	0.80445	.;.;.;D;.;D	0.000020	0.62929	D	0.000000	0.999505;0.999505;0.999505;0.999505;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S50T;S50T;S50T;S50T;.	.;.;.;2.91;2.91;2.91	0.84121	.;.;.;M;M;M	-4.94;-4.94;-4.94;-4.94;-4.94;-4.94	0.98409	D;D;D;D;D;D	.;-2.45;-2.76;-2.72;-2.7;-2.45	0.58569	.;N;D;D;D;N	.;.;0.571;0.666;0.507;0.593	0.67477	1.0807	0.98903	D	0.9677	0.98976	D	10	0.8599238;0.8599238;0.8599238;0.8599238;0.8599238;0.8599238	0.85207	D;D;D;D;D;D	0.489284	0.94972	D	.;0.826;0.826;0.826;0.826;0.826	0.94466	0.652;0.652;0.652;0.652;0.652;0.652;	0.78963	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S50T;S50T;S50T;S50T;S50T;S50T;	Gain of sheet (P = 0.1208);Gain of sheet (P = 0.1208);Gain of sheet (P = 0.1208);Gain of sheet (P = 0.1208);Gain of sheet (P = 0.1208);Gain of sheet (P = 0.1208);	0.855012293559;0.855012293559;0.855012293559;0.855012293559;0.855012293559;0.855012293559	0.85361	.;.;.;.;.;0.891449435254008	0.89114	.;.;.;.;.;1.00703198026	0.74620	0.774022817612	0.78027	T	.;.;.;.;.;0.912478	0.98363	.;.;.;.;.;D	0.241337	0.77787	D	0.108888	0.77499	D	0.993687212467194	0.84585	D	0.90421;0.887111;0.90181;0.887111;0.90041;0.90161	0.66396	D;D;D;D;D;D	.;.;.;.;.;0.87135774	0.88969	.;.;.;.;.;0.84888124	0.91429	.;.;.;.;.;0.87135774	0.88971	.;.;.;.;.;0.84888124	0.91430	.;.;.;-4.272;-4.54;-4.093	0.56583	.;.;.;T;T;T	.;.;.;.;.;0.4587210341507483	0.54126	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	0.6003;0.5;0.4291;0.5108;0.3191;0.4722	0.68892	P;A;A;A;B;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.105684	0.82280	27.8	3.840671	0.76782	26.5	0.99391507355950859	0.62383	0.89168	0.49472	D	ALL	0.896409	0.83745	D	0.722551552193194	0.81111	7.446294	0.637227348634777	0.77663	6.722822	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	5.369000	0.65892	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.979000	0.57723	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094584	A	C	I	S	.	16	31105905	16	31013406	49;49;49;49;49;49	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.146T>G;c.146T>G;c.146T>G;c.146T>G;c.146T>G	.;p.I49S;p.I49S;p.I49S;p.I49S;p.I49S	c.146T>G;c.146T>G;c.146T>G;c.146T>G;c.146T>G;c.146T>G	p.Ile49Ser;p.Ile49Ser;p.Ile49Ser;p.Ile49Ser;p.Ile49Ser;p.Ile49Ser	c.146T>G;c.146T>G;c.146T>G;c.146T>G;c.146T>G;c.146T>G	p.Ile49Ser;p.Ile49Ser;p.Ile49Ser;p.Ile49Ser;p.Ile49Ser;p.Ile49Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	ATC;ATC;ATC;ATC;ATC;ATC	2;2;2;2;2;2	0;0;0;0;0;0	A	./.	./.	./.	./.	.;0.001;0.001;0.001;0.001;0.001	0.78490	.;D;D;D;D;D	0.022;0.119;0.002;0.047;0.002;0.06	0.79402	D;T;D;D;D;T	.;.;.;0.999;.;0.64	0.77913	.;.;.;D;.;P	.;.;.;0.929;.;0.229	0.66367	.;.;.;D;.;B	0.000153	0.49130	D	0.000000	0.898958;0.898958;0.898958;0.898958;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	I49S;I49S;I49S;I49S;.	.;.;.;2.52;2.52;2.52	0.73523	.;.;.;M;M;M	-4.73;-4.73;-4.73;-4.73;-4.73;-4.73	0.98066	D;D;D;D;D;D	.;-4.28;-5.16;-5.05;-5.16;-4.37	0.83422	.;D;D;D;D;D	.;.;0.778;0.769;0.697;0.659	0.77507	1.0418	0.97947	D	0.9410	0.98064	D	10	0.9236884;0.9236884;0.9236884;0.9236884;0.9236884;0.9236884	0.91719	D;D;D;D;D;D	0.809414	0.98513	D	.;0.888;0.888;0.888;0.888;0.888	0.96762	0.754;0.754;0.754;0.754;0.754;0.754;	0.88402	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	I49S;I49S;I49S;I49S;I49S;I49S;	Gain of disorder (P = 0.0063);Gain of disorder (P = 0.0063);Gain of disorder (P = 0.0063);Gain of disorder (P = 0.0063);Gain of disorder (P = 0.0063);Gain of disorder (P = 0.0063);	0.85788427305;0.85788427305;0.85788427305;0.85788427305;0.85788427305;0.85788427305	0.85651	.;.;.;.;.;0.9203149281346172	0.92007	.;.;.;.;.;0.612297111466	0.55827	0.781706273556	0.79185	T	.;.;.;.;.;0.848665	0.96535	.;.;.;.;.;D	0.332666	0.85343	D	0.240075	0.85150	D	0.997423768043518	0.91524	D	0.975502;0.974303;0.973803;0.974303;0.975502;0.966603	0.91380	D;D;D;D;D;D	.;.;.;.;.;0.9444344	0.95699	.;.;.;.;.;0.9129206	0.95896	.;.;.;.;.;0.9444344	0.95699	.;.;.;.;.;0.9129206	0.95897	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.2048168804410561	0.27308	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.9543;0.9389;0.9285;0.9327;0.9135;0.8728	0.87383	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.948450	0.76867	26.6	3.091213	0.56841	23.8	0.99134192704416091	0.53356	0.88523	0.48490	D	ALL	0.896559	0.83776	D	0.425079676172305	0.62804	4.502609	0.374623305195234	0.60005	4.183449	0.999999999999562	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	3.52	0.39415	6.305000	0.72774	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.969000	0.54022	0.8308:0.0:0.0:0.1692	8.7345	0.33679	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094585	T	G	I	L	.	16	31105906	16	31013407	49;49;49;49;49;49	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.145A>C;c.145A>C;c.145A>C;c.145A>C;c.145A>C	.;p.I49L;p.I49L;p.I49L;p.I49L;p.I49L	c.145A>C;c.145A>C;c.145A>C;c.145A>C;c.145A>C;c.145A>C	p.Ile49Leu;p.Ile49Leu;p.Ile49Leu;p.Ile49Leu;p.Ile49Leu;p.Ile49Leu	c.145A>C;c.145A>C;c.145A>C;c.145A>C;c.145A>C;c.145A>C	p.Ile49Leu;p.Ile49Leu;p.Ile49Leu;p.Ile49Leu;p.Ile49Leu;p.Ile49Leu	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	ATC;ATC;ATC;ATC;ATC;ATC	1;1;1;1;1;1	0;0;0;0;0;0	T	./.	./.	./.	./.	.;0.075;0.011;0.02;0.013;0.021	0.55530	.;T;D;D;D;D	0.143;0.148;0.029;0.074;0.032;0.104	0.54541	T;T;D;T;D;T	.;.;.;0.782;.;0.173	0.44333	.;.;.;P;.;B	.;.;.;0.367;.;0.122	0.43430	.;.;.;B;.;B	0.000153	0.49130	D	0.000000	1;0.940612;0.940612;0.940612;0.940612	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;I49L;I49L;I49L;I49L	.;.;.;2.52;2.52;2.52	0.73523	.;.;.;M;M;M	-4.66;-4.66;-4.66;-4.66;-4.66;-4.66	0.97956	D;D;D;D;D;D	.;-1.3;-1.7;-1.53;-1.7;-1.32	0.40468	.;N;N;N;N;N	.;.;0.561;0.46;0.369;0.4	0.58543	0.9990	0.97171	D	0.9350	0.97860	D	10	0.70105886;0.70105886;0.70105886;0.70105886;0.70105886;0.70105886	0.72447	D;D;D;D;D;D	0.613852	0.96637	D	.;0.669;0.669;0.669;0.669;0.669	0.87722	0.697;0.697;0.697;0.697;0.697;0.697;	0.83406	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	I49L;I49L;I49L;I49L;I49L;I49L;	Loss of catalytic residue at I49 (P = 0.0357);Loss of catalytic residue at I49 (P = 0.0357);Loss of catalytic residue at I49 (P = 0.0357);Loss of catalytic residue at I49 (P = 0.0357);Loss of catalytic residue at I49 (P = 0.0357);Loss of catalytic residue at I49 (P = 0.0357);	0.572793788404;0.572793788404;0.572793788404;0.572793788404;0.572793788404;0.572793788404	0.56946	.;.;.;.;.;0.6738290826786193	0.67320	.;.;.;.;.;0.449607347212	0.44747	0.771678626537	0.77676	T	.;.;.;.;.;0.588055	0.86612	.;.;.;.;.;D	0.2006	0.73949	D	0.050372	0.73608	D	0.962274730205536	0.66321	D	0.962804;0.961004;0.960254;0.961004;0.962804;0.950905	0.86152	D;D;D;D;D;D	.;.;.;.;.;0.7702439	0.82063	.;.;.;.;.;0.6003244	0.76781	.;.;.;.;.;0.7702439	0.82064	.;.;.;.;.;0.6003244	0.76782	.;.;.;0.0;0.0;-4.726	0.59903	.;.;.;T;T;T	.;.;.;.;.;0.19553383951803266	0.25799	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.5153;0.3678;0.4339;0.4163;0.4218;0.3096	0.65270	A;A;A;A;A;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.557865	0.65591	24.9	3.075552	0.56484	23.7	0.9802585724685684	0.37674	0.71520	0.35048	D	ALL	0.499502	0.53316	N	0.12312276685622	0.47543	2.978538	0.108363581786193	0.44976	2.769075	0.999999999997232	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	3.54	0.39650	1.372000	0.33866	.	.	0.609000	0.47794	1.000000	0.71638	1.000000	0.68203	0.959000	0.51448	0.0:0.1959:0.0:0.8041	6.2302	0.19941	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094588	C	A	A	S	rs1229209080	16	31105909	16	31013410	48;48;48;48;48;48	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.142G>T;c.142G>T;c.142G>T;c.142G>T;c.142G>T	.;p.A48S;p.A48S;p.A48S;p.A48S;p.A48S	c.142G>T;c.142G>T;c.142G>T;c.142G>T;c.142G>T;c.142G>T	p.Ala48Ser;p.Ala48Ser;p.Ala48Ser;p.Ala48Ser;p.Ala48Ser;p.Ala48Ser	c.142G>T;c.142G>T;c.142G>T;c.142G>T;c.142G>T;c.142G>T	p.Ala48Ser;p.Ala48Ser;p.Ala48Ser;p.Ala48Ser;p.Ala48Ser;p.Ala48Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GCC;GCC;GCC;GCC;GCC;GCC	1;1;1;1;1;1	0;0;0;0;0;0	C	./.	./.	./.	./.	.;0.819;0.484;0.789;0.557;1.0	0.08140	.;T;T;T;T;T	0.248;0.801;0.368;0.508;0.447;0.838	0.23845	T;T;T;T;T;T	.;.;.;0.623;.;0.196	0.39993	.;.;.;P;.;B	.;.;.;0.101;.;0.23	0.38212	.;.;.;B;.;B	0.000204	0.47681	D	0.000000	1;0.985845;0.985845;0.985845;0.985845	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;A48S;A48S;A48S;A48S	.;.;.;-0.1;-0.1;-0.1	0.04694	.;.;.;N;N;N	-4.59;-4.59;-4.59;-4.59;-4.59;-4.59	0.97830	D;D;D;D;D;D	.;0.78;0.65;0.7;0.62;0.89	0.02442	.;N;N;N;N;N	.;.;0.244;0.182;0.177;0.153	0.27554	0.2000	0.85908	D	0.6327	0.87127	D	10	0.2070044;0.2070044;0.2070044;0.2070044;0.2070044;0.2070044	0.36981	T;T;T;T;T;T	0.358263	0.92445	D	.;0.355;0.355;0.355;0.355;0.355	0.67600	0.346;0.346;0.346;0.346;0.346;0.346;	0.34112	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	A48S;A48S;A48S;A48S;A48S;A48S;	Gain of loop (P = 0.0851);Gain of loop (P = 0.0851);Gain of loop (P = 0.0851);Gain of loop (P = 0.0851);Gain of loop (P = 0.0851);Gain of loop (P = 0.0851);	0.485348376517;0.485348376517;0.485348376517;0.485348376517;0.485348376517;0.485348376517	0.48166	.;.;.;.;.;0.5067830607352471	0.50600	.;.;.;.;.;0.388573688024	0.40119	0.688379526138	0.65473	T	.;.;.;.;.;0.39665	0.75523	.;.;.;.;.;T	0.0572081	0.59260	T	-0.155601	0.58746	T	0.54460334777832	0.34275	D	0.859414;0.792821;0.864713;0.789921;0.865513;0.841416	0.56452	D;T;D;T;D;T	.;.;.;.;.;0.18206732	0.39407	.;.;.;.;.;0.12679839	0.30533	.;.;.;.;.;0.18206732	0.39407	.;.;.;.;.;0.12679839	0.30533	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.057525943229718074	0.01403	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.0895;0.0901;0.1421;0.1095;0.0984;0.089	0.31228	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.192204	0.34543	20.8	2.119916	0.35427	20.8	0.96605718207752866	0.30423	0.45827	0.27624	N	ALL	0.209124	0.33514	N	-0.407621388221448	0.25201	1.366332	-0.209147787309124	0.31205	1.763941	0.999999999999725	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	3.61	0.40494	0.770000	0.26280	.	.	0.549000	0.26987	0.975000	0.34726	0.997000	0.33255	0.926000	0.46234	0.2007:0.6976:0.0:0.1017	5.3543	0.15357	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094590	G	A	T	I	rs772860822	16	31105911	16	31013412	47;47;47;47;47;47	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.140C>T;c.140C>T;c.140C>T;c.140C>T;c.140C>T	.;p.T47I;p.T47I;p.T47I;p.T47I;p.T47I	c.140C>T;c.140C>T;c.140C>T;c.140C>T;c.140C>T;c.140C>T	p.Thr47Ile;p.Thr47Ile;p.Thr47Ile;p.Thr47Ile;p.Thr47Ile;p.Thr47Ile	c.140C>T;c.140C>T;c.140C>T;c.140C>T;c.140C>T;c.140C>T	p.Thr47Ile;p.Thr47Ile;p.Thr47Ile;p.Thr47Ile;p.Thr47Ile;p.Thr47Ile	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	ACC;ACC;ACC;ACC;ACC;ACC	2;2;2;2;2;2	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.102;0.079;0.148;0.119;0.162	0.33753	.;T;T;T;T;T	0.006;0.149;0.011;0.115;0.013;0.152	0.70582	D;T;D;T;D;T	.;.;.;0.998;.;0.771	0.73220	.;.;.;D;.;P	.;.;.;0.865;.;0.31	0.61524	.;.;.;P;.;B	0.004180	0.34034	N	0.136067	1;0.996495;0.996495;0.996495;0.996495	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;T47I;T47I;T47I;T47I	.;.;.;1.95;1.95;1.95	0.52479	.;.;.;M;M;M	-4.68;-4.68;-4.68;-4.68;-4.68;-4.68	0.97989	D;D;D;D;D;D	.;-2.34;-2.77;-2.76;-2.77;-2.43	0.58733	.;N;D;D;D;N	.;.;0.383;0.285;0.267;0.285	0.42443	0.9424	0.96282	D	0.9218	0.97412	D	10	0.29186112;0.29186112;0.29186112;0.29186112;0.29186112;0.29186112	0.46764	T;T;T;T;T;T	0.28923	0.90505	D	.;0.537;0.537;0.537;0.537;0.537	0.80605	0.407;0.407;0.407;0.407;0.407;0.407;	0.44066	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	T47I;T47I;T47I;T47I;T47I;T47I;	Gain of sheet (P = 0.0344);Gain of sheet (P = 0.0344);Gain of sheet (P = 0.0344);Gain of sheet (P = 0.0344);Gain of sheet (P = 0.0344);Gain of sheet (P = 0.0344);	0.642587913866;0.642587913866;0.642587913866;0.642587913866;0.642587913866;0.642587913866	0.63963	.;.;.;.;.;0.5765422188380976	0.57583	.;.;.;.;.;0.858553327071	0.68866	0.786093115807	0.79849	T	.;.;.;.;.;0.828651	0.95885	.;.;.;.;.;D	-0.08917	0.38213	T	0.00405107	0.70598	D	0.610491216182709	0.36820	D	0.961904;0.928407;0.961204;0.927707;0.959904;0.958204	0.85651	D;D;D;D;D;D	.;.;.;.;.;0.47702235	0.65719	.;.;.;.;.;0.52409303	0.72504	.;.;.;.;.;0.47702235	0.65720	.;.;.;.;.;0.52409303	0.72505	.;.;.;-5.331;-5.948;-5.673	0.73277	.;.;.;T;T;T	.;.;.;.;.;0.13633611924271158	0.14901	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.4485;0.2539;0.4366;0.3348;0.3215;0.2636	0.62132	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.499261	0.41225	22.4	2.489028	0.43466	22.5	0.99727789070745598	0.82549	0.41513	0.26674	N	ALL	0.421369	0.48781	N	0.216084018545275	0.51978	3.375103	0.17944444033818	0.48721	3.084313	0.999999999999689	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	3.6	0.40374	1.966000	0.40105	.	.	0.618000	0.50648	0.892000	0.31242	1.000000	0.68203	0.916000	0.45140	0.0:0.0:0.8247:0.1753	11.7964	0.51374	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6	4.961e-05	6	6.342e-05	0	0	6	6.659e-04	0	0	0	0	0	0	0	0	6	5.663e-05	6	7.115e-05	0	0	6	6.829e-04	0	0	0	0	0	0	0	0	6	6.644e-05	6	8.619e-05	0	0	6	6.665e-04	0	0	0	0	0	0	0	0	segdup	22	236776	9.291480e-05	0	0	14426	0.000000e+00	0	22	33830	6.503100e-04	0	0	9704	0.000000e+00	0	0	17822	0.000000e+00	0	0	19882	0.000000e+00	0	0	105170	0.000000e+00	0	0	30064	0.000000e+00	0	22	33830	6.503100e-04	0	14	104244	1.343000e-04	0	22	195816	1.123500e-04	0	22	225270	9.766060e-05	0	22	231584	9.499790e-05	0	0	6424	0.000000e+00	0	14	16692	8.387250e-04	0	0	2202	0.000000e+00	0	0	8664	0.000000e+00	0	0	12230	0.000000e+00	0	0	40838	0.000000e+00	0	0	15354	0.000000e+00	0	14	16692	8.387250e-04	0	0	14388	0.000000e+00	0	22	29772	7.389490e-04	0	0	5876	0.000000e+00	0	0	12980	0.000000e+00	0	0	15416	0.000000e+00	0	0	82680	0.000000e+00	0	0	30056	0.000000e+00	0	22	29772	7.389490e-04	0	0	13298	0.000000e+00	0	22	33558	6.555810e-04	0	0	9320	0.000000e+00	0	0	17246	0.000000e+00	0	0	19868	0.000000e+00	0	0	96554	0.000000e+00	0	0	29986	0.000000e+00	0	22	33558	6.555810e-04	0	0	10940	0.000000e+00	0	22	33718	6.524700e-04	0	0	9660	0.000000e+00	0	0	17818	0.000000e+00	0	0	19880	0.000000e+00	0	0	103694	0.000000e+00	0	0	30064	0.000000e+00	0	22	33718	6.524700e-04	0	.	1	152244	6.568400e-06	0	1	15288	6.541080e-05	0	0	41472	0.000000e+00	0	0	912	0.000000e+00	0	1	15288	6.541080e-05	0	0	3472	0.000000e+00	0	0	5196	0.000000e+00	0	0	10626	0.000000e+00	0	0	316	0.000000e+00	0	0	68038	0.000000e+00	0	0	4832	0.000000e+00	0	0	32914	0.000000e+00	0	1	134826	7.416970e-06	0	1	147986	6.757400e-06	0	1	80802	1.237590e-05	0	0	9102	0.000000e+00	0	0	60	0.000000e+00	0	0	4690	0.000000e+00	0	0	136	0.000000e+00	0	0	2428	0.000000e+00	0	0	5496	0.000000e+00	0	0	246	0.000000e+00	0	0	6852	0.000000e+00	0	0	3114	0.000000e+00	0	0	32494	0.000000e+00	0	0	862	0.000000e+00	0	1	14842	6.737640e-05	0	0	3388	0.000000e+00	0	0	5196	0.000000e+00	0	0	6986	0.000000e+00	0	0	310	0.000000e+00	0	0	63916	0.000000e+00	0	0	4830	0.000000e+00	0	0	41152	0.000000e+00	0	0	912	0.000000e+00	0	1	15100	6.622520e-05	0	0	3302	0.000000e+00	0	0	4960	0.000000e+00	0	0	10626	0.000000e+00	0	0	304	0.000000e+00	0	0	64808	0.000000e+00	0	0	4800	0.000000e+00	0	0	24846	0.000000e+00	0	0	112	0.000000e+00	0	1	12914	7.743530e-05	0	0	998	0.000000e+00	0	0	3754	0.000000e+00	0	0	10534	0.000000e+00	0	0	272	0.000000e+00	0	0	21048	0.000000e+00	0	0	4804	0.000000e+00	0	0	7618	0	0	108	0	0	84	0	0	2708	0	0	146	0	2	610	0.003278688524590164	0	24	0	0	94	0	0	470	0	0	2816	0	0	108	0	2	11862	1.686056314280897E-4	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094590	G	C	T	S	.	16	31105911	16	31013412	47;47;47;47;47;47	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.140C>G;c.140C>G;c.140C>G;c.140C>G;c.140C>G	.;p.T47S;p.T47S;p.T47S;p.T47S;p.T47S	c.140C>G;c.140C>G;c.140C>G;c.140C>G;c.140C>G;c.140C>G	p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser	c.140C>G;c.140C>G;c.140C>G;c.140C>G;c.140C>G;c.140C>G	p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	ACC;ACC;ACC;ACC;ACC;ACC	2;2;2;2;2;2	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.468;0.38;0.601;0.525;0.662	0.11191	.;T;T;T;T;T	0.179;0.622;0.319;0.482;0.398;0.605	0.29540	T;T;T;T;T;T	.;.;.;0.885;.;0.003	0.48692	.;.;.;P;.;B	.;.;.;0.57;.;0.005	0.49854	.;.;.;P;.;B	0.004180	0.34034	N	0.136067	1;0.999669;0.999669;0.999669;0.999669	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;T47S;T47S;T47S;T47S	.;.;.;1.255;1.255;1.255	0.31814	.;.;.;L;L;L	-4.54;-4.54;-4.54;-4.54;-4.54;-4.54	0.97732	D;D;D;D;D;D	.;-0.03;-0.02;0.0;-0.05;0.25	0.07736	.;N;N;N;N;N	.;.;0.222;0.108;0.096;0.105	0.24883	0.6376	0.92387	D	0.8800	0.96015	D	10	0.25405827;0.25405827;0.25405827;0.25405827;0.25405827;0.25405827	0.42781	T;T;T;T;T;T	0.128393	0.81033	D	.;0.339;0.339;0.339;0.339;0.339	0.66106	0.302;0.302;0.302;0.302;0.302;0.302;	0.27003	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	T47S;T47S;T47S;T47S;T47S;T47S;	Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);	0.561523483268;0.561523483268;0.561523483268;0.561523483268;0.561523483268;0.561523483268	0.55814	.;.;.;.;.;0.44702040671758775	0.44620	.;.;.;.;.;0.342841823336	0.36211	0.704250574112	0.67759	T	.;.;.;.;.;0.415587	0.76879	.;.;.;.;.;T	0.0367553	0.56619	T	-0.18498	0.56058	T	0.663561642169952	0.39052	D	0.748625;0.637636;0.745725;0.638236;0.745725;0.735426	0.36937	T;T;T;T;T;T	.;.;.;.;.;0.4142145	0.61704	.;.;.;.;.;0.23949386	0.49300	.;.;.;.;.;0.4142145	0.61705	.;.;.;.;.;0.23949386	0.49299	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.06400969233106515	0.02008	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1073;0.0767;0.1655;0.1062;0.111;0.095	0.36495	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.952109	0.29660	18.89	1.953685	0.32025	19.37	0.97869458802624243	0.36520	0.38388	0.25977	N	ALL	0.335725	0.43407	N	-0.132915235286515	0.35964	2.072557	-0.075990271754459	0.36385	2.116812	0.999999999999689	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	3.6	0.40374	1.966000	0.40105	.	.	0.618000	0.50648	0.892000	0.31242	1.000000	0.68203	0.916000	0.45140	0.0:0.0:0.8247:0.1753	11.7964	0.51374	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094591	T	A	T	S	.	16	31105912	16	31013413	47;47;47;47;47;47	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.139A>T;c.139A>T;c.139A>T;c.139A>T;c.139A>T	.;p.T47S;p.T47S;p.T47S;p.T47S;p.T47S	c.139A>T;c.139A>T;c.139A>T;c.139A>T;c.139A>T;c.139A>T	p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser	c.139A>T;c.139A>T;c.139A>T;c.139A>T;c.139A>T;c.139A>T	p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser;p.Thr47Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	ACC;ACC;ACC;ACC;ACC;ACC	1;1;1;1;1;1	0;0;0;0;0;0	T	./.	./.	./.	./.	.;0.468;0.38;0.601;0.525;0.662	0.11191	.;T;T;T;T;T	0.179;0.622;0.319;0.482;0.398;0.605	0.29540	T;T;T;T;T;T	.;.;.;0.885;.;0.003	0.48692	.;.;.;P;.;B	.;.;.;0.57;.;0.005	0.49854	.;.;.;P;.;B	0.004180	0.34034	N	0.136067	1;0.999463;0.999463;0.999463;0.999463	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;T47S;T47S;T47S;T47S	.;.;.;1.255;1.255;1.255	0.31814	.;.;.;L;L;L	-4.54;-4.54;-4.54;-4.54;-4.54;-4.54	0.97732	D;D;D;D;D;D	.;-0.03;-0.02;0.0;-0.05;0.25	0.07736	.;N;N;N;N;N	.;.;0.222;0.108;0.096;0.105	0.24883	0.4879	0.90377	D	0.8501	0.95001	D	10	0.21360236;0.21360236;0.21360236;0.21360236;0.21360236;0.21360236	0.37857	T;T;T;T;T;T	0.152624	0.83401	D	.;0.308;0.308;0.308;0.308;0.308	0.62947	0.302;0.302;0.302;0.302;0.302;0.302;	0.27003	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	T47S;T47S;T47S;T47S;T47S;T47S;	Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);	0.498323335527;0.498323335527;0.498323335527;0.498323335527;0.498323335527;0.498323335527	0.49468	.;.;.;.;.;0.44702042048862217	0.44620	.;.;.;.;.;0.342841823336	0.36211	0.704250574112	0.67759	T	.;.;.;.;.;0.415587	0.76879	.;.;.;.;.;T	0.0186953	0.54206	T	-0.210922	0.53606	T	0.43065357208252	0.30085	T	0.748625;0.637636;0.745725;0.638236;0.745725;0.735426	0.36937	T;T;T;T;T;T	.;.;.;.;.;0.31804377	0.54474	.;.;.;.;.;0.12564856	0.30271	.;.;.;.;.;0.31804377	0.54474	.;.;.;.;.;0.12564856	0.30270	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.06400969233106515	0.02008	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1073;0.0767;0.1655;0.1062;0.111;0.095	0.36495	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.442485	0.21023	15.36	1.755488	0.28205	17.87	0.96695454349065357	0.30752	0.33250	0.24783	N	ALL	0.348543	0.44263	N	-0.349165103316303	0.27303	1.496885	-0.320174959357551	0.27448	1.52311	0.999999999998699	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	2.34	0.28071	0.007000	0.13074	.	.	0.609000	0.47794	0.885000	0.31090	1.000000	0.68203	0.918000	0.45347	0.2181:0.1602:0.0:0.6217	2.5268	0.04408	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094593	C	G	G	A	.	16	31105914	16	31013415	46;46;46;46;46;46	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.137G>C;c.137G>C;c.137G>C;c.137G>C;c.137G>C	.;p.G46A;p.G46A;p.G46A;p.G46A;p.G46A	c.137G>C;c.137G>C;c.137G>C;c.137G>C;c.137G>C;c.137G>C	p.Gly46Ala;p.Gly46Ala;p.Gly46Ala;p.Gly46Ala;p.Gly46Ala;p.Gly46Ala	c.137G>C;c.137G>C;c.137G>C;c.137G>C;c.137G>C;c.137G>C	p.Gly46Ala;p.Gly46Ala;p.Gly46Ala;p.Gly46Ala;p.Gly46Ala;p.Gly46Ala	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GGC;GGC;GGC;GGC;GGC;GGC	2;2;2;2;2;2	0;0;0;0;0;0	C	./.	./.	./.	./.	.;0.988;0.107;0.21;0.022;0.072	0.48642	.;T;T;T;D;T	1.0;0.098;0.067;0.05;0.085;0.358	0.48080	T;T;T;T;T;T	.;.;.;0.995;.;0.952	0.67487	.;.;.;D;.;P	.;.;.;0.64;.;0.77	0.56828	.;.;.;P;.;P	0.000153	0.49130	D	0.000000	0.998399;0.998399;0.998399;0.998399;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	G46A;G46A;G46A;G46A;.	.;.;.;1.465;1.465;1.465	0.36909	.;.;.;L;L;L	-4.79;-4.79;-4.79;-4.79;-4.79;-4.79	0.98155	D;D;D;D;D;D	.;-2.22;-2.48;-2.43;-2.78;-2.1	0.58896	.;N;N;N;D;N	.;.;0.396;0.426;0.442;0.484	0.51851	0.9363	0.96193	D	0.9240	0.97486	D	10	0.85968304;0.85968304;0.85968304;0.85968304;0.85968304;0.85968304	0.85181	D;D;D;D;D;D	0.230358	0.88226	D	.;0.693;0.693;0.693;0.693;0.693	0.88867	0.753;0.753;0.753;0.753;0.753;0.753;	0.88319	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	G46A;G46A;G46A;G46A;G46A;G46A;	Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);Loss of sheet (P = 0.0817);	0.756070473558;0.756070473558;0.756070473558;0.756070473558;0.756070473558;0.756070473558	0.75385	.;.;.;.;.;0.6837472020356453	0.68313	.;.;.;.;.;0.881614506349	0.69794	0.831785678864	0.86835	D	.;.;.;.;.;0.664391	0.89967	.;.;.;.;.;D	0.200497	0.73938	D	0.0502242	0.73598	D	0.964564800262451	0.66996	D	0.941706;0.954605;0.941706;0.956904;0.941806;0.920508	0.83579	D;D;D;D;D;D	.;.;.;.;.;0.44385558	0.63650	.;.;.;.;.;0.45182362	0.68108	.;.;.;.;.;0.44385558	0.63651	.;.;.;.;.;0.45182362	0.68109	.;.;.;-3.364;-3.477;-3.435	0.31067	.;.;.;T;T;T	.;.;.;.;.;0.1292397535740152	0.13476	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.591;0.4076;0.6241;0.4703;0.4379;0.4315	0.69869	P;A;P;A;A;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.070986	0.53613	23.6	3.234064	0.60346	24.2	0.99723117018661078	0.82195	0.85930	0.45122	D	ALL	0.832220	0.75064	D	0.33390951743172	0.57897	3.95896	0.356778132468055	0.58918	4.065411	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	5.382000	0.65964	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.910000	0.44547	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094600	C	G	D	H	.	16	31105921	16	31013422	44;44;44;44;44;44	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.130G>C;c.130G>C;c.130G>C;c.130G>C;c.130G>C	.;p.D44H;p.D44H;p.D44H;p.D44H;p.D44H	c.130G>C;c.130G>C;c.130G>C;c.130G>C;c.130G>C;c.130G>C	p.Asp44His;p.Asp44His;p.Asp44His;p.Asp44His;p.Asp44His;p.Asp44His	c.130G>C;c.130G>C;c.130G>C;c.130G>C;c.130G>C;c.130G>C	p.Asp44His;p.Asp44His;p.Asp44His;p.Asp44His;p.Asp44His;p.Asp44His	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GAC;GAC;GAC;GAC;GAC;GAC	1;1;1;1;1;1	0;0;0;0;0;0	C	./.	./.	./.	./.	.;0.002;0.001;0.001;0.001;0.002	0.78490	.;D;D;D;D;D	0.008;0.003;0.008;0.004;0.011;0.004	0.76473	D;D;D;D;D;D	.;.;.;1.0;.;0.994	0.90584	.;.;.;D;.;D	.;.;.;0.989;.;0.848	0.78396	.;.;.;D;.;P	0.000099	0.51296	D	0.000000	0.999879;0.999879;0.999879;0.999879;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	D44H;D44H;D44H;D44H;.	.;.;.;2.985;2.985;2.985	0.85602	.;.;.;M;M;M	-4.86;-4.86;-4.86;-4.86;-4.86;-4.86	0.98263	D;D;D;D;D;D	.;-5.99;-6.98;-6.85;-6.98;-6.04	0.93582	.;D;D;D;D;D	.;.;0.792;0.864;0.819;0.819	0.86085	1.0956	0.99473	D	0.9650	0.98883	D	10	0.9782393;0.9782393;0.9782393;0.9782393;0.9782393;0.9782393	0.97691	D;D;D;D;D;D	0.769396	0.98176	D	.;0.932;0.932;0.932;0.932;0.932	0.98415	0.894;0.894;0.894;0.894;0.894;0.894;	0.97506	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	D44H;D44H;D44H;D44H;D44H;D44H;	Gain of MoRF binding (P = 0.0527);Gain of MoRF binding (P = 0.0527);Gain of MoRF binding (P = 0.0527);Gain of MoRF binding (P = 0.0527);Gain of MoRF binding (P = 0.0527);Gain of MoRF binding (P = 0.0527);	0.806166363099;0.806166363099;0.806166363099;0.806166363099;0.806166363099;0.806166363099	0.80435	.;.;.;.;.;0.9375115900468802	0.93731	.;.;.;.;.;1.27222038898	0.82305	0.858597457409	0.90903	D	.;.;.;.;.;0.96062	0.99491	.;.;.;.;.;D	0.308594	0.83640	D	0.205498	0.83428	D	0.99623316526413	0.88931	D	0.941006;0.937806;0.940606;0.947905;0.950005;0.928607	0.80823	D;D;D;D;D;D	.;.;.;.;.;0.97892314	0.99026	.;.;.;.;.;0.9694251	0.99440	.;.;.;.;.;0.97892314	0.99026	.;.;.;.;.;0.9694251	0.99440	.;.;.;-4.422;-4.617;0.0	0.57995	.;.;.;T;T;T	.;.;.;.;.;0.6957896928839353	0.77412	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9765;0.977;0.9609;0.9435;0.8429;0.9518	0.90572	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.360613	0.89465	31	4.079037	0.84964	28.4	0.99445755319415741	0.65021	0.88010	0.47755	D	ALL	0.889273	0.82319	D	0.627253017293599	0.74905	6.212697	0.517351735555357	0.69156	5.320571	0.999999999999995	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	3.67	0.41236	5.369000	0.65892	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.967000	0.53440	0.1775:0.8225:0.0:0.0	11.7076	0.50870	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094612	G	C	R	G	.	16	31105933	16	31013434	40;40;40;40;40;40	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.118C>G;c.118C>G;c.118C>G;c.118C>G;c.118C>G	.;p.R40G;p.R40G;p.R40G;p.R40G;p.R40G	c.118C>G;c.118C>G;c.118C>G;c.118C>G;c.118C>G;c.118C>G	p.Arg40Gly;p.Arg40Gly;p.Arg40Gly;p.Arg40Gly;p.Arg40Gly;p.Arg40Gly	c.118C>G;c.118C>G;c.118C>G;c.118C>G;c.118C>G;c.118C>G	p.Arg40Gly;p.Arg40Gly;p.Arg40Gly;p.Arg40Gly;p.Arg40Gly;p.Arg40Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CGC;CGC;CGC;CGC;CGC;CGC	1;1;1;1;1;1	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.061;0.004;0.007;0.004;0.009	0.65419	.;T;D;D;D;D	0.009;0.018;0.01;0.013;0.015;0.025	0.66756	D;D;D;D;D;D	.;.;.;0.99;.;0.998	0.73220	.;.;.;D;.;D	.;.;.;0.691;.;0.957	0.69900	.;.;.;P;.;D	0.000162	0.48594	D	0.000000	0.997635;0.997635;0.997635;0.997635;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R40G;R40G;R40G;R40G;.	.;.;.;2.495;2.495;2.495	0.72670	.;.;.;M;M;M	-4.76;-4.76;-4.76;-4.76;-4.76;-4.76	0.98111	D;D;D;D;D;D	.;-4.31;-4.59;-4.57;-4.83;-4.08	0.80943	.;D;D;D;D;D	.;.;0.542;0.704;0.71;0.758	0.75650	1.0759	0.98756	D	0.9587	0.98667	D	9	0.86198604;0.86198604;0.86198604;0.86198604;0.86198604;0.86198604	0.85423	D;D;D;D;D;D	0.774505	0.98219	D	.;0.852;0.852;0.852;0.852;0.852	0.95433	0.632;0.632;0.632;0.632;0.632;0.632;	0.76810	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R40G;R40G;R40G;R40G;R40G;R40G;	Loss of MoRF binding (P = 0.0268);Loss of MoRF binding (P = 0.0268);Loss of MoRF binding (P = 0.0268);Loss of MoRF binding (P = 0.0268);Loss of MoRF binding (P = 0.0268);Loss of MoRF binding (P = 0.0268);	0.867067325559;0.867067325559;0.867067325559;0.867067325559;0.867067325559;0.867067325559	0.86577	.;.;.;.;.;0.8105705110978977	0.81012	.;.;.;.;.;1.08353906917	0.77205	0.744663238525	0.73659	T	.;.;.;.;.;0.838351	0.96207	.;.;.;.;.;D	0.45157	0.92550	D	0.410872	0.92457	D	0.997436225414276	0.91547	D	0.959904;0.950805;0.960254;0.949405;0.959304;0.958704	0.85028	D;D;D;D;D;D	.;.;.;.;.;0.95988065	0.97268	.;.;.;.;.;0.8713907	0.92962	.;.;.;.;.;0.95988065	0.97268	.;.;.;.;.;0.8713907	0.92963	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;0.28029333965911785	0.37548	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.6205;0.3343;0.5977;0.4276;0.3228;0.3818	0.69722	P;B;P;A;B;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.941362	0.76629	26.6	3.478677	0.66577	24.9	0.99772420496082648	0.86003	0.73518	0.35961	D	ALL	0.740986	0.68506	D	0.496299448170297	0.66874	5.006907	0.442127350974553	0.64214	4.671335	0.999999999999994	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	2.790000	0.47512	.	.	0.618000	0.50648	1.000000	0.71638	1.000000	0.68203	0.990000	0.65344	0.0:0.0:1.0:0.0	14.878	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094612	G	T	R	S	.	16	31105933	16	31013434	40;40;40;40;40;40	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.118C>A;c.118C>A;c.118C>A;c.118C>A;c.118C>A	.;p.R40S;p.R40S;p.R40S;p.R40S;p.R40S	c.118C>A;c.118C>A;c.118C>A;c.118C>A;c.118C>A;c.118C>A	p.Arg40Ser;p.Arg40Ser;p.Arg40Ser;p.Arg40Ser;p.Arg40Ser;p.Arg40Ser	c.118C>A;c.118C>A;c.118C>A;c.118C>A;c.118C>A;c.118C>A	p.Arg40Ser;p.Arg40Ser;p.Arg40Ser;p.Arg40Ser;p.Arg40Ser;p.Arg40Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CGC;CGC;CGC;CGC;CGC;CGC	1;1;1;1;1;1	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.154;0.004;0.027;0.005;0.011	0.65419	.;T;D;D;D;D	0.011;0.022;0.012;0.016;0.017;0.035	0.64786	D;D;D;D;D;D	.;.;.;0.951;.;0.994	0.66517	.;.;.;P;.;D	.;.;.;0.542;.;0.957	0.69900	.;.;.;P;.;D	0.000162	0.48594	D	0.000000	0.997717;0.997717;0.997717;0.997717;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R40S;R40S;R40S;R40S;.	.;.;.;2.495;2.495;2.495	0.72670	.;.;.;M;M;M	-4.73;-4.73;-4.73;-4.73;-4.73;-4.73	0.98066	D;D;D;D;D;D	.;-3.02;-3.14;-3.23;-3.38;-2.81	0.66780	.;D;D;D;D;D	.;.;0.535;0.71;0.745;0.74	0.74462	1.0679	0.98536	D	0.9508	0.98399	D	9	0.79670554;0.79670554;0.79670554;0.79670554;0.79670554;0.79670554	0.79135	D;D;D;D;D;D	0.776589	0.98237	D	.;0.852;0.852;0.852;0.852;0.852	0.95433	0.596;0.596;0.596;0.596;0.596;0.596;	0.72617	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R40S;R40S;R40S;R40S;R40S;R40S;	Loss of MoRF binding (P = 0.0344);Loss of MoRF binding (P = 0.0344);Loss of MoRF binding (P = 0.0344);Loss of MoRF binding (P = 0.0344);Loss of MoRF binding (P = 0.0344);Loss of MoRF binding (P = 0.0344);	0.709258847686;0.709258847686;0.709258847686;0.709258847686;0.709258847686;0.709258847686	0.70672	.;.;.;.;.;0.8174216282854624	0.81699	.;.;.;.;.;0.943750144719	0.72321	0.747016310692	0.74007	T	.;.;.;.;.;0.77387	0.93969	.;.;.;.;.;D	0.404427	0.90167	D	0.343155	0.90044	D	0.996175050735474	0.88812	D	0.957954;0.929307;0.958404;0.927207;0.957404;0.938006	0.84340	D;D;D;D;D;D	.;.;.;.;.;0.88925517	0.90444	.;.;.;.;.;0.7119896	0.83008	.;.;.;.;.;0.88925517	0.90445	.;.;.;.;.;0.7119896	0.83009	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.17997396640707758	0.23140	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.739;0.4381;0.7903;0.5681;0.5266;0.4978	0.76837	P;A;P;P;A;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.336963	0.89019	29.9	3.883812	0.78229	26.8	0.99662880316265268	0.78074	0.64236	0.32342	D	ALL	0.594184	0.58922	D	0.477361313610108	0.65770	4.864507	0.428781136596413	0.63364	4.568819	0.999999999999994	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	2.790000	0.47512	.	.	0.618000	0.50648	1.000000	0.71638	1.000000	0.68203	0.990000	0.65344	0.0:0.0:1.0:0.0	14.878	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094618	C	T	D	N	.	16	31105939	16	31013440	38;38;38;38;38;38	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.112G>A;c.112G>A;c.112G>A;c.112G>A;c.112G>A	.;p.D38N;p.D38N;p.D38N;p.D38N;p.D38N	c.112G>A;c.112G>A;c.112G>A;c.112G>A;c.112G>A;c.112G>A	p.Asp38Asn;p.Asp38Asn;p.Asp38Asn;p.Asp38Asn;p.Asp38Asn;p.Asp38Asn	c.112G>A;c.112G>A;c.112G>A;c.112G>A;c.112G>A;c.112G>A	p.Asp38Asn;p.Asp38Asn;p.Asp38Asn;p.Asp38Asn;p.Asp38Asn;p.Asp38Asn	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GAT;GAT;GAT;GAT;GAT;GAT	1;1;1;1;1;1	0;0;0;0;0;0	C	./.	./.	./.	./.	.;0.856;0.263;0.36;0.271;0.407	0.16412	.;T;T;T;T;T	0.301;0.349;0.246;0.231;0.454;0.543	0.25061	T;T;T;T;T;T	.;.;.;0.095;.;0.001	0.25437	.;.;.;B;.;B	.;.;.;0.034;.;0.005	0.22546	.;.;.;B;.;B	0.029222	0.25484	N	0.279739	1;1;1;1;0.999222	0.21485	N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	D38N;D38N;D38N;D38N;.	.;.;.;1.32;1.32;1.32	0.33002	.;.;.;L;L;L	-4.65;-4.65;-4.65;-4.65;-4.65;-4.65	0.97938	D;D;D;D;D;D	.;-0.34;-0.77;-0.61;-0.67;-0.39	0.21429	.;N;N;N;N;N	.;.;0.283;0.197;0.191;0.132	0.32037	0.0029	0.82317	D	0.6905	0.89320	D	9	0.060133576;0.060133576;0.060133576;0.060133576;0.060133576;0.060133576	0.07340	T;T;T;T;T;T	0.11643	0.79591	D	.;0.227;0.227;0.227;0.227;0.227	0.52620	0.51;0.51;0.51;0.51;0.51;0.51;	0.60693	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	D38N;D38N;D38N;D38N;D38N;D38N;	Gain of MoRF binding (P = 0.0241);Gain of MoRF binding (P = 0.0241);Gain of MoRF binding (P = 0.0241);Gain of MoRF binding (P = 0.0241);Gain of MoRF binding (P = 0.0241);Gain of MoRF binding (P = 0.0241);	0.365120060079;0.365120060079;0.365120060079;0.365120060079;0.365120060079;0.365120060079	0.36123	.;.;.;.;.;0.5871605952975828	0.58646	.;.;.;.;.;0.371095094246	0.38610	0.673688411713	0.63364	T	.;.;.;.;.;0.554185	0.84959	.;.;.;.;.;D	0.0148225	0.53680	T	-0.216485	0.53075	T	0.110361620783806	0.13460	T	0.878912;0.824018;0.875412;0.824018;0.878912;0.879712	0.59601	D;T;D;T;D;D	.;.;.;.;.;0.27089202	0.50161	.;.;.;.;.;0.10633884	0.25581	.;.;.;.;.;0.27089202	0.50160	.;.;.;.;.;0.10633884	0.25580	.;.;.;-5.236;-6.09;-2.908	0.74263	.;.;.;T;T;T	.;.;.;.;.;0.0916363406391895	0.05836	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1165;0.0962;0.1495;0.1061;0.1003;0.0924	0.33039	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.608066	0.23563	16.43	1.028675	0.17297	13.62	0.95043723645111566	0.26052	0.05286	0.11130	N	AEFGBHCIJ	0.129539	0.24776	N	-1.03214287482723	0.07942	0.3707122	-1.02909355322715	0.09149	0.4535562	0.999999999997078	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-1.11	0.09336	0.434000	0.21212	.	.	0.549000	0.26987	0.003000	0.16062	0.002000	0.18203	0.974000	0.55675	0.0:0.5386:0.1367:0.3247	5.3694	0.15433	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094621	G	C	R	G	.	16	31105942	16	31013443	37;37;37;37;37;37	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.109C>G;c.109C>G;c.109C>G;c.109C>G;c.109C>G	.;p.R37G;p.R37G;p.R37G;p.R37G;p.R37G	c.109C>G;c.109C>G;c.109C>G;c.109C>G;c.109C>G;c.109C>G	p.Arg37Gly;p.Arg37Gly;p.Arg37Gly;p.Arg37Gly;p.Arg37Gly;p.Arg37Gly	c.109C>G;c.109C>G;c.109C>G;c.109C>G;c.109C>G;c.109C>G	p.Arg37Gly;p.Arg37Gly;p.Arg37Gly;p.Arg37Gly;p.Arg37Gly;p.Arg37Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CGG;CGG;CGG;CGG;CGG;CGG	1;1;1;1;1;1	2;2;2;2;2;2	G	./.	./.	./.	./.	.;0.329;0.23;0.346;0.155;0.06	0.37326	.;T;T;T;T;T	0.109;0.084;0.11;0.067;0.115;0.161	0.44302	T;T;T;T;T;T	.;.;.;0.897;.;0.08	0.49385	.;.;.;P;.;B	.;.;.;0.398;.;0.048	0.44426	.;.;.;B;.;B	0.214541	0.03410	N	1.659310	1;1;1;1;0.999871	0.19925	N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R37G;R37G;R37G;R37G;.	.;.;.;1.245;1.245;1.245	0.31408	.;.;.;L;L;L	-4.61;-4.61;-4.61;-4.61;-4.61;-4.61	0.97866	D;D;D;D;D;D	.;-2.31;-2.44;-2.4;-2.48;-1.95	0.54059	.;N;N;N;N;N	.;.;0.269;0.212;0.236;0.177	0.30461	0.3785	0.88774	D	0.8500	0.94998	D	9	0.24218574;0.24218574;0.24218574;0.24218574;0.24218574;0.24218574	0.41410	T;T;T;T;T;T	0.336536	0.91898	D	.;0.344;0.344;0.344;0.344;0.344	0.66582	0.425;0.425;0.425;0.425;0.425;0.425;	0.47021	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R37G;R37G;R37G;R37G;R37G;R37G;	Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);	0.617340952311;0.617340952311;0.617340952311;0.617340952311;0.617340952311;0.617340952311	0.61424	.;.;.;.;.;0.6161412002552709	0.61546	.;.;.;.;.;0.622517808553	0.56515	0.469716131687	0.34641	T	.;.;.;.;.;0.659163	0.89750	.;.;.;.;.;D	0.0513582	0.58517	T	-0.164004	0.57991	T	0.536513924598694	0.33975	D	0.906609;0.854015;0.906609;0.852615;0.906609;0.914708	0.69569	D;D;D;D;D;D	.;.;.;.;.;0.44778553	0.63901	.;.;.;.;.;0.31098878	0.57108	.;.;.;.;.;0.44778553	0.63901	.;.;.;.;.;0.31098878	0.57107	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;0.099397374088446	0.07216	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1229;0.0772;0.1621;0.1037;0.0976;0.0905	0.35808	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.289187	0.18841	14.31	0.546862	0.11341	9.834	0.87567348977737858	0.17320	0.06865	0.12890	N	AEFGBHCIJ	0.175077	0.30224	N	-1.26394399642534	0.04118	0.1852704	-1.31171479996715	0.04278	0.2014375	0.999999999996994	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-0.0144	0.13305	-0.089000	0.11146	.	.	-0.174000	0.10959	0.010000	0.18352	0.014000	0.20376	0.952000	0.50033	0.0:0.2259:0.409:0.3651	8.876	0.34504	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094632	C	T	R	H	rs1391461576	16	31105953	16	31013454	33;33;33;33;33;33	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.98G>A;c.98G>A;c.98G>A;c.98G>A;c.98G>A	.;p.R33H;p.R33H;p.R33H;p.R33H;p.R33H	c.98G>A;c.98G>A;c.98G>A;c.98G>A;c.98G>A;c.98G>A	p.Arg33His;p.Arg33His;p.Arg33His;p.Arg33His;p.Arg33His;p.Arg33His	c.98G>A;c.98G>A;c.98G>A;c.98G>A;c.98G>A;c.98G>A	p.Arg33His;p.Arg33His;p.Arg33His;p.Arg33His;p.Arg33His;p.Arg33His	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CGC;CGC;CGC;CGC;CGC;CGC	2;2;2;2;2;2	0;0;0;0;0;0	C	./.	./.	./.	./.	.;0.147;0.033;0.064;0.046;0.107	0.44358	.;T;D;T;D;T	0.093;0.101;0.164;0.046;0.206;0.153	0.49120	T;T;T;D;T;T	.;.;.;0.121;.;0.019	0.26708	.;.;.;B;.;B	.;.;.;0.054;.;0.008	0.25828	.;.;.;B;.;B	0.004435	0.33751	N	0.139018	0.788552;0.788552;0.788552;0.788552;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R33H;R33H;R33H;R33H;.	.;.;.;1.485;1.485;1.485	0.37223	.;.;.;L;L;L	-4.68;-4.68;-4.68;-4.68;-4.68;-4.68	0.97989	D;D;D;D;D;D	.;-2.44;-2.86;-2.59;-2.93;-2.41	0.61284	.;N;D;D;D;N	.;.;0.283;0.132;0.139;0.131	0.32037	0.4660	0.90063	D	0.8325	0.94387	D	9	0.28588408;0.28588408;0.28588408;0.28588408;0.28588408;0.28588408	0.46171	T;T;T;T;T;T	0.437286	0.94097	D	.;0.420;0.420;0.420;0.420;0.420	0.72930	0.505;0.505;0.505;0.505;0.505;0.505;	0.59924	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R33H;R33H;R33H;R33H;R33H;R33H;	Loss of MoRF binding (P = 0.0237);Loss of MoRF binding (P = 0.0237);Loss of MoRF binding (P = 0.0237);Loss of MoRF binding (P = 0.0237);Loss of MoRF binding (P = 0.0237);Loss of MoRF binding (P = 0.0237);	0.533614126537;0.533614126537;0.533614126537;0.533614126537;0.533614126537;0.533614126537	0.53011	.;.;.;.;.;0.6247752119616968	0.62410	.;.;.;.;.;0.473616337154	0.46569	0.598114490509	0.52638	T	.;.;.;.;.;0.79742	0.94798	.;.;.;.;.;D	0.156425	0.69869	D	-0.0130829	0.69484	D	0.494761019945145	0.32438	T	0.850515;0.850515;0.845715;0.850515;0.849215;0.850515	0.53399	D;D;T;D;T;D	.;.;.;.;.;0.35916507	0.57772	.;.;.;.;.;0.28032398	0.54007	.;.;.;.;.;0.35916507	0.57772	.;.;.;.;.;0.28032398	0.54006	.;.;.;-4.422;-4.617;0.0	0.57995	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.1363;0.2024;0.2569;0.1527;0.1059;0.1485	0.49167	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.329106	0.37485	21.7	2.356147	0.40546	22.2	0.99785313025679523	0.87131	0.45781	0.27614	N	AEFGBHCIJ	0.194746	0.32181	N	-0.290439954888979	0.29517	1.637532	-0.216397611253903	0.30947	1.746965	0.999999999999042	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	2.68	0.30839	0.382000	0.20364	.	.	0.549000	0.26987	0.987000	0.36337	1.000000	0.68203	0.929000	0.46594	0.0:0.7057:0.0:0.2943	6.5294	0.21516	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094633	G	A	R	C	.	16	31105954	16	31013455	33;33;33;33;33;33	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.97C>T;c.97C>T;c.97C>T;c.97C>T;c.97C>T	.;p.R33C;p.R33C;p.R33C;p.R33C;p.R33C	c.97C>T;c.97C>T;c.97C>T;c.97C>T;c.97C>T;c.97C>T	p.Arg33Cys;p.Arg33Cys;p.Arg33Cys;p.Arg33Cys;p.Arg33Cys;p.Arg33Cys	c.97C>T;c.97C>T;c.97C>T;c.97C>T;c.97C>T;c.97C>T	p.Arg33Cys;p.Arg33Cys;p.Arg33Cys;p.Arg33Cys;p.Arg33Cys;p.Arg33Cys	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CGC;CGC;CGC;CGC;CGC;CGC	1;1;1;1;1;1	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.031;0.001;0.008;0.001;0.001	0.78490	.;D;D;D;D;D	0.002;0.002;0.002;0.001;0.003;0.024	0.83351	D;D;D;D;D;D	.;.;.;1.0;.;0.995	0.90584	.;.;.;D;.;D	.;.;.;0.953;.;0.751	0.69275	.;.;.;D;.;P	0.004435	0.33751	N	0.139018	0.999668;0.999668;0.999668;0.999668;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	R33C;R33C;R33C;R33C;.	.;.;.;2.175;2.175;2.175	0.60977	.;.;.;M;M;M	-4.74;-4.74;-4.74;-4.74;-4.74;-4.74	0.98081	D;D;D;D;D;D	.;-4.39;-5.13;-4.71;-5.33;-4.38	0.84601	.;D;D;D;D;D	.;.;0.401;0.268;0.237;0.282	0.44187	1.0158	0.97458	D	0.9400	0.98030	D	9	0.7845144;0.7845144;0.7845144;0.7845144;0.7845144;0.7845144	0.78132	D;D;D;D;D;D	0.661435	0.97157	D	.;0.689;0.689;0.689;0.689;0.689	0.88679	0.47;0.47;0.47;0.47;0.47;0.47;	0.54376	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	R33C;R33C;R33C;R33C;R33C;R33C;	Loss of MoRF binding (P = 0.0145);Loss of MoRF binding (P = 0.0145);Loss of MoRF binding (P = 0.0145);Loss of MoRF binding (P = 0.0145);Loss of MoRF binding (P = 0.0145);Loss of MoRF binding (P = 0.0145);	0.886768913384;0.886768913384;0.886768913384;0.886768913384;0.886768913384;0.886768913384	0.88565	.;.;.;.;.;0.7283096911754633	0.72774	.;.;.;.;.;1.3161196186	0.83331	0.657635450363	0.61071	T	.;.;.;.;.;0.883747	0.97583	.;.;.;.;.;D	0.237897	0.77463	D	0.103946	0.77171	D	0.991299092769623	0.81572	D	0.952105;0.952105;0.951105;0.952105;0.951905;0.952105	0.81652	D;D;D;D;D;D	.;.;.;.;.;0.8214242	0.85316	.;.;.;.;.;0.657305	0.79931	.;.;.;.;.;0.8214242	0.85317	.;.;.;.;.;0.657305	0.79932	.;.;.;-4.622;-4.455;-5.942	0.73235	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.4747;0.4602;0.4677;0.3843;0.2249;0.4106	0.63405	A;A;A;A;B;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.412136	0.90272	31	4.188154	0.87975	29.4	0.99889516151036584	0.96359	0.70819	0.34750	D	AEFGBHCIJ	0.631060	0.61218	D	0.487455389189043	0.66355	4.939588	0.437703421487818	0.63930	4.637073	0.999999999999985	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	2.421000	0.44343	.	.	0.618000	0.50648	0.997000	0.40164	1.000000	0.68203	0.926000	0.46234	0.0:0.0:0.8057:0.1943	10.4416	0.43655	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094636	C	T	A	T	rs1319950423	16	31105957	16	31013458	32;32;32;32;32;32	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.94G>A;c.94G>A;c.94G>A;c.94G>A;c.94G>A	.;p.A32T;p.A32T;p.A32T;p.A32T;p.A32T	c.94G>A;c.94G>A;c.94G>A;c.94G>A;c.94G>A;c.94G>A	p.Ala32Thr;p.Ala32Thr;p.Ala32Thr;p.Ala32Thr;p.Ala32Thr;p.Ala32Thr	c.94G>A;c.94G>A;c.94G>A;c.94G>A;c.94G>A;c.94G>A	p.Ala32Thr;p.Ala32Thr;p.Ala32Thr;p.Ala32Thr;p.Ala32Thr;p.Ala32Thr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GCG;GCG;GCG;GCG;GCG;GCG	1;1;1;1;1;1	0;0;0;0;0;0	C	./.	./.	./.	./.	.;0.505;0.078;0.271;0.085;0.322	0.33923	.;T;T;T;T;T	0.045;0.193;0.06;0.094;0.095;0.515	0.49390	D;T;T;T;T;T	.;.;.;0.995;.;0.643	0.67487	.;.;.;D;.;P	.;.;.;0.894;.;0.565	0.63417	.;.;.;P;.;P	0.005620	0.32654	N	0.142257	0.692501;0.692501;0.692501;0.692501;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	A32T;A32T;A32T;A32T;.	.;.;.;1.725;1.725;1.725	0.44537	.;.;.;L;L;L	-4.59;-4.59;-4.59;-4.59;-4.59;-4.59	0.97830	D;D;D;D;D;D	.;-0.81;-1.21;-0.96;-1.21;-0.73	0.30762	.;N;N;N;N;N	.;.;0.348;0.238;0.248;0.249	0.38950	1.1075	0.99844	D	0.9250	0.97520	D	9	0.388007;0.388007;0.388007;0.388007;0.388007;0.388007	0.54684	T;T;T;T;T;T	0.518854	0.95415	D	.;0.433;0.433;0.433;0.433;0.433	0.73879	0.391;0.391;0.391;0.391;0.391;0.391;	0.41443	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	A32T;A32T;A32T;A32T;A32T;A32T;	Gain of relative solvent accessibility (P = 0.0479);Gain of relative solvent accessibility (P = 0.0479);Gain of relative solvent accessibility (P = 0.0479);Gain of relative solvent accessibility (P = 0.0479);Gain of relative solvent accessibility (P = 0.0479);Gain of relative solvent accessibility (P = 0.0479);	0.744016184196;0.744016184196;0.744016184196;0.744016184196;0.744016184196;0.744016184196	0.74171	.;.;.;.;.;0.4910948641670605	0.49030	.;.;.;.;.;0.887394481255	0.70061	0.618222951889	0.55478	T	.;.;.;.;.;0.544752	0.84477	.;.;.;.;.;D	0.138524	0.68185	D	-0.0387961	0.67782	D	0.976252853870392	0.71296	D	0.872413;0.871313;0.871113;0.869813;0.872413;0.873613	0.58243	D;D;D;D;D;D	.;.;.;.;.;0.5203656	0.68280	.;.;.;.;.;0.4110977	0.65351	.;.;.;.;.;0.5203656	0.68281	.;.;.;.;.;0.4110977	0.65351	.;.;.;-4.272;-4.54;-4.093	0.56583	.;.;.;T;T;T	.;.;.;.;.;0.12203229107749468	0.11648	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.2234;0.1236;0.2448;0.1448;0.1492;0.1152	0.47923	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.076560	0.53734	23.6	3.227686	0.60184	24.1	0.99870135620838663	0.94815	0.75127	0.36771	D	AEFGBHCIJ	0.405314	0.47825	N	0.284229367725214	0.55349	3.698988	0.28918346281899	0.54906	3.654486	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	1.083000	0.30427	.	.	0.549000	0.26987	0.994000	0.38300	1.000000	0.68203	0.914000	0.44937	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094639	C	A	A	S	.	16	31105960	16	31013461	31;31;31;31;31;31	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.91G>T;c.91G>T;c.91G>T;c.91G>T;c.91G>T	.;p.A31S;p.A31S;p.A31S;p.A31S;p.A31S	c.91G>T;c.91G>T;c.91G>T;c.91G>T;c.91G>T;c.91G>T	p.Ala31Ser;p.Ala31Ser;p.Ala31Ser;p.Ala31Ser;p.Ala31Ser;p.Ala31Ser	c.91G>T;c.91G>T;c.91G>T;c.91G>T;c.91G>T;c.91G>T	p.Ala31Ser;p.Ala31Ser;p.Ala31Ser;p.Ala31Ser;p.Ala31Ser;p.Ala31Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GCG;GCG;GCG;GCG;GCG;GCG	1;1;1;1;1;1	0;0;0;0;0;0	C	./.	./.	./.	./.	.;0.397;0.062;0.394;0.067;0.074	0.36912	.;T;T;T;T;T	0.242;0.134;0.238;0.199;0.327;0.76	0.34241	T;T;T;T;T;T	.;.;.;0.949;.;0.652	0.53761	.;.;.;P;.;P	.;.;.;0.492;.;0.525	0.48375	.;.;.;P;.;P	0.000204	0.47681	D	0.000000	1;0.997383;0.997383;0.997383;0.997383	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;A31S;A31S;A31S;A31S	.;.;.;1.79;1.79;1.79	0.46772	.;.;.;L;L;L	-4.67;-4.67;-4.67;-4.67;-4.67;-4.67	0.97973	D;D;D;D;D;D	.;-0.75;-0.9;-0.89;-0.9;-0.69	0.24244	.;N;N;N;N;N	.;.;0.418;0.202;0.227;0.201	0.45803	0.8022	0.94438	D	0.8948	0.96508	D	9	0.36816296;0.36816296;0.36816296;0.36816296;0.36816296;0.36816296	0.53266	T;T;T;T;T;T	0.398979	0.93355	D	.;0.467;0.467;0.467;0.467;0.467	0.76222	0.458;0.458;0.458;0.458;0.458;0.458;	0.52427	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	A31S;A31S;A31S;A31S;A31S;A31S;	Gain of disorder (P = 0.0516);Gain of disorder (P = 0.0516);Gain of disorder (P = 0.0516);Gain of disorder (P = 0.0516);Gain of disorder (P = 0.0516);Gain of disorder (P = 0.0516);	0.691832038465;0.691832038465;0.691832038465;0.691832038465;0.691832038465;0.691832038465	0.68918	.;.;.;.;.;0.57274050443795	0.57202	.;.;.;.;.;0.884093682391	0.69895	0.565013945103	0.47974	T	.;.;.;.;.;0.538761	0.84168	.;.;.;.;.;D	0.0975983	0.64032	D	-0.0975833	0.63585	T	0.965623497962952	0.67325	D	0.871813;0.862114;0.872113;0.862114;0.871813;0.880212	0.59782	D;D;D;D;D;D	.;.;.;.;.;0.45814654	0.64555	.;.;.;.;.;0.28106308	0.54085	.;.;.;.;.;0.45814654	0.64556	.;.;.;.;.;0.28106308	0.54084	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.10047908027929857	0.07416	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1421;0.1182;0.2003;0.1323;0.1319;0.1032	0.42404	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.856655	0.48949	23.1	2.787535	0.50018	23.1	0.99556232010510648	0.71459	0.67333	0.33395	D	ALL	0.334044	0.43293	N	0.195847673202372	0.51000	3.284845	0.227996402721576	0.51408	3.323472	0.99999999999989	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	0.757000	0.26098	.	.	0.549000	0.26987	0.998000	0.41325	1.000000	0.68203	0.904000	0.43992	0.0:0.8998:0.0:0.1002	8.8944	0.34615	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094644	A	C	V	G	rs1354359469	16	31105965	16	31013466	29;29;29;29;29;29	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.86T>G;c.86T>G;c.86T>G;c.86T>G;c.86T>G	.;p.V29G;p.V29G;p.V29G;p.V29G;p.V29G	c.86T>G;c.86T>G;c.86T>G;c.86T>G;c.86T>G;c.86T>G	p.Val29Gly;p.Val29Gly;p.Val29Gly;p.Val29Gly;p.Val29Gly;p.Val29Gly	c.86T>G;c.86T>G;c.86T>G;c.86T>G;c.86T>G;c.86T>G	p.Val29Gly;p.Val29Gly;p.Val29Gly;p.Val29Gly;p.Val29Gly;p.Val29Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GTG;GTG;GTG;GTG;GTG;GTG	2;2;2;2;2;2	0;0;0;0;0;0	A	./.	./.	./.	./.	.;0.0;0.0;0.0;0.0;0.0	0.91255	.;D;D;D;D;D	0.0;0.0;0.0;0.0;0.0;0.001	0.92824	D;D;D;D;D;D	.;.;.;1.0;.;0.999	0.90584	.;.;.;D;.;D	.;.;.;0.998;.;0.998	0.88582	.;.;.;D;.;D	0.000555	0.43413	D	0.000000	1;1;1;1;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	V29G;V29G;V29G;V29G;.	.;.;.;2.965;2.965;2.965	0.85198	.;.;.;M;M;M	-4.75;-4.75;-4.75;-4.75;-4.75;-4.75	0.98096	D;D;D;D;D;D	.;-5.96;-6.98;-6.71;-6.97;-6.26	0.93582	.;D;D;D;D;D	.;.;0.55;0.608;0.593;0.517	0.62526	1.0956	0.99473	D	0.9595	0.98694	D	9	0.95639;0.95639;0.95639;0.95639;0.95639;0.95639	0.95004	D;D;D;D;D;D	0.748228	0.97990	D	.;0.925;0.925;0.925;0.925;0.925	0.98154	0.79;0.79;0.79;0.79;0.79;0.79;	0.91217	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	V29G;V29G;V29G;V29G;V29G;V29G;	Gain of disorder (P = 0.0239);Gain of disorder (P = 0.0239);Gain of disorder (P = 0.0239);Gain of disorder (P = 0.0239);Gain of disorder (P = 0.0239);Gain of disorder (P = 0.0239);	0.883428530414;0.883428530414;0.883428530414;0.883428530414;0.883428530414;0.883428530414	0.88228	.;.;.;.;.;0.9231973709002013	0.92296	.;.;.;.;.;1.31374050941	0.83276	0.758956193924	0.75774	T	.;.;.;.;.;0.955506	0.99388	.;.;.;.;.;D	0.419641	0.91002	D	0.365009	0.90890	D	0.997597634792328	0.91939	D	0.572243;0.572043;0.573543;0.572043;0.573543;0.572043	0.20534	T;T;T;T;T;T	.;.;.;.;.;0.9898941	0.99759	.;.;.;.;.;0.98859274	0.99968	.;.;.;.;.;0.9898941	0.99759	.;.;.;.;.;0.98859274	0.99968	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;0.6870136823976243	0.76420	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.8349;0.8034;0.7807;0.7712;0.5492;0.7571	0.78979	P;P;P;P;A;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.327742	0.88837	29.8	3.928325	0.79793	27.1	0.99567414009811639	0.72197	0.93098	0.57322	D	ALL	0.923703	0.90061	D	0.690511083747996	0.79011	6.988375	0.598285387498335	0.74816	6.201982	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.681000	0.61353	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.787000	0.37188	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	152230	6.569010e-06	0	1	41472	2.411270e-05	0	1	41472	2.411270e-05	0	0	912	0.000000e+00	0	0	15278	0.000000e+00	0	0	3472	0.000000e+00	0	0	5190	0.000000e+00	0	0	10626	0.000000e+00	0	0	316	0.000000e+00	0	0	68034	0.000000e+00	0	0	4838	0.000000e+00	0	0	32924	0.000000e+00	0	1	134814	7.417630e-06	0	1	147982	6.757580e-06	0	0	80792	0.000000e+00	0	0	9106	0.000000e+00	0	0	60	0.000000e+00	0	0	4690	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5498	0.000000e+00	0	0	246	0.000000e+00	0	0	6852	0.000000e+00	0	0	3116	0.000000e+00	0	1	32498	3.077110e-05	0	0	862	0.000000e+00	0	0	14832	0.000000e+00	0	0	3388	0.000000e+00	0	0	5190	0.000000e+00	0	0	6988	0.000000e+00	0	0	310	0.000000e+00	0	0	63908	0.000000e+00	0	0	4836	0.000000e+00	0	1	41150	2.430130e-05	0	0	912	0.000000e+00	0	0	15090	0.000000e+00	0	0	3302	0.000000e+00	0	0	4958	0.000000e+00	0	0	10626	0.000000e+00	0	0	304	0.000000e+00	0	0	64812	0.000000e+00	0	0	4806	0.000000e+00	0	0	24850	0.000000e+00	0	0	112	0.000000e+00	0	0	12906	0.000000e+00	0	0	998	0.000000e+00	0	0	3748	0.000000e+00	0	0	10534	0.000000e+00	0	0	272	0.000000e+00	0	0	21044	0.000000e+00	0	0	4810	0.000000e+00	0	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094648	G	A	H	Y	.	16	31105969	16	31013470	28;28;28;28;28;28	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.82C>T;c.82C>T;c.82C>T;c.82C>T;c.82C>T	.;p.H28Y;p.H28Y;p.H28Y;p.H28Y;p.H28Y	c.82C>T;c.82C>T;c.82C>T;c.82C>T;c.82C>T;c.82C>T	p.His28Tyr;p.His28Tyr;p.His28Tyr;p.His28Tyr;p.His28Tyr;p.His28Tyr	c.82C>T;c.82C>T;c.82C>T;c.82C>T;c.82C>T;c.82C>T	p.His28Tyr;p.His28Tyr;p.His28Tyr;p.His28Tyr;p.His28Tyr;p.His28Tyr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CAC;CAC;CAC;CAC;CAC;CAC	1;1;1;1;1;1	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.972;0.249;0.626;0.17;0.208	0.22833	.;T;T;T;T;T	0.0;0.317;0.0;0.24;0.0;0.411	0.92824	D;T;D;T;D;T	.;.;.;0.998;.;0.997	0.73220	.;.;.;D;.;D	.;.;.;0.994;.;0.995	0.83170	.;.;.;D;.;D	0.000107	0.50451	D	0.000000	0.999619;0.999619;0.999619;0.999619;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	H28Y;H28Y;H28Y;H28Y;.	.;.;.;0.835;0.835;0.835	0.21042	.;.;.;L;L;L	-4.58;-4.58;-4.58;-4.58;-4.58;-4.58	0.97812	D;D;D;D;D;D	.;-2.7;-2.63;-2.8;-3.0;-2.78	0.62343	.;D;D;D;D;D	.;.;0.629;0.74;0.724;0.738	0.74007	0.9493	0.96384	D	0.9175	0.97267	D	9	0.75361526;0.75361526;0.75361526;0.75361526;0.75361526;0.75361526	0.75818	D;D;D;D;D;D	0.283161	0.90303	D	.;0.746;0.746;0.746;0.746;0.746	0.91242	0.618;0.618;0.618;0.618;0.618;0.618;	0.75232	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	H28Y;H28Y;H28Y;H28Y;H28Y;H28Y;	Gain of catalytic residue at H28 (P = 0.034);Gain of catalytic residue at H28 (P = 0.034);Gain of catalytic residue at H28 (P = 0.034);Gain of catalytic residue at H28 (P = 0.034);Gain of catalytic residue at H28 (P = 0.034);Gain of catalytic residue at H28 (P = 0.034);	0.726510675483;0.726510675483;0.726510675483;0.726510675483;0.726510675483;0.726510675483	0.72409	.;.;.;.;.;0.9160488544523668	0.91579	.;.;.;.;.;1.25871091773	0.81975	0.81995934248	0.85021	D	.;.;.;.;.;0.5806	0.86260	.;.;.;.;.;D	0.289106	0.82083	D	0.177504	0.81851	D	0.992480278015137	0.82974	D	0.829517;0.828817;0.817118;0.828817;0.827017;0.834017	0.50309	T;T;T;T;T;T	.;.;.;.;.;0.60831606	0.73138	.;.;.;.;.;0.5748452	0.75371	.;.;.;.;.;0.60831606	0.73139	.;.;.;.;.;0.5748452	0.75372	.;.;.;-5.902;-6.141;-5.692	0.74603	.;.;.;T;T;T	.;.;.;.;.;0.15830812687569826	0.19174	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.4301;0.1992;0.3435;0.2664;0.2456;0.1859	0.61197	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.622093	0.67269	25.1	3.272575	0.61321	24.3	0.995102839008708	0.68558	0.92991	0.57050	D	ALL	0.952940	0.96881	D	0.517294325744776	0.68112	5.172632	0.509190367355146	0.68605	5.243428	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.761000	0.74740	.	.	0.618000	0.50648	1.000000	0.71638	1.000000	0.68203	0.591000	0.31164	0.0:0.0:1.0:0.0	14.878	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094648	G	C	H	D	.	16	31105969	16	31013470	28;28;28;28;28;28	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.82C>G;c.82C>G;c.82C>G;c.82C>G;c.82C>G	.;p.H28D;p.H28D;p.H28D;p.H28D;p.H28D	c.82C>G;c.82C>G;c.82C>G;c.82C>G;c.82C>G;c.82C>G	p.His28Asp;p.His28Asp;p.His28Asp;p.His28Asp;p.His28Asp;p.His28Asp	c.82C>G;c.82C>G;c.82C>G;c.82C>G;c.82C>G;c.82C>G	p.His28Asp;p.His28Asp;p.His28Asp;p.His28Asp;p.His28Asp;p.His28Asp	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CAC;CAC;CAC;CAC;CAC;CAC	1;1;1;1;1;1	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.071;0.004;0.025;0.005;0.008	0.65419	.;T;D;D;D;D	0.0;0.009;0.0;0.009;0.0;0.012	0.92824	D;D;D;D;D;D	.;.;.;1.0;.;0.999	0.90584	.;.;.;D;.;D	.;.;.;0.996;.;0.997	0.86255	.;.;.;D;.;D	0.000107	0.50451	D	0.000000	0.999849;0.999849;0.999849;0.999849;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	H28D;H28D;H28D;H28D;.	.;.;.;2.255;2.255;2.255	0.64187	.;.;.;M;M;M	-4.73;-4.73;-4.73;-4.73;-4.73;-4.73	0.98066	D;D;D;D;D;D	.;-6.34;-7.1;-6.91;-7.23;-6.46	0.94300	.;D;D;D;D;D	.;.;0.753;0.835;0.822;0.826	0.83066	1.0578	0.98289	D	0.9486	0.98324	D	9	0.9640422;0.9640422;0.9640422;0.9640422;0.9640422;0.9640422	0.95855	D;D;D;D;D;D	0.435656	0.94067	D	.;0.932;0.932;0.932;0.932;0.932	0.98415	0.82;0.82;0.82;0.82;0.82;0.82;	0.93328	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	H28D;H28D;H28D;H28D;H28D;H28D;	Gain of ubiquitination at K30 (P = 0.0393);Gain of ubiquitination at K30 (P = 0.0393);Gain of ubiquitination at K30 (P = 0.0393);Gain of ubiquitination at K30 (P = 0.0393);Gain of ubiquitination at K30 (P = 0.0393);Gain of ubiquitination at K30 (P = 0.0393);	0.80362806865;0.80362806865;0.80362806865;0.80362806865;0.80362806865;0.80362806865	0.80179	.;.;.;.;.;0.9652065036850049	0.96507	.;.;.;.;.;1.37714289507	0.84704	0.81154280901	0.83728	D	.;.;.;.;.;0.90586	0.98189	.;.;.;.;.;D	0.447998	0.92392	D	0.405741	0.92298	D	0.992706835269928	0.83255	D	0.89721;0.891311;0.883612;0.891311;0.89651;0.89531	0.64041	D;D;D;D;D;D	.;.;.;.;.;0.91718453	0.92975	.;.;.;.;.;0.89427644	0.94570	.;.;.;.;.;0.91718453	0.92976	.;.;.;.;.;0.89427644	0.94570	.;.;.;-4.729;-5.173;-0.64	0.66189	.;.;.;T;T;T	.;.;.;.;.;0.5797722165778848	0.64663	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	0.9198;0.7403;0.9049;0.8152;0.7332;0.6394	0.84184	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.243987	0.86777	29.1	3.783831	0.74953	26.2	0.98971490003092044	0.49540	0.94014	0.59854	D	ALL	0.956494	0.97507	D	0.653657960290615	0.76607	6.517592	0.596339921282236	0.74675	6.177862	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.761000	0.74740	.	.	0.618000	0.50648	1.000000	0.71638	1.000000	0.68203	0.591000	0.31164	0.0:0.0:1.0:0.0	14.878	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094653	G	C	A	G	.	16	31105974	16	31013475	26;26;26;26;26;26	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.77C>G;c.77C>G;c.77C>G;c.77C>G;c.77C>G	.;p.A26G;p.A26G;p.A26G;p.A26G;p.A26G	c.77C>G;c.77C>G;c.77C>G;c.77C>G;c.77C>G;c.77C>G	p.Ala26Gly;p.Ala26Gly;p.Ala26Gly;p.Ala26Gly;p.Ala26Gly;p.Ala26Gly	c.77C>G;c.77C>G;c.77C>G;c.77C>G;c.77C>G;c.77C>G	p.Ala26Gly;p.Ala26Gly;p.Ala26Gly;p.Ala26Gly;p.Ala26Gly;p.Ala26Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GCG;GCG;GCG;GCG;GCG;GCG	2;2;2;2;2;2	0;0;0;0;0;0	G	./.	./.	./.	./.	.;0.004;0.005;0.003;0.006;0.007	0.68238	.;D;D;D;D;D	0.0;0.006;0.0;0.01;0.0;0.018	0.92824	D;D;D;D;D;D	.;.;.;0.998;.;0.714	0.73220	.;.;.;D;.;P	.;.;.;0.92;.;0.544	0.65550	.;.;.;D;.;P	0.005639	0.32637	N	0.142313	0.937872;0.937872;0.937872;0.937872;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	A26G;A26G;A26G;A26G;.	.;.;.;2.82;2.82;2.82	0.82106	.;.;.;M;M;M	-4.76;-4.76;-4.76;-4.76;-4.76;-4.76	0.98111	D;D;D;D;D;D	.;-3.01;-3.59;-3.28;-3.69;-3.11	0.70432	.;D;D;D;D;D	.;.;0.573;0.588;0.588;0.557	0.60833	1.0731	0.98675	D	0.9566	0.98595	D	9	0.8856777;0.8856777;0.8856777;0.8856777;0.8856777;0.8856777	0.87895	D;D;D;D;D;D	0.505344	0.95217	D	.;0.804;0.804;0.804;0.804;0.804	0.93621	0.755;0.755;0.755;0.755;0.755;0.755;	0.88484	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	A26G;A26G;A26G;A26G;A26G;A26G;	Loss of stability (P = 0.1132);Loss of stability (P = 0.1132);Loss of stability (P = 0.1132);Loss of stability (P = 0.1132);Loss of stability (P = 0.1132);Loss of stability (P = 0.1132);	0.803159424316;0.803159424316;0.803159424316;0.803159424316;0.803159424316;0.803159424316	0.80131	.;.;.;.;.;0.7915854187109194	0.79110	.;.;.;.;.;0.976515596739	0.73583	0.663694798946	0.61938	T	.;.;.;.;.;0.844727	0.96410	.;.;.;.;.;D	0.226321	0.76374	D	0.0873178	0.76066	D	0.989543199539185	0.79774	D	0.948305;0.948805;0.951605;0.959204;0.947905;0.936406	0.84623	D;D;D;D;D;D	.;.;.;.;.;0.78403664	0.82902	.;.;.;.;.;0.7196066	0.83446	.;.;.;.;.;0.78403664	0.82904	.;.;.;.;.;0.7196066	0.83447	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;0.43518144612253823	0.52164	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	0.5491;0.3843;0.4868;0.4954;0.3514;0.4116	0.66747	A;A;A;A;A;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	4.033071	0.79758	27.2	3.648825	0.71030	25.5	0.99678701538721493	0.79108	0.97225	0.73430	D	ALL	0.953949	0.97066	D	0.588802897907614	0.72476	5.811615	0.543155587963985	0.70924	5.577112	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	6.466000	0.73458	.	.	0.618000	0.50648	1.000000	0.71638	1.000000	0.68203	0.488000	0.28746	0.0:0.0:1.0:0.0	14.878	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094663	A	C	S	A	.	16	31105984	16	31013485	23;23;23;23;23;23	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.67T>G;c.67T>G;c.67T>G;c.67T>G;c.67T>G	.;p.S23A;p.S23A;p.S23A;p.S23A;p.S23A	c.67T>G;c.67T>G;c.67T>G;c.67T>G;c.67T>G;c.67T>G	p.Ser23Ala;p.Ser23Ala;p.Ser23Ala;p.Ser23Ala;p.Ser23Ala;p.Ser23Ala	c.67T>G;c.67T>G;c.67T>G;c.67T>G;c.67T>G;c.67T>G	p.Ser23Ala;p.Ser23Ala;p.Ser23Ala;p.Ser23Ala;p.Ser23Ala;p.Ser23Ala	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCG;TCG;TCG;TCG;TCG;TCG	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.043;0.021;0.022;0.032;0.058	0.49117	.;D;D;D;D;T	0.139;0.123;0.094;0.08;0.192;0.115	0.41913	T;T;T;T;T;T	.;.;.;0.234;.;0.992	0.64738	.;.;.;B;.;D	.;.;.;0.143;.;0.989	0.78396	.;.;.;B;.;D	0.000349	0.45440	D	0.000000	0.997561;0.997561;0.997561;0.997561;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S23A;S23A;S23A;S23A;.	.;.;.;2.61;2.61;2.61	0.76335	.;.;.;M;M;M	-5.14;-5.14;-5.14;-5.14;-5.14;-5.14	0.98763	D;D;D;D;D;D	.;-2.26;-2.7;-2.58;-2.7;-2.39	0.57599	.;N;D;D;D;N	.;.;0.668;0.701;0.661;0.673	0.70527	1.0903	0.99251	D	0.9663	0.98927	D	9	0.9522537;0.9522537;0.9522537;0.9522537;0.9522537;0.9522537	0.94567	D;D;D;D;D;D	0.579742	0.96230	D	.;0.754;0.754;0.754;0.754;0.754	0.91583	0.859;0.859;0.859;0.859;0.859;0.859;	0.95718	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S23A;S23A;S23A;S23A;S23A;S23A;	Loss of MoRF binding (P = 0.1798);Loss of MoRF binding (P = 0.1798);Loss of MoRF binding (P = 0.1798);Loss of MoRF binding (P = 0.1798);Loss of MoRF binding (P = 0.1798);Loss of MoRF binding (P = 0.1798);	0.674137056861;0.674137056861;0.674137056861;0.674137056861;0.674137056861;0.674137056861	0.67137	.;.;.;.;.;0.8965595218674801	0.89626	.;.;.;.;.;1.05593504078	0.76314	0.738820910454	0.72799	T	.;.;.;.;.;0.696771	0.91232	.;.;.;.;.;D	0.219953	0.75772	D	0.0781711	0.75456	D	0.97586977481842	0.71123	D	0.612939;0.589541;0.858514;0.89671;0.626037;0.59994	0.63922	T;T;D;D;T;T	.;.;.;.;.;0.68991005	0.77507	.;.;.;.;.;0.62899643	0.78362	.;.;.;.;.;0.68991005	0.77508	.;.;.;.;.;0.62899643	0.78363	.;.;.;-3.364;-3.477;-3.435	0.31067	.;.;.;T;T;T	.;.;.;.;.;0.25390345437374656	0.34343	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.5512;0.4111;0.4939;0.3866;0.3125;0.3311	0.66837	A;A;A;A;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.599524	0.66679	25.0	3.029425	0.55404	23.6	0.98910799226635493	0.48363	0.96921	0.71669	D	ALL	0.833095	0.75136	D	0.229148969265297	0.52616	3.434681	0.129621292339452	0.46070	2.859205	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.614000	0.60886	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.179000	0.21265	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094663	A	G	S	P	.	16	31105984	16	31013485	23;23;23;23;23;23	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.67T>C;c.67T>C;c.67T>C;c.67T>C;c.67T>C	.;p.S23P;p.S23P;p.S23P;p.S23P;p.S23P	c.67T>C;c.67T>C;c.67T>C;c.67T>C;c.67T>C;c.67T>C	p.Ser23Pro;p.Ser23Pro;p.Ser23Pro;p.Ser23Pro;p.Ser23Pro;p.Ser23Pro	c.67T>C;c.67T>C;c.67T>C;c.67T>C;c.67T>C;c.67T>C	p.Ser23Pro;p.Ser23Pro;p.Ser23Pro;p.Ser23Pro;p.Ser23Pro;p.Ser23Pro	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TCG;TCG;TCG;TCG;TCG;TCG	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.004;0.003;0.002;0.005;0.006	0.72154	.;D;D;D;D;D	0.05;0.024;0.034;0.018;0.069;0.021	0.59732	T;D;D;D;T;D	.;.;.;0.998;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.905;.;0.998	0.88582	.;.;.;P;.;D	0.000349	0.45440	D	0.000000	0.999884;0.999884;0.999884;0.999884;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S23P;S23P;S23P;S23P;.	.;.;.;2.955;2.955;2.955	0.85029	.;.;.;M;M;M	-5.23;-5.23;-5.23;-5.23;-5.23;-5.23	0.98892	D;D;D;D;D;D	.;-4.02;-4.73;-4.57;-4.73;-4.27	0.80085	.;D;D;D;D;D	.;.;0.823;0.895;0.894;0.888	0.89465	1.0902	0.99247	D	0.9706	0.99074	D	9	0.97667414;0.97667414;0.97667414;0.97667414;0.97667414;0.97667414	0.97465	D;D;D;D;D;D	0.704314	0.97585	D	.;0.865;0.865;0.865;0.865;0.865	0.95912	0.88;0.88;0.88;0.88;0.88;0.88;	0.96835	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S23P;S23P;S23P;S23P;S23P;S23P;	Loss of MoRF binding (P = 0.0867);Loss of MoRF binding (P = 0.0867);Loss of MoRF binding (P = 0.0867);Loss of MoRF binding (P = 0.0867);Loss of MoRF binding (P = 0.0867);Loss of MoRF binding (P = 0.0867);	0.713293215259;0.713293215259;0.713293215259;0.713293215259;0.713293215259;0.713293215259	0.71078	.;.;.;.;.;0.9865176477321461	0.98644	.;.;.;.;.;1.31764041123	0.83366	0.75214612484	0.74763	T	.;.;.;.;.;0.956842	0.99416	.;.;.;.;.;D	0.396184	0.89692	D	0.331314	0.89563	D	0.995477497577667	0.87491	D	0.934107;0.926107;0.940906;0.963704;0.940906;0.924008	0.86510	D;D;D;D;D;D	.;.;.;.;.;0.98224926	0.99277	.;.;.;.;.;0.9776921	0.99753	.;.;.;.;.;0.98224926	0.99277	.;.;.;.;.;0.9776921	0.99753	.;.;.;-3.663;-3.405;-4.659	0.58755	.;.;.;T;T;T	.;.;.;.;.;0.8089692024099852	0.88430	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9118;0.9254;0.8348;0.854;0.5986;0.8559	0.84631	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.837448	0.73316	26.0	3.264123	0.61104	24.2	0.99547253397889812	0.70898	0.96638	0.70151	D	ALL	0.933625	0.92578	D	0.440377049662677	0.63661	4.604005	0.275776172454234	0.54129	3.578826	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.614000	0.60886	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.179000	0.21265	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094665	A	C	L	R	.	16	31105986	16	31013487	22;22;22;22;22;22	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.65T>G;c.65T>G;c.65T>G;c.65T>G;c.65T>G	.;p.L22R;p.L22R;p.L22R;p.L22R;p.L22R	c.65T>G;c.65T>G;c.65T>G;c.65T>G;c.65T>G;c.65T>G	p.Leu22Arg;p.Leu22Arg;p.Leu22Arg;p.Leu22Arg;p.Leu22Arg;p.Leu22Arg	c.65T>G;c.65T>G;c.65T>G;c.65T>G;c.65T>G;c.65T>G	p.Leu22Arg;p.Leu22Arg;p.Leu22Arg;p.Leu22Arg;p.Leu22Arg;p.Leu22Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CTC;CTC;CTC;CTC;CTC;CTC	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.001;0.0;0.0;0.0;0.0	0.91255	.;D;D;D;D;D	0.0;0.001;0.0;0.001;0.0;0.001	0.92824	D;D;D;D;D;D	.;.;.;1.0;.;0.973	0.90584	.;.;.;D;.;D	.;.;.;0.999;.;0.908	0.92359	.;.;.;D;.;P	0.095385	0.20126	N	0.361765	0.989917;0.989917;0.989917;0.989917;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	L22R;L22R;L22R;L22R;.	.;.;.;2.845;2.845;2.845	0.82663	.;.;.;M;M;M	-4.83;-4.83;-4.83;-4.83;-4.83;-4.83	0.98213	D;D;D;D;D;D	.;-4.75;-5.55;-5.39;-5.59;-5.01	0.86527	.;D;D;D;D;D	.;.;0.818;0.881;0.886;0.876	0.88466	1.0961	0.99494	D	0.9637	0.98838	D	9	0.93326145;0.93326145;0.93326145;0.93326145;0.93326145;0.93326145	0.92660	D;D;D;D;D;D	0.553766	0.95897	D	.;0.805;0.805;0.805;0.805;0.805	0.93660	0.715;0.715;0.715;0.715;0.715;0.715;	0.85051	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	L22R;L22R;L22R;L22R;L22R;L22R;	Gain of MoRF binding (P = 0.0039);Gain of MoRF binding (P = 0.0039);Gain of MoRF binding (P = 0.0039);Gain of MoRF binding (P = 0.0039);Gain of MoRF binding (P = 0.0039);Gain of MoRF binding (P = 0.0039);	0.815658754186;0.815658754186;0.815658754186;0.815658754186;0.815658754186;0.815658754186	0.81392	.;.;.;.;.;0.9791935230528356	0.97910	.;.;.;.;.;1.39614750633	0.85088	0.712262511253	0.68922	T	.;.;.;.;.;0.942039	0.99098	.;.;.;.;.;D	0.45939	0.92901	D	0.422106	0.92813	D	0.997969686985016	0.92874	D	0.940606;0.940206;0.934906;0.939106;0.934906;0.955304	0.82980	D;D;D;D;D;D	.;.;.;.;.;0.9569627	0.96973	.;.;.;.;.;0.92508584	0.96754	.;.;.;.;.;0.9569627	0.96973	.;.;.;.;.;0.92508584	0.96754	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;0.8272332443105329	0.89889	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9628;0.9535;0.8824;0.9074;0.7831;0.9056	0.88414	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.630014	0.67481	25.1	3.146329	0.58189	23.9	0.99485650120384672	0.67124	0.96346	0.68690	D	ALL	0.861271	0.77931	D	0.411109410500463	0.62031	4.412741	0.242053819389713	0.52198	3.39631	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.614000	0.60886	.	.	0.691000	0.84096	0.907000	0.31601	1.000000	0.68203	0.077000	0.17074	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094668	A	C	V	G	.	16	31105989	16	31013490	21;21;21;21;21;21	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.62T>G;c.62T>G;c.62T>G;c.62T>G;c.62T>G	.;p.V21G;p.V21G;p.V21G;p.V21G;p.V21G	c.62T>G;c.62T>G;c.62T>G;c.62T>G;c.62T>G;c.62T>G	p.Val21Gly;p.Val21Gly;p.Val21Gly;p.Val21Gly;p.Val21Gly;p.Val21Gly	c.62T>G;c.62T>G;c.62T>G;c.62T>G;c.62T>G;c.62T>G	p.Val21Gly;p.Val21Gly;p.Val21Gly;p.Val21Gly;p.Val21Gly;p.Val21Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GTG;GTG;GTG;GTG;GTG;GTG	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.395;0.126;0.311;0.165;0.118	0.28148	.;T;T;T;T;T	0.276;0.055;0.211;0.036;0.237;0.135	0.52060	T;T;T;D;T;T	.;.;.;0.011;.;0.0	0.15914	.;.;.;B;.;B	.;.;.;0.006;.;0.0	0.12133	.;.;.;B;.;B	0.793302	0.09380	N	0.886009	0.996797;0.996797;0.996797;0.996797;0.999808	0.22899	N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	V21G;V21G;V21G;V21G;.	.;.;.;0.69;0.69;0.69	0.16971	.;.;.;N;N;N	-4.8;-4.8;-4.8;-4.8;-4.8;-4.8	0.98169	D;D;D;D;D;D	.;-2.65;-3.26;-3.07;-3.43;-2.87	0.67359	.;D;D;D;D;D	.;.;0.251;0.162;0.179;0.19	0.28381	0.1240	0.84604	D	0.7661	0.92040	D	9	0.22143808;0.22143808;0.22143808;0.22143808;0.22143808;0.22143808	0.38868	T;T;T;T;T;T	0.09915	0.77060	D	.;0.270;0.270;0.270;0.270;0.270	0.58507	0.673;0.673;0.673;0.673;0.673;0.673;	0.81101	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	V21G;V21G;V21G;V21G;V21G;V21G;	Loss of stability (P = 0.0254);Loss of stability (P = 0.0254);Loss of stability (P = 0.0254);Loss of stability (P = 0.0254);Loss of stability (P = 0.0254);Loss of stability (P = 0.0254);	0.569914523039;0.569914523039;0.569914523039;0.569914523039;0.569914523039;0.569914523039	0.56656	.;.;.;.;.;0.7317405516175141	0.73119	.;.;.;.;.;0.480338031982	0.47047	0.504719376564	0.39485	T	.;.;.;.;.;0.770734	0.93861	.;.;.;.;.;D	0.0250819	0.55066	T	-0.201748	0.54480	T	0.0294539220631123	0.01906	T	0.685131;0.616438;0.670533;0.577142;0.671133;0.674733	0.29365	T;T;T;T;T;T	.;.;.;.;.;0.27688935	0.50748	.;.;.;.;.;0.2263383	0.47608	.;.;.;.;.;0.27688935	0.50748	.;.;.;.;.;0.2263383	0.47607	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;0.1071171106539239	0.08684	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.107;0.0749;0.1759;0.0908;0.0754;0.0734	0.38462	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	0.016373	0.04305	1.441	0.494951	0.10711	9.356	0.85134129335459974	0.15706	0.14224	0.18289	N	AEFDGBHCI	0.127563	0.24497	N	-1.26029188835357	0.04165	0.1874773	-1.32319065794023	0.04132	0.1942542	0.99999999999995	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-4.34	0.03412	-0.505000	0.06448	.	.	-0.181000	0.10308	0.000000	0.06391	0.000000	0.08366	0.043000	0.14563	0.1804:0.3002:0.5194:0.0	8.248	0.30860	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094671	A	G	L	S	.	16	31105992	16	31013493	20;20;20;20;20;20	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.59T>C;c.59T>C;c.59T>C;c.59T>C;c.59T>C	.;p.L20S;p.L20S;p.L20S;p.L20S;p.L20S	c.59T>C;c.59T>C;c.59T>C;c.59T>C;c.59T>C;c.59T>C	p.Leu20Ser;p.Leu20Ser;p.Leu20Ser;p.Leu20Ser;p.Leu20Ser;p.Leu20Ser	c.59T>C;c.59T>C;c.59T>C;c.59T>C;c.59T>C;c.59T>C	p.Leu20Ser;p.Leu20Ser;p.Leu20Ser;p.Leu20Ser;p.Leu20Ser;p.Leu20Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TTA;TTA;TTA;TTA;TTA;TTA	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.001;0.001;0.001;0.001;0.001	0.78490	.;D;D;D;D;D	0.002;0.002;0.002;0.002;0.003;0.003	0.79402	D;D;D;D;D;D	.;.;.;0.999;.;0.624	0.77913	.;.;.;D;.;P	.;.;.;0.943;.;0.609	0.67921	.;.;.;D;.;P	0.348720	0.13849	N	0.511841	1;0.999998;0.999998;0.999998;0.999998	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;L20S;L20S;L20S;L20S	.;.;.;2.605;2.605;2.605	0.76211	.;.;.;M;M;M	-5.14;-5.14;-5.14;-5.14;-5.14;-5.14	0.98763	D;D;D;D;D;D	.;-3.79;-4.4;-4.12;-4.33;-3.84	0.77308	.;D;D;D;D;D	.;.;0.56;0.598;0.583;0.604	0.62188	1.0578	0.98289	D	0.9614	0.98759	D	9	0.90306264;0.90306264;0.90306264;0.90306264;0.90306264;0.90306264	0.89669	D;D;D;D;D;D	0.629277	0.96811	D	.;0.693;0.693;0.693;0.693;0.693	0.88867	0.722;0.722;0.722;0.722;0.722;0.722;	0.85673	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	L20S;L20S;L20S;L20S;L20S;L20S;	Loss of stability (P = 0.0116);Loss of stability (P = 0.0116);Loss of stability (P = 0.0116);Loss of stability (P = 0.0116);Loss of stability (P = 0.0116);Loss of stability (P = 0.0116);	0.785462475727;0.785462475727;0.785462475727;0.785462475727;0.785462475727;0.785462475727	0.78348	.;.;.;.;.;0.9467077629221673	0.94653	.;.;.;.;.;1.14369453892	0.79008	0.614505827427	0.54953	T	.;.;.;.;.;0.900898	0.98055	.;.;.;.;.;D	0.220809	0.75853	D	0.0794003	0.75537	D	0.945909678936005	0.62359	D	0.905809;0.882012;0.913709;0.925407;0.912709;0.89671	0.72589	D;D;D;D;D;D	.;.;.;.;.;0.84986275	0.87325	.;.;.;.;.;0.79060197	0.87683	.;.;.;.;.;0.84986275	0.87327	.;.;.;.;.;0.79060197	0.87684	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.3430861884896965	0.44072	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.7074;0.5878;0.7418;0.659;0.5272;0.5061	0.74706	P;P;P;P;A;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.153502	0.55498	23.8	2.664343	0.47322	22.9	0.9940949252244905	0.63216	0.86791	0.46149	D	AEFDGBHCI	0.801702	0.72734	D	0.178285063617311	0.50157	3.20849	0.0349006920370886	0.41347	2.482616	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.614000	0.60886	.	.	0.691000	0.84096	0.151000	0.23669	0.996000	0.32793	0.019000	0.11356	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094680	A	T	L	Q	rs1158566246	16	31106001	16	31013502	17;17;17;17;17;17	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.50T>A;c.50T>A;c.50T>A;c.50T>A;c.50T>A	.;p.L17Q;p.L17Q;p.L17Q;p.L17Q;p.L17Q	c.50T>A;c.50T>A;c.50T>A;c.50T>A;c.50T>A;c.50T>A	p.Leu17Gln;p.Leu17Gln;p.Leu17Gln;p.Leu17Gln;p.Leu17Gln;p.Leu17Gln	c.50T>A;c.50T>A;c.50T>A;c.50T>A;c.50T>A;c.50T>A	p.Leu17Gln;p.Leu17Gln;p.Leu17Gln;p.Leu17Gln;p.Leu17Gln;p.Leu17Gln	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CTG;CTG;CTG;CTG;CTG;CTG	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.02;0.005;0.01;0.015;0.049	0.63226	.;D;D;D;D;D	0.003;0.026;0.003;0.021;0.004;0.115	0.76473	D;D;D;D;D;T	.;.;.;0.994;.;0.975	0.66517	.;.;.;D;.;D	.;.;.;0.805;.;0.845	0.60432	.;.;.;P;.;P	0.098210	0.19991	N	0.363840	1;0.878916;0.878916;0.878916;0.878916	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;L17Q;L17Q;L17Q;L17Q	.;.;.;2.16;2.16;2.16	0.60381	.;.;.;M;M;M	-4.92;-4.92;-4.92;-4.92;-4.92;-4.92	0.98371	D;D;D;D;D;D	.;-2.47;-3.08;-2.63;-2.92;-2.17	0.63323	.;N;D;D;D;N	.;.;0.687;0.701;0.709;0.672	0.71232	1.0215	0.97561	D	0.9411	0.98068	D	9	0.7086171;0.7086171;0.7086171;0.7086171;0.7086171;0.7086171	0.72899	D;D;D;D;D;D	0.413591	0.93649	D	.;0.677;0.677;0.677;0.677;0.677	0.88109	0.566;0.566;0.566;0.566;0.566;0.566;	0.68768	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	L17Q;L17Q;L17Q;L17Q;L17Q;L17Q;	Gain of solvent accessibility (P = 0.0374);Gain of solvent accessibility (P = 0.0374);Gain of solvent accessibility (P = 0.0374);Gain of solvent accessibility (P = 0.0374);Gain of solvent accessibility (P = 0.0374);Gain of solvent accessibility (P = 0.0374);	0.787372057377;0.787372057377;0.787372057377;0.787372057377;0.787372057377;0.787372057377	0.78540	.;.;.;.;.;0.8034397730555554	0.80297	.;.;.;.;.;0.975277089992	0.73547	0.598231971264	0.52655	T	.;.;.;.;.;0.899001	0.98005	.;.;.;.;.;D	0.251796	0.78769	D	0.123911	0.78494	D	0.91194874048233	0.56768	D	0.89951;0.90351;0.915608;0.915608;0.914109;0.917608	0.70392	D;D;D;D;D;D	.;.;.;.;.;0.58388394	0.71820	.;.;.;.;.;0.5147765	0.71963	.;.;.;.;.;0.58388394	0.71821	.;.;.;.;.;0.5147765	0.71964	.;.;.;-3.867;-4.522;-3.169	0.56244	.;.;.;T;T;T	.;.;.;.;.;0.6518972615897234	0.72416	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.7205;0.5879;0.6696;0.5356;0.4716;0.5805	0.73809	P;P;P;A;A;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.227495	0.57251	23.9	3.102706	0.57123	23.8	0.99205223581004043	0.55412	0.73803	0.36099	D	ALL	0.487553	0.52625	N	0.152806329826022	0.48945	3.100589	0.0272775731266145	0.40985	2.454896	0.999999999999997	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	3.136000	0.50249	.	.	0.691000	0.84096	0.666000	0.28313	1.000000	0.68203	0.008000	0.08271	0.8998:0.0:0.1002:0.0	7.0474	0.24231	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	232858	4.294460e-06	0	0	14122	0.000000e+00	0	0	33694	0.000000e+00	0	0	9674	0.000000e+00	0	0	17774	0.000000e+00	0	0	18112	0.000000e+00	0	1	103786	9.635210e-06	0	0	29978	0.000000e+00	0	1	103786	9.635210e-06	0	0	102462	0.000000e+00	0	1	193842	5.158840e-06	0	1	222146	4.501540e-06	0	1	227794	4.389930e-06	0	0	6250	0.000000e+00	0	0	16630	0.000000e+00	0	0	2232	0.000000e+00	0	0	8684	0.000000e+00	0	0	11014	0.000000e+00	0	0	40608	0.000000e+00	0	0	15270	0.000000e+00	0	.	.	.	.	0	14084	0.000000e+00	0	0	29650	0.000000e+00	0	0	5882	0.000000e+00	0	0	12882	0.000000e+00	0	0	14100	0.000000e+00	0	1	82748	1.208490e-05	0	0	29972	0.000000e+00	0	1	82748	1.208490e-05	0	0	13114	0.000000e+00	0	0	33444	0.000000e+00	0	0	9320	0.000000e+00	0	0	17252	0.000000e+00	0	0	18102	0.000000e+00	0	1	95680	1.045150e-05	0	0	29904	0.000000e+00	0	1	95680	1.045150e-05	0	0	10654	0.000000e+00	0	0	33574	0.000000e+00	0	0	9624	0.000000e+00	0	0	17770	0.000000e+00	0	0	18110	0.000000e+00	0	1	102434	9.762380e-06	0	0	29978	0.000000e+00	0	1	102434	9.762380e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094683	C	A	C	F	.	16	31106004	16	31013505	16;16;16;16;16;16	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.47G>T;c.47G>T;c.47G>T;c.47G>T;c.47G>T	.;p.C16F;p.C16F;p.C16F;p.C16F;p.C16F	c.47G>T;c.47G>T;c.47G>T;c.47G>T;c.47G>T;c.47G>T	p.Cys16Phe;p.Cys16Phe;p.Cys16Phe;p.Cys16Phe;p.Cys16Phe;p.Cys16Phe	c.47G>T;c.47G>T;c.47G>T;c.47G>T;c.47G>T;c.47G>T	p.Cys16Phe;p.Cys16Phe;p.Cys16Phe;p.Cys16Phe;p.Cys16Phe;p.Cys16Phe	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGC;TGC;TGC;TGC;TGC;TGC	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.055;0.033;0.034;0.055;0.068	0.44358	.;T;D;D;T;T	0.225;0.087;0.167;0.065;0.272;0.07	0.44702	T;T;T;T;T;T	.;.;.;0.347;.;0.999	0.77913	.;.;.;B;.;D	.;.;.;0.069;.;0.998	0.88582	.;.;.;B;.;D	0.000068	0.52346	D	0.000000	0.999997;0.999997;0.999997;0.999997;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	C16F;C16F;C16F;C16F;.	.;.;.;2.92;2.92;2.92	0.84325	.;.;.;M;M;M	-4.8;-4.8;-4.8;-4.8;-4.8;-4.8	0.98169	D;D;D;D;D;D	.;-8.43;-9.9;-9.27;-9.83;-8.85	0.98740	.;D;D;D;D;D	.;.;0.706;0.812;0.788;0.824	0.81957	1.0833	0.98991	D	0.9654	0.98897	D	9	0.9714898;0.9714898;0.9714898;0.9714898;0.9714898;0.9714898	0.96764	D;D;D;D;D;D	0.579793	0.96230	D	.;0.765;0.765;0.765;0.765;0.765	0.92046	0.807;0.807;0.807;0.807;0.807;0.807;	0.92442	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	C16F;C16F;C16F;C16F;C16F;C16F;	Loss of catalytic residue at L17 (P = 0.0116);Loss of catalytic residue at L17 (P = 0.0116);Loss of catalytic residue at L17 (P = 0.0116);Loss of catalytic residue at L17 (P = 0.0116);Loss of catalytic residue at L17 (P = 0.0116);Loss of catalytic residue at L17 (P = 0.0116);	0.761626786136;0.761626786136;0.761626786136;0.761626786136;0.761626786136;0.761626786136	0.75946	.;.;.;.;.;0.9707041209793089	0.97059	.;.;.;.;.;1.46008428999	0.86329	0.809763431549	0.83456	D	.;.;.;.;.;0.947433	0.99218	.;.;.;.;.;D	0.510342	0.94577	D	0.495295	0.94497	D	0.998431265354156	0.94140	D	0.847515;0.847115;0.847115;0.847115;0.847515;0.848715	0.53056	T;T;T;T;T;T	.;.;.;.;.;0.9816503	0.99234	.;.;.;.;.;0.9159324	0.96110	.;.;.;.;.;0.9816503	0.99234	.;.;.;.;.;0.9159324	0.96111	.;.;.;-5.207;-5.24;-5.86	0.72623	.;.;.;T;T;T	.;.;.;.;.;0.5960045299120605	0.66289	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	0.6715;0.7544;0.6022;0.6085;0.4458;0.747	0.75243	P;P;P;P;A;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.572170	0.65964	24.9	3.554760	0.68512	25.2	0.94996474371278672	0.25952	0.92789	0.56549	D	ALL	0.868197	0.78824	D	0.205088615590447	0.51446	3.325709	0.184617696634659	0.49003	3.108976	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	3.416000	0.52463	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.041000	0.14368	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094683	C	G	C	S	rs1386462679	16	31106004	16	31013505	16;16;16;16;16;16	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.47G>C;c.47G>C;c.47G>C;c.47G>C;c.47G>C	.;p.C16S;p.C16S;p.C16S;p.C16S;p.C16S	c.47G>C;c.47G>C;c.47G>C;c.47G>C;c.47G>C;c.47G>C	p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser	c.47G>C;c.47G>C;c.47G>C;c.47G>C;c.47G>C;c.47G>C	p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGC;TGC;TGC;TGC;TGC;TGC	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.185;0.001;0.173;0.001;0.002	0.78490	.;T;D;T;D;D	0.014;0.132;0.014;0.135;0.023;0.105	0.62352	D;T;D;T;D;T	.;.;.;0.996;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.851;.;0.997	0.86255	.;.;.;P;.;D	0.000068	0.52346	D	0.000000	0.999986;0.999986;0.999986;0.999986;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	C16S;C16S;C16S;C16S;.	.;.;.;1.95;1.95;1.95	0.52479	.;.;.;M;M;M	-4.51;-4.51;-4.51;-4.51;-4.51;-4.51	0.97672	D;D;D;D;D;D	.;-7.64;-9.07;-8.2;-9.07;-8.06	0.98162	.;D;D;D;D;D	.;.;0.691;0.801;0.794;0.744	0.79696	1.0184	0.97505	D	0.9366	0.97914	D	9	0.9478049;0.9478049;0.9478049;0.9478049;0.9478049;0.9478049	0.94109	D;D;D;D;D;D	0.489039	0.94968	D	.;0.842;0.842;0.842;0.842;0.842	0.95063	0.756;0.756;0.756;0.756;0.756;0.756;	0.88567	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	C16S;C16S;C16S;C16S;C16S;C16S;	Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);	0.640766565566;0.640766565566;0.640766565566;0.640766565566;0.640766565566;0.640766565566	0.63780	.;.;.;.;.;0.9262583413565675	0.92603	.;.;.;.;.;1.29764976787	0.82940	0.799300611019	0.81857	T	.;.;.;.;.;0.825211	0.95768	.;.;.;.;.;D	0.384696	0.89008	D	0.490659	0.94407	D	0.993713200092316	0.84629	D	0.806319;0.791221;0.791221;0.791221;0.806319;0.821518	0.48098	T;T;T;T;T;T	.;.;.;.;.;0.95700103	0.96977	.;.;.;.;.;0.91142994	0.95790	.;.;.;.;.;0.95700103	0.96977	.;.;.;.;.;0.91142994	0.95791	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.2045308491285621	0.27264	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.7128;0.5187;0.7347;0.5006;0.439;0.455	0.74405	P;A;P;A;A;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.481940	0.63625	24.7	3.350764	0.63315	24.5	0.98668184524660396	0.44428	0.89932	0.50726	D	ALL	0.838881	0.75635	D	0.382820978596349	0.60491	4.238571	0.317465473304466	0.56565	3.820079	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	3.416000	0.52463	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.041000	0.14368	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	232718	4.297050e-06	0	0	14128	0.000000e+00	0	0	33676	0.000000e+00	0	0	9678	0.000000e+00	0	1	17800	5.617980e-05	0	0	17990	0.000000e+00	0	0	103720	0.000000e+00	0	0	30008	0.000000e+00	0	1	17800	5.617980e-05	0	1	102436	9.762190e-06	0	1	193790	5.160220e-06	0	1	222042	4.503650e-06	0	1	227616	4.393360e-06	0	0	6264	0.000000e+00	0	0	16610	0.000000e+00	0	0	2230	0.000000e+00	0	1	8694	1.150220e-04	0	0	10938	0.000000e+00	0	0	40638	0.000000e+00	0	0	15284	0.000000e+00	0	1	8694	1.150220e-04	0	0	14090	0.000000e+00	0	0	29628	0.000000e+00	0	0	5884	0.000000e+00	0	1	12898	7.753140e-05	0	0	14028	0.000000e+00	0	0	82734	0.000000e+00	0	0	30002	0.000000e+00	0	1	12898	7.753140e-05	0	0	13130	0.000000e+00	0	0	33428	0.000000e+00	0	0	9322	0.000000e+00	0	1	17272	5.789720e-05	0	0	17980	0.000000e+00	0	0	95646	0.000000e+00	0	0	29934	0.000000e+00	0	1	17272	5.789720e-05	0	0	10636	0.000000e+00	0	0	33558	0.000000e+00	0	0	9628	0.000000e+00	0	1	17796	5.619240e-05	0	0	17988	0.000000e+00	0	0	102352	0.000000e+00	0	0	30008	0.000000e+00	0	1	17796	5.619240e-05	0	.	1	152232	6.568920e-06	0	1	5190	1.926780e-04	0	0	41468	0.000000e+00	0	0	912	0.000000e+00	0	0	15284	0.000000e+00	0	0	3472	0.000000e+00	0	1	5190	1.926780e-04	0	0	10628	0.000000e+00	0	0	316	0.000000e+00	0	0	68032	0.000000e+00	0	0	4836	0.000000e+00	0	0	32916	0.000000e+00	0	1	134814	7.417630e-06	0	1	147982	6.757580e-06	0	0	80790	0.000000e+00	0	0	9100	0.000000e+00	0	0	60	0.000000e+00	0	0	4690	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5498	0.000000e+00	0	0	246	0.000000e+00	0	0	6852	0.000000e+00	0	0	3114	0.000000e+00	0	0	32492	0.000000e+00	0	0	862	0.000000e+00	0	0	14838	0.000000e+00	0	0	3388	0.000000e+00	0	1	5190	1.926780e-04	0	0	6988	0.000000e+00	0	0	310	0.000000e+00	0	0	63908	0.000000e+00	0	0	4834	0.000000e+00	0	0	41146	0.000000e+00	0	0	912	0.000000e+00	0	0	15096	0.000000e+00	0	0	3302	0.000000e+00	0	1	4954	2.018570e-04	0	0	10628	0.000000e+00	0	0	304	0.000000e+00	0	0	64812	0.000000e+00	0	0	4804	0.000000e+00	0	0	24844	0.000000e+00	0	0	112	0.000000e+00	0	0	12910	0.000000e+00	0	0	998	0.000000e+00	0	0	3748	0.000000e+00	0	0	10536	0.000000e+00	0	0	272	0.000000e+00	0	0	21042	0.000000e+00	0	0	4808	0.000000e+00	0	0	9690	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14050	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094683	C	T	C	Y	.	16	31106004	16	31013505	16;16;16;16;16;16	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.47G>A;c.47G>A;c.47G>A;c.47G>A;c.47G>A	.;p.C16Y;p.C16Y;p.C16Y;p.C16Y;p.C16Y	c.47G>A;c.47G>A;c.47G>A;c.47G>A;c.47G>A;c.47G>A	p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr	c.47G>A;c.47G>A;c.47G>A;c.47G>A;c.47G>A;c.47G>A	p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr;p.Cys16Tyr	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGC;TGC;TGC;TGC;TGC;TGC	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.007;0.007;0.006;0.01;0.013	0.61437	.;D;D;D;D;D	0.09;0.003;0.071;0.005;0.121;0.005	0.76473	T;D;T;D;T;D	.;.;.;0.993;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.769;.;0.998	0.88582	.;.;.;P;.;D	0.000068	0.52346	D	0.000000	0.999993;0.999993;0.999993;0.999993;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	C16Y;C16Y;C16Y;C16Y;.	.;.;.;2.92;2.92;2.92	0.84325	.;.;.;M;M;M	-4.8;-4.8;-4.8;-4.8;-4.8;-4.8	0.98169	D;D;D;D;D;D	.;-8.37;-9.86;-9.21;-9.66;-8.66	0.98712	.;D;D;D;D;D	.;.;0.698;0.826;0.797;0.832	0.82761	1.0833	0.98991	D	0.9654	0.98897	D	9	0.9771249;0.9771249;0.9771249;0.9771249;0.9771249;0.9771249	0.97529	D;D;D;D;D;D	0.545511	0.95787	D	.;0.832;0.832;0.832;0.832;0.832	0.94691	0.82;0.82;0.82;0.82;0.82;0.82;	0.93328	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	C16Y;C16Y;C16Y;C16Y;C16Y;C16Y;	Loss of catalytic residue at L17 (P = 0.011);Loss of catalytic residue at L17 (P = 0.011);Loss of catalytic residue at L17 (P = 0.011);Loss of catalytic residue at L17 (P = 0.011);Loss of catalytic residue at L17 (P = 0.011);Loss of catalytic residue at L17 (P = 0.011);	0.720694500034;0.720694500034;0.720694500034;0.720694500034;0.720694500034;0.720694500034	0.71823	.;.;.;.;.;0.9752127989756995	0.97511	.;.;.;.;.;1.54232769698	0.87737	0.864194869995	0.91729	D	.;.;.;.;.;0.947433	0.99218	.;.;.;.;.;D	0.516134	0.94792	D	0.503614	0.94716	D	0.998305082321167	0.93779	D	0.875013;0.874313;0.874313;0.874313;0.875013;0.875612	0.58729	D;D;D;D;D;D	.;.;.;.;.;0.9829928	0.99329	.;.;.;.;.;0.9405677	0.97805	.;.;.;.;.;0.9829928	0.99330	.;.;.;.;.;0.9405677	0.97805	.;.;.;-5.902;-6.141;-5.692	0.74603	.;.;.;T;T;T	.;.;.;.;.;0.7077918256212332	0.78761	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9214;0.9276;0.8697;0.8035;0.7026;0.8878	0.84812	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.555607	0.65533	24.9	3.522792	0.67706	25.1	0.97519099734741876	0.34395	0.92108	0.54962	D	ALL	0.864422	0.78322	D	0.466290674953169	0.65134	4.78433	0.368119971622506	0.59606	4.13997	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	3.416000	0.52463	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.041000	0.14368	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094684	A	G	C	R	rs763546199	16	31106005	16	31013506	16;16;16;16;16;16	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.46T>C;c.46T>C;c.46T>C;c.46T>C;c.46T>C	.;p.C16R;p.C16R;p.C16R;p.C16R;p.C16R	c.46T>C;c.46T>C;c.46T>C;c.46T>C;c.46T>C;c.46T>C	p.Cys16Arg;p.Cys16Arg;p.Cys16Arg;p.Cys16Arg;p.Cys16Arg;p.Cys16Arg	c.46T>C;c.46T>C;c.46T>C;c.46T>C;c.46T>C;c.46T>C	p.Cys16Arg;p.Cys16Arg;p.Cys16Arg;p.Cys16Arg;p.Cys16Arg;p.Cys16Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGC;TGC;TGC;TGC;TGC;TGC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.001;0.001;0.001;0.001;0.001	0.78490	.;D;D;D;D;D	0.005;0.007;0.005;0.007;0.008;0.007	0.72224	D;D;D;D;D;D	.;.;.;0.999;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.952;.;0.998	0.88582	.;.;.;D;.;D	0.000068	0.52346	D	0.000000	1;1;1;1;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	C16R;C16R;C16R;C16R;.	.;.;.;2.92;2.92;2.92	0.84325	.;.;.;M;M;M	-4.79;-4.79;-4.79;-4.79;-4.79;-4.79	0.98155	D;D;D;D;D;D	.;-9.36;-11.0;-10.25;-11.03;-9.9	0.99325	.;D;D;D;D;D	.;.;0.774;0.854;0.837;0.881	0.87917	1.0937	0.99390	D	0.9632	0.98821	D	9	0.97034824;0.97034824;0.97034824;0.97034824;0.97034824;0.97034824	0.96618	D;D;D;D;D;D	0.711648	0.97655	D	.;0.877;0.877;0.877;0.877;0.877	0.96354	0.765;0.765;0.765;0.765;0.765;0.765;	0.89293	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	C16R;C16R;C16R;C16R;C16R;C16R;	Gain of MoRF binding (P = 2e-04);Gain of MoRF binding (P = 2e-04);Gain of MoRF binding (P = 2e-04);Gain of MoRF binding (P = 2e-04);Gain of MoRF binding (P = 2e-04);Gain of MoRF binding (P = 2e-04);	0.841246646516;0.841246646516;0.841246646516;0.841246646516;0.841246646516;0.841246646516	0.83973	.;.;.;.;.;0.9888620561812487	0.98880	.;.;.;.;.;1.57986739276	0.88370	0.855355918407	0.90420	D	.;.;.;.;.;0.932677	0.98874	.;.;.;.;.;D	0.530609	0.95178	D	0.524407	0.95106	D	0.999635696411133	0.98254	D	0.79842;0.79802;0.79802;0.79802;0.79842;0.79972	0.44511	T;T;T;T;T;T	.;.;.;.;.;0.98863846	0.99691	.;.;.;.;.;0.98178697	0.99862	.;.;.;.;.;0.98863846	0.99691	.;.;.;.;.;0.98178697	0.99862	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;0.7465952578758677	0.82870	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.9779;0.9705;0.9522;0.9056;0.8615;0.9577	0.90737	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.813454	0.72599	25.9	3.496425	0.67016	25.0	0.9881332395061172	0.46655	0.93252	0.57722	D	ALL	0.859703	0.77742	D	0.508528796513087	0.67592	5.102315	0.389623121455434	0.60925	4.285695	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.198000	0.58217	.	.	0.691000	0.84096	0.998000	0.41325	1.000000	0.68203	0.047000	0.14932	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	8.307e-06	1	1.188e-05	0	0	0	0	0	0	0	0	1	2.159e-05	0	0	1	9.471e-06	1	1.323e-05	0	0	0	0	0	0	0	0	1	2.549e-05	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	233610	4.280640e-06	0	0	14192	0.000000e+00	0	0	33780	0.000000e+00	0	0	9684	0.000000e+00	0	0	17850	0.000000e+00	0	0	18226	0.000000e+00	0	1	104104	9.605780e-06	0	0	30044	0.000000e+00	0	1	104104	9.605780e-06	0	1	102852	9.722710e-06	0	0	194448	0.000000e+00	0	1	222876	4.486800e-06	0	1	228478	4.376790e-06	0	0	6312	0.000000e+00	0	0	16660	0.000000e+00	0	0	2230	0.000000e+00	0	0	8728	0.000000e+00	0	0	11090	0.000000e+00	0	1	40746	2.454230e-05	0	0	15304	0.000000e+00	0	1	40746	2.454230e-05	0	0	14154	0.000000e+00	0	0	29732	0.000000e+00	0	0	5886	0.000000e+00	0	0	12942	0.000000e+00	0	0	14200	0.000000e+00	0	0	82960	0.000000e+00	0	0	30038	0.000000e+00	0	.	.	.	.	0	13188	0.000000e+00	0	0	33534	0.000000e+00	0	0	9326	0.000000e+00	0	0	17324	0.000000e+00	0	0	18216	0.000000e+00	0	1	95982	1.041860e-05	0	0	29972	0.000000e+00	0	1	95982	1.041860e-05	0	0	10672	0.000000e+00	0	0	33660	0.000000e+00	0	0	9634	0.000000e+00	0	0	17846	0.000000e+00	0	0	18224	0.000000e+00	0	1	102736	9.733690e-06	0	0	30044	0.000000e+00	0	1	102736	9.733690e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094684	A	T	C	S	.	16	31106005	16	31013506	16;16;16;16;16;16	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.46T>A;c.46T>A;c.46T>A;c.46T>A;c.46T>A	.;p.C16S;p.C16S;p.C16S;p.C16S;p.C16S	c.46T>A;c.46T>A;c.46T>A;c.46T>A;c.46T>A;c.46T>A	p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser	c.46T>A;c.46T>A;c.46T>A;c.46T>A;c.46T>A;c.46T>A	p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser;p.Cys16Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGC;TGC;TGC;TGC;TGC;TGC	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.185;0.001;0.173;0.001;0.002	0.78490	.;T;D;T;D;D	0.014;0.132;0.014;0.135;0.023;0.105	0.62352	D;T;D;T;D;T	.;.;.;0.996;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.851;.;0.997	0.86255	.;.;.;P;.;D	0.000068	0.52346	D	0.000000	0.99997;0.99997;0.99997;0.99997;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	C16S;C16S;C16S;C16S;.	.;.;.;1.95;1.95;1.95	0.52479	.;.;.;M;M;M	-4.51;-4.51;-4.51;-4.51;-4.51;-4.51	0.97672	D;D;D;D;D;D	.;-7.64;-9.07;-8.2;-9.07;-8.06	0.98162	.;D;D;D;D;D	.;.;0.691;0.801;0.794;0.744	0.79696	1.0158	0.97458	D	0.9325	0.97774	D	9	0.95147496;0.95147496;0.95147496;0.95147496;0.95147496;0.95147496	0.94486	D;D;D;D;D;D	0.610484	0.96598	D	.;0.871;0.871;0.871;0.871;0.871	0.96133	0.756;0.756;0.756;0.756;0.756;0.756;	0.88567	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	C16S;C16S;C16S;C16S;C16S;C16S;	Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);Loss of stability (P = 0.0104);	0.633643890239;0.633643890239;0.633643890239;0.633643890239;0.633643890239;0.633643890239	0.63064	.;.;.;.;.;0.9262583275855331	0.92603	.;.;.;.;.;1.29764976787	0.82940	0.799300611019	0.81857	T	.;.;.;.;.;0.825211	0.95768	.;.;.;.;.;D	0.507882	0.94533	D	0.491761	0.94452	D	0.994770228862762	0.86277	D	0.806319;0.791221;0.791221;0.791221;0.806319;0.821518	0.48098	T;T;T;T;T;T	.;.;.;.;.;0.9543727	0.96710	.;.;.;.;.;0.8903596	0.94293	.;.;.;.;.;0.9543727	0.96711	.;.;.;.;.;0.8903596	0.94293	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;0.2045308491285621	0.27264	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.7128;0.5187;0.7347;0.5006;0.439;0.455	0.74405	P;A;P;A;A;A	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.678465	0.68773	25.3	3.380383	0.64055	24.6	0.98649485709581364	0.44164	0.93078	0.57271	D	ALL	0.859703	0.77742	D	0.362841519893487	0.59421	4.121356	0.295060553547765	0.55249	3.688247	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.198000	0.58217	.	.	0.691000	0.84096	0.998000	0.41325	1.000000	0.68203	0.047000	0.14932	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094686	A	C	L	R	.	16	31106007	16	31013508	15;15;15;15;15;15	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.44T>G;c.44T>G;c.44T>G;c.44T>G;c.44T>G	.;p.L15R;p.L15R;p.L15R;p.L15R;p.L15R	c.44T>G;c.44T>G;c.44T>G;c.44T>G;c.44T>G;c.44T>G	p.Leu15Arg;p.Leu15Arg;p.Leu15Arg;p.Leu15Arg;p.Leu15Arg;p.Leu15Arg	c.44T>G;c.44T>G;c.44T>G;c.44T>G;c.44T>G;c.44T>G	p.Leu15Arg;p.Leu15Arg;p.Leu15Arg;p.Leu15Arg;p.Leu15Arg;p.Leu15Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CTT;CTT;CTT;CTT;CTT;CTT	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.001;0.001;0.001;0.001;0.001	0.78490	.;D;D;D;D;D	0.003;0.003;0.003;0.002;0.004;0.003	0.79402	D;D;D;D;D;D	.;.;.;1.0;.;0.999	0.90584	.;.;.;D;.;D	.;.;.;0.999;.;0.999	0.92359	.;.;.;D;.;D	0.000670	0.42516	D	0.000000	0.999894;0.999894;0.999894;0.999894;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	L15R;L15R;L15R;L15R;.	.;.;.;2.755;2.755;2.755	0.80505	.;.;.;M;M;M	-5.0;-5.0;-5.0;-5.0;-5.0;-5.0	0.98525	D;D;D;D;D;D	.;-2.79;-2.9;-3.03;-2.77;-2.48	0.62747	.;D;D;D;D;N	.;.;0.84;0.888;0.875;0.894	0.89353	1.0907	0.99267	D	0.9615	0.98763	D	9	0.96384335;0.96384335;0.96384335;0.96384335;0.96384335;0.96384335	0.95832	D;D;D;D;D;D	0.710051	0.97640	D	.;0.887;0.887;0.887;0.887;0.887	0.96725	0.798;0.798;0.798;0.798;0.798;0.798;	0.91802	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	L15R;L15R;L15R;L15R;L15R;L15R;	Gain of MoRF binding (P = 0.004);Gain of MoRF binding (P = 0.004);Gain of MoRF binding (P = 0.004);Gain of MoRF binding (P = 0.004);Gain of MoRF binding (P = 0.004);Gain of MoRF binding (P = 0.004);	0.836179551335;0.836179551335;0.836179551335;0.836179551335;0.836179551335;0.836179551335	0.83462	.;.;.;.;.;0.9789939945344968	0.97890	.;.;.;.;.;0.856855166878	0.68779	0.702115297318	0.67450	T	.;.;.;.;.;0.913327	0.98385	.;.;.;.;.;D	0.486375	0.93906	D	0.460867	0.93829	D	0.949847459793091	0.63204	D	0.682432;0.684632;0.684632;0.680832;0.684632;0.679332	0.29288	T;T;T;T;T;T	.;.;.;.;.;0.8683684	0.88733	.;.;.;.;.;0.7735818	0.86637	.;.;.;.;.;0.8683684	0.88735	.;.;.;.;.;0.7735818	0.86638	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;0.6639792452426025	0.73791	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;P	.;.;.;.;.;P	.;.;.;.;.;P	0.8937;0.8624;0.7587;0.7684;0.6124;0.8243	0.82330	P;P;P;P;P;P	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.662477	0.68338	25.3	3.523440	0.67706	25.1	0.99547907684546766	0.70961	0.95831	0.66340	D	ALL	0.852807	0.76972	D	0.547772154978051	0.69948	5.429963	0.433345312353998	0.63654	4.603567	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.614000	0.60886	.	.	0.691000	0.84096	0.994000	0.38300	1.000000	0.68203	0.058000	0.15825	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094687	G	C	L	V	rs2057316510	16	31106008	16	31013509	15;15;15;15;15;15	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.43C>G;c.43C>G;c.43C>G;c.43C>G;c.43C>G	.;p.L15V;p.L15V;p.L15V;p.L15V;p.L15V	c.43C>G;c.43C>G;c.43C>G;c.43C>G;c.43C>G;c.43C>G	p.Leu15Val;p.Leu15Val;p.Leu15Val;p.Leu15Val;p.Leu15Val;p.Leu15Val	c.43C>G;c.43C>G;c.43C>G;c.43C>G;c.43C>G;c.43C>G	p.Leu15Val;p.Leu15Val;p.Leu15Val;p.Leu15Val;p.Leu15Val;p.Leu15Val	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CTT;CTT;CTT;CTT;CTT;CTT	1;1;1;1;1;1	0;0;0;0;0;0	G	G/G	G/G	G/G	G/G	.;0.304;0.312;0.3;0.356;0.249	0.17183	.;T;T;T;T;T	0.186;0.41;0.237;0.196;0.31;0.266	0.28860	T;T;T;T;T;T	.;.;.;0.998;.;0.997	0.73220	.;.;.;D;.;D	.;.;.;0.996;.;0.997	0.86255	.;.;.;D;.;D	0.000670	0.42516	D	0.000000	0.999178;0.999178;0.999178;0.999178;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	L15V;L15V;L15V;L15V;.	.;.;.;1.515;1.515;1.515	0.38264	.;.;.;L;L;L	-4.86;-4.86;-4.86;-4.86;-4.86;-4.86	0.98263	D;D;D;D;D;D	.;-1.31;-1.15;-1.51;-1.05;-1.18	0.36787	.;N;N;N;N;N	.;.;0.361;0.407;0.416;0.366	0.45615	1.0268	0.97657	D	0.9422	0.98105	D	9	0.7098017;0.7098017;0.7098017;0.7098017;0.7098017;0.7098017	0.72970	D;D;D;D;D;D	0.355301	0.92374	D	.;0.567;0.567;0.567;0.567;0.567	0.82346	0.68;0.68;0.68;0.68;0.68;0.68;	0.81788	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	L15V;L15V;L15V;L15V;L15V;L15V;	Gain of MoRF binding (P = 0.1282);Gain of MoRF binding (P = 0.1282);Gain of MoRF binding (P = 0.1282);Gain of MoRF binding (P = 0.1282);Gain of MoRF binding (P = 0.1282);Gain of MoRF binding (P = 0.1282);	0.700363075419;0.700363075419;0.700363075419;0.700363075419;0.700363075419;0.700363075419	0.69776	.;.;.;.;.;0.8628345752006309	0.86247	.;.;.;.;.;1.13197071687	0.78652	0.59284645319	0.51896	T	.;.;.;.;.;0.630716	0.88552	.;.;.;.;.;D	0.167387	0.70884	D	0.00266381	0.70509	D	0.901585161685944	0.55435	D	0.823018;0.824218;0.824218;0.822818;0.824218;0.821518	0.48580	T;T;T;T;T;T	.;.;.;.;.;0.5125108	0.67825	.;.;.;.;.;0.4333024	0.66887	.;.;.;.;.;0.5125108	0.67826	.;.;.;.;.;0.4333024	0.66888	.;.;.;-3.811;-3.829;-4.523	0.56265	.;.;.;T;T;T	.;.;.;.;.;0.13189783970746732	0.14014	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1671;0.1568;0.1878;0.1837;0.1404;0.1178	0.40489	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.430611	0.39718	22.2	2.835087	0.51051	23.2	0.99239033765833962	0.56469	0.77501	0.38112	D	ALL	0.370346	0.45675	N	0.343020265828932	0.58371	4.009007	0.285536592327594	0.54693	3.633637	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	2.993000	0.49114	.	.	0.618000	0.50648	0.995000	0.38783	1.000000	0.68203	0.062000	0.16114	0.0:0.0:1.0:0.0	14.878	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0	6962	0	0	84	0	0	84	0	0	2210	0	0	146	0	0	610	0	0	24	0	0	94	0	0	466	0	0	2294	0	0	108	0	0	10680	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094690	C	G	A	P	rs993371943	16	31106011	16	31013512	14;14;14;14;14;14	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.40G>C;c.40G>C;c.40G>C;c.40G>C;c.40G>C	.;p.A14P;p.A14P;p.A14P;p.A14P;p.A14P	c.40G>C;c.40G>C;c.40G>C;c.40G>C;c.40G>C;c.40G>C	p.Ala14Pro;p.Ala14Pro;p.Ala14Pro;p.Ala14Pro;p.Ala14Pro;p.Ala14Pro	c.40G>C;c.40G>C;c.40G>C;c.40G>C;c.40G>C;c.40G>C	p.Ala14Pro;p.Ala14Pro;p.Ala14Pro;p.Ala14Pro;p.Ala14Pro;p.Ala14Pro	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GCT;GCT;GCT;GCT;GCT;GCT	1;1;1;1;1;1	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.08;0.013;0.013;0.031;0.128	0.53900	.;T;D;D;D;T	0.026;0.073;0.022;0.06;0.034;0.213	0.57587	D;T;D;T;D;T	.;.;.;0.999;.;0.999	0.77913	.;.;.;D;.;D	.;.;.;0.921;.;0.988	0.77976	.;.;.;D;.;D	0.000204	0.47681	D	0.000000	1;0.93265;0.93265;0.93265;0.93265	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;A14P;A14P;A14P;A14P	.;.;.;2.175;2.175;2.175	0.60977	.;.;.;M;M;M	-4.88;-4.88;-4.88;-4.88;-4.88;-4.88	0.98296	D;D;D;D;D;D	.;-2.36;-2.65;-2.69;-2.82;-2.56	0.59545	.;N;D;D;D;D	.;.;0.732;0.742;0.719;0.751	0.75009	1.0014	0.97211	D	0.9426	0.98119	D	9	0.89056045;0.89056045;0.89056045;0.89056045;0.89056045;0.89056045	0.88396	D;D;D;D;D;D	0.617745	0.96681	D	.;0.770;0.770;0.770;0.770;0.770	0.92253	0.761;0.761;0.761;0.761;0.761;0.761;	0.88972	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	A14P;A14P;A14P;A14P;A14P;A14P;	Loss of helix (P = 0.0444);Loss of helix (P = 0.0444);Loss of helix (P = 0.0444);Loss of helix (P = 0.0444);Loss of helix (P = 0.0444);Loss of helix (P = 0.0444);	0.686322331401;0.686322331401;0.686322331401;0.686322331401;0.686322331401;0.686322331401	0.68363	.;.;.;.;.;0.8764633824200021	0.87613	.;.;.;.;.;1.26608907093	0.82163	0.564990341663	0.47970	T	.;.;.;.;.;0.796988	0.94783	.;.;.;.;.;D	0.294441	0.82518	D	0.185168	0.82293	D	0.979336321353912	0.72779	D	0.808919;0.812119;0.810019;0.805419;0.812119;0.815518	0.47040	T;T;T;T;T;T	.;.;.;.;.;0.90179086	0.91544	.;.;.;.;.;0.7925921	0.87807	.;.;.;.;.;0.90179086	0.91545	.;.;.;.;.;0.7925921	0.87807	.;.;.;-3.663;-3.405;-4.659	0.58755	.;.;.;T;T;T	.;.;.;.;.;0.3890104379660225	0.48243	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	0.4723;0.3618;0.5038;0.391;0.2825;0.3164	0.64754	A;A;A;A;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.738370	0.46420	22.9	3.569153	0.68905	25.2	0.99571974242124861	0.72440	0.64783	0.32520	D	ALL	0.439443	0.49842	N	0.364800865933651	0.59526	4.132683	0.300198157325219	0.55552	3.71811	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	1.987000	0.40309	.	.	-0.253000	0.07101	0.087000	0.22510	0.987000	0.30940	0.100000	0.18284	0.1943:0.8057:0.0:0.0	10.4416	0.43655	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	152240	1.313720e-05	0	1	5190	1.926780e-04	0	1	41466	2.411610e-05	0	0	912	0.000000e+00	0	0	15280	0.000000e+00	0	0	3472	0.000000e+00	0	1	5190	1.926780e-04	0	0	10630	0.000000e+00	0	0	316	0.000000e+00	0	0	68044	0.000000e+00	0	0	4836	0.000000e+00	0	0	32916	0.000000e+00	0	2	134818	1.483480e-05	0	2	147982	1.351520e-05	0	2	80798	2.475310e-05	0	0	9100	0.000000e+00	0	0	60	0.000000e+00	0	0	4688	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5498	0.000000e+00	0	0	246	0.000000e+00	0	0	6854	0.000000e+00	0	0	3114	0.000000e+00	0	1	32490	3.077870e-05	0	0	862	0.000000e+00	0	0	14834	0.000000e+00	0	0	3388	0.000000e+00	0	1	5190	1.926780e-04	0	0	6988	0.000000e+00	0	0	310	0.000000e+00	0	0	63918	0.000000e+00	0	0	4834	0.000000e+00	0	1	41144	2.430490e-05	0	0	912	0.000000e+00	0	0	15092	0.000000e+00	0	0	3302	0.000000e+00	0	1	4954	2.018570e-04	0	0	10630	0.000000e+00	0	0	304	0.000000e+00	0	0	64816	0.000000e+00	0	0	4804	0.000000e+00	0	1	24840	4.025760e-05	0	0	112	0.000000e+00	0	0	12906	0.000000e+00	0	0	998	0.000000e+00	0	1	3748	2.668090e-04	0	0	10538	0.000000e+00	0	0	272	0.000000e+00	0	0	21056	0.000000e+00	0	0	4808	0.000000e+00	0	0	9690	0	0	114	0	0	86	0	0	2780	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2894	0	0	112	0	0	14046	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094692	A	C	L	R	.	16	31106013	16	31013514	13;13;13;13;13;13	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.38T>G;c.38T>G;c.38T>G;c.38T>G;c.38T>G	.;p.L13R;p.L13R;p.L13R;p.L13R;p.L13R	c.38T>G;c.38T>G;c.38T>G;c.38T>G;c.38T>G;c.38T>G	p.Leu13Arg;p.Leu13Arg;p.Leu13Arg;p.Leu13Arg;p.Leu13Arg;p.Leu13Arg	c.38T>G;c.38T>G;c.38T>G;c.38T>G;c.38T>G;c.38T>G	p.Leu13Arg;p.Leu13Arg;p.Leu13Arg;p.Leu13Arg;p.Leu13Arg;p.Leu13Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CTC;CTC;CTC;CTC;CTC;CTC	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.035;0.006;0.008;0.011;0.056	0.61437	.;D;D;D;D;T	0.017;0.049;0.012;0.024;0.014;0.087	0.63918	D;D;D;D;D;T	.;.;.;0.999;.;0.878	0.77913	.;.;.;D;.;P	.;.;.;0.952;.;0.712	0.69102	.;.;.;D;.;P	0.084952	0.20668	N	0.353403	0.912037;0.912037;0.912037;0.912037;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	L13R;L13R;L13R;L13R;.	.;.;.;2.34;2.34;2.34	0.67151	.;.;.;M;M;M	-4.92;-4.92;-4.92;-4.92;-4.92;-4.92	0.98371	D;D;D;D;D;D	.;-2.35;-2.65;-2.59;-2.68;-2.26	0.57275	.;N;D;D;D;N	.;.;0.611;0.614;0.626;0.658	0.66787	1.0011	0.97206	D	0.9343	0.97836	D	9	0.76201475;0.76201475;0.76201475;0.76201475;0.76201475;0.76201475	0.76418	D;D;D;D;D;D	0.694106	0.97486	D	.;0.696;0.696;0.696;0.696;0.696	0.89007	0.517;0.517;0.517;0.517;0.517;0.517;	0.61763	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	L13R;L13R;L13R;L13R;L13R;L13R;	Gain of MoRF binding (P = 0.019);Gain of MoRF binding (P = 0.019);Gain of MoRF binding (P = 0.019);Gain of MoRF binding (P = 0.019);Gain of MoRF binding (P = 0.019);Gain of MoRF binding (P = 0.019);	0.82471854896;0.82471854896;0.82471854896;0.82471854896;0.82471854896;0.82471854896	0.82306	.;.;.;.;.;0.9064351851252557	0.90616	.;.;.;.;.;1.29156118664	0.82799	0.664928138256	0.62113	T	.;.;.;.;.;0.808065	0.95174	.;.;.;.;.;D	0.221294	0.75899	D	0.0800969	0.75583	D	0.974477469921112	0.70524	D	0.832517;0.832517;0.839916;0.839916;0.839916;0.839916	0.51465	T;T;T;T;T;T	.;.;.;.;.;0.5162883	0.68046	.;.;.;.;.;0.361846	0.61601	.;.;.;.;.;0.5162883	0.68047	.;.;.;.;.;0.361846	0.61600	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;0.2590756878710106	0.34999	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.4032;0.1638;0.3566;0.1475;0.2233;0.2243	0.59755	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.381405	0.61062	24.3	3.720007	0.73036	25.9	0.99633256566096717	0.76203	0.85381	0.44508	D	ALL	0.575425	0.57782	D	0.323214977162914	0.57340	3.901163	0.296343579191158	0.55326	3.695732	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	1.958000	0.40027	.	.	0.691000	0.84096	0.908000	0.31627	0.996000	0.32793	0.404000	0.26872	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094693	G	T	L	I	.	16	31106014	16	31013515	13;13;13;13;13;13	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.37C>A;c.37C>A;c.37C>A;c.37C>A;c.37C>A	.;p.L13I;p.L13I;p.L13I;p.L13I;p.L13I	c.37C>A;c.37C>A;c.37C>A;c.37C>A;c.37C>A;c.37C>A	p.Leu13Ile;p.Leu13Ile;p.Leu13Ile;p.Leu13Ile;p.Leu13Ile;p.Leu13Ile	c.37C>A;c.37C>A;c.37C>A;c.37C>A;c.37C>A;c.37C>A	p.Leu13Ile;p.Leu13Ile;p.Leu13Ile;p.Leu13Ile;p.Leu13Ile;p.Leu13Ile	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CTC;CTC;CTC;CTC;CTC;CTC	1;1;1;1;1;1	0;0;0;0;0;0	G	G/G	G/G	G/G	G/G	.;0.213;0.118;0.16;0.21;0.166	0.28148	.;T;T;T;T;T	0.28;0.281;0.295;0.123;0.368;0.287	0.35582	T;T;T;T;T;T	.;.;.;0.975;.;0.013	0.58077	.;.;.;D;.;B	.;.;.;0.672;.;0.041	0.53180	.;.;.;P;.;B	0.084952	0.20668	N	0.353403	1;0.912725;0.912725;0.912725;0.912725	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;L13I;L13I;L13I;L13I	.;.;.;1.535;1.535;1.535	0.38868	.;.;.;L;L;L	-4.79;-4.79;-4.79;-4.79;-4.79;-4.79	0.98155	D;D;D;D;D;D	.;-0.41;-0.2;-0.4;-0.13;-0.23	0.14000	.;N;N;N;N;N	.;.;0.176;0.183;0.202;0.187	0.22357	0.6435	0.92461	D	0.8702	0.95684	D	9	0.30362004;0.30362004;0.30362004;0.30362004;0.30362004;0.30362004	0.47892	T;T;T;T;T;T	0.291184	0.90569	D	.;0.396;0.396;0.396;0.396;0.396	0.71084	0.423;0.423;0.423;0.423;0.423;0.423;	0.46693	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	L13I;L13I;L13I;L13I;L13I;L13I;	Gain of MoRF binding (P = 0.191);Gain of MoRF binding (P = 0.191);Gain of MoRF binding (P = 0.191);Gain of MoRF binding (P = 0.191);Gain of MoRF binding (P = 0.191);Gain of MoRF binding (P = 0.191);	0.424789488895;0.424789488895;0.424789488895;0.424789488895;0.424789488895;0.424789488895	0.42097	.;.;.;.;.;0.5790608997283333	0.57835	.;.;.;.;.;0.591853979123	0.54606	0.605465650558	0.53676	T	.;.;.;.;.;0.447347	0.78965	.;.;.;.;.;T	0.0935565	0.63587	D	-0.103389	0.63135	T	0.632862329483032	0.37737	D	0.751925;0.751925;0.760024;0.760024;0.760024;0.760024	0.38453	T;T;T;T;T;T	.;.;.;.;.;0.14555891	0.33362	.;.;.;.;.;0.100687906	0.24083	.;.;.;.;.;0.14555891	0.33361	.;.;.;.;.;0.100687906	0.24082	.;.;.;-5.331;-5.948;-5.673	0.73277	.;.;.;T;T;T	.;.;.;.;.;0.13150839844812934	0.13936	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1298;0.123;0.1753;0.1468;0.13;0.1277	0.38354	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.319131	0.19257	14.52	1.845155	0.29898	18.54	0.98552329026466901	0.42858	0.78602	0.38804	D	ALL	0.291700	0.40276	N	-0.189103682477839	0.33587	1.907215	-0.154972506159024	0.33217	1.897841	0.999999999999855	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	2.6	0.30173	0.834000	0.27171	.	.	0.618000	0.50648	0.970000	0.34288	0.679000	0.26109	0.564000	0.30507	0.092:0.1674:0.7406:0.0	7.5179	0.26781	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094698	A	C	V	G	.	16	31106019	16	31013520	11;11;11;11;11;11	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.32T>G;c.32T>G;c.32T>G;c.32T>G;c.32T>G	.;p.V11G;p.V11G;p.V11G;p.V11G;p.V11G	c.32T>G;c.32T>G;c.32T>G;c.32T>G;c.32T>G;c.32T>G	p.Val11Gly;p.Val11Gly;p.Val11Gly;p.Val11Gly;p.Val11Gly;p.Val11Gly	c.32T>G;c.32T>G;c.32T>G;c.32T>G;c.32T>G;c.32T>G	p.Val11Gly;p.Val11Gly;p.Val11Gly;p.Val11Gly;p.Val11Gly;p.Val11Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GTG;GTG;GTG;GTG;GTG;GTG	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.074;0.071;0.061;0.06;0.057	0.37966	.;T;T;T;T;T	0.074;0.048;0.068;0.017;0.091;0.09	0.60337	T;D;T;D;T;T	.;.;.;0.949;.;0.085	0.53761	.;.;.;P;.;B	.;.;.;0.406;.;0.091	0.44683	.;.;.;B;.;B	0.475393	0.12228	N	0.702414	0.999978;0.999978;0.999978;0.999978;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	V11G;V11G;V11G;V11G;.	.;.;.;1.54;1.54;1.54	0.38927	.;.;.;L;L;L	-4.79;-4.79;-4.79;-4.79;-4.79;-4.79	0.98155	D;D;D;D;D;D	.;-2.46;-2.62;-2.55;-2.59;-2.33	0.56301	.;N;D;D;D;N	.;.;0.406;0.263;0.262;0.314	0.44666	0.4472	0.89793	D	0.8568	0.95231	D	9	0.5368574;0.5368574;0.5368574;0.5368574;0.5368574;0.5368574	0.63496	D;D;D;D;D;D	0.469081	0.94648	D	.;0.558;0.558;0.558;0.558;0.558	0.81831	0.659;0.659;0.659;0.659;0.659;0.659;	0.79689	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	V11G;V11G;V11G;V11G;V11G;V11G;	Gain of disorder (P = 0.0357);Gain of disorder (P = 0.0357);Gain of disorder (P = 0.0357);Gain of disorder (P = 0.0357);Gain of disorder (P = 0.0357);Gain of disorder (P = 0.0357);	0.756260990155;0.756260990155;0.756260990155;0.756260990155;0.756260990155;0.756260990155	0.75404	.;.;.;.;.;0.7466074299192744	0.74606	.;.;.;.;.;0.606692958991	0.55509	0.542287170887	0.44769	T	.;.;.;.;.;0.704477	0.91519	.;.;.;.;.;D	0.159197	0.70125	D	-0.00910055	0.69743	D	0.881456017494202	0.53152	D	0.70353;0.70353;0.70353;0.70353;0.708229;0.69823	0.31875	T;T;T;T;T;T	.;.;.;.;.;0.36890858	0.58504	.;.;.;.;.;0.29942077	0.55976	.;.;.;.;.;0.36890858	0.58504	.;.;.;.;.;0.29942077	0.55975	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;0.2507743942069671	0.33939	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	.;.;.;.;.;B	0.1073;0.0749;0.1526;0.0901;0.0831;0.0702	0.33755	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.870895	0.28118	18.26	2.150830	0.36087	21.0	0.98518093861219658	0.42434	0.54912	0.29733	D	ALL	0.319073	0.42258	N	-0.538462041618383	0.20847	1.102052	-0.569139747130726	0.20299	1.093056	0.99999999999963	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-2.35	0.06302	-0.223000	0.09182	.	.	0.691000	0.84096	0.332000	0.25606	0.000000	0.08366	0.822000	0.38733	0.3888:0.0:0.6112:0.0	10.2896	0.42769	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094698	A	T	V	E	.	16	31106019	16	31013520	11;11;11;11;11;11	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.32T>A;c.32T>A;c.32T>A;c.32T>A;c.32T>A	.;p.V11E;p.V11E;p.V11E;p.V11E;p.V11E	c.32T>A;c.32T>A;c.32T>A;c.32T>A;c.32T>A;c.32T>A	p.Val11Glu;p.Val11Glu;p.Val11Glu;p.Val11Glu;p.Val11Glu;p.Val11Glu	c.32T>A;c.32T>A;c.32T>A;c.32T>A;c.32T>A;c.32T>A	p.Val11Glu;p.Val11Glu;p.Val11Glu;p.Val11Glu;p.Val11Glu;p.Val11Glu	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GTG;GTG;GTG;GTG;GTG;GTG	2;2;2;2;2;2	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.222;0.328;0.325;0.33;0.287	0.18823	.;T;T;T;T;T	0.525;0.498;0.483;0.217;0.593;0.585	0.26145	T;T;T;T;T;T	.;.;.;0.949;.;0.007	0.53761	.;.;.;P;.;B	.;.;.;0.649;.;0.009	0.52426	.;.;.;P;.;B	0.475393	0.12228	N	0.702414	0.931093;0.931093;0.931093;0.931093;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	V11E;V11E;V11E;V11E;.	.;.;.;1.74;1.74;1.74	0.45129	.;.;.;L;L;L	-4.79;-4.79;-4.79;-4.79;-4.79;-4.79	0.98155	D;D;D;D;D;D	.;-0.58;-0.63;-0.85;-0.36;-0.36	0.23156	.;N;N;N;N;N	.;.;0.604;0.448;0.427;0.467	0.62188	0.7675	0.94008	D	0.9143	0.97160	D	9	0.45155373;0.45155373;0.45155373;0.45155373;0.45155373;0.45155373	0.58730	T;T;T;T;T;T	0.520189	0.95434	D	.;0.511;0.511;0.511;0.511;0.511	0.79033	0.667;0.667;0.667;0.667;0.667;0.667;	0.80502	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	V11E;V11E;V11E;V11E;V11E;V11E;	Gain of disorder (P = 0.0268);Gain of disorder (P = 0.0268);Gain of disorder (P = 0.0268);Gain of disorder (P = 0.0268);Gain of disorder (P = 0.0268);Gain of disorder (P = 0.0268);	0.76962436859;0.76962436859;0.76962436859;0.76962436859;0.76962436859;0.76962436859	0.76751	.;.;.;.;.;0.8589609209164469	0.85859	.;.;.;.;.;0.797457833787	0.66099	0.594091773033	0.52071	T	.;.;.;.;.;0.61633	0.87912	.;.;.;.;.;D	0.124779	0.66850	D	-0.0585403	0.66434	T	0.792499601840973	0.45853	D	0.713029;0.713029;0.713029;0.713029;0.716728;0.711029	0.32905	T;T;T;T;T;T	.;.;.;.;.;0.33492666	0.55872	.;.;.;.;.;0.22686988	0.47678	.;.;.;.;.;0.33492666	0.55872	.;.;.;.;.;0.22686988	0.47677	.;.;.;-4.511;-4.949;-2.298	0.63307	.;.;.;T;T;T	.;.;.;.;.;0.485604086632429	0.56343	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	.;.;.;.;.;U	0.3838;0.2486;0.367;0.2794;0.2519;0.1692	0.58651	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.253525	0.18355	14.05	1.606937	0.25612	16.89	0.97126978166667166	0.32482	0.46030	0.27669	N	ALL	0.151639	0.27617	N	-0.430935312679165	0.24392	1.316672	-0.498233175873923	0.22203	1.204778	0.99999999999963	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-2.35	0.06302	-0.223000	0.09182	.	.	0.691000	0.84096	0.332000	0.25606	0.000000	0.08366	0.822000	0.38733	0.3888:0.0:0.6112:0.0	10.2896	0.42769	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094701	C	A	W	L	rs766721996	16	31106022	16	31013523	10;10;10;10;10;10	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.29G>T;c.29G>T;c.29G>T;c.29G>T;c.29G>T	.;p.W10L;p.W10L;p.W10L;p.W10L;p.W10L	c.29G>T;c.29G>T;c.29G>T;c.29G>T;c.29G>T;c.29G>T	p.Trp10Leu;p.Trp10Leu;p.Trp10Leu;p.Trp10Leu;p.Trp10Leu;p.Trp10Leu	c.29G>T;c.29G>T;c.29G>T;c.29G>T;c.29G>T;c.29G>T	p.Trp10Leu;p.Trp10Leu;p.Trp10Leu;p.Trp10Leu;p.Trp10Leu;p.Trp10Leu	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGG;TGG;TGG;TGG;TGG;TGG	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.237;0.039;0.046;0.097;0.1	0.42487	.;T;D;D;T;T	0.088;0.07;0.068;0.055;0.092;0.095	0.46862	T;T;T;T;T;T	.;.;.;0.055;.;0.001	0.22733	.;.;.;B;.;B	.;.;.;0.03;.;0.003	0.21741	.;.;.;B;.;B	0.237029	0.15794	N	0.540328	1;0.943259;0.943259;0.943259;0.943259	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;W10L;W10L;W10L;W10L	.;.;.;2.305;2.305;2.305	0.65957	.;.;.;M;M;M	-4.57;-4.57;-4.57;-4.57;-4.57;-4.57	0.97792	D;D;D;D;D;D	.;-3.2;-3.33;-3.38;-3.21;-2.79	0.66780	.;D;D;D;D;D	.;.;0.397;0.372;0.363;0.354	0.43803	0.3561	0.88432	D	0.7826	0.92617	D	9	0.34379238;0.34379238;0.34379238;0.34379238;0.34379238;0.34379238	0.51385	T;T;T;T;T;T	0.26924	0.89814	D	.;0.386;0.386;0.386;0.386;0.386	0.70276	0.472;0.472;0.472;0.472;0.472;0.472;	0.54699	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	W10L;W10L;W10L;W10L;W10L;W10L;	Loss of loop (P = 0.0374);Loss of loop (P = 0.0374);Loss of loop (P = 0.0374);Loss of loop (P = 0.0374);Loss of loop (P = 0.0374);Loss of loop (P = 0.0374);	0.762971822872;0.762971822872;0.762971822872;0.762971822872;0.762971822872;0.762971822872	0.76081	.;.;.;.;.;0.8843596247260906	0.88403	.;.;.;.;.;0.66186013312	0.58944	0.561425507069	0.47469	T	.;.;.;.;.;0.410329	0.76510	.;.;.;.;.;T	0.172391	0.71343	D	0.00985079	0.70972	D	0.867599070072174	0.51760	D	0.772623;0.772623;0.771423;0.771423;0.772623;0.771423	0.40374	T;T;T;T;T;T	.;.;.;.;.;0.3658301	0.58276	.;.;.;.;.;0.23629291	0.48897	.;.;.;.;.;0.3658301	0.58276	.;.;.;.;.;0.23629291	0.48896	.;.;.;0.0;0.0;-4.726	0.59903	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.1803;0.105;0.2559;0.1566;0.1416;0.1338	0.49068	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.554468	0.42437	22.5	2.838718	0.51145	23.2	0.94374127315104694	0.24742	0.81238	0.40684	D	ALL	0.411792	0.48212	N	-0.454867847117711	0.23576	1.266986	-0.324579530843774	0.27308	1.514327	0.999999999999997	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	3.66	0.41111	1.348000	0.33592	.	.	0.549000	0.26987	0.327000	0.25564	0.047000	0.21741	0.836000	0.39433	0.1935:0.8065:0.0:0.0	10.4313	0.43595	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	234222	4.269450e-06	0	0	14352	0.000000e+00	0	0	33822	0.000000e+00	0	0	9688	0.000000e+00	0	0	17908	0.000000e+00	0	0	18390	0.000000e+00	0	1	104340	9.584050e-06	0	0	30004	0.000000e+00	0	1	104340	9.584050e-06	0	0	103656	0.000000e+00	0	1	195468	5.115930e-06	0	1	223428	4.475710e-06	0	1	229022	4.366390e-06	0	0	6422	0.000000e+00	0	0	16692	0.000000e+00	0	0	2234	0.000000e+00	0	0	8788	0.000000e+00	0	0	11368	0.000000e+00	0	0	41064	0.000000e+00	0	0	15288	0.000000e+00	0	.	.	.	.	0	14314	0.000000e+00	0	0	29776	0.000000e+00	0	0	5894	0.000000e+00	0	0	13028	0.000000e+00	0	0	14522	0.000000e+00	0	1	83390	1.199180e-05	0	0	29998	0.000000e+00	0	1	83390	1.199180e-05	0	0	13346	0.000000e+00	0	0	33584	0.000000e+00	0	0	9320	0.000000e+00	0	0	17388	0.000000e+00	0	0	18380	0.000000e+00	0	1	96154	1.040000e-05	0	0	29928	0.000000e+00	0	1	96154	1.040000e-05	0	0	10800	0.000000e+00	0	0	33708	0.000000e+00	0	0	9640	0.000000e+00	0	0	17904	0.000000e+00	0	0	18388	0.000000e+00	0	1	102928	9.715530e-06	0	0	30004	0.000000e+00	0	1	102928	9.715530e-06	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094702	A	C	W	G	.	16	31106023	16	31013524	10;10;10;10;10;10	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.28T>G;c.28T>G;c.28T>G;c.28T>G;c.28T>G	.;p.W10G;p.W10G;p.W10G;p.W10G;p.W10G	c.28T>G;c.28T>G;c.28T>G;c.28T>G;c.28T>G;c.28T>G	p.Trp10Gly;p.Trp10Gly;p.Trp10Gly;p.Trp10Gly;p.Trp10Gly;p.Trp10Gly	c.28T>G;c.28T>G;c.28T>G;c.28T>G;c.28T>G;c.28T>G	p.Trp10Gly;p.Trp10Gly;p.Trp10Gly;p.Trp10Gly;p.Trp10Gly;p.Trp10Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGG;TGG;TGG;TGG;TGG;TGG	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.096;0.016;0.019;0.029;0.067	0.51853	.;T;D;D;D;T	0.003;0.08;0.004;0.044;0.004;0.102	0.76473	D;T;D;D;D;T	.;.;.;0.974;.;0.322	0.57829	.;.;.;D;.;B	.;.;.;0.736;.;0.163	0.55529	.;.;.;P;.;B	0.237029	0.15794	N	0.540328	0.999937;0.999864;0.999864;0.999864;0.999864	0.51612	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;W10G;W10G;W10G;W10G	.;.;.;2.305;2.305;2.305	0.65957	.;.;.;M;M;M	-4.75;-4.75;-4.75;-4.75;-4.75;-4.75	0.98096	D;D;D;D;D;D	.;-4.01;-4.08;-4.35;-4.21;-3.68	0.76900	.;D;D;D;D;D	.;.;0.5;0.515;0.512;0.539	0.56662	0.3603	0.88497	D	0.8220	0.94015	D	9	0.44774866;0.44774866;0.44774866;0.44774866;0.44774866;0.44774866	0.58504	T;T;T;T;T;T	0.186018	0.85848	D	.;0.563;0.563;0.563;0.563;0.563	0.82118	0.485;0.485;0.485;0.485;0.485;0.485;	0.56780	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	W10G;W10G;W10G;W10G;W10G;W10G;	Gain of disorder (P = 0.0178);Gain of disorder (P = 0.0178);Gain of disorder (P = 0.0178);Gain of disorder (P = 0.0178);Gain of disorder (P = 0.0178);Gain of disorder (P = 0.0178);	0.677309924921;0.677309924921;0.677309924921;0.677309924921;0.677309924921;0.677309924921	0.67457	.;.;.;.;.;0.9051047241726521	0.90483	.;.;.;.;.;0.66186013312	0.58944	0.537873506546	0.44145	T	.;.;.;.;.;0.451798	0.79238	.;.;.;.;.;T	0.193913	0.73326	D	0.0407661	0.72979	D	0.850652873516083	0.50222	D	0.654634;0.654634;0.652935;0.652935;0.654634;0.652935	0.26482	T;T;T;T;T;T	.;.;.;.;.;0.3225702	0.54855	.;.;.;.;.;0.2709861	0.52994	.;.;.;.;.;0.3225702	0.54855	.;.;.;.;.;0.2709861	0.52993	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.1154;0.0553;0.1567;0.0848;0.0767;0.066	0.34667	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.850301	0.27736	18.11	1.581426	0.25202	16.74	0.87947415016455299	0.17601	0.36152	0.25467	N	ALL	0.222557	0.34704	N	-0.51057082383754	0.21736	1.155796	-0.60438403388704	0.19379	1.039525	0.999999999999438	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-1.42	0.08446	0.348000	0.19784	.	.	0.691000	0.84096	0.041000	0.21027	0.000000	0.08366	0.832000	0.39227	0.3686:0.0:0.2763:0.3551	2.5336	0.04422	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase|Vitamin K epoxide reductase;.;Vitamin K epoxide reductase;Vitamin K epoxide reductase|Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094704	C	A	G	V	.	16	31106025	16	31013526	9;9;9;9;9;9	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.26G>T;c.26G>T;c.26G>T;c.26G>T;c.26G>T	.;p.G9V;p.G9V;p.G9V;p.G9V;p.G9V	c.26G>T;c.26G>T;c.26G>T;c.26G>T;c.26G>T;c.26G>T	p.Gly9Val;p.Gly9Val;p.Gly9Val;p.Gly9Val;p.Gly9Val;p.Gly9Val	c.26G>T;c.26G>T;c.26G>T;c.26G>T;c.26G>T;c.26G>T	p.Gly9Val;p.Gly9Val;p.Gly9Val;p.Gly9Val;p.Gly9Val;p.Gly9Val	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GGC;GGC;GGC;GGC;GGC;GGC	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.178;0.035;0.068;0.039;0.11	0.43708	.;T;D;T;D;T	0.054;0.137;0.064;0.043;0.104;0.287	0.49942	T;T;T;D;T;T	.;.;.;1.0;.;1.0	0.90584	.;.;.;D;.;D	.;.;.;1.0;.;0.994	0.97372	.;.;.;D;.;D	0.000177	0.48594	D	0.000000	0.999912;0.999912;0.999912;0.999912;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	G9V;G9V;G9V;G9V;.	.;.;.;2.125;2.125;2.125	0.59049	.;.;.;M;M;M	-4.71;-4.71;-4.71;-4.71;-4.71;-4.71	0.98035	D;D;D;D;D;D	.;-1.51;-1.68;-1.92;-1.66;-1.3	0.44657	.;N;N;N;N;N	.;.;0.623;0.718;0.729;0.755	0.75374	0.9785	0.96835	D	0.9251	0.97524	D	9	0.7588868;0.7588868;0.7588868;0.7588868;0.7588868;0.7588868	0.76192	D;D;D;D;D;D	0.388986	0.93145	D	.;0.646;0.646;0.646;0.646;0.646	0.86586	0.593;0.593;0.593;0.593;0.593;0.593;	0.72247	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	G9V;G9V;G9V;G9V;G9V;G9V;	Loss of disorder (P = 0.0542);Loss of disorder (P = 0.0542);Loss of disorder (P = 0.0542);Loss of disorder (P = 0.0542);Loss of disorder (P = 0.0542);Loss of disorder (P = 0.0542);	0.850100710662;0.850100710662;0.850100710662;0.850100710662;0.850100710662;0.850100710662	0.84866	.;.;.;.;.;0.7295319531102886	0.72898	.;.;.;.;.;1.31374050941	0.83276	0.613283455372	0.54780	T	.;.;.;.;.;0.15779	0.50054	.;.;.;.;.;T	0.326565	0.84930	D	0.231312	0.84733	D	0.989737093448639	0.79956	D	0.915508;0.914708;0.918208;0.918208;0.918208;0.915508	0.70605	D;D;D;D;D;D	.;.;.;.;.;0.5398349	0.69387	.;.;.;.;.;0.33146515	0.59005	.;.;.;.;.;0.5398349	0.69388	.;.;.;.;.;0.33146515	0.59004	.;.;.;-3.811;-3.829;-4.523	0.56265	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.3;0.1768;0.2909;0.2228;0.2439;0.3213	0.54602	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.488912	0.63809	24.7	3.497074	0.67044	25.0	0.994300946951586	0.64227	0.88051	0.47813	D	ALL	0.770502	0.70543	D	0.315376428367255	0.56936	3.859414	0.237904231699927	0.51965	3.374623	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	5.114000	0.64486	.	.	0.549000	0.26987	0.957000	0.33433	1.000000	0.68203	0.822000	0.38733	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094705	C	T	G	S	.	16	31106026	16	31013527	9;9;9;9;9;9	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.25G>A;c.25G>A;c.25G>A;c.25G>A;c.25G>A	.;p.G9S;p.G9S;p.G9S;p.G9S;p.G9S	c.25G>A;c.25G>A;c.25G>A;c.25G>A;c.25G>A;c.25G>A	p.Gly9Ser;p.Gly9Ser;p.Gly9Ser;p.Gly9Ser;p.Gly9Ser;p.Gly9Ser	c.25G>A;c.25G>A;c.25G>A;c.25G>A;c.25G>A;c.25G>A	p.Gly9Ser;p.Gly9Ser;p.Gly9Ser;p.Gly9Ser;p.Gly9Ser;p.Gly9Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GGC;GGC;GGC;GGC;GGC;GGC	1;1;1;1;1;1	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.421;0.056;0.191;0.063;0.208	0.38185	.;T;T;T;T;T	0.199;0.371;0.222;0.117;0.351;0.725	0.36365	T;T;T;T;T;T	.;.;.;1.0;.;1.0	0.90584	.;.;.;D;.;D	.;.;.;0.999;.;0.987	0.92359	.;.;.;D;.;D	0.000177	0.48594	D	0.000000	1;0.938499;0.938499;0.938499;0.938499	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;G9S;G9S;G9S;G9S	.;.;.;2.125;2.125;2.125	0.59049	.;.;.;M;M;M	-4.67;-4.67;-4.67;-4.67;-4.67;-4.67	0.97973	D;D;D;D;D;D	.;-0.8;-0.84;-1.07;-0.84;-0.64	0.27876	.;N;N;N;N;N	.;.;0.468;0.587;0.532;0.522	0.60749	0.9407	0.96258	D	0.9151	0.97187	D	9	0.40175948;0.40175948;0.40175948;0.40175948;0.40175948;0.40175948	0.55616	T;T;T;T;T;T	0.377317	0.92889	D	.;0.449;0.449;0.449;0.449;0.449	0.75004	0.475;0.475;0.475;0.475;0.475;0.475;	0.55182	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	G9S;G9S;G9S;G9S;G9S;G9S;	Gain of glycosylation at P8 (P = 0.1009);Gain of glycosylation at P8 (P = 0.1009);Gain of glycosylation at P8 (P = 0.1009);Gain of glycosylation at P8 (P = 0.1009);Gain of glycosylation at P8 (P = 0.1009);Gain of glycosylation at P8 (P = 0.1009);	0.698225102665;0.698225102665;0.698225102665;0.698225102665;0.698225102665;0.698225102665	0.69561	.;.;.;.;.;0.6891917319920934	0.68859	.;.;.;.;.;1.16132611022	0.79496	0.596824467182	0.52456	T	.;.;.;.;.;0.119711	0.44143	.;.;.;.;.;T	0.208162	0.74658	D	0.0612341	0.74327	D	0.983109295368195	0.74897	D	0.928907;0.928407;0.931907;0.931907;0.931907;0.928907	0.74605	D;D;D;D;D;D	.;.;.;.;.;0.35983744	0.57823	.;.;.;.;.;0.23309003	0.48489	.;.;.;.;.;0.35983744	0.57823	.;.;.;.;.;0.23309003	0.48488	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.2038;0.135;0.1932;0.1569;0.1743;0.1721	0.42906	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.017822	0.52424	23.4	2.950293	0.53593	23.5	0.99796035303081299	0.88106	0.69927	0.34383	D	ALL	0.328248	0.42897	N	0.195176550750362	0.50968	3.281868	0.127242479347883	0.45948	2.848998	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	3.290000	0.51461	.	.	0.549000	0.26987	0.953000	0.33222	1.000000	0.68203	0.819000	0.38590	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094708	G	A	P	S	rs200328478	16	31106029	16	31013530	8;8;8;8;8;8	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.22C>T;c.22C>T;c.22C>T;c.22C>T;c.22C>T	.;p.P8S;p.P8S;p.P8S;p.P8S;p.P8S	c.22C>T;c.22C>T;c.22C>T;c.22C>T;c.22C>T;c.22C>T	p.Pro8Ser;p.Pro8Ser;p.Pro8Ser;p.Pro8Ser;p.Pro8Ser;p.Pro8Ser	c.22C>T;c.22C>T;c.22C>T;c.22C>T;c.22C>T;c.22C>T	p.Pro8Ser;p.Pro8Ser;p.Pro8Ser;p.Pro8Ser;p.Pro8Ser;p.Pro8Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	CCT;CCT;CCT;CCT;CCT;CCT	1;1;1;1;1;1	0;0;0;0;0;0	G	G/G	G/G	G/G	G/G	.;0.008;0.004;0.005;0.003;0.005	0.68238	.;D;D;D;D;D	0.0;0.011;0.0;0.013;0.0;0.018	0.92824	D;D;D;D;D;D	.;.;.;1.0;.;1.0	0.90584	.;.;.;D;.;D	.;.;.;0.998;.;0.999	0.92359	.;.;.;D;.;D	0.000215	0.47681	D	0.000000	0.998826;0.998826;0.998826;0.998826;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	P8S;P8S;P8S;P8S;.	.;.;.;2.495;2.495;2.495	0.72670	.;.;.;M;M;M	-4.72;-3.44;-5.3;-5.39;-5.16;-4.88	0.99055	D;D;D;D;D;D	.;-2.58;-2.78;-2.86;-2.96;-2.49	0.61722	.;D;D;D;D;N	.;.;0.457;0.455;0.463;0.523	0.55280	1.0052	0.97276	D	0.9478	0.98297	D	9	0.64735746;0.64735746;0.64735746;0.64735746;0.64735746;0.64735746	0.69403	D;D;D;D;D;D	0.505362	0.95217	D	.;0.676;0.676;0.676;0.676;0.676	0.88061	.;.;.;.;.;.;	.	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	0.686079328405;0.686079328405;0.686079328405;0.686079328405;0.686079328405;0.686079328405	0.68339	.;.;.;.;.;0.8470932086683814	0.84670	.;.;.;.;.;1.17107731969	0.79766	0.57991194725	0.50074	T	.;.;.;.;.;0.512886	0.82814	.;.;.;.;.;D	0.268512	0.80307	D	0.147922	0.80052	D	0.986567974090576	0.77251	D	0.928807;0.928807;0.928807;0.928807;0.928807;0.928807	0.73814	D;D;D;D;D;D	.;.;.;.;.;0.2560972	0.48648	.;.;.;.;.;0.35429463	0.60976	.;.;.;.;.;0.2560972	0.48648	.;.;.;.;.;0.35429463	0.60976	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.2391;0.1277;0.2073;0.1609;0.1707;0.2659	0.50035	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.794902	0.72040	25.8	3.473967	0.66439	24.9	0.99895492591197177	0.96819	0.89795	0.50493	D	ALL	0.681390	0.64476	D	0.290517144975822	0.55666	3.730764	0.233468319461094	0.51713	3.351583	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	5.286000	0.65444	.	.	0.618000	0.50648	1.000000	0.71638	1.000000	0.68203	0.806000	0.37994	0.0:0.0:1.0:0.0	13.1904	0.59129	41	0.97903	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	1	9.92063492063492E-4	0	0.0	.	.	.	.	.	.	.	.	.	.	1	8.312e-06	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	9.476e-06	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1.115e-05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	152236	6.568750e-06	0	1	5192	1.926040e-04	0	0	41468	0.000000e+00	0	0	912	0.000000e+00	0	0	15282	0.000000e+00	0	0	3470	0.000000e+00	0	1	5192	1.926040e-04	0	0	10626	0.000000e+00	0	0	316	0.000000e+00	0	0	68038	0.000000e+00	0	0	4838	0.000000e+00	0	1	32916	3.038040e-05	0	1	134812	7.417740e-06	0	1	147986	6.757400e-06	0	1	80794	1.237720e-05	0	0	9102	0.000000e+00	0	0	60	0.000000e+00	0	0	4690	0.000000e+00	0	0	136	0.000000e+00	0	1	2428	4.118620e-04	0	0	5494	0.000000e+00	0	0	246	0.000000e+00	0	0	6854	0.000000e+00	0	0	3116	0.000000e+00	0	0	32490	0.000000e+00	0	0	862	0.000000e+00	0	0	14836	0.000000e+00	0	0	3386	0.000000e+00	0	1	5192	1.926040e-04	0	0	6984	0.000000e+00	0	0	310	0.000000e+00	0	0	63912	0.000000e+00	0	0	4836	0.000000e+00	0	0	41150	0.000000e+00	0	0	912	0.000000e+00	0	0	15094	0.000000e+00	0	0	3302	0.000000e+00	0	1	4958	2.016940e-04	0	0	10626	0.000000e+00	0	0	304	0.000000e+00	0	0	64810	0.000000e+00	0	0	4806	0.000000e+00	0	0	24842	0.000000e+00	0	0	112	0.000000e+00	0	0	12908	0.000000e+00	0	0	996	0.000000e+00	0	1	3750	2.666670e-04	0	0	10534	0.000000e+00	0	0	272	0.000000e+00	0	0	21050	0.000000e+00	0	0	4810	0.000000e+00	0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094709	G	C	S	R	.	16	31106030	16	31013531	7;7;7;7;7;7	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.21C>G;c.21C>G;c.21C>G;c.21C>G;c.21C>G	.;p.S7R;p.S7R;p.S7R;p.S7R;p.S7R	c.21C>G;c.21C>G;c.21C>G;c.21C>G;c.21C>G;c.21C>G	p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg	c.21C>G;c.21C>G;c.21C>G;c.21C>G;c.21C>G;c.21C>G	p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	3;3;3;3;3;3	2;2;2;2;2;2	G	G/G	G/G	G/G	G/G	.;0.191;0.064;0.07;0.043;0.36	0.41364	.;T;T;T;D;T	0.01;0.246;0.02;0.119;0.02;0.565	0.65728	D;T;D;T;D;T	.;.;.;0.062;.;0.01	0.23277	.;.;.;B;.;B	.;.;.;0.022;.;0.01	0.19653	.;.;.;B;.;B	0.500702	0.11953	N	0.745447	1;0.999319;0.999319;0.999319;0.999319	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S7R;S7R;S7R;S7R	.;.;.;1.7;1.7;1.7	0.43825	.;.;.;L;L;L	-4.1;-3.02;-4.17;-4.56;-4.13;-4.74	0.98081	D;D;D;D;D;D	.;-0.46;-0.14;-0.54;-0.29;-0.22	0.16598	.;N;N;N;N;N	.;.;0.216;0.17;0.186;0.221	0.24758	0.1121	0.84395	D	0.7432	0.91234	D	9	0.13946351;0.13946351;0.13946351;0.13946351;0.13946351;0.13946351	0.26516	T;T;T;T;T;T	0.224104	0.87934	D	.;0.171;0.171;0.171;0.171;0.171	0.43483	0.349;0.349;0.349;0.349;0.349;0.349;	0.34598	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S7R;S7R;S7R;S7R;S7R;S7R;	Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);	0.428169733428;0.428169733428;0.428169733428;0.428169733428;0.428169733428;0.428169733428	0.42434	.;.;.;.;.;0.6947743303400704	0.69418	.;.;.;.;.;0.411865483993	0.41935	0.487967669964	0.37157	T	.;.;.;.;.;0.082008	0.36728	.;.;.;.;.;T	0.0966296	0.63926	D	-0.0989747	0.63477	T	0.149850722280172	0.17092	T	0.631037;0.633437;0.631037;0.633437;0.631037;0.633437	0.24778	T;T;T;T;T;T	.;.;.;.;.;0.1247495	0.29261	.;.;.;.;.;0.096555464	0.22948	.;.;.;.;.;0.1247495	0.29261	.;.;.;.;.;0.096555464	0.22947	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.3885;0.2445;0.4404;0.2689;0.2676;0.266	0.61725	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.887558	0.28428	18.39	1.616895	0.25792	16.95	0.99629090639987472	0.75898	0.73197	0.35808	D	ALL	0.277554	0.39204	N	-0.649891048155514	0.17464	0.8988514	-0.586749446894534	0.19839	1.066186	0.999999999999718	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	1.61	0.22752	1.440000	0.34634	.	.	0.618000	0.50648	0.996000	0.39380	0.000000	0.08366	0.795000	0.37519	0.2945:0.0:0.7055:0.0	6.7764	0.22808	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094709	G	T	S	R	.	16	31106030	16	31013531	7;7;7;7;7;7	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.21C>A;c.21C>A;c.21C>A;c.21C>A;c.21C>A	.;p.S7R;p.S7R;p.S7R;p.S7R;p.S7R	c.21C>A;c.21C>A;c.21C>A;c.21C>A;c.21C>A;c.21C>A	p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg	c.21C>A;c.21C>A;c.21C>A;c.21C>A;c.21C>A;c.21C>A	p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	3;3;3;3;3;3	2;2;2;2;2;2	G	G/G	G/G	G/G	G/G	.;0.191;0.064;0.07;0.043;0.36	0.41364	.;T;T;T;D;T	0.01;0.246;0.02;0.119;0.02;0.565	0.65728	D;T;D;T;D;T	.;.;.;0.062;.;0.01	0.23277	.;.;.;B;.;B	.;.;.;0.022;.;0.01	0.19653	.;.;.;B;.;B	0.500702	0.11953	N	0.745447	1;0.999241;0.999241;0.999241;0.999241	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S7R;S7R;S7R;S7R	.;.;.;1.7;1.7;1.7	0.43825	.;.;.;L;L;L	-4.1;-3.02;-4.17;-4.56;-4.13;-4.74	0.98081	D;D;D;D;D;D	.;-0.46;-0.14;-0.54;-0.29;-0.22	0.16598	.;N;N;N;N;N	.;.;0.216;0.17;0.186;0.221	0.24758	0.1121	0.84395	D	0.7432	0.91234	D	9	0.14045861;0.14045861;0.14045861;0.14045861;0.14045861;0.14045861	0.26698	T;T;T;T;T;T	0.226154	0.88031	D	.;0.164;0.164;0.164;0.164;0.164	0.42212	0.349;0.349;0.349;0.349;0.349;0.349;	0.34598	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S7R;S7R;S7R;S7R;S7R;S7R;	Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);	0.428169733428;0.428169733428;0.428169733428;0.428169733428;0.428169733428;0.428169733428	0.42434	.;.;.;.;.;0.694774316569036	0.69418	.;.;.;.;.;0.411865483993	0.41935	0.487967669964	0.37157	T	.;.;.;.;.;0.082008	0.36728	.;.;.;.;.;T	0.0966395	0.63926	D	-0.0989605	0.63479	T	0.146706210131298	0.16838	T	0.631037;0.633437;0.631037;0.633437;0.631037;0.633437	0.24778	T;T;T;T;T;T	.;.;.;.;.;0.1247495	0.29261	.;.;.;.;.;0.096555464	0.22948	.;.;.;.;.;0.1247495	0.29261	.;.;.;.;.;0.096555464	0.22947	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.3885;0.2445;0.4404;0.2689;0.2676;0.266	0.61725	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.834933	0.27448	17.99	1.581815	0.25202	16.74	0.99637919635441963	0.76449	0.79201	0.39202	D	ALL	0.295229	0.40539	N	-0.649891048155514	0.17464	0.8988514	-0.586749446894534	0.19839	1.066186	0.999999999999718	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	1.61	0.22752	1.440000	0.34634	.	.	0.618000	0.50648	0.996000	0.39380	0.000000	0.08366	0.795000	0.37519	0.2945:0.0:0.7055:0.0	6.7764	0.22808	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094710	C	T	S	N	rs755166588	16	31106031	16	31013532	7;7;7;7;7;7	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.20G>A;c.20G>A;c.20G>A;c.20G>A;c.20G>A	.;p.S7N;p.S7N;p.S7N;p.S7N;p.S7N	c.20G>A;c.20G>A;c.20G>A;c.20G>A;c.20G>A;c.20G>A	p.Ser7Asn;p.Ser7Asn;p.Ser7Asn;p.Ser7Asn;p.Ser7Asn;p.Ser7Asn	c.20G>A;c.20G>A;c.20G>A;c.20G>A;c.20G>A;c.20G>A	p.Ser7Asn;p.Ser7Asn;p.Ser7Asn;p.Ser7Asn;p.Ser7Asn;p.Ser7Asn	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.39;0.22;0.265;0.43;0.655	0.18956	.;T;T;T;T;T	0.287;0.355;0.565;0.438;0.457;0.573	0.21210	T;T;T;T;T;T	.;.;.;0.0;.;0.0	0.02946	.;.;.;B;.;B	.;.;.;0.0;.;0.0	0.01387	.;.;.;B;.;B	0.500702	0.11953	N	0.745447	0.95321;1;1;1;1	0.37820	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S7N;S7N;S7N;S7N	.;.;.;-0.245;-0.245;-0.245	0.03879	.;.;.;N;N;N	-4.09;-3.0;-4.16;-4.55;-4.12;-4.72	0.98051	D;D;D;D;D;D	.;-0.61;-0.23;-0.33;-0.3;-0.21	0.18042	.;N;N;N;N;N	.;.;0.114;0.085;0.09;0.095	0.10198	-0.4932	0.68894	T	0.6404	0.87430	D	9	0.055051237;0.055051237;0.055051237;0.055051237;0.055051237;0.055051237	0.05957	T;T;T;T;T;T	0.057565	0.67010	D	.;0.250;0.250;0.250;0.250;0.250	0.55888	0.294;0.294;0.294;0.294;0.294;0.294;	0.25720	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S7N;S7N;S7N;S7N;S7N;S7N;	Loss of disorder (P = 0.1156);Loss of disorder (P = 0.1156);Loss of disorder (P = 0.1156);Loss of disorder (P = 0.1156);Loss of disorder (P = 0.1156);Loss of disorder (P = 0.1156);	0.299770980665;0.299770980665;0.299770980665;0.299770980665;0.299770980665;0.299770980665	0.29595	.;.;.;.;.;0.5811750427101748	0.58046	.;.;.;.;.;0.343003301115	0.36226	0.484229624271	0.36640	T	.;.;.;.;.;0.072224	0.34401	.;.;.;.;.;T	-0.110775	0.34641	T	-0.396897	0.33746	T	0.0406285547110611	0.03805	T	0.523348;0.539146;0.523348;0.539146;0.523348;0.539146	0.18203	T;T;T;T;T;T	.;.;.;.;.;0.096776545	0.22800	.;.;.;.;.;0.06351476	0.12592	.;.;.;.;.;0.096776545	0.22799	.;.;.;.;.;0.06351476	0.12592	.;.;.;-5.236;-6.09;-2.908	0.74263	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.0733;0.0664;0.123;0.07;0.0643;0.0722	0.25753	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	0.623171	0.10520	7.736	0.241631	0.07688	6.437	0.90333356539124299	0.19598	0.07098	0.13124	N	ALL	0.075632	0.15193	N	-1.51262203335931	0.01766	0.07736019	-1.51948712043194	0.02195	0.1005619	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-6.99	0.01449	-0.414000	0.07179	.	.	-1.011000	0.01765	0.898000	0.31380	0.000000	0.08366	0.774000	0.36673	0.1148:0.5945:0.0:0.2907	8.0916	0.29964	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	segdup	1	230868	4.331480e-06	0	0	14010	0.000000e+00	0	0	33556	0.000000e+00	0	0	9596	0.000000e+00	0	0	17794	0.000000e+00	0	0	17926	0.000000e+00	0	1	102612	9.745450e-06	0	0	29722	0.000000e+00	0	1	102612	9.745450e-06	0	0	102260	0.000000e+00	0	0	192928	0.000000e+00	0	1	220600	4.533090e-06	0	1	225878	4.427170e-06	0	0	6242	0.000000e+00	0	0	16568	0.000000e+00	0	0	2196	0.000000e+00	0	0	8726	0.000000e+00	0	0	11064	0.000000e+00	0	0	40566	0.000000e+00	0	0	15126	0.000000e+00	0	.	.	.	.	0	13972	0.000000e+00	0	0	29512	0.000000e+00	0	0	5814	0.000000e+00	0	0	12958	0.000000e+00	0	0	14150	0.000000e+00	0	0	82310	0.000000e+00	0	0	29716	0.000000e+00	0	.	.	.	.	0	13054	0.000000e+00	0	0	33330	0.000000e+00	0	0	9252	0.000000e+00	0	0	17294	0.000000e+00	0	0	17916	0.000000e+00	0	1	94824	1.054590e-05	0	0	29652	0.000000e+00	0	1	94824	1.054590e-05	0	0	10616	0.000000e+00	0	0	33448	0.000000e+00	0	0	9548	0.000000e+00	0	0	17790	0.000000e+00	0	0	17924	0.000000e+00	0	1	101246	9.876930e-06	0	0	29722	0.000000e+00	0	1	101246	9.876930e-06	0	.	2	152256	1.313580e-05	0	1	41474	2.411150e-05	0	1	41474	2.411150e-05	0	0	912	0.000000e+00	0	0	15282	0.000000e+00	0	0	3470	0.000000e+00	0	0	5194	0.000000e+00	0	0	10628	0.000000e+00	0	0	316	0.000000e+00	0	1	68050	1.469510e-05	0	0	4838	0.000000e+00	0	0	32926	0.000000e+00	0	2	134836	1.483280e-05	0	2	147998	1.351370e-05	0	1	80814	1.237410e-05	0	0	9106	0.000000e+00	0	0	60	0.000000e+00	0	0	4690	0.000000e+00	0	0	136	0.000000e+00	0	0	2430	0.000000e+00	0	0	5498	0.000000e+00	0	0	246	0.000000e+00	0	0	6854	0.000000e+00	0	0	3116	0.000000e+00	0	1	32496	3.077300e-05	0	0	862	0.000000e+00	0	0	14836	0.000000e+00	0	0	3386	0.000000e+00	0	0	5194	0.000000e+00	0	0	6988	0.000000e+00	0	0	310	0.000000e+00	0	1	63926	1.564310e-05	0	0	4836	0.000000e+00	0	1	41154	2.429900e-05	0	0	912	0.000000e+00	0	0	15094	0.000000e+00	0	0	3302	0.000000e+00	0	0	4960	0.000000e+00	0	0	10628	0.000000e+00	0	0	304	0.000000e+00	0	1	64816	1.542830e-05	0	0	4806	0.000000e+00	0	1	24848	4.024470e-05	0	0	112	0.000000e+00	0	0	12908	0.000000e+00	0	0	996	0.000000e+00	0	0	3752	0.000000e+00	0	0	10536	0.000000e+00	0	0	272	0.000000e+00	0	0	21060	0.000000e+00	0	0	4810	0.000000e+00	0	0	9688	0	0	114	0	0	86	0	0	2784	0	0	146	0	0	610	0	0	26	0	0	98	0	0	496	0	0	2898	0	0	112	0	0	14048	0	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094711	T	C	S	G	.	16	31106032	16	31013533	7;7;7;7;7;7	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.19A>G;c.19A>G;c.19A>G;c.19A>G;c.19A>G	.;p.S7G;p.S7G;p.S7G;p.S7G;p.S7G	c.19A>G;c.19A>G;c.19A>G;c.19A>G;c.19A>G;c.19A>G	p.Ser7Gly;p.Ser7Gly;p.Ser7Gly;p.Ser7Gly;p.Ser7Gly;p.Ser7Gly	c.19A>G;c.19A>G;c.19A>G;c.19A>G;c.19A>G;c.19A>G	p.Ser7Gly;p.Ser7Gly;p.Ser7Gly;p.Ser7Gly;p.Ser7Gly;p.Ser7Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	1;1;1;1;1;1	0;0;0;0;0;0	T	T/T	T/T	T/T	T/T	.;0.099;0.015;0.017;0.042;0.341	0.52492	.;T;D;D;D;T	0.016;0.185;0.034;0.092;0.031;0.44	0.60972	D;T;D;T;D;T	.;.;.;0.013;.;0.002	0.16609	.;.;.;B;.;B	.;.;.;0.015;.;0.007	0.17295	.;.;.;B;.;B	0.500702	0.11953	N	0.745447	1;1;1;1;0.963438	0.26024	N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S7G;S7G;S7G;S7G;.	.;.;.;1.7;1.7;1.7	0.43825	.;.;.;L;L;L	-4.12;-3.04;-4.19;-4.58;-4.15;-4.76	0.98111	D;D;D;D;D;D	.;-1.08;-1.18;-1.04;-1.19;-0.97	0.30346	.;N;N;N;N;N	.;.;0.184;0.12;0.138;0.184	0.19995	0.2860	0.87333	D	0.7968	0.93118	D	9	0.095963895;0.095963895;0.095963895;0.095963895;0.095963895;0.095963895	0.17179	T;T;T;T;T;T	0.072592	0.71571	D	.;0.148;0.148;0.148;0.148;0.148	0.39182	0.318;0.318;0.318;0.318;0.318;0.318;	0.29581	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S7G;S7G;S7G;S7G;S7G;S7G;	Loss of MoRF binding (P = 0.1218);Loss of MoRF binding (P = 0.1218);Loss of MoRF binding (P = 0.1218);Loss of MoRF binding (P = 0.1218);Loss of MoRF binding (P = 0.1218);Loss of MoRF binding (P = 0.1218);	0.387689773709;0.387689773709;0.387689773709;0.387689773709;0.387689773709;0.387689773709	0.38380	.;.;.;.;.;0.682774319763916	0.68216	.;.;.;.;.;0.345641568364	0.36468	0.456154227257	0.32784	T	.;.;.;.;.;0.108679	0.42191	.;.;.;.;.;T	0.0231466	0.54805	T	-0.204528	0.54216	T	0.0700664083085715	0.08660	T	0.79802;0.79912;0.79802;0.79912;0.79802;0.79912	0.44420	T;T;T;T;T;T	.;.;.;.;.;0.18912008	0.40440	.;.;.;.;.;0.08482781	0.19541	.;.;.;.;.;0.18912008	0.40439	.;.;.;.;.;0.08482781	0.19541	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.1301;0.0892;0.1406;0.0997;0.1062;0.0921	0.30842	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	2.342150	0.37780	21.8	2.042924	0.33838	20.2	0.97059845328790528	0.32188	0.30358	0.24062	N	ALL	0.216889	0.34208	N	-0.763060634442313	0.14280	0.7100975	-0.726661423519334	0.16298	0.8615251	0.999999999999676	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	2.14	0.26518	1.563000	0.35972	.	.	0.609000	0.47794	0.938000	0.32564	0.001000	0.17328	0.785000	0.37106	0.1911:0.0:0.1989:0.61	4.7801	0.12568	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094711	T	G	S	R	.	16	31106032	16	31013533	7;7;7;7;7;7	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.19A>C;c.19A>C;c.19A>C;c.19A>C;c.19A>C	.;p.S7R;p.S7R;p.S7R;p.S7R;p.S7R	c.19A>C;c.19A>C;c.19A>C;c.19A>C;c.19A>C;c.19A>C	p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg	c.19A>C;c.19A>C;c.19A>C;c.19A>C;c.19A>C;c.19A>C	p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg;p.Ser7Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	1;1;1;1;1;1	0;0;0;0;0;0	T	T/T	T/T	T/T	T/T	.;0.191;0.064;0.07;0.043;0.36	0.41364	.;T;T;T;D;T	0.01;0.246;0.02;0.119;0.02;0.565	0.65728	D;T;D;T;D;T	.;.;.;0.062;.;0.01	0.23277	.;.;.;B;.;B	.;.;.;0.022;.;0.01	0.19653	.;.;.;B;.;B	0.500702	0.11953	N	0.745447	1;1;1;1;0.963438	0.26024	N;N;N;N;N	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	S7R;S7R;S7R;S7R;.	.;.;.;1.7;1.7;1.7	0.43825	.;.;.;L;L;L	-4.1;-3.02;-4.17;-4.56;-4.13;-4.74	0.98081	D;D;D;D;D;D	.;-0.46;-0.14;-0.54;-0.29;-0.22	0.16598	.;N;N;N;N;N	.;.;0.216;0.17;0.186;0.221	0.24758	0.1937	0.85801	D	0.7358	0.90969	D	9	0.09652609;0.09652609;0.09652609;0.09652609;0.09652609;0.09652609	0.17319	T;T;T;T;T;T	0.068017	0.70330	D	.;0.145;0.145;0.145;0.145;0.145	0.38592	0.349;0.349;0.349;0.349;0.349;0.349;	0.34598	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S7R;S7R;S7R;S7R;S7R;S7R;	Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);Gain of MoRF binding (P = 7e-04);	0.406945738958;0.406945738958;0.406945738958;0.406945738958;0.406945738958;0.406945738958	0.40305	.;.;.;.;.;0.6947743027980016	0.69418	.;.;.;.;.;0.411865483993	0.41935	0.487967669964	0.37157	T	.;.;.;.;.;0.082008	0.36728	.;.;.;.;.;T	0.088801	0.63054	D	-0.11022	0.62594	T	0.142263919115067	0.16468	T	0.631037;0.633437;0.631037;0.633437;0.631037;0.633437	0.24778	T;T;T;T;T;T	.;.;.;.;.;0.13828734	0.31987	.;.;.;.;.;0.095178336	0.22561	.;.;.;.;.;0.13828734	0.31987	.;.;.;.;.;0.095178336	0.22561	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.3885;0.2445;0.4404;0.2689;0.2676;0.266	0.61725	A;B;A;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.848525	0.27703	18.09	1.597315	0.25451	16.84	0.99554277430036764	0.71335	0.22953	0.21917	N	ALL	0.188795	0.31606	N	-0.75194669507399	0.14580	0.7275026	-0.716566027056704	0.16548	0.8759404	0.999999999999676	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	2.14	0.26518	1.563000	0.35972	.	.	0.609000	0.47794	0.938000	0.32564	0.001000	0.17328	0.785000	0.37106	0.1911:0.0:0.1989:0.61	4.7801	0.12568	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094714	C	A	G	W	.	16	31106035	16	31013536	6;6;6;6;6;6	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.16G>T;c.16G>T;c.16G>T;c.16G>T;c.16G>T	.;p.G6W;p.G6W;p.G6W;p.G6W;p.G6W	c.16G>T;c.16G>T;c.16G>T;c.16G>T;c.16G>T;c.16G>T	p.Gly6Trp;p.Gly6Trp;p.Gly6Trp;p.Gly6Trp;p.Gly6Trp;p.Gly6Trp	c.16G>T;c.16G>T;c.16G>T;c.16G>T;c.16G>T;c.16G>T	p.Gly6Trp;p.Gly6Trp;p.Gly6Trp;p.Gly6Trp;p.Gly6Trp;p.Gly6Trp	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	GGG;GGG;GGG;GGG;GGG;GGG	1;1;1;1;1;1	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.034;0.007;0.03;0.014;0.019	0.59928	.;D;D;D;D;D	0.022;0.008;0.01;0.007;0.023;0.021	0.69154	D;D;D;D;D;D	.;.;.;0.979;.;0.758	0.59044	.;.;.;D;.;P	.;.;.;0.792;.;0.319	0.57793	.;.;.;P;.;B	0.925421	0.07502	N	1.045680	0.999806;0.999557;0.999557;0.999557;0.999557	0.49283	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;G6W;G6W;G6W;G6W	.;.;.;1.5;1.5;1.5	0.37844	.;.;.;L;L;L	-4.13;-3.04;-4.28;-4.65;-4.2;-4.76	0.98111	D;D;D;D;D;D	.;-1.63;-1.73;-1.69;-1.67;-1.37	0.41046	.;N;N;N;N;N	.;.;0.239;0.221;0.219;0.263	0.29774	0.3962	0.89039	D	0.8532	0.95108	D	9	0.30375034;0.30375034;0.30375034;0.30375034;0.30375034;0.30375034	0.47904	T;T;T;T;T;T	0.403104	0.93440	D	.;0.416;0.416;0.416;0.416;0.416	0.72631	0.315;0.315;0.315;0.315;0.315;0.315;	0.29096	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	G6W;G6W;G6W;G6W;G6W;G6W;	Gain of MoRF binding (P = 0.0029);Gain of MoRF binding (P = 0.0029);Gain of MoRF binding (P = 0.0029);Gain of MoRF binding (P = 0.0029);Gain of MoRF binding (P = 0.0029);Gain of MoRF binding (P = 0.0029);	0.652220884204;0.652220884204;0.652220884204;0.652220884204;0.652220884204;0.652220884204	0.64932	.;.;.;.;.;0.7289214005263235	0.72836	.;.;.;.;.;0.786750793736	0.65562	0.465602993965	0.34078	T	.;.;.;.;.;0.215603	0.57753	.;.;.;.;.;T	0.110471	0.65402	D	-0.0790932	0.64972	T	0.6927270757428	0.40375	D	0.883612;0.883612;0.883612;0.883612;0.883612;0.883612	0.60617	D;D;D;D;D;D	.;.;.;.;.;0.14829761	0.33863	.;.;.;.;.;0.112181515	0.27065	.;.;.;.;.;0.14829761	0.33862	.;.;.;.;.;0.112181515	0.27065	.;.;.;-4.94;-4.56;-6.696	0.77767	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.2388;0.1718;0.2434;0.1824;0.178;0.2005	0.47773	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.507629	0.21996	15.79	1.751651	0.28146	17.84	0.98939215106816514	0.48902	0.29384	0.23807	N	ALL	0.432966	0.49462	N	-0.765257339163129	0.14222	0.7067175	-0.957484185237254	0.10749	0.5434204	0.999999999999999	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	-7.49	0.01212	-0.020000	0.12466	.	.	0.549000	0.26987	0.347000	0.25734	0.000000	0.08366	0.784000	0.37066	0.0:0.1994:0.4242:0.3764	6.9188	0.23556	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094716	C	G	W	S	.	16	31106037	16	31013538	5;5;5;5;5;5	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.14G>C;c.14G>C;c.14G>C;c.14G>C;c.14G>C	.;p.W5S;p.W5S;p.W5S;p.W5S;p.W5S	c.14G>C;c.14G>C;c.14G>C;c.14G>C;c.14G>C;c.14G>C	p.Trp5Ser;p.Trp5Ser;p.Trp5Ser;p.Trp5Ser;p.Trp5Ser;p.Trp5Ser	c.14G>C;c.14G>C;c.14G>C;c.14G>C;c.14G>C;c.14G>C	p.Trp5Ser;p.Trp5Ser;p.Trp5Ser;p.Trp5Ser;p.Trp5Ser;p.Trp5Ser	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGG;TGG;TGG;TGG;TGG;TGG	2;2;2;2;2;2	0;0;0;0;0;0	C	C/C	C/C	C/C	C/C	.;0.568;0.014;0.133;0.034;0.09	0.53172	.;T;D;T;D;T	0.0;0.096;0.0;0.035;0.0;0.122	0.92824	D;T;D;D;D;T	.;.;.;0.999;.;0.997	0.77913	.;.;.;D;.;D	.;.;.;0.996;.;0.915	0.84481	.;.;.;D;.;D	0.000412	0.44736	D	0.000000	0.99995;0.99995;0.99995;0.99995;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	W5S;W5S;W5S;W5S;.	.;.;.;2.05;2.05;2.05	0.56469	.;.;.;M;M;M	-4.04;-2.96;-4.22;-4.61;-4.13;-4.68	0.97989	D;D;D;D;D;D	.;-1.92;-2.28;-2.23;-2.32;-1.53	0.51478	.;N;N;N;N;N	.;.;0.479;0.56;0.54;0.553	0.58458	0.9785	0.96835	D	0.9251	0.97524	D	9	0.77020836;0.77020836;0.77020836;0.77020836;0.77020836;0.77020836	0.77022	D;D;D;D;D;D	0.49571	0.95071	D	.;0.680;0.680;0.680;0.680;0.680	0.88252	0.464;0.464;0.464;0.464;0.464;0.464;	0.53404	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	W5S;W5S;W5S;W5S;W5S;W5S;	Gain of glycosylation at W5 (P = 0.0067);Gain of glycosylation at W5 (P = 0.0067);Gain of glycosylation at W5 (P = 0.0067);Gain of glycosylation at W5 (P = 0.0067);Gain of glycosylation at W5 (P = 0.0067);Gain of glycosylation at W5 (P = 0.0067);	0.88848896193;0.88848896193;0.88848896193;0.88848896193;0.88848896193;0.88848896193	0.88738	.;.;.;.;.;0.7883702815237363	0.78789	.;.;.;.;.;1.50458477683	0.87103	0.640694737434	0.58662	T	.;.;.;.;.;0.203452	0.56193	.;.;.;.;.;T	0.305041	0.83367	D	0.200394	0.83151	D	0.971056580543518	0.69174	D	0.870213;0.870213;0.870213;0.870213;0.870213;0.870213	0.57527	D;D;D;D;D;D	.;.;.;.;.;0.33108127	0.55559	.;.;.;.;.;0.26062322	0.51827	.;.;.;.;.;0.33108127	0.55559	.;.;.;.;.;0.26062322	0.51826	.;.;.;-3.704;-3.855;-2.754	0.40709	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.1779;0.1048;0.1839;0.1636;0.1523;0.1866	0.40295	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.404345	0.61642	24.4	3.545576	0.68289	25.1	0.98541879047361791	0.42732	0.93610	0.58689	D	ALL	0.821726	0.74222	D	0.490552279345994	0.66537	4.962959	0.473443763024808	0.66234	4.925829	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	4.848000	0.62573	.	.	0.549000	0.26987	1.000000	0.71638	1.000000	0.68203	0.756000	0.36000	0.0:1.0:0.0:0.0	14.8781	0.70147	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094717	A	C	W	G	.	16	31106038	16	31013539	5;5;5;5;5;5	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.13T>G;c.13T>G;c.13T>G;c.13T>G;c.13T>G	.;p.W5G;p.W5G;p.W5G;p.W5G;p.W5G	c.13T>G;c.13T>G;c.13T>G;c.13T>G;c.13T>G;c.13T>G	p.Trp5Gly;p.Trp5Gly;p.Trp5Gly;p.Trp5Gly;p.Trp5Gly;p.Trp5Gly	c.13T>G;c.13T>G;c.13T>G;c.13T>G;c.13T>G;c.13T>G	p.Trp5Gly;p.Trp5Gly;p.Trp5Gly;p.Trp5Gly;p.Trp5Gly;p.Trp5Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	TGG;TGG;TGG;TGG;TGG;TGG	1;1;1;1;1;1	0;0;0;0;0;0	A	A/A	A/A	A/A	A/A	.;0.208;0.002;0.013;0.008;0.019	0.72154	.;T;D;D;D;D	0.0;0.002;0.0;0.002;0.0;0.011	0.92824	D;D;D;D;D;D	.;.;.;0.996;.;0.997	0.70673	.;.;.;D;.;D	.;.;.;0.991;.;0.915	0.79672	.;.;.;D;.;D	0.000412	0.44736	D	0.000000	0.835855;0.835855;0.835855;0.835855;1	0.81001	D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;without_aae	W5G;W5G;W5G;W5G;.	.;.;.;2.4;2.4;2.4	0.69460	.;.;.;M;M;M	-4.08;-3.0;-4.25;-4.64;-4.17;-4.72	0.98051	D;D;D;D;D;D	.;-2.14;-2.43;-2.36;-2.7;-1.83	0.57599	.;N;N;N;D;N	.;.;0.502;0.572;0.559;0.583	0.60410	0.9622	0.96579	D	0.9192	0.97324	D	9	0.80709016;0.80709016;0.80709016;0.80709016;0.80709016;0.80709016	0.80035	D;D;D;D;D;D	0.749026	0.97997	D	.;0.773;0.773;0.773;0.773;0.773	0.92378	0.456;0.456;0.456;0.456;0.456;0.456;	0.52102	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	W5G;W5G;W5G;W5G;W5G;W5G;	Gain of relative solvent accessibility (P = 0.0098);Gain of relative solvent accessibility (P = 0.0098);Gain of relative solvent accessibility (P = 0.0098);Gain of relative solvent accessibility (P = 0.0098);Gain of relative solvent accessibility (P = 0.0098);Gain of relative solvent accessibility (P = 0.0098);	0.794440821244;0.794440821244;0.794440821244;0.794440821244;0.794440821244;0.794440821244	0.79252	.;.;.;.;.;0.7751214860003801	0.77462	.;.;.;.;.;1.57748551578	0.88335	0.626783192158	0.56688	T	.;.;.;.;.;0.395489	0.75436	.;.;.;.;.;T	0.385259	0.89045	D	0.315622	0.88907	D	0.976963341236115	0.71621	D	0.644036;0.644036;0.644036;0.644036;0.644036;0.644036	0.25562	T;T;T;T;T;T	.;.;.;.;.;0.36817744	0.58449	.;.;.;.;.;0.33591917	0.59400	.;.;.;.;.;0.36817744	0.58450	.;.;.;.;.;0.33591917	0.59399	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.0942;0.0571;0.1029;0.083;0.0822;0.1059	0.19598	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	3.697822	0.69298	25.4	3.545498	0.68289	25.1	0.96947720085923605	0.31723	0.94816	0.62428	D	ALL	0.874006	0.79666	D	0.468495253916913	0.65260	4.8002	0.449254013225981	0.64670	4.727464	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.63	4.63	0.57175	5.673000	0.67781	.	.	0.691000	0.84096	1.000000	0.71638	1.000000	0.68203	0.729000	0.35066	1.0:0.0:0.0:0.0	11.9543	0.52260	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;Vitamin K epoxide reductase;.;.;Vitamin K epoxide reductase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094721	G	C	S	R	.	16	31106042	16	31013543	3;3;3;3;3;3	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.9C>G;c.9C>G;c.9C>G;c.9C>G;c.9C>G	.;p.S3R;p.S3R;p.S3R;p.S3R;p.S3R	c.9C>G;c.9C>G;c.9C>G;c.9C>G;c.9C>G;c.9C>G	p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg	c.9C>G;c.9C>G;c.9C>G;c.9C>G;c.9C>G;c.9C>G	p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	3;3;3;3;3;3	2;2;2;2;2;2	G	G/G	G/G	G/G	G/G	.;0.091;0.038;0.073;0.112;0.168	0.42783	.;T;D;T;T;T	0.022;0.195;0.024;0.118;0.026;0.317	0.57587	D;T;D;T;D;T	.;.;.;0.879;.;0.009	0.48338	.;.;.;P;.;B	.;.;.;0.481;.;0.007	0.47102	.;.;.;P;.;B	0.363774	0.13630	N	0.644243	1;0.999308;0.999308;0.999308;0.999308	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S3R;S3R;S3R;S3R	.;.;.;1.245;1.245;1.245	0.31408	.;.;.;L;L;L	-4.17;-3.09;-4.36;-4.74;-4.27;-4.82	0.98198	D;D;D;D;D;D	.;-0.57;-0.75;-0.78;-0.62;-0.43	0.21644	.;N;N;N;N;N	.;.;0.182;0.165;0.183;0.174	0.19861	0.4733	0.90168	D	0.8270	0.94193	D	9	0.23196867;0.23196867;0.23196867;0.23196867;0.23196867;0.23196867	0.40182	T;T;T;T;T;T	0.435059	0.94056	D	.;0.243;0.243;0.243;0.243;0.243	0.54921	0.316;0.316;0.316;0.316;0.316;0.316;	0.29258	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S3R;S3R;S3R;S3R;S3R;S3R;	Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);	0.484400871567;0.484400871567;0.484400871567;0.484400871567;0.484400871567;0.484400871567	0.48070	.;.;.;.;.;0.5905497157341753	0.58984	.;.;.;.;.;0.431131314501	0.43331	0.511439919472	0.40424	T	.;.;.;.;.;0.106554	0.41800	.;.;.;.;.;T	0.0800132	0.62041	D	-0.122843	0.61568	T	0.482402116060257	0.31985	T	0.79802;0.79802;0.79802;0.79802;0.79802;0.79802	0.44234	T;T;T;T;T;T	.;.;.;.;.;0.0980977	0.23132	.;.;.;.;.;0.08229979	0.18774	.;.;.;.;.;0.0980977	0.23131	.;.;.;.;.;0.08229979	0.18773	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.2102;0.1424;0.2088;0.1574;0.1766;0.1688	0.43788	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.728710	0.25565	17.22	2.044409	0.33860	20.2	0.99554763740660646	0.71397	0.51058	0.28807	D	ALL	0.145716	0.26899	N	-0.336574966546116	0.27767	1.526196	-0.275969256080319	0.28892	1.614437	0.999999999999916	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.1	3.06	0.34374	0.778000	0.26393	.	.	0.618000	0.50648	0.863000	0.30666	0.908000	0.28083	0.431000	0.27472	0.3785:0.35:0.2715:0.0	2.0626	0.03377	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;.;.;.;.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094721	G	T	S	R	.	16	31106042	16	31013543	3;3;3;3;3;3	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.9C>A;c.9C>A;c.9C>A;c.9C>A;c.9C>A	.;p.S3R;p.S3R;p.S3R;p.S3R;p.S3R	c.9C>A;c.9C>A;c.9C>A;c.9C>A;c.9C>A;c.9C>A	p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg	c.9C>A;c.9C>A;c.9C>A;c.9C>A;c.9C>A;c.9C>A	p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	3;3;3;3;3;3	2;2;2;2;2;2	G	G/G	G/G	G/G	G/G	.;0.091;0.038;0.073;0.112;0.168	0.42783	.;T;D;T;T;T	0.022;0.195;0.024;0.118;0.026;0.317	0.57587	D;T;D;T;D;T	.;.;.;0.879;.;0.009	0.48338	.;.;.;P;.;B	.;.;.;0.481;.;0.007	0.47102	.;.;.;P;.;B	0.363774	0.13630	N	0.644243	1;0.999308;0.999308;0.999308;0.999308	0.81001	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S3R;S3R;S3R;S3R	.;.;.;1.245;1.245;1.245	0.31408	.;.;.;L;L;L	-4.17;-3.09;-4.36;-4.74;-4.27;-4.82	0.98198	D;D;D;D;D;D	.;-0.57;-0.75;-0.78;-0.62;-0.43	0.21644	.;N;N;N;N;N	.;.;0.182;0.165;0.183;0.174	0.19861	0.4733	0.90168	D	0.8270	0.94193	D	9	0.23209819;0.23209819;0.23209819;0.23209819;0.23209819;0.23209819	0.40198	T;T;T;T;T;T	0.446564	0.94264	D	.;0.236;0.236;0.236;0.236;0.236	0.53931	0.316;0.316;0.316;0.316;0.316;0.316;	0.29258	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S3R;S3R;S3R;S3R;S3R;S3R;	Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);	0.484400871567;0.484400871567;0.484400871567;0.484400871567;0.484400871567;0.484400871567	0.48070	.;.;.;.;.;0.5905496881921064	0.58984	.;.;.;.;.;0.431131314501	0.43331	0.511439919472	0.40424	T	.;.;.;.;.;0.106554	0.41800	.;.;.;.;.;T	0.0800118	0.62041	D	-0.122845	0.61568	T	0.482402116060257	0.31985	T	0.79802;0.79802;0.79802;0.79802;0.79802;0.79802	0.44234	T;T;T;T;T;T	.;.;.;.;.;0.0980977	0.23132	.;.;.;.;.;0.08229979	0.18774	.;.;.;.;.;0.0980977	0.23131	.;.;.;.;.;0.08229979	0.18773	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.2102;0.1424;0.2088;0.1574;0.1766;0.1688	0.43788	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	1.694362	0.24986	16.99	2.021211	0.33396	19.90	0.99576970163347422	0.72742	0.43640	0.27142	N	ALL	0.127464	0.24485	N	-0.336574966546116	0.27767	1.526196	-0.275969256080319	0.28892	1.614437	0.999999999999916	0.74766	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.1	3.06	0.34374	0.778000	0.26393	.	.	0.618000	0.50648	0.863000	0.30666	0.908000	0.28083	0.431000	0.27472	0.3785:0.35:0.2715:0.0	2.0626	0.03377	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;.;.;.;.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094723	T	C	S	G	.	16	31106044	16	31013545	3;3;3;3;3;3	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.7A>G;c.7A>G;c.7A>G;c.7A>G;c.7A>G	.;p.S3G;p.S3G;p.S3G;p.S3G;p.S3G	c.7A>G;c.7A>G;c.7A>G;c.7A>G;c.7A>G;c.7A>G	p.Ser3Gly;p.Ser3Gly;p.Ser3Gly;p.Ser3Gly;p.Ser3Gly;p.Ser3Gly	c.7A>G;c.7A>G;c.7A>G;c.7A>G;c.7A>G;c.7A>G	p.Ser3Gly;p.Ser3Gly;p.Ser3Gly;p.Ser3Gly;p.Ser3Gly;p.Ser3Gly	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	1;1;1;1;1;1	0;0;0;0;0;0	T	T/T	T/T	T/T	T/T	.;0.012;0.007;0.005;0.022;0.03	0.63226	.;D;D;D;D;D	0.066;0.543;0.057;0.236;0.071;0.463	0.46406	T;T;T;T;T;T	.;.;.;0.597;.;0.002	0.39250	.;.;.;P;.;B	.;.;.;0.14;.;0.003	0.33554	.;.;.;B;.;B	0.363774	0.13630	N	0.644243	0.999955;0.999999;0.999999;0.999999;0.999999	0.52396	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S3G;S3G;S3G;S3G	.;.;.;1.245;1.245;1.245	0.31408	.;.;.;L;L;L	-4.15;-3.07;-4.34;-4.72;-4.24;-4.8	0.98169	D;D;D;D;D;D	.;-1.0;-1.25;-1.27;-1.29;-1.07	0.32387	.;N;N;N;N;N	.;.;0.116;0.08;0.082;0.074	0.10483	-0.1252	0.79513	T	0.6928	0.89404	D	9	0.09794819;0.09794819;0.09794819;0.09794819;0.09794819;0.09794819	0.17676	T;T;T;T;T;T	0.113362	0.79184	D	.;0.211;0.211;0.211;0.211;0.211	0.50185	0.169;0.169;0.169;0.169;0.169;0.169;	0.07419	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S3G;S3G;S3G;S3G;S3G;S3G;	Loss of glycosylation at S3 (P = 0.0042);Loss of glycosylation at S3 (P = 0.0042);Loss of glycosylation at S3 (P = 0.0042);Loss of glycosylation at S3 (P = 0.0042);Loss of glycosylation at S3 (P = 0.0042);Loss of glycosylation at S3 (P = 0.0042);	0.319686207203;0.319686207203;0.319686207203;0.319686207203;0.319686207203;0.319686207203	0.31575	.;.;.;.;.;0.5397422001755917	0.53899	.;.;.;.;.;0.348342674058	0.36705	0.472333312035	0.35001	T	.;.;.;.;.;0.130251	0.45903	.;.;.;.;.;T	0.000864267	0.51772	T	-0.236535	0.51137	T	0.40746533870697	0.29223	T	0.761924;0.761924;0.761924;0.761924;0.761924;0.761924	0.38711	T;T;T;T;T;T	.;.;.;.;.;0.13826814	0.31985	.;.;.;.;.;0.08295885	0.18974	.;.;.;.;.;0.13826814	0.31985	.;.;.;.;.;0.08295885	0.18974	.;.;.;-3.327;-3.249;-3.773	0.38610	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.0791;0.0649;0.0785;0.0668;0.0714;0.066	0.07365	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	0.598866	0.10243	7.502	0.980731	0.16678	13.30	0.94788998847960537	0.25527	0.04250	0.09777	N	ALL	0.074002	0.14820	N	-1.18366382217193	0.05247	0.2387314	-1.27825819779757	0.04725	0.2235593	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.1	-8.2	0.00918	-0.941000	0.04035	.	.	0.609000	0.47794	0.207000	0.24389	0.000000	0.08366	0.338000	0.25386	0.2006:0.3784:0.2007:0.2203	1.2519	0.01864	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;.;.;.;.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
16	31094723	T	G	S	R	rs1464695762	16	31106044	16	31013545	3;3;3;3;3;3	AC135050.2;AC135050.2;VKORC1;VKORC1;VKORC1;VKORC1	ENSG00000255439;ENSG00000255439;ENSG00000167397;ENSG00000167397;ENSG00000167397;ENSG00000167397	ENST00000532364;ENST00000529564;ENST00000300851;ENST00000319788;ENST00000354895;ENST00000394975	ENSP00000460316;ENSP00000431371;ENSP00000300851;ENSP00000326135;ENSP00000346969;ENSP00000378426	.;.;F8W9H0;Q9BQB6-2;Q9BQB6-3;Q9BQB6	.;.;F8W9H0_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN;VKOR1_HUMAN	.;c.7A>C;c.7A>C;c.7A>C;c.7A>C;c.7A>C	.;p.S3R;p.S3R;p.S3R;p.S3R;p.S3R	c.7A>C;c.7A>C;c.7A>C;c.7A>C;c.7A>C;c.7A>C	p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg	c.7A>C;c.7A>C;c.7A>C;c.7A>C;c.7A>C;c.7A>C	p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg;p.Ser3Arg	alternative2;principal5;.;.;.;principal1	.;Y;Y;Y;Y;Y	4;4;2;1;1;1	.;YES;.;.;.;YES	-;-;-;-;-;-	AGC;AGC;AGC;AGC;AGC;AGC	1;1;1;1;1;1	0;0;0;0;0;0	T	T/T	T/T	T/T	T/T	.;0.091;0.038;0.073;0.112;0.168	0.42783	.;T;D;T;T;T	0.022;0.195;0.024;0.118;0.026;0.317	0.57587	D;T;D;T;D;T	.;.;.;0.879;.;0.009	0.48338	.;.;.;P;.;B	.;.;.;0.481;.;0.007	0.47102	.;.;.;P;.;B	0.363774	0.13630	N	0.644243	0.999955;0.999995;0.999995;0.999995;0.999995	0.52396	D;N;N;N;N	without_aae;simple_aae;simple_aae;simple_aae;simple_aae	.;S3R;S3R;S3R;S3R	.;.;.;1.245;1.245;1.245	0.31408	.;.;.;L;L;L	-4.17;-3.09;-4.36;-4.74;-4.27;-4.82	0.98198	D;D;D;D;D;D	.;-0.57;-0.75;-0.78;-0.62;-0.43	0.21644	.;N;N;N;N;N	.;.;0.182;0.165;0.183;0.174	0.19861	0.1706	0.85410	D	0.7710	0.92213	D	9	0.1415999;0.1415999;0.1415999;0.1415999;0.1415999;0.1415999	0.26902	T;T;T;T;T;T	0.181979	0.85590	D	.;0.264;0.264;0.264;0.264;0.264	0.57741	0.316;0.316;0.316;0.316;0.316;0.316;	0.29258	Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;Q9BQB6;	S3R;S3R;S3R;S3R;S3R;S3R;	Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);Gain of MoRF binding (P = 5e-04);	0.345632371893;0.345632371893;0.345632371893;0.345632371893;0.345632371893;0.345632371893	0.34166	.;.;.;.;.;0.5905497295052098	0.58984	.;.;.;.;.;0.431131314501	0.43331	0.511439919472	0.40424	T	.;.;.;.;.;0.106554	0.41800	.;.;.;.;.;T	0.0507998	0.58445	T	-0.164806	0.57916	T	0.62570196390152	0.37440	D	0.79802;0.79802;0.79802;0.79802;0.79802;0.79802	0.44234	T;T;T;T;T;T	.;.;.;.;.;0.11531783	0.27212	.;.;.;.;.;0.07337074	0.15937	.;.;.;.;.;0.11531783	0.27212	.;.;.;.;.;0.07337074	0.15937	.;.;.;-3.938;-3.562;-3.776	0.42755	.;.;.;T;T;T	.;.;.;.;.;.	.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	.;.;.;.;.;.	0.2102;0.1424;0.2088;0.1574;0.1766;0.1688	0.43788	B;B;B;B;B;B	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	.;.;.;.;.;.;	0.183092	0.05786	2.933	0.622374	0.12246	10.50	0.98644911210698061	0.44110	0.13728	0.18019	N	ALL	0.117939	0.23082	N	-1.06504267092278	0.07295	0.3384804	-1.19628578550321	0.05972	0.2860698	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	.	.	4.1	-8.2	0.00918	-0.941000	0.04035	.	.	0.609000	0.47794	0.207000	0.24389	0.000000	0.08366	0.338000	0.25386	0.2006:0.3784:0.2007:0.2203	1.2519	0.01864	41	0.97903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.;.;.;.;.;.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
